[{"text": " Tomudex  treatment resulted in the decrease in p27(kip1) expression, with an increase in  cyclin E  and cdk2 protein expression and kinase activities 24 h after a 2-h exposure", "triple_list": [["cyclin", "ANTAGONIST", "cyclin E"]]}, {"text": " Tomudex  treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and  cdk2  protein expression and kinase activities 24 h after a 2-h exposure", "triple_list": [["Tomudex", "PRODUCT-OF", "activities"]]}, {"text": " Tomudex  treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and  kinase  activities 24 h after a 2-h exposure", "triple_list": [["increase", "DOWNREGULATOR", "kinase"]]}, {"text": "The studies with dThyd rescue from  cyclin E  cdk2 protein overexpression and growth inhibition by  Tomudex  indicate that increased  cyclin E -cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance", "triple_list": [["Tomudex", "PRODUCT-OF", "cyclin E"]]}, {"text": "The studies with dThyd rescue from cyclin E- cdk2  protein overexpression and growth inhibition by  Tomudex  indicate that increased cyclin E- cdk2  protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance", "triple_list": [["Tomudex", "AGONIST", "indicate"]]}, {"text": "The studies with dThyd rescue from  cyclin E -cdk2 protein overexpression and growth inhibition by  Tomudex  indicate that increased  cyclin E  cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance", "triple_list": [["overexpression", "DOWNREGULATOR", "cyclin E"]]}, {"text": "The studies with dThyd rescue from cyclin E- cdk2  protein overexpression and growth inhibition by  Tomudex  indicate that increased cyclin E- cdk2  protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance", "triple_list": [["Tomudex", "ANTAGONIST", "imbalance"]]}, {"text": "These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by  Tomudex  and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in  cyclin E  and cdk2 kinase activities", "triple_list": [["Tomudex", "ANTAGONIST", "These"]]}, {"text": "These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by  Tomudex  and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and  cdk2  kinase activities", "triple_list": [["Tomudex", "ANTAGONIST", "induced"]]}, {"text": "These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by  Tomudex  and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2  kinase  activities", "triple_list": [["Tomudex", "PRODUCT-OF", "and"]]}, {"text": "Studies were carried out in vitro to evaluate downstream molecular alterations induced as a consequence of the potent and sustained inhibition of  thymidylate synthase  by  Tomudex   Twenty-four hours following the initial 2-h treatment with  Tomudex , human A253 head and neck squamous carcinoma cells, not expressing p53 and p21(WAF1), were accumulated with DNA content characteristic of early S phase of the cell cycle with a concomitant reduction of cells in G1 and G2/M phases", "triple_list": [["Tomudex", "ACTIVATOR", "carried"]]}, {"text": " Tomudex  treatment resulted in the decrease in  p27(kip1)  expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure", "triple_list": [["protein", "PRODUCT-OF", "p27(kip1)"]]}, {"text": "Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the  thymidylate synthase  inhibitor  Tomudex    Tomudex  (ZD1694) is a specific antifolate-based  thymidylate synthase  inhibitor active in a variety of solid tumor malignancies", "triple_list": [["E-cdk2", "ANTAGONIST", "thymidylate synthase"]]}, {"text": " Tomudex  (ZD1694) is a specific antifolate-based  thymidylate synthase  inhibitor active in a variety of solid tumor malignancies", "triple_list": [["Tomudex", "ACTIVATOR", "inhibitor"]]}, {"text": "The studies with dThyd rescue from  cyclin E  cdk2 protein overexpression and growth inhibition by  Tomudex  indicate that increased  cyclin E -cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance", "triple_list": [["associated", "PRODUCT-OF", "cyclin E"]]}, {"text": "The studies with dThyd rescue from cyclin E- cdk2  protein overexpression and growth inhibition by  Tomudex  indicate that increased cyclin E- cdk2  protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance", "triple_list": [["and", "PRODUCT-OF", "cdk2"]]}, {"text": "The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by  Tomudex  indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of  thymidylate synthase  and resultant dNTP pool imbalance", "triple_list": [["E-cdk2", "ANTAGONIST", "thymidylate synthase"]]}, {"text": "These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of  thymidylate synthase  by  Tomudex  and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2 kinase activities", "triple_list": [["Tomudex", "AGONIST", "of"]]}, {"text": "These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by  Tomudex  and kilobase DNA fragmentation may correlate with the reduction of  p27(kip1)  expression and the increase in cyclin E and cdk2 kinase activities", "triple_list": [["in", "PRODUCT-OF", "p27(kip1)"]]}, {"text": "In the long term,  orlistat  has been shown to be more effective than placebo in reducing body weight and serum total and  low-density lipoprotein  cholesterol levels", "triple_list": [["than", "PRODUCT-OF", "low-density lipoprotein"]]}, {"text": " Orlistat  is a new inhibitor of  pancreatic lipase  enzyme", "triple_list": [["Orlistat", "AGONIST", "pancreatic lipase"]]}, {"text": " Cyclopentenone prostaglandins  were potent inhibitors of  iNOS  induction and were more effective than their precursors, prostaglandins E2 and D2", "triple_list": [["Cyclopentenone prostaglandins", "AGONIST", "were"]]}, {"text": "Cyclopentenone prostaglandins were potent inhibitors of  iNOS  induction and were more effective than their precursors,  prostaglandins E2 and D2   15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) was the most potent prostaglandin among those tested", "triple_list": [["prostaglandins E2 and D2", "AGONIST", "J2"]]}, {"text": "In activated microglia,  15d-PGJ2  suppressed  iNOS promoter  activity, iNOS mRNA, and protein levels", "triple_list": [["In", "ANTAGONIST", "iNOS promoter"]]}, {"text": "In activated microglia,  15d-PGJ2  suppressed  iNOS  promoter activity,  iNOS  mRNA, and protein levels", "triple_list": [["15d-PGJ2", "ACTIVATOR", "levels"]]}, {"text": " Cyclopentenone prostaglandins  suppress activation of microglia: down-regulation of  inducible nitric-oxide synthase  by 15-deoxy-Delta12,14-prostaglandin J2", "triple_list": [["down-regulation", "AGONIST", "inducible nitric-oxide synthase"]]}, {"text": "Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of  inducible nitric-oxide synthase  by  15-deoxy-Delta12,14-prostaglandin J2   Mechanisms leading to down-regulation of activated microglia and astrocytes are poorly understood, in spite of the potentially detrimental role of activated glia in neurodegeneration", "triple_list": [["are", "ANTAGONIST", "inducible nitric-oxide synthase"]]}, {"text": " 15d-PGJ2  did not block nuclear translocation or DNA-binding activity of the transcription factor  NFkappaB , but it did inhibit the activity of an  NFkappaB  reporter construct, suggesting that the mechanism of suppression of microglial iNOS by  15d-PGJ2  may involve interference with  NFkappaB  transcriptional activity in the nucleus", "triple_list": [["nuclear", "PRODUCT-OF", "NFkappaB"]]}, {"text": " 15d-PGJ2  did not block nuclear translocation or DNA-binding activity of the transcription factor NFkappaB, but it did inhibit the activity of an NFkappaB reporter construct, suggesting that the mechanism of suppression of microglial  iNOS  by  15d-PGJ2  may involve interference with NFkappaB transcriptional activity in the nucleus", "triple_list": [["suggesting", "PRODUCT-OF", "iNOS"]]}, {"text": " Phospholipase A2  inhibitors  p-bromophenacyl bromide  and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes", "triple_list": [["p-bromophenacyl bromide", "PRODUCT-OF", "interleukin-2"]]}, {"text": "Pretreatment of the splenocytes with both BPB and AACOCF3 suppressed  phorbol 12-myristate 13-acetate  plus ionomycin-induced  IL-2  secretion in a concentration-dependent manner", "triple_list": [["manner", "PRODUCT-OF", "IL-2"]]}, {"text": "Likewise,  IL-2  steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM  BPB  and 20 microM AACOCF3", "triple_list": [["BPB", "ACTIVATOR", "a"]]}, {"text": "Likewise, IL-2 steady-state mRNA expression was inhibited by both  PLA2  inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM  BPB  and 20 microM AACOCF3", "triple_list": [["BPB", "PRODUCT-OF", "inhibited"]]}, {"text": "Likewise,  IL-2  steady-state mRNA expression was inhibited by both PLA2 inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM  AACOCF3   Taken together, these data demonstrated that PLA2 inhibitors BPB and  AACOCF3  are robust inhibitors of  IL-2  expression at both the mRNA and protein levels in murine splenocytes", "triple_list": [["AACOCF3", "ANTAGONIST", "and"]]}, {"text": "Likewise, IL-2 steady-state mRNA expression was inhibited by both  PLA2  inhibitors in a concentration-dependent fashion with > 90% inhibition at 1 microM BPB and 20 microM  AACOCF3   Taken together, these data demonstrated that  PLA2  inhibitors BPB and  AACOCF3  are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes", "triple_list": [["BPB", "PRODUCT-OF", "PLA2"]]}, {"text": "Taken together, these data demonstrated that  PLA2  inhibitors  BPB  and AACOCF3 are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes", "triple_list": [["BPB", "PRODUCT-OF", "in"]]}, {"text": "Taken together, these data demonstrated that PLA2 inhibitors  BPB  and AACOCF3 are robust inhibitors of  IL-2  expression at both the mRNA and protein levels in murine splenocytes", "triple_list": [["BPB", "ANTAGONIST", "these"]]}, {"text": "Taken together, these data demonstrated that  PLA2  inhibitors BPB and  AACOCF3  are robust inhibitors of IL-2 expression at both the mRNA and protein levels in murine splenocytes", "triple_list": [["robust", "PRODUCT-OF", "PLA2"]]}, {"text": "Taken together, these data demonstrated that PLA2 inhibitors BPB and  AACOCF3  are robust inhibitors of  IL-2  expression at both the mRNA and protein levels in murine splenocytes", "triple_list": [["AACOCF3", "PRODUCT-OF", "splenocytes"]]}, {"text": "Phospholipase A2 inhibitors  p-bromophenacyl bromide  and arachidonyl trifluoromethyl ketone suppressed  interleukin-2  (IL-2) expression in murine primary splenocytes", "triple_list": [["(IL-2)", "AGONIST", "interleukin-2"]]}, {"text": "Phospholipase A2 inhibitors  p-bromophenacyl bromide  and arachidonyl trifluoromethyl ketone suppressed interleukin-2 ( IL-2   expression in murine primary splenocytes", "triple_list": [["inhibitors", "AGONIST", "IL-2"]]}, {"text": " Phospholipase A2  inhibitors p-bromophenacyl bromide and  arachidonyl trifluoromethyl ketone  suppressed interleukin-2 (IL-2) expression in murine primary splenocytes", "triple_list": [["arachidonyl trifluoromethyl ketone", "PRODUCT-OF", "suppressed"]]}, {"text": "Phospholipase A2 inhibitors p-bromophenacyl bromide and  arachidonyl trifluoromethyl ketone  suppressed  interleukin-2  (IL-2) expression in murine primary splenocytes", "triple_list": [["arachidonyl trifluoromethyl ketone", "AGONIST", "inhibitors"]]}, {"text": "Phospholipase A2 inhibitors p-bromophenacyl bromide and  arachidonyl trifluoromethyl ketone  suppressed interleukin-2 ( IL-2   expression in murine primary splenocytes", "triple_list": [["ketone", "PRODUCT-OF", "IL-2"]]}, {"text": "Therefore, the objective of the present study was to investigate the effects of  PLA2  inhibitors  p-bromophenacyl bromide  (BPB) and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes", "triple_list": [["ketone", "AGONIST", "PLA2"]]}, {"text": "Therefore, the objective of the present study was to investigate the effects of  PLA2  inhibitors p-bromophenacyl bromide ( BPB   and arachidonyl trifluoromethyl ketone (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes", "triple_list": [["BPB", "ANTAGONIST", "PLA2"]]}, {"text": "Therefore, the objective of the present study was to investigate the effects of  PLA2  inhibitors p-bromophenacyl bromide (BPB) and  arachidonyl trifluoromethyl ketone  (AACOCF3) on interleukin-2 (IL-2) expression in murine primary splenocytes", "triple_list": [["the", "AGONIST", "PLA2"]]}, {"text": "Therefore, the objective of the present study was to investigate the effects of  PLA2  inhibitors p-bromophenacyl bromide (BPB) and arachidonyl trifluoromethyl ketone ( AACOCF3   on interleukin-2 (IL-2) expression in murine primary splenocytes", "triple_list": [["trifluoromethyl", "AGONIST", "PLA2"]]}, {"text": "Pretreatment of the splenocytes with both  BPB  and AACOCF3 suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced  IL-2  secretion in a concentration-dependent manner", "triple_list": [["plus", "ANTAGONIST", "IL-2"]]}, {"text": "Pretreatment of the splenocytes with both BPB and  AACOCF3  suppressed phorbol 12-myristate 13-acetate plus ionomycin-induced  IL-2  secretion in a concentration-dependent manner", "triple_list": [["secretion", "PRODUCT-OF", "IL-2"]]}, {"text": "Inhibition > 90% of  IL-2  secretion was observed at 1 microM  BPB  and 10 microM AACOCF3 compared to the respective vehicle control", "triple_list": [["BPB", "ANTAGONIST", "compared"]]}, {"text": "Inhibition > 90% of  IL-2  secretion was observed at 1 microM BPB and 10 microM  AACOCF3  compared to the respective vehicle control", "triple_list": [[">", "AGONIST", "IL-2"]]}, {"text": " c-fos  expression was induced in urethane-anaesthetized rats by intracisternal  capsaicin  administration", "triple_list": [["capsaicin", "AGONIST", "was"]]}, {"text": "Sumatriptan and LY 344864 decreased the number of  capsaicin  induced  c-fos  like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1))", "triple_list": [["kg(-1))", "PRODUCT-OF", "c-fos"]]}, {"text": " Sumatriptan  and LY 344864 decreased the number of capsaicin-induced  c-fos  like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1))", "triple_list": [["capsaicin-induced", "PRODUCT-OF", "c-fos"]]}, {"text": "Sumatriptan and  LY 344864  decreased the number of capsaicin-induced  c-fos  like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1))", "triple_list": [["344864", "ANTAGONIST", "c-fos"]]}, {"text": "To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective  5-HT1F  receptor agonist ( LY 344864   on c-fos protein expression in the trigeminal nucleus caudalis", "triple_list": [["To", "ACTIVATOR", "5-HT1F"]]}, {"text": "The effect of sumatriptan, but not of LY 344864, was prevented by pretreatment with the antagonist  SDZ 21-009   which displays high affinity for  rat 5-HT1B  receptors", "triple_list": [["SDZ 21-009", "PRODUCT-OF", "not"]]}, {"text": "Both  BB-94  and captopril also prevented substrate degradation by  gelatinase A and B  released in conditioned medium by cultured cells", "triple_list": [["cells", "ACTIVATOR", "gelatinase A and B"]]}, {"text": "We have examined the effects of the synthetic  matrix metalloproteinase  inhibitor,  batimastat  (BB-94) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice", "triple_list": [["batimastat", "ANTAGONIST", "(3LL)"]]}, {"text": "We have examined the effects of the synthetic  matrix metalloproteinase  inhibitor, batimastat ( BB-94   and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice", "triple_list": [["BB-94", "ACTIVATOR", "metalloproteinase"]]}, {"text": "Inhibition of  gelatinase A  (MMP-2) by  batimastat  and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma", "triple_list": [["batimastat", "ANTAGONIST", "Inhibition"]]}, {"text": "Inhibition of gelatinase A ( MMP-2   by  batimastat  and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma", "triple_list": [["batimastat", "PRODUCT-OF", "and"]]}, {"text": "Inhibition of  gelatinase A  (MMP-2) by batimastat and  captopril  reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma", "triple_list": [["captopril", "AGONIST", "gelatinase A"]]}, {"text": "Inhibition of gelatinase A ( MMP-2   by batimastat and  captopril  reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma", "triple_list": [["captopril", "ACTIVATOR", "reduces"]]}, {"text": "We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat (BB-94) and the  angiotensin-converting enzyme  inhibitor,  captopril   on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice", "triple_list": [["vitro,", "ACTIVATOR", "angiotensin-converting enzyme"]]}, {"text": "Here we report that  captopril  treatment resulted in decreased transcription and protein levels of  gelatinase A  by 3LL cells", "triple_list": [["in", "AGONIST", "gelatinase A"]]}, {"text": "Thus our data suggest that the  COX-2  preference of  meloxicam  observed in vitro may not result in clinical advantages when the higher dose of 15 mg is needed", "triple_list": [["COX-2", "ACTIVATOR", "COX-2"]]}, {"text": "The effects of  meloxicam  were compared with those of diclofenac, a nonselective  COX  inhibitor", "triple_list": [["COX", "PRODUCT-OF", "COX"]]}, {"text": "The effects of meloxicam were compared with those of  diclofenac   a nonselective  COX  inhibitor", "triple_list": [["nonselective", "PRODUCT-OF", "COX"]]}, {"text": "METHODS:  COX-1  inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg  meloxicam  and 75 mg diclofenac and at steady state (15 mg  meloxicam  daily and 150 mg diclofenac daily)", "triple_list": [["meloxicam", "AGONIST", "whole"]]}, {"text": "METHODS:  COX-1  inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg  diclofenac  and at steady state (15 mg meloxicam daily and 150 mg  diclofenac  daily)", "triple_list": [["diclofenac", "ANTAGONIST", "inhibition"]]}, {"text": "METHODS:  COX-1  inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg  meloxicam  and 75 mg diclofenac and at steady state (15 mg  meloxicam  daily and 150 mg diclofenac daily)", "triple_list": [["meloxicam", "ACTIVATOR", "diclofenac"]]}, {"text": "METHODS:  COX-1  inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg  diclofenac  and at steady state (15 mg meloxicam daily and 150 mg  diclofenac  daily)", "triple_list": [["ex", "PRODUCT-OF", "COX-1"]]}, {"text": "OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by  meloxicam   which has been reported to preferentially inhibit  cyclooxygenase-2  (COX-2)", "triple_list": [["meloxicam", "PRODUCT-OF", "cyclooxygenase-2"]]}, {"text": "OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by  meloxicam   which has been reported to preferentially inhibit cyclooxygenase-2 ( COX-2  ", "triple_list": [["meloxicam", "ACTIVATOR", "human"]]}, {"text": "OBJECTIVE: To evaluate the extent of  human cyclooxygenase-1  (COX-1) inhibition by  meloxicam   which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2)", "triple_list": [["To", "PRODUCT-OF", "human cyclooxygenase-1"]]}, {"text": "OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 ( COX-1   inhibition by  meloxicam   which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2)", "triple_list": [["meloxicam", "ANTAGONIST", "COX-1"]]}, {"text": "Of the  PDE  inhibitors tested,  dipyridamole  was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and cGMP hydrolysis, respectively", "triple_list": [["dipyridamole", "ANTAGONIST", "effective,"]]}, {"text": "Of the  PDE  inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of  cAMP  and cGMP hydrolysis, respectively", "triple_list": [["cAMP", "ACTIVATOR", "the"]]}, {"text": "Of the  PDE  inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of cAMP and  cGMP  hydrolysis, respectively", "triple_list": [["1.2", "ANTAGONIST", "PDE"]]}, {"text": "Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both  cAMP  and cGMP ( PDE10A  ", "triple_list": [["a", "DOWNREGULATOR", "PDE10A"]]}, {"text": "Cloning and characterization of a novel  human phosphodiesterase  that hydrolyzes both  cAMP  and cGMP (PDE10A)", "triple_list": [["(PDE10A)", "DOWNREGULATOR", "human phosphodiesterase"]]}, {"text": "Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and  cGMP  ( PDE10A  ", "triple_list": [["of", "AGONIST", "PDE10A"]]}, {"text": "Cloning and characterization of a novel  human phosphodiesterase  that hydrolyzes both cAMP and  cGMP  (PDE10A)", "triple_list": [["cGMP", "ANTAGONIST", "human"]]}, {"text": "Recombinant  PDE10A  transfected and expressed in COS-7 cells hydrolyzed  cAMP  and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with  cAMP ", "triple_list": [["cAMP", "AGONIST", "that"]]}, {"text": "Recombinant  PDE10A  transfected and expressed in COS-7 cells hydrolyzed cAMP and  cGMP  with Km values of 0.26 and 7.2 microM, respectively, and Vmax with  cGMP  was almost twice that with cAMP", "triple_list": [["cGMP", "DOWNREGULATOR", "that"]]}, {"text": "Recombinant  PDE10A  transfected and expressed in COS-7 cells hydrolyzed cAMP and  cGMP  with Km values of 0.26 and 7.2 microM, respectively, and Vmax with  cGMP  was almost twice that with cAMP", "triple_list": [["cGMP", "AGONIST", "of"]]}, {"text": "Recombinant  PDE10A  transfected and expressed in COS-7 cells hydrolyzed  cAMP  and cGMP with Km values of 0.26 and 7.2 microM, respectively, and Vmax with cGMP was almost twice that with  cAMP   Of the PDE inhibitors tested, dipyridamole was most effective, with IC50 values of 1.2 and 0.45 microM for inhibition of  cAMP  and cGMP hydrolysis, respectively", "triple_list": [["cAMP", "DOWNREGULATOR", "with"]]}, {"text": "To begin to examine whether these changes are mediated by alterations in gene expression for  tryptophan hydroxylase  (TPH), the rate-limiting enzyme in  5-HT  biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR)", "triple_list": [["to", "DOWNREGULATOR", "tryptophan hydroxylase"]]}, {"text": "To begin to examine whether these changes are mediated by alterations in gene expression for tryptophan hydroxylase ( TPH  , the rate-limiting enzyme in  5-HT  biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR)", "triple_list": [["mRNA", "AGONIST", "TPH"]]}, {"text": "In contrast, there was little change in mRNA levels for  GTP cyclohydrolase I  (GTPCH), the rate limiting enzyme in synthesis of the  tetrahydrobiopterin  (BH4), the obligate cofactor for TPH", "triple_list": [["tetrahydrobiopterin", "ANTAGONIST", "in"]]}, {"text": "In contrast, there was little change in mRNA levels for GTP cyclohydrolase I ( GTPCH  , the rate limiting enzyme in synthesis of the  tetrahydrobiopterin  (BH4), the obligate cofactor for TPH", "triple_list": [["tetrahydrobiopterin", "AGONIST", "of"]]}, {"text": "In contrast, there was little change in mRNA levels for  GTP cyclohydrolase I  (GTPCH), the rate limiting enzyme in synthesis of the tetrahydrobiopterin ( BH4  , the obligate cofactor for TPH", "triple_list": [["little", "DOWNREGULATOR", "GTP cyclohydrolase I"]]}, {"text": "In contrast, there was little change in mRNA levels for GTP cyclohydrolase I ( GTPCH  , the rate limiting enzyme in synthesis of the tetrahydrobiopterin ( BH4  , the obligate cofactor for TPH", "triple_list": [["tetrahydrobiopterin", "AGONIST", "GTPCH"]]}, {"text": "We evaluated the effects of  angiotensin II  and an angiotensin-converting enzyme inhibitor ( cilazapril   on nerve blood flow (NBF) and electrophysiology in control and diabetic rats", "triple_list": [["control", "ANTAGONIST", "angiotensin II"]]}, {"text": "We evaluated the effects of angiotensin II and an  angiotensin-converting enzyme  inhibitor ( cilazapril   on nerve blood flow (NBF) and electrophysiology in control and diabetic rats", "triple_list": [["angiotensin", "PRODUCT-OF", "angiotensin-converting enzyme"]]}, {"text": "We topically applied the nitric oxide synthase ( NOS   inhibitor,  NG-nitro-L-arginine   on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet", "triple_list": [["NG-nitro-L-arginine", "PRODUCT-OF", "on"]]}, {"text": "We topically applied the  nitric oxide synthase  (NOS) inhibitor,  NG-nitro-L-arginine   on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet", "triple_list": [["NG-nitro-L-arginine", "ANTAGONIST", "oxide"]]}, {"text": "The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective  alpha 1A-adrenoceptor  antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective  alpha 1A-adrenoceptor  agonist  A-61603  (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and  alpha 1A-adrenoceptor  involvement", "triple_list": [["A-61603", "ACTIVATOR", "account"]]}, {"text": "The putative  alpha 1L-adrenoceptor  antagonist  JTH-601   but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA", "triple_list": [["not", "PRODUCT-OF", "alpha 1L-adrenoceptor"]]}, {"text": "The putative alpha 1L-adrenoceptor antagonist JTH-601, but not the  alpha 1B-adrenoceptor  antagonist  chloroethylclonidine  (10 microM) antagonized noradrenaline-induced contractions of SMA", "triple_list": [["noradrenaline-induced", "DOWNREGULATOR", "alpha 1B-adrenoceptor"]]}, {"text": "The potency of the selective  alpha 1D-adrenoceptor  antagonist  BMY 7378  against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement", "triple_list": [["BMY 7378", "ACTIVATOR", "against"]]}, {"text": "The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective  alpha 1A-adrenoceptor  antagonist  RS-17053  against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective  alpha 1A-adrenoceptor  agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and  alpha 1A-adrenoceptor  involvement", "triple_list": [["and", "PRODUCT-OF", "alpha 1A-adrenoceptor"]]}, {"text": "In phosphotriesterase and physostigmine-treated mice, a 4- and 2-fold higher  sarin  dose, respectively, was needed to cause a 50% inhibition of brain  AChE  activity", "triple_list": [["sarin", "PRODUCT-OF", "was"]]}, {"text": "The acute toxicity of  organophosphorus  (OP) compounds in mammals is due to their irreversible inhibition of  acetylcholinesterase  (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels", "triple_list": [["organophosphorus", "ANTAGONIST", "(AChE)"]]}, {"text": "The acute toxicity of  organophosphorus  (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase ( AChE   in the nervous system, which leads to increased synaptic acetylcholine levels", "triple_list": [["AChE", "ANTAGONIST", "AChE"]]}, {"text": "The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of  acetylcholine sterase (AChE) in the nervous system, which leads to increased synaptic  acetylcholine  levels", "triple_list": [["acetylcholine", "DOWNREGULATOR", "acetylcholine"]]}, {"text": "The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of  acetylcholine sterase ( AChE   in the nervous system, which leads to increased synaptic  acetylcholine  levels", "triple_list": [["acetylcholine", "ACTIVATOR", "due"]]}, {"text": " Torasemide  inhibits  angiotensin II  induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats", "triple_list": [["Torasemide", "AGONIST", "hypertensive"]]}, {"text": "Isometric contraction induced by a submaximal concentration of  Ang II  (10(-7) mol/L) was reduced in a dose-dependent way by  torasemide  (IC(50)=0.5+/-0.04 micromol/L)", "triple_list": [["a", "PRODUCT-OF", "Ang II"]]}, {"text": "The stimulatory effect of [Ca(2+)](i) induced by a submaximal concentration of  Ang II  (10(-7) mol/L) was blocked by  torasemide  (IC(50)=0.5+/-0.3 nmol/L)", "triple_list": [["torasemide", "ACTIVATOR", "induced"]]}, {"text": "Our findings suggest that  torasemide  blocks the vasoconstrictor action of  Ang II  in vitro", "triple_list": [["Ang", "PRODUCT-OF", "Ang II"]]}, {"text": "This action can be related to the ability of  torasemide  to block the increase of [Ca(2+)](i) induced by  Ang II  in VSMCs", "triple_list": [["torasemide", "ANTAGONIST", "action"]]}, {"text": "On phosphorylation of  Ser40  by  protein kinase A   the affinity for H4biopterin increased ([S]0.5 = 11 +/- 2 microM) and the negative cooperativity was amplified (h = 0.27 +/- 0.03)", "triple_list": [["Ser40", "DOWNREGULATOR", "was"]]}, {"text": " Ribonucleotide reductase  activity was found to be strongly increased in the  gemcitabine  selected line and purine nucleoside phosphorylase was increased in the 2-chlorodeoxyadenosine-selected line", "triple_list": [["gemcitabine", "DOWNREGULATOR", "reductase"]]}, {"text": "Ribonucleotide reductase activity was found to be strongly increased in the gemcitabine-selected line and  purine nucleoside phosphorylase  was increased in the  2-chlorodeoxyadenosine  selected line", "triple_list": [["nucleoside", "AGONIST", "purine nucleoside phosphorylase"]]}, {"text": " Endothelial NO synthase  expression was increased by  cilazapril  but not by losartan", "triple_list": [["cilazapril", "AGONIST", "by"]]}, {"text": " Human and rat renin  and angiotensinogen genes were downregulated in dTGR and were increased by  losartan  and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed", "triple_list": [["receptor", "AGONIST", "Human and rat renin"]]}, {"text": "Human and rat renin and  angiotensinogen  genes were downregulated in dTGR and were increased by  losartan  and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed", "triple_list": [["losartan", "AGONIST", "increased"]]}, {"text": " Human and rat renin  and angiotensinogen genes were downregulated in dTGR and were increased by losartan and  cilazapril  treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed", "triple_list": [["ACE", "PRODUCT-OF", "Human and rat renin"]]}, {"text": "Human and rat renin and  angiotensinogen  genes were downregulated in dTGR and were increased by losartan and  cilazapril  treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed", "triple_list": [["AT1A", "DOWNREGULATOR", "angiotensinogen"]]}, {"text": "Combination treatment with the selective  5-HT1A  antagonist  WAY100635  produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone", "triple_list": [["WAY100635", "AGONIST", "produced"]]}, {"text": "The beta-adrenergic/ 5-HT1A  receptor antagonist  (+/-)pindolol  and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA", "triple_list": [["receptor", "DOWNREGULATOR", "5-HT1A"]]}, {"text": "The  kinase  activity of EGFR was little inhibited by  TT-B  in a cell-free system.", "triple_list": [["system.", "AGONIST", "kinase"]]}, {"text": "The kinase activity of  EGFR  was little inhibited by  TT-B  in a cell-free system.", "triple_list": [["TT-B", "AGONIST", "The"]]}, {"text": "We report here that  lovastatin   a drug clinically used for lowering cholesterol levels, inhibits the interaction of  human LFA-1  with its counter-receptor intercellular adhesion molecule-1", "triple_list": [["lovastatin", "PRODUCT-OF", "clinically"]]}, {"text": "We report here that  lovastatin   a drug clinically used for lowering cholesterol levels, inhibits the interaction of human LFA-1 with its counter-receptor  intercellular adhesion molecule-1   Using nuclear magnetic resonance spectroscopy and X-ray crystallography we show that the inhibitor binds to a highly conserved domain of the LFA-1 alpha-chain called the I-domain", "triple_list": [["lovastatin", "ACTIVATOR", "used"]]}, {"text": "Structural basis for  LFA-1  inhibition upon  lovastatin  binding to the CD11a I-domain", "triple_list": [["CD11a", "AGONIST", "LFA-1"]]}, {"text": "The inhibitory effect of endothelin-1 on the contraction induced by 5-HT is abolished by deendothelialization, by the  endothelin ET(B) receptor  antagonist  RES 701-1   by indomethacin, or by glibenclamide", "triple_list": [["RES 701-1", "ACTIVATOR", "on"]]}, {"text": "The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the  thromboxane A2 receptor  antagonists  GR32191  and ridogrel", "triple_list": [["GR32191", "AGONIST", "modified"]]}, {"text": "The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the  thromboxane A2 receptor  antagonists GR32191 and  ridogrel   U46619 potentiates the 5-HT-effect in mesenteric arteries", "triple_list": [["the", "AGONIST", "thromboxane A2 receptor"]]}, {"text": "This work showed that appropriate structural modification of  diphenidol  can lead to  M2  selective muscarinic antagonists of possible interest in the field of Alzheimer's disease.", "triple_list": [["can", "AGONIST", "M2"]]}, {"text": "A series of 2-carbonyl analogues of the muscarinic antagonist  diphenidol  bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the  M2 and M3 muscarinic receptor  subtypes was evaluated by functional tests", "triple_list": [["diphenidol", "ACTIVATOR", "of"]]}, {"text": "Synthesis and antagonistic activity at  muscarinic receptor  subtypes of some 2-carbonyl derivatives of  diphenidol   A series of 2-carbonyl analogues of the muscarinic antagonist  diphenidol  bearing 1-substituents of different lipophilic, electronic, and steric properties was synthesized and their affinity for the M2 and M3  muscarinic receptor  subtypes was evaluated by functional tests", "triple_list": [["diphenidol", "DOWNREGULATOR", "diphenidol"]]}, {"text": "Synthesis and antagonistic activity at  muscarinic receptor  subtypes of some  2-carbonyl  derivatives of diphenidol", "triple_list": [["and", "DOWNREGULATOR", "muscarinic receptor"]]}, {"text": "This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific  renin  angiotensin-aldosterone system (RAAS) blockade by  renin -inhibitor  remikiren  could be predicted from pretreatment renal vascular tone", "triple_list": [["remikiren", "ANTAGONIST", "from"]]}, {"text": "This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific renin- angiotensin  aldosterone system (RAAS) blockade by renin-inhibitor  remikiren  could be predicted from pretreatment renal vascular tone", "triple_list": [["remikiren", "PRODUCT-OF", "pretreatment"]]}, {"text": "This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific  renin -angiotensin-aldosterone system (RAAS) blockade by  renin  inhibitor  remikiren  could be predicted from pretreatment renal vascular tone", "triple_list": [["remikiren", "PRODUCT-OF", "renin"]]}, {"text": "Compared with WT,  DeltaKPQ  I(Na) was more sensitive to  flecainide   and  flecainide  preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na)", "triple_list": [["flecainide", "AGONIST", "DeltaKPQ"]]}, {"text": "Compared with WT,  DeltaKPQ  I(Na) was more sensitive to  flecainide , and  flecainide  preferentially inhibited late I(Na) (mean current between 20 and 23.5 ms after depolarization) compared with peak I(Na)", "triple_list": [["depolarization)", "ACTIVATOR", "DeltaKPQ"]]}, {"text": " Flecainide  block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted ( DeltaKPQ   stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings", "triple_list": [["of", "AGONIST", "DeltaKPQ"]]}, {"text": " Flecainide  block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the  long QT syndrome 3 (LQT3) sodium channel alpha  subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings", "triple_list": [["into", "PRODUCT-OF", "long QT syndrome 3 (LQT3) sodium channel alpha"]]}, {"text": "Preferential block of late sodium current in the  LQT3 DeltaKPQ mutant  by the class I(C) antiarrhythmic  flecainide   Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings", "triple_list": [["the", "ACTIVATOR", "LQT3 DeltaKPQ mutant"]]}, {"text": "We conclude that  DeltaKPQ  interacts differently with  flecainide  than with WT, leading to increased block and slowed recovery, especially for late I(Na)", "triple_list": [["differently", "PRODUCT-OF", "DeltaKPQ"]]}, {"text": "In this report, we evaluated the growth-inhibitory effects of  sulindac sulfide   a  COX-1  and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines", "triple_list": [["a", "AGONIST", "COX-1"]]}, {"text": "In this report, we evaluated the growth-inhibitory effects of  sulindac sulfide   a COX-1 and  COX-2  inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines", "triple_list": [["COX-2", "ANTAGONIST", "COX-2"]]}, {"text": "In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and  nordihydroguaiaretic acid  (NDGA), a  lipoxygenase  inhibitor on human lung cancer cell lines", "triple_list": [["nordihydroguaiaretic acid", "PRODUCT-OF", "on"]]}, {"text": "In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid ( NDGA  , a  lipoxygenase  inhibitor on human lung cancer cell lines", "triple_list": [["COX", "ANTAGONIST", "lipoxygenase"]]}, {"text": "Science, 9(266) (1994) 1709-1713) greatly attenuates the  lithium  induced potentiation of  GluR3   Additionally, experiments with the non-desensitizing site-directed mutant  GluR3 (L507Y) (Stern-Bach, Y., Russo, S., Neuman, M", "triple_list": [["experiments", "AGONIST", "GluR3"]]}, {"text": "Neuron, 21 (1998) 907-918) further confirms that  lithium  enhances  GluR3  responses by reducing desensitization, since  lithium 's effects are reversed in this mutant", "triple_list": [["lithium", "DOWNREGULATOR", "confirms"]]}, {"text": "Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that  lithium  produces a large potentiation of the  GluR3 flop  splice variant and suggested that  lithium  might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N", "triple_list": [["and", "AGONIST", "GluR3 flop"]]}, {"text": "Specifically,  aniracetam   which potentiates wild-type  AMPA receptors   is ineffective on the non-desensitizing GluR3(L507Y) mutant, but has synergistic effects with lithium on wild-type receptors.", "triple_list": [["aniracetam", "AGONIST", "receptors"]]}, {"text": "Specifically, aniracetam, which potentiates wild-type AMPA receptors, is ineffective on the non-desensitizing  GluR3  L507Y) mutant, but has synergistic effects with  lithium  on wild-type receptors.", "triple_list": [["lithium", "ANTAGONIST", "the"]]}, {"text": "Specifically, aniracetam, which potentiates wild-type AMPA receptors, is ineffective on the non-desensitizing GluR3( L507Y   mutant, but has synergistic effects with  lithium  on wild-type receptors.", "triple_list": [["lithium", "AGONIST", "on"]]}, {"text": "Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that  lithium  produces a large potentiation of the  GluR3 flop  splice variant and suggested that  lithium  might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N", "triple_list": [["lithium", "AGONIST", "is"]]}, {"text": "It was concluded that  PGE1  selectively reduces both N- and R-type Ca2+ currents by activating a  G-protein  probably through the EP3 receptor in paratracheal ganglion cells.", "triple_list": [["PGE1", "AGONIST", "probably"]]}, {"text": "Prostaglandin E1, E2,  STA2  (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit  HVA Ca2+ channels  was sulprostone>PGE2, PGE1> STA2 >>17-phenyl-trinor-PGE2", "triple_list": [["(HVA", "PRODUCT-OF", "HVA Ca2+ channels"]]}, {"text": "Prostaglandin E1, E2, STA2 (a stable analogue of  thromboxane A2  , 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit  HVA Ca2+ channels  was sulprostone>PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2", "triple_list": [["potency", "ANTAGONIST", "HVA Ca2+ channels"]]}, {"text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2),  17-phenyl-trinor-PGE2  (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit  HVA Ca2+ channels  was sulprostone>PGE2, PGE1>STA2>> 17-phenyl-trinor-PGE2 ", "triple_list": [["17-phenyl-trinor-PGE2", "ACTIVATOR", "was"]]}, {"text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and  sulprostone  (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit  HVA Ca2+ channels  was  sulprostone >PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2", "triple_list": [["E1,", "ANTAGONIST", "HVA Ca2+ channels"]]}, {"text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and  sulprostone  (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit  HVA Ca2+ channels  was  sulprostone  PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2", "triple_list": [["sulprostone", "AGONIST", "the"]]}, {"text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor- PGE2  (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit  HVA Ca2+ channels  was sulprostone> PGE2   PGE1>STA2>>17-phenyl-trinor- PGE2 ", "triple_list": [["PGE2", "ACTIVATOR", "the"]]}, {"text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit  HVA Ca2+ channels  was sulprostone>PGE2,  PGE1  STA2>>17-phenyl-trinor-PGE2", "triple_list": [["EP1-selective", "ANTAGONIST", "HVA Ca2+ channels"]]}, {"text": "Prostaglandin E1, E2,  STA2  (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit  HVA Ca2+ channels  was sulprostone>PGE2, PGE1> STA2  >17-phenyl-trinor-PGE2", "triple_list": [["17-phenyl-trinor-PGE2", "ACTIVATOR", "HVA Ca2+ channels"]]}, {"text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2),  17-phenyl-trinor-PGE2  (an EP1-selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit  HVA Ca2+ channels  was sulprostone>PGE2, PGE1>STA2>> 17-phenyl-trinor-PGE2   SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the  HVA Ca2+ channels  is possibly mediated by the EP3 receptor", "triple_list": [["17-phenyl-trinor-PGE2", "PRODUCT-OF", "of"]]}, {"text": "SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the  PGE1 - or PGE2-induced inhibition of the HVA ICa, thereby indicating that  PGE1   and PGE2-induced inhibition of the  HVA Ca2+ channels  is possibly mediated by the EP3 receptor", "triple_list": [["ICa,", "PRODUCT-OF", "HVA Ca2+ channels"]]}, {"text": "SC-51089 (10(-5) M), a selective EP1-receptor antagonist, showed no effect on the PGE1- or  PGE2 -induced inhibition of the HVA ICa, thereby indicating that PGE1- and  PGE2  induced inhibition of the  HVA Ca2+ channels  is possibly mediated by the EP3 receptor", "triple_list": [["PGE2", "ANTAGONIST", "EP1-receptor"]]}, {"text": "The inhibitory effect of PGE1 or sulprostone was prevented by pretreatment with pertussis toxin [islet activating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the  protein kinase C  (PKC) inhibitor  chelerythrine  blocked the action of PMA", "triple_list": [["chelerythrine", "AGONIST", "action"]]}, {"text": "The inhibitory effect of PGE1 or sulprostone was prevented by pretreatment with pertussis toxin [islet activating protein (IAP)] or phorbol-12-myristate-13-acetate (PMA), and the protein kinase C ( PKC   inhibitor  chelerythrine  blocked the action of PMA", "triple_list": [["chelerythrine", "PRODUCT-OF", "PMA"]]}, {"text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2),  17-phenyl-trinor-PGE2  (an  EP1  selective agonist) and sulprostone (an EP3-selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was sulprostone>PGE2, PGE1>STA2>> 17-phenyl-trinor-PGE2 ", "triple_list": [["17-phenyl-trinor-PGE2", "ACTIVATOR", "(an"]]}, {"text": "Prostaglandin E1, E2, STA2 (a stable analogue of thromboxane A2), 17-phenyl-trinor-PGE2 (an EP1-selective agonist) and  sulprostone  (an  EP3  selective agonist) inhibited the HVA Ca2+ current (HVA ICa) dose-dependently, and the rank order of potency to inhibit HVA Ca2+ channels was  sulprostone >PGE2, PGE1>STA2>>17-phenyl-trinor-PGE2", "triple_list": [["sulprostone", "ANTAGONIST", ">PGE2,"]]}, {"text": " SC-51089  (10(-5) M), a selective  EP1-receptor  antagonist, showed no effect on the PGE1- or PGE2-induced inhibition of the HVA ICa, thereby indicating that PGE1- and PGE2-induced inhibition of the HVA Ca2+ channels is possibly mediated by the EP3 receptor", "triple_list": [["and", "AGONIST", "EP1-receptor"]]}, {"text": " PR mRNA  abundance in both myometruim and leiomyomata (center and marginal area) was significantly decreased in 4 patients continuing  mifepristone  treatment before the operation but not in the other 2 patients stopping RU486 1 month before operation", "triple_list": [["mifepristone", "AGONIST", "in"]]}, {"text": "One of the mechanism of  mifepristone  action on decreasing leiomyomata volume may be related to suppression on expression of  PR gene   It seems that suppression on transcription of  PR gene  is reversible, but on translation of  PR gene  may maintain in a relatively longer period.", "triple_list": [["mifepristone", "PRODUCT-OF", "PR gene"]]}, {"text": "To investigate the possibility that  felbamate 's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of  felbamate  block of recombinant  NMDA receptors  composed of the NR1a subunit and various NR2 subunits", "triple_list": [["To", "ANTAGONIST", "NMDA receptors"]]}, {"text": "To investigate the possibility that  felbamate 's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of  felbamate  block of recombinant NMDA receptors composed of the  NR1a  subunit and various NR2 subunits", "triple_list": [["various", "ACTIVATOR", "NR1a"]]}, {"text": "To investigate the possibility that  felbamate 's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of  felbamate  block of recombinant NMDA receptors composed of the NR1a subunit and various  NR2  subunits", "triple_list": [["felbamate", "ANTAGONIST", "toxicity"]]}, {"text": " Felbamate  produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the  rat NR1a  subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)", "triple_list": [["Felbamate", "ACTIVATOR", "2.4"]]}, {"text": " Felbamate  produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the  NR2A   NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)", "triple_list": [["NR2A", "ACTIVATOR", "NR2A"]]}, {"text": " Felbamate  produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A,  NR2B  or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)", "triple_list": [["NR1a", "PRODUCT-OF", "NR2B"]]}, {"text": " Felbamate  produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A, NR2B or  NR2C  subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV)", "triple_list": [["Felbamate", "PRODUCT-OF", "for"]]}, {"text": " Felbamate  block of recombinant  N-methyl-D-aspartate receptors   selectivity for the NR2B subunit", "triple_list": [["Felbamate", "PRODUCT-OF", "of"]]}, {"text": " Felbamate  block of recombinant N-methyl-D-aspartate receptors: selectivity for the  NR2B  subunit", "triple_list": [["Felbamate", "PRODUCT-OF", "the"]]}, {"text": "The higher affinity of  felbamate  block of  NMDA receptors  containing the NR2B subunit could be accounted for by more rapid association and slower dissociation from these sites", "triple_list": [["sites", "ACTIVATOR", "NMDA receptors"]]}, {"text": "The higher affinity of  felbamate  block of NMDA receptors containing the  NR2B  subunit could be accounted for by more rapid association and slower dissociation from these sites", "triple_list": [["felbamate", "AGONIST", "NR2B"]]}, {"text": "We conclude that  felbamate  exhibits modest selectivity for  NMDA receptors  composed of NR1a/NR2B subunits", "triple_list": [["felbamate", "ACTIVATOR", "selectivity"]]}, {"text": "We conclude that  felbamate  exhibits modest selectivity for NMDA receptors composed of  NR1a  NR2B subunits", "triple_list": [["felbamate", "ACTIVATOR", "modest"]]}, {"text": "We conclude that  felbamate  exhibits modest selectivity for NMDA receptors composed of NR1a/ NR2B  subunits", "triple_list": [["modest", "ANTAGONIST", "NR2B"]]}, {"text": "The anticonvulsant  felbamate  blocks  N-methyl-D-asparate (NMDA) receptors  but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists", "triple_list": [["receptor", "PRODUCT-OF", "N-methyl-D-asparate (NMDA) receptors"]]}, {"text": "This selectivity could, in part, account for the more favorable clinical profile of  felbamate  in comparison with  NMDA receptor  antagonists that do not show subunit selectivity.", "triple_list": [["felbamate", "DOWNREGULATOR", "could,"]]}, {"text": "The anticonvulsant  felbamate  blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other  NMDA receptor  antagonists", "triple_list": [["fails", "PRODUCT-OF", "NMDA receptor"]]}, {"text": "Comparison of the effect of  rofecoxib  (a  cyclooxygenase 2  inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial", "triple_list": [["rofecoxib", "ACTIVATOR", "and"]]}, {"text": "OBJECTIVE: This randomized, double-blind study tested the hypothesis that  rofecoxib   a drug that specifically inhibits  cyclooxygenase 2   would cause fewer gastroduodenal ulcers than ibuprofen (in a multicenter trial), and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design)", "triple_list": [["inhibits", "ACTIVATOR", "cyclooxygenase 2"]]}, {"text": "Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of  zileuton   a specific inhibitor of  5-lipoxygenase  (5-LOX) and a clinically used anti-asthmatic drug", "triple_list": [["zileuton", "ANTAGONIST", "of"]]}, {"text": "Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of  zileuton   a specific inhibitor of 5-lipoxygenase ( 5-LOX   and a clinically used anti-asthmatic drug", "triple_list": [["zileuton", "ANTAGONIST", "to"]]}, {"text": "Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to  zileuton   suggesting that troglitazone inhibits LT production by direct inhibition of  5-LOX  activity", "triple_list": [["inhibits", "PRODUCT-OF", "5-LOX"]]}, {"text": "Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to zileuton, suggesting that  troglitazone  inhibits LT production by direct inhibition of  5-LOX  activity", "triple_list": [["troglitazone", "ACTIVATOR", "activity"]]}, {"text": "These findings suggest that  troglitazone  inhibits antigen-induced LT production in the IgE-sensitized RBL-2H3 cells and A23187-stimulated rat peritoneal neutrophils by direct inhibition of  5-LOX  activity.", "triple_list": [["troglitazone", "ANTAGONIST", "activity."]]}, {"text": "The above results indicate that polyamine depletion delays the onset of apoptosis in IEC-6 cells and confers protection against DNA damaging agents, suggesting that  polyamines  might be involved in the  caspase  activating signal cascade.", "triple_list": [["depletion", "AGONIST", "caspase"]]}, {"text": "Addition of  putrescine  restored the induction of apoptosis as indicated by an increase in the number of detached cells and  caspase 3  activity", "triple_list": [["putrescine", "DOWNREGULATOR", "indicated"]]}, {"text": "Depletion of putrescine, spermidine, and spermine by  DL-alpha-difluoromethylornithine  (DFMO), a specific inhibitor of  ornithine decarboxylase  (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index", "triple_list": [["DL-alpha-difluoromethylornithine", "ANTAGONIST", "index"]]}, {"text": "Depletion of putrescine, spermidine, and spermine by  DL-alpha-difluoromethylornithine  (DFMO), a specific inhibitor of ornithine decarboxylase ( ODC   that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index", "triple_list": [["DL-alpha-difluoromethylornithine", "ANTAGONIST", "ODC"]]}, {"text": "Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine ( DFMO  , a specific inhibitor of  ornithine decarboxylase  (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index", "triple_list": [["spermidine,", "ANTAGONIST", "ornithine decarboxylase"]]}, {"text": "Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine ( DFMO  , a specific inhibitor of ornithine decarboxylase ( ODC   that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index", "triple_list": [["decarboxylase", "ANTAGONIST", "ODC"]]}, {"text": "Inhibition of  S-adenosylmethionine decarboxylase  by a specific inhibitor [ diethylglyoxal bis-(guanylhydrazone)   DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC", "triple_list": [["diethylglyoxal", "ANTAGONIST", "S-adenosylmethionine decarboxylase"]]}, {"text": "Inhibition of  S-adenosylmethionine decarboxylase  by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone);  DEGBG   led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC", "triple_list": [["a", "ACTIVATOR", "S-adenosylmethionine decarboxylase"]]}, {"text": "Depletion of  putrescine   spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of  ornithine decarboxylase  (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index", "triple_list": [["and", "AGONIST", "ornithine decarboxylase"]]}, {"text": "Depletion of  putrescine   spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase ( ODC   that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index", "triple_list": [["putrescine", "DOWNREGULATOR", "inhibitor"]]}, {"text": "Depletion of putrescine,  spermidine   and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of  ornithine decarboxylase  (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index", "triple_list": [["spermidine", "ANTAGONIST", "inhibitor"]]}, {"text": "Depletion of putrescine,  spermidine   and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase ( ODC   that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index", "triple_list": [["spermidine", "ACTIVATOR", "apoptotic"]]}, {"text": "Depletion of putrescine, spermidine, and  spermine  by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of  ornithine decarboxylase  (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index", "triple_list": [["spermine", "ACTIVATOR", "the"]]}, {"text": "Depletion of putrescine, spermidine, and  spermine  by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase ( ODC   that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index", "triple_list": [["spermidine,", "ACTIVATOR", "ODC"]]}, {"text": "Inhibition of  S-adenosylmethionine decarboxylase  by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of  spermidine  and spermine with a significant accumulation of putrescine and induction of ODC", "triple_list": [["with", "DOWNREGULATOR", "S-adenosylmethionine decarboxylase"]]}, {"text": "Inhibition of  S-adenosylmethionine decarboxylase  by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and  spermine  with a significant accumulation of putrescine and induction of ODC", "triple_list": [["spermine", "ANTAGONIST", "by"]]}, {"text": "In addition, by comparing the combined administration of  (+/-)pindolol  with either WAY100635, GR127935 or isamoltane, we have determined that  (+/-)pindolol  produces much of its acute potentiation of fluoxetine-induced increases in extracellular 5-HT via its action at the 5-HT(1B/D) receptor in addition to any activity it has at the presynaptic  5-HT(1A)  receptor.", "triple_list": [["in", "DOWNREGULATOR", "5-HT(1A)"]]}, {"text": "This effect has been attributed to the antagonist effects of  pindolol  at the  5-HT(1A)  receptor", "triple_list": [["the", "ACTIVATOR", "5-HT(1A)"]]}, {"text": "In the present study, we compared the pharmacology of  (+/-)pindolol   WAY-100635 (a  5-HT(1A)  antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat", "triple_list": [["(+/-)pindolol", "AGONIST", "the"]]}, {"text": "In the present study, we compared the pharmacology of (+/-)pindolol,  WAY-100635  (a  5-HT(1A)  antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat", "triple_list": [["microdialysis", "AGONIST", "5-HT(1A)"]]}, {"text": "In the present study, we compared the pharmacology of (+/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and  isamoltane  (a  5-HT(1B)  antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat", "triple_list": [["isamoltane", "PRODUCT-OF", "antagonist),"]]}, {"text": " Orlistat  treatment also results in modest improvements in total cholesterol,  low-density lipoprotein   blood pressure, and fasting glucose and insulin concentrations", "triple_list": [["Orlistat", "ANTAGONIST", "Orlistat"]]}, {"text": " Orlistat  treatment also results in modest improvements in total cholesterol, low-density lipoprotein, blood pressure, and fasting glucose and  insulin  concentrations", "triple_list": [["Orlistat", "AGONIST", "treatment"]]}, {"text": " Orlistat   a new  lipase  inhibitor for the management of obesity", "triple_list": [["Orlistat", "AGONIST", "obesity"]]}, {"text": "In the liver of rats given  flutamide  as initiating agent at the dose of 500 mg/kg/week for 6 successive weeks,  gamma-glutamyltraspeptidase  positive foci were detected only in 3 of 10 rats", "triple_list": [["flutamide", "AGONIST", "rats"]]}, {"text": " Flutamide   an effective competitive inhibitor of the  androgen receptor  used orally for palliative treatment of prostatic carcinoma and regulation of prostatic hyperplasia was evaluated for its genotoxic effects in the intact rat and in primary cultures of human hepatocytes", "triple_list": [["Flutamide", "ANTAGONIST", "inhibitor"]]}, {"text": "N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of  phenylalanine hydroxylase :  N(5)-methyl   and N(5)-hydroxymethyl H(4)biopterin inhibited  phenylalanine hydroxylase   whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect", "triple_list": [["N(5)-methyl", "PRODUCT-OF", "phenylalanine"]]}, {"text": "N(5)-Substituted H(4)biopterin derivatives were not oxidized to products serving as substrates for dihydropteridine reductase and,depending on the substituent, were competitive inhibitors of  phenylalanine hydroxylase : N(5)-methyl- and  N(5)-hydroxymethyl H(4)biopterin  inhibited  phenylalanine hydroxylase   whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect", "triple_list": [[":", "AGONIST", "phenylalanine hydroxylase"]]}, {"text": "Our data demonstrate differences in the mechanism of stimulation of  phenylalanine hydroxylase  and nitric oxide synthase by  H(4)biopterin   They are compatible with a novel, non-classical, redox-active contribution of  H(4)biopterin  to the catalysis of the nitric oxide synthase reaction.", "triple_list": [["H(4)biopterin", "PRODUCT-OF", "phenylalanine hydroxylase"]]}, {"text": " N(5)-Substituted H(4)biopterin  derivatives were not oxidized to products serving as substrates for  dihydropteridine reductase  and,depending on the substituent, were competitive inhibitors of phenylalanine hydroxylase: N(5)-methyl- and N(5)-hydroxymethyl H(4)biopterin inhibited phenylalanine hydroxylase, whereas N(5)-formyl- and N(5)-acetyl H(4)biopterin had no effect", "triple_list": [["no", "AGONIST", "dihydropteridine reductase"]]}, {"text": "In this study, we examined whether  betaxolol  and other  beta-adrenoceptor  antagonists interact directly with neurotoxin binding to sites 1 and 2 of the voltage-sensitive sodium channel (Na(+) channel) in rat cerebrocortical synaptosomes", "triple_list": [["binding", "DOWNREGULATOR", "beta-adrenoceptor"]]}, {"text": " Betaxolol   a  beta(1)-adrenoceptor  antagonist used for the treatment of glaucoma, is known to be neuroprotective in paradigms of ischaemia/excitotoxicity", "triple_list": [["of", "AGONIST", "beta(1)-adrenoceptor"]]}, {"text": "Comparison of all the  beta-adrenoceptor  antagonists tested revealed a potency order of  propranolol  betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=timolol>atenolol", "triple_list": [["propranolol", "ACTIVATOR", "a"]]}, {"text": "Comparison of all the  beta-adrenoceptor  antagonists tested revealed a potency order of propranolol> betaxolol  approximately levo betaxolol >levobunolol approximately carteolol>/=timolol>atenolol", "triple_list": [["betaxolol", "PRODUCT-OF", "antagonists"]]}, {"text": "Comparison of all the  beta-adrenoceptor  antagonists tested revealed a potency order of propranolol>betaxolol approximately  levobetaxolol  levobunolol approximately carteolol>/=timolol>atenolol", "triple_list": [["levobetaxolol", "AGONIST", "all"]]}, {"text": "Comparison of all the  beta-adrenoceptor  antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol> levobunolol  approximately carteolol>/=timolol>atenolol", "triple_list": [["order", "PRODUCT-OF", "beta-adrenoceptor"]]}, {"text": "Comparison of all the  beta-adrenoceptor  antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately  carteolol  /=timolol>atenolol", "triple_list": [["carteolol", "PRODUCT-OF", "beta-adrenoceptor"]]}, {"text": "Comparison of all the  beta-adrenoceptor  antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/= timolol  atenolol", "triple_list": [["approximately", "ACTIVATOR", "beta-adrenoceptor"]]}, {"text": "Comparison of all the  beta-adrenoceptor  antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=timolol> atenolol   None of the drugs caused a significant inhibition of [(3)H]-saxitoxin binding to neurotoxin receptor site 1, even at concentrations as high as 250 microM", "triple_list": [["atenolol", "DOWNREGULATOR", "at"]]}, {"text": " Betaxolol   a  beta(1)-adrenoceptor  antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists", "triple_list": [["Betaxolol", "PRODUCT-OF", "beta(1)-adrenoceptor"]]}, {"text": " Betaxolol   a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other  beta-adrenoceptor  antagonists", "triple_list": [["Betaxolol", "PRODUCT-OF", "Na(+)"]]}, {"text": "5-Fluorouracil ( 5-FU  , 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of  thymidylate synthase  (TS)", "triple_list": [["5-FU", "ACTIVATOR", "DNA"]]}, {"text": "5-Fluorouracil ( 5-FU  , 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase ( TS  ", "triple_list": [["5-FU", "AGONIST", "("]]}, {"text": " 5-Fluorouracil  (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of  thymidylate synthase  (TS)", "triple_list": [["5-Fluorouracil", "PRODUCT-OF", "are"]]}, {"text": " 5-Fluorouracil  (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase ( TS  ", "triple_list": [["are", "AGONIST", "TS"]]}, {"text": "When DLD-1/FdUrd cells expressing increased  TS  mRNA were treated with FdUrd and  F3(d)Thd  for only 4 h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were markedly different for FdUrd and  F3(d)Thd , suggesting that the cytotoxicity with short-time exposure to  F3(d)Thd  is due to a mechanism other than  TS  inhibition, although the cytotoxicity of  F3(d)Thd  in the short-time is low compared to that of long-time exposure", "triple_list": [["cells", "ANTAGONIST", "TS"]]}, {"text": "In conclusion,  F3(d)Thd   an antimetabolite that inhibits  TS  activity, may be effective against 5-FU and/or FdUrd-resistance in colorectal cancer cells caused by amplification of  TS  and/or deletion of orotate phosphoribosyltransferase.", "triple_list": [["F3(d)Thd", "PRODUCT-OF", "TS"]]}, {"text": "5-Fluorouracil (5-FU),  5-fluoro-2'-deoxyuridine  (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of  thymidylate synthase  (TS)", "triple_list": [["thymidylate", "ACTIVATOR", "thymidylate synthase"]]}, {"text": "5-Fluorouracil (5-FU),  5-fluoro-2'-deoxyuridine  (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase ( TS  ", "triple_list": [["5-fluoro-2'-deoxyuridine", "AGONIST", "metabolized"]]}, {"text": "5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine ( FdUrd   and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of  thymidylate synthase  (TS)", "triple_list": [["FdUrd", "ANTAGONIST", "DNA"]]}, {"text": "5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine ( FdUrd   and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase ( TS  ", "triple_list": [["which", "PRODUCT-OF", "TS"]]}, {"text": "5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and  5-trifluorothymidine  (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of  thymidylate synthase  (TS)", "triple_list": [["synthase", "AGONIST", "thymidylate synthase"]]}, {"text": "5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and  5-trifluorothymidine  (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase ( TS  ", "triple_list": [["5-trifluorothymidine", "ANTAGONIST", "5-Fluorouracil"]]}, {"text": "5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine ( F3(d)Thd   are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of  thymidylate synthase  (TS)", "triple_list": [["F3(d)Thd", "AGONIST", "F3(d)Thd"]]}, {"text": "5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine ( F3(d)Thd   are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase ( TS  ", "triple_list": [["(", "ANTAGONIST", "TS"]]}, {"text": "Stereochemical studies established that  PAM  inactivation by  4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid  is stereospecific with respect to the moiety at the P(2) position, which is consistent with previous results with substrates and reversible inhibitors", "triple_list": [["PAM", "AGONIST", "PAM"]]}, {"text": "In contrast,  2, 4-dioxo-5-acetamido-6-phenylhexanoic acid   which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both  PAM  and dopamine-beta-hydroxylase.", "triple_list": [["in", "ACTIVATOR", "PAM"]]}, {"text": "In contrast,  2, 4-dioxo-5-acetamido-6-phenylhexanoic acid   which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both PAM and  dopamine-beta-hydroxylase  ", "triple_list": [["2, 4-dioxo-5-acetamido-6-phenylhexanoic acid", "ACTIVATOR", "both"]]}, {"text": "Kinetic parameters for  PAM  inactivation by  4-oxo-5-acetamido-6-phenyl-hex-2-enoic acid and 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid  were obtained by using both the conventional dilution assay method and the more complex progress curve method", "triple_list": [["for", "PRODUCT-OF", "PAM"]]}, {"text": "Endogenously produced asymmetrically methylated  arginine  residues are competitive inhibitors of all three isoforms of  nitric oxide synthase  (NOS)", "triple_list": [["residues", "PRODUCT-OF", "nitric oxide synthase"]]}, {"text": "Endogenously produced asymmetrically methylated  arginine  residues are competitive inhibitors of all three isoforms of nitric oxide synthase ( NOS  ", "triple_list": [["arginine", "ACTIVATOR", "Endogenously"]]}, {"text": "The enzyme dimethyl arginine  dimethylaminohydrolase (DDAH) specifically hydrolyzes these asymmetrically methylated  arginine  residues to citrulline and methylamines", "triple_list": [["residues", "ACTIVATOR", "dimethylarginine dimethylaminohydrolase"]]}, {"text": "The enzyme dimethyl arginine  dimethylaminohydrolase ( DDAH   specifically hydrolyzes these asymmetrically methylated  arginine  residues to citrulline and methylamines", "triple_list": [["arginine", "AGONIST", "hydrolyzes"]]}, {"text": "Previously we have proposed that regulation of asymmetric  methylarginine  concentration by  DDAH  may provide a novel mechanism for the regulation of NOS activity in vivo", "triple_list": [["the", "ACTIVATOR", "DDAH"]]}, {"text": "Experimental cystathioninuria was induced in rats by administration of the  cystathionine gamma-lyase  inhibitor,  D,L-propargylglycine   The cystathionine metabolites, cystathionine ketimine (CK) and perhydro-1,4-thiazepine-3,5-dicarboxylic acid (PHTZDC), were identified in whole brain and various regions of the brain in  D,L-propargylglycine -treated rats", "triple_list": [["D,L-propargylglycine", "AGONIST", "cystathionine"]]}, {"text": "A prerequisite for this hypothesis was the unproved assumption that rabbit and human  alpha(2A)-adrenoceptors  are equally activated by  rilmenidine   Because  alpha(2A)-adrenoceptors  in the brain and on cardiovascular sympathetic nerve terminals are identical, the latter were used as a model for the former to confirm or disprove this assumption", "triple_list": [["by", "PRODUCT-OF", "alpha(2A)-adrenoceptors"]]}, {"text": "On the basis of data obtained in rabbits, the imidazoline receptor ligand  rilmenidine  has been suggested to decrease blood pressure in humans by activating central  alpha(2A)-adrenoceptors   A prerequisite for this hypothesis was the unproved assumption that rabbit and human  alpha(2A)-adrenoceptors  are equally activated by  rilmenidine ", "triple_list": [["rilmenidine", "DOWNREGULATOR", "data"]]}, {"text": "Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of  alpha(2)-adrenoceptor  agonists in inhibiting the electrically (2 Hz) evoked [(3)H]norepinephrine release and of antagonists in counteracting the  alpha(2)-adrenoceptor  mediated inhibition induced by  moxonidine   In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the alpha(2)-autoreceptors, sharing this property with rauwolscine, phentolamine, and idazoxan", "triple_list": [["moxonidine", "AGONIST", "sharing"]]}, {"text": "The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with  alpha(2A)-autoreceptors   at which, however, both rilmenidine and  oxymetazoline  exhibit different properties (antagonism and agonism, respectively)", "triple_list": [["oxymetazoline", "ACTIVATOR", "artery"]]}, {"text": "In the rabbit pulmonary artery,  rilmenidine  and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the  alpha(2)-autoreceptors   sharing this property with rauwolscine, phentolamine, and idazoxan", "triple_list": [["agonists,", "ACTIVATOR", "alpha(2)-autoreceptors"]]}, {"text": "In the rabbit pulmonary artery, rilmenidine and  oxymetazoline  are potent full agonists, whereas in the human atrial appendages they are antagonists at the  alpha(2)-autoreceptors   sharing this property with rauwolscine, phentolamine, and idazoxan", "triple_list": [["pulmonary", "ACTIVATOR", "alpha(2)-autoreceptors"]]}, {"text": "In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the  alpha(2)-autoreceptors   sharing this property with  rauwolscine   phentolamine, and idazoxan", "triple_list": [["rauwolscine", "AGONIST", "potent"]]}, {"text": "In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the  alpha(2)-autoreceptors   sharing this property with rauwolscine,  phentolamine   and idazoxan", "triple_list": [["human", "DOWNREGULATOR", "alpha(2)-autoreceptors"]]}, {"text": "In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the  alpha(2)-autoreceptors   sharing this property with rauwolscine, phentolamine, and  idazoxan   In contrast, prazosin is ineffective", "triple_list": [["idazoxan", "ACTIVATOR", "at"]]}, {"text": "The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with  alpha(2A)-autoreceptors   at which, however, both  rilmenidine  and oxymetazoline exhibit different properties (antagonism and agonism, respectively)", "triple_list": [["artery", "DOWNREGULATOR", "alpha(2A)-autoreceptors"]]}, {"text": "The antagonistic property of  rilmenidine  at  human alpha(2A)-adrenoceptors  indicates that in contrast to the suggestion based on rabbit data, the hypotensive property of the drug in humans is not due to activation of alpha(2A)-adrenoceptors but other, presumably I(1)-imidazoline receptors, are probably involved.", "triple_list": [["in", "ACTIVATOR", "human alpha(2A)-adrenoceptors"]]}, {"text": " U50, 488H  caused a significant down-regulation of the  hkor   although etorphine did not", "triple_list": [["caused", "PRODUCT-OF", "hkor"]]}, {"text": "Expression of the dominant negative mutants arrestin-2(319-418) or dynamin I-K44A significantly reduced  U50,488H  induced down-regulation of the  hkor   Coexpression of GRK2 or GRK2 and arrestin-2 permitted etorphine to induce down-regulation of the  hkor , although expression of arrestin-2 or dynamin I alone did not", "triple_list": [["U50,488H", "ANTAGONIST", "Coexpression"]]}, {"text": "Coexpression of GRK2 or GRK2 and arrestin-2 permitted  etorphine  to induce down-regulation of the  hkor   although expression of arrestin-2 or dynamin I alone did not", "triple_list": [["I", "ACTIVATOR", "hkor"]]}, {"text": "Expression of the dominant negative mutants  rab5A  N133I or rab7-N125I blunted  U50,488H  induced down-regulation", "triple_list": [["U50,488H", "AGONIST", "blunted"]]}, {"text": "Expression of the dominant negative mutants rab5A- N133I  or rab7-N125I blunted  U50,488H  induced down-regulation", "triple_list": [["negative", "AGONIST", "N133I"]]}, {"text": "Expression of the dominant negative mutants rab5A-N133I or  rab7  N125I blunted  U50,488H  induced down-regulation", "triple_list": [["negative", "ANTAGONIST", "rab7"]]}, {"text": "Expression of the dominant negative mutants rab5A-N133I or rab7- N125I  blunted  U50,488H  induced down-regulation", "triple_list": [["dominant", "ANTAGONIST", "N125I"]]}, {"text": "Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or  proteasome  inhibitors ( proteasome  inhibitor I,  MG-132   or lactacystin) decreased the extent of U50,488H-induced down-regulation", "triple_list": [["MG-132", "ANTAGONIST", "inhibitor"]]}, {"text": "Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or  proteasome  inhibitors ( proteasome  inhibitor I, MG-132, or  lactacystin   decreased the extent of U50,488H-induced down-regulation", "triple_list": [["lactacystin", "ACTIVATOR", "extent"]]}, {"text": "These results indicate that  U50,488H  induced down-regulation of the  hkor  involves GRK-, arrestin-2-, dynamin-, rab5-, and rab7-dependent mechanisms and receptors seem to be trafficked to lysosomes and proteasomes for degradation", "triple_list": [["indicate", "ACTIVATOR", "hkor"]]}, {"text": "Thus,  U50,488H  induced internalization and down-regulation of the  hkor  share initial common mechanisms", "triple_list": [["U50,488H", "ANTAGONIST", "hkor"]]}, {"text": "Previously, we showed that the  human kappa-opioid receptor  (hkor) stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged  U50,488H  treatment", "triple_list": [["U50,488H", "ACTIVATOR", "down-regulation"]]}, {"text": "Previously, we showed that the human kappa-opioid receptor ( hkor   stably expressed in Chinese hamster ovary (CHO) cells underwent down-regulation after prolonged  U50,488H  treatment", "triple_list": [["human", "ANTAGONIST", "hkor"]]}, {"text": "The  BH(4)  treatment was associated with a 2-fold increase in  eNOS  activity as well as a 70% reduction in endothelial O(2)(-) production compared with those in fructose-fed rats", "triple_list": [["rats", "AGONIST", "eNOS"]]}, {"text": "The  BH(4)  treatment also partially improved the  insulin  sensitivity and blood pressure, as well as the serum triglyceride concentration, in the fructose-fed rats", "triple_list": [["BH(4)", "ANTAGONIST", "insulin"]]}, {"text": "Moreover, BH(4) treatment of the  fructose  fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors,  nuclear factor-kappaB  and activating protein-1, which were increased in  fructose -fed rats", "triple_list": [["fructose", "AGONIST", "activating"]]}, {"text": "Moreover, BH(4) treatment of the  fructose  fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and  activating protein-1   which were increased in  fructose -fed rats", "triple_list": [["fructose", "PRODUCT-OF", "redox-sensitive"]]}, {"text": "Moreover, BH(4) treatment of the  fructose -fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors,  nuclear factor-kappaB  and activating protein-1, which were increased in  fructose  fed rats", "triple_list": [["aortic", "ANTAGONIST", "nuclear factor-kappaB"]]}, {"text": "Moreover, BH(4) treatment of the  fructose -fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and  activating protein-1   which were increased in  fructose  fed rats", "triple_list": [["fructose", "PRODUCT-OF", "transcription"]]}, {"text": "Moreover,  BH(4)  treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors,  nuclear factor-kappaB  and activating protein-1, which were increased in fructose-fed rats", "triple_list": [["BH(4)", "AGONIST", "fructose-fed"]]}, {"text": "Moreover,  BH(4)  treatment of the fructose-fed rats markedly reduced the lipid peroxide content of both aortic and cardiac tissues and inhibited the activation of 2 redox-sensitive transcription factors, nuclear factor-kappaB and  activating protein-1   which were increased in fructose-fed rats", "triple_list": [["BH(4)", "ACTIVATOR", "of"]]}, {"text": "Fumarate reductase ( FRD   is the key enzyme in  fumarate  respiration induced by anaerobic growth of bacteria", "triple_list": [["fumarate", "ACTIVATOR", "of"]]}, {"text": " Fumarate reductase  (FRD) is the key enzyme in  fumarate  respiration induced by anaerobic growth of bacteria", "triple_list": [["fumarate", "AGONIST", "is"]]}, {"text": "The frdA gene coding for subunit A of FRD, and two control genes,  copA  and copP associated with the export of  copper  out of H", "triple_list": [["copper", "AGONIST", "associated"]]}, {"text": "The frdA gene coding for subunit A of FRD, and two control genes, copA and  copP  associated with the export of  copper  out of H", "triple_list": [["frdA", "ANTAGONIST", "copP"]]}, {"text": "METHODS: Part A compared the effects of placebo to four doses of a  5-HT(4)  receptor antagonist (SB-207266) on the  cisapride  mediated increase in plasma aldosterone (a  5-HT(4)  mediated response) and orocaecal transit in 18 subjects", "triple_list": [["(SB-207266)", "ANTAGONIST", "5-HT(4)"]]}, {"text": "Effects of a  serotonin 5-HT(4) receptor  antagonist  SB-207266  on gastrointestinal motor and sensory function in humans", "triple_list": [["serotonin", "DOWNREGULATOR", "serotonin 5-HT(4) receptor"]]}, {"text": "METHODS: Part A compared the effects of placebo to four doses of a  5-HT(4)  receptor antagonist ( SB-207266   on the cisapride mediated increase in plasma aldosterone (a  5-HT(4)  mediated response) and orocaecal transit in 18 subjects", "triple_list": [["of", "AGONIST", "5-HT(4)"]]}, {"text": "METHODS: Part A compared the effects of placebo to four doses of a  5-HT(4)  receptor antagonist ( SB-207266   on the cisapride mediated increase in plasma aldosterone (a  5-HT(4)  mediated response) and orocaecal transit in 18 subjects", "triple_list": [["SB-207266", "ACTIVATOR", "the"]]}, {"text": "Moreover,  IGFBP-rP2  noticeably increased in response to TGF-beta1 and  all-trans retinoic acid  (atRA) in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC", "triple_list": [["(atRA)", "AGONIST", "IGFBP-rP2"]]}, {"text": "Moreover,  IGFBP-rP2  noticeably increased in response to TGF-beta1 and all-trans retinoic acid ( atRA   in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC", "triple_list": [["atRA", "DOWNREGULATOR", "HPEC"]]}, {"text": "Although the data collected on  IGFBP-rP3  in prostate are modest, its role as a growth stimulator and/or protooncogene is supported by its preferential expression in cancerous cells and its down-regulation by  atRA  ", "triple_list": [["as", "ANTAGONIST", "IGFBP-rP3"]]}, {"text": "Activation of endogenous  somatostatin receptor subtype 2  (sst2) by  somatostatin-14  or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect", "triple_list": [["no", "PRODUCT-OF", "somatostatin receptor subtype 2"]]}, {"text": "Activation of endogenous somatostatin receptor subtype 2 ( sst2   by  somatostatin-14  or activation of transiently transfected rat D2 dopamine receptors (rD2(long)) by quinpirole had no effect", "triple_list": [["sst2", "ANTAGONIST", "sst2"]]}, {"text": "Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected  rat D2 dopamine receptors  (rD2(long)) by  quinpirole  had no effect", "triple_list": [["quinpirole", "AGONIST", "rat"]]}, {"text": "Activation of endogenous somatostatin receptor subtype 2 (sst2) by somatostatin-14 or activation of transiently transfected rat D2 dopamine receptors ( rD2  long)) by  quinpirole  had no effect", "triple_list": [["dopamine", "PRODUCT-OF", "rD2"]]}, {"text": "In contrast, in the same system,  N  type currents, formed from transiently transfected alpha(1B)/alpha(2)delta-1/beta(3), showed strong  G-protein  mediated inhibition", "triple_list": [["contrast,", "ANTAGONIST", "G-protein"]]}, {"text": "High  p53  protein levels, but not genetic or functional  p53  status, were associated with increased  topotecan  induced DNA/topoisomerase I complex formation", "triple_list": [["topotecan", "DOWNREGULATOR", "not"]]}, {"text": " Topotecan  is a  topoisomerase I  inhibitor which is currently evaluated as an adjuvant agent for malignant glioma", "triple_list": [["is", "PRODUCT-OF", "topoisomerase I"]]}, {"text": " Pranlukast  is a new, orally active, selective inhibitor of  CysLt1  leukotriene receptor", "triple_list": [["Pranlukast", "AGONIST", "CysLt1"]]}, {"text": " Pranlukast  is a new, orally active, selective inhibitor of CysLt1  leukotriene receptor   The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma", "triple_list": [["in", "ACTIVATOR", "leukotriene receptor"]]}, {"text": "Clinical effects of  pranlukast   an oral  leukotriene receptor  antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial", "triple_list": [["pranlukast", "AGONIST", "a"]]}, {"text": "In addition, ADP was shown to strongly antagonize  TOP2  mediated DNA cleavage induced by  ATP  sensitive but not  ATP -insensitive  TOP2  poisons", "triple_list": [["ATP", "ANTAGONIST", "TOP2"]]}, {"text": "Second, C427A mutant human TOP2alpha, which exhibits reduced  ATP ase activity, was shown to exhibit cross-resistance to all  ATP -sensitive but not  ATP  insensitive TOP2 poisons", "triple_list": [["ATP", "ACTIVATOR", "ATP"]]}, {"text": "In contrast, in the presence of  Ca  UFH accelerated the inhibition of  factor Xa  by antithrombin 10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin", "triple_list": [["the", "ANTAGONIST", "factor Xa"]]}, {"text": "In contrast, in the presence of  Ca  UFH accelerated the inhibition of factor Xa by  antithrombin  10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin", "triple_list": [["more", "AGONIST", "antithrombin"]]}, {"text": " Follicle-stimulating hormone  (FSH), a dimeric glycoprotein synthesized in the anterior pituitary gland, is important for the production of sex  steroids  and gametes", "triple_list": [["steroids", "AGONIST", "gland,"]]}, {"text": "Follicle-stimulating hormone ( FSH  , a dimeric glycoprotein synthesized in the anterior pituitary gland, is important for the production of sex  steroids  and gametes", "triple_list": [["steroids", "ANTAGONIST", "pituitary"]]}, {"text": "Humans with  FSH beta  gene mutations tend to have a more severe phenotype than those with FSHR gene mutations, although infertility and varying degrees of impaired sex  steroid  production occur in both types of mutations", "triple_list": [["Humans", "ANTAGONIST", "FSH beta"]]}, {"text": "Re-feeding normal chow or a high  sucrose  diet for 24 h after a 48-h fast increased both  ACS1  and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies", "triple_list": [["sucrose", "PRODUCT-OF", "a"]]}, {"text": "Re-feeding normal chow or a high  sucrose  diet for 24 h after a 48-h fast increased both ACS1 and  ACS4  protein expression 1.5-2.0-fold, consistent with inhibition studies", "triple_list": [["protein", "AGONIST", "ACS4"]]}, {"text": "Consistent with these locations,  N-ethylmaleimide   an inhibitor of  ACS4   inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum", "triple_list": [["N-ethylmaleimide", "PRODUCT-OF", "MAM"]]}, {"text": "Consistent with these locations,  N-ethylmaleimide   an inhibitor of  ACS 4, inhibited  ACS  activity 47% in MAM and 28% in endoplasmic reticulum", "triple_list": [["inhibited", "ACTIVATOR", "ACS"]]}, {"text": " Troglitazone   a second  ACS4  inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM", "triple_list": [["<10%", "ACTIVATOR", "ACS4"]]}, {"text": " Troglitazone   a second  ACS 4 inhibitor, inhibited  ACS  activity <10% in microsomes and mitochondria and 45% in MAM", "triple_list": [["Troglitazone", "PRODUCT-OF", "activity"]]}, {"text": " Triacsin C   a competitive inhibitor of both  ACS1  and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria", "triple_list": [["inhibitor", "ACTIVATOR", "ACS1"]]}, {"text": " Triacsin C   a competitive inhibitor of both ACS1 and  ACS4   inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria", "triple_list": [["hitherto", "PRODUCT-OF", "ACS4"]]}, {"text": " Triacsin C   a competitive inhibitor of both  ACS 1 and  ACS 4, inhibited  ACS  activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive  ACS  is present in mitochondria", "triple_list": [["and", "ACTIVATOR", "ACS"]]}, {"text": "These results suggest that  ACS1  and ACS4 may be linked to  triacylglycerol  synthesis", "triple_list": [["linked", "DOWNREGULATOR", "ACS1"]]}, {"text": "These results suggest that ACS1 and  ACS4  may be linked to  triacylglycerol  synthesis", "triple_list": [["triacylglycerol", "ACTIVATOR", "triacylglycerol"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium>neostigmine=physostigmine =tacrine> pyridostigmine  edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["pyridostigmine", "ACTIVATOR", "Moreover,"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium>neostigmine=physostigmine =tacrine> pyridostigmine  edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["pyridostigmine", "PRODUCT-OF", "greatest"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine= edrophonium  galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["edrophonium", "ANTAGONIST", "potency"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine= edrophonium  galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["Moreover,", "PRODUCT-OF", "acetylcholinesterase"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium= galanthamine  >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["[3H]-oxotremorine-M", "AGONIST", "acetylcholinesterase"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium= galanthamine  >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["galanthamine", "ACTIVATOR", "indicated"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine > desoxypeganine  parathion>gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["desoxypeganine", "AGONIST", "(ambenonium>neostigmine=physostigmine"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine > desoxypeganine  parathion>gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["desoxypeganine", "ACTIVATOR", "potency"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine> parathion  gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["parathion", "ANTAGONIST", "=tacrine>pyridostigmine=edrophonium=galanthamine"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine> parathion  gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["order", "ACTIVATOR", "acetylcholinesterase"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion> gramine   indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [[">desoxypeganine>parathion>", "ANTAGONIST", "acetylcholinesterase"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion> gramine   indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["gramine", "ACTIVATOR", "to"]]}, {"text": "The capacity of  acetylcholinesterase  inhibitors, with the exception of  tacrine  and ambenonium, to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors", "triple_list": [["tacrine", "AGONIST", "benzilate"]]}, {"text": "The capacity of  acetylcholinesterase  inhibitors, with the exception of tacrine and  ambenonium   to displace bound [3H]-oxotremorine-M in preference to [3H]quinuclinidyl benzilate predicts that the former compounds could act as potential agonists at muscarinic receptors", "triple_list": [["tacrine", "ANTAGONIST", "acetylcholinesterase"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  ( ambenonium  neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["ambenonium", "AGONIST", "Moreover,"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  ( ambenonium  neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["indicated", "PRODUCT-OF", "acetylcholinesterase"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium> neostigmine  physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["the", "ANTAGONIST", "acetylcholinesterase"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium> neostigmine  physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["neostigmine", "ANTAGONIST", "=tacrine>pyridostigmine=edrophonium=galanthamine"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium>neostigmine= physostigmine  =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["physostigmine", "ACTIVATOR", "in"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium>neostigmine= physostigmine  =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["the", "ANTAGONIST", "acetylcholinesterase"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium>neostigmine=physostigmine = tacrine  pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["the", "ANTAGONIST", "acetylcholinesterase"]]}, {"text": "Moreover, the rank order for potency in inhibiting  acetylcholinesterase  (ambenonium>neostigmine=physostigmine = tacrine  pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of  acetylcholinesterase  also displaced [3H]-oxotremorine-M to the greatest extent", "triple_list": [["order", "PRODUCT-OF", "acetylcholinesterase"]]}, {"text": " Carvedilol  reduced the risk of death or heart failure in patients with above-median levels of  N-BNP  or adrenomedullin, or both, to rates not significantly different from those observed in patients with levels below the median value", "triple_list": [["not", "ACTIVATOR", "N-BNP"]]}, {"text": " Carvedilol  reduced the risk of death or heart failure in patients with above-median levels of N-BNP or  adrenomedullin   or both, to rates not significantly different from those observed in patients with levels below the median value", "triple_list": [["both,", "AGONIST", "adrenomedullin"]]}, {"text": " Carvedilol  reduced mortality and heart failure in patients with higher pre-treatment plasma  N-BNP  and adrenomedullin.", "triple_list": [["Carvedilol", "PRODUCT-OF", "and"]]}, {"text": " Carvedilol  reduced mortality and heart failure in patients with higher pre-treatment plasma N-BNP and  adrenomedullin  ", "triple_list": [["and", "AGONIST", "adrenomedullin"]]}, {"text": " Indomethacin  completely antagonizes  CA  activity, i.e", "triple_list": [["Indomethacin", "AGONIST", "antagonizes"]]}, {"text": " Indomethacin  activates  carbonic anhydrase  and antagonizes the effect of the specific  carbonic anhydrase  inhibitor acetazolamide, by a direct mechanism of action", "triple_list": [["Indomethacin", "ANTAGONIST", "of"]]}, {"text": " Indomethacin  activates  carbonic anhydrase  and antagonizes the effect of the specific  carbonic anhydrase  inhibitor acetazolamide, by a direct mechanism of action", "triple_list": [["Indomethacin", "PRODUCT-OF", "the"]]}, {"text": "CONCLUSIONS: Our results show that  indomethacin   a known cyclooxygenase (COX) inhibitor, is also an activator of  CA   Our data also prove that  indomethacin  is not only an activator of  CA  but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme", "triple_list": [["indomethacin", "PRODUCT-OF", "this"]]}, {"text": "Our data also prove that  indomethacin  is not only an activator of  CA  but also antagonizes the effect of acetazolamide, a specific inhibitor of this enzyme", "triple_list": [["of", "ANTAGONIST", "CA"]]}, {"text": "In view of the role of  CA  in acid-base balance as well as the fact that an increase or decrease in its activity is accompanied by an increase or decrease in intra- and extracellular pH, our results suggest that: firstly,  CA  activation induced by  indomethacin  might cause changes in COX activity; secondly, PGs are synthetized as a consequence of the changes in COX activity, a hypothesis that requires further study.", "triple_list": [["In", "AGONIST", "CA"]]}, {"text": " Acetazolamide   a specific inhibitor of  CA   reduces the activity of  CA  I and  CA  II from red cells", "triple_list": [["Acetazolamide", "AGONIST", "from"]]}, {"text": " Acetazolamide   a specific inhibitor of CA, reduces the activity of  CA I  and  CA I I from red cells", "triple_list": [["from", "PRODUCT-OF", "CA I"]]}, {"text": " Acetazolamide   a specific inhibitor of CA, reduces the activity of CA I and  CA II  from red cells", "triple_list": [["Acetazolamide", "PRODUCT-OF", "Acetazolamide"]]}, {"text": "abolishes the inhibitory effect of  acetazolamide  on  CA   In humans, an increase or decrease in erythrocyte  CA  II activity is correlated with an increase or decrease in gastric acid secretion", "triple_list": [["acetazolamide", "PRODUCT-OF", "increase"]]}, {"text": "Indomethacin activates  carbonic anhydrase  and antagonizes the effect of the specific  carbonic anhydrase  inhibitor  acetazolamide   by a direct mechanism of action", "triple_list": [["acetazolamide", "ACTIVATOR", "a"]]}, {"text": "Indomethacin activates  carbonic anhydrase  and antagonizes the effect of the specific  carbonic anhydrase  inhibitor  acetazolamide   by a direct mechanism of action", "triple_list": [["direct", "PRODUCT-OF", "carbonic anhydrase"]]}, {"text": "CONCLUSIONS: Our results show that  indomethacin   a known  cyclooxygenase  (COX) inhibitor, is also an activator of CA", "triple_list": [["known", "ACTIVATOR", "cyclooxygenase"]]}, {"text": "CONCLUSIONS: Our results show that  indomethacin   a known cyclooxygenase ( COX   inhibitor, is also an activator of CA", "triple_list": [["also", "ACTIVATOR", "COX"]]}, {"text": "Our data also prove that indomethacin is not only an activator of  CA  but also antagonizes the effect of  acetazolamide   a specific inhibitor of this enzyme", "triple_list": [["but", "ANTAGONIST", "CA"]]}, {"text": "The antipsychotic drugs  sertindole  and pimozide block  erg3   a human brain K(+) channel", "triple_list": [["sertindole", "AGONIST", "erg3"]]}, {"text": "The antipsychotic drugs  sertindole  and pimozide block erg3, a  human brain K(+) channel   The antipsychotic drugs  sertindole  and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; erg1)", "triple_list": [["sertindole", "ANTAGONIST", "interval"]]}, {"text": "The antipsychotic drugs sertindole and  pimozide  block  erg3   a human brain K(+) channel", "triple_list": [["pimozide", "PRODUCT-OF", "channel"]]}, {"text": "The antipsychotic drugs sertindole and  pimozide  block erg3, a  human brain K(+) channel   The antipsychotic drugs sertindole and  pimozide  are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; erg1)", "triple_list": [["pimozide", "AGONIST", "channel"]]}, {"text": "Block of  erg3  by  sertindole  also displayed a positive voltage-dependence", "triple_list": [["sertindole", "ANTAGONIST", "voltage-dependence"]]}, {"text": " Pimozide  blocked  erg3  channel currents with an IC(50) of 103 nM and significant inhibition was noted at concentrations of 10 nM and higher", "triple_list": [["significant", "AGONIST", "erg3"]]}, {"text": "We conclude that  erg3  can be blocked by certain antipsychotic drugs like  sertindole  and pimozide", "triple_list": [["sertindole", "PRODUCT-OF", "by"]]}, {"text": "We conclude that  erg3  can be blocked by certain antipsychotic drugs like sertindole and  pimozide   Inhibition of  erg3  or related K(+) channels in the brain may contribute to the efficacy/side effect profiles of some antipsychotic drugs.", "triple_list": [["efficacy/side", "ANTAGONIST", "erg3"]]}, {"text": "The antipsychotic drugs  sertindole  and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the  cardiac K(+) channel  known as HERG (human ether-a-go-go-related gene; erg1)", "triple_list": [["the", "AGONIST", "cardiac K(+) channel"]]}, {"text": "The antipsychotic drugs  sertindole  and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as  HERG  (human ether-a-go-go-related gene; erg1)", "triple_list": [["sertindole", "PRODUCT-OF", "erg1)"]]}, {"text": "The antipsychotic drugs  sertindole  and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG ( human ether-a-go-go-related gene   erg1)", "triple_list": [["sertindole", "ACTIVATOR", "known"]]}, {"text": "The antipsychotic drugs  sertindole  and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene;  erg1  ", "triple_list": [["(human", "AGONIST", "erg1"]]}, {"text": "The antipsychotic drugs sertindole and  pimozide  are known to prolong the QT interval on the electrocardiogram via a high affinity block of the  cardiac K(+) channel  known as HERG (human ether-a-go-go-related gene; erg1)", "triple_list": [["(human", "ANTAGONIST", "cardiac K(+) channel"]]}, {"text": "The antipsychotic drugs sertindole and  pimozide  are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as  HERG  (human ether-a-go-go-related gene; erg1)", "triple_list": [["affinity", "PRODUCT-OF", "HERG"]]}, {"text": "The antipsychotic drugs sertindole and  pimozide  are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG ( human ether-a-go-go-related gene   erg1)", "triple_list": [["antipsychotic", "AGONIST", "human ether-a-go-go-related gene"]]}, {"text": "The antipsychotic drugs sertindole and  pimozide  are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene;  erg1  ", "triple_list": [["the", "ACTIVATOR", "erg1"]]}, {"text": " Amiloride  is a specific inhibitor of  uPA  but does not inhibit tPA", "triple_list": [["Amiloride", "PRODUCT-OF", "uPA"]]}, {"text": " ZD1839  (\"Iressa\"), a quinazoline  tyrosine kinase  inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials", "triple_list": [["ZD1839", "ACTIVATOR", "phase"]]}, {"text": " ZD1839  (\"Iressa\"), a quinazoline tyrosine kinase inhibitor selective for the  EGFR   has shown good activity in preclinical studies and in the early phase of clinical trials", "triple_list": [["for", "AGONIST", "EGFR"]]}, {"text": "ZD1839 (\" Iressa  ), a quinazoline  tyrosine kinase  inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials", "triple_list": [["preclinical", "AGONIST", "tyrosine kinase"]]}, {"text": "ZD1839 (\" Iressa  ), a quinazoline tyrosine kinase inhibitor selective for the  EGFR   has shown good activity in preclinical studies and in the early phase of clinical trials", "triple_list": [["the", "PRODUCT-OF", "EGFR"]]}, {"text": "The  tyrosine kinase  inhibitor  ZD1839  (\"Iressa\") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells", "triple_list": [["inhibits", "AGONIST", "tyrosine kinase"]]}, {"text": "The tyrosine kinase inhibitor  ZD1839  (\"Iressa\") inhibits  HER2  driven signaling and suppresses the growth of  HER2 -overexpressing tumor cells", "triple_list": [["of", "ANTAGONIST", "HER2"]]}, {"text": "The tyrosine kinase inhibitor ZD1839 (\" Iressa  ) inhibits  HER2 -driven signaling and suppresses the growth of  HER2  overexpressing tumor cells", "triple_list": [["Iressa", "ANTAGONIST", ")"]]}, {"text": "The  tyrosine kinase  inhibitor ZD1839 (\" Iressa  ) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells", "triple_list": [["suppresses", "PRODUCT-OF", "tyrosine kinase"]]}, {"text": "The tyrosine kinase inhibitor ZD1839 (\" Iressa  ) inhibits  HER2  driven signaling and suppresses the growth of  HER2 -overexpressing tumor cells", "triple_list": [["Iressa", "PRODUCT-OF", "ZD1839"]]}, {"text": "In an earlier report, DRD2 E8 A/A genotype was associated with reduced responsiveness to the  dopamine D2  agonist  apomorphine   however, it is not clear whether both findings share the same biological basis", "triple_list": [["apomorphine", "ANTAGONIST", "with"]]}, {"text": "Mitiglinide ( KAD-1229  , a new anti-diabetic drug, is thought to stimulate  insulin  secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells", "triple_list": [["to", "AGONIST", "insulin"]]}, {"text": " Mitiglinide  (KAD-1229), a new anti-diabetic drug, is thought to stimulate  insulin  secretion by closing the ATP-sensitive K+ (K(ATP)) channels in pancreatic beta-cells", "triple_list": [["stimulate", "AGONIST", "insulin"]]}, {"text": "Mitiglinide ( KAD-1229  , a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the  ATP-sensitive K+ (K(ATP)) channels  in pancreatic beta-cells", "triple_list": [["KAD-1229", "ACTIVATOR", "thought"]]}, {"text": " Mitiglinide  (KAD-1229), a new anti-diabetic drug, is thought to stimulate insulin secretion by closing the  ATP-sensitive K+ (K(ATP)) channels  in pancreatic beta-cells", "triple_list": [["anti-diabetic", "ACTIVATOR", "ATP-sensitive K+ (K(ATP)) channels"]]}, {"text": "Patch-clamp analysis using inside-out recording configuration showed that  mitiglinide  inhibits the  Kir6.2  SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either  Kir6.2 /SUR2A or  Kir6.2 /SUR2B channel currents even at high doses (more than 10 microM)", "triple_list": [["mitiglinide", "ANTAGONIST", "10"]]}, {"text": "Patch-clamp analysis using inside-out recording configuration showed that  mitiglinide  inhibits the Kir6.2/ SUR1  channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 microM)", "triple_list": [["mitiglinide", "PRODUCT-OF", "currents"]]}, {"text": " Nateglinide  inhibits  Kir6.2  SUR1 and  Kir6.2 /SUR2B channels at 100 nM, and inhibits  Kir6.2 /SUR2A channels at high concentrations (1 microM)", "triple_list": [["high", "ANTAGONIST", "Kir6.2"]]}, {"text": " Nateglinide  inhibits Kir6.2/ SUR1  and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM)", "triple_list": [["microM)", "ANTAGONIST", "SUR1"]]}, {"text": " Nateglinide  inhibits  Kir6.2 /SUR1 and  Kir6.2  SUR2B channels at 100 nM, and inhibits  Kir6.2 /SUR2A channels at high concentrations (1 microM)", "triple_list": [["Kir6.2", "ACTIVATOR", "Kir6.2"]]}, {"text": " Nateglinide  inhibits Kir6.2/SUR1 and Kir6.2/ SUR2B  channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM)", "triple_list": [["Nateglinide", "PRODUCT-OF", "nM,"]]}, {"text": " Nateglinide  inhibits  Kir6.2 /SUR1 and  Kir6.2 /SUR2B channels at 100 nM, and inhibits  Kir6.2  SUR2A channels at high concentrations (1 microM)", "triple_list": [["Nateglinide", "PRODUCT-OF", "Kir6.2"]]}, {"text": " Nateglinide  inhibits Kir6.2/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/ SUR2A  channels at high concentrations (1 microM)", "triple_list": [["microM)", "ANTAGONIST", "SUR2A"]]}, {"text": "These results indicate that, similar to the sulfonylureas,  mitiglinide  is highly specific to the Kir6.2/SUR1 complex, i.e., the pancreatic beta-cell  K(ATP) channel   and suggest that  mitiglinide  may be a clinically useful anti-diabetic drug.", "triple_list": [["Kir6.2/SUR1", "DOWNREGULATOR", "K(ATP) channel"]]}, {"text": "In the present study, we investigated the effect of  fenoterol  induced constitutive  beta(2)-adrenoceptor  activity on muscarinic receptor agonist- and histamine-induced bovine tracheal smooth muscle contractions", "triple_list": [["fenoterol", "ANTAGONIST", "smooth"]]}, {"text": "Effect of  fenoterol  induced constitutive  beta(2)-adrenoceptor  activity on contractile receptor function in airway smooth muscle", "triple_list": [["fenoterol", "ANTAGONIST", "smooth"]]}, {"text": "In conclusion,  fenoterol  induced constitutive  beta(2)-adrenoceptor  activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist timolol", "triple_list": [["fenoterol", "DOWNREGULATOR", "reduces"]]}, {"text": "After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full  muscarinic receptor  agonist methacholine, the partial  muscarinic receptor  agonist  4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium  (McN-A-343) and histamine", "triple_list": [["the", "PRODUCT-OF", "muscarinic receptor"]]}, {"text": "After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full  muscarinic receptor  agonist methacholine, the partial  muscarinic receptor  agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and  histamine   Fenoterol treatment significantly reduced the sensitivity (pEC(50)) to methacholine in a time-dependent manner, without affecting maximal contraction (E(max))", "triple_list": [["the", "ACTIVATOR", "muscarinic receptor"]]}, {"text": "In conclusion, fenoterol-induced constitutive  beta(2)-adrenoceptor  activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist  timolol   Moreover, after  beta(2)-adrenoceptor  agonist treatment, inverse agonism by beta-adrenoceptor antagonists may cause enhanced airway reactivity to contractile mediators.", "triple_list": [["smooth", "ACTIVATOR", "beta(2)-adrenoceptor"]]}, {"text": "After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full  muscarinic receptor  agonist  methacholine   the partial  muscarinic receptor  agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine", "triple_list": [["washout", "PRODUCT-OF", "muscarinic receptor"]]}, {"text": "The inhibition of  aminopeptidase  activity in the presence of  bestatin  and puromycin inhibitors was also investigated", "triple_list": [["in", "PRODUCT-OF", "aminopeptidase"]]}, {"text": "The inhibition of  aminopeptidase  activity in the presence of bestatin and  puromycin  inhibitors was also investigated", "triple_list": [["inhibitors", "PRODUCT-OF", "aminopeptidase"]]}, {"text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of  L-arginine  for  aminopeptidase B   The vaginal aminopeptidase enzymatic activity of different species was determined spectrofluorometrically", "triple_list": [["N,", "AGONIST", "aminopeptidase B"]]}, {"text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity:  4-methoxy-2-naphthylamide  of L-alanine for  aminopeptidase N    4-methoxy-2-naphthylamide  of L-leucine for leucine aminopeptidase,  4-methoxy-2-naphthylamide  of L-glutamic acid for aminopeptidase A and  4-methoxy-2-naphthylamide  of L-arginine for aminopeptidase B", "triple_list": [["4-methoxy-2-naphthylamide", "AGONIST", "aminopeptidase N"]]}, {"text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of  L-alanine  for  aminopeptidase N   4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B", "triple_list": [["L-alanine", "AGONIST", "of"]]}, {"text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity:  4-methoxy-2-naphthylamide  of L-alanine for aminopeptidase N,  4-methoxy-2-naphthylamide  of L-leucine for  leucine aminopeptidase    4-methoxy-2-naphthylamide  of L-glutamic acid for aminopeptidase A and  4-methoxy-2-naphthylamide  of L-arginine for aminopeptidase B", "triple_list": [["4-methoxy-2-naphthylamide", "DOWNREGULATOR", "L-arginine"]]}, {"text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of  L-leucine  for  leucine aminopeptidase   4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B", "triple_list": [["leucine", "ANTAGONIST", "leucine aminopeptidase"]]}, {"text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity:  4-methoxy-2-naphthylamide  of L-alanine for aminopeptidase N,  4-methoxy-2-naphthylamide  of L-leucine for leucine aminopeptidase,  4-methoxy-2-naphthylamide  of L-glutamic acid for  aminopeptidase A  and  4-methoxy-2-naphthylamide  of L-arginine for aminopeptidase B", "triple_list": [["of", "DOWNREGULATOR", "aminopeptidase A"]]}, {"text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of  L-glutamic acid  for  aminopeptidase A  and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B", "triple_list": [["L-arginine", "ANTAGONIST", "aminopeptidase A"]]}, {"text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity:  4-methoxy-2-naphthylamide  of L-alanine for aminopeptidase N,  4-methoxy-2-naphthylamide  of L-leucine for leucine aminopeptidase,  4-methoxy-2-naphthylamide  of L-glutamic acid for aminopeptidase A and  4-methoxy-2-naphthylamide  of L-arginine for  aminopeptidase B   The vaginal aminopeptidase enzymatic activity of different species was determined spectrofluorometrically", "triple_list": [["A", "ANTAGONIST", "aminopeptidase B"]]}, {"text": "PURPOSE: Testosterone-to-estradiol ratio levels in infertile men improve during treatment with the  aromatase  inhibitor,  testolactone   and resulting changes in semen parameters", "triple_list": [["semen", "PRODUCT-OF", "aromatase"]]}, {"text": "We evaluated the effect of  anastrozole   a more selective  aromatase  inhibitor, on the hormonal and semen profiles of infertile men with abnormal baseline testosterone-to-estradiol ratios", "triple_list": [["anastrozole", "ACTIVATOR", "anastrozole"]]}, {"text": "Also in contrast to effects of multiple  METH  injections, 1) MDMA caused little or no decrease in binding of the  DAT  ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport", "triple_list": [["transport", "PRODUCT-OF", "DAT"]]}, {"text": "Also in contrast to effects of multiple METH injections, 1)  MDMA  caused little or no decrease in binding of the  DAT  ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the  MDMA  induced reduction in plasmalemmal DA transport", "triple_list": [["MDMA", "ACTIVATOR", "Also"]]}, {"text": "Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the  DA T ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of  DA  prevented the MDMA-induced reduction in plasmalemmal  DA  transport", "triple_list": [["DA", "ACTIVATOR", "depletion"]]}, {"text": "Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the  DA T ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of  DA  prevented the MDMA-induced reduction in plasmalemmal  DA  transport", "triple_list": [["DA", "ANTAGONIST", "to"]]}, {"text": "In addition to affecting  DA T function, MDMA rapidly decreased vesicular  DA  transport as assessed in striatal vesicles prepared from treated rats", "triple_list": [["MDMA", "ANTAGONIST", "DAT"]]}, {"text": "It is not yet clear whether  tamoxifen  can reduce breast cancer incidence in women with BRCA1 and  BRCA2  mutations, although preliminary evidence favors benefit for at least those with a  BRCA2  mutation", "triple_list": [["cancer", "AGONIST", "BRCA2"]]}, {"text": "It is not yet clear whether  tamoxifen  can reduce breast cancer incidence in women with BRCA1 and  BRCA2  mutations, although preliminary evidence favors benefit for at least those with a  BRCA2  mutation", "triple_list": [["tamoxifen", "AGONIST", "for"]]}, {"text": "In addition, we found that  MCP-1  transcription and translation was completely inhibited by  mimosine   while MIP-2 transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T", "triple_list": [["mimosine", "PRODUCT-OF", "by"]]}, {"text": "In addition, we found that MCP-1 transcription and translation was completely inhibited by  mimosine   while  MIP-2  transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T", "triple_list": [["yet", "AGONIST", "MIP-2"]]}, {"text": "Inhibition of  MCP-1  and MIP-2 transcription and translation by  mimosine  in muscle tissue infected with the parasite Trichinella spiralis", "triple_list": [["mimosine", "AGONIST", "tissue"]]}, {"text": "Inhibition of MCP-1 and  MIP-2  transcription and translation by  mimosine  in muscle tissue infected with the parasite Trichinella spiralis", "triple_list": [["Inhibition", "AGONIST", "MIP-2"]]}, {"text": "The selective  PDE 4  inhibitors, and to a certain extent the PDE3 inhibitors amrinone and  milrinone   reduced the GM-CSF release in a concentration dependent manner", "triple_list": [["the", "ANTAGONIST", "PDE 4"]]}, {"text": "The selective PDE 4 inhibitors, and to a certain extent the  PDE3  inhibitors amrinone and  milrinone   reduced the GM-CSF release in a concentration dependent manner", "triple_list": [["selective", "ACTIVATOR", "PDE3"]]}, {"text": "The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors amrinone and  milrinone   reduced the  GM-CSF  release in a concentration dependent manner", "triple_list": [["milrinone", "AGONIST", "GM-CSF"]]}, {"text": " Amrinone  and milrinone, selective  PDE3  inhibitors, suppressed TNF secretion to a lesser extent", "triple_list": [["Amrinone", "PRODUCT-OF", "secretion"]]}, {"text": " Amrinone  and milrinone, selective PDE3 inhibitors, suppressed  TNF  secretion to a lesser extent", "triple_list": [["and", "PRODUCT-OF", "TNF"]]}, {"text": "Amrinone and  milrinone   selective  PDE3  inhibitors, suppressed TNF secretion to a lesser extent", "triple_list": [["milrinone", "ACTIVATOR", "milrinone"]]}, {"text": "Amrinone and  milrinone   selective PDE3 inhibitors, suppressed  TNF  secretion to a lesser extent", "triple_list": [["milrinone", "ANTAGONIST", "extent"]]}, {"text": "The effects of  theophylline  (unspecific  PDE  inhibitor), vinpocetine ( PDE 1 inhibitor), EHNA ( PDE 2 inhibitor) and the  PDE 5 inhibitors zaprinast and E 4021 were weak", "triple_list": [["the", "ANTAGONIST", "PDE"]]}, {"text": "The effects of theophylline (unspecific PDE inhibitor),  vinpocetine  ( PDE1  inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak", "triple_list": [["vinpocetine", "PRODUCT-OF", "and"]]}, {"text": "The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the  PDE5  inhibitors  zaprinast  and E 4021 were weak", "triple_list": [["zaprinast", "ANTAGONIST", "the"]]}, {"text": "The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the  PDE5  inhibitors zaprinast and  E 4021  were weak", "triple_list": [["zaprinast", "ACTIVATOR", "PDE5"]]}, {"text": "In human blood, the tested glucocorticoids  beclomethasone   dexamethasone and fluticasone inhibited the LPS induced  TNF  release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced  TNF  release, with the exception of dexamethasone, was much less pronounced", "triple_list": [["release", "ACTIVATOR", "TNF"]]}, {"text": "In human blood, the tested glucocorticoids  beclomethasone   dexamethasone and fluticasone inhibited the LPS induced  TNF  release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced  TNF  release, with the exception of dexamethasone, was much less pronounced", "triple_list": [["In", "ACTIVATOR", "TNF"]]}, {"text": "In human blood, the tested glucocorticoids beclomethasone,  dexamethasone  and fluticasone inhibited the LPS induced  TNF  release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced  TNF  release, with the exception of  dexamethasone , was much less pronounced", "triple_list": [["of", "ANTAGONIST", "TNF"]]}, {"text": "In human blood, the tested glucocorticoids beclomethasone,  dexamethasone  and fluticasone inhibited the LPS induced  TNF  release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced  TNF  release, with the exception of  dexamethasone , was much less pronounced", "triple_list": [["exception", "ACTIVATOR", "TNF"]]}, {"text": "In human blood, the tested glucocorticoids beclomethasone, dexamethasone and  fluticasone  inhibited the LPS induced  TNF  release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced  TNF  release, with the exception of dexamethasone, was much less pronounced", "triple_list": [["fluticasone", "AGONIST", "potently"]]}, {"text": "In human blood, the tested glucocorticoids beclomethasone, dexamethasone and  fluticasone  inhibited the LPS induced  TNF  release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced  TNF  release, with the exception of dexamethasone, was much less pronounced", "triple_list": [["the", "ANTAGONIST", "TNF"]]}, {"text": "The selective  PDE 4  inhibitors, and to a certain extent the PDE3 inhibitors  amrinone  and milrinone, reduced the GM-CSF release in a concentration dependent manner", "triple_list": [["extent", "ANTAGONIST", "PDE 4"]]}, {"text": "The selective PDE 4 inhibitors, and to a certain extent the  PDE3  inhibitors  amrinone  and milrinone, reduced the GM-CSF release in a concentration dependent manner", "triple_list": [["manner", "AGONIST", "PDE3"]]}, {"text": "The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors  amrinone  and milrinone, reduced the  GM-CSF  release in a concentration dependent manner", "triple_list": [["amrinone", "PRODUCT-OF", "The"]]}, {"text": "Central  5-HT3  receptor stimulation by  m-CPBG  increases blood glucose in rats", "triple_list": [["m-CPBG", "AGONIST", "stimulation"]]}, {"text": "Injections of  m-CPBG   a selective  5-HT3  receptor agonist, induced a significant increase in blood glucose in non-stressed rats in both fasted and in fed states", "triple_list": [["both", "ANTAGONIST", "5-HT3"]]}, {"text": "The hyperglycemic effect of  m-CPBG  central administration was blocked by pretreatment with ondansetron, a specific  5-HT3  receptor antagonist, indicating that the effects here obtained with  m-CPBG  were a result of its interaction with  5-HT3  receptors", "triple_list": [["m-CPBG", "DOWNREGULATOR", "here"]]}, {"text": "CONCLUSIONS:  CysLTs  produced after antigen provocation sequentially induced IL-5 production from some immune component cells via  CysLT1  receptor activation", "triple_list": [["CysLTs", "PRODUCT-OF", "CysLTs"]]}, {"text": "Increased  IL-5  activity in the serum was inhibited by both  pranlukast  and MCI-826 by over 90%", "triple_list": [["pranlukast", "AGONIST", "in"]]}, {"text": "Increased  IL-5  activity in the serum was inhibited by both pranlukast and  MCI-826  by over 90%", "triple_list": [["90%", "ACTIVATOR", "IL-5"]]}, {"text": " Minocycline  inhibits  cytochrome c  release and delays progression of amyotrophic lateral sclerosis in mice", "triple_list": [["Minocycline", "AGONIST", "amyotrophic"]]}, {"text": "We find that  minocycline  inhibits mitochondrial permeability-transition-mediated  cytochrome c  release", "triple_list": [["permeability-transition-mediated", "AGONIST", "cytochrome c"]]}, {"text": " Minocycline  mediated inhibition of  cytochrome c  release is demonstrated in vivo, in cells, and in isolated mitochondria", "triple_list": [["Minocycline", "ACTIVATOR", "in"]]}, {"text": "We also shortly discuss the ongoing debate on whether  NO  is the actual reaction product of  NO S catalysis, as well as the phenomenon of  NO -mediated autoinhibition", "triple_list": [["as", "AGONIST", "NOS"]]}, {"text": "CONCLUSIONS: In the maximum registered dosage,  nabumetone  inhibits thromboxane production much more than meloxicam, signifying less  COX-2  selectivity of the former", "triple_list": [["than", "ANTAGONIST", "COX-2"]]}, {"text": " COX-1  inhibition was measured as percentage inhibition of serum  TXB2  generation in clotting whole blood, and as closure time with use of the platelet function analyser PFA-100", "triple_list": [["TXB2", "AGONIST", "with"]]}, {"text": " N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide  (NS-398), a selective  cyclooxygenase-2  inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis", "triple_list": [["N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide", "ANTAGONIST", "apoptosis"]]}, {"text": "N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide ( NS-398  , a selective  cyclooxygenase-2  inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis", "triple_list": [["inhibitor,", "PRODUCT-OF", "cyclooxygenase-2"]]}, {"text": "BACKGROUND AND AIMS:  Glutamic acid decarboxylase  (GAD, EC 4.1.1.15) catalyses the conversion of  glutamate  to gamma-aminobutyric acid (GABA)", "triple_list": [["gamma-aminobutyric", "AGONIST", "Glutamic acid decarboxylase"]]}, {"text": "BACKGROUND AND AIMS: Glutamic acid decarboxylase ( GAD   EC 4.1.1.15) catalyses the conversion of  glutamate  to gamma-aminobutyric acid (GABA)", "triple_list": [["glutamate", "ACTIVATOR", "of"]]}, {"text": "BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD,  EC 4.1.1.15   catalyses the conversion of  glutamate  to gamma-aminobutyric acid (GABA)", "triple_list": [["glutamate", "ANTAGONIST", "glutamate"]]}, {"text": "BACKGROUND AND AIMS:  Glutamic acid decarboxylase  (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to  gamma-aminobutyric acid  (GABA)", "triple_list": [["catalyses", "AGONIST", "Glutamic acid decarboxylase"]]}, {"text": "BACKGROUND AND AIMS: Glutamic acid decarboxylase ( GAD   EC 4.1.1.15) catalyses the conversion of glutamate to  gamma-aminobutyric acid  (GABA)", "triple_list": [["gamma-aminobutyric acid", "ANTAGONIST", "glutamate"]]}, {"text": "BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD,  EC 4.1.1.15   catalyses the conversion of glutamate to  gamma-aminobutyric acid  (GABA)", "triple_list": [["the", "DOWNREGULATOR", "EC 4.1.1.15"]]}, {"text": "BACKGROUND AND AIMS:  Glutamic acid decarboxylase  (GAD, EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid ( GABA  ", "triple_list": [["(GAD,", "ANTAGONIST", "Glutamic acid decarboxylase"]]}, {"text": "BACKGROUND AND AIMS: Glutamic acid decarboxylase ( GAD   EC 4.1.1.15) catalyses the conversion of glutamate to gamma-aminobutyric acid ( GABA  ", "triple_list": [["GABA", "ACTIVATOR", "GAD"]]}, {"text": "BACKGROUND AND AIMS: Glutamic acid decarboxylase (GAD,  EC 4.1.1.15   catalyses the conversion of glutamate to gamma-aminobutyric acid ( GABA  ", "triple_list": [["catalyses", "ACTIVATOR", "EC 4.1.1.15"]]}, {"text": "OBJECTIVE: Celecoxib and  rofecoxib  are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the  cyclo-oxygenase-2  (COX-2) isoenzyme at therapeutic concentrations", "triple_list": [["selectively", "ANTAGONIST", "cyclo-oxygenase-2"]]}, {"text": "OBJECTIVE: Celecoxib and  rofecoxib  are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 ( COX-2   isoenzyme at therapeutic concentrations", "triple_list": [["new", "AGONIST", "COX-2"]]}, {"text": "This study was conducted in order to understand the association between acute renal failure and the two  COX-2  inhibitors  celecoxib  and rofecoxib", "triple_list": [["two", "ACTIVATOR", "COX-2"]]}, {"text": "This study was conducted in order to understand the association between acute renal failure and the two  COX-2  inhibitors celecoxib and  rofecoxib   METHODS: A search was performed in the US Food and Drug Administration's (FDA) Adverse Event Reporting System (AERS) to identify cases of renal failure submitted to the FDA", "triple_list": [["rofecoxib", "AGONIST", "Administration's"]]}, {"text": "OBJECTIVE:  Celecoxib  and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the  cyclo-oxygenase-2  (COX-2) isoenzyme at therapeutic concentrations", "triple_list": [["OBJECTIVE:", "PRODUCT-OF", "cyclo-oxygenase-2"]]}, {"text": "OBJECTIVE:  Celecoxib  and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 ( COX-2   isoenzyme at therapeutic concentrations", "triple_list": [["selectively", "AGONIST", "COX-2"]]}, {"text": "The results reinforce previous assumptions that  dopamine  may interact with eicosanoid metabolism by means of  D(2) receptor  activation, and implicate an involvement of cPLA(2) and COX-2 in this effect", "triple_list": [["receptor", "AGONIST", "D(2) receptor"]]}, {"text": "It was also antagonized by the non-specific  cyclooxygenase  (COX) inhibitor,  indomethacin   and by the selective COX-2 inhibitor, NS-398, but not by the specific COX-1 inhibitor, valeryl salicylate", "triple_list": [["indomethacin", "ANTAGONIST", "(COX)"]]}, {"text": "It was also antagonized by the non-specific cyclooxygenase ( COX   inhibitor,  indomethacin   and by the selective  COX -2 inhibitor, NS-398, but not by the specific  COX -1 inhibitor, valeryl salicylate", "triple_list": [["antagonized", "PRODUCT-OF", "COX"]]}, {"text": "It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective  COX-2  inhibitor,  NS-398   but not by the specific COX-1 inhibitor, valeryl salicylate", "triple_list": [["antagonized", "AGONIST", "COX-2"]]}, {"text": "It was also antagonized by the non-specific cyclooxygenase (COX) inhibitor, indomethacin, and by the selective COX-2 inhibitor, NS-398, but not by the specific  COX-1  inhibitor,  valeryl salicylate   Both the non-specific phospholipase A(2) inhibitor, quinacrine, and an inhibitor of cPLA(2) and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective", "triple_list": [["valeryl salicylate", "PRODUCT-OF", "but"]]}, {"text": "Both the non-specific  phospholipase A(2)  inhibitor,  quinacrine   and an inhibitor of cPLA(2) and iPLA(2), AACOF3, counteracted the effect; in contrast, a selective iPLA(2) inhibitor, BEL, and a selective sPLA(2) inhibitor, TAPC, were ineffective", "triple_list": [["quinacrine", "ANTAGONIST", "effect;"]]}, {"text": "The effect was counteracted by the  D(2)  antagonist  eticlopride   pertussis toxin, the inhibitor of intracellular Ca(2+) release TMB-8, incubation in Ca(2+)-free experimental medium, and PKC desensitization obtained by chronic pretreatment with the phorbol ester TPA", "triple_list": [["pertussis", "DOWNREGULATOR", "D(2)"]]}, {"text": "Dopamine D(2) receptor-induced  COX-2  mediated production of  prostaglandin E(2)  in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent", "triple_list": [["prostaglandin E(2)", "ANTAGONIST", "simultaneous"]]}, {"text": " Minocycline  treatment prevents the formation of activated  caspase-3   a known effector of apoptosis, as well as the appearance of a calpain cleaved substrate, a marker of excitotoxic/necrotic cell death", "triple_list": [["of", "PRODUCT-OF", "caspase-3"]]}, {"text": "In addition to this pronounced loss of function,  M1766L  also showed a 10-fold increase in the persistent late  sodium  current", "triple_list": [["sodium", "DOWNREGULATOR", "of"]]}, {"text": " Valdecoxib  is a potent and specific inhibitor of  cyclooxygenase-2   which is used for the treatment of rheumatoid arthritis, osteoarthritis, and the dysmenorrhea pain", "triple_list": [["Valdecoxib", "ACTIVATOR", "used"]]}, {"text": "Disposition of a specific  cyclooxygenase-2  inhibitor,  valdecoxib   in human", "triple_list": [["valdecoxib", "ACTIVATOR", "a"]]}, {"text": "Thus,  bupropion  acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits  DAT  and NET function", "triple_list": [["Thus,", "AGONIST", "DAT"]]}, {"text": "Thus,  bupropion  acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and  NET  function", "triple_list": [["bupropion", "PRODUCT-OF", "NET"]]}, {"text": "The combination of  nAChR  and transporter inhibition produced by  bupropion  may contribute to its clinical efficacy as a smoking cessation agent.", "triple_list": [["contribute", "ACTIVATOR", "nAChR"]]}, {"text": " Bupropion   an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters ( DAT  and NET, respectively)", "triple_list": [["Bupropion", "PRODUCT-OF", "respectively)"]]}, {"text": " Bupropion   an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and  NET   respectively)", "triple_list": [["Bupropion", "AGONIST", "and"]]}, {"text": "To eliminate the interaction of  bupropion  with  DAT  or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer", "triple_list": [["in", "ACTIVATOR", "DAT"]]}, {"text": "To eliminate the interaction of  bupropion  with DAT or  NET   nomifensine or desipramine, respectively, was included in the superfusion buffer", "triple_list": [["bupropion", "ACTIVATOR", "or"]]}, {"text": "The clinical profile of the  angiotensin II receptor  blocker  eprosartan   Angiotensin II receptor antagonists block angiotensin II type 1 (AT1) receptors and reduce the pressor effects of angiotensin in the vasculature", "triple_list": [["receptor", "AGONIST", "angiotensin II receptor"]]}, {"text": "In clinical trials  eprosartan  has proven to be at least as effective as the  ACE  inhibitor enalapril in reducing BP, but with a significantly lower incidence of side effects", "triple_list": [["eprosartan", "PRODUCT-OF", "of"]]}, {"text": "The esterified- BM , however, had only partial transactivation agonistic activity in cells transfected with  rat GR   whereas  BM  and esterified-DEX had full transactivation agonistic activity", "triple_list": [["in", "ACTIVATOR", "rat GR"]]}, {"text": "The esterified-BM, however, had only partial transactivation agonistic activity in cells transfected with  rat GR   whereas BM and esterified- DEX  had full transactivation agonistic activity", "triple_list": [["DEX", "ACTIVATOR", "rat GR"]]}, {"text": "Moreover, in rat hepatoma H4-II-E cells, the esterified- BM  failed to induce tyrosine aminotransferase, which is regulated by  GR  mediated transactivation activity", "triple_list": [["rat", "PRODUCT-OF", "GR"]]}, {"text": "Consistent with the weak transactivation activity of esterified- BM  mediated by  rat GR   there were few side effects, evaluated by thymus involution and body weight loss, in an antigen-induced asthmatic model in rats", "triple_list": [["BM", "PRODUCT-OF", "there"]]}, {"text": " Dexamethasone  (DEX), betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either  human or rat GR   These GCs also had full transactivation agonistic activity in CV-1 cells transfected with human GR", "triple_list": [["also", "ACTIVATOR", "human or rat GR"]]}, {"text": "Dexamethasone ( DEX  , betamethasone (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either  human or rat GR   These GCs also had full transactivation agonistic activity in CV-1 cells transfected with human GR", "triple_list": [["(BM),", "PRODUCT-OF", "human or rat GR"]]}, {"text": "Dexamethasone (DEX),  betamethasone  (BM), and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either  human or rat GR   These GCs also had full transactivation agonistic activity in CV-1 cells transfected with human GR", "triple_list": [["betamethasone", "PRODUCT-OF", "cells"]]}, {"text": "Dexamethasone (DEX), betamethasone ( BM  , and their esterified-derivatives had full transrepression agonistic activity in a reporter assay using CV-1 cells transfected with either  human or rat GR   These GCs also had full transactivation agonistic activity in CV-1 cells transfected with human GR", "triple_list": [["BM", "ACTIVATOR", "GR"]]}, {"text": "The esterified- BM   however, had only partial transactivation agonistic activity in cells transfected with  rat GR   whereas  BM  and esterified-DEX had full transactivation agonistic activity", "triple_list": [["with", "PRODUCT-OF", "rat GR"]]}, {"text": "Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme ( NifS   that is involved in the activation of sulphur from  l-cysteine   and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed", "triple_list": [["cluster", "ANTAGONIST", "NifS"]]}, {"text": " Mazindol  analogues as potential inhibitors of the  cocaine binding site  at the dopamine transporter", "triple_list": [["Mazindol", "ANTAGONIST", "Mazindol"]]}, {"text": " Mazindol  analogues as potential inhibitors of the cocaine binding site at the  dopamine transporter   A series of mazindol (2) and homomazindol (3) analogues with a variety of electron-donating and electron-withdrawing groups in the pendant aryl group and the benzo ring C, as well as H, methoxy, and alkyl groups replacing the hydroxyl group were synthesized, and their binding affinities at the  dopamine transporter  (DAT) on rat or guinea pig striatal membranes were determined", "triple_list": [["(3)", "ACTIVATOR", "dopamine transporter"]]}, {"text": "Several active analogues were also evaluated for their ability to block uptake of DA,  5-HT   and NE and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK- hSERT   and HEK-hNET cells", "triple_list": [["their", "ACTIVATOR", "hSERT"]]}, {"text": "Several active analogues were also evaluated for their ability to block uptake of DA, 5-HT, and  NE  and inhibit binding of [(125)I] RTI-55 at HEK-hDAT, HEK-hSERT, and HEK-h NE T cells", "triple_list": [["NE", "ACTIVATOR", "NE"]]}, {"text": "Several active analogues were also evaluated for their ability to block uptake of  DA   5-HT, and NE and inhibit binding of [(125)I] RTI-55 at HEK-h DA T  HEK-hSERT, and HEK-hNET cells", "triple_list": [["active", "DOWNREGULATOR", "hDAT"]]}, {"text": "Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the  ATP  inhibition of  K(IR)6.2  SUR1, but had no effect on homomeric  K(IR)6.2  channels", "triple_list": [["no", "ANTAGONIST", "K(IR)6.2"]]}, {"text": "Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the  ATP  inhibition of K(IR)6.2/ SUR1   but had no effect on homomeric K(IR)6.2 channels", "triple_list": [["the", "ACTIVATOR", "SUR1"]]}, {"text": "These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to DeltaNK( ATP ) channels decreased their P(O(max)) and apparent IC(50) for  ATP  in the absence of Mg(2+)", "triple_list": [["ATP", "ACTIVATOR", "DeltaNK(ATP) channels"]]}, {"text": "Since  gemfibrozil  is known to activate  peroxisome proliferator-activated receptor-alpha  (PPAR-alpha), we investigated the role of PPAR-alpha in  gemfibrozil -mediated inhibition of iNOS", "triple_list": [["the", "DOWNREGULATOR", "peroxisome proliferator-activated receptor-alpha"]]}, {"text": "Since  gemfibrozil  is known to activate peroxisome proliferator-activated receptor-alpha ( PPAR-alpha  , we investigated the role of  PPAR-alpha  in  gemfibrozil -mediated inhibition of iNOS", "triple_list": [["gemfibrozil", "ANTAGONIST", "receptor-alpha"]]}, {"text": "Since  gemfibrozil  is known to activate peroxisome proliferator-activated receptor-alpha ( PPAR-alpha ), we investigated the role of  PPAR-alpha  in  gemfibrozil  mediated inhibition of iNOS", "triple_list": [["is", "PRODUCT-OF", "PPAR-alpha"]]}, {"text": " Gemfibrozil  induced  peroxisome proliferator-responsive element  (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha", "triple_list": [["mutant", "AGONIST", "peroxisome proliferator-responsive element"]]}, {"text": " Gemfibrozil  induced peroxisome proliferator-responsive element ( PPRE  -dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha", "triple_list": [["Gemfibrozil", "DOWNREGULATOR", "inhibited"]]}, {"text": "Inhibition of  human iNOS promoter  driven luciferase activity by  gemfibrozil  in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS", "triple_list": [["by", "ANTAGONIST", "human iNOS promoter"]]}, {"text": "Inhibition of human  iNOS  promoter-driven luciferase activity by  gemfibrozil  in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of  iNOS   Since  gemfibrozil  is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in  gemfibrozil -mediated inhibition of  iNOS ", "triple_list": [["iNOS", "ANTAGONIST", "iNOS"]]}, {"text": "Since  gemfibrozil  is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in  gemfibrozil  mediated inhibition of  iNOS   Gemfibrozil induced peroxisome proliferator-responsive element (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha", "triple_list": [["gemfibrozil", "ANTAGONIST", "role"]]}, {"text": "However, DeltahPPAR-alpha was unable to abrogate  gemfibrozil  mediated inhibition of  iNOS  suggesting that  gemfibrozil  inhibits  iNOS  independent of PPAR-alpha", "triple_list": [["of", "PRODUCT-OF", "iNOS"]]}, {"text": "However, DeltahPPAR-alpha was unable to abrogate  gemfibrozil -mediated inhibition of  iNOS  suggesting that  gemfibrozil  inhibits  iNOS  independent of PPAR-alpha", "triple_list": [["gemfibrozil", "ACTIVATOR", "of"]]}, {"text": " Gemfibrozil   a lipid-lowering drug, inhibits the induction of  nitric-oxide synthase  in human astrocytes", "triple_list": [["Gemfibrozil", "AGONIST", "lipid-lowering"]]}, {"text": " Gemfibrozil   a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of  inducible nitric-oxide synthase  (iNOS) in human U373MG astroglial cells and primary astrocytes", "triple_list": [["production", "PRODUCT-OF", "inducible nitric-oxide synthase"]]}, {"text": " Gemfibrozil   a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase ( iNOS   in human U373MG astroglial cells and primary astrocytes", "triple_list": [["primary", "PRODUCT-OF", "iNOS"]]}, {"text": " Gemfibrozil   a lipid-lowering drug, inhibited  cytokine  induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes", "triple_list": [["of", "PRODUCT-OF", "cytokine"]]}, {"text": "Interestingly,  gemfibrozil  strongly inhibited the activation of  NF-kappaB   AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells", "triple_list": [["of", "PRODUCT-OF", "NF-kappaB"]]}, {"text": "Interestingly,  gemfibrozil  strongly inhibited the activation of NF-kappaB,  AP-1   and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells", "triple_list": [["gemfibrozil", "PRODUCT-OF", "activation"]]}, {"text": "Interestingly,  gemfibrozil  strongly inhibited the activation of NF-kappaB, AP-1, and  C/EBPbeta  but not that of GAS in cytokine-stimulated astroglial cells", "triple_list": [["but", "AGONIST", "C/EBPbeta"]]}, {"text": "These results suggest that  gemfibrozil  inhibits the induction of  iNOS  probably by inhibiting the activation of NF-kappaB, AP-1, and C/EBPbeta and that  gemfibrozil , a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.", "triple_list": [["gemfibrozil", "AGONIST", "by"]]}, {"text": "These results suggest that  gemfibrozil  inhibits the induction of iNOS probably by inhibiting the activation of  NF-kappaB   AP-1, and C/EBPbeta and that  gemfibrozil , a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.", "triple_list": [["gemfibrozil", "AGONIST", "gemfibrozil"]]}, {"text": "These results suggest that  gemfibrozil  inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB,  AP-1   and C/EBPbeta and that  gemfibrozil , a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.", "triple_list": [["its", "AGONIST", "AP-1"]]}, {"text": "These results suggest that  gemfibrozil  inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB, AP-1, and  C/EBPbeta  and that  gemfibrozil , a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.", "triple_list": [["gemfibrozil", "ACTIVATOR", "gemfibrozil"]]}, {"text": "Similar to  gemfibrozil   clofibrate, another fibrate drug, also inhibited the expression of  iNOS   Inhibition of human  iNOS  promoter-driven luciferase activity by  gemfibrozil  in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of  iNOS ", "triple_list": [["gemfibrozil", "ACTIVATOR", "inhibited"]]}, {"text": "Similar to gemfibrozil,  clofibrate   another fibrate drug, also inhibited the expression of  iNOS   Inhibition of human  iNOS  promoter-driven luciferase activity by gemfibrozil in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of  iNOS ", "triple_list": [["clofibrate", "ANTAGONIST", "the"]]}, {"text": "Similar to gemfibrozil, clo fibrate , another  fibrate  drug, also inhibited the expression of  iNOS   Inhibition of human  iNOS  promoter-driven luciferase activity by gemfibrozil in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of  iNOS ", "triple_list": [["fibrate", "PRODUCT-OF", "that"]]}, {"text": "Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of  NO  and the expression of  inducible nitric-oxide synthase  (i NO S) in human U373MG astroglial cells and primary astrocytes", "triple_list": [["U373MG", "ACTIVATOR", "inducible nitric-oxide synthase"]]}, {"text": "Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of  NO  and the expression of inducible nitric-oxide synthase (i NO S  in human U373MG astroglial cells and primary astrocytes", "triple_list": [["NO", "ANTAGONIST", "S"]]}, {"text": "Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible  nitric-oxide  synthase ( iNOS   in human U373MG astroglial cells and primary astrocytes", "triple_list": [["U373MG", "DOWNREGULATOR", "iNOS"]]}, {"text": "Lisuride dose dependently decreased body temperature in rats with a potency similar to that of the selective  5-HT(1A)  agonist  LY 293284   The hypothermic effect of lisuride was prevented by pre-injection of pMPPI, but not by ketanserin or haloperidol", "triple_list": [["LY 293284", "DOWNREGULATOR", "body"]]}, {"text": "RESULTS: In drug discrimination studies,  lisuride  fully mimicked the  5-HT(1A)  agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine", "triple_list": [["lisuride", "ANTAGONIST", "failed"]]}, {"text": "RESULTS: In drug discrimination studies, lisuride fully mimicked the  5-HT(1A)  agonist  LY 293284   only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine", "triple_list": [["LY", "DOWNREGULATOR", "5-HT(1A)"]]}, {"text": "Only pMPPI [ 4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride  , a selective  5-HT(1A)  antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD", "triple_list": [["without", "PRODUCT-OF", "5-HT(1A)"]]}, {"text": "We hypothesized that the  HED  compounds would be most potent at the  norepinephrine transporter  (NET) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers", "triple_list": [["potent", "ACTIVATOR", "norepinephrine transporter"]]}, {"text": "We hypothesized that the  HED  compounds would be most potent at the norepinephrine transporter ( NET   compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers", "triple_list": [["HED", "AGONIST", "to"]]}, {"text": "Stereospecific inhibition of  monoamine uptake transporters  by  meta-hydroxyephedrine  isomers", "triple_list": [["meta-hydroxyephedrine", "ACTIVATOR", "monoamine uptake transporters"]]}, {"text": "To extend structure-activity analyses of binding sites within  monoamine transporters  and to determine which stereoisomer displayed the best selectivity for PET imaging applications, we tested the  HED  compounds for their abilities to inhibit [(3)H]neurotransmitter uptake into platelets, transfected cells, and chromaffin vesicles", "triple_list": [["extend", "AGONIST", "monoamine transporters"]]}, {"text": "Culture of HepG2 cells with  griseofulvin  has now been shown to induce both the formation of intracellular aggregates containing  K18  as well as an increase in the abundance of  K18  mRNA", "triple_list": [["abundance", "DOWNREGULATOR", "K18"]]}, {"text": "Culture of HepG2 cells with  griseofulvin  has now been shown to induce both the formation of intracellular aggregates containing  K18  as well as an increase in the abundance of  K18  mRNA", "triple_list": [["griseofulvin", "ANTAGONIST", "well"]]}, {"text": "They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the  5-LOX  inhibitor  REV 5901   and the  5-LOX  activating protein (FLAP) inhibitor MK-886", "triple_list": [["REV 5901", "AGONIST", "MK-886"]]}, {"text": "They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the  5-LOX activating protein  (FLAP) inhibitor  MK-886   The FLAP inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin", "triple_list": [["included", "PRODUCT-OF", "5-LOX activating protein"]]}, {"text": "They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein ( FLAP   inhibitor  MK-886   The  FLAP  inhibitor also reduced respiratory burst activity in a more potent manner than indomethacin", "triple_list": [["COX-1", "PRODUCT-OF", "FLAP"]]}, {"text": "They included the COX-1 inhibitor indomethacin; the  COX-2  inhibitor  NS-398   the mixed COX-1/ COX-2  inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886", "triple_list": [["NS-398", "ANTAGONIST", "5-LOX"]]}, {"text": "They included the  COX-1  inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed  COX-1  COX-2 inhibitor  ibuprofen   the nitric oxide (NO) derivatives of indomethacin,  ibuprofen  and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886", "triple_list": [["activating", "AGONIST", "COX-1"]]}, {"text": "They included the COX-1 inhibitor indomethacin; the  COX-2  inhibitor NS-398; the mixed COX-1/ COX-2  inhibitor  ibuprofen   the nitric oxide (NO) derivatives of indomethacin,  ibuprofen  and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886", "triple_list": [["COX-1", "AGONIST", "COX-2"]]}, {"text": "The  COX  pathway generates inflammatory  prostaglandins   while the 5-LOX pathway generates inflammatory leukotrienes", "triple_list": [["leukotrienes", "DOWNREGULATOR", "COX"]]}, {"text": "The COX pathway generates inflammatory prostaglandins, while the  5-LOX  pathway generates inflammatory  leukotrienes   We found that inhibitors of both these pathways suppressed neurotoxicity in a dose-dependent fashion", "triple_list": [["pathway", "ANTAGONIST", "5-LOX"]]}, {"text": "This observation suggests that  MDMA  induced reductions in  SERT  density do not represent neuroadaptive responses to decreased levels of brain serotonin, but may occur in response to some other stimulus or to the neurotoxic effects of  MDMA .", "triple_list": [["to", "ANTAGONIST", "SERT"]]}, {"text": "Low levels of  serotonin  may reduce the density of the  serotonin  transporter (SERT) by either increasing trafficking or reducing synthesis; a \"neuroadaptive response\"", "triple_list": [["\"neuroadaptive", "AGONIST", "serotonin transporter"]]}, {"text": "Low levels of  serotonin  may reduce the density of the  serotonin  transporter ( SERT   by either increasing trafficking or reducing synthesis; a \"neuroadaptive response\"", "triple_list": [["a", "ANTAGONIST", "SERT"]]}, {"text": "To determine whether  3,4-methylenedioxymethamphetamine  (MDMA)-induced reductions in  SERT  density could be related to such a mechanism, p-chlorophenylalanine or MDMA was administered to rats, and brain serotonin and  SERT  density were measured", "triple_list": [["reductions", "ACTIVATOR", "SERT"]]}, {"text": "To determine whether 3,4-methylenedioxymethamphetamine ( MDMA  -induced reductions in  SERT  density could be related to such a mechanism, p-chlorophenylalanine or  MDMA  was administered to rats, and brain serotonin and  SERT  density were measured", "triple_list": [["be", "ACTIVATOR", "SERT"]]}, {"text": "However, only  MDMA  reduced  SERT  density", "triple_list": [["MDMA", "AGONIST", "However,"]]}, {"text": "The selective  norepinephrine (NE) transporter  inhibitor  atomoxetine  (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD)", "triple_list": [["(NE)", "AGONIST", "norepinephrine (NE) transporter"]]}, {"text": "The selective  norepinephrine (NE) transporter  inhibitor a tomoxetine  (formerly called  tomoxetine  or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD)", "triple_list": [["tomoxetine", "ACTIVATOR", "tomoxetine"]]}, {"text": "The selective  norepinephrine (NE) transporter  inhibitor atomoxetine (formerly called tomoxetine or  LY139603   has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD)", "triple_list": [["LY139603", "PRODUCT-OF", "alleviate"]]}, {"text": " Rasagiline  does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit  MAO-B  but not MAO-A.", "triple_list": [["Rasagiline", "ANTAGONIST", "behavioural"]]}, {"text": " Rasagiline  does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit MAO-B but not  MAO-A  ", "triple_list": [["syndromes", "PRODUCT-OF", "MAO-A"]]}, {"text": " Rasagiline  [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible  monoamine oxidase  (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease", "triple_list": [["Rasagiline", "AGONIST", "being"]]}, {"text": " Rasagiline  [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible monoamine oxidase ( MAO   inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease", "triple_list": [["for", "PRODUCT-OF", "MAO"]]}, {"text": "Rasagiline [N-propargyl-1R(+)-aminoindan;  TVP1012   is a potent irreversible  monoamine oxidase  (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease", "triple_list": [["Parkinson's", "PRODUCT-OF", "monoamine oxidase"]]}, {"text": "Rasagiline [N-propargyl-1R(+)-aminoindan;  TVP1012   is a potent irreversible monoamine oxidase ( MAO   inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease", "triple_list": [["treatment", "ACTIVATOR", "MAO"]]}, {"text": "Reserpine-induced ptosis was reversed by  rasagiline  at doses above 2 mg x kg(-1) i.p., which inhibit  MAO-A  as well as MAO-B, but not at MAO-B-selective doses", "triple_list": [["inhibit", "ACTIVATOR", "MAO-A"]]}, {"text": "Reserpine-induced ptosis was reversed by  rasagiline  at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as  MAO-B   but not at  MAO-B -selective doses", "triple_list": [["doses", "AGONIST", "MAO-B"]]}, {"text": "However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both  MAO-A  and MAO-B by  tranylcypromine  together with the monoamine precursors", "triple_list": [["kg(-1)", "PRODUCT-OF", "MAO-A"]]}, {"text": "However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and  MAO-B  by  tranylcypromine  together with the monoamine precursors", "triple_list": [["not", "AGONIST", "MAO-B"]]}, {"text": "However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both  MAO-A  and MAO-B by tranylcypromine together with the  monoamine  precursors", "triple_list": [["kg(-1)", "ANTAGONIST", "MAO-A"]]}, {"text": "However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and  MAO-B  by tranylcypromine together with the  monoamine  precursors", "triple_list": [["both", "ACTIVATOR", "MAO-B"]]}, {"text": "Rasagiline [ N-propargyl-1R(+)-aminoindan   TVP1012] is a potent irreversible  monoamine oxidase  (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease", "triple_list": [["N-propargyl-1R(+)-aminoindan", "ANTAGONIST", "treatment"]]}, {"text": "Rasagiline [ N-propargyl-1R(+)-aminoindan   TVP1012] is a potent irreversible monoamine oxidase ( MAO   inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease", "triple_list": [["irreversible", "PRODUCT-OF", "MAO"]]}, {"text": "Interestingly, the allele of PRO1 was shown to enhance the activities of  gamma-glutamyl kinase  and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of  L-proline  synthesis from L-glutamate and which together may form a complex in vivo", "triple_list": [["L-proline", "ANTAGONIST", "in"]]}, {"text": "Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and  gamma-glutamyl phosphate reductase   both of which catalyze the first two steps of  L-proline  synthesis from L-glutamate and which together may form a complex in vivo", "triple_list": [["of", "DOWNREGULATOR", "gamma-glutamyl phosphate reductase"]]}, {"text": "Interestingly, the allele of PRO1 was shown to enhance the activities of  gamma-glutamyl kinase  and gamma-glutamyl phosphate reductase, both of which catalyze the first two steps of L-proline synthesis from  L-glutamate  and which together may form a complex in vivo", "triple_list": [["L-glutamate", "ANTAGONIST", "and"]]}, {"text": "Interestingly, the allele of PRO1 was shown to enhance the activities of gamma-glutamyl kinase and  gamma-glutamyl phosphate reductase   both of which catalyze the first two steps of L-proline synthesis from  L-glutamate  and which together may form a complex in vivo", "triple_list": [["which", "ANTAGONIST", "gamma-glutamyl phosphate reductase"]]}, {"text": " L-proline  accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the PRO1 gene encoding  gamma-glutamyl kinase   We previously isolated a mutant which showed a high tolerance to freezing that correlated with higher levels of intracellular  L-proline  derived from  L-proline  analogue-resistant mutants", "triple_list": [["L-proline", "DOWNREGULATOR", "mutants"]]}, {"text": "When cultured in liquid minimal medium, yeast cells expressing the mutated  gamma-glutamyl kinase  were found to accumulate intracellular  L-proline  and showed a prominent increase in cell viability after freezing at -20 degrees C compared to the viability of cells harboring the wild-type PRO1 gene", "triple_list": [["L-proline", "ACTIVATOR", "mutated"]]}, {"text": "These results suggest that the altered  gamma-glutamyl kinase  results in stabilization of the complex or has an indirect effect on gamma-glutamyl phosphate reductase activity, which leads to an increase in  L-proline  production in Saccharomyces cerevisiae", "triple_list": [["L-proline", "DOWNREGULATOR", "has"]]}, {"text": "These results suggest that the altered gamma-glutamyl kinase results in stabilization of the complex or has an indirect effect on  gamma-glutamyl phosphate reductase  activity, which leads to an increase in  L-proline  production in Saccharomyces cerevisiae", "triple_list": [["on", "ANTAGONIST", "gamma-glutamyl phosphate reductase"]]}, {"text": "Within the class of  AII  blockers,  eprosartan  differs from other currently available agents in terms of chemical structure, as it is a non-biphenyl, non-tetrazole, non-peptide antagonist with a dual pharmacological mode of action", "triple_list": [["it", "ACTIVATOR", "AII"]]}, {"text": "In clinical trials, eprosartan has been demonstrated to be at least as effective in reducing blood pressure as the  ACE  inhibitor  enalapril   and has significantly lower side effects", "triple_list": [["enalapril", "PRODUCT-OF", "least"]]}, {"text": " D-Serine  was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the  N-methyl-D-aspartate (NMDA)-type receptors   Racemization of serine is catalyzed by serine racemase, a pyridoxal 5'-phosphate-dependent enzyme expressed mainly in brain and liver", "triple_list": [["racemase,", "ACTIVATOR", "N-methyl-D-aspartate (NMDA)-type receptors"]]}, {"text": " Mouse brain serine racemase  catalyzes specific elimination of  L-serine  to pyruvate", "triple_list": [["L-serine", "AGONIST", "pyruvate"]]}, {"text": " Mouse brain serine racemase  catalyzes specific elimination of L-serine to  pyruvate   D-Serine was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the N-methyl-D-aspartate (NMDA)-type receptors", "triple_list": [["pyruvate", "ANTAGONIST", "to"]]}, {"text": "Racemization of  serine  is catalyzed by  serine  racemase  a pyridoxal 5'-phosphate-dependent enzyme expressed mainly in brain and liver", "triple_list": [["serine", "AGONIST", "serine"]]}, {"text": "EGF-stimulated phosphorylation of ERK and Bad is blocked by pretreatment with  U0126   a selective  MAP kinase kinase (MKK)1/2  inhibitor", "triple_list": [["is", "AGONIST", "MAP kinase kinase (MKK)1/2"]]}, {"text": " EGF  stimulated phosphorylation of ERK and Bad is blocked by pretreatment with  U0126   a selective MAP kinase kinase (MKK)1/2 inhibitor", "triple_list": [["U0126", "AGONIST", "phosphorylation"]]}, {"text": "EGF-stimulated phosphorylation of  ERK  and Bad is blocked by pretreatment with  U0126   a selective MAP kinase kinase (MKK)1/2 inhibitor", "triple_list": [["U0126", "AGONIST", "inhibitor"]]}, {"text": "EGF-stimulated phosphorylation of ERK and  Bad  is blocked by pretreatment with  U0126   a selective MAP kinase kinase (MKK)1/2 inhibitor", "triple_list": [["U0126", "PRODUCT-OF", "a"]]}, {"text": "Similarly, pretreatment with  sulindac sulfide  blocks the ability of  EGF  to induce ERK1/2 and Bad phosphorylation, but also down-regulates total Bad but not ERK1/2 protein levels", "triple_list": [["also", "AGONIST", "EGF"]]}, {"text": "Similarly, pretreatment with  sulindac sulfide  blocks the ability of EGF to induce ERK1/2 and  Bad  phosphorylation, but also down-regulates total  Bad  but not ERK1/2 protein levels", "triple_list": [["sulindac sulfide", "PRODUCT-OF", "down-regulates"]]}, {"text": "Similarly, pretreatment with  sulindac sulfide  blocks the ability of EGF to induce ERK1/2 and  Bad  phosphorylation, but also down-regulates total  Bad  but not ERK1/2 protein levels", "triple_list": [["ability", "PRODUCT-OF", "Bad"]]}, {"text": "The ability of  sulindac  to block  ERK1/2  signaling by the EGF receptor may account for at least part of its potent growth-inhibitory effects against cancer cells.", "triple_list": [["part", "ACTIVATOR", "ERK1/2"]]}, {"text": "The ability of  sulindac  to block ERK1/2 signaling by the  EGF receptor  may account for at least part of its potent growth-inhibitory effects against cancer cells.", "triple_list": [["sulindac", "ACTIVATOR", "by"]]}, {"text": " Sulindac  and selective  cyclooxygenase (COX)-2  inhibitors cause regression of colonic polyps in familial polyposis patients", "triple_list": [["and", "ACTIVATOR", "cyclooxygenase (COX)-2"]]}, {"text": " Sulindac  metabolites and other nonsteroidal anti-inflammatory drugs selectively inhibit  ERK1/2  phosphorylation in human colon cancer cells", "triple_list": [["Sulindac", "PRODUCT-OF", "human"]]}, {"text": " Sulindac sulfide  inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and  Bad  in human colon cancer cells", "triple_list": [["epidermal", "ANTAGONIST", "Bad"]]}, {"text": " Sulindac sulfide  inhibits  epidermal growth factor  induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells", "triple_list": [["cells", "PRODUCT-OF", "epidermal growth factor"]]}, {"text": "db/db mice treated with  DRF 2655  showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes  carnitine palmitoyltransferase  and carnitine acetyltransferase, respectively", "triple_list": [["5-", "AGONIST", "carnitine palmitoyltransferase"]]}, {"text": "db/db mice treated with  DRF 2655  showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and  carnitine acetyltransferase   respectively", "triple_list": [["in", "PRODUCT-OF", "carnitine acetyltransferase"]]}, {"text": "db/db mice treated with  DRF 2655  showed 5- and 3.6-fold inhibition in  phosphoenolpyruvate carboxykinase  and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively", "triple_list": [["DRF 2655", "ACTIVATOR", "2655"]]}, {"text": "db/db mice treated with  DRF 2655  showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and  glucose 6-phosphatase  activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively", "triple_list": [["and", "ACTIVATOR", "glucose 6-phosphatase"]]}, {"text": "OBJECTIVE: Preclinical evaluation of  DRF 2655   a peroxisome proliferator-activated receptor alpha (PPARalpha) and  PPARgamma  agonist, as a body-weight lowering, hypolipidemic and euglycemic agent", "triple_list": [["DRF 2655", "PRODUCT-OF", "PPARgamma"]]}, {"text": "OBJECTIVE: Preclinical evaluation of  DRF 2655   a  peroxisome proliferator-activated receptor alpha  (PPARalpha) and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent", "triple_list": [["DRF 2655", "ANTAGONIST", "and"]]}, {"text": "OBJECTIVE: Preclinical evaluation of  DRF 2655   a peroxisome proliferator-activated receptor alpha ( PPARalpha   and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent", "triple_list": [["receptor", "ACTIVATOR", "PPARalpha"]]}, {"text": "RESULTS:  DRF 2655  showed concentration-dependent transactivation of  PPARalpha  and PPARgamma", "triple_list": [["DRF 2655", "DOWNREGULATOR", "concentration-dependent"]]}, {"text": "RESULTS:  DRF 2655  showed concentration-dependent transactivation of PPARalpha and  PPARgamma   In the 3T3L1 cell-differentiation study,  DRF 2655  and rosiglitazone showed 369% and 471% increases, respectively, in triglyceride accumulation", "triple_list": [["DRF 2655", "PRODUCT-OF", "and"]]}, {"text": " Cetrorelix  completely blocked the rise of levels of the two most abundant species, 5.0 kb and 4.5 kb, of the  GnRH-R  mRNA, during both the infantile and the juvenile periods", "triple_list": [["rise", "ACTIVATOR", "GnRH-R"]]}, {"text": " Cetrorelix  also abolished the developmental rise of the  gonadotropin beta  subunit mRNAs during the two periods of the study", "triple_list": [["Cetrorelix", "AGONIST", "two"]]}, {"text": "With the use of  sildenafil   it has been clearly, clinically demonstrated that the selective inhibition of  PDE5  is an appropriate, effective, safe method for the treatment of ED of all aetiologies and severities.", "triple_list": [["inhibition", "ANTAGONIST", "PDE5"]]}, {"text": "Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of  sildenafil  (Viagra, Pfizer) - the first approved selective  PDE  inhibitor for the treatment of ED", "triple_list": [["post-marketing,", "PRODUCT-OF", "PDE"]]}, {"text": "Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of sildenafil ( Viagra   Pfizer) - the first approved selective  PDE  inhibitor for the treatment of ED", "triple_list": [["studies,", "ACTIVATOR", "PDE"]]}, {"text": " Sildenafil  is inhibitory of  PDE5  at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods", "triple_list": [["visual", "ANTAGONIST", "PDE5"]]}, {"text": " Sildenafil  is inhibitory of  PDE 5 at a rate tenfold higher than for the next  PDE  ( PDE 6), which produces visual changes through the retinal rods", "triple_list": [["Sildenafil", "AGONIST", "rate"]]}, {"text": " Sildenafil  is inhibitory of PDE5 at a rate tenfold higher than for the next PDE ( PDE6  , which produces visual changes through the retinal rods", "triple_list": [["PDE6", "PRODUCT-OF", "PDE6"]]}, {"text": "The scientific basis of this treatment of ED includes relaxation of the corpus cavernosum smooth muscle tissue by inhibition of  PDE5  that breaks down  cGMP   the key pathway for the production of erectile function in humans", "triple_list": [["humans", "DOWNREGULATOR", "PDE5"]]}, {"text": "administration of very low doses of  okadaic acid  (0.001-1 pg/mouse) and cantharidin (0.001-1 ng/mouse), which inhibit  PP2A   produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.)", "triple_list": [["okadaic acid", "ANTAGONIST", "dose-dependent"]]}, {"text": "administration of very low doses of okadaic acid (0.001-1 pg/mouse) and  cantharidin  (0.001-1 ng/mouse), which inhibit  PP2A   produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.)", "triple_list": [["acid", "ANTAGONIST", "PP2A"]]}, {"text": "On the other hand, high doses of  okadaic acid  (10 ng/mouse, i.c.v.) and cantharidin (1 microg/mouse, i.c.v.), which also block  PP1   and calyculin-A (0.1 fg/mouse-1 ng/mouse, i.c.v.), which inhibits equally both  PP1  and PP2A, did not modify the morphine-induced antinociception", "triple_list": [["which", "AGONIST", "PP1"]]}, {"text": "On the other hand, high doses of okadaic acid (10 ng/mouse, i.c.v.) and  cantharidin  (1 microg/mouse, i.c.v.), which also block  PP1   and calyculin-A (0.1 fg/mouse-1 ng/mouse, i.c.v.), which inhibits equally both  PP1  and PP2A, did not modify the morphine-induced antinociception", "triple_list": [["cantharidin", "PRODUCT-OF", "the"]]}, {"text": "On the other hand, high doses of okadaic acid (10 ng/mouse, i.c.v.) and cantharidin (1 microg/mouse, i.c.v.), which also block  PP1 , and  calyculin-A  (0.1 fg/mouse-1 ng/mouse, i.c.v.), which inhibits equally both  PP1  and PP2A, did not modify the morphine-induced antinociception", "triple_list": [["also", "AGONIST", "PP1"]]}, {"text": "On the other hand, high doses of okadaic acid (10 ng/mouse, i.c.v.) and cantharidin (1 microg/mouse, i.c.v.), which also block PP1, and  calyculin-A  (0.1 fg/mouse-1 ng/mouse, i.c.v.), which inhibits equally both PP1 and  PP2A   did not modify the morphine-induced antinociception", "triple_list": [["also", "PRODUCT-OF", "PP2A"]]}, {"text": "The ratio between the GDC/ SHMT  and C1-THF synthase/ SHMT  pathways of  Ser  synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1", "triple_list": [["Ser", "ACTIVATOR", "synthase/"]]}, {"text": "The ratio between the GDC/ SHMT  and C1-THF synthase/ SHMT  pathways of  Ser  synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1", "triple_list": [["[alpha-(13)C]Gly", "DOWNREGULATOR", "SHMT"]]}, {"text": "The ratio between the  GDC  SHMT and C1-THF synthase/SHMT pathways of Ser synthesis from  [alpha-(13)C]Gly  and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1", "triple_list": [["[alpha-(13)C]Gly", "ANTAGONIST", "9"]]}, {"text": "The ratio between the GDC/SHMT and  C1-THF synthase  SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and  [(13)C]formate   respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1", "triple_list": [["[(13)C]formate", "DOWNREGULATOR", ":"]]}, {"text": "On the other hand, the accumulation of  Ser  through the C1-THF synthase/ SHMT  pathway in glyD plants was 2.5-fold greater than that in WT plants", "triple_list": [["was", "ACTIVATOR", "SHMT"]]}, {"text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the  glycine  decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with  glycine  (Gly) as one-carbon (1-C) source", "triple_list": [["glycine", "ACTIVATOR", "(1-C)"]]}, {"text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the  glycine  decarboxylase complex ( GDC   EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with  glycine  (Gly) as one-carbon (1-C) source", "triple_list": [["glycine", "ACTIVATOR", "the"]]}, {"text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the  glycine  decarboxylase complex (GDC,  EC 2.1.1.10   and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with  glycine  (Gly) as one-carbon (1-C) source", "triple_list": [["glycine", "ANTAGONIST", "route"]]}, {"text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the  glycine  decarboxylase complex (GDC, EC 2.1.1.10) and  serine hydroxymethyltransferase  (SHMT, EC 2.1.2.1) with  glycine  (Gly) as one-carbon (1-C) source", "triple_list": [["glycine", "DOWNREGULATOR", "the"]]}, {"text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the  glycine  decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase ( SHMT   EC 2.1.2.1) with  glycine  (Gly) as one-carbon (1-C) source", "triple_list": [["glycine", "DOWNREGULATOR", "the"]]}, {"text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the  glycine  decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT,  EC 2.1.2.1   with  glycine  (Gly) as one-carbon (1-C) source", "triple_list": [["glycine", "DOWNREGULATOR", "(1-C)"]]}, {"text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the  glycine decarboxylase complex  (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine ( Gly   as one-carbon (1-C) source", "triple_list": [["Gly", "ANTAGONIST", "with"]]}, {"text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex ( GDC   EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine ( Gly   as one-carbon (1-C) source", "triple_list": [["Gly", "AGONIST", "Gly"]]}, {"text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC,  EC 2.1.1.10   and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine ( Gly   as one-carbon (1-C) source", "triple_list": [["glycine", "AGONIST", "EC 2.1.1.10"]]}, {"text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and  serine hydroxymethyltransferase  (SHMT, EC 2.1.2.1) with glycine ( Gly   as one-carbon (1-C) source", "triple_list": [["the", "ANTAGONIST", "serine hydroxymethyltransferase"]]}, {"text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase ( SHMT   EC 2.1.2.1) with glycine ( Gly   as one-carbon (1-C) source", "triple_list": [["the", "AGONIST", "SHMT"]]}, {"text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT,  EC 2.1.2.1   with glycine ( Gly   as one-carbon (1-C) source", "triple_list": [["as", "AGONIST", "EC 2.1.2.1"]]}, {"text": "An alternative THF-dependent pathway involves the  C1-THF synthase  SHMT activities with  formate  as 1-C source", "triple_list": [["as", "AGONIST", "C1-THF synthase"]]}, {"text": "An alternative THF-dependent pathway involves the C1-THF synthase/ SHMT  activities with  formate  as 1-C source", "triple_list": [["formate", "ACTIVATOR", "involves"]]}, {"text": "Firstly, transgenic plants overexpressing  formate  dehydrogenase (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in  formate  metabolism", "triple_list": [["function", "AGONIST", "formate dehydrogenase"]]}, {"text": "Firstly, transgenic plants overexpressing  formate  dehydrogenase ( FDH   EC 1.2.1.2) were used to continue our previous studies on the function of  FDH  in  formate  metabolism", "triple_list": [["used", "AGONIST", "FDH"]]}, {"text": "Firstly, transgenic plants overexpressing  formate  dehydrogenase (FDH,  EC 1.2.1.2   were used to continue our previous studies on the function of FDH in  formate  metabolism", "triple_list": [["on", "DOWNREGULATOR", "EC 1.2.1.2"]]}, {"text": "Firstly, transgenic plants overexpressing  formate  dehydrogenase ( FDH , EC 1.2.1.2) were used to continue our previous studies on the function of  FDH  in  formate  metabolism", "triple_list": [["function", "ACTIVATOR", "FDH"]]}, {"text": "We concluded that  FDH  has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of  formate  to CO(2) by the  FDH  reaction is the primary and preferred fate of the organic acid in Arabidopsis", "triple_list": [["to", "AGONIST", "FDH"]]}, {"text": "We concluded that  FDH  has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of formate to  CO(2)  by the  FDH  reaction is the primary and preferred fate of the organic acid in Arabidopsis", "triple_list": [["CO(2)", "ACTIVATOR", "Arabidopsis"]]}, {"text": "The beta subunit has been cloned and shown to lower the K(m) of  methionine adenosyltransferase II alpha2  (the MAT2A product) for methionine and to render the enzyme more susceptible to  S-adenosylmethionine  inhibition", "triple_list": [["S-adenosylmethionine", "PRODUCT-OF", "susceptible"]]}, {"text": "The beta subunit has been cloned and shown to lower the K(m) of methionine adenosyltransferase II alpha2 (the  MAT2A  product) for methionine and to render the enzyme more susceptible to  S-adenosylmethionine  inhibition", "triple_list": [["S-adenosylmethionine", "ACTIVATOR", "shown"]]}, {"text": "BACKGROUND & AIMS: Of the 2 genes ( MAT1A , MAT2A) encoding methionine adenosyltransferase, the enzyme that synthesizes  S-adenosylmethionine    MAT1A   is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues", "triple_list": [["S-adenosylmethionine", "ACTIVATOR", "whereas"]]}, {"text": "BACKGROUND & AIMS: Of the 2 genes ( MAT1A   MAT2A) encoding methionine adenosyltransferase, the enzyme that synthesizes  S-adenosylmethionine    MAT1A , is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues", "triple_list": [["expressed", "ACTIVATOR", "MAT1A"]]}, {"text": "BACKGROUND & AIMS: Of the 2 genes (MAT1A,  MAT2A   encoding methionine adenosyltransferase, the enzyme that synthesizes  S-adenosylmethionine   MAT1A, is expressed in liver, whereas  MAT2A  is expressed in extrahepatic tissues", "triple_list": [["S-adenosylmethionine", "ACTIVATOR", "expressed"]]}, {"text": "BACKGROUND & AIMS: Of the 2 genes (MAT1A, MAT2A) encoding  methionine adenosyltransferase   the enzyme that synthesizes  S-adenosylmethionine   MAT1A, is expressed in liver, whereas MAT2A is expressed in extrahepatic tissues", "triple_list": [["the", "ACTIVATOR", "methionine adenosyltransferase"]]}, {"text": "The beta subunit has been cloned and shown to lower the K(m) of  methionine  adenosyltransferase II alpha2 (the MAT2A product) for  methionine  and to render the enzyme more susceptible to S-adenosyl methionine  inhibition", "triple_list": [["II", "ACTIVATOR", "methionine adenosyltransferase II alpha2"]]}, {"text": "The beta subunit has been cloned and shown to lower the K(m) of  methionine  adenosyltransferase II alpha2 (the  MAT2A  product) for  methionine  and to render the enzyme more susceptible to S-adenosyl methionine  inhibition", "triple_list": [["methionine", "DOWNREGULATOR", "render"]]}, {"text": "The protein exhibited modest  H(2)O(2)  dependent  peroxidase  activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)", "triple_list": [["and", "PRODUCT-OF", "peroxidase"]]}, {"text": "The protein exhibited modest H(2)O(2)-dependent  peroxidase  activities with  guaiacol   potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)", "triple_list": [["guaiacol", "ACTIVATOR", "and"]]}, {"text": "The protein exhibited modest H(2)O(2)-dependent  peroxidase  activities with guaiacol,  potassium iodide   and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)", "triple_list": [["potassium iodide", "DOWNREGULATOR", "potassium"]]}, {"text": "The protein exhibited modest H(2)O(2)-dependent  peroxidase  activities with guaiacol, potassium iodide, and  2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid  (ABTS)", "triple_list": [["2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid", "AGONIST", "with"]]}, {"text": "The protein exhibited modest H(2)O(2)-dependent  peroxidase  activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid ( ABTS  ", "triple_list": [["iodide,", "AGONIST", "peroxidase"]]}, {"text": "However,  topiramate  at low concentrations causes slow inhibition of  GluR5  kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of  GluR5  kainate receptor responses.", "triple_list": [["topiramate", "AGONIST", "suppression"]]}, {"text": "However,  topiramate  at low concentrations causes slow inhibition of GluR5  kainate receptor  mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5  kainate receptor  responses.", "triple_list": [["topiramate", "ANTAGONIST", "it"]]}, {"text": "However,  topiramate  at low concentrations causes slow inhibition of  GluR5  kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of  GluR5  kainate receptor responses.", "triple_list": [["topiramate", "AGONIST", "currents"]]}, {"text": "However,  topiramate  at low concentrations causes slow inhibition of GluR5  kainate receptor -mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5  kainate receptor  responses.", "triple_list": [["protect", "PRODUCT-OF", "kainate receptor"]]}, {"text": "The selective  GluR5  kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the  GluR5  kainate receptor antagonist  LY293558   Intra-amygdala infusion of ATPA in the rat induces limbic status epilepticus; in some animals, recurrent spontaneous seizures occur for months after the ATPA treatment", "triple_list": [["agonist", "PRODUCT-OF", "GluR5"]]}, {"text": "The selective GluR5  kainate receptor  agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5  kainate receptor  antagonist  LY293558   Intra-amygdala infusion of ATPA in the rat induces limbic status epilepticus; in some animals, recurrent spontaneous seizures occur for months after the ATPA treatment", "triple_list": [["LY293558", "ACTIVATOR", "induces"]]}, {"text": "Purified  PAOh1  SMO oxidizes both  spermine  (K(m)=1.6 microM) and N(1)-acetyl spermine  (K(m)=51 microM), but does not oxidize spermidine", "triple_list": [["(K(m)=51", "ACTIVATOR", "PAOh1"]]}, {"text": "Purified PAOh1/ SMO  oxidizes both  spermine  (K(m)=1.6 microM) and N(1)-acetyl spermine  (K(m)=51 microM), but does not oxidize spermidine", "triple_list": [["not", "AGONIST", "SMO"]]}, {"text": "Purified  PAOh1  SMO oxidizes both spermine (K(m)=1.6 microM) and  N(1)-acetylspermine  (K(m)=51 microM), but does not oxidize spermidine", "triple_list": [["Purified", "DOWNREGULATOR", "PAOh1"]]}, {"text": "Purified PAOh1/ SMO  oxidizes both spermine (K(m)=1.6 microM) and  N(1)-acetylspermine  (K(m)=51 microM), but does not oxidize spermidine", "triple_list": [["(K(m)=51", "AGONIST", "SMO"]]}, {"text": "The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of  spermine  by  PAOh1  SMO", "triple_list": [["spermine", "AGONIST", "oxidize"]]}, {"text": "The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of  spermine  by PAOh1/ SMO   The results of these studies are consistent with the hypothesis that PAOh1/ SMO  represents a new addition to the polyamine metabolic pathway that may represent a new target for antineoplastic drug development.", "triple_list": [["purified", "DOWNREGULATOR", "SMO"]]}, {"text": "The discovery of an inducible  oxidase  whose apparent substrate preference is  spermine  indicates that polyamine catabolism is more complex than that originally proposed", "triple_list": [["spermine", "ANTAGONIST", "catabolism"]]}, {"text": "Even though the activities of  MAT  and GNMT were elevated, the concentration of liver  S-adenosylmethionine  was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice", "triple_list": [["S-adenosylmethionine", "ACTIVATOR", "increased"]]}, {"text": "Even though the activities of MAT and  GNMT  were elevated, the concentration of liver  S-adenosylmethionine  was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice", "triple_list": [["S-adenosylmethionine", "ANTAGONIST", "decreased"]]}, {"text": "Even though the activities of  MAT  and GNMT were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and  S-adenosylhomocysteine  increased (113%, p<0.001) in the dwarf mice", "triple_list": [["dwarf", "ANTAGONIST", "MAT"]]}, {"text": "Even though the activities of MAT and  GNMT  were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and  S-adenosylhomocysteine  increased (113%, p<0.001) in the dwarf mice", "triple_list": [["S-adenosylhomocysteine", "AGONIST", "and"]]}, {"text": "Treatment with  diclofenac  resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated  caspase-3  after 6 hr, indicating that  diclofenac  may cause apoptosis of neuronal cells via activation of the caspase cascade", "triple_list": [["diclofenac", "PRODUCT-OF", "after"]]}, {"text": "Treatment with  diclofenac  resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated  caspase -3 after 6 hr, indicating that  diclofenac  may cause apoptosis of neuronal cells via activation of the  caspase  cascade", "triple_list": [["-3", "DOWNREGULATOR", "caspase"]]}, {"text": " Kynurenic acid  (KA) is an endogenous  glutamate receptor  antagonist at the level of the different ionotropic  glutamate receptor s", "triple_list": [["Kynurenic acid", "ACTIVATOR", "antagonist"]]}, {"text": " Kynurenic acid  (KA) is an endogenous glutamate receptor antagonist at the level of the different  ionotropic glutamate receptors   One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)", "triple_list": [["enzymes", "AGONIST", "ionotropic glutamate receptors"]]}, {"text": "Kynurenic acid ( KA   is an endogenous  glutamate receptor  antagonist at the level of the different ionotropic  glutamate receptor s", "triple_list": [["receptor", "DOWNREGULATOR", "glutamate receptor"]]}, {"text": "Kynurenic acid ( KA   is an endogenous glutamate receptor antagonist at the level of the different  ionotropic glutamate receptors   One of the enzymes responsible for the production of  KA , kynurenine aminotransferase I ( KA TI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)", "triple_list": [["Kynurenic", "DOWNREGULATOR", "ionotropic glutamate receptors"]]}, {"text": "One of the enzymes responsible for the production of  KA    kynurenine aminotransferase I  ( KA TI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)", "triple_list": [["transamination", "ANTAGONIST", "kynurenine aminotransferase I"]]}, {"text": "One of the enzymes responsible for the production of  KA   kynurenine aminotransferase I ( KA TI , also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15)", "triple_list": [["glutamine", "AGONIST", "KATI"]]}, {"text": "One of the enzymes responsible for the production of KA,  kynurenine aminotransferase I  (KATI), also catalyses the reversible transamination of  glutamine  to oxoglutaramic acid (GTK, EC 2.6.1.15)", "triple_list": [["(KATI),", "ANTAGONIST", "kynurenine aminotransferase I"]]}, {"text": "One of the enzymes responsible for the production of KA, kynurenine aminotransferase I ( KATI  , also catalyses the reversible transamination of  glutamine  to oxoglutaramic acid (GTK, EC 2.6.1.15)", "triple_list": [["glutamine", "AGONIST", "transamination"]]}, {"text": "One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of  glutamine  to oxoglutaramic acid ( GTK   EC 2.6.1.15)", "triple_list": [["glutamine", "ANTAGONIST", "EC"]]}, {"text": "One of the enzymes responsible for the production of KA,  kynurenine aminotransferase I  (KATI), also catalyses the reversible transamination of glutamine to  oxoglutaramic acid  (GTK, EC 2.6.1.15)", "triple_list": [["of", "AGONIST", "kynurenine aminotransferase I"]]}, {"text": "One of the enzymes responsible for the production of KA, kynurenine aminotransferase I ( KATI  , also catalyses the reversible transamination of glutamine to  oxoglutaramic acid  (GTK, EC 2.6.1.15)", "triple_list": [["(", "ACTIVATOR", "KATI"]]}, {"text": "One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to  oxoglutaramic acid  ( GTK   EC 2.6.1.15)", "triple_list": [["production", "ACTIVATOR", "GTK"]]}, {"text": "One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to  oxoglutaramic acid  (GTK,  EC 2.6.1.15  ", "triple_list": [["transamination", "DOWNREGULATOR", "EC 2.6.1.15"]]}, {"text": "These compounds are competitive and, in a few cases, non-competitive inhibitors for  AChE   the most potent being compound (14), though three-fold less active than  tacrine   The BuChE inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than  tacrine ", "triple_list": [["the", "ANTAGONIST", "AChE"]]}, {"text": "The acetylcholinesterase ( AChE   and butyrylcholinesterase (BuChE) inhibitory activities of a series of  pyrano[2,3-b]quinolines  (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["acetylcholinesterase", "AGONIST", "AChE"]]}, {"text": "The acetylcholinesterase (AChE) and  butyrylcholinesterase  (BuChE) inhibitory activities of a series of  pyrano[2,3-b]quinolines  (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["inhibitory", "PRODUCT-OF", "butyrylcholinesterase"]]}, {"text": "The  acetylcholinesterase  (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of  pyrano[2,3-b]quinolines  (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["pyrano[2,3-b]quinolines", "AGONIST", "of"]]}, {"text": "The acetylcholinesterase (AChE) and butyrylcholinesterase ( BuChE   inhibitory activities of a series of  pyrano[2,3-b]quinolines  (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["(AChE)", "PRODUCT-OF", "BuChE"]]}, {"text": "The  BuChE  inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than  tacrine   Furthermore, the products 12 and 13 are selective and moderate AChE inhibitors.", "triple_list": [["14,", "AGONIST", "BuChE"]]}, {"text": "The acetylcholinesterase ( AChE   and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3),  [1,8]naphthyridines  (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["[1,8]naphthyridines", "AGONIST", "(BuChE)"]]}, {"text": "The acetylcholinesterase (AChE) and  butyrylcholinesterase  (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3),  [1,8]naphthyridines  (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["(16)", "PRODUCT-OF", "butyrylcholinesterase"]]}, {"text": "The  acetylcholinesterase  (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3),  [1,8]naphthyridines  (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["of", "ACTIVATOR", "acetylcholinesterase"]]}, {"text": "The acetylcholinesterase (AChE) and butyrylcholinesterase ( BuChE   inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3),  [1,8]naphthyridines  (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["acetylcholinesterase", "ANTAGONIST", "BuChE"]]}, {"text": "The acetylcholinesterase ( AChE   and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6),  4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines  (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["series", "ANTAGONIST", "AChE"]]}, {"text": "The acetylcholinesterase (AChE) and  butyrylcholinesterase  (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6),  4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines  (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines", "AGONIST", "of"]]}, {"text": "The  acetylcholinesterase  (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6),  4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines  (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["(11-13)/", "PRODUCT-OF", "acetylcholinesterase"]]}, {"text": "The acetylcholinesterase (AChE) and butyrylcholinesterase ( BuChE   inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6),  4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines  (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines", "PRODUCT-OF", "are"]]}, {"text": "The acetylcholinesterase ( AChE   and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/  4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine  (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["and", "AGONIST", "AChE"]]}, {"text": "The acetylcholinesterase (AChE) and  butyrylcholinesterase  (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/  4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine  (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine", "PRODUCT-OF", "[1,8]naphthyridines"]]}, {"text": "The  acetylcholinesterase  (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/  4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine  (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine", "ACTIVATOR", "acetylcholinesterase"]]}, {"text": "The acetylcholinesterase (AChE) and butyrylcholinesterase ( BuChE   inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/  4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine  (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["[1,8]naphthyridines", "PRODUCT-OF", "BuChE"]]}, {"text": "The acetylcholinesterase ( AChE   and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14),  4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline  (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["series", "AGONIST", "AChE"]]}, {"text": "The acetylcholinesterase (AChE) and  butyrylcholinesterase  (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14),  4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline  (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline", "ACTIVATOR", "inhibitory"]]}, {"text": "The  acetylcholinesterase  (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14),  4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline  (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["(14),", "ANTAGONIST", "acetylcholinesterase"]]}, {"text": "The acetylcholinesterase (AChE) and butyrylcholinesterase ( BuChE   inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14),  4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline  (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described", "triple_list": [["4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline", "PRODUCT-OF", "4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine"]]}, {"text": "The acetylcholinesterase ( AChE   and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/  4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine  (16) are described", "triple_list": [["4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine", "AGONIST", "(5,"]]}, {"text": "The acetylcholinesterase (AChE) and  butyrylcholinesterase  (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/  4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine  (16) are described", "triple_list": [["4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline", "AGONIST", "butyrylcholinesterase"]]}, {"text": "The  acetylcholinesterase  (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/  4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine  (16) are described", "triple_list": [["4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine", "PRODUCT-OF", "activities"]]}, {"text": "The acetylcholinesterase (AChE) and butyrylcholinesterase ( BuChE   inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/  4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine  (16) are described", "triple_list": [["(11-13)/", "AGONIST", "BuChE"]]}, {"text": "Nevertheless, 3 mM  DMA   a higher concentration that inhibits  NHE1   NHE2, and NHE3, significantly increased DBS", "triple_list": [["DMA", "PRODUCT-OF", "NHE2,"]]}, {"text": "Nevertheless, 3 mM  DMA   a higher concentration that inhibits NHE1,  NHE2   and NHE3, significantly increased DBS", "triple_list": [["DMA", "ANTAGONIST", "and"]]}, {"text": "Nevertheless, 3 mM  DMA   a higher concentration that inhibits NHE1, NHE2, and  NHE3   significantly increased DBS", "triple_list": [["DMA", "ANTAGONIST", "3"]]}, {"text": "Moreover,  S1611  and S3226, both specific inhibitors of  NHE3  only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH", "triple_list": [["S1611", "ACTIVATOR", "and"]]}, {"text": "Moreover, S1611 and  S3226   both specific inhibitors of  NHE3  only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH", "triple_list": [["S3226", "AGONIST", "Na+-free"]]}, {"text": "Nevertheless, coperfusion with 0.1 and 0.3 mM  5-nitro-2-(3-phenylpropylamino) benzoic acid   which inhibits the  cystic fibrosis transmembrane conductor regulator  (CFTR), dose dependently inhibited S3226-induced DBS", "triple_list": [["(CFTR),", "AGONIST", "cystic fibrosis transmembrane conductor regulator"]]}, {"text": "Nevertheless, coperfusion with 0.1 and 0.3 mM  5-nitro-2-(3-phenylpropylamino) benzoic acid   which inhibits the cystic fibrosis transmembrane conductor regulator ( CFTR  , dose dependently inhibited S3226-induced DBS", "triple_list": [["5-nitro-2-(3-phenylpropylamino) benzoic acid", "PRODUCT-OF", "acid"]]}, {"text": " 5-(N,N-dimethyl)-amiloride  (50 microM; DMA), a concentration that selectively inhibits the  NHE  isoforms  NHE 1 and  NHE 2, but not  NHE 3, did not affect DBS", "triple_list": [["5-(N,N-dimethyl)-amiloride", "ACTIVATOR", "and"]]}, {"text": " 5-(N,N-dimethyl)-amiloride  (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms  NHE1  and NHE2, but not NHE3, did not affect DBS", "triple_list": [["5-(N,N-dimethyl)-amiloride", "AGONIST", "a"]]}, {"text": " 5-(N,N-dimethyl)-amiloride  (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and  NHE2   but not NHE3, did not affect DBS", "triple_list": [["DMA),", "PRODUCT-OF", "NHE2"]]}, {"text": " 5-(N,N-dimethyl)-amiloride  (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not  NHE3   did not affect DBS", "triple_list": [["DBS", "ACTIVATOR", "NHE3"]]}, {"text": "5-(N,N-dimethyl)-amiloride (50 microM;  DMA  , a concentration that selectively inhibits the  NHE  isoforms  NHE 1 and  NHE 2, but not  NHE 3, did not affect DBS", "triple_list": [["DMA", "ACTIVATOR", "not"]]}, {"text": "5-(N,N-dimethyl)-amiloride (50 microM;  DMA  , a concentration that selectively inhibits the NHE isoforms  NHE1  and NHE2, but not NHE3, did not affect DBS", "triple_list": [["DMA", "PRODUCT-OF", "NHE"]]}, {"text": "5-(N,N-dimethyl)-amiloride (50 microM;  DMA  , a concentration that selectively inhibits the NHE isoforms NHE1 and  NHE2   but not NHE3, did not affect DBS", "triple_list": [["DMA", "ACTIVATOR", ","]]}, {"text": "5-(N,N-dimethyl)-amiloride (50 microM;  DMA  , a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not  NHE3   did not affect DBS", "triple_list": [["DMA", "AGONIST", "not"]]}, {"text": "In conclusion, only specific apical NHE3 inhibition increased DBS, whereas prostaglandin synthesis, Na+- HCO3 - cotransporter activation, or intracellular  HCO3   formation by  carbonic anhydrase  was not involved", "triple_list": [["HCO3", "AGONIST", "carbonic"]]}, {"text": "Inhibition of  GluR5  kainate receptors could represent a key mechanism underlying the anticonvulsant activity of  topiramate   Moreover, these results support the concept that  GluR5  kainate receptors represent a novel target for antiepileptic drug development.", "triple_list": [["topiramate", "AGONIST", "for"]]}, {"text": "Inhibition of GluR5  kainate receptors  could represent a key mechanism underlying the anticonvulsant activity of  topiramate   Moreover, these results support the concept that GluR5  kainate receptors  represent a novel target for antiepileptic drug development.", "triple_list": [["kainate", "ANTAGONIST", "kainate receptors"]]}, {"text": "In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala,  topiramate  at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by  kainate receptors  containing the GluR5 subunit", "triple_list": [["topiramate", "ANTAGONIST", "amygdala,"]]}, {"text": "In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala,  topiramate  at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by kainate receptors containing the  GluR5  subunit", "triple_list": [["topiramate", "PRODUCT-OF", "excitatory"]]}, {"text": " Topiramate  also partially depressed predominantly  AMPA-receptor  mediated EPSCs, but with lower efficacy", "triple_list": [["EPSCs,", "ANTAGONIST", "AMPA-receptor"]]}, {"text": "Selective antagonism of  GluR5  kainate-receptor-mediated synaptic currents by  topiramate  in rat basolateral amygdala neurons", "triple_list": [["topiramate", "PRODUCT-OF", "rat"]]}, {"text": "Selective antagonism of GluR5  kainate-receptor  mediated synaptic currents by  topiramate  in rat basolateral amygdala neurons", "triple_list": [["basolateral", "DOWNREGULATOR", "kainate-receptor"]]}, {"text": "Weekly subcutaneous  decitabine  produces cumulative increases in  HbF  and total hemoglobin through a noncytotoxic mechanism of action", "triple_list": [["decitabine", "ANTAGONIST", "Weekly"]]}, {"text": "Weekly subcutaneous  decitabine  produces cumulative increases in HbF and total  hemoglobin  through a noncytotoxic mechanism of action", "triple_list": [["decitabine", "PRODUCT-OF", "subcutaneous"]]}, {"text": "We examined if subcutaneous  decitabine  could increase  HbF  levels and improve SSD pathophysiology without cytotoxicity", "triple_list": [["decitabine", "ANTAGONIST", "subcutaneous"]]}, {"text": "The  cytosine  analog 5-aza-2'-deoxycytidine (decitabine) hypomethylates DNA by inhibiting  DNA methyltransferase   We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity", "triple_list": [["cytosine", "AGONIST", "cytotoxicity"]]}, {"text": "The cytosine analog  5-aza-2'-deoxycytidine  (decitabine) hypomethylates DNA by inhibiting  DNA methyltransferase   We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity", "triple_list": [["SSD", "ANTAGONIST", "DNA methyltransferase"]]}, {"text": "The cytosine analog 5-aza-2'-deoxycytidine ( decitabine   hypomethylates DNA by inhibiting  DNA methyltransferase   We examined if subcutaneous  decitabine  could increase HbF levels and improve SSD pathophysiology without cytotoxicity", "triple_list": [["cytotoxicity", "ANTAGONIST", "DNA methyltransferase"]]}, {"text": " Aliskiren  represents the first in a novel class of  renin  inhibitors with the potential for treatment of hypertension and related cardiovascular diseases.", "triple_list": [["Aliskiren", "PRODUCT-OF", "in"]]}, {"text": "This led to the discovery of  aliskiren   a highly potent and selective inhibitor of  human renin  in vitro, and in vivo; once-daily oral doses of  aliskiren  inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients", "triple_list": [["aliskiren", "ACTIVATOR", "and"]]}, {"text": "This led to the discovery of  aliskiren , a highly potent and selective inhibitor of human  renin  in vitro, and in vivo; once-daily oral doses of  aliskiren  inhibit  renin  and lower blood pressure in sodium-depleted marmosets and hypertensive human patients", "triple_list": [["aliskiren", "ANTAGONIST", "vivo;"]]}, {"text": "Structure-based design of  aliskiren   a novel orally effective  renin  inhibitor", "triple_list": [["aliskiren", "AGONIST", "Structure-based"]]}, {"text": "CONCLUSION: A long-term intake of ethanol solution down-regulates the phosphorylation of  CREB  in the nucleus accumbens, and those changes can be reversed by  naloxone   which may be one kind of the molecular mechanisms associated with ethanol dependence.", "triple_list": [["naloxone", "ANTAGONIST", "ethanol"]]}, {"text": "The decrement of  p-CREB  protein in the nucleus accumbens remained at 24 h (-35 %) and 72 h (-28 %) of  ethanol  withdrawal, which recovered toward control level after 7 d of  ethanol  withdrawal", "triple_list": [["ethanol", "PRODUCT-OF", "at"]]}, {"text": "The decrement of  p-CREB  protein in the nucleus accumbens remained at 24 h (-35 %) and 72 h (-28 %) of  ethanol  withdrawal, which recovered toward control level after 7 d of  ethanol  withdrawal", "triple_list": [["ethanol", "ANTAGONIST", "(-28"]]}, {"text": "However, when naloxone was administered concurrently with  ethanol  treatment, it antagonized the down-regulation of  p-CREB  protein in the nucleus accumbens (142 %) of rats exposed to  ethanol ", "triple_list": [["ethanol", "PRODUCT-OF", "down-regulation"]]}, {"text": "However, when naloxone was administered concurrently with  ethanol  treatment, it antagonized the down-regulation of  p-CREB  protein in the nucleus accumbens (142 %) of rats exposed to  ethanol   CONCLUSION: A long-term intake of  ethanol  solution down-regulates the phosphorylation of CREB in the nucleus accumbens, and those changes can be reversed by naloxone, which may be one kind of the molecular mechanisms associated with  ethanol  dependence.", "triple_list": [["ethanol", "PRODUCT-OF", "of"]]}, {"text": "CONCLUSION: A long-term intake of  ethanol  solution down-regulates the phosphorylation of  CREB  in the nucleus accumbens, and those changes can be reversed by naloxone, which may be one kind of the molecular mechanisms associated with  ethanol  dependence.", "triple_list": [["ethanol", "ACTIVATOR", "associated"]]}, {"text": "RESULTS:  Ethanol  given to rats in drinking water decreased the level of  p-CREB  protein in the nucleus accumbens (-75 %) at the time of exposure to ethanol", "triple_list": [["in", "AGONIST", "p-CREB"]]}, {"text": " 2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid  (1) is a potent  AMPA receptor  agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of  AMPA receptor s", "triple_list": [["agonist", "PRODUCT-OF", "AMPA receptor"]]}, {"text": "The failure of the myometrium to respond to  ritodrine  (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and  beta 2-adrenergic receptor  concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls", "triple_list": [["animals", "ACTIVATOR", "beta 2-adrenergic receptor"]]}, {"text": "Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the  isoprenaline  responses of the atria and the pA2 values were 8.60 and 8.98 at the  beta 1-adrenoceptors  of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors", "triple_list": [["and", "ANTAGONIST", "beta 1-adrenoceptors"]]}, {"text": " Labetalol  (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the  beta 1-adrenoceptors  of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors", "triple_list": [["M)", "DOWNREGULATOR", "beta 1-adrenoceptors"]]}, {"text": "Labetalol (> or = 3 x 10(-8) M) and  dilevalol  (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the  beta 1-adrenoceptors  of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors", "triple_list": [["dilevalol", "DOWNREGULATOR", "and"]]}, {"text": "The isoprenaline attenuation responses of the portal vein were inhibited by  labetalol  and dilevalol (both at > or = 10(-7) M) and the pA2 value for the  labetalol  at  beta 2-adrenoceptors  was 7.59", "triple_list": [["labetalol", "ACTIVATOR", "labetalol"]]}, {"text": "It is concluded that  labetalol  and dilevalol are  beta 1-adrenoceptor  selective antagonists.", "triple_list": [["labetalol", "DOWNREGULATOR", "dilevalol"]]}, {"text": "It is concluded that labetalol and  dilevalol  are  beta 1-adrenoceptor  selective antagonists.", "triple_list": [["labetalol", "AGONIST", "beta 1-adrenoceptor"]]}, {"text": "These results suggest that  prostacyclin  may play a role in downregulating  tissue factor  expression in monocytes, at least in part via elevation of intracellular levels of cyclic AMP.", "triple_list": [["prostacyclin", "ANTAGONIST", "a"]]}, {"text": "These results suggest that prostacyclin may play a role in downregulating  tissue factor  expression in monocytes, at least in part via elevation of intracellular levels of  cyclic AMP  ", "triple_list": [["cyclic AMP", "PRODUCT-OF", "suggest"]]}, {"text": "The present studies were undertaken to determine whether stable analogues of  prostacyclin   a potent endothelium-derived platelet inhibitor and vasodilator, could inhibit  tissue factor  expression by human monocytic cells", "triple_list": [["analogues", "ANTAGONIST", "tissue factor"]]}, {"text": "Preincubation for 30 minutes with  iloprost   ciprostene, and carbacyclin led to a dose-dependent inhibition of  tissue factor  expression induced by all three challenging agents", "triple_list": [["of", "AGONIST", "tissue factor"]]}, {"text": "Preincubation for 30 minutes with iloprost,  ciprostene   and carbacyclin led to a dose-dependent inhibition of  tissue factor  expression induced by all three challenging agents", "triple_list": [["carbacyclin", "PRODUCT-OF", "tissue factor"]]}, {"text": "Preincubation for 30 minutes with iloprost, ciprostene, and  carbacyclin  led to a dose-dependent inhibition of  tissue factor  expression induced by all three challenging agents", "triple_list": [["carbacyclin", "PRODUCT-OF", "three"]]}, {"text": " Prostacyclin  analogues inhibit  tissue factor  expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism", "triple_list": [["factor", "ANTAGONIST", "tissue factor"]]}, {"text": "This effect was potentiated by  isobutylmethylxanthine   an inhibitor of  phosphodiesterase   The inhibitory effects of iloprost on tissue factor expression were also potentiated by  isobutylmethylxanthine  and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP", "triple_list": [["isobutylmethylxanthine", "AGONIST", "inhibitory"]]}, {"text": "The inhibitory effects of iloprost on  tissue factor  expression were also potentiated by  isobutylmethylxanthine  and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP", "triple_list": [["isobutylmethylxanthine", "ANTAGONIST", "dibutyryl"]]}, {"text": "The inhibitory effects of iloprost on  tissue factor  expression were also potentiated by isobutylmethylxanthine and mimicked by  forskolin  and dibutyryl cyclic AMP but not dibutyryl cyclic GMP", "triple_list": [["and", "ANTAGONIST", "tissue factor"]]}, {"text": "The inhibitory effects of iloprost on  tissue factor  expression were also potentiated by isobutylmethylxanthine and mimicked by forskolin and d ibutyryl cyclic AMP  but not dibutyryl cyclic GMP", "triple_list": [["ibutyryl cyclic AMP", "AGONIST", "ibutyryl"]]}, {"text": "On study day 1,  candoxatril  acutely increased plasma  ANP  levels, suppressed aldosterone and decreased right atrial and pulmonary capillary wedge pressures", "triple_list": [["candoxatril", "DOWNREGULATOR", "suppressed"]]}, {"text": "On study day 10, the acute effects of  candoxatril  were similar to those on day 1 (i.e.,  ANP  was further increased, aldosterone was suppressed, and right and left ventricular filling pressures were decreased)", "triple_list": [["1", "PRODUCT-OF", "ANP"]]}, {"text": " Candoxatril  is a novel, orally active inhibitor of  neutral endopeptidase  EC 3.4.24.11, the enzyme that degrades atrial natriuretic peptide (ANP)", "triple_list": [["Candoxatril", "PRODUCT-OF", "atrial"]]}, {"text": " Candoxatril  is a novel, orally active inhibitor of neutral endopeptidase  EC 3.4.24.11   the enzyme that degrades atrial natriuretic peptide (ANP)", "triple_list": [["Candoxatril", "ANTAGONIST", "degrades"]]}, {"text": "Effectiveness of  endopeptidase  inhibition ( candoxatril   in congestive heart failure", "triple_list": [["candoxatril", "ACTIVATOR", "inhibition"]]}, {"text": "These results suggest that  clomipramine  induces hyperglycemia in mice by blocking the  5-HT(2B )  nd/or 5-HT(2C) receptors, which results in facilitation of adrenaline release.", "triple_list": [["induces", "ACTIVATOR", "5-HT(2B )"]]}, {"text": "These results suggest that  clomipramine  induces hyperglycemia in mice by blocking the 5-HT(2B )and/or  5-HT(2C)  receptors, which results in facilitation of adrenaline release.", "triple_list": [["clomipramine", "AGONIST", "of"]]}, {"text": "The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the  5-HT(1A/1B)-receptor  antagonist  (-)-propranolol  and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it", "triple_list": [["(-)-propranolol", "PRODUCT-OF", "antagonist"]]}, {"text": "The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the  5-HT(3/4)-receptor  antagonist  tropisetron  did not affect it", "triple_list": [["hyperglycemia,", "AGONIST", "5-HT(3/4)-receptor"]]}, {"text": "The  5-HT(2B/2C)-receptor  antagonist  SB 206553  facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect", "triple_list": [["ketanserin", "PRODUCT-OF", "5-HT(2B/2C)-receptor"]]}, {"text": "The 5-HT(2B/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the  5-HT(2A)  receptor antagonist  ketanserin  was without effect", "triple_list": [["ketanserin", "DOWNREGULATOR", "clomipramine,"]]}, {"text": "The 5-HT(1/2/5/7)-receptor antagonist methysergide and the  5-HT(2A/2B/2C)-receptor  antagonist  LY 53857  enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it", "triple_list": [["methysergide", "AGONIST", "5-HT(2A/2B/2C)-receptor"]]}, {"text": "The potent  histamine H(1)-receptor  antagonist  cetirizine  (Zyrtec) is a racemic mixture of levo cetirizine  (now available under the trademark Xyzal and dextro cetirizine ", "triple_list": [["the", "PRODUCT-OF", "histamine H(1)-receptor"]]}, {"text": "The potent  histamine H(1)-receptor  antagonist cetirizine ( Zyrtec   is a racemic mixture of levocetirizine (now available under the trademark Xyzal and dextrocetirizine", "triple_list": [["(now", "AGONIST", "histamine H(1)-receptor"]]}, {"text": "The potent  histamine H(1)-receptor  antagonist cetirizine (Zyrtec) is a racemic mixture of  levocetirizine  (now available under the trademark Xyzal and dextrocetirizine", "triple_list": [["potent", "DOWNREGULATOR", "histamine H(1)-receptor"]]}, {"text": "Compared pharmacological characteristics in humans of racemic  cetirizine  and levo cetirizine , two  histamine H1-receptor  antagonists", "triple_list": [["characteristics", "ACTIVATOR", "histamine H1-receptor"]]}, {"text": "Compared pharmacological characteristics in humans of racemic cetirizine and  levocetirizine   two  histamine H1-receptor  antagonists", "triple_list": [["Compared", "AGONIST", "histamine H1-receptor"]]}, {"text": "The potent  histamine H(1)-receptor  antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark  Xyzal  and dextrocetirizine", "triple_list": [["Xyzal", "ACTIVATOR", "dextrocetirizine"]]}, {"text": "The potent  histamine H(1)-receptor  antagonist cetirizine (Zyrtec) is a racemic mixture of levocetirizine (now available under the trademark Xyzal and  dextrocetirizine   In this Commentary, we examine some biological properties of cetirizine and levocetirizine, namely enantioselectivity in pharmacological activity and pharmacokinetic properties, with emphasis on the possibility of racemization, the compared behavior of the two enantiomers, and the potential for interactions with other drugs", "triple_list": [["dextrocetirizine", "AGONIST", "racemization,"]]}, {"text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor  chloramine T  (CT), to destroy  plasmatic PAI-1  and alpha2-antiplasmin", "triple_list": [["Ten", "AGONIST", "plasmatic PAI-1"]]}, {"text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor  chloramine T  (CT), to destroy plasmatic PAI-1 and alpha2-anti plasmin   After 0 to 80 minutes (37 degrees C), 50-microL samples were withdrawn and added to 100 microL 1.5 M arginine, pH 8.7, and oxidized with 50 microL of 20 mM CT", "triple_list": [["that", "PRODUCT-OF", "plasmin"]]}, {"text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T ( CT  , to destroy  plasmatic PAI-1  and alpha2-antiplasmin", "triple_list": [["CT", "PRODUCT-OF", "was"]]}, {"text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen (1O2) donor chloramine T ( CT  , to destroy plasmatic PAI-1 and alpha2-anti plasmin   After 0 to 80 minutes (37 degrees C), 50-microL samples were withdrawn and added to 100 microL 1.5 M arginine, pH 8.7, and oxidized with 50 microL of 20 mM  CT ", "triple_list": [["CT", "PRODUCT-OF", "was"]]}, {"text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the  singlet oxygen  (1O2) donor chloramine T (CT), to destroy  plasmatic PAI-1  and alpha2-antiplasmin", "triple_list": [["singlet oxygen", "ANTAGONIST", "and"]]}, {"text": "Ten IU/mL urokinase was also incubated with pooled plasma of stroke patients, that was previously oxidized with the singlet oxygen ( 1O2   donor chloramine T (CT), to destroy  plasmatic PAI-1  and alpha2-antiplasmin", "triple_list": [["stroke", "PRODUCT-OF", "plasmatic PAI-1"]]}, {"text": "For determination of  plasmin  activity, 10 microL thereof was incubated with 150 microL 1.5 M  arginine   pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C)", "triple_list": [["(15", "DOWNREGULATOR", "plasmin"]]}, {"text": "For determination of [ PA  Pli]-activity,  arginine  was added after this incubation", "triple_list": [["determination", "AGONIST", "PA"]]}, {"text": "For determination of [PA+ Pli  -activity,  arginine  was added after this incubation", "triple_list": [["determination", "ACTIVATOR", "Pli"]]}, {"text": " P2Y(2) receptor  agonist  INS37217  enhances functional recovery after detachment caused by subretinal injection in normal and rds mice", "triple_list": [["INS37217", "DOWNREGULATOR", "after"]]}, {"text": "Activation of  alpha 2B-adrenoceptors  mediates the cardiovascular effects of  etomidate   BACKGROUND: The intravenous anesthetic  etomidate  exhibits structural similarities to specific alpha2-adrenoceptor agonists of the type such as dexmedetomidine", "triple_list": [["etomidate", "PRODUCT-OF", "etomidate"]]}, {"text": "In alpha2B-receptor-expressing HEK293 cells,  etomidate  rapidly increased phosphorylation of the  extracellular signal-related kinases  ERK1/2", "triple_list": [["alpha2B-receptor-expressing", "AGONIST", "extracellular signal-related kinases"]]}, {"text": "In alpha2B-receptor-expressing HEK293 cells,  etomidate  rapidly increased phosphorylation of the extracellular signal-related kinases  ERK1/2   CONCLUSIONS: These results indicate that  etomidate  acts as an agonist at alpha2-adrenoceptors, which appears in vivo primarily as an alpha2B-receptor-mediated increase in blood pressure", "triple_list": [["cells,", "DOWNREGULATOR", "ERK1/2"]]}, {"text": "METHODS: Sedative and cardiovascular responses to etomidate and the alpha2-agonist,  dexmedetomidine   were determined in mice deficient in  alpha2-receptor  subtypes", "triple_list": [["dexmedetomidine", "ANTAGONIST", "in"]]}, {"text": "BACKGROUND: The intravenous anesthetic etomidate exhibits structural similarities to specific  alpha2-adrenoceptor  agonists of the type such as  dexmedetomidine   The current study was performed to elucidate the possible interaction of etomidate with  alpha2-adrenoceptor s in mice lacking individual  alpha2-adrenoceptor  subtypes (alpha2-KO)", "triple_list": [["to", "DOWNREGULATOR", "alpha2-adrenoceptor"]]}, {"text": "CONCLUSIONS: These results indicate that  etomidate  acts as an agonist at  alpha2-adrenoceptors   which appears in vivo primarily as an alpha2B-receptor-mediated increase in blood pressure", "triple_list": [["etomidate", "ANTAGONIST", "primarily"]]}, {"text": "Inhibition of binding of the  alpha2-receptor  antagonist  [3H]RX821002  to recombinant  alpha2-receptor s by etomidate was tested in human embryonic kidney (HEK293) cells in vitro", "triple_list": [["[3H]RX821002", "DOWNREGULATOR", "Inhibition"]]}, {"text": "Inhibition of binding of the alpha2-receptor antagonist  [3H]RX821002  to recombinant  alpha2-receptors  by etomidate was tested in human embryonic kidney (HEK293) cells in vitro", "triple_list": [["[3H]RX821002", "AGONIST", "by"]]}, {"text": "In membranes from HEK293 cells transfected with  alpha2-receptors   etomidate inhibited binding of the alpha2-antagonist,  [3H]RX821002   with higher potency from alpha2B- and alpha2C-receptors than from alpha2A-receptors (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm)", "triple_list": [["[3H]RX821002", "PRODUCT-OF", "(Ki"]]}, {"text": "In membranes from HEK293 cells transfected with alpha2-receptors, etomidate inhibited binding of the alpha2-antagonist,  [3H]RX821002   with higher potency from alpha2B- and alpha2C-receptors than from  alpha2A-receptors  (Ki alpha2A 208 microm, alpha2B 26 microm, alpha2C 56 microm)", "triple_list": [["[3H]RX821002", "DOWNREGULATOR", "with"]]}, {"text": " Cat-1   the transporter for the essential  amino acids   arginine and lysine, is one of the up-regulated genes", "triple_list": [["amino acids", "AGONIST", "up-regulated"]]}, {"text": " Cat-1   the transporter for the essential amino acids,  arginine  and lysine, is one of the up-regulated genes", "triple_list": [["arginine", "AGONIST", "essential"]]}, {"text": " Cat-1   the transporter for the essential amino acids, arginine and  lysine   is one of the up-regulated genes", "triple_list": [["the", "DOWNREGULATOR", "Cat-1"]]}, {"text": "Blockade of  NMDA receptors  by  memantine  could theoretically confer disease-modifying activity in AD by inhibiting the \"weak\" NMDA receptor-dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia", "triple_list": [["memantine", "AGONIST", "the"]]}, {"text": "Blockade of  NMDA receptor s by  memantine  could theoretically confer disease-modifying activity in AD by inhibiting the \"weak\"  NMDA receptor  dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia", "triple_list": [["the", "PRODUCT-OF", "NMDA receptor"]]}, {"text": "Moreover, recent in vitro studies suggest that  memantine  abrogates  beta-amyloid  (Abeta) toxicity and possibly inhibits Abeta production", "triple_list": [["memantine", "AGONIST", "suggest"]]}, {"text": "Moreover, recent in vitro studies suggest that  memantine  abrogates beta-amyloid ( Abeta   toxicity and possibly inhibits  Abeta  production", "triple_list": [["memantine", "ACTIVATOR", "Moreover,"]]}, {"text": "Moreover, recent in vitro studies suggest that  memantine  abrogates beta-amyloid ( Abeta ) toxicity and possibly inhibits  Abeta  production", "triple_list": [["studies", "AGONIST", "Abeta"]]}, {"text": " Memantine  is an uncompetitive (channel blocking)  NMDA receptor  antagonist", "triple_list": [["Memantine", "DOWNREGULATOR", "(channel"]]}, {"text": "Like other  NMDA receptor  antagonists,  memantine  at high concentrations can inhibit mechanisms of synaptic plasticity that are believed to underlie learning and memory", "triple_list": [["memantine", "AGONIST", "memantine"]]}, {"text": "Considerable attention has focused on the investigation of theories to explain the better tolerability of  memantine  over other  NMDA receptor  antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801)", "triple_list": [["investigation", "ACTIVATOR", "NMDA receptor"]]}, {"text": "BACKGROUND:  Rivastigmine  is a carbamate drug designed to inhibit both  acetylcholinesterase  and butyrylcholinesterase by reversibly covalently bonding to these enzymes", "triple_list": [["reversibly", "PRODUCT-OF", "acetylcholinesterase"]]}, {"text": "BACKGROUND:  Rivastigmine  is a carbamate drug designed to inhibit both acetylcholinesterase and  butyrylcholinesterase  by reversibly covalently bonding to these enzymes", "triple_list": [["Rivastigmine", "AGONIST", "reversibly"]]}, {"text": "BACKGROUND: Rivastigmine is a  carbamate  drug designed to inhibit both  acetylcholinesterase  and butyrylcholinesterase by reversibly covalently bonding to these enzymes", "triple_list": [["these", "AGONIST", "acetylcholinesterase"]]}, {"text": "BACKGROUND: Rivastigmine is a  carbamate  drug designed to inhibit both acetylcholinesterase and  butyrylcholinesterase  by reversibly covalently bonding to these enzymes", "triple_list": [["BACKGROUND:", "ACTIVATOR", "butyrylcholinesterase"]]}, {"text": "Glycylsarcosine coadministration could inhibit the uptake of  cefadroxil  in  PEPT2  +/+) mice (p < 0.01) but not  PEPT2 (-/-) mice", "triple_list": [["mice", "AGONIST", "PEPT2"]]}, {"text": "Glycylsarcosine coadministration could inhibit the uptake of  cefadroxil  in  PEPT2 (+/+) mice (p < 0.01) but not  PEPT2  -/-) mice", "triple_list": [["cefadroxil", "ACTIVATOR", "(+/+)"]]}, {"text": "Although a proton-stimulated uptake of  cefadroxil  was demonstrated in  PEPT2  +/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in  PEPT2 (-/-) mice", "triple_list": [["observed", "ANTAGONIST", "PEPT2"]]}, {"text": "Although a proton-stimulated uptake of  cefadroxil  was demonstrated in  PEPT2 (+/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in  PEPT2  -/-) mice", "triple_list": [["demonstrated", "AGONIST", "PEPT2"]]}, {"text": "Mechanisms of  cefadroxil  uptake in the choroid plexus: studies in wild-type and  PEPT2  knockout mice", "triple_list": [["cefadroxil", "DOWNREGULATOR", "cefadroxil"]]}, {"text": "These findings demonstrate that  PEPT2  is the primary transporter responsible for  cefadroxil  uptake in the choroid plexus", "triple_list": [["cefadroxil", "AGONIST", "cefadroxil"]]}, {"text": "At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM  cefadroxil  was reduced by 83% in  PEPT2  -/-) mice as compared with  PEPT2 (+/+) mice (p < 0.001)", "triple_list": [["cefadroxil", "DOWNREGULATOR", "degrees"]]}, {"text": "At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM  cefadroxil  was reduced by 83% in  PEPT2 (-/-) mice as compared with  PEPT2  +/+) mice (p < 0.001)", "triple_list": [["as", "DOWNREGULATOR", "PEPT2"]]}, {"text": "The choroid plexus uptake of  [(3)H]cefadroxil  was studied in  peptide transporter 2  (PEPT2) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability", "triple_list": [["of", "DOWNREGULATOR", "peptide transporter 2"]]}, {"text": "The choroid plexus uptake of  [(3)H]cefadroxil  was studied in peptide transporter 2 ( PEPT2   wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability", "triple_list": [["[(3)H]cefadroxil", "ACTIVATOR", "choroid"]]}, {"text": "Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma  IL-6  level would be in periphery; at least in part, mediated by blocking nor epinephrine - and/or  epinephrine  induced increase of  IL-6  level in macrophage rather than in the brain", "triple_list": [["epinephrine", "ANTAGONIST", "at"]]}, {"text": "Ginsenosides Rb2, Rd and Rg1 significantly decreased  norepinephrine  and/or epinephrine-induced increase of  IL-6  level in macrophage cell line (RAW 264.7)", "triple_list": [["norepinephrine", "DOWNREGULATOR", "increase"]]}, {"text": "Ginsenosides Rb2, Rd and Rg1 significantly decreased nor epinephrine  and/or  epinephrine  induced increase of  IL-6  level in macrophage cell line (RAW 264.7)", "triple_list": [["of", "PRODUCT-OF", "IL-6"]]}, {"text": "Thus, it can be suggested that the inhibitory action of ginseng saponins against the immobilization stress-induced increase of plasma  IL-6  level would be in periphery; at least in part, mediated by blocking  norepinephrine   and/or epinephrine-induced increase of  IL-6  level in macrophage rather than in the brain", "triple_list": [["be", "DOWNREGULATOR", "IL-6"]]}, {"text": "The inhibitory effect of  ginseng saponins  on the stress-induced plasma  interleukin-6  level in mice", "triple_list": [["ginseng saponins", "AGONIST", "plasma"]]}, {"text": "Ginseng total  saponins   ginsenosides Rb2, Rg1 and Rd administered intraperitoneally attenuated the immobilization stress-induced increase in plasma  IL-6  level", "triple_list": [["saponins", "ACTIVATOR", "saponins"]]}, {"text": "Ginseng total saponins,  ginsenosides Rb2, Rg1 and Rd  administered intraperitoneally attenuated the immobilization stress-induced increase in plasma  IL-6  level", "triple_list": [["and", "ACTIVATOR", "IL-6"]]}, {"text": " Ginsenosides Rb2, Rd and Rg1  significantly decreased norepinephrine and/or epinephrine-induced increase of  IL-6  level in macrophage cell line (RAW 264.7)", "triple_list": [["level", "AGONIST", "IL-6"]]}, {"text": "Thus, it can be suggested that the inhibitory action of  ginseng saponins  against the immobilization stress-induced increase of plasma  IL-6  level would be in periphery; at least in part, mediated by blocking norepinephrine- and/or epinephrine-induced increase of  IL-6  level in macrophage rather than in the brain", "triple_list": [["it", "AGONIST", "IL-6"]]}, {"text": "Thus, it can be suggested that the inhibitory action of  ginseng saponins  against the immobilization stress-induced increase of plasma  IL-6  level would be in periphery; at least in part, mediated by blocking norepinephrine- and/or epinephrine-induced increase of  IL-6  level in macrophage rather than in the brain", "triple_list": [["immobilization", "PRODUCT-OF", "IL-6"]]}, {"text": "The  alpha(1)-adrenoceptor  antagonist,  tamsulosin   is selective for alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors", "triple_list": [["is", "AGONIST", "alpha(1)-adrenoceptor"]]}, {"text": "The alpha(1)-adrenoceptor antagonist,  tamsulosin   is selective for  alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors   Both placebo-controlled and comparative studies with other agents have demonstrated  tamsulosin  to be an effective treatment for patients with lower urinary symptoms suggestive of benign prostatic hyperplasia", "triple_list": [["for", "DOWNREGULATOR", "alpha(1A)- and alpha(1D)- over alpha(1B)-adrenoceptors"]]}, {"text": "On the other hand, in patients with a mean serum  carvedilol  level (Cmin) of less than 2.5 nmol/l up to 2 weeks after the start of carvedilol  therapy, the degree of reduction in the  BNP  value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol/l", "triple_list": [["other", "ACTIVATOR", "BNP"]]}, {"text": "On the other hand, in patients with a mean serum  carvedilol  level (Cmin) of less than 2.5 nmol/l up to 2 weeks after the start of carvedilol  therapy, the degree of reduction in the  BNP  value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol/l", "triple_list": [["the", "AGONIST", "BNP"]]}, {"text": " CPT I  (carnitine palmitoyltransferase I) catalyses the conversion of palmitoyl-CoA into  palmitoylcarnitine  in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria", "triple_list": [["palmitoyl-CoA", "DOWNREGULATOR", "CPT I"]]}, {"text": "CPT I ( carnitine palmitoyltransferase I   catalyses the conversion of palmitoyl-CoA into  palmitoylcarnitine  in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria", "triple_list": [["palmitoylcarnitine", "DOWNREGULATOR", "I"]]}, {"text": " CPT I  (carnitine palmitoyltransferase I) catalyses the conversion of  palmitoyl-CoA  into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria", "triple_list": [["I)", "ANTAGONIST", "CPT I"]]}, {"text": "CPT I ( carnitine palmitoyltransferase I   catalyses the conversion of  palmitoyl-CoA  into palmitoylcarnitine in the presence of L-carnitine, facilitating the entry of fatty acids into mitochondria", "triple_list": [["palmitoylcarnitine", "ACTIVATOR", "carnitine palmitoyltransferase I"]]}, {"text": " TAS-102  currently undergoing clinical trials, has been demonstrated to have at least two mechanisms, inhibition of  TS  and incorporation into DNA", "triple_list": [["TAS-102", "ANTAGONIST", "TAS-102"]]}, {"text": "In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and  thymidilate synthase  (TS) in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of  TAS-102   Antitumor activity of  TAS-102  appears to be associated with TK, tumor growth and TS", "triple_list": [["of", "PRODUCT-OF", "thymidilate synthase"]]}, {"text": "In the present study, we measured the enzyme activity of thymidine kinase (TK), thymidine phosphorylase (TP) and thymidilate synthase ( TS   in human cancer xenografts to investigate the contribution of these enzymes to the sensitivity of  TAS-102   Antitumor activity of  TAS-102  appears to be associated with TK, tumor growth and  TS ", "triple_list": [["phosphorylase", "AGONIST", "TS"]]}, {"text": "Sepracor in the US is developing ar formoterol  [R,R- formoterol ], a single isomer form of the  beta(2)-adrenoceptor  agonist  formoterol  [e formoterol ]", "triple_list": [["the", "ACTIVATOR", "beta(2)-adrenoceptor"]]}, {"text": "Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the  beta(2)-adrenoceptor  agonist formoterol [ eformoterol  ", "triple_list": [["Sepracor", "PRODUCT-OF", "beta(2)-adrenoceptor"]]}, {"text": "Increased phosphorylation of  p95ErbB2  and AKT in response to HRG was abrogated to varying degrees by  GW572016   In contrast, trastuzumab did not inhibit  p95ErbB2  phosphorylation or the expression of downstream phospho-Erk1/2, phospho-AKT, or cyclin D", "triple_list": [["GW572016", "PRODUCT-OF", "and"]]}, {"text": "Increased phosphorylation of p95ErbB2 and  AKT  in response to HRG was abrogated to varying degrees by  GW572016   In contrast, trastuzumab did not inhibit p95ErbB2 phosphorylation or the expression of downstream phospho-Erk1/2, phospho- AKT , or cyclin D", "triple_list": [["phosphorylation", "ANTAGONIST", "AKT"]]}, {"text": " GW572016   a reversible small molecule inhibitor of  EGFR  and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts", "triple_list": [["tumor", "ACTIVATOR", "EGFR"]]}, {"text": " GW572016   a reversible small molecule inhibitor of EGFR and  ErbB2  tyrosine kinases, inhibits baseline p95 ErbB2  phosphorylation in BT474 cells and tumor xenografts", "triple_list": [["ErbB2", "ANTAGONIST", "ErbB2"]]}, {"text": " GW572016   a reversible small molecule inhibitor of EGFR and ErbB2  tyrosine kinases   inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts", "triple_list": [["xenografts", "ACTIVATOR", "tyrosine kinases"]]}, {"text": " GW572016   a reversible small molecule inhibitor of EGFR and ErbB2 tyrosine kinases, inhibits baseline  p95ErbB2  phosphorylation in BT474 cells and tumor xenografts", "triple_list": [["GW572016", "AGONIST", "reversible"]]}, {"text": "Inhibition of  p95ErbB2   p185ErbB2, and EGFR phosphorylation by  GW572016  resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels", "triple_list": [["GW572016", "ANTAGONIST", "of"]]}, {"text": "Inhibition of p95ErbB2,  p185ErbB2   and EGFR phosphorylation by  GW572016  resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels", "triple_list": [["and", "PRODUCT-OF", "p185ErbB2"]]}, {"text": "Inhibition of p95ErbB2, p185ErbB2, and  EGFR  phosphorylation by  GW572016  resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels", "triple_list": [["GW572016", "ANTAGONIST", "in"]]}, {"text": "Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by  GW572016  resulted in the inhibition of downstream phospho- Erk1/2   phospho-AKT, and cyclin D steady-state protein levels", "triple_list": [["protein", "ANTAGONIST", "Erk1/2"]]}, {"text": "Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by  GW572016  resulted in the inhibition of downstream phospho-Erk1/2, phospho- AKT   and cyclin D steady-state protein levels", "triple_list": [["GW572016", "AGONIST", "D"]]}, {"text": "Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by  GW572016  resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and  cyclin D  steady-state protein levels", "triple_list": [["GW572016", "AGONIST", "by"]]}, {"text": "Truncated  ErbB2  receptor (p95 ErbB2 ) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ ErbB2  kinase inhibitor  GW572016   The expression of the NH2 terminally truncated  ErbB2  receptor (p95 ErbB2 ) in breast cancer correlates with metastatic disease progression compared with the expression of full-length p185 ErbB2 ", "triple_list": [["GW572016", "AGONIST", "ErbB3"]]}, {"text": "(3)H-CGP 12177A saturation binding, in the presence of  propranolol   increased approximately 5-fold following overexpression of  beta(1)-adrenoceptors   6", "triple_list": [["propranolol", "DOWNREGULATOR", "in"]]}, {"text": " CGP 12177A  mediates cardiostimulation by activation of the 'putative' beta(4)-adrenoceptor; however, it has recently been reported that disruption of the  beta(1)-adrenoceptor  gene abolishes this effect", "triple_list": [["gene", "DOWNREGULATOR", "beta(1)-adrenoceptor"]]}, {"text": " CGP 12177A  mediates cardiostimulation by activation of the 'putative'  beta(4)-adrenoceptor   however, it has recently been reported that disruption of the beta(1)-adrenoceptor gene abolishes this effect", "triple_list": [["CGP 12177A", "AGONIST", "has"]]}, {"text": " CGP 12177A  but not isoprenaline initiated arrhythmias at lower concentrations following  beta(1)-adrenoceptor  overexpression", "triple_list": [["CGP 12177A", "ANTAGONIST", "following"]]}, {"text": " (125)I-Cyanopindolol  saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in  beta(1)-adrenoceptors   (3)H-CGP 12177A saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of  beta(1)-adrenoceptors ", "triple_list": [["saturation", "AGONIST", "beta(1)-adrenoceptors"]]}, {"text": " (3)H-CGP 12177A  saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of  beta(1)-adrenoceptors   6", "triple_list": [["(3)H-CGP 12177A", "AGONIST", "presence"]]}, {"text": "Agents that have only begun to undergo clinical evaluation include  CI-1033   an irreversible pan- erbB  tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)", "triple_list": [["dual", "AGONIST", "erbB"]]}, {"text": "Agents that have only begun to undergo clinical evaluation include  CI-1033   an irreversible pan-erbB  tyrosine kinase  inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2)", "triple_list": [["growth", "ANTAGONIST", "tyrosine kinase"]]}, {"text": "Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine  kinase  inhibitor, and  PKI166  and GW572016, both examples of dual  kinase  inhibitors (inhibiting epidermal growth factor receptor and Her2)", "triple_list": [["PKI166", "PRODUCT-OF", "growth"]]}, {"text": "Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and  PKI166  and GW572016, both examples of dual kinase inhibitors (inhibiting  epidermal growth factor receptor  and Her2)", "triple_list": [["PKI166", "PRODUCT-OF", "Her2)"]]}, {"text": "Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and  PKI166  and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and  Her2  ", "triple_list": [["irreversible", "AGONIST", "Her2"]]}, {"text": "Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine  kinase  inhibitor, and PKI166 and  GW572016   both examples of dual  kinase  inhibitors (inhibiting epidermal growth factor receptor and Her2)", "triple_list": [["GW572016", "PRODUCT-OF", "(inhibiting"]]}, {"text": "Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and  GW572016   both examples of dual kinase inhibitors (inhibiting  epidermal growth factor receptor  and Her2)", "triple_list": [["and", "ACTIVATOR", "epidermal growth factor receptor"]]}, {"text": "Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and  GW572016   both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and  Her2  ", "triple_list": [["evaluation", "PRODUCT-OF", "Her2"]]}, {"text": " Epidermal growth factor receptor  inhibitors currently under investigation include the small molecules  gefitinib  (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)", "triple_list": [["receptor", "ACTIVATOR", "Epidermal growth factor receptor"]]}, {"text": " Epidermal growth factor receptor  inhibitors currently under investigation include the small molecules gefitinib ( Iressa   ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)", "triple_list": [["Iressa", "AGONIST", "antibodies"]]}, {"text": " Epidermal growth factor receptor  inhibitors currently under investigation include the small molecules gefitinib (Iressa,  ZD1839   and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)", "triple_list": [["receptor", "PRODUCT-OF", "Epidermal growth factor receptor"]]}, {"text": " Epidermal growth factor receptor  inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and  erlotinib  (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)", "triple_list": [["the", "AGONIST", "Epidermal growth factor receptor"]]}, {"text": " Epidermal growth factor receptor  inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib ( Tarceva   OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)", "triple_list": [["Tarceva", "AGONIST", "(Iressa,"]]}, {"text": " Epidermal growth factor receptor  inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva,  OSI-774  , as well as monoclonal antibodies such as cetuximab (IMC-225, Erbitux)", "triple_list": [["OSI-774", "PRODUCT-OF", "small"]]}, {"text": " Epidermal growth factor receptor  inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as  cetuximab  (IMC-225, Erbitux)", "triple_list": [["small", "AGONIST", "Epidermal growth factor receptor"]]}, {"text": " Epidermal growth factor receptor  inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab ( IMC-225   Erbitux)", "triple_list": [["gefitinib", "ANTAGONIST", "Epidermal growth factor receptor"]]}, {"text": " Epidermal growth factor receptor  inhibitors currently under investigation include the small molecules gefitinib (Iressa, ZD1839) and erlotinib (Tarceva, OSI-774), as well as monoclonal antibodies such as cetuximab (IMC-225,  Erbitux  ", "triple_list": [["ZD1839)", "ACTIVATOR", "Epidermal growth factor receptor"]]}, {"text": " Phosphatidylserine  (PtdSer) is made in mammalian cells by two  PtdSer synthases   PSS1 and PSS2", "triple_list": [["made", "DOWNREGULATOR", "PtdSer synthases"]]}, {"text": " Phosphatidylserine  (PtdSer) is made in mammalian cells by two PtdSer synthases,  PSS1  and PSS2", "triple_list": [["Phosphatidylserine", "AGONIST", "PSS1"]]}, {"text": " Phosphatidylserine  (PtdSer) is made in mammalian cells by two PtdSer synthases, PSS1 and  PSS2   In the plasma membrane PtdSer is normally localized on the inner leaflet but undergoes transbilayer movement during apoptosis and becomes exposed on the cell surface", "triple_list": [["on", "ACTIVATOR", "PSS2"]]}, {"text": "Moreover, a normal level of expression of  PSS1  and/or PSS2 is not required for generating the pool of  PtdSer  externalized during apoptosis.", "triple_list": [["PtdSer", "AGONIST", "generating"]]}, {"text": "Moreover, a normal level of expression of PSS1 and/or  PSS2  is not required for generating the pool of  PtdSer  externalized during apoptosis.", "triple_list": [["level", "DOWNREGULATOR", "PSS2"]]}, {"text": "In this study, we have synthesized novel  alpha-hydroxyphenylamide  analogues of diphenylhydantoin and examined their ability to inhibit  human Na(V)1.5  sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells", "triple_list": [["ability", "AGONIST", "human Na(V)1.5"]]}, {"text": "In this study, we have synthesized novel  alpha-hydroxyphenylamide  analogues of diphenylhydantoin and examined their ability to inhibit human Na(V)1.5  sodium channels  expressed in Chinese Hamster Ovary (CHO-K1) cells", "triple_list": [["channels", "AGONIST", "sodium channels"]]}, {"text": "In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of  diphenylhydantoin  and examined their ability to inhibit  human Na(V)1.5  sodium channels expressed in Chinese Hamster Ovary (CHO-K1) cells", "triple_list": [["diphenylhydantoin", "ACTIVATOR", "expressed"]]}, {"text": "In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of  diphenylhydantoin  and examined their ability to inhibit human Na(V)1.5  sodium channels  expressed in Chinese Hamster Ovary (CHO-K1) cells", "triple_list": [["synthesized", "PRODUCT-OF", "sodium channels"]]}, {"text": "In comparison to  diphenylhydantoin   the novel chloro-substituted alpha-hydroxyphenylamide compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of  Na(V)1.5  channels with an IC(50) value of 14.5 microM", "triple_list": [["diphenylhydantoin", "AGONIST", "14.5"]]}, {"text": "In comparison to diphenylhydantoin, the novel  chloro  substituted alpha-hydroxyphenylamide compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of  Na(V)1.5  channels with an IC(50) value of 14.5 microM", "triple_list": [["chloro", "ACTIVATOR", "as"]]}, {"text": "In comparison to diphenylhydantoin, the novel chloro-substituted  alpha-hydroxyphenylamide  compounds produced as much as a 20-fold greater tonic and frequency-dependent blockade of  Na(V)1.5  channels with an IC(50) value of 14.5 microM", "triple_list": [["alpha-hydroxyphenylamide", "ACTIVATOR", "frequency-dependent"]]}, {"text": " Phenytoin  (diphenylhydantoin, DPH) is an established  sodium channel  blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain", "triple_list": [["Phenytoin", "PRODUCT-OF", "and"]]}, {"text": "Block of human NaV1.5  sodium channels  by novel  alpha-hydroxyphenylamide  analogues of phenytoin", "triple_list": [["alpha-hydroxyphenylamide", "ACTIVATOR", "alpha-hydroxyphenylamide"]]}, {"text": "Block of  human NaV1.5  sodium channels by novel  alpha-hydroxyphenylamide  analogues of phenytoin", "triple_list": [["alpha-hydroxyphenylamide", "AGONIST", "of"]]}, {"text": "Block of human NaV1.5  sodium channels  by novel alpha-hydroxyphenylamide analogues of  phenytoin   Voltage-gated sodium (Na) channels are a critical component of electrically excitable cells", "triple_list": [["phenytoin", "ACTIVATOR", "sodium channels"]]}, {"text": "Block of  human NaV1.5  sodium channels by novel alpha-hydroxyphenylamide analogues of  phenytoin   Voltage-gated sodium (Na) channels are a critical component of electrically excitable cells", "triple_list": [["phenytoin", "AGONIST", "by"]]}, {"text": "Phenytoin ( diphenylhydantoin   DPH) is an established  sodium channel  blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain", "triple_list": [["(", "ANTAGONIST", "sodium channel"]]}, {"text": "Phenytoin (diphenylhydantoin,  DPH   is an established  sodium channel  blocker and is a useful anticonvulsant and class 1b antiarrhythmic, and has been effectively used in the treatment of neuropathic pain", "triple_list": [["DPH", "PRODUCT-OF", "established"]]}, {"text": "In this study, we have synthesized novel alpha-hydroxyphenylamide analogues of diphenylhydantoin and examined their ability to inhibit  human Na(V)1.5   sodium  channels expressed in Chinese Hamster Ovary (CHO-K1) cells", "triple_list": [["sodium", "AGONIST", "cells"]]}, {"text": "Block of  human NaV1.5   sodium  channels by novel alpha-hydroxyphenylamide analogues of phenytoin", "triple_list": [["human", "ACTIVATOR", "human NaV1.5"]]}, {"text": "Our results indicate that Salix extract 1520L inhibits  COX-2  mediated  PGE2  release through compounds other than salicin or salicylate", "triple_list": [["other", "AGONIST", "COX-2"]]}, {"text": "The IC50-values obtained for the inhibition of lipopolysaccharide (LPS)-induced release of prostaglandin E2 ( PGE2 ) reflecting  cyclooxygenase (COX)-2  mediated  PGE2  release were 47 microg/ml and 0.6 microg/ml, for the Salix extract 1520L and rofecoxib-like research compound L745337, respectively", "triple_list": [["(", "ANTAGONIST", "cyclooxygenase (COX)-2"]]}, {"text": "To investigate the mechanism and consequences of inhibition of  QR2  by the  quinolines  further, we have used steady-state and transient-state kinetics to define the mechanism of  QR2 ", "triple_list": [["QR2", "ACTIVATOR", "QR2"]]}, {"text": "To investigate the mechanism and consequences of inhibition of  QR2  by the  quinolines  further, we have used steady-state and transient-state kinetics to define the mechanism of  QR2   Importantly, we have shown that  QR2  when isolated from an overproducing strain of E", "triple_list": [["quinolines", "ANTAGONIST", "we"]]}, {"text": "Kinetic mechanism of  quinone oxidoreductase 2  and its inhibition by the antimalarial  quinolines   Quinone oxidoreductase 2 (QR2) purified from human red blood cells was recently shown to be a potential target of the quinoline antimalarial compounds [Graves et al., (2002) Mol", "triple_list": [["quinolines", "ANTAGONIST", "al.,"]]}, {"text": "Our studies shed light on the possible in vivo potency of the  quinolines  and provide a foundation for future studies aimed at creating more potent  QR2  inhibitors and at understanding the physiological significance of  QR2 .", "triple_list": [["provide", "AGONIST", "QR2"]]}, {"text": " QR2  catalyzes the two-electron reduction of menadione via the oxidation of N-alkylated or  N-ribosylated nicotinamides   To investigate the mechanism and consequences of inhibition of  QR2  by the quinolines further, we have used steady-state and transient-state kinetics to define the mechanism of  QR2 ", "triple_list": [["catalyzes", "DOWNREGULATOR", "QR2"]]}, {"text": " QR2  catalyzes the two-electron reduction of  menadione  via the oxidation of N-alkylated or N-ribosylated nicotinamides", "triple_list": [["menadione", "ANTAGONIST", "catalyzes"]]}, {"text": " QR2  catalyzes the two-electron reduction of menadione via the oxidation of  N-alkylated  or N-ribosylated nicotinamides", "triple_list": [["the", "AGONIST", "QR2"]]}, {"text": "Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] ( BLT-4  , blocked  ABCA1  mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)", "triple_list": [["BLT-4", "PRODUCT-OF", ","]]}, {"text": "Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] ( BLT-4  , blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of  SR-BI  (IC(50) approximately 55-60 microM)", "triple_list": [["a", "ACTIVATOR", "SR-BI"]]}, {"text": "Reciprocally,  glyburide  blocked SR-BI-mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of  ABCA1  (IC(50) approximately 275-300 microM)", "triple_list": [["glyburide", "AGONIST", "lipid"]]}, {"text": "Reciprocally,  glyburide  blocked  SR-BI  mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of ABCA1 (IC(50) approximately 275-300 microM)", "triple_list": [["glyburide", "AGONIST", "that"]]}, {"text": "Cross-inhibition of  SR-BI   and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and  glyburide   Scavenger receptor class B type I ( SR-BI ) and ABCA1 are structurally dissimilar cell surface proteins that play key roles in HDL metabolism", "triple_list": [["Scavenger", "ANTAGONIST", "SR-BI"]]}, {"text": "Cross-inhibition of SR-BI- and  ABCA1  mediated cholesterol transport by the small molecules BLT-4 and  glyburide   Scavenger receptor class B type I (SR-BI) and  ABCA1  are structurally dissimilar cell surface proteins that play key roles in HDL metabolism", "triple_list": [["glyburide", "ANTAGONIST", "BLT-4"]]}, {"text": "The reciprocal inhibition of  SR-BI  and ABCA1 by BLT-4 and  glyburide  raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport.", "triple_list": [["glyburide", "AGONIST", "similar"]]}, {"text": "The reciprocal inhibition of SR-BI and  ABCA1  by BLT-4 and  glyburide  raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport.", "triple_list": [["glyburide", "ACTIVATOR", "The"]]}, {"text": "The activities of  ABCA1  and other ATP binding cassette superfamily members are inhibited by the drug  glyburide   and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs", "triple_list": [["lipid", "PRODUCT-OF", "ABCA1"]]}, {"text": "The activities of ABCA1 and other  ATP binding cassette superfamily  members are inhibited by the drug  glyburide   and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs", "triple_list": [["glyburide", "ANTAGONIST", "other"]]}, {"text": "Here, we show that one  BLT   [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] ( BLT -4), blocked  ABCA1  mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)", "triple_list": [["inhibition", "AGONIST", "ABCA1"]]}, {"text": "Here, we show that one  BLT   [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] ( BLT -4), blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of  SR-BI  (IC(50) approximately 55-60 microM)", "triple_list": [["ABCA1-mediated", "ACTIVATOR", "SR-BI"]]}, {"text": "Here, we show that one BLT, [ 1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea   (BLT-4), blocked  ABCA1  mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)", "triple_list": [["1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea", "ANTAGONIST", "that"]]}, {"text": "Here, we show that one BLT, [ 1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea   (BLT-4), blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of  SR-BI  (IC(50) approximately 55-60 microM)", "triple_list": [["(BLT-4),", "ACTIVATOR", "SR-BI"]]}, {"text": "Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked  ABCA1  mediated  cholesterol  efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM)", "triple_list": [["(BLT-4),", "AGONIST", "ABCA1"]]}, {"text": "Cross-inhibition of  SR-BI   and ABCA1-mediated  cholesterol  transport by the small molecules BLT-4 and glyburide", "triple_list": [["cholesterol", "ANTAGONIST", "and"]]}, {"text": "Cross-inhibition of SR-BI- and  ABCA1  mediated  cholesterol  transport by the small molecules BLT-4 and glyburide", "triple_list": [["cholesterol", "DOWNREGULATOR", "BLT-4"]]}, {"text": " SR-BI  is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of  cholesteryl esters  from lipid-rich HDL to cells and the efflux of unesterified cholesterol from cells to HDL", "triple_list": [["HDL", "ANTAGONIST", "SR-BI"]]}, {"text": " SR-BI  is a receptor that binds HDL with high affinity and mediates both the selective lipid uptake of cholesteryl esters from lipid-rich HDL to cells and the efflux of unesterified  cholesterol  from cells to HDL", "triple_list": [["SR-BI", "ANTAGONIST", "SR-BI"]]}, {"text": " ABCA1  mediates the efflux of unesterified  cholesterol  and phospholipids from cells to lipid-poor apolipoprotein A-I (apoA-I)", "triple_list": [["phospholipids", "ANTAGONIST", "ABCA1"]]}, {"text": "Some of these derivatives showed good inhibitory potency against two  human CA  isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and  methazolamide   The lipophilicity of the best CA inhibitors was determined and expressed as their experimental log k' IAM and theoretical ClogP value", "triple_list": [["processes,", "ANTAGONIST", "human CA"]]}, {"text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes,  CA I   and  CA I I, of the same order of magnitude as the clinically used drugs acetazolamide and  methazolamide   The lipophilicity of the best CA inhibitors was determined and expressed as their experimental log k' IAM and theoretical ClogP value", "triple_list": [["methazolamide", "ACTIVATOR", "the"]]}, {"text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and  CA II   of the same order of magnitude as the clinically used drugs acetazolamide and  methazolamide   The lipophilicity of the best CA inhibitors was determined and expressed as their experimental log k' IAM and theoretical ClogP value", "triple_list": [["methazolamide", "PRODUCT-OF", "and"]]}, {"text": " Carbonic anhydrase  inhibitors:  aromatic and heterocyclic sulfonamides  incorporating adamantyl moieties with strong anticonvulsant activity", "triple_list": [["aromatic and heterocyclic sulfonamides", "PRODUCT-OF", "Carbonic"]]}, {"text": " Carbonic anhydrase  inhibitors: aromatic and heterocyclic sulfonamides incorporating  adamantyl  moieties with strong anticonvulsant activity", "triple_list": [["adamantyl", "PRODUCT-OF", "strong"]]}, {"text": "Some of these derivatives showed good inhibitory potency against two  human CA  isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs  acetazolamide  and methazolamide", "triple_list": [["isozymes", "AGONIST", "human CA"]]}, {"text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes,  CA I   and  CA I I, of the same order of magnitude as the clinically used drugs  acetazolamide  and methazolamide", "triple_list": [["acetazolamide", "ACTIVATOR", "of"]]}, {"text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and  CA II   of the same order of magnitude as the clinically used drugs  acetazolamide  and methazolamide", "triple_list": [["acetazolamide", "ANTAGONIST", "CA II"]]}, {"text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1,  kuraridin  ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on  diacylglycerol acyltransferase  (DGAT)", "triple_list": [["kuraridin", "AGONIST", "were"]]}, {"text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1,  kuraridin  ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase ( DGAT  ", "triple_list": [["kuraridin", "PRODUCT-OF", "the"]]}, {"text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2),  kurarinol  ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on  diacylglycerol acyltransferase  (DGAT)", "triple_list": [["flavescens", "ACTIVATOR", "diacylglycerol acyltransferase"]]}, {"text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2),  kurarinol  ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase ( DGAT  ", "triple_list": [["isolated", "ACTIVATOR", "DGAT"]]}, {"text": "These data suggest that the  lavandulyl  side chain and the position of the hydroxy group are important for high  DGAT  inhibitory activity", "triple_list": [["group", "ACTIVATOR", "DGAT"]]}, {"text": "These data suggest that the lavandulyl side chain and the position of the  hydroxy  group are important for high  DGAT  inhibitory activity", "triple_list": [["hydroxy", "AGONIST", "suggest"]]}, {"text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3),  kushenol H  ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on  diacylglycerol acyltransferase  (DGAT)", "triple_list": [["kushenol H", "ANTAGONIST", "("]]}, {"text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3),  kushenol H  ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase ( DGAT  ", "triple_list": [["kushenol H", "ANTAGONIST", "H"]]}, {"text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and  kushenol K  ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on  diacylglycerol acyltransferase  (DGAT)", "triple_list": [["were", "ACTIVATOR", "diacylglycerol acyltransferase"]]}, {"text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and  kushenol K  ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase ( DGAT  ", "triple_list": [["kushenol K", "AGONIST", "DGAT"]]}, {"text": "In vitro inhibition of  diacylglycerol acyltransferase  by  prenylflavonoids  from Sophora flavescens", "triple_list": [["prenylflavonoids", "AGONIST", "Sophora"]]}, {"text": "Four prenylflavonoids,  kurarinone  ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on  diacylglycerol acyltransferase  (DGAT)", "triple_list": [["kurarinone", "ACTIVATOR", "acyltransferase"]]}, {"text": "Four prenylflavonoids,  kurarinone  ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase ( DGAT  ", "triple_list": [["kurarinone", "PRODUCT-OF", "H"]]}, {"text": "The  flavonoids  inhibited  DGAT  activity in a dose-dependent manner with IC50 values of 10.9 microM ( 1), 9.8 microM ( 2), 8.6 microM ( 3), 142.0 microM ( 4) and 250 microM ( 5)", "triple_list": [["flavonoids", "PRODUCT-OF", "microM"]]}, {"text": "Four prenylflavonoids, kurarinone ( 1), a  chalcone  of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on  diacylglycerol acyltransferase  (DGAT)", "triple_list": [["chalcone", "PRODUCT-OF", "from"]]}, {"text": "Four prenylflavonoids, kurarinone ( 1), a  chalcone  of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase ( DGAT  ", "triple_list": [["chalcone", "ANTAGONIST", "were"]]}, {"text": "Four  prenylflavonoids   kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on  diacylglycerol acyltransferase  (DGAT)", "triple_list": [["prenylflavonoids", "AGONIST", "isolated"]]}, {"text": "Four  prenylflavonoids   kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase ( DGAT  ", "triple_list": [["2),", "ANTAGONIST", "DGAT"]]}, {"text": "At 10(-6)M in transcription assays, none of these compounds showed progestin agonist activity, whereas  mifepristone  and its monodemethylated metabolite manifested slight  glucocorticoid  agonist activity", "triple_list": [["agonist", "ANTAGONIST", "glucocorticoid"]]}, {"text": " I3A  induced a higher level of secretion of the inflammatory cytokine  interleukin 6  compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction", "triple_list": [["I3A", "AGONIST", "displayed"]]}, {"text": " I3A  induced a higher level of secretion of the inflammatory  cytokine  interleukin 6 compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction", "triple_list": [["I3A", "ANTAGONIST", "6"]]}, {"text": "I3A induced a higher level of secretion of the inflammatory cytokine  interleukin 6  compared with  PMA  in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction", "triple_list": [["in", "AGONIST", "interleukin 6"]]}, {"text": "I3A induced a higher level of secretion of the inflammatory  cytokine  interleukin 6 compared with  PMA  in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction", "triple_list": [["PMA", "DOWNREGULATOR", "the"]]}, {"text": "The in vitro kinase activity of  PKC-alpha  induced by  I3A  was lower than that induced by PMA", "triple_list": [["I3A", "DOWNREGULATOR", "kinase"]]}, {"text": "The in vitro kinase activity of  PKC-alpha  induced by I3A was lower than that induced by  PMA   The novel pattern of behavior of I3A makes it of great interest for further evaluation.", "triple_list": [["PMA", "PRODUCT-OF", "The"]]}, {"text": " PKC  isoforms did show different sensitivity and selectivity for down-regulation by  I3A  and phorbol 12-myristate 13-acetate (PMA) in WEHI-231, HOP-92, and Colo-205 cells", "triple_list": [["I3A", "ANTAGONIST", "cells"]]}, {"text": " PKC  isoforms did show different sensitivity and selectivity for down-regulation by I3A and  phorbol 12-myristate 13-acetate  (PMA) in WEHI-231, HOP-92, and Colo-205 cells", "triple_list": [["phorbol 12-myristate 13-acetate", "AGONIST", "sensitivity"]]}, {"text": " PKC  isoforms did show different sensitivity and selectivity for down-regulation by I3A and phorbol 12-myristate 13-acetate ( PMA   in WEHI-231, HOP-92, and Colo-205 cells", "triple_list": [["and", "ACTIVATOR", "PKC"]]}, {"text": " 5-FU  interferes with DNA synthesis by blocking  thymidylate synthase  (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD)", "triple_list": [["5-FU", "ACTIVATOR", "synthase"]]}, {"text": " 5-FU  interferes with DNA synthesis by blocking thymidylate synthase ( TS   but is inactivated by dihydropyrimidine dehydrogenase (DPD)", "triple_list": [["5-FU", "AGONIST", "5-FU"]]}, {"text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to  5-fluorouracil  (5-FU) by thymidine phosphorylase ( TP   inside target tissues", "triple_list": [["is", "DOWNREGULATOR", "TP"]]}, {"text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to  5-fluorouracil  (5-FU) by  thymidine phosphorylase  (TP) inside target tissues", "triple_list": [["to", "AGONIST", "thymidine phosphorylase"]]}, {"text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil ( 5-FU   by thymidine phosphorylase ( TP   inside target tissues", "triple_list": [["(", "AGONIST", "TP"]]}, {"text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil ( 5-FU   by  thymidine phosphorylase  (TP) inside target tissues", "triple_list": [["fluoropyrimidine", "DOWNREGULATOR", "thymidine phosphorylase"]]}, {"text": "PURPOSE: The  fluoropyrimidine carbamate  (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase ( TP   inside target tissues", "triple_list": [["fluoropyrimidine carbamate", "DOWNREGULATOR", "target"]]}, {"text": "PURPOSE: The  fluoropyrimidine carbamate  (capecitabine) is converted to 5-fluorouracil (5-FU) by  thymidine phosphorylase  (TP) inside target tissues", "triple_list": [["inside", "ACTIVATOR", "thymidine phosphorylase"]]}, {"text": "Favorable enzyme profiles (high  TP  and low DPD) generate high intratumor levels of  5-FU  that are effective against many tumors, especially those with low TS", "triple_list": [["5-FU", "DOWNREGULATOR", "of"]]}, {"text": "Favorable enzyme profiles (high TP and low  DPD   generate high intratumor levels of  5-FU  that are effective against many tumors, especially those with low TS", "triple_list": [["especially", "DOWNREGULATOR", "DPD"]]}, {"text": "PURPOSE: The fluoropyrimidine carbamate ( capecitabine   is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase ( TP   inside target tissues", "triple_list": [["capecitabine", "DOWNREGULATOR", "phosphorylase"]]}, {"text": "PURPOSE: The fluoropyrimidine carbamate ( capecitabine   is converted to 5-fluorouracil (5-FU) by  thymidine phosphorylase  (TP) inside target tissues", "triple_list": [["capecitabine", "ANTAGONIST", "converted"]]}, {"text": " SL-11158  inhibited  SSAT  activity with a mixed type of inhibition in which the analogue had a 70-fold higher affinity for the enzyme than the natural substrate, spermine", "triple_list": [["SL-11158", "ANTAGONIST", "SSAT"]]}, {"text": "bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [ BW-1 , a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of  BW-1   acted as substrate for  PAO   The Enc", "triple_list": [["BW-1", "ACTIVATOR", "bis(Ethyl)"]]}, {"text": "The  M564G  mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate,  acetyl-CoA   Kinetic constants of the mutant CrAT showed modification in favor of longer acyl-CoAs as substrates", "triple_list": [["lower", "AGONIST", "M564G"]]}, {"text": "The M564G mutated  CrAT  showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type  CrAT , and lower activity toward its natural substrate,  acetyl-CoA   Kinetic constants of the mutant  CrAT  showed modification in favor of longer acyl-CoAs as substrates", "triple_list": [["toward", "ANTAGONIST", "CrAT"]]}, {"text": "The M564G mutated  CrAT  showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type  CrAT   and lower activity toward its natural substrate,  acetyl-CoA   Kinetic constants of the mutant  CrAT  showed modification in favor of longer acyl-CoAs as substrates", "triple_list": [["acyl-CoAs", "DOWNREGULATOR", "CrAT"]]}, {"text": "Kinetic constants of the mutant  CrAT  showed modification in favor of longer  acyl-CoAs  as substrates", "triple_list": [["CrAT", "AGONIST", "CrAT"]]}, {"text": "In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in  carnitine octanoyltransferase  (COT) decreased activity toward its natural substrates, medium- and long-chain  acyl-CoAs   and increased activity toward short-chain  acyl-CoAs ", "triple_list": [["increased", "DOWNREGULATOR", "carnitine octanoyltransferase"]]}, {"text": "In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase ( COT   decreased activity toward its natural substrates, medium- and long-chain  acyl-CoAs   and increased activity toward short-chain  acyl-CoAs ", "triple_list": [["glycine", "ANTAGONIST", "COT"]]}, {"text": "In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in  carnitine octanoyltransferase  (COT) decreased activity toward its natural substrates, medium- and long-chain  acyl-CoAs , and increased activity toward short-chain  acyl-CoAs   Another CrAT mutant, M564A, was prepared and tested in the same way, with similar results", "triple_list": [["methionine", "AGONIST", "carnitine octanoyltransferase"]]}, {"text": "In the reverse case, mutation of the orthologous glycine (Gly553) to methionine in carnitine octanoyltransferase ( COT   decreased activity toward its natural substrates, medium- and long-chain  acyl-CoAs , and increased activity toward short-chain  acyl-CoAs   Another CrAT mutant, M564A, was prepared and tested in the same way, with similar results", "triple_list": [["acyl-CoAs", "AGONIST", "M564A,"]]}, {"text": "We conclude that Met564 blocks the entry of medium- and long-chain  acyl-CoAs  to the catalytic site of  CrAT   Three-dimensional models of wild-type and mutated  CrAT  and COT support this hypothesis", "triple_list": [["acyl-CoAs", "ACTIVATOR", "to"]]}, {"text": " Carnitine acetyltransferases  (CrAT) catalyze the reversible conversion of  acetyl-CoA  and carnitine to acetylcarnitine and free CoA", "triple_list": [["acetyl-CoA", "ANTAGONIST", "CoA"]]}, {"text": "Carnitine acetyltransferases ( CrAT   catalyze the reversible conversion of  acetyl-CoA  and carnitine to acetylcarnitine and free CoA", "triple_list": [["free", "DOWNREGULATOR", "CrAT"]]}, {"text": " Carnitine acetyltransferases  (CrAT) catalyze the reversible conversion of acetyl-CoA and  carnitine  to acetyl carnitine  and free CoA", "triple_list": [["(CrAT)", "ACTIVATOR", "Carnitine acetyltransferases"]]}, {"text": "Carnitine acetyltransferases ( CrAT   catalyze the reversible conversion of acetyl-CoA and  carnitine  to acetyl carnitine  and free CoA", "triple_list": [["Carnitine", "ANTAGONIST", "CrAT"]]}, {"text": " Carnitine acetyltransferases  (CrAT) catalyze the reversible conversion of acetyl-CoA and carnitine to  acetylcarnitine  and free CoA", "triple_list": [["acetylcarnitine", "DOWNREGULATOR", "and"]]}, {"text": "Carnitine acetyltransferases ( CrAT   catalyze the reversible conversion of acetyl-CoA and carnitine to  acetylcarnitine  and free CoA", "triple_list": [["reversible", "ANTAGONIST", "CrAT"]]}, {"text": "The  M564G  mutated CrAT showed higher activity toward longer chain  acyl-CoAs   activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA", "triple_list": [["acyl-CoAs", "ACTIVATOR", "CrAT,"]]}, {"text": "The M564G mutated  CrAT  showed higher activity toward longer chain  acyl-CoAs   activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type  CrAT , and lower activity toward its natural substrate, acetyl-CoA", "triple_list": [["acyl-CoAs", "ACTIVATOR", "acetyl-CoA"]]}, {"text": "The M564G mutated  CrAT  showed higher activity toward longer chain  acyl-CoAs   activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type  CrAT   and lower activity toward its natural substrate, acetyl-CoA", "triple_list": [["chain", "ANTAGONIST", "CrAT"]]}, {"text": "The  M564G  mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward  myristoyl-CoA  was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA", "triple_list": [["natural", "AGONIST", "M564G"]]}, {"text": "The M564G mutated  CrAT  showed higher activity toward longer chain acyl-CoAs: activity toward  myristoyl-CoA  was 1250-fold higher than that of the wild-type  CrAT , and lower activity toward its natural substrate, acetyl-CoA", "triple_list": [["myristoyl-CoA", "ANTAGONIST", "that"]]}, {"text": "The M564G mutated  CrAT  showed higher activity toward longer chain acyl-CoAs: activity toward  myristoyl-CoA  was 1250-fold higher than that of the wild-type  CrAT   and lower activity toward its natural substrate, acetyl-CoA", "triple_list": [["activity", "DOWNREGULATOR", "CrAT"]]}, {"text": "No influence of moderate hepatic impairment on the pharmacokinetics of  lumiracoxib   an oral  COX-2  selective inhibitor", "triple_list": [["of", "AGONIST", "COX-2"]]}, {"text": "The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel  cyclooxygenase-2  (COX-2) selective inhibitor  lumiracoxib  (Prexige), so that dose recommendations for clinical use can be provided", "triple_list": [["lumiracoxib", "AGONIST", "cyclooxygenase-2"]]}, {"text": "The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel cyclooxygenase-2 ( COX-2   selective inhibitor  lumiracoxib  (Prexige), so that dose recommendations for clinical use can be provided", "triple_list": [["lumiracoxib", "ACTIVATOR", "on"]]}, {"text": "The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel  cyclooxygenase-2  (COX-2) selective inhibitor lumiracoxib ( Prexige  , so that dose recommendations for clinical use can be provided", "triple_list": [["novel", "AGONIST", "cyclooxygenase-2"]]}, {"text": "The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel cyclooxygenase-2 ( COX-2   selective inhibitor lumiracoxib ( Prexige  , so that dose recommendations for clinical use can be provided", "triple_list": [["Prexige", "PRODUCT-OF", "influence"]]}, {"text": "bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists  SB224289  (300 microg/kg;  5-HT1B  , BRL15572 (300 microg/kg; 5-HT1D), rauwolscine (300 microg/kg; alpha2),  SB224289  + BRL15572 (300 microg/kg each),  SB224289  + rauwolscine (300 microg/kg each), BRL15572 + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1),  SB224289  (300 microg/kg) + prazosin (100 microg/kg),  SB224289  (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg),  SB224289  (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A),  SB224289  (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or  SB224289  (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)", "triple_list": [["SB224289", "ACTIVATOR", "microg/kg)"]]}, {"text": "bolus injection of, either physiological saline (0.3 ml/kg; control), or the antagonists SB224289 (300 microg/kg; 5-HT1B),  BRL15572  (300 microg/kg;  5-HT1D  , rauwolscine (300 microg/kg; alpha2), SB224289 +  BRL15572  (300 microg/kg each), SB224289 + rauwolscine (300 microg/kg each),  BRL15572  + rauwolscine (300 microg/kg each), rauwolscine (300 microg/kg) + prazosin (100 microg/kg; alpha1), SB224289 (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + rauwolscine (300 microg/kg) + prazosin (100 microg/kg), SB224289 (300 microg/kg) + prazosin (100 microg/kg) + BRL44408 (1,000 microg/kg; alpha2A), SB224289 (300 microg/kg) + prazosin (100 microg/kg)+ imiloxan (1,000 microg/kg; alpha2B), or SB224289 (300 microg/kg) + prazosin (100 microg/kg) + MK912 (300 microg/kg; alpha2C)", "triple_list": [["BRL15572", "ACTIVATOR", "(300"]]}, {"text": "To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of  PSMA  a series of  phenylalkylphosphonamidate  derivatives of glutamic acid were synthesized and evaluated for their inhibitory potencies against  PSMA   Both the phenyl- and benzylphosphonamidates (1a and 1b) exhibited only modest inhibitory potency against", "triple_list": [["phenylalkylphosphonamidate", "ACTIVATOR", "phenylalkylphosphonamidate"]]}, {"text": "To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of  PSMA  a series of phenylalkylphosphonamidate derivatives of  glutamic acid  were synthesized and evaluated for their inhibitory potencies against  PSMA   Both the phenyl- and benzylphosphonamidates (1a and 1b) exhibited only modest inhibitory potency against", "triple_list": [["glutamic acid", "PRODUCT-OF", "the"]]}, {"text": "These findings suggest that the anti-allodynia effect of  CP-101,606  is ascribable to blockade of  NR2B  receptors at the brain, but not at the spinal cord", "triple_list": [["brain,", "ACTIVATOR", "NR2B"]]}, {"text": "In order to examine the site of action of an  NR2B  subtype-selective NMDA antagonist  CP-101,606   we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration", "triple_list": [["of", "ACTIVATOR", "NR2B"]]}, {"text": "In order to examine the site of action of an NR2B subtype-selective  NMDA  antagonist  CP-101,606   we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration", "triple_list": [["CP-101,606", "PRODUCT-OF", "NR2B"]]}, {"text": "Brain but not spinal  NR2B  receptor is responsible for the anti-allodynic effect of an  NR2B  subunit-selective antagonist  CP-101,606  in a rat chronic constriction injury model", "triple_list": [["CP-101,606", "AGONIST", "rat"]]}, {"text": "Brain but not spinal  NR2B  receptor is responsible for the anti-allodynic effect of an  NR2B  subunit-selective antagonist  CP-101,606  in a rat chronic constriction injury model", "triple_list": [["CP-101,606", "ACTIVATOR", "is"]]}, {"text": "In contrast, intrathecal injection of a non-selective  NMDA  antagonist,  memantine   significantly inhibited CCI-induced mechanical allodynia at a dose of 300 nmol, indicating the difference in the site of action between the non-selective  NMDA  antagonist and the NR2B-specific  NMDA  antagonist.", "triple_list": [["memantine", "PRODUCT-OF", "antagonist"]]}, {"text": "We demonstrate that among the three nitrates, only  SNP  inhibits  HIF-1  activation in response to hypoxia", "triple_list": [["only", "AGONIST", "HIF-1"]]}, {"text": " SNP  inhibits the accumulation of  HIF-1alpha   the regulatory subunit of HIF-1, and the transcriptional activation of  HIF-1alpha  via a mechanism that is not dependent on either NO or soluble guanylate cyclase.", "triple_list": [["SNP", "ACTIVATOR", "HIF-1alpha"]]}, {"text": " SNP  inhibits the accumulation of  HIF-1 alpha, the regulatory subunit of  HIF-1   and the transcriptional activation of  HIF-1 alpha via a mechanism that is not dependent on either NO or soluble guanylate cyclase.", "triple_list": [["a", "ANTAGONIST", "HIF-1"]]}, {"text": " SNP  inhibits the accumulation of  HIF-1alpha , the regulatory subunit of HIF-1, and the transcriptional activation of  HIF-1alpha  via a mechanism that is not dependent on either NO or soluble guanylate cyclase.", "triple_list": [["SNP", "PRODUCT-OF", "subunit"]]}, {"text": "The inhibitory effect of  sodium nitroprusside  on  HIF-1  activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway", "triple_list": [["activation", "ACTIVATOR", "HIF-1"]]}, {"text": "As opposed to the rat and flounder orthologs,  hNaDC-3  was hardly inhibited by  lithium  concentrations up to 5 mM", "triple_list": [["lithium", "AGONIST", "up"]]}, {"text": "Using whole-cell voltage clamp, we examined  mibefradil  block of four  Na+ channel  isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)", "triple_list": [["(brain),", "ANTAGONIST", "Na+ channel"]]}, {"text": "Using whole-cell voltage clamp, we examined  mibefradil  block of four Na+ channel isoforms expressed in human embryonic kidney cells:  Nav1.5  (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)", "triple_list": [["mibefradil", "ACTIVATOR", "we"]]}, {"text": "Using whole-cell voltage clamp, we examined  mibefradil  block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac),  Nav1.4  (skeletal muscle), Nav1.2 (brain), and Nav1.7 (peripheral nerve)", "triple_list": [["nerve)", "ACTIVATOR", "Nav1.4"]]}, {"text": "Using whole-cell voltage clamp, we examined  mibefradil  block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle),  Nav1.2  (brain), and Nav1.7 (peripheral nerve)", "triple_list": [["mibefradil", "PRODUCT-OF", "Nav1.5"]]}, {"text": "Using whole-cell voltage clamp, we examined  mibefradil  block of four Na+ channel isoforms expressed in human embryonic kidney cells: Nav1.5 (cardiac), Nav1.4 (skeletal muscle), Nav1.2 (brain), and  Nav1.7  (peripheral nerve)", "triple_list": [["mibefradil", "PRODUCT-OF", "(brain),"]]}, {"text": " Mibefradil  blocked  Nav1.5  in a use/frequency-dependent manner, indicating preferential binding to states visited during depolarization", "triple_list": [["Mibefradil", "ACTIVATOR", "to"]]}, {"text": " Mibefradil  blocked currents of all  Na+ channel  isoforms with similar affinity and a dependence on holding potential, and drug off-rate was slowed at depolarized potentials (k(off) was 0.024/s at -130 mV and 0.007/s at -100 mV for Nav1.5)", "triple_list": [["Mibefradil", "ANTAGONIST", "similar"]]}, {"text": " Mibefradil  blocked currents of all Na+ channel isoforms with similar affinity and a dependence on holding potential, and drug off-rate was slowed at depolarized potentials (k(off) was 0.024/s at -130 mV and 0.007/s at -100 mV for  Nav1.5  ", "triple_list": [["Mibefradil", "PRODUCT-OF", "Nav1.5"]]}, {"text": "State-dependent  mibefradil  block of  Na+ channels   Mibefradil is a T-type Ca2+ channel antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and  Na+ channels ", "triple_list": [["Mibefradil", "ANTAGONIST", "Na+ channels"]]}, {"text": "In addition, inhibiting the binding of the fast inactivation lid ( Nav1.5  ICM + MTSET) did not alter  mibefradil  block, confirming that the drug does not preferentially interact with the fast-inactivated state", "triple_list": [["MTSET)", "AGONIST", "Nav1.5"]]}, {"text": "When selectively applied to channels after inducing slow inactivation with a 60-s pulse to -10 mV,  mibefradil  (1 microM) produced 45% fractional block in  Nav1.5  and greater block (88%) in an isoform (Nav1.4) that slow-inactivates more completely", "triple_list": [["mibefradil", "ANTAGONIST", "an"]]}, {"text": "When selectively applied to channels after inducing slow inactivation with a 60-s pulse to -10 mV,  mibefradil  (1 microM) produced 45% fractional block in Nav1.5 and greater block (88%) in an isoform ( Nav1.4   that slow-inactivates more completely", "triple_list": [["mibefradil", "PRODUCT-OF", "an"]]}, {"text": "Our results suggest that  mibefradil  blocks  Na+ channels  in a state-dependent manner that does not depend on fast inactivation but probably involves interaction with one or more slow-inactivated state(s).", "triple_list": [["state-dependent", "AGONIST", "Na+ channels"]]}, {"text": " Mibefradil  is a  T-type Ca2+ channel  antagonist with reported cross-reactivity with other classes of ion channels, including K+, Cl-, and Na+ channels", "triple_list": [["cross-reactivity", "DOWNREGULATOR", "T-type Ca2+ channel"]]}, {"text": "Extracellular application of meclofenamate (EC(50) = 25 microM) and  diclofenac  (EC(50) = 2.6 microM) resulted in the activation of  KCNQ2/Q3  K(+) currents, heterologously expressed in Chinese hamster ovary cells", "triple_list": [["diclofenac", "ANTAGONIST", "currents,"]]}, {"text": "Extracellular application of  meclofenamate  (EC(50) = 25 microM) and diclofenac (EC(50) = 2.6 microM) resulted in the activation of  KCNQ2/Q3  K(+) currents, heterologously expressed in Chinese hamster ovary cells", "triple_list": [["meclofenamate", "PRODUCT-OF", "in"]]}, {"text": " Pranlukast   a leukotriene receptor antagonist, inhibits  interleukin-5  production via a mechanism distinct from leukotriene receptor antagonism", "triple_list": [["mechanism", "PRODUCT-OF", "interleukin-5"]]}, {"text": " Pranlukast  induced inhibition of  IL-5  mRNA expression was noted in various cells, irrespective of their CysLTR1 mRNA expression status", "triple_list": [["Pranlukast", "ACTIVATOR", "noted"]]}, {"text": "CONCLUSION: Our results indicate that  pranlukast  inhibits  IL-5  synthesis via a mechanism distinct from CysLTR1 antagonism.", "triple_list": [["CONCLUSION:", "ANTAGONIST", "IL-5"]]}, {"text": "The aim of this study was to determine the mechanism of  pranlukast  induced  interleukin-5  (IL-5) inhibition in allergic inflammation", "triple_list": [["this", "ANTAGONIST", "interleukin-5"]]}, {"text": "The aim of this study was to determine the mechanism of  pranlukast  induced interleukin-5 ( IL-5   inhibition in allergic inflammation", "triple_list": [["pranlukast", "ANTAGONIST", "inhibition"]]}, {"text": "RESULTS: Pretreatment of lung tissues with  pranlukast  alone significantly decreased the amount of  IL-5  protein in the culture medium by 40%", "triple_list": [["pranlukast", "AGONIST", "IL-5"]]}, {"text": " Pranlukast   a  leukotriene receptor  antagonist, inhibits interleukin-5 production via a mechanism distinct from  leukotriene receptor  antagonism", "triple_list": [["distinct", "PRODUCT-OF", "leukotriene receptor"]]}, {"text": " Pranlukast   a  leukotriene receptor  antagonist, inhibits interleukin-5 production via a mechanism distinct from  leukotriene receptor  antagonism", "triple_list": [["a", "AGONIST", "leukotriene receptor"]]}, {"text": "BACKGROUND:  Pranlukast   a  cysteinyl leukotriene receptor 1  (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation", "triple_list": [["contraction,", "AGONIST", "cysteinyl leukotriene receptor 1"]]}, {"text": "BACKGROUND:  Pranlukast   a cysteinyl leukotriene receptor 1 ( CysLTR1   antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation", "triple_list": [["Pranlukast", "ACTIVATOR", "but"]]}, {"text": "CONCLUSION: Our results indicate that  pranlukast  inhibits IL-5 synthesis via a mechanism distinct from  CysLTR1  antagonism.", "triple_list": [["pranlukast", "AGONIST", "that"]]}, {"text": "CONCLUSION: Oral  quinidine  is effective in suppressing the gain of function in  IKr  responsible for some cases of short QT syndrome with a mutation in HERG and thus restoring normal rate dependence of the QT interval and rendering ventricular tachycardia/ventricular fibrillation noninducible.", "triple_list": [["quinidine", "ANTAGONIST", "in"]]}, {"text": "INTRODUCTION: The principal aim of this study was to assess the efficacy of  quinidine  in suppressing  IKr  in vitro and in modulating the rate dependence of the QT interval in the \"SQT1\" form of the short QT syndrome", "triple_list": [["quinidine", "PRODUCT-OF", "INTRODUCTION:"]]}, {"text": "Firstly, the V(max) of  GAD  was increased when ApoCaM was present whereas the affinity for the substrate,  glutamate   was not affected", "triple_list": [["glutamate", "DOWNREGULATOR", "the"]]}, {"text": " L-serine  dehydratase (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of  L-serine  and L-threonine to yield pyruvate or 2-oxobutyrate", "triple_list": [["L-serine", "ANTAGONIST", "L-serine dehydratase"]]}, {"text": " L-serine  dehydratase ( SDH  , a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of  L-serine  and L-threonine to yield pyruvate or 2-oxobutyrate", "triple_list": [["L-serine", "ANTAGONIST", "SDH"]]}, {"text": " L-serine dehydratase  (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and  L-threonine  to yield pyruvate or 2-oxobutyrate", "triple_list": [["deamination", "ACTIVATOR", "L-serine dehydratase"]]}, {"text": "L-serine dehydratase ( SDH  , a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and  L-threonine  to yield pyruvate or 2-oxobutyrate", "triple_list": [["L-threonine", "ACTIVATOR", "of"]]}, {"text": " L-serine dehydratase  (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield  pyruvate  or 2-oxobutyrate", "triple_list": [["phosphate-dependent", "ANTAGONIST", "L-serine dehydratase"]]}, {"text": "L-serine dehydratase ( SDH  , a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield  pyruvate  or 2-oxobutyrate", "triple_list": [["pyruvate", "ACTIVATOR", "SDH"]]}, {"text": " L-serine dehydratase  (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or  2-oxobutyrate   The crystal structure of  L-serine dehydratase  from human liver (hSDH) has been solved at 2.5 A-resolution by molecular replacement", "triple_list": [["2-oxobutyrate", "ACTIVATOR", "(SDH),"]]}, {"text": "L-serine dehydratase ( SDH  , a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or  2-oxobutyrate   The crystal structure of L-serine dehydratase from human liver (h SDH ) has been solved at 2.5 A-resolution by molecular replacement", "triple_list": [["solved", "DOWNREGULATOR", "SDH"]]}, {"text": " Docetaxel  is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of  bcl-2  inactivation, which induce apoptosis", "triple_list": [["Docetaxel", "ACTIVATOR", "of"]]}, {"text": "Docetaxel is a semisynthetic  taxane  that inhibit tumor growth by induction of microtubule stabilization and promotion of  bcl-2  inactivation, which induce apoptosis", "triple_list": [["taxane", "PRODUCT-OF", "a"]]}, {"text": "Treatment with  carvedilol  reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and  NGF-beta  to the baseline values", "triple_list": [["carvedilol", "AGONIST", "to"]]}, {"text": "Treatment with  carvedilol  reversed both protein and mRNA of  HIF-1alpha   VEGF, BNP, and NGF-beta to the baseline values", "triple_list": [["carvedilol", "ANTAGONIST", "baseline"]]}, {"text": "Treatment with  carvedilol  reversed both protein and mRNA of HIF-1alpha,  VEGF   BNP, and NGF-beta to the baseline values", "triple_list": [["carvedilol", "PRODUCT-OF", "Treatment"]]}, {"text": "Treatment with  carvedilol  reversed both protein and mRNA of HIF-1alpha, VEGF,  BNP   and NGF-beta to the baseline values", "triple_list": [["both", "ACTIVATOR", "BNP"]]}, {"text": "Increased immunohistochemical labeling of  HIF-1alpha   VEGF, and BNP in the ventricular myocardium was observed in the shunt group and  carvedilol  again normalized the labeling", "triple_list": [["and", "AGONIST", "HIF-1alpha"]]}, {"text": "Increased immunohistochemical labeling of HIF-1alpha,  VEGF   and BNP in the ventricular myocardium was observed in the shunt group and  carvedilol  again normalized the labeling", "triple_list": [["and", "AGONIST", "VEGF"]]}, {"text": "Increased immunohistochemical labeling of HIF-1alpha, VEGF, and  BNP  in the ventricular myocardium was observed in the shunt group and  carvedilol  again normalized the labeling", "triple_list": [["in", "PRODUCT-OF", "BNP"]]}, {"text": "Treatment with  carvedilol  is associated with a reversal of abnormal regulation of  HIF-1alpha  and VEGF in the failing ventricular myocardium.", "triple_list": [["in", "PRODUCT-OF", "HIF-1alpha"]]}, {"text": "Treatment with  carvedilol  is associated with a reversal of abnormal regulation of HIF-1alpha and  VEGF  in the failing ventricular myocardium.", "triple_list": [["in", "ANTAGONIST", "VEGF"]]}, {"text": "Mutation of arginine 228 to  lysine  enhances the  glucosyltransferase  activity of bovine beta-1,4-galactosyltransferase I", "triple_list": [["lysine", "ANTAGONIST", "228"]]}, {"text": "Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from  UDP-Glc  to GlcNAc ( Glc-T  activity), albeit at only 0.3% efficiency", "triple_list": [["(Gal-T", "ACTIVATOR", "Glc-T"]]}, {"text": " Beta-1,4-galactosyltransferase I  (beta4Gal-T1) normally transfers Gal from  UDP-Gal  to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency", "triple_list": [["UDP-Gal", "DOWNREGULATOR", "UDP-Glc"]]}, {"text": "Beta-1,4-galactosyltransferase I (beta4 Gal-T 1) normally transfers Gal from  UDP-Gal  to GlcNAc in the presence of Mn(2+) ion ( Gal-T  activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency", "triple_list": [["UDP-Glc", "ACTIVATOR", "Gal-T"]]}, {"text": "Beta-1,4-galactosyltransferase I ( beta4Gal-T1   normally transfers Gal from  UDP-Gal  to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency", "triple_list": [["UDP-Gal", "ACTIVATOR", "efficiency"]]}, {"text": "In this study, using a model of  gentamicin C  (GMC)-induced reduction in  SGLT1  activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in  SGLT1  activity", "triple_list": [["in", "ANTAGONIST", "SGLT1"]]}, {"text": "In this study, using a model of gentamicin C ( GMC  -induced reduction in  SGLT1  activity, we examined whether ligands for megalin protect LLC-PK1 cells from the  GMC -induced reduction in  SGLT1  activity", "triple_list": [["GMC", "ANTAGONIST", "In"]]}, {"text": "In this study, using a model of gentamicin C ( GMC )-induced reduction in  SGLT1  activity, we examined whether ligands for megalin protect LLC-PK1 cells from the  GMC  induced reduction in  SGLT1  activity", "triple_list": [["activity,", "ACTIVATOR", "SGLT1"]]}, {"text": "Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in  SGLT1  activity induced by  gentamicin C   Megalin, a family of endocytic receptors related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular aminoglycoside accumulation", "triple_list": [["gentamicin C", "ANTAGONIST", "of"]]}, {"text": "We previously reported that  aminoglycoside  antibiotics reduce  SGLT1  dependent glucose transport in pig proximal tubular epithelial LLC-PK1 cells in parallel with the order of their nephrotoxicity", "triple_list": [["aminoglycoside", "ANTAGONIST", "parallel"]]}, {"text": "Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the  SGLT1  dependent  methyl alpha-D-glucopyranoside  (AMG) uptake and levels of  SGLT1  expression were determined", "triple_list": [["methyl alpha-D-glucopyranoside", "AGONIST", "and"]]}, {"text": "Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the  SGLT1  dependent methyl alpha-D-glucopyranoside ( AMG   uptake and levels of  SGLT1  expression were determined", "triple_list": [["AMG", "ANTAGONIST", "determined"]]}, {"text": "Megalin, a family of  endocytic receptors  related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular  aminoglycoside  accumulation", "triple_list": [["aminoglycoside", "AGONIST", "a"]]}, {"text": "Megalin, a family of endocytic receptors related to the  low-density lipoprotein (LDL) receptor   is a major pathway for proximal tubular  aminoglycoside  accumulation", "triple_list": [["(LDL)", "ANTAGONIST", "low-density lipoprotein (LDL) receptor"]]}, {"text": "Synergistic cytotoxicity was demonstrated, and  pemetrexed  significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of  dCK  in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines", "triple_list": [["pemetrexed", "PRODUCT-OF", "decreased"]]}, {"text": "Synergistic cytotoxicity was demonstrated, and  pemetrexed  significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the  human nucleoside equilibrative transporter 1  (hENT1) in all cell lines", "triple_list": [["pemetrexed", "PRODUCT-OF", "Calu-6"]]}, {"text": "Synergistic cytotoxicity was demonstrated, and  pemetrexed  significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 ( hENT1   in all cell lines", "triple_list": [["pemetrexed", "DOWNREGULATOR", "apoptosis,"]]}, {"text": "These data demonstrated that 1) gemcitabine and  pemetrexed  synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3)  pemetrexed  enhances  dCK  and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.", "triple_list": [["pemetrexed", "DOWNREGULATOR", "of"]]}, {"text": "These data demonstrated that 1) gemcitabine and  pemetrexed  synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3)  pemetrexed  enhances dCK and  hENT1  expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.", "triple_list": [["hENT1", "ANTAGONIST", "hENT1"]]}, {"text": "Synergistic cytotoxicity was demonstrated, and  pemetrexed  significantly decreased the amount of  phosphorylated Akt   enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines", "triple_list": [["cells,", "ACTIVATOR", "phosphorylated Akt"]]}, {"text": "These data demonstrated that 1)  gemcitabine  and pemetrexed synergistically interact against NSCLC cells through the suppression of  Akt  phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.", "triple_list": [["gemcitabine", "AGONIST", "thus"]]}, {"text": "These data demonstrated that 1) gemcitabine and  pemetrexed  synergistically interact against NSCLC cells through the suppression of  Akt  phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3)  pemetrexed  enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.", "triple_list": [["pemetrexed", "PRODUCT-OF", "chemotherapy"]]}, {"text": " Phenytoin  is principally metabolized by  CYP2C9   and both are probable substrates of the drug transporter P-glycoprotein", "triple_list": [["Phenytoin", "ACTIVATOR", "drug"]]}, {"text": " Phenytoin  is principally metabolized by CYP2C9, and both are probable substrates of the  drug transporter  P-glycoprotein", "triple_list": [["Phenytoin", "ACTIVATOR", "and"]]}, {"text": " Phenytoin  is principally metabolized by CYP2C9, and both are probable substrates of the drug transporter  P-glycoprotein   We therefore assessed whether variation in these genes associates with the clinical use of carbamazepine and phenytoin in cohorts of 425 and 281 patients, respectively", "triple_list": [["in", "AGONIST", "P-glycoprotein"]]}, {"text": " Am80  inhibited VEGF-induced phosphorylation of  VEGF receptor   In addition, VEGF-induced formation of tube-like structures in vitro and neovascularization in mouse corneas were significantly inhibited by  Am80 ", "triple_list": [["tube-like", "AGONIST", "VEGF receptor"]]}, {"text": " Am80  inhibited  VEGF  induced phosphorylation of  VEGF  receptor", "triple_list": [["Am80", "ANTAGONIST", "VEGF"]]}, {"text": "In addition,  VEGF  induced formation of tube-like structures in vitro and neovascularization in mouse corneas were significantly inhibited by  Am80   These findings clearly demonstrate that  Am80  is a potential inhibitor of angiogenesis caused by the interaction between vascular endothelial cells and myeloma cells, and might be a useful therapeutic agent against MM.", "triple_list": [["Am80", "AGONIST", "corneas"]]}, {"text": " Am80  slightly inhibited the growth of both myeloma cells and HUVECs, and remarkably inhibited the growth of HUVECs stimulated by  VEGF    Am80  showed little growth inhibition of bone marrow stromal cells (BMSCs), but it markedly inhibited migration of HUVECs by cocultured myeloma cells", "triple_list": [["Am80", "AGONIST", "bone"]]}, {"text": "When  amiloride  was dropped on the eye surface on the first day of irradiation and subsequently daily until the end of the experiment,  u-PA  activity in both cornea and tear fluid was strongly inhibited", "triple_list": [["tear", "AGONIST", "u-PA"]]}, {"text": "In conclusion, early application of  amiloride  inhibited  u-PA  activity in UVB-irradiated corneas as well as in tear fluid and diminished the development of corneal pathology.", "triple_list": [["amiloride", "ACTIVATOR", "diminished"]]}, {"text": "The purpose of the present study was to test our hypothesis that  amiloride   a specific  u-PA  inhibitor, effectively decreases  u-PA  activity in cornea as well as in tear fluid and favourably affects corneal healing", "triple_list": [["affects", "ACTIVATOR", "u-PA"]]}, {"text": "The purpose of the present study was to test our hypothesis that  amiloride   a specific  u-PA  inhibitor, effectively decreases  u-PA  activity in cornea as well as in tear fluid and favourably affects corneal healing", "triple_list": [["The", "ANTAGONIST", "u-PA"]]}, {"text": "Effects of inhibition of  urokinase-type plasminogen activator  (u-PA) by  amiloride  in the cornea and tear fluid of eyes irradiated with UVB", "triple_list": [["amiloride", "PRODUCT-OF", "the"]]}, {"text": "Effects of inhibition of urokinase-type plasminogen activator ( u-PA   by  amiloride  in the cornea and tear fluid of eyes irradiated with UVB", "triple_list": [["u-PA", "AGONIST", "u-PA"]]}, {"text": "Therefore, comparative histochemical and biochemical studies of  u-PA  and the effects of amiloride were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate  Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin   Rabbit eyes were repeatedly irradiated with UVB for 9 days and during the irradiation topically treated with amiloride (1 mg/ml saline) or placebo (saline) (dropwise, 5 times daily)", "triple_list": [["for", "DOWNREGULATOR", "u-PA"]]}, {"text": "In contrast, the selective  beta2AR  antagonists ICI-118,551 and butoxamine inhibited  isoproterenol  mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively)", "triple_list": [["contrast,", "ANTAGONIST", "beta2AR"]]}, {"text": "Together, this pharmacological profile of subtype-selective betaAR antagonists indicates that in this model,  beta1AR  activation is responsible for the enhanced hippocampal CA3 network activity initiated by  isoproterenol  ", "triple_list": [["enhanced", "ANTAGONIST", "beta1AR"]]}, {"text": "The selective  betaAR  agonist  isoproterenol  caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region", "triple_list": [["region", "PRODUCT-OF", "betaAR"]]}, {"text": "The selective  beta1AR  antagonists atenolol and metoprolol blocked  isoproterenol  induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively", "triple_list": [["isoproterenol", "DOWNREGULATOR", "The"]]}, {"text": "In contrast, the selective  beta2AR  antagonists ICI-118,551 and  butoxamine  inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively)", "triple_list": [["butoxamine", "PRODUCT-OF", "selective"]]}, {"text": "The selective  beta1AR  antagonists  atenolol  and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively", "triple_list": [["atenolol", "AGONIST", "atenolol"]]}, {"text": "The selective  beta1AR  antagonists atenolol and  metoprolol  blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively", "triple_list": [["metoprolol", "PRODUCT-OF", "+/-"]]}, {"text": "In contrast, the selective  beta2AR  antagonists  ICI-118,551  and butoxamine inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively)", "triple_list": [["the", "DOWNREGULATOR", "beta2AR"]]}, {"text": "On the basis of FIP1L1-PDGFRa fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the FIP1L1-PDGFRa positive cases the  tyrosine kinase  inhibitor  imatinib mesylate  (Glivec) would be effective.", "triple_list": [["imatinib mesylate", "ANTAGONIST", "gene"]]}, {"text": "Furthermore, experiments showed that treatment with  DEC  results in a reduction in the amount of  COX-1  protein in peritoneal exudate cells", "triple_list": [["DEC", "ACTIVATOR", "the"]]}, {"text": "Experimental as well as clinical reports support the hypothesis that  calcium channel  blockers such as  verapamil  may be an appropriate therapeutic approach in LQTS", "triple_list": [["support", "ANTAGONIST", "calcium channel"]]}, {"text": "METHODS AND RESULTS: In 8 Langendorff-perfused rabbit hearts,  veratridine  (0.1 microM), an inhibitor of  sodium channel  inactivation, led to a marked increase in QT-interval and simultaneously recorded monophasic ventricular action potentials (MAPs) (p < 0.05) thereby mimicking LQT3", "triple_list": [["veratridine", "ACTIVATOR", "marked"]]}, {"text": "The positive correlation between  vitamin A  and  immunoglobulin A  concentrations might be the result of the  vitamin A  inductive effect during immunoglobulins A synthesis", "triple_list": [["immunoglobulins", "ANTAGONIST", "immunoglobulin A"]]}, {"text": "The positive correlation between  vitamin A  and immunoglobulin A concentrations might be the result of the  vitamin A  inductive effect during  immunoglobulins A  synthesis", "triple_list": [["vitamin A", "PRODUCT-OF", "A"]]}, {"text": "The positive correlation between  vitamin A  and  immunoglobulin A  concentrations might be the result of the  vitamin A  inductive effect during immunoglobulins A synthesis", "triple_list": [["of", "DOWNREGULATOR", "immunoglobulin A"]]}, {"text": "The positive correlation between  vitamin A  and immunoglobulin A concentrations might be the result of the  vitamin A  inductive effect during  immunoglobulins A  synthesis", "triple_list": [["vitamin A", "AGONIST", "result"]]}, {"text": " Monocarboxylate transporters  (MCTs) are proton-linked membrane carriers involved in the transport of  monocarboxylates  such as lactate, pyruvate, as well as ketone bodies", "triple_list": [["monocarboxylates", "DOWNREGULATOR", "well"]]}, {"text": "Monocarboxylate transporters ( MCTs   are proton-linked membrane carriers involved in the transport of  monocarboxylates  such as lactate, pyruvate, as well as ketone bodies", "triple_list": [["the", "ACTIVATOR", "MCTs"]]}, {"text": " Monocarboxylate transporters  (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as  lactate   pyruvate, as well as ketone bodies", "triple_list": [["lactate", "DOWNREGULATOR", "as"]]}, {"text": "Monocarboxylate transporters ( MCTs   are proton-linked membrane carriers involved in the transport of monocarboxylates such as  lactate   pyruvate, as well as ketone bodies", "triple_list": [["transport", "AGONIST", "MCTs"]]}, {"text": " Monocarboxylate transporters  (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate,  pyruvate   as well as ketone bodies", "triple_list": [["pyruvate", "AGONIST", "in"]]}, {"text": "Monocarboxylate transporters ( MCTs   are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate,  pyruvate   as well as ketone bodies", "triple_list": [["pyruvate", "AGONIST", "the"]]}, {"text": " Monocarboxylate transporters  (MCTs) are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as  ketone  bodies", "triple_list": [["proton-linked", "AGONIST", "Monocarboxylate transporters"]]}, {"text": "Monocarboxylate transporters ( MCTs   are proton-linked membrane carriers involved in the transport of monocarboxylates such as lactate, pyruvate, as well as  ketone  bodies", "triple_list": [["of", "DOWNREGULATOR", "MCTs"]]}, {"text": "Interestingly, part of  MCT2  immunoreactivity is located at postsynaptic sites, suggesting a particular role of  monocarboxylates  and their transporters in synaptic transmission", "triple_list": [["monocarboxylates", "DOWNREGULATOR", "of"]]}, {"text": " Thiazolidinediones  are a new class of anti-diabetic agents which increase  insulin  sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of  insulin  responsive genes involved in glucose and lipid metabolism", "triple_list": [["new", "PRODUCT-OF", "insulin"]]}, {"text": " Thiazolidinediones  are a new class of anti-diabetic agents which increase  insulin  sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of  insulin -responsive genes involved in glucose and lipid metabolism", "triple_list": [["Thiazolidinediones", "PRODUCT-OF", "a"]]}, {"text": "The difference in structure of  troglitazone  did not account for its inhibitory effect on  ENT1  because Vitamin E did not inhibit [3H]adenosine uptake by HASMCs", "triple_list": [["troglitazone", "ACTIVATOR", "did"]]}, {"text": "Using the nucleoside transporter deficient PK15NTD cells stably expressing  ENT1  and ENT2, it was found that  troglitazone  inhibited  ENT1  but had no effect on ENT2", "triple_list": [["but", "PRODUCT-OF", "ENT1"]]}, {"text": "From these results, it is suggested that  troglitazone  may enhance the vasodilatory effect of adenosine by inhibiting  ENT1   Pharmacologically,  troglitazone  is a novel inhibitor of  ENT1 .", "triple_list": [["it", "ANTAGONIST", "ENT1"]]}, {"text": "Pharmacologically,  troglitazone  is a novel inhibitor of  ENT1  ", "triple_list": [["troglitazone", "ACTIVATOR", "ENT1"]]}, {"text": "The effect of  troglitazone  on  ENT1  was PPAR(gamma)-independent and kinetic studies revealed that  troglitazone  was a competitive inhibitor of  ENT1   In contrast, pioglitazone and ciglitazone had minimal effects on [3H]adenosine uptake by HASMCs", "triple_list": [["[3H]adenosine", "ANTAGONIST", "ENT1"]]}, {"text": " (R)-Ketoprofen  (1) was previously reported to be a potent and specific noncompetitive inhibitor of  CXCL8  induced human PMNs chemotaxis", "triple_list": [["a", "AGONIST", "CXCL8"]]}, {"text": " 2-Arylpropionic  CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive  CXCL8  inhibitors", "triple_list": [["as", "PRODUCT-OF", "CXCL8"]]}, {"text": " Thalidomide  reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased  cytochrome c   but had no effect on that of COX-1, in MCF-7 and HL-60", "triple_list": [["bcl-2", "AGONIST", "cytochrome c"]]}, {"text": " Thalidomide  reduced  COX-2  expression accompanied by a decrease of bcl-2 protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60", "triple_list": [["cytochrome", "ACTIVATOR", "COX-2"]]}, {"text": " Thalidomide  reduced COX-2 expression accompanied by a decrease of  bcl-2  protein, TNFalpha, VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60", "triple_list": [["Thalidomide", "ACTIVATOR", "had"]]}, {"text": " Thalidomide  reduced COX-2 expression accompanied by a decrease of bcl-2 protein,  TNFalpha   VEGF, GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60", "triple_list": [["Thalidomide", "AGONIST", "accompanied"]]}, {"text": " Thalidomide  reduced COX-2 expression accompanied by a decrease of bcl-2 protein, TNFalpha,  VEGF   GSH and an increased cytochrome c, but had no effect on that of COX-1, in MCF-7 and HL-60", "triple_list": [["effect", "ANTAGONIST", "VEGF"]]}, {"text": " Thalidomide  inhibits growth of tumors through  COX-2  degradation independent of antiangiogenesis", "triple_list": [["Thalidomide", "AGONIST", "antiangiogenesis"]]}, {"text": "These results demonstrated that  thalidomide  might inhibit growth of tumors through  COX-2  degradation independent of antiangiogenesis.", "triple_list": [["of", "ANTAGONIST", "COX-2"]]}, {"text": "In conclusion, of the seven NSAIDs investigated,  niflumic acid  was the most potent inhibitor of recombinant  UGT1A9  via 4-MUG in a competitive manner.", "triple_list": [["via", "AGONIST", "UGT1A9"]]}, {"text": "In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant  human UDP-glucuronosyltransferase 1A9  -potent inhibition by  niflumic acid   The inhibitory potencies of non-steroidal anti-inflammatory drugs (NSAIDs) on UDP-glucuronosyltransferase (UGT) 1A9 activity were investigated in recombinant human UGT1A9 using 4-methylumbelliferone (4-MU) as a substrate for glucuronidation", "triple_list": [["niflumic acid", "PRODUCT-OF", "The"]]}, {"text": "We used mutagenesis of these residues, combined with an investigation of  hERG  block by close analogs of  clofilium  and ibutilide, to assess how specific alterations in drug structure affected potency and binding interactions", "triple_list": [["clofilium", "ACTIVATOR", "residues,"]]}, {"text": "We used mutagenesis of these residues, combined with an investigation of  hERG  block by close analogs of clofilium and  ibutilide   to assess how specific alterations in drug structure affected potency and binding interactions", "triple_list": [["by", "PRODUCT-OF", "hERG"]]}, {"text": "Tissue-type plasminogen activator (tPA), a  serine  protease well known for generating plasmin, has been demonstrated to induce  matrix metalloproteinase-9  (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts", "triple_list": [["serine", "PRODUCT-OF", "metalloproteinase-9"]]}, {"text": "Tissue-type  plasmin ogen activator (tPA), a  serine  protease well known for generating  plasmin   has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts", "triple_list": [["a", "AGONIST", "plasmin"]]}, {"text": "Furthermore, tPA induced rapid  tyrosine  phosphorylation on the beta subunit of LRP-1, which was followed by the activation of  Mek1  and its downstream Erk-1 and -2", "triple_list": [["tPA", "PRODUCT-OF", "Mek1"]]}, {"text": "Furthermore, tPA induced rapid  tyrosine  phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream  Erk-1 and -2   Blockade of Erk-1/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells", "triple_list": [["its", "ANTAGONIST", "Erk-1 and -2"]]}, {"text": "Expression of L-type pyruvate kinase ( L-PK   is upregulated in the liver by dietary  carbohydrate   Previously, 3  carbohydrate /insulin response elements were identified in the 5'-flanking region of the  L-PK  gene up to bp -170", "triple_list": [["carbohydrate", "ANTAGONIST", "the"]]}, {"text": "Expression of  L-type pyruvate kinase  (L-PK) is upregulated in the liver by dietary  carbohydrate   Previously, 3  carbohydrate /insulin response elements were identified in the 5'-flanking region of the L-PK gene up to bp -170", "triple_list": [["carbohydrate", "ANTAGONIST", "Previously,"]]}, {"text": "Our results have shown that  MMP-9  messenger ribonucleic acid (mRNA) expression was inhibited by  doxycycline  starting at 10 mg/kg/day (P<0.02)", "triple_list": [["ribonucleic", "PRODUCT-OF", "MMP-9"]]}, {"text": " Minocycline  showed more potent inhibition on  MMP-9  mRNA expression, starting at 1 (P<0.005) and further at more than 30 (P<0.001) mg/kg/day", "triple_list": [["(P<0.001)", "AGONIST", "MMP-9"]]}, {"text": "At the enzymatic activity level,  doxycycline  started to suppress  MMP-9  activity at 5 mg/kg/day (P<0.001), while minocycline had an effect at a lower dose, 1 mg/kg/day (P<0.02)", "triple_list": [["doxycycline", "PRODUCT-OF", "minocycline"]]}, {"text": "We also assessed the potential relevant signaling pathway in vitro to elucidate the mechanisms underlying the  MMP-9  inhibition by  tetracyclines   In vitro, minocycline, but not doxycycline, inhibits  MMP-9 , at least in part, via the extracellular signaling-related kinase 1/2 (ERK1/2)-mediated pathway", "triple_list": [["tetracyclines", "PRODUCT-OF", "via"]]}, {"text": "In vitro,  minocycline   but not doxycycline, inhibits  MMP-9   at least in part, via the extracellular signaling-related kinase 1/2 (ERK1/2)-mediated pathway", "triple_list": [["inhibits", "PRODUCT-OF", "MMP-9"]]}, {"text": "In vitro, minocycline, but not  doxycycline   inhibits  MMP-9   at least in part, via the extracellular signaling-related kinase 1/2 (ERK1/2)-mediated pathway", "triple_list": [["but", "ANTAGONIST", "MMP-9"]]}, {"text": "This study provided the evidence that the  tetracyclines  inhibit stimulated cerebral  MMP-9  at multiple levels and are effective at very low doses, offering great potential for therapeutic use.", "triple_list": [["tetracyclines", "ACTIVATOR", "low"]]}, {"text": " Doxycycline  was shown to decrease cerebral  MMP-9  activities and angiogenesis induced by vascular endothelial growth factor (VEGF)", "triple_list": [["Doxycycline", "ANTAGONIST", "cerebral"]]}, {"text": " Doxycycline  was shown to decrease cerebral MMP-9 activities and angiogenesis induced by  vascular endothelial growth factor  (VEGF)", "triple_list": [["cerebral", "AGONIST", "vascular endothelial growth factor"]]}, {"text": " Doxycycline  was shown to decrease cerebral MMP-9 activities and angiogenesis induced by vascular endothelial growth factor ( VEGF  ", "triple_list": [["Doxycycline", "AGONIST", "VEGF"]]}, {"text": " Omega class GSTs  have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of  monomethylarsonate   an intermediate in the pathway of arsenic biotransformation", "triple_list": [["monomethylarsonate", "ACTIVATOR", "the"]]}, {"text": "Galanin attenuates  cyclic AMP regulatory element-binding protein  (CREB) phosphorylation induced by chronic  morphine  and naloxone challenge in Cath.a cells and primary striatal cultures", "triple_list": [["morphine", "PRODUCT-OF", "and"]]}, {"text": "Galanin attenuates cyclic AMP regulatory element-binding protein ( CREB   phosphorylation induced by chronic  morphine  and naloxone challenge in Cath.a cells and primary striatal cultures", "triple_list": [["CREB", "AGONIST", "CREB"]]}, {"text": "Galanin attenuates  cyclic AMP regulatory element-binding protein  (CREB) phosphorylation induced by chronic morphine and  naloxone  challenge in Cath.a cells and primary striatal cultures", "triple_list": [["naloxone", "AGONIST", "challenge"]]}, {"text": "Galanin attenuates cyclic AMP regulatory element-binding protein ( CREB   phosphorylation induced by chronic morphine and  naloxone  challenge in Cath.a cells and primary striatal cultures", "triple_list": [["naloxone", "DOWNREGULATOR", "cells"]]}, {"text": "A dose of 25 microg kg(-1) day(-1) of  formoterol  elicited greater EDL and soleus hypertrophy than salmeterol, but resulted in similar  beta-adrenoceptor  downregulation", "triple_list": [["of", "ANTAGONIST", "beta-adrenoceptor"]]}, {"text": "A dose of 25 microg kg(-1) day(-1) of formoterol elicited greater EDL and soleus hypertrophy than  salmeterol   but resulted in similar  beta-adrenoceptor  downregulation", "triple_list": [["salmeterol", "ANTAGONIST", "25"]]}, {"text": "Two beta(2)-agonists,  formoterol  and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater  beta(2)-adrenoceptor  selectivity", "triple_list": [["formoterol", "ANTAGONIST", "and"]]}, {"text": "Two beta(2)-agonists, formoterol and  salmeterol   are approved for treating asthma and have an extended duration of action and increased safety, associated with greater  beta(2)-adrenoceptor  selectivity", "triple_list": [["salmeterol", "ACTIVATOR", "and"]]}, {"text": "Systemic administration of  beta2-adrenoceptor  agonists,  formoterol  and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses", "triple_list": [["and", "ANTAGONIST", "beta2-adrenoceptor"]]}, {"text": "Systemic administration of  beta2-adrenoceptor  agonists, formoterol and  salmeterol   elicit skeletal muscle hypertrophy in rats at micromolar doses", "triple_list": [["salmeterol", "DOWNREGULATOR", "muscle"]]}, {"text": "In this study, we demonstrate significant inhibitory activity of  dasatinib  against both wild-type  KIT  and the  KIT D816V mutation in the nanomolar range in in vitro and cell-based kinase assays", "triple_list": [["dasatinib", "PRODUCT-OF", "the"]]}, {"text": "In this study, we demonstrate significant inhibitory activity of  dasatinib  against both wild-type  KIT  and the  KIT  816V mutation in the nanomolar range in in vitro and cell-based kinase assays", "triple_list": [["dasatinib", "PRODUCT-OF", "demonstrate"]]}, {"text": "In this study, we demonstrate significant inhibitory activity of  dasatinib  against both wild-type KIT and the KIT D816V  mutation in the nanomolar range in in vitro and cell-based kinase assays", "triple_list": [["vitro", "AGONIST", "D816V"]]}, {"text": "Additionally,  dasatinib  leads to growth inhibition of a  KIT  816V-harboring human masto-cytosis cell line", "triple_list": [["dasatinib", "ANTAGONIST", "inhibition"]]}, {"text": "Additionally,  dasatinib  leads to growth inhibition of a KIT D816V  harboring human masto-cytosis cell line", "triple_list": [["masto-cytosis", "ANTAGONIST", "D816V"]]}, {"text": " Dasatinib  (BMS-354825) inhibits  KIT  816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis", "triple_list": [["Dasatinib", "AGONIST", "Dasatinib"]]}, {"text": " Dasatinib  (BMS-354825) inhibits KIT D816V   an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis", "triple_list": [["inhibits", "ACTIVATOR", "D816V"]]}, {"text": "Dasatinib ( BMS-354825   inhibits KIT D816V   an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis", "triple_list": [["BMS-354825", "ACTIVATOR", "BMS-354825"]]}, {"text": " Dasatinib  (BMS-354825) is a novel orally bioavailable  SRC  ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)", "triple_list": [["has", "PRODUCT-OF", "SRC"]]}, {"text": " Dasatinib  (BMS-354825) is a novel orally bioavailable SRC/ ABL  inhibitor that has activity against multiple imatinib-resistant BCR- ABL  isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)", "triple_list": [["is", "PRODUCT-OF", "ABL"]]}, {"text": "Dasatinib ( BMS-354825   is a novel orally bioavailable  SRC  ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)", "triple_list": [["chronic", "ANTAGONIST", "SRC"]]}, {"text": "Dasatinib ( BMS-354825   is a novel orally bioavailable SRC/ ABL  inhibitor that has activity against multiple imatinib-resistant BCR- ABL  isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML)", "triple_list": [["BMS-354825", "AGONIST", "of"]]}, {"text": "BACKGROUND: Since the introduction of the first  cholinesterase  inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs,  donepezil   galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetyl cholinesterase ", "triple_list": [["donepezil", "ACTIVATOR", "the"]]}, {"text": "BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs,  donepezil   galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme  acetylcholinesterase   The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease", "triple_list": [["they", "ACTIVATOR", "acetylcholinesterase"]]}, {"text": "BACKGROUND: Since the introduction of the first  cholinesterase  inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil,  galantamine  and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetyl cholinesterase ", "triple_list": [["an", "ANTAGONIST", "cholinesterase"]]}, {"text": "BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil,  galantamine  and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme  acetylcholinesterase   The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease", "triple_list": [["galantamine", "ANTAGONIST", "important"]]}, {"text": "BACKGROUND: Since the introduction of the first  cholinesterase  inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and  rivastigmine   to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetyl cholinesterase ", "triple_list": [["rivastigmine", "AGONIST", "of"]]}, {"text": "BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and  rivastigmine   to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme  acetylcholinesterase   The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease", "triple_list": [["and", "ANTAGONIST", "acetylcholinesterase"]]}, {"text": "BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of  acetylcholine   an important neurotransmitter associated with memory, by blocking the enzyme  acetylcholine sterase  The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease", "triple_list": [["consider", "DOWNREGULATOR", "acetylcholinesterase"]]}, {"text": "These unexpected and intriguing complexities seem likely to have some as yet undefined role in regulating  SSAT  activity or stability as a part of  polyamine  homeostasis", "triple_list": [["activity", "ACTIVATOR", "SSAT"]]}, {"text": " Spermidine/spermine N1-acetyltransferase  (SSAT) is a key enzyme in the control of  polyamine  levels in human cells, as acetylation of spermidine and spermine triggers export or degradation", "triple_list": [["Spermidine/spermine", "AGONIST", "Spermidine/spermine N1-acetyltransferase"]]}, {"text": " Spermidine/spermine N1-acetyltransferase  (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of  spermidine  and spermine triggers export or degradation", "triple_list": [["in", "AGONIST", "Spermidine/spermine N1-acetyltransferase"]]}, {"text": "Spermidine/ spermine  N1-acetyltransferase (SSAT) is a key enzyme in the control of polyamine levels in human cells, as acetylation of spermidine and  spermine  triggers export or degradation", "triple_list": [["key", "AGONIST", "Spermidine/spermine N1-acetyltransferase"]]}, {"text": "In general,  rifampicin  can act on a pattern:  rifampicin  activates the  nuclear pregnane X receptor  that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities", "triple_list": [["rifampicin", "PRODUCT-OF", "nuclear"]]}, {"text": "In general,  rifampicin  can act on a pattern:  rifampicin  activates the  nuclear pregnane X receptor  that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities", "triple_list": [["nuclear", "DOWNREGULATOR", "nuclear pregnane X receptor"]]}, {"text": "The concomitantly administered effects of  rifampicin  on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by  p-glycoprotein  in the gastrointestinal tract and liver", "triple_list": [["rifampicin", "DOWNREGULATOR", "P450"]]}, {"text": "The concomitantly administered effects of  rifampicin  on other drugs can result in their altered metabolism or transportation that are metabolised by  cytochromes P450  or transported by p-glycoprotein in the gastrointestinal tract and liver", "triple_list": [["are", "DOWNREGULATOR", "cytochromes P450"]]}, {"text": "Withdrawal from free-choice  ethanol  consumption results in increased packing density of  glutamine synthetase  immunoreactive astrocytes in the prelimbic cortex of alcohol-preferring rats", "triple_list": [["in", "AGONIST", "glutamine synthetase"]]}, {"text": "Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released  glutamate  and its conversion to glutamine through the enzyme  glutamine synthetase  (GS)", "triple_list": [["glutamate", "DOWNREGULATOR", "of"]]}, {"text": "Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released  glutamate  and its conversion to glutamine through the enzyme glutamine synthetase ( GS  ", "triple_list": [["may", "ACTIVATOR", "GS"]]}, {"text": "Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to  glutamine  through the enzyme  glutamine  synthetase (GS)", "triple_list": [["glutamine", "DOWNREGULATOR", "astrocytes"]]}, {"text": "Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to  glutamine  through the enzyme  glutamine  synthetase ( GS  ", "triple_list": [["are", "DOWNREGULATOR", "GS"]]}, {"text": "CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired  pyridoxal kinase  for the conversion of  pyridoxine  and pyridoxal to PLP", "triple_list": [["pyridoxine", "AGONIST", "kinase"]]}, {"text": "CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired  pyridoxal  kinase for the conversion of pyridoxine and  pyridoxal  to PLP", "triple_list": [["pyridoxal", "DOWNREGULATOR", "an"]]}, {"text": "CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired  pyridoxal kinase  for the conversion of pyridoxine and pyridoxal to  PLP   This may explain the many published studies of benefits of high-dose vitamin B6 supplementation in some children and adults with autism.", "triple_list": [["PLP", "DOWNREGULATOR", "of"]]}, {"text": "In this article, the action of  dasatinib  (BMS-354825) is contrasted with that of imatinib, a  kinase  inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders", "triple_list": [["dasatinib", "ACTIVATOR", "myelogenous"]]}, {"text": "In this article, the action of dasatinib ( BMS-354825   is contrasted with that of imatinib, a  kinase  inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders", "triple_list": [["used", "ANTAGONIST", "kinase"]]}, {"text": "In this article, the action of dasatinib (BMS-354825) is contrasted with that of  imatinib   a  kinase  inhibitor that is currently being used to treat chronic myelogenous leukemia and other disorders", "triple_list": [["imatinib", "ANTAGONIST", "is"]]}, {"text": "The work of Chen and colleagues shows that  dasatinib  is a particularly potent inhibitor of  PDGFR  and that the compound also targets Src kinase", "triple_list": [["dasatinib", "AGONIST", "PDGFR"]]}, {"text": "The work of Chen and colleagues shows that  dasatinib  is a particularly potent inhibitor of PDGFR and that the compound also targets  Src kinase   The authors suggest that this combination of activities could be useful in the treatment of vascular obstructive diseases", "triple_list": [["vascular", "PRODUCT-OF", "Src kinase"]]}, {"text": "In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the  PGE1  mediated stimulation of  Na,K-ATPase beta  subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089", "triple_list": [["PGE1", "DOWNREGULATOR", "evidence"]]}, {"text": "In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of  Na,K-ATPase beta  subunit gene transcription includes the stimulatory effect of  17-phenyl trinor PGE2   as well as the inhibitory effects of SC-51089", "triple_list": [["involvement", "ANTAGONIST", "Na,K-ATPase beta"]]}, {"text": "Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the  PKC I vector (encoding the  PKC  inhibitory domain), the  PKC  inhibitor Go 6976,  thapsigargin   as well as the calmodulin antagonists W7 and W13.", "triple_list": [["thapsigargin", "ACTIVATOR", "the"]]}, {"text": "In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of  Na,K-ATPase beta  subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of  SC-51089   Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the calmodulin antagonists W7 and W13.", "triple_list": [["SC-51089", "AGONIST", "trinor"]]}, {"text": "Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the  PKC I vector (encoding the  PKC  inhibitory domain), the  PKC  inhibitor  Go 6976   thapsigargin, as well as the calmodulin antagonists W7 and W13.", "triple_list": [["Go 6976", "AGONIST", "stimulation"]]}, {"text": "The involvement of  EP1  and EP2 receptors is indicated by studies with the  EP1  selective agonist  17-phenyl trinor PGE2   and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 ( EP1  specific) and AH 6809 ( EP1  and EP2 specific)", "triple_list": [["17-phenyl trinor PGE2", "DOWNREGULATOR", "studies"]]}, {"text": "The involvement of  EP1  and EP2 receptors is indicated by studies with the  EP1  selective agonist  17-phenyl trinor PGE2   and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 ( EP1  specific) and AH 6809 ( EP1  and EP2 specific)", "triple_list": [["17-phenyl trinor PGE2", "PRODUCT-OF", "butaprost"]]}, {"text": "The involvement of EP1 and  EP2 receptors  is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist  butaprost  (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific)", "triple_list": [["butaprost", "ANTAGONIST", "17-phenyl"]]}, {"text": "The involvement of EP1 and  EP2  receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the  EP2  selective agonist  butaprost  (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and  EP2  specific)", "triple_list": [["butaprost", "ACTIVATOR", "(which"]]}, {"text": "The involvement of  EP1  and EP2 receptors is indicated by studies with the  EP1  selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists  SC-51089  ( EP1  specific) and AH 6809 ( EP1  and EP2 specific)", "triple_list": [["SC-51089", "DOWNREGULATOR", "of"]]}, {"text": "The involvement of  EP1  and EP2 receptors is indicated by studies with the  EP1  selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists  SC-51089  ( EP1  specific) and AH 6809 ( EP1  and EP2 specific)", "triple_list": [["PGE2,", "DOWNREGULATOR", "EP1"]]}, {"text": "The involvement of  EP1  and EP2 receptors is indicated by studies with the  EP1  selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists  SC-51089  ( EP1  specific) and AH 6809 ( EP1  and EP2 specific)", "triple_list": [["SC-51089", "ACTIVATOR", "agonist"]]}, {"text": "The involvement of  EP1  and EP2 receptors is indicated by studies with the  EP1  selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 ( EP1  specific) and  AH 6809  ( EP1  and EP2 specific)", "triple_list": [["AH 6809", "ACTIVATOR", "17-phenyl"]]}, {"text": "The involvement of EP1 and  EP2 receptors  is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and  AH 6809  (EP1 and EP2 specific)", "triple_list": [["AH 6809", "DOWNREGULATOR", "selective"]]}, {"text": "The involvement of  EP1  and EP2 receptors is indicated by studies with the  EP1  selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 ( EP1  specific) and  AH 6809  ( EP1  and EP2 specific)", "triple_list": [["agonist", "DOWNREGULATOR", "EP1"]]}, {"text": "The involvement of EP1 and  EP2  receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the  EP2  selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and  AH 6809  (EP1 and  EP2  specific)", "triple_list": [["AH 6809", "DOWNREGULATOR", "by"]]}, {"text": "Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the  calmodulin  antagonists  W7  and W13.", "triple_list": [["W7", "DOWNREGULATOR", "and"]]}, {"text": "Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the  calmodulin  antagonists W7 and  W13  ", "triple_list": [["Go", "PRODUCT-OF", "calmodulin"]]}, {"text": "The involvement of  EP1  and EP2 receptors is indicated by studies with the  EP1  selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 ( EP1  specific) and  AH 6809  ( EP1  and EP2 specific)", "triple_list": [["AH 6809", "AGONIST", "EP2"]]}, {"text": "The involvement of EP1 and  EP2  receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the  EP2  selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and  AH 6809  (EP1 and  EP2  specific)", "triple_list": [["trinor", "DOWNREGULATOR", "EP2"]]}, {"text": "Cotreatment with  U0126  and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2,  JNK   and beta-catenin", "triple_list": [["U0126", "DOWNREGULATOR", "cells"]]}, {"text": "Cotreatment with U0126 and  YC-1  synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2,  JNK   and beta-catenin", "triple_list": [["YC-1", "PRODUCT-OF", "JNK"]]}, {"text": "Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of  sulindac  treatment on ERK1/2,  JNK   and beta-catenin", "triple_list": [["sulindac", "AGONIST", "in"]]}, {"text": " Sulindac  metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate  cyclic GMP-dependent protein kinase  (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis", "triple_list": [["Sulindac", "ANTAGONIST", "consistent"]]}, {"text": " Sulindac  metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase ( PKG  ; (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis", "triple_list": [["kinase", "DOWNREGULATOR", "PKG"]]}, {"text": "Cotreatment with  U0126  and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, JNK, and  beta-catenin   These results indicate that sulindac metabolites modulate ERK1/2 and PKG pathways independently in colon cancer cells and suggest that the full apoptotic effect of sulindac is mediated by more than one pathway", "triple_list": [["U0126", "ACTIVATOR", "sulindac"]]}, {"text": "Cotreatment with U0126 and  YC-1  synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of sulindac treatment on ERK1/2, JNK, and  beta-catenin   These results indicate that sulindac metabolites modulate ERK1/2 and PKG pathways independently in colon cancer cells and suggest that the full apoptotic effect of sulindac is mediated by more than one pathway", "triple_list": [["YC-1", "AGONIST", "modulate"]]}, {"text": "Cotreatment with U0126 and YC-1 synergistically increases apoptosis in colorectal cancer cells and recapitulates the effects of  sulindac  treatment on ERK1/2, JNK, and  beta-catenin   These results indicate that  sulindac  metabolites modulate ERK1/2 and PKG pathways independently in colon cancer cells and suggest that the full apoptotic effect of  sulindac  is mediated by more than one pathway", "triple_list": [["sulindac", "PRODUCT-OF", "beta-catenin"]]}, {"text": " Sulindac  metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate  c-jun NH2-terminal kinase  (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis", "triple_list": [["GMP", "ACTIVATOR", "c-jun NH2-terminal kinase"]]}, {"text": " Sulindac  metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase ( JNK  ; (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease beta-catenin protein expression at times and doses consistent with apoptosis", "triple_list": [["Sulindac", "ACTIVATOR", "cyclic"]]}, {"text": " Sulindac  metabolites simultaneously (a) increase cellular cyclic GMP and subsequently activate cyclic GMP-dependent protein kinase (PKG); (b) activate c-jun NH2-terminal kinase (JNK); (c) inhibit extracellular signal-regulated kinase 1/2 (ERK1/2); and (d) decrease  beta-catenin  protein expression at times and doses consistent with apoptosis", "triple_list": [["c-jun", "PRODUCT-OF", "beta-catenin"]]}, {"text": " Glyphosate  affects aromatic amino acid biosynthesis by inhibiting  5-enolpyruvylshikimate-3-phosphate synthase  (EPSPS)", "triple_list": [["inhibiting", "ACTIVATOR", "5-enolpyruvylshikimate-3-phosphate synthase"]]}, {"text": " Glyphosate  affects aromatic amino acid biosynthesis by inhibiting 5-enolpyruvylshikimate-3-phosphate synthase ( EPSPS  ", "triple_list": [["acid", "ANTAGONIST", "EPSPS"]]}, {"text": " Glufosinate  inhibits  glutamine synthetase  and blocks biosynthesis of glutamine", "triple_list": [["glutamine", "AGONIST", "glutamine synthetase"]]}, {"text": "Glufosinate inhibits  glutamine  synthetase and blocks biosynthesis of  glutamine   AHAS gene variants that confer tolerance to AHAS inhibitors have been discovered in plants through selection or mutagenesis", "triple_list": [["glutamine", "DOWNREGULATOR", "have"]]}, {"text": "A pronounced  NET  knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by  NET  inhibiting ADs such as  reboxetine   desipramine, and imipramine", "triple_list": [["reboxetine", "ACTIVATOR", "such"]]}, {"text": "A pronounced  NET  knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by  NET  inhibiting ADs such as reboxetine,  desipramine   and imipramine", "triple_list": [["desipramine", "PRODUCT-OF", "the"]]}, {"text": "A pronounced  NET  knockout-induced shortening of the immobility time in the TST (by ca 50%) compared to WT mice was not reduced any further by  NET  inhibiting ADs such as reboxetine, desipramine, and  imipramine   Citalopram, which is devoid of affinity for the  NET , exerted a significant reduction of immobility time in the  NET -/- mice", "triple_list": [["imipramine", "PRODUCT-OF", "the"]]}, {"text": " Reboxetine   a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the  human norepinephrine transporter   Inasmuch as PTSD may be associated with dysregulation of noradrenergic activity, the present double-blind randomized clinical trial intended to evaluate reboxetine's efficacy in the management of MVA-related PTSD and to compare its efficacy with a medication commonly used in PTSD, the selective serotonin reuptake inhibitor fluvoxamine", "triple_list": [["high", "ANTAGONIST", "human norepinephrine transporter"]]}, {"text": "Evidence has accumulated in the last few years that the expression of the  microsomal/peroxidase antigen  (M/TPO-Ag) in thyroid cells is induced by TSH, through pathways which involve intracellular  cAMP  accumulation and protein synthesis", "triple_list": [["cAMP", "ANTAGONIST", "the"]]}, {"text": "Evidence has accumulated in the last few years that the expression of the microsomal/peroxidase antigen ( M/TPO-Ag   in thyroid cells is induced by TSH, through pathways which involve intracellular  cAMP  accumulation and protein synthesis", "triple_list": [["that", "DOWNREGULATOR", "M/TPO-Ag"]]}, {"text": "TSH and  cAMP  also increase the levels of the specific mRNA for  TPO  in thyroid cells from different species", "triple_list": [["cAMP", "PRODUCT-OF", "TSH"]]}, {"text": "Rats were fed experimental diets containing SPI or  casein  as a  nitrogen  source", "triple_list": [["nitrogen", "ACTIVATOR", "source"]]}, {"text": " Theophylline  exposure resulted in a sustained increase in mRNA expression for  CysS  and PDE3A, but PDE4D gene expression was unchanged", "triple_list": [["in", "PRODUCT-OF", "CysS"]]}, {"text": " Theophylline  exposure resulted in a sustained increase in mRNA expression for CysS and  PDE3A   but PDE4D gene expression was unchanged", "triple_list": [["Theophylline", "PRODUCT-OF", "sustained"]]}, {"text": "Multiple exposure to  theophylline   a phosphodiesterase ( PDE   inhibitor, induces acinar hypertrophy in the salivary gland", "triple_list": [["inhibitor,", "PRODUCT-OF", "PDE"]]}, {"text": "Multiple exposure to  theophylline   a  phosphodiesterase  (PDE) inhibitor, induces acinar hypertrophy in the salivary gland", "triple_list": [["induces", "ANTAGONIST", "phosphodiesterase"]]}, {"text": "However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and  RSD1235   a novel mixed  ion channel  blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I(Na) greatly, mimicking LQT3", "triple_list": [["RSD1235", "ACTIVATOR", "specific"]]}, {"text": "The  Na channel  block caused by  lidocaine  and RSD1235 can be through the open or inactivated states of the channel, but both equivalently inhibit a late component of Na current (I(Na)), recorded at 22 degrees C using whole-cell patch clamp of Nav 1.5 expressed in HEK cells", "triple_list": [["lidocaine", "ACTIVATOR", "expressed"]]}, {"text": "The  Na channel  block caused by lidocaine and  RSD1235  can be through the open or inactivated states of the channel, but both equivalently inhibit a late component of Na current (I(Na)), recorded at 22 degrees C using whole-cell patch clamp of Nav 1.5 expressed in HEK cells", "triple_list": [["degrees", "AGONIST", "Na channel"]]}, {"text": " GW9662   a PPARgamma antagonist, prevented (P < 0.01) the lutein-induced  iNOS  mRNA downregulation in HD11 cells", "triple_list": [["GW9662", "AGONIST", "a"]]}, {"text": " GW9662   a  PPARgamma  antagonist, prevented (P < 0.01) the lutein-induced iNOS mRNA downregulation in HD11 cells", "triple_list": [["GW9662", "ACTIVATOR", "0.01)"]]}, {"text": "Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide ( ramelteon   TAK-375), a selective  MT1/MT2 receptor  agonist, on motor coordination was studied using rota-rod performance in mice", "triple_list": [["was", "ACTIVATOR", "MT1/MT2 receptor"]]}, {"text": "Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide (ramelteon,  TAK-375  , a selective  MT1/MT2 receptor  agonist, on motor coordination was studied using rota-rod performance in mice", "triple_list": [["TAK-375", "PRODUCT-OF", "TAK-375"]]}, {"text": "Effect of  ramelteon  (TAK-375), a selective  MT1/MT2 receptor  agonist, on motor performance in mice", "triple_list": [["ramelteon", "ACTIVATOR", "MT1/MT2 receptor"]]}, {"text": "Effect of ramelteon ( TAK-375  , a selective  MT1/MT2 receptor  agonist, on motor performance in mice", "triple_list": [["TAK-375", "ANTAGONIST", "TAK-375"]]}, {"text": "Effect of  (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide  (ramelteon, TAK-375), a selective  MT1/MT2 receptor  agonist, on motor coordination was studied using rota-rod performance in mice", "triple_list": [["TAK-375),", "DOWNREGULATOR", "MT1/MT2 receptor"]]}, {"text": " Sorafenib  (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and  tyrosine kinases  VEGFR/PDGFR in tumor vasculature", "triple_list": [["Sorafenib", "PRODUCT-OF", "vasculature"]]}, {"text": " Sorafenib  (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases  VEGFR  PDGFR in tumor vasculature", "triple_list": [["Sorafenib", "ANTAGONIST", "a"]]}, {"text": " Sorafenib  (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/ PDGFR  in tumor vasculature", "triple_list": [["Sorafenib", "PRODUCT-OF", "vasculature"]]}, {"text": " Sorafenib  (BAY 43-9006, Nexavar), a dual-action inhibitor that targets  RAF  MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature", "triple_list": [["tyrosine", "PRODUCT-OF", "RAF"]]}, {"text": " Sorafenib  (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/ MEK  ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature", "triple_list": [["pathway", "PRODUCT-OF", "MEK"]]}, {"text": " Sorafenib  (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ ERK  pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature", "triple_list": [["Sorafenib", "ACTIVATOR", "ERK"]]}, {"text": "Sorafenib ( BAY 43-9006   Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and  tyrosine kinases  VEGFR/PDGFR in tumor vasculature", "triple_list": [["VEGFR/PDGFR", "ACTIVATOR", "tyrosine kinases"]]}, {"text": "Sorafenib ( BAY 43-9006   Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases  VEGFR  PDGFR in tumor vasculature", "triple_list": [["BAY 43-9006", "AGONIST", "tumor"]]}, {"text": "Sorafenib ( BAY 43-9006   Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/ PDGFR  in tumor vasculature", "triple_list": [["that", "ANTAGONIST", "PDGFR"]]}, {"text": "Sorafenib ( BAY 43-9006   Nexavar), a dual-action inhibitor that targets  RAF  MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature", "triple_list": [["RAF", "ANTAGONIST", "RAF"]]}, {"text": "Sorafenib ( BAY 43-9006   Nexavar), a dual-action inhibitor that targets RAF/ MEK  ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature", "triple_list": [["that", "PRODUCT-OF", "MEK"]]}, {"text": "Sorafenib ( BAY 43-9006   Nexavar), a dual-action inhibitor that targets RAF/MEK/ ERK  pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature", "triple_list": [["tumor", "AGONIST", "ERK"]]}, {"text": "Sorafenib (BAY 43-9006,  Nexavar  , a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and  tyrosine kinases  VEGFR/PDGFR in tumor vasculature", "triple_list": [["Nexavar", "PRODUCT-OF", "kinases"]]}, {"text": "Sorafenib (BAY 43-9006,  Nexavar  , a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases  VEGFR  PDGFR in tumor vasculature", "triple_list": [["Nexavar", "AGONIST", "in"]]}, {"text": "Sorafenib (BAY 43-9006,  Nexavar  , a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/ PDGFR  in tumor vasculature", "triple_list": [["Nexavar", "AGONIST", "(BAY"]]}, {"text": "Sorafenib (BAY 43-9006,  Nexavar  , a dual-action inhibitor that targets  RAF  MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature", "triple_list": [["43-9006,", "PRODUCT-OF", "RAF"]]}, {"text": "Sorafenib (BAY 43-9006,  Nexavar  , a dual-action inhibitor that targets RAF/ MEK  ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature", "triple_list": [["Nexavar", "AGONIST", "ERK"]]}, {"text": "Sorafenib (BAY 43-9006,  Nexavar  , a dual-action inhibitor that targets RAF/MEK/ ERK  pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature", "triple_list": [["that", "AGONIST", "ERK"]]}, {"text": "Further characterization of  sorafenib  revealed that this molecule was a multikinase inhibitor that targeted the  vascular endothelial growth factor receptor  family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis", "triple_list": [["inhibitor", "ANTAGONIST", "vascular endothelial growth factor receptor"]]}, {"text": "Further characterization of  sorafenib  revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family ( VEGFR-2  and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis", "triple_list": [["(PDGFR-beta", "ANTAGONIST", "VEGFR-2"]]}, {"text": "Further characterization of  sorafenib  revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and  VEGFR-3   and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis", "triple_list": [["sorafenib", "AGONIST", "of"]]}, {"text": "Further characterization of  sorafenib  revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and  platelet-derived growth factor receptor  family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis", "triple_list": [["that", "AGONIST", "platelet-derived growth factor receptor"]]}, {"text": "Further characterization of  sorafenib  revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family ( PDGFR-beta  and Kit), which play key roles in tumor progression and angiogenesis", "triple_list": [["progression", "ACTIVATOR", "PDGFR-beta"]]}, {"text": "Further characterization of  sorafenib  revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and  Kit  , which play key roles in tumor progression and angiogenesis", "triple_list": [["molecule", "ACTIVATOR", "Kit"]]}, {"text": "Thus,  sorafenib  may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of  Raf  and Kit signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling)", "triple_list": [["sorafenib", "ANTAGONIST", "a"]]}, {"text": "Thus,  sorafenib  may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and  Kit  signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling)", "triple_list": [["of", "AGONIST", "Kit"]]}, {"text": "Thus,  sorafenib  may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and/or on tumor angiogenesis (through inhibition of  VEGFR  and PDGFR signaling)", "triple_list": [["inhibition", "AGONIST", "VEGFR"]]}, {"text": "Thus,  sorafenib  may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and  PDGFR  signaling)", "triple_list": [["Kit", "PRODUCT-OF", "PDGFR"]]}, {"text": "A novel class of  biaryl urea  that inhibits  C-RAF  kinase was discovered using a combination of medicinal and combinatorial chemistry approaches", "triple_list": [["and", "PRODUCT-OF", "C-RAF"]]}, {"text": "A novel class of  biaryl urea  that inhibits C-RAF  kinase  was discovered using a combination of medicinal and combinatorial chemistry approaches", "triple_list": [["biaryl urea", "PRODUCT-OF", "combination"]]}, {"text": " Sorafenib  inhibited the  kinase  activity of both C-RAF and B-RAF (wild type and V600E mutant)", "triple_list": [["of", "ACTIVATOR", "kinase"]]}, {"text": " Sorafenib  inhibited the kinase activity of both  C-RAF  and B-RAF (wild type and V600E mutant)", "triple_list": [["V600E", "AGONIST", "C-RAF"]]}, {"text": " Sorafenib  inhibited the kinase activity of both C-RAF and  B-RAF  (wild type and V600E mutant)", "triple_list": [["Sorafenib", "ACTIVATOR", "the"]]}, {"text": " Sorafenib  inhibited the kinase activity of both C-RAF and B-RAF (wild type and  V600E  mutant)", "triple_list": [["Sorafenib", "ANTAGONIST", "activity"]]}, {"text": "In the present study, we have evaluated possible participation of  monocarboxylate transporters  (MCTs) responsible for the bidirectional membrane transport of  pyruvate  in the cytoprotective property in osteoblasts", "triple_list": [["transporters", "ACTIVATOR", "monocarboxylate transporters"]]}, {"text": "In the present study, we have evaluated possible participation of monocarboxylate transporters ( MCTs   responsible for the bidirectional membrane transport of  pyruvate  in the cytoprotective property in osteoblasts", "triple_list": [["transporters", "DOWNREGULATOR", "MCTs"]]}, {"text": "Discovery and optimization of  anthranilic acid sulfonamides  as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of  albumin  binding", "triple_list": [["the", "ANTAGONIST", "albumin"]]}, {"text": "When HUVECs were stimulated by thrombin without extracellular L-arginine,  Nor-NOHA  dose-dependently increased the  NOS  activity and the NO release with maximal effects at 20 microM", "triple_list": [["with", "AGONIST", "NOS"]]}, {"text": "Extracellular  L-arginine  also dose-dependently increased NO release and  arginase  activity", "triple_list": [["L-arginine", "PRODUCT-OF", "NO"]]}, {"text": "To determine whether  arginase s modulate the endothelial NO synthesis, we investigated the effects of the competitive  arginase  inhibitor  N(omega)-hydroxy-nor-L-arginine  (Nor-NOHA) on the activity of NOS,  arginase s, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)", "triple_list": [["the", "PRODUCT-OF", "arginase"]]}, {"text": "To determine whether  arginase s modulate the endothelial NO synthesis, we investigated the effects of the competitive  arginase  inhibitor N(omega)-hydroxy-nor-L-arginine ( Nor-NOHA   on the activity of NOS,  arginase s, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)", "triple_list": [["vein", "ACTIVATOR", "arginase"]]}, {"text": "In unstimulated cells,  Nor-NOHA  dose-dependently reduced the  arginase  activity with maximal inhibition at 20 microM", "triple_list": [["activity", "PRODUCT-OF", "arginase"]]}, {"text": "However, despite activation of L-arginine uptake, the inhibition of  arginase  activity by  Nor-NOHA  was still significant", "triple_list": [["Nor-NOHA", "AGONIST", "of"]]}, {"text": "These data suggest that endothelial  NO  synthesis depends on the activity of  arginase II  in mitochondria and l-arginine carriers in cell membrane.", "triple_list": [["NO", "DOWNREGULATOR", "depends"]]}, {"text": "Reduced synthesis of  nitric oxide  (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of  constitutive nitric-oxide synthase  (NOS) and cytosolic arginase I and mitochondrial arginase II", "triple_list": [["arginase", "AGONIST", "constitutive nitric-oxide synthase"]]}, {"text": "Reduced synthesis of  nitric oxide  (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase ( NOS   and cytosolic arginase I and mitochondrial arginase II", "triple_list": [["substrate", "ACTIVATOR", "NOS"]]}, {"text": "Reduced synthesis of  nitric oxide  (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic  arginase I  and mitochondrial  arginase I I", "triple_list": [["nitric oxide", "AGONIST", "of"]]}, {"text": "Reduced synthesis of  nitric oxide  (NO) contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and  mitochondrial arginase II   To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor-NOHA) on the activity of NOS, arginases, and L-arginine transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)", "triple_list": [["nitric oxide", "AGONIST", "arginase"]]}, {"text": "To determine whether  arginases  modulate the endothelial  NO  synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor- NO HA) on the activity of  NO S,  arginases , and L-arginine transporter and on  NO  release at surface of human umbilical vein endothelial cells (HUVECs)", "triple_list": [["NO", "DOWNREGULATOR", "NO"]]}, {"text": "Reduced synthesis of nitric oxide ( NO   contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of  constitutive nitric-oxide synthase  ( NO S) and cytosolic arginase I and mitochondrial arginase II", "triple_list": [["NO", "ACTIVATOR", "Reduced"]]}, {"text": "Reduced synthesis of nitric oxide ( NO   contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase ( NO S  and cytosolic arginase I and mitochondrial arginase II", "triple_list": [["NO", "AGONIST", "synthesis"]]}, {"text": "Reduced synthesis of nitric oxide ( NO   contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase ( NO S) and cytosolic  arginase I  and mitochondrial  arginase I I", "triple_list": [["NO", "ACTIVATOR", "I"]]}, {"text": "Reduced synthesis of nitric oxide ( NO   contributes to the endothelial dysfunction and may be related to limited availability of L-arginine, the common substrate of constitutive nitric-oxide synthase ( NO S) and cytosolic arginase I and  mitochondrial arginase II   To determine whether arginases modulate the endothelial  NO  synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor-L-arginine (Nor- NO HA) on the activity of  NO S, arginases, and L-arginine transporter and on  NO  release at surface of human umbilical vein endothelial cells (HUVECs)", "triple_list": [["NO", "DOWNREGULATOR", "NO"]]}, {"text": " Mitochondrial arginase II  modulates  nitric-oxide  synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells", "triple_list": [["in", "AGONIST", "Mitochondrial arginase II"]]}, {"text": " Mitochondrial arginase II  modulates nitric-oxide synthesis through nonfreely exchangeable  L-arginine  pools in human endothelial cells", "triple_list": [["L-arginine", "ACTIVATOR", "nonfreely"]]}, {"text": "Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of  L-arginine   the common substrate of  constitutive nitric-oxide synthase  (NOS) and cytosolic arginase I and mitochondrial arginase II", "triple_list": [["may", "ANTAGONIST", "constitutive nitric-oxide synthase"]]}, {"text": "Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of  L-arginine   the common substrate of constitutive nitric-oxide synthase ( NOS   and cytosolic arginase I and mitochondrial arginase II", "triple_list": [["common", "AGONIST", "NOS"]]}, {"text": "Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of  L-arginine   the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic  arginase I  and mitochondrial  arginase I I", "triple_list": [["L-arginine", "AGONIST", "and"]]}, {"text": "Reduced synthesis of nitric oxide (NO) contributes to the endothelial dysfunction and may be related to limited availability of  L-arginine   the common substrate of constitutive nitric-oxide synthase (NOS) and cytosolic arginase I and  mitochondrial arginase II   To determine whether arginases modulate the endothelial NO synthesis, we investigated the effects of the competitive arginase inhibitor N(omega)-hydroxy-nor- L-arginine  (Nor-NOHA) on the activity of NOS, arginases, and  L-arginine  transporter and on NO release at surface of human umbilical vein endothelial cells (HUVECs)", "triple_list": [["nitric", "ACTIVATOR", "mitochondrial arginase II"]]}, {"text": "These G-proteins are likely to be involved in the  adrenaline -induced inhibition of dihydropyridine-sensitive Ca2+ currents and in other signal transduction pathways contributing to the  adrenaline  induced inhibition of  insulin  secretion.", "triple_list": [["adrenaline", "ANTAGONIST", "be"]]}, {"text": " Somatostatin  which also inhibits  insulin  secretion was less efficient (inhibition by 20%)", "triple_list": [["Somatostatin", "ACTIVATOR", "insulin"]]}, {"text": " Adrenaline  inhibits  insulin  secretion via pertussis toxin-sensitive mechanisms", "triple_list": [["Adrenaline", "ACTIVATOR", "mechanisms"]]}, {"text": "In contrast to  adrenaline  and somatostatin, galanin, another inhibitor of  insulin  secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner", "triple_list": [["another", "ACTIVATOR", "insulin"]]}, {"text": "In contrast to adrenaline and  somatostatin   galanin, another inhibitor of  insulin  secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner", "triple_list": [["somatostatin", "AGONIST", "about"]]}, {"text": "Epididymal tissue from wild-type mice responded in vitro to  noradrenaline  and isoprenaline with increased glycerol release, reduced  IL-6  release, and increased cAMP accumulation", "triple_list": [["noradrenaline", "AGONIST", "reduced"]]}, {"text": "Epididymal tissue from wild-type mice responded in vitro to noradrenaline and  isoprenaline  with increased glycerol release, reduced  IL-6  release, and increased cAMP accumulation", "triple_list": [["vitro", "AGONIST", "IL-6"]]}, {"text": "Comparison of  cyclooxygenase  inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and  bromfenac sodium   OBJECTIVE: To compare the  cyclooxygenase  (COX) activity and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) ketorolac tromethamine (ketorolac) and  bromfenac sodium  (bromfenac)", "triple_list": [["bromfenac sodium", "PRODUCT-OF", "ketorolac"]]}, {"text": "Comparison of  cyclooxygenase  inhibitory activity and ocular anti-inflammatory effects of  ketorolac tromethamine  and bromfenac sodium", "triple_list": [["effects", "ACTIVATOR", "cyclooxygenase"]]}, {"text": "RESULTS:  Ketorolac  was six times more active against COX-1 (IC(50) = 0.02 microM) than  COX-2  (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against  COX-2  (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM)", "triple_list": [["Ketorolac", "PRODUCT-OF", "approximately"]]}, {"text": "RESULTS:  Ketorolac  was six times more active against  COX-1  (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while bromfenac was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than  COX-1  (IC(50) = 0.210 microM)", "triple_list": [["(IC(50)", "PRODUCT-OF", "COX-1"]]}, {"text": "RESULTS: Ketorolac was six times more active against  COX-1  (IC(50) = 0.02 microM) than COX-2 (IC(50) = 0.12 microM) while  bromfenac  was approximately 32 times more active against COX-2 (IC(50) = 0.0066 microM) than  COX-1  (IC(50) = 0.210 microM)", "triple_list": [["bromfenac", "AGONIST", "more"]]}, {"text": "RESULTS: Ketorolac was six times more active against COX-1 (IC(50) = 0.02 microM) than  COX-2  (IC(50) = 0.12 microM) while  bromfenac  was approximately 32 times more active against  COX-2  (IC(50) = 0.0066 microM) than COX-1 (IC(50) = 0.210 microM)", "triple_list": [["0.0066", "AGONIST", "COX-2"]]}, {"text": "METHODS:  Cyclooxygenase  activity and selectivity was determined in vitro by measuring  prostaglandin E(2)  (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid", "triple_list": [["COX-1", "AGONIST", "Cyclooxygenase"]]}, {"text": "METHODS:  Cyclooxygenase  activity and selectivity was determined in vitro by measuring prostaglandin E(2) ( PGE(2)   production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid", "triple_list": [["(", "ANTAGONIST", "Cyclooxygenase"]]}, {"text": "Density functional theory calculations using the hybrid functional B3LYP have been performed to study the  methyl  transfer step in glycine N- methyl transferase (GNMT)", "triple_list": [["methyl", "ACTIVATOR", "transferase"]]}, {"text": "Density functional theory calculations using the hybrid functional B3LYP have been performed to study the  methyl  transfer step in glycine N- methyl transferase ( GNMT  ", "triple_list": [["methyl", "DOWNREGULATOR", "calculations"]]}, {"text": "The starting point for the calculations is the recent X-ray crystal structure of  GNMT  complexed with  SAM  and acetate", "triple_list": [["GNMT", "ANTAGONIST", "GNMT"]]}, {"text": "In healthy rats,  ATB-429  dose dependently (25, 50, or 100 mg/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal  c-FOS  mRNA, whereas mesalamine had no effect", "triple_list": [["attenuated", "PRODUCT-OF", "c-FOS"]]}, {"text": "ATB-429-induced antinociception was reversed by  glibenclamide   a  ATP-sensitive K(+) (K(ATP)) channel  inhibitor", "triple_list": [["glibenclamide", "AGONIST", "antinociception"]]}, {"text": "Colonic  cyclooxygenase-2  and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by  ATB-429   but not by mesalamine", "triple_list": [["ATB-429", "ANTAGONIST", "by"]]}, {"text": "Colonic cyclooxygenase-2 and  interkeukin-1beta  mRNA and spinal c-FOS mRNA expression were significantly down-regulated by  ATB-429   but not by mesalamine", "triple_list": [["significantly", "ACTIVATOR", "interkeukin-1beta"]]}, {"text": "Colonic cyclooxygenase-2 and interkeukin-1beta mRNA and spinal  c-FOS  mRNA expression were significantly down-regulated by  ATB-429   but not by mesalamine", "triple_list": [["ATB-429", "PRODUCT-OF", "and"]]}, {"text": "Liver  BHMT  activity was 1.3-fold higher in rats fed the Met deficient diet containing  choline   which was reflected in corresponding increases in mRNA content and immunodetectable protein", "triple_list": [["choline", "DOWNREGULATOR", "reflected"]]}, {"text": "Independent of dietary  choline   supplemental Met increased hepatic  BHMT  activity approximately 30%", "triple_list": [["choline", "ANTAGONIST", "dietary"]]}, {"text": "Independent of dietary choline, supplemental  Met  increased hepatic  BHMT  activity approximately 30%", "triple_list": [["increased", "PRODUCT-OF", "BHMT"]]}, {"text": " Choline dehydrogenase  (CHDH) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in  choline  oxidation", "triple_list": [["choline", "AGONIST", "and"]]}, {"text": "Choline dehydrogenase ( CHDH   and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in  choline  oxidation", "triple_list": [["choline", "AGONIST", "("]]}, {"text": "Choline dehydrogenase (CHDH) and  betaine-homocysteine methyltransferase  (BHMT) are 2 enzymes involved in  choline  oxidation", "triple_list": [["choline", "DOWNREGULATOR", "methyltransferase"]]}, {"text": "Choline dehydrogenase (CHDH) and betaine-homocysteine methyltransferase ( BHMT   are 2 enzymes involved in  choline  oxidation", "triple_list": [["Choline", "DOWNREGULATOR", "BHMT"]]}, {"text": "The beta(2)-adrenoceptor ( beta(2)-AR   agonists  clenbuterol  and fenoterol have similar beneficial effects in animal models of heart failure", "triple_list": [["The", "ACTIVATOR", "beta(2)-AR"]]}, {"text": "The  beta(2)-adrenoceptor  (beta(2)-AR) agonists  clenbuterol  and fenoterol have similar beneficial effects in animal models of heart failure", "triple_list": [["clenbuterol", "DOWNREGULATOR", "beneficial"]]}, {"text": "The beta(2)-adrenoceptor ( beta(2)-AR   agonists clenbuterol and  fenoterol  have similar beneficial effects in animal models of heart failure", "triple_list": [["have", "DOWNREGULATOR", "beta(2)-AR"]]}, {"text": "The  beta(2)-adrenoceptor  (beta(2)-AR) agonists clenbuterol and  fenoterol  have similar beneficial effects in animal models of heart failure", "triple_list": [["fenoterol", "ANTAGONIST", "models"]]}, {"text": " beta(1)-Adrenoceptor  antagonism (10 mg kg(-1)  bisoprolol   prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551)", "triple_list": [["beta(1)-Adrenoceptor", "DOWNREGULATOR", "beta(1)-Adrenoceptor"]]}, {"text": " CP-690550   a  JAK3  inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials", "triple_list": [["synthetic", "ANTAGONIST", "JAK3"]]}, {"text": "The beneficial role of  17beta-estradiol  on blood pressure, cardiac hypertrophy, vascular  osteopontin  expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of medroxyprogesterone acetate", "triple_list": [["medroxyprogesterone", "DOWNREGULATOR", "osteopontin"]]}, {"text": "The beneficial role of 17beta-estradiol on blood pressure, cardiac hypertrophy, vascular  osteopontin  expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of  medroxyprogesterone acetate   In contrast, drospirenone was either neutral or additive to 17beta-estradiol in protecting against aldosterone salt-induced cardiovascular injury and inflammation", "triple_list": [["medroxyprogesterone acetate", "PRODUCT-OF", "cardiovascular"]]}, {"text": "We examined the anti-inflammatory effect of licofelone on atherosclerotic lesions as well as in isolated neutrophils from whole blood of rabbits compared with a selective inhibitor of  COX-2    rofecoxib   We also assessed the antithrombotic effect of licofelone in rabbit platelet-rich plasma", "triple_list": [["rofecoxib", "PRODUCT-OF", "also"]]}, {"text": " Licofelone  reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area,  monocyte chemoattractant protein-1  (MCP-1) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma", "triple_list": [["macrophages", "ACTIVATOR", "monocyte chemoattractant protein-1"]]}, {"text": " Licofelone  reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 ( MCP-1   gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma", "triple_list": [["atheroma", "AGONIST", "MCP-1"]]}, {"text": " Licofelone  reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 (MCP-1) gene expression, and the activation of  nuclear factor-kappaB  in rabbit atheroma", "triple_list": [["intima/media", "ACTIVATOR", "nuclear factor-kappaB"]]}, {"text": " Licofelone   a balanced inhibitor of  cyclooxygenase  and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis", "triple_list": [["Licofelone", "AGONIST", "model"]]}, {"text": " Licofelone   a balanced inhibitor of cyclooxygenase and  5-lipoxygenase   reduces inflammation in a rabbit model of atherosclerosis", "triple_list": [["reduces", "PRODUCT-OF", "5-lipoxygenase"]]}, {"text": " Licofelone   a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to  cycloxygenase-1  blockade-mediated antithrombotic effect and a better gastrointestinal tolerability", "triple_list": [["enzymes,", "ACTIVATOR", "cycloxygenase-1"]]}, {"text": " Licofelone   a dual anti-inflammatory drug that inhibits  5-lipoxygenase  (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability", "triple_list": [["Licofelone", "PRODUCT-OF", "(COX)"]]}, {"text": " Licofelone   a dual anti-inflammatory drug that inhibits 5-lipoxygenase ( LOX   and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability", "triple_list": [["blockade-mediated", "PRODUCT-OF", "LOX"]]}, {"text": " Licofelone   a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and  cyclooxygenase  (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability", "triple_list": [["Licofelone", "ACTIVATOR", "(COX)"]]}, {"text": " Licofelone   a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase ( COX   enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability", "triple_list": [["better", "PRODUCT-OF", "COX"]]}, {"text": "Moreover,  licofelone  inhibited  COX-2  and 5-LOX protein expression in vascular lesions", "triple_list": [["and", "AGONIST", "COX-2"]]}, {"text": "Moreover,  licofelone  inhibited COX-2 and  5-LOX  protein expression in vascular lesions", "triple_list": [["licofelone", "ANTAGONIST", "lesions"]]}, {"text": " Rofecoxib  only diminished  COX-2  protein expression and MCP-1 gene expression in vascular atheroma", "triple_list": [["vascular", "ANTAGONIST", "COX-2"]]}, {"text": " Rofecoxib  only diminished COX-2 protein expression and  MCP-1  gene expression in vascular atheroma", "triple_list": [["Rofecoxib", "ANTAGONIST", "in"]]}, {"text": " Licofelone  almost abolished  5-LOX  activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood", "triple_list": [["Licofelone", "ACTIVATOR", "abolished"]]}, {"text": "Licofelone almost abolished  5-LOX  activity by inhibiting  leukotriene B4  generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood", "triple_list": [["leukotriene B4", "ACTIVATOR", "almost"]]}, {"text": "Licofelone almost abolished  5-LOX  activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet  thromboxane B2  production from whole blood", "triple_list": [["by", "DOWNREGULATOR", "5-LOX"]]}, {"text": "Chronic insulin (24 h) activates NHE3 through the classic  phosphatidylinositol 3-kinase  serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor  wortmannin  or a dominant-negative SGK1", "triple_list": [["and", "ANTAGONIST", "phosphatidylinositol 3-kinase"]]}, {"text": "Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 ( PI3K  SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the  PI3K  inhibitor  wortmannin  or a dominant-negative SGK1", "triple_list": [["wortmannin", "ANTAGONIST", "insulin"]]}, {"text": "Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 ( PI3K -SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the  PI3K  inhibitor  wortmannin  or a dominant-negative SGK1", "triple_list": [["3-kinase-serum-", "PRODUCT-OF", "PI3K"]]}, {"text": "The potent and selective third-generation  aromatase  inhibitors anastrozole,  letrozole  and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies", "triple_list": [["inhibitors", "ANTAGONIST", "aromatase"]]}, {"text": " Anastrozole  and letrozole are both non-steroidal  aromatase  inhibitors that compete with the substrate for binding to the enzyme active site", "triple_list": [["Anastrozole", "ACTIVATOR", "compete"]]}, {"text": "Anastrozole and  letrozole  are both non-steroidal  aromatase  inhibitors that compete with the substrate for binding to the enzyme active site", "triple_list": [["letrozole", "ANTAGONIST", "both"]]}, {"text": "The potent and selective third-generation  aromatase  inhibitors  anastrozole   letrozole and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies", "triple_list": [["anastrozole", "ANTAGONIST", "introduced"]]}, {"text": " Estrogens  are biosynthesised from androgens by the  CYP450  enzyme complex called aromatase", "triple_list": [["Estrogens", "ANTAGONIST", "androgens"]]}, {"text": " Estrogens  are biosynthesised from androgens by the CYP450 enzyme complex called  aromatase   Aromatase is expressed in the ovary, placenta, brain, bone, adipose tissue and breast tissue", "triple_list": [["bone,", "ANTAGONIST", "aromatase"]]}, {"text": "In breast cancer, intratumoural  aromatase  is the source for local  estrogen  production in the tissue", "triple_list": [["the", "ACTIVATOR", "aromatase"]]}, {"text": "Estrogens are biosynthesised from  androgens  by the CYP450 enzyme complex called  aromatase   Aromatase is expressed in the ovary, placenta, brain, bone, adipose tissue and breast tissue", "triple_list": [["androgens", "ACTIVATOR", "biosynthesised"]]}, {"text": "Furthermore,  auranofin  inhibited  NF-kappaB  activation induced by MyD88-dependent downstream signaling components of TLR4, MyD88, IKKbeta, and p65", "triple_list": [["MyD88-dependent", "PRODUCT-OF", "NF-kappaB"]]}, {"text": " Auranofin   as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of  TLR4   Toll-like receptors (TLRs), which are activated by invading microorganisms or endogenous molecules, evoke immune and inflammatory responses", "triple_list": [["Auranofin", "AGONIST", "(TLRs),"]]}, {"text": " IRF3  activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by  auranofin   Our results first demonstrate that  auranofin  suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4", "triple_list": [["also", "ANTAGONIST", "IRF3"]]}, {"text": "IRF3 activation induced by MyD88-independent signaling components,  TRIF  and TBK1, was also downregulated by  auranofin   Our results first demonstrate that  auranofin  suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4", "triple_list": [["components,", "PRODUCT-OF", "TRIF"]]}, {"text": "IRF3 activation induced by MyD88-independent signaling components, TRIF and  TBK1   was also downregulated by  auranofin   Our results first demonstrate that  auranofin  suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4", "triple_list": [["auranofin", "AGONIST", "also"]]}, {"text": "Our results first demonstrate that  auranofin  suppresses the multiple steps in  TLR4  signaling, especially the homodimerization of  TLR4 ", "triple_list": [["auranofin", "AGONIST", "TLR4"]]}, {"text": "Our results first demonstrate that  auranofin  suppresses the multiple steps in  TLR4  signaling, especially the homodimerization of  TLR4   The results suggest that the suppression of  TLR4  activity by  auranofin  may be the molecular mechanism through which  auranofin  exerts anti-rheumatic activity.", "triple_list": [["auranofin", "AGONIST", "TLR4"]]}, {"text": "The results suggest that the suppression of  TLR4  activity by  auranofin  may be the molecular mechanism through which  auranofin  exerts anti-rheumatic activity.", "triple_list": [["by", "ANTAGONIST", "TLR4"]]}, {"text": "The results suggest that the suppression of  TLR4  activity by  auranofin  may be the molecular mechanism through which  auranofin  exerts anti-rheumatic activity.", "triple_list": [["auranofin", "ANTAGONIST", "suppression"]]}, {"text": "Our results demonstrated that  auranofin  suppressed  TLR4  mediated activation of transcription factors, NF-kappaB and IRF3, and expression of COX-2, a pro-inflammatory enzyme", "triple_list": [["auranofin", "ANTAGONIST", "TLR4"]]}, {"text": "Our results demonstrated that  auranofin  suppressed TLR4-mediated activation of transcription factors,  NF-kappaB  and IRF3, and expression of COX-2, a pro-inflammatory enzyme", "triple_list": [["auranofin", "PRODUCT-OF", "enzyme"]]}, {"text": "Our results demonstrated that  auranofin  suppressed TLR4-mediated activation of transcription factors, NF-kappaB and  IRF3   and expression of COX-2, a pro-inflammatory enzyme", "triple_list": [["that", "AGONIST", "IRF3"]]}, {"text": "Our results demonstrated that  auranofin  suppressed TLR4-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of  COX-2   a pro-inflammatory enzyme", "triple_list": [["of", "ANTAGONIST", "COX-2"]]}, {"text": "This suppression was well correlated with the inhibitory effect of  auranofin  on the homodimerization of  TLR4  induced by an agonist", "triple_list": [["effect", "PRODUCT-OF", "TLR4"]]}, {"text": "On the basis of our findings with structurally similar  arylhydroxylamine  metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of  arylhydroxylamine  carcinogens was catalyzed by  NADH cytochrome b5 reductase  (b5R) and cytochrome b5 (cyt b5)", "triple_list": [["by", "ANTAGONIST", "NADH cytochrome b5 reductase"]]}, {"text": "On the basis of our findings with structurally similar  arylhydroxylamine  metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of  arylhydroxylamine  carcinogens was catalyzed by NADH cytochrome b5 reductase ( b5R   and cytochrome b5 (cyt b5)", "triple_list": [["structurally", "AGONIST", "b5R"]]}, {"text": "On the basis of our findings with structurally similar  arylhydroxylamine  metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of  arylhydroxylamine  carcinogens was catalyzed by NADH  cytochrome b5  reductase (b5R) and  cytochrome b5  (cyt b5)", "triple_list": [["arylhydroxylamine", "DOWNREGULATOR", "carcinogens"]]}, {"text": "On the basis of our findings with structurally similar  arylhydroxylamine  metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of  arylhydroxylamine  carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and cytochrome b5 ( cyt b5  ", "triple_list": [["carcinogens", "DOWNREGULATOR", "cyt b5"]]}, {"text": "We found that reduction of the carcinogenic  hydroxylamines  of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only  human b5R  and cyt b5", "triple_list": [["purified", "AGONIST", "human b5R"]]}, {"text": "We found that reduction of the carcinogenic  hydroxylamines  of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and  cyt b5   Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems", "triple_list": [["b5", "ACTIVATOR", "cyt b5"]]}, {"text": "We found that reduction of the carcinogenic hydroxylamines of the  aromatic amine  4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only  human b5R  and cyt b5", "triple_list": [["aromatic amine", "AGONIST", "b5R"]]}, {"text": "We found that reduction of the carcinogenic hydroxylamines of the  aromatic amine  4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and  cyt b5   Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems", "triple_list": [["aromatic amine", "ACTIVATOR", "56-346-fold"]]}, {"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine  4-aminobiphenyl  (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only  human b5R  and cyt b5", "triple_list": [["hydroxylamines", "ANTAGONIST", "human b5R"]]}, {"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine  4-aminobiphenyl  (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and  cyt b5   Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems", "triple_list": [["4-aminobiphenyl", "AGONIST", "found"]]}, {"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl ( 4-ABP   found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only  human b5R  and cyt b5", "triple_list": [["4-ABP", "AGONIST", "the"]]}, {"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl ( 4-ABP   found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and  cyt b5   Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems", "triple_list": [["4-ABP", "AGONIST", "smoke)"]]}, {"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the  heterocyclic amine  2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only  human b5R  and cyt b5", "triple_list": [["amine", "ANTAGONIST", "human b5R"]]}, {"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the  heterocyclic amine  2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and  cyt b5   Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems", "triple_list": [["(4-ABP;", "DOWNREGULATOR", "cyt b5"]]}, {"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine  2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine  (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only  human b5R  and cyt b5", "triple_list": [["2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine", "ANTAGONIST", "purified"]]}, {"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine  2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine  (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and  cyt b5   Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems", "triple_list": [["system", "AGONIST", "cyt b5"]]}, {"text": "Reductive detoxification of  arylhydroxylamine  carcinogens by human NADH  cytochrome b5  reductase and  cytochrome b5   Heterocyclic and aromatic amine carcinogens are thought to lead to tumor initiation via the formation of DNA adducts, and bioactivation to  arylhydroxylamine  metabolites is necessary for reactivity with DNA", "triple_list": [["carcinogens", "ANTAGONIST", "cytochrome b5"]]}, {"text": "Reductive detoxification of  arylhydroxylamine  carcinogens by  human NADH cytochrome b5 reductase  and cytochrome b5", "triple_list": [["and", "DOWNREGULATOR", "human NADH cytochrome b5 reductase"]]}, {"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine ( PhIP   found in grilled meats) was indeed catalyzed by a purified system containing only  human b5R  and cyt b5", "triple_list": [["of", "DOWNREGULATOR", "human b5R"]]}, {"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine ( PhIP   found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and  cyt b5   Specific activities were 56-346-fold higher in the purified system as compared to human liver microsomes (HLM), with similar Michaelis-Menten constants (K(m) values) in both systems", "triple_list": [["that", "DOWNREGULATOR", "cyt b5"]]}, {"text": "Polyclonal antisera to either  b5R  or cyt b5 significantly inhibited  N-hydroxy-4-aminobiphenyl  (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)", "triple_list": [["antisera", "ACTIVATOR", "b5R"]]}, {"text": "Polyclonal antisera to either b5R or  cyt b5  significantly inhibited  N-hydroxy-4-aminobiphenyl  (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive  cyt b5  protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP)", "triple_list": [["N-hydroxy-4-aminobiphenyl", "ACTIVATOR", "protein"]]}, {"text": "Polyclonal antisera to either  b5R  or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl ( NHOH-4-ABP   reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both  NHOH-4-ABP  and N-hydroxy-PhIP (NHOH-PhIP)", "triple_list": [["both", "ANTAGONIST", "b5R"]]}, {"text": "Polyclonal antisera to either b5R or  cyt b5  significantly inhibited N-hydroxy-4-aminobiphenyl ( NHOH-4-ABP   reduction by 95 and 89%, respectively, and immunoreactive  cyt b5  protein content in individual HLM was significantly correlated with individual reduction of both  NHOH-4-ABP  and N-hydroxy-PhIP (NHOH-PhIP)", "triple_list": [["NHOH-4-ABP", "AGONIST", "reduction"]]}, {"text": "Imatinib was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that  imatinib  may affect mature osteoclasts through the inhibition of  c-FMS   Taken together, these results suggest that  imatinib  could be of clinical value in treating diseases where bone destruction can occur due to excessive M-CSF production such as osteoporosis, inflammatory-and tumor-induced osteolysis.", "triple_list": [["imatinib", "ACTIVATOR", "(RANKL)-induced"]]}, {"text": "Recent studies have reported that  imatinib mesylate   a kinase inhibitor that targets the intracellular  tyrosine kinase  BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS", "triple_list": [["imatinib mesylate", "ANTAGONIST", "c-FMS"]]}, {"text": "Recent studies have reported that  imatinib mesylate   a kinase inhibitor that targets the intracellular tyrosine kinase  BCR  ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS", "triple_list": [["is", "ANTAGONIST", "BCR"]]}, {"text": "Recent studies have reported that  imatinib mesylate   a kinase inhibitor that targets the intracellular tyrosine kinase BCR- ABL  and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS", "triple_list": [["c-FMS", "PRODUCT-OF", "ABL"]]}, {"text": "Recent studies have reported that  imatinib mesylate   a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the  platelet derived growth factor (PDGF) receptor   is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS", "triple_list": [["imatinib mesylate", "ACTIVATOR", "intracellular"]]}, {"text": "Recent studies have reported that  imatinib mesylate   a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the  macrophage colony stimulating factor (M-CSF) receptor   c-FMS", "triple_list": [["platelet", "PRODUCT-OF", "macrophage colony stimulating factor (M-CSF) receptor"]]}, {"text": "Recent studies have reported that  imatinib mesylate   a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor,  c-FMS   Given that M-CSF signalling through  c-FMS  plays an important role in osteoclast biology, we speculated that blocking such a pathway with imatinib may modulate osteoclast activity", "triple_list": [["imatinib mesylate", "ANTAGONIST", "and"]]}, {"text": "Recent studies have reported that  imatinib mesylate   a  kinase  inhibitor that targets the intracellular tyrosine  kinase  BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS", "triple_list": [["imatinib mesylate", "ANTAGONIST", "imatinib"]]}, {"text": "Given that  M-CSF  signalling through c-FMS plays an important role in osteoclast biology, we speculated that blocking such a pathway with  imatinib  may modulate osteoclast activity", "triple_list": [["imatinib", "AGONIST", "an"]]}, {"text": "Given that M-CSF signalling through  c-FMS  plays an important role in osteoclast biology, we speculated that blocking such a pathway with  imatinib  may modulate osteoclast activity", "triple_list": [["may", "PRODUCT-OF", "c-FMS"]]}, {"text": " Imatinib  was also found to inhibit  M-CSF  induced osteoclast survival as well as  M-CSF -induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS", "triple_list": [["the", "AGONIST", "M-CSF"]]}, {"text": " Imatinib  was also found to inhibit  M-CSF -induced osteoclast survival as well as  M-CSF  induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS", "triple_list": [["1alpha", "ANTAGONIST", "M-CSF"]]}, {"text": "Before the next drug intake,  MAO-A  inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with  moclobemide  but not with toloxatone", "triple_list": [["moclobemide", "ANTAGONIST", "not"]]}, {"text": "Before the next drug intake,  MAO-A  inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with moclobemide but not with  toloxatone   5", "triple_list": [["drug", "PRODUCT-OF", "MAO-A"]]}, {"text": "The effects of two reversible, predominantly  monoamine oxidase-A  (MAO-A) inhibitors,  moclobemide  (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects", "triple_list": [["healthy", "PRODUCT-OF", "monoamine oxidase-A"]]}, {"text": "Comparison of the  monoamine oxidase  inhibiting properties of two reversible and selective  monoamine oxidase -A inhibitors  moclobemide  and toloxatone, and assessment of their effect on psychometric performance in healthy subjects", "triple_list": [["of", "ANTAGONIST", "monoamine oxidase"]]}, {"text": "Comparison of the monoamine oxidase inhibiting properties of two reversible and selective  monoamine oxidase-A  inhibitors  moclobemide  and toloxatone, and assessment of their effect on psychometric performance in healthy subjects", "triple_list": [["moclobemide", "ACTIVATOR", "reversible"]]}, {"text": "Comparison of the  monoamine oxidase  inhibiting properties of two reversible and selective  monoamine oxidase -A inhibitors moclobemide and  toloxatone   and assessment of their effect on psychometric performance in healthy subjects", "triple_list": [["of", "ACTIVATOR", "monoamine oxidase"]]}, {"text": "Comparison of the monoamine oxidase inhibiting properties of two reversible and selective  monoamine oxidase-A  inhibitors moclobemide and  toloxatone   and assessment of their effect on psychometric performance in healthy subjects", "triple_list": [["Comparison", "ACTIVATOR", "monoamine oxidase-A"]]}, {"text": "The effects of two reversible, predominantly  monoamine oxidase-A  (MAO-A) inhibitors, moclobemide (150 mg three times daily) and  toloxatone  (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects", "triple_list": [["metabolites", "ANTAGONIST", "monoamine oxidase-A"]]}, {"text": "Clinical pharmacology of  enalkiren   a novel, dipeptide  renin  inhibitor", "triple_list": [["novel,", "AGONIST", "renin"]]}, {"text": "Clinical pharmacology of enalkiren, a novel,  dipeptide   renin  inhibitor", "triple_list": [["dipeptide", "ACTIVATOR", "dipeptide"]]}, {"text": " Enalkiren  (A-64662), a potent, dipeptide  renin  inhibitor, mimics the transition state of the human  renin  substrate, angiotensinogen", "triple_list": [["Enalkiren", "ANTAGONIST", "transition"]]}, {"text": " Enalkiren  (A-64662), a potent, dipeptide renin inhibitor, mimics the transition state of the  human renin  substrate, angiotensinogen", "triple_list": [["Enalkiren", "ANTAGONIST", "human"]]}, {"text": "Enalkiren ( A-64662  , a potent, dipeptide  renin  inhibitor, mimics the transition state of the human  renin  substrate, angiotensinogen", "triple_list": [["A-64662", "ACTIVATOR", "("]]}, {"text": "Enalkiren ( A-64662  , a potent, dipeptide renin inhibitor, mimics the transition state of the  human renin  substrate, angiotensinogen", "triple_list": [["A-64662", "ACTIVATOR", "a"]]}, {"text": "The results of clinical trials with  enalkiren  are encouraging, and suggest that  renin  inhibitors may be safe, useful therapeutic agents in the management of hypertension.", "triple_list": [["enalkiren", "AGONIST", "trials"]]}, {"text": " Enalkiren  has been shown to produce dose-related suppression of plasma  renin  activity (PRA) and angiotensin II when administered intravenously", "triple_list": [["plasma", "AGONIST", "renin"]]}, {"text": " Enalkiren  has been shown to produce dose-related suppression of plasma renin activity (PRA) and  angiotensin II  when administered intravenously", "triple_list": [["produce", "AGONIST", "angiotensin II"]]}, {"text": "Enalkiren (A-64662), a potent,  dipeptide   renin  inhibitor, mimics the transition state of the human  renin  substrate, angiotensinogen", "triple_list": [["dipeptide", "ACTIVATOR", "the"]]}, {"text": "Enalkiren (A-64662), a potent,  dipeptide  renin inhibitor, mimics the transition state of the  human renin  substrate, angiotensinogen", "triple_list": [["human", "ACTIVATOR", "human renin"]]}, {"text": "Results showed that neonatal  quinpirole  treatment induced  D2  priming that was eliminated by olanzapine treatment", "triple_list": [["priming", "ANTAGONIST", "D2"]]}, {"text": "Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal  NGF   BDNF and ChAT that was eliminated by  olanzapine  treatment", "triple_list": [["BDNF", "ANTAGONIST", "NGF"]]}, {"text": "Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF,  BDNF  and ChAT that was eliminated by  olanzapine  treatment", "triple_list": [["olanzapine", "PRODUCT-OF", "hippocampal"]]}, {"text": "Brain tissue analyses revealed that neonatal quinpirole treatment produced a significant decrease in hippocampal NGF, BDNF and  ChAT  that was eliminated by  olanzapine  treatment", "triple_list": [["olanzapine", "AGONIST", "by"]]}, {"text": "Results showed that neonatal quinpirole treatment induced  D2  priming that was eliminated by  olanzapine  treatment", "triple_list": [["olanzapine", "AGONIST", "treatment"]]}, {"text": "Brain tissue analyses revealed that neonatal  quinpirole  treatment produced a significant decrease in hippocampal  NGF   BDNF and ChAT that was eliminated by olanzapine treatment", "triple_list": [["treatment", "AGONIST", "NGF"]]}, {"text": "Brain tissue analyses revealed that neonatal  quinpirole  treatment produced a significant decrease in hippocampal NGF,  BDNF  and ChAT that was eliminated by olanzapine treatment", "triple_list": [["significant", "ANTAGONIST", "BDNF"]]}, {"text": "Brain tissue analyses revealed that neonatal  quinpirole  treatment produced a significant decrease in hippocampal NGF, BDNF and  ChAT  that was eliminated by olanzapine treatment", "triple_list": [["produced", "ACTIVATOR", "ChAT"]]}, {"text": "Neonatal  quinpirole  treatment produced a significant decrease in  BDNF  and ChAT in the frontal cortex that was unaffected by olanzapine treatment", "triple_list": [["quinpirole", "PRODUCT-OF", "quinpirole"]]}, {"text": "Neonatal  quinpirole  treatment produced a significant decrease in BDNF and  ChAT  in the frontal cortex that was unaffected by olanzapine treatment", "triple_list": [["Neonatal", "AGONIST", "ChAT"]]}, {"text": "These results show that  olanzapine  eliminates  D2 receptor  priming and cognitive impairment and also alleviates decreases in neurotrophins and acetylcholinergic markers produced by D2 priming in the hippocampus.", "triple_list": [["These", "ANTAGONIST", "D2 receptor"]]}, {"text": "Histamine content,  HDC  activity and  HDC  mRNA expression in nasal mucosa were also significantly increased after  TDI  provocation", "triple_list": [["were", "ANTAGONIST", "HDC"]]}, {"text": "Histamine content,  HDC  activity and  HDC  mRNA expression in nasal mucosa were also significantly increased after  TDI  provocation", "triple_list": [["TDI", "DOWNREGULATOR", "mucosa"]]}, {"text": "Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content,  HDC  activity and  HDC  mRNA induced by  TDI  in  TDI -sensitized rats", "triple_list": [["TDI", "ANTAGONIST", "and"]]}, {"text": "Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content,  HDC  activity and  HDC  mRNA induced by  TDI  in  TDI -sensitized rats", "triple_list": [["TDI", "ANTAGONIST", "suppressed"]]}, {"text": "Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content,  HDC  activity and  HDC  mRNA induced by  TDI  in  TDI  sensitized rats", "triple_list": [["TDI", "DOWNREGULATOR", "of"]]}, {"text": "Repression of  HDC  gene expression and  HDC  activity by  dexamethasone  may underlie its therapeutic effect in the treatment of allergy.", "triple_list": [["dexamethasone", "ANTAGONIST", "of"]]}, {"text": "Repression of  HDC  gene expression and  HDC  activity by  dexamethasone  may underlie its therapeutic effect in the treatment of allergy.", "triple_list": [["therapeutic", "ACTIVATOR", "HDC"]]}, {"text": " Dexamethasone  suppresses histamine synthesis by repressing both transcription and activity of  HDC  in allergic rats", "triple_list": [["Dexamethasone", "ACTIVATOR", "of"]]}, {"text": "Pretreatment with  dexamethasone  significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content,  HDC  activity and  HDC  mRNA induced by TDI in TDI-sensitized rats", "triple_list": [["suppressed", "ACTIVATOR", "HDC"]]}, {"text": "Pretreatment with  dexamethasone  significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content,  HDC  activity and  HDC  mRNA induced by TDI in TDI-sensitized rats", "triple_list": [["dexamethasone", "ANTAGONIST", "dexamethasone"]]}, {"text": "However the regulatory mechanism of  histamine  synthesis by  HDC  remains to be elucidated", "triple_list": [["histamine", "DOWNREGULATOR", "regulatory"]]}, {"text": "BACKGROUND: Histamine synthesized by  histidine decarboxylase  (HDC) from  L-histidine  is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity", "triple_list": [["L-histidine", "DOWNREGULATOR", "major"]]}, {"text": "BACKGROUND: Histamine synthesized by histidine decarboxylase ( HDC   from  L-histidine  is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity", "triple_list": [["of", "ACTIVATOR", "HDC"]]}, {"text": "BACKGROUND:  Histamine  synthesized by  histidine decarboxylase  (HDC) from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity", "triple_list": [["the", "AGONIST", "histidine decarboxylase"]]}, {"text": "BACKGROUND:  Histamine  synthesized by histidine decarboxylase ( HDC   from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity", "triple_list": [["major", "DOWNREGULATOR", "HDC"]]}, {"text": "CONCLUSIONS: These findings indicate that increased synthesis of  histamine  through up-regulation of  HDC  gene expression and  HDC  activity in nasal mucosa plays an important role in the development of nasal hypersensitivity", "triple_list": [["activity", "ANTAGONIST", "HDC"]]}, {"text": "CONCLUSIONS: These findings indicate that increased synthesis of  histamine  through up-regulation of  HDC  gene expression and  HDC  activity in nasal mucosa plays an important role in the development of nasal hypersensitivity", "triple_list": [["histamine", "AGONIST", "synthesis"]]}, {"text": "Methionine synthase reductase ( MTRR   is an enzyme involved in the conversion of  Hcy  to methionine", "triple_list": [["Hcy", "DOWNREGULATOR", "synthase"]]}, {"text": " Methionine synthase reductase  (MTRR) is an enzyme involved in the conversion of  Hcy  to methionine", "triple_list": [["enzyme", "ACTIVATOR", "Methionine synthase reductase"]]}, {"text": "Methionine synthase reductase ( MTRR   is an enzyme involved in the conversion of Hcy to  methionine   We hypothesized that certain genetic polymorphisms of  MTRR  leading to reduced enzyme activity may cause hyperhomocysteinemia and affect bone metabolism", "triple_list": [["enzyme", "ANTAGONIST", "MTRR"]]}, {"text": " Methionine synthase reductase  (MTRR) is an enzyme involved in the conversion of Hcy to  methionine   We hypothesized that certain genetic polymorphisms of MTRR leading to reduced enzyme activity may cause hyperhomocysteinemia and affect bone metabolism", "triple_list": [["polymorphisms", "ACTIVATOR", "Methionine synthase reductase"]]}, {"text": " GPxs  reduce hydroperoxides to the corresponding  alcohols  by means of glutathione (GSH)", "triple_list": [["alcohols", "DOWNREGULATOR", "of"]]}, {"text": "The non-selective  adenosine receptor  antagonist ( caffeine  , and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice", "triple_list": [["the", "AGONIST", "adenosine receptor"]]}, {"text": "The non-selective adenosine receptor antagonist (caffeine), and the selective  adenosine A1 receptor  antagonist ( DPCPX  , injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice", "triple_list": [["DPCPX", "DOWNREGULATOR", "application"]]}, {"text": "The concomitant application of subconvulsive dose of pentetrazole (55.0 mg/kg) with low dose of  flumazenil  (5.0 mg/kg) - a  BDZ receptor  antagonist, immediately induced BDZ withdrawal signs in these animals", "triple_list": [["flumazenil", "AGONIST", "pentetrazole"]]}, {"text": "In the interaction of  GAL  and CAR,  AChE  inhibition was stronger but without any statistical significance", "triple_list": [["GAL", "PRODUCT-OF", "AChE"]]}, {"text": "OBJECTIVES: The alkaloid  galantamine  (GAL), which exhibits a combined  anticholinesterase  and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases", "triple_list": [["a", "ACTIVATOR", "anticholinesterase"]]}, {"text": "OBJECTIVES: The alkaloid galantamine ( GAL  , which exhibits a combined  anticholinesterase  and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases", "triple_list": [["GAL", "PRODUCT-OF", ","]]}, {"text": "RESULTS: Following administration of the highest of the  GAL  doses used (2.5; 5; 10 mg/kg i.m.),  AChE  activity decreased mainly in the frontal cortex, hippocampus and hypophysis", "triple_list": [["and", "AGONIST", "AChE"]]}, {"text": "Pharmacogenetic analysis of two genes, the  warfarin  metabolic enzyme  CYP2C9  and  warfarin  target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on  warfarin  maintenance dose", "triple_list": [["warfarin", "ACTIVATOR", "enzyme"]]}, {"text": "Possession of  CYP2C9  2 or  CYP2C9 *3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean  warfarin  dose", "triple_list": [["warfarin", "AGONIST", "result"]]}, {"text": "Possession of  CYP2C9 *2 or  CYP2C9  3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean  warfarin  dose", "triple_list": [["in", "ACTIVATOR", "CYP2C9"]]}, {"text": "The identification of the  succinate  receptor SUCNR1 in platelets is of particular interest, because physiologically relevant concentrations of  succinate  were shown to potentiate the effect of low doses of a variety of platelet agonists.", "triple_list": [["succinate", "DOWNREGULATOR", "relevant"]]}, {"text": "The identification of the  succinate  receptor  SUCNR1  in platelets is of particular interest, because physiologically relevant concentrations of  succinate  were shown to potentiate the effect of low doses of a variety of platelet agonists.", "triple_list": [["succinate", "ACTIVATOR", "the"]]}, {"text": "The activity of  polymerases  containing mutations known to confer resistance to  foscarnet  (V715M, T700A and N495K) was inhibited by concentrations of  foscarnet  eight to 14 times higher than those required to inhibit wild-type  polymerases ", "triple_list": [["foscarnet", "PRODUCT-OF", "foscarnet"]]}, {"text": "The activity of polymerases containing mutations known to confer resistance to  foscarnet  ( V715M   T700A and N495K) was inhibited by concentrations of  foscarnet  eight to 14 times higher than those required to inhibit wild-type polymerases", "triple_list": [["foscarnet", "ANTAGONIST", "The"]]}, {"text": "The activity of polymerases containing mutations known to confer resistance to  foscarnet  (V715M,  T700A  and N495K) was inhibited by concentrations of  foscarnet  eight to 14 times higher than those required to inhibit wild-type polymerases", "triple_list": [["mutations", "ACTIVATOR", "T700A"]]}, {"text": "The activity of polymerases containing mutations known to confer resistance to  foscarnet  (V715M, T700A and  N495K   was inhibited by concentrations of  foscarnet  eight to 14 times higher than those required to inhibit wild-type polymerases", "triple_list": [["foscarnet", "PRODUCT-OF", "foscarnet"]]}, {"text": "The activity of  polymerases  containing mutations known to confer resistance to  foscarnet  (V715M, T700A and N495K) was inhibited by concentrations of  foscarnet  eight to 14 times higher than those required to inhibit wild-type  polymerases   Our in-house non-radioactive phenotypic assay was sensitive and reproducible", "triple_list": [["sensitive", "ACTIVATOR", "polymerases"]]}, {"text": "Development and validation of a non-radioactive  DNA polymerase  assay for studying cytomegalovirus resistance to  foscarnet   Phenotypic characterisation of the human cytomegalovirus (HCMV) pUL54  DNA polymerase  is a useful tool for testing for mutations in the UL54 gene thought to render HCMV resistant to  foscarnet ", "triple_list": [["foscarnet", "ACTIVATOR", "HCMV"]]}, {"text": " Adenine phosphoribosyltransferase  plays a role in purine salvage by catalyzing the direct conversion of  adenine  to adenosine monophosphate", "triple_list": [["adenine", "AGONIST", "monophosphate"]]}, {"text": " Adenine phosphoribosyltransferase  plays a role in purine salvage by catalyzing the direct conversion of adenine to  adenosine monophosphate   The involvement of the purine salvage pathway in tumor proliferation and angiogenesis makes adenine phosphoribosyltransferase a potential target for oncology drug discovery", "triple_list": [["adenosine monophosphate", "ANTAGONIST", "purine"]]}, {"text": "Antitumor activity of  sorafenib  in  FLT3  driven leukemic cells", "triple_list": [["Antitumor", "PRODUCT-OF", "FLT3"]]}, {"text": "The demonstration that  sorafenib  exhibits potent target inhibition and efficacy in  FLT3  driven models suggests that this compound may have a therapeutic benefit for patients with  FLT3 -driven leukemias.", "triple_list": [["benefit", "AGONIST", "FLT3"]]}, {"text": "The demonstration that  sorafenib  exhibits potent target inhibition and efficacy in  FLT3 -driven models suggests that this compound may have a therapeutic benefit for patients with  FLT3  driven leukemias.", "triple_list": [["sorafenib", "PRODUCT-OF", "that"]]}, {"text": "We show that  sorafenib  (BAY 43-9006, Nexavar) potently inhibits  FLT3  enzymatic and signaling activities", "triple_list": [["potently", "AGONIST", "FLT3"]]}, {"text": "We show that sorafenib ( BAY 43-9006   Nexavar) potently inhibits  FLT3  enzymatic and signaling activities", "triple_list": [["BAY 43-9006", "PRODUCT-OF", "activities"]]}, {"text": "We show that sorafenib (BAY 43-9006,  Nexavar   potently inhibits  FLT3  enzymatic and signaling activities", "triple_list": [["potently", "PRODUCT-OF", "FLT3"]]}, {"text": "In HEK293 cells stably transfected with  FLT3 -WT or  FLT3 -ITD,  sorafenib  blocked basal and ligand dependent  FLT3  mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1/2 and Stat5 phosphorylation", "triple_list": [["sorafenib", "ACTIVATOR", "and"]]}, {"text": "In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD,  sorafenib  blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as  extracellular signal-regulated kinase1/2  and Stat5 phosphorylation", "triple_list": [["and", "ACTIVATOR", "extracellular signal-regulated kinase1/2"]]}, {"text": "In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD,  sorafenib  blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1/2 and  Stat5  phosphorylation", "triple_list": [["sorafenib", "PRODUCT-OF", "blocked"]]}, {"text": "In leukemia cell lines MV4-11 and EOL-1,  sorafenib  treatment resulted in decreased cell proliferation and inhibition of  FLT3  signaling", "triple_list": [["cell", "PRODUCT-OF", "FLT3"]]}, {"text": "The growth of the  FLT3  independent RS4-11 cell line was only weakly inhibited by  sorafenib   Cell cycle arrest and induction of apoptosis were observed upon treatment with  sorafenib  in MV4-11 and EOL-1 cells", "triple_list": [["sorafenib", "AGONIST", "treatment"]]}, {"text": "They all expressed ASS, but not  ornithine  transcarbamylase (OTC), the enzyme that converts  ornithine   the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS", "triple_list": [["converted", "ANTAGONIST", "ornithine transcarbamylase"]]}, {"text": "They all expressed ASS, but not  ornithine  transcarbamylase ( OTC  , the enzyme that converts  ornithine   the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS", "triple_list": [["ornithine", "ACTIVATOR", "arginine"]]}, {"text": "They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of  arginine  with  rhArg   to citrulline, which is converted back to  arginine  via ASS", "triple_list": [["arginine", "AGONIST", "is"]]}, {"text": "They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with  rhArg   to  citrulline   which is converted back to arginine via ASS", "triple_list": [["which", "ACTIVATOR", "rhArg"]]}, {"text": "They all expressed  ASS , but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of  arginine  with rhArg, to citrulline, which is converted back to  arginine  via  ASS   Transfection of HCC cells with OTC resulted in resistance to rhArg", "triple_list": [["ornithine", "DOWNREGULATOR", "ASS"]]}, {"text": "This surprising correlation between the lack of OTC expression and sensitivity of ASS-positive HCC cells shows that OTC-deficient HCCs are sensitive to  rhArg  mediated  arginine  depletion", "triple_list": [["arginine", "ANTAGONIST", "between"]]}, {"text": "Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to  arginine  depletion with  arginine -depleting enzymes  We have also shown that the rhArg native enzyme and the pegylated rhArg (rhArg-peg(5,000mw)) gave similar anticancer efficacy in vitro", "triple_list": [["the", "AGONIST", "arginine-depleting enzymes"]]}, {"text": "Unlike mouse RetSat (mRetSat),  zRetSat A  had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of  all-trans-retinol  to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively", "triple_list": [["all-trans-retinol", "ANTAGONIST", "had"]]}, {"text": "Specifically,  all-trans-13,14-dihydroretinol  is transiently oxidized to all-trans-13,14-dihydroretinoic acid before being oxidized further by  Cyp26  enzymes", "triple_list": [["all-trans-13,14-dihydroretinol", "AGONIST", "further"]]}, {"text": "Specificity of  zebrafish retinol saturase   formation of  all-trans-13,14-dihydroretinol  and all-trans-7,8- dihydroretinol", "triple_list": [["dihydroretinol", "ACTIVATOR", "zebrafish retinol saturase"]]}, {"text": "Specificity of  zebrafish retinol saturase   formation of all-trans-13,14-dihydroretinol and  all-trans-7,8- dihydroretinol   Metabolism of vitamin A, all-trans-retinol, leads to the formation of 11-cis-retinaldehyde, the visual chromophore, and all-trans-retinoic acid, which is involved in the regulation of gene expression through the retinoic acid receptor", "triple_list": [["receptor", "ACTIVATOR", "zebrafish retinol saturase"]]}, {"text": "Unlike mouse RetSat (mRetSat),  zRetSat A  had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either  all-trans-13,14-dihydroretinol  or all-trans-7,8-dihydroretinol, respectively", "triple_list": [["all-trans-13,14-dihydroretinol", "ANTAGONIST", "bond"]]}, {"text": "Unlike mouse RetSat (mRetSat),  zRetSat A  had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or  all-trans-7,8-dihydroretinol   respectively", "triple_list": [["all-trans-13,14-dihydroretinol", "DOWNREGULATOR", "zRetSat A"]]}, {"text": " zRetSat A  also saturated the 13-14 or 7-8 double bonds of  all-trans-3,4-didehydroretinol  (vitamin A2), a second endogenous form of vitamin A in zebrafish", "triple_list": [["7-8", "ACTIVATOR", "zRetSat A"]]}, {"text": " zRetSat A  also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol ( vitamin A2  , a second endogenous form of vitamin A in zebrafish", "triple_list": [["in", "ANTAGONIST", "zRetSat A"]]}, {"text": "The latter reaction, catalyzed by  aspartoacylase  (ASPA), produces  acetyl  groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter", "triple_list": [["been", "DOWNREGULATOR", "aspartoacylase"]]}, {"text": "The latter reaction, catalyzed by aspartoacylase ( ASPA  , produces  acetyl  groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter", "triple_list": [["acetyl", "ANTAGONIST", "aspartate"]]}, {"text": "The latter reaction, catalyzed by  aspartoacylase  (ASPA), produces acetyl groups plus  aspartate  and has been proposed to occur in both soluble and membranous subfractions of white matter", "triple_list": [["aspartate", "AGONIST", "(ASPA),"]]}, {"text": "The latter reaction, catalyzed by aspartoacylase ( ASPA  , produces acetyl groups plus  aspartate  and has been proposed to occur in both soluble and membranous subfractions of white matter", "triple_list": [["aspartate", "ANTAGONIST", "and"]]}, {"text": " LDH  is responsible for  pyruvate  conversion to lactate through glycolysis", "triple_list": [["pyruvate", "ANTAGONIST", "LDH"]]}, {"text": " LDH  is responsible for pyruvate conversion to  lactate  through glycolysis", "triple_list": [["is", "DOWNREGULATOR", "LDH"]]}, {"text": "OBJECTIVE: The aim was to test whether the common deletion [T/-] in the promoter of  FADS2  affects the PUFA biosynthetic pathway and consequently modifies the effect of  alpha-linolenic acid  (ALA) on myocardial infarction (MI)", "triple_list": [["of", "DOWNREGULATOR", "FADS2"]]}, {"text": "OBJECTIVE: The aim was to test whether the common deletion [T/-] in the promoter of  FADS2  affects the PUFA biosynthetic pathway and consequently modifies the effect of alpha-linolenic acid ( ALA   on myocardial infarction (MI)", "triple_list": [["ALA", "ANTAGONIST", "aim"]]}, {"text": "OBJECTIVE: The aim was to test whether the common deletion [T/-] in the promoter of  FADS2  affects the  PUFA  biosynthetic pathway and consequently modifies the effect of alpha-linolenic acid (ALA) on myocardial infarction (MI)", "triple_list": [["to", "ACTIVATOR", "FADS2"]]}, {"text": "These data support the conclusion that renal ecto- phosphodiesterase  activity is not mediated by PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE9, PDE10, or PDE11 and is inhibited by high concentrations of  dipyridamole   Ecto- phosphodiesterase  has some pharmacological characteristics similar to PDE8.", "triple_list": [["PDE2,", "AGONIST", "phosphodiesterase"]]}, {"text": "A broad-spectrum  phosphodiesterase  (PDE) inhibitor ( 1,3-isobutyl-1-methylxanthine   300 microM, n=6) and an ecto- phosphodiesterase  inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively", "triple_list": [["1,3-isobutyl-1-methylxanthine", "PRODUCT-OF", "an"]]}, {"text": "A broad-spectrum phosphodiesterase ( PDE   inhibitor ( 1,3-isobutyl-1-methylxanthine   300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively", "triple_list": [["(", "ACTIVATOR", "PDE"]]}, {"text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM],  PDE3  ( milrinone   10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity", "triple_list": [["microM],", "ACTIVATOR", "PDE3"]]}, {"text": "Blockade of  PDE1  ( 8-methoxymethyl-3-isobutyl-1-methylxanthine   100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity", "triple_list": [["20-1724", "PRODUCT-OF", "PDE1"]]}, {"text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM),  PDE2  [ erythro-9-(2-hydroxy-3-nonyl)adenine   30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity", "triple_list": [["30", "ANTAGONIST", "PDE2"]]}, {"text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM),  PDE4  (Ro 20-1724 [ 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one  , 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity", "triple_list": [["4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one", "PRODUCT-OF", "ecto-phosphodiesterase"]]}, {"text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM),  PDE5  and PDE6 ( zaprinast   30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity", "triple_list": [["zaprinast", "ACTIVATOR", "ecto-phosphodiesterase"]]}, {"text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and  PDE6  ( zaprinast   30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity", "triple_list": [["zaprinast", "PRODUCT-OF", "microM]"]]}, {"text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and  PDE7  [ BRL-50481  (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity", "triple_list": [["BRL-50481", "AGONIST", "PDE7"]]}, {"text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and  PDE7  [BRL-50481 ( 5-nitro-2,N,N-trimethylbenzenesulfonamide  , 10 microM] did not alter renal ecto-phosphodiesterase activity", "triple_list": [["5-nitro-2,N,N-trimethylbenzenesulfonamide", "ACTIVATOR", "100"]]}, {"text": "Administration of a concentration (100 microM) of  dipyridamole  that blocks  PDE8  inhibited ecto-phosphodiesterase activity (by 44%)", "triple_list": [["a", "ANTAGONIST", "PDE8"]]}, {"text": "Administration of a concentration (100 microM) of  dipyridamole  that blocks PDE8 inhibited ecto- phosphodiesterase  activity (by 44%)", "triple_list": [["phosphodiesterase", "AGONIST", "phosphodiesterase"]]}, {"text": "However, a lower concentration of  dipyridamole  (3 microM) that blocks  PDE9   PDE10, and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity", "triple_list": [["dipyridamole", "ANTAGONIST", "dipyridamole"]]}, {"text": "However, a lower concentration of  dipyridamole  (3 microM) that blocks PDE9,  PDE10   and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity", "triple_list": [["lower", "PRODUCT-OF", "PDE10"]]}, {"text": "However, a lower concentration of  dipyridamole  (3 microM) that blocks PDE9, PDE10, and  PDE11   but not PDE8, did not inhibit ecto-phosphodiesterase activity", "triple_list": [["dipyridamole", "PRODUCT-OF", "ecto-phosphodiesterase"]]}, {"text": "In kidneys, stimulation of adenylyl cyclase causes egress of  cAMP , conversion of  cAMP  to AMP by ecto- phosphodiesterase   and metabolism of AMP to adenosine by ecto-5'-nucleotidase", "triple_list": [["ecto-", "DOWNREGULATOR", "phosphodiesterase"]]}, {"text": "In kidneys, stimulation of adenylyl cyclase causes egress of c AMP , conversion of c AMP  to  AMP  by ecto- phosphodiesterase   and metabolism of  AMP  to adenosine by ecto-5'-nucleotidase", "triple_list": [["AMP", "DOWNREGULATOR", "of"]]}, {"text": "In kidneys, stimulation of adenylyl cyclase causes egress of c AMP , conversion of c AMP  to  AMP  by ecto-phosphodiesterase, and metabolism of  AMP  to adenosine by  ecto-5'-nucleotidase   Although much is known about  ecto-5'-nucleotidase , the renal ecto-phosphodiesterase remains uncharacterized", "triple_list": [["of", "ANTAGONIST", "ecto-5'-nucleotidase"]]}, {"text": "In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to  adenosine  by  ecto-5'-nucleotidase   Although much is known about  ecto-5'-nucleotidase , the renal ecto-phosphodiesterase remains uncharacterized", "triple_list": [["In", "DOWNREGULATOR", "ecto-5'-nucleotidase"]]}, {"text": "Gene expression profiling (GEP) of GIST-S, GIST-R cells and two  IM  resistant GIST patients demonstrated that  KIT  is downregulated implying a major role in  IM  resistance", "triple_list": [["GIST-S,", "ANTAGONIST", "KIT"]]}, {"text": "Gene expression profiling (GEP) of GIST-S, GIST-R cells and two  IM  resistant GIST patients demonstrated that  KIT  is downregulated implying a major role in  IM  resistance", "triple_list": [["expression", "ACTIVATOR", "KIT"]]}, {"text": "Molecular modeling of the kinase domain of mutant  c-Kit  (V654A) and AXL showed no binding to IM but efficient binding to  MP470   a novel  c-Kit  AXL kinase inhibitor", "triple_list": [["to", "ANTAGONIST", "c-Kit"]]}, {"text": "Molecular modeling of the kinase domain of mutant c-Kit (V654A) and  AXL  showed no binding to IM but efficient binding to  MP470   a novel c-Kit/ AXL  kinase inhibitor", "triple_list": [["modeling", "PRODUCT-OF", "AXL"]]}, {"text": "Molecular modeling of the  kinase  domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to  MP470   a novel c-Kit/AXL  kinase  inhibitor", "triple_list": [["MP470", "ACTIVATOR", "to"]]}, {"text": "OBJECTIVES: The aim of the current study was to assess the activity of  rolipram   a nonsubtype-selective  PDE4  inhibitor, in several animal models predictive of antipsychotic-like efficacy and side-effect liability and to use  PDE4 B wild-type and knockout mice to begin to understand the subtypes involved in the activity of  rolipram ", "triple_list": [["the", "ANTAGONIST", "PDE4"]]}, {"text": "These results suggest that  PDE4B  mediates the antipsychotic effects of rolipram in CAR and that the  PDE4B  regulated  cyclic adenosine monophosphate  signaling pathway may play a role in the pathophysiology and pharmacotherapy of psychosis.", "triple_list": [["cyclic adenosine monophosphate", "ACTIVATOR", "PDE4B"]]}, {"text": "Improvements from baseline in mean  glycosylated haemoglobin  (HbA(1c)) were significantly greater with  sitagliptin  monotherapy than with placebo in patients with type 2 diabetes", "triple_list": [["sitagliptin", "PRODUCT-OF", "significantly"]]}, {"text": "Improvements from baseline in mean glycosylated haemoglobin ( HbA(1c)   were significantly greater with  sitagliptin  monotherapy than with placebo in patients with type 2 diabetes", "triple_list": [["sitagliptin", "AGONIST", "in"]]}, {"text": "As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment,  sitagliptin  improved  HbA(1c)  to a significantly greater extent than placebo when added to metformin or pioglitazone and was noninferior to glipizide when added to metformin", "triple_list": [["despite", "ANTAGONIST", "HbA(1c)"]]}, {"text": " Sitagliptin   an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the  incretin hormones  glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide", "triple_list": [["Sitagliptin", "DOWNREGULATOR", "DPP-4"]]}, {"text": " Sitagliptin   an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones  glucagon-like peptide-1  and glucose-dependent insulinotropic polypeptide", "triple_list": [["Sitagliptin", "DOWNREGULATOR", "hormones"]]}, {"text": " Sitagliptin   an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and  glucose-dependent insulinotropic polypeptide   This increases active incretin and insulin levels, and decreases glucagon levels and post-glucose-load glucose excursion", "triple_list": [["insulin", "AGONIST", "glucose-dependent insulinotropic polypeptide"]]}, {"text": "As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved  HbA(1c)  to a significantly greater extent than placebo when added to  metformin  or pioglitazone and was noninferior to glipizide when added to  metformin ", "triple_list": [["added", "ANTAGONIST", "HbA(1c)"]]}, {"text": "As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved  HbA(1c)  to a significantly greater extent than placebo when added to metformin or  pioglitazone  and was noninferior to glipizide when added to metformin", "triple_list": [["and", "ANTAGONIST", "HbA(1c)"]]}, {"text": " Sitagliptin   an oral dipeptidyl peptidase-4 ( DPP-4 ) inhibitor, improves glycaemic control by inhibiting  DPP-4  inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide", "triple_list": [["Sitagliptin", "ACTIVATOR", "("]]}, {"text": " Sitagliptin   an oral  dipeptidyl peptidase-4  (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide", "triple_list": [["Sitagliptin", "ANTAGONIST", "glucagon-like"]]}, {"text": " Sitagliptin   an oral dipeptidyl peptidase-4 ( DPP-4   inhibitor, improves glycaemic control by inhibiting  DPP-4  inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide", "triple_list": [["glucose-dependent", "PRODUCT-OF", "DPP-4"]]}, {"text": "As add-on therapy in patients with suboptimal glycaemic control despite oral antihyperglycaemic treatment, sitagliptin improved  HbA(1c)  to a significantly greater extent than placebo when added to  metformin  or pioglitazone and was noninferior to glipizide when added to  metformin   Sitagliptin was well tolerated when administered alone or in combination with other antihyperglycaemics, with an adverse event profile similar to that shown with placebo", "triple_list": [["that", "ACTIVATOR", "HbA(1c)"]]}, {"text": "There was also an increase in  c-kit   Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the  parathion  treated cells", "triple_list": [["Ezrin,", "PRODUCT-OF", "c-kit"]]}, {"text": "There was also an increase in c-kit,  Trio   Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the  parathion  treated cells", "triple_list": [["There", "PRODUCT-OF", "Trio"]]}, {"text": "There was also an increase in c-kit, Trio,  Rho-A   Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the  parathion  treated cells", "triple_list": [["Trio,", "AGONIST", "Rho-A"]]}, {"text": "There was also an increase in c-kit, Trio, Rho-A,  Rac-3   EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the  parathion  treated cells", "triple_list": [["parathion", "ANTAGONIST", "the"]]}, {"text": "There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR,  Notch-4   Dvl-2, Ezrin, beta catenin and mutant p53 protein expression in the  parathion  treated cells", "triple_list": [["parathion", "ANTAGONIST", "Notch-4"]]}, {"text": "There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4,  Dvl-2   Ezrin, beta catenin and mutant p53 protein expression in the  parathion  treated cells", "triple_list": [["treated", "ANTAGONIST", "Dvl-2"]]}, {"text": "There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2,  Ezrin   beta catenin and mutant p53 protein expression in the  parathion  treated cells", "triple_list": [["parathion", "DOWNREGULATOR", "treated"]]}, {"text": "There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin,  beta catenin  and mutant p53 protein expression in the  parathion  treated cells", "triple_list": [["Notch-4,", "PRODUCT-OF", "beta catenin"]]}, {"text": "There was also an increase in c-kit, Trio, Rho-A, Rac-3, EGFR, Notch-4, Dvl-2, Ezrin, beta catenin and mutant  p53  protein expression in the  parathion  treated cells", "triple_list": [["parathion", "DOWNREGULATOR", "the"]]}, {"text": " Parathion  is a  cholinesterase  inhibitor that induces the hydrolysis of body choline esters, including acetylcholine at cholinergic synapses", "triple_list": [["Parathion", "ACTIVATOR", "induces"]]}, {"text": " Indomethacin  treatment led to an increase in lipid peroxidation,  glutathione peroxidase  and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa", "triple_list": [["Indomethacin", "ANTAGONIST", "lipid"]]}, {"text": " Indomethacin  treatment led to an increase in lipid peroxidation, glutathione peroxidase and  glucose-6-phosphate dehydrogenase  activities and to a decrease in catalase activity and glutathione levels in gastric mucosa", "triple_list": [["catalase", "PRODUCT-OF", "glucose-6-phosphate dehydrogenase"]]}, {"text": " Indomethacin  treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in  catalase  activity and glutathione levels in gastric mucosa", "triple_list": [["Indomethacin", "ANTAGONIST", "activities"]]}, {"text": " Sulindac sulfide  inhibited  PPARdelta  protein expression and  PPARdelta  transcriptional activity", "triple_list": [["Sulindac sulfide", "ANTAGONIST", "PPARdelta"]]}, {"text": " Sulindac sulfide  inhibited  PPARdelta  protein expression and  PPARdelta  transcriptional activity", "triple_list": [["Sulindac sulfide", "PRODUCT-OF", "PPARdelta"]]}, {"text": " Sulindac sulfide  inhibited  14-3-3epsilon proteins  in HT-29 and DLD-1 cells in a time- and concentration-dependent manner", "triple_list": [["Sulindac sulfide", "ANTAGONIST", "in"]]}, {"text": " Indomethacin  and SC-236, a selective  cyclooxygenase-2  (COX-2) inhibitor, exerted a similar effect as sulindac", "triple_list": [["(COX-2)", "ACTIVATOR", "cyclooxygenase-2"]]}, {"text": " Indomethacin  and SC-236, a selective cyclooxygenase-2 ( COX-2   inhibitor, exerted a similar effect as sulindac", "triple_list": [["sulindac", "PRODUCT-OF", "COX-2"]]}, {"text": "Indomethacin and  SC-236   a selective  cyclooxygenase-2  (COX-2) inhibitor, exerted a similar effect as sulindac", "triple_list": [["similar", "AGONIST", "cyclooxygenase-2"]]}, {"text": "Indomethacin and  SC-236   a selective cyclooxygenase-2 ( COX-2   inhibitor, exerted a similar effect as sulindac", "triple_list": [["inhibitor,", "ACTIVATOR", "COX-2"]]}, {"text": "Under isotonic conditions,  N-ethylmaleimide  (NEM) produced  KCC  activation and transient cell shrinkage", "triple_list": [["activation", "ANTAGONIST", "KCC"]]}, {"text": "Under isotonic conditions, N-ethylmaleimide ( NEM   produced  KCC  activation and transient cell shrinkage", "triple_list": [["conditions,", "ANTAGONIST", "KCC"]]}, {"text": "A  KCC  inhibitor- [(dihydroindenyl)oxy] alkanoic acid  (DIOA)-blocked RVD more in HCEC than RCEC", "triple_list": [["[(dihydroindenyl)oxy]", "ACTIVATOR", "KCC"]]}, {"text": "A  KCC  inhibitor-[(dihydroindenyl)oxy] alkanoic acid ( DIOA  -blocked RVD more in HCEC than RCEC", "triple_list": [["RCEC", "ANTAGONIST", "KCC"]]}, {"text": "PURPOSE:  Dasatinib  (BMS-354825), a potent oral multi-targeted  kinase  inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance", "triple_list": [["Dasatinib", "PRODUCT-OF", "kinase"]]}, {"text": "PURPOSE:  Dasatinib  (BMS-354825), a potent oral multi-targeted kinase inhibitor against  SRC  and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance", "triple_list": [["recently", "PRODUCT-OF", "SRC"]]}, {"text": "PURPOSE:  Dasatinib  (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and  BCR  ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance", "triple_list": [["of", "AGONIST", "BCR"]]}, {"text": "PURPOSE:  Dasatinib  (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR- ABL   has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance", "triple_list": [["Dasatinib", "PRODUCT-OF", "Dasatinib"]]}, {"text": "Preclinical pharmacokinetics and in vitro metabolism of  dasatinib  (BMS-354825): a potent oral multi-targeted  kinase  inhibitor against SRC and BCR-ABL", "triple_list": [["dasatinib", "ACTIVATOR", "kinase"]]}, {"text": "Preclinical pharmacokinetics and in vitro metabolism of  dasatinib  (BMS-354825): a potent oral multi-targeted kinase inhibitor against  SRC  and BCR-ABL", "triple_list": [["dasatinib", "AGONIST", "pharmacokinetics"]]}, {"text": "Preclinical pharmacokinetics and in vitro metabolism of  dasatinib  (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and  BCR  ABL", "triple_list": [["dasatinib", "ANTAGONIST", "vitro"]]}, {"text": "Preclinical pharmacokinetics and in vitro metabolism of  dasatinib  (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR- ABL   PURPOSE: Dasatinib (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR- ABL , has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance", "triple_list": [["dasatinib", "ANTAGONIST", "been"]]}, {"text": "Preclinical pharmacokinetics and in vitro metabolism of dasatinib ( BMS-354825  : a potent oral multi-targeted  kinase  inhibitor against SRC and BCR-ABL", "triple_list": [["BMS-354825", "PRODUCT-OF", "BMS-354825"]]}, {"text": "Preclinical pharmacokinetics and in vitro metabolism of dasatinib ( BMS-354825  : a potent oral multi-targeted kinase inhibitor against  SRC  and BCR-ABL", "triple_list": [["a", "ACTIVATOR", "SRC"]]}, {"text": "Preclinical pharmacokinetics and in vitro metabolism of dasatinib ( BMS-354825  : a potent oral multi-targeted kinase inhibitor against SRC and  BCR  ABL", "triple_list": [["BMS-354825", "PRODUCT-OF", "multi-targeted"]]}, {"text": "Preclinical pharmacokinetics and in vitro metabolism of dasatinib ( BMS-354825  : a potent oral multi-targeted kinase inhibitor against SRC and BCR- ABL   PURPOSE: Dasatinib ( BMS-354825 ), a potent oral multi-targeted kinase inhibitor against SRC and BCR- ABL , has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance", "triple_list": [["BMS-354825", "ACTIVATOR", "multi-targeted"]]}, {"text": "PURPOSE: Dasatinib ( BMS-354825  , a potent oral multi-targeted  kinase  inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance", "triple_list": [["imatinib-acquired", "ANTAGONIST", "kinase"]]}, {"text": "PURPOSE: Dasatinib ( BMS-354825  , a potent oral multi-targeted kinase inhibitor against  SRC  and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance", "triple_list": [["potent", "AGONIST", "SRC"]]}, {"text": "PURPOSE: Dasatinib ( BMS-354825  , a potent oral multi-targeted kinase inhibitor against SRC and  BCR  ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance", "triple_list": [["BCR", "AGONIST", "BCR"]]}, {"text": "PURPOSE: Dasatinib ( BMS-354825  , a potent oral multi-targeted kinase inhibitor against SRC and BCR- ABL   has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance", "triple_list": [["ABL", "AGONIST", "ABL"]]}, {"text": "Interestingly, a  Val-349 to Ile  mutant was inhibited with equal potency to human COX-2 with  2,6-dichloro  , 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency", "triple_list": [["Interestingly,", "PRODUCT-OF", "Val-349 to Ile"]]}, {"text": "Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to  human COX-2  with  2,6-dichloro  , 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency", "triple_list": [["2,6-dichloro", "ACTIVATOR", "lumiracoxib,"]]}, {"text": "Interestingly, a  Val-349 to Ile  mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-,  2,6-dimethyl  , or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency", "triple_list": [["2,6-dimethyl", "AGONIST", "showed"]]}, {"text": "Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to  human COX-2  with 2,6-dichloro-,  2,6-dimethyl  , or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency", "triple_list": [["2,6-dimethyl", "ANTAGONIST", "Interestingly,"]]}, {"text": "Interestingly, a  Val-349 to Ile  mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or  2-chloro-6-methyl  substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency", "triple_list": [["2-chloro-6-methyl", "ACTIVATOR", "2,6-dimethyl-,"]]}, {"text": "Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to  human COX-2  with 2,6-dichloro-, 2,6-dimethyl-, or  2-chloro-6-methyl  substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency", "triple_list": [["2-chloro-6-methyl", "AGONIST", "inhibitors"]]}, {"text": "Interestingly, a  Val-349 to Ile  mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of  lumiracoxib   actually showed an increase in potency", "triple_list": [["or", "ACTIVATOR", "Val-349 to Ile"]]}, {"text": "Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to  human COX-2  with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of  lumiracoxib   actually showed an increase in potency", "triple_list": [["lumiracoxib", "PRODUCT-OF", "lumiracoxib"]]}, {"text": "Taken together with a recent crystal structure of a  lumiracoxib -COX-2 complex, the kinetic analyses presented herein of the inhibition of mutant  COX-2s  by  lumiracoxib  allows the definition of the molecular basis of COX-2 inhibition.", "triple_list": [["lumiracoxib", "ACTIVATOR", "herein"]]}, {"text": "Using standard assays,  lumiracoxib  was found to be a poor inhibitor of purified  ovine COX-1  and a relatively weak inhibitor of purified human COX-2", "triple_list": [["lumiracoxib", "AGONIST", "was"]]}, {"text": "Using standard assays,  lumiracoxib  was found to be a poor inhibitor of purified ovine COX-1 and a relatively weak inhibitor of purified  human COX-2   The extent of COX-2 inhibition plateaued at around 50% and suggested that the inhibitor may be reversibly bound to the enzyme", "triple_list": [["around", "AGONIST", "human COX-2"]]}, {"text": "Kinetic studies with  lumiracoxib  demonstrated that it was a time-dependent and slowly reversible inhibitor of  human COX-2  that exhibited at least two binding steps during inhibition", "triple_list": [["lumiracoxib", "ACTIVATOR", "with"]]}, {"text": "Lumiracoxib is the first example of a marketed  COX-2  inhibitor of the  arylacetic acid  class, and it is reported to be the most selective COXIB in vivo", "triple_list": [["selective", "PRODUCT-OF", "COX-2"]]}, {"text": " Lumiracoxib  is the first example of a marketed  COX-2  inhibitor of the arylacetic acid class, and it is reported to be the most selective COXIB in vivo", "triple_list": [["vivo", "ANTAGONIST", "COX-2"]]}, {"text": "Inhibition studies demonstrated that the  methyl  group on the phenylacetic acid ring is required for  COX-2  selectivity", "triple_list": [["that", "ACTIVATOR", "COX-2"]]}, {"text": "Inhibition studies demonstrated that the methyl group on the  phenylacetic acid  ring is required for  COX-2  selectivity", "triple_list": [["phenylacetic acid", "AGONIST", "phenylacetic"]]}, {"text": "Molecular determinants for the selective inhibition of  cyclooxygenase-2  by  lumiracoxib   Lumiracoxib is the first example of a marketed COX-2 inhibitor of the arylacetic acid class, and it is reported to be the most selective COXIB in vivo", "triple_list": [["lumiracoxib", "PRODUCT-OF", "inhibitor"]]}, {"text": "The chemical identity and position of the substituents on the lower  aniline  ring were important in determining the potency and extent of  COX  inhibition as well as  COX -2 selectivity", "triple_list": [["the", "ANTAGONIST", "COX"]]}, {"text": "Mutation of Ser-530 to Ala or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type  human COX-2  and key  lumiracoxib  analogs", "triple_list": [["lumiracoxib", "ACTIVATOR", "to"]]}, {"text": "Differences in magnitude of  Na(+)  dependent l-alanine uptake through  ASCT2  between WKY and SHR PTE cells correlated positively with differences in  ASCT2  protein expression, this being more abundant in WKY PTE cells", "triple_list": [["Na(+)", "AGONIST", "through"]]}, {"text": "Differences in magnitude of Na(+)-dependent  l-alanine  uptake through  ASCT2  between WKY and SHR PTE cells correlated positively with differences in  ASCT2  protein expression, this being more abundant in WKY PTE cells", "triple_list": [["l-alanine", "DOWNREGULATOR", "SHR"]]}, {"text": "In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity  Na(+)  dependent amino acid transporter, with functional features of  ASCT2  transport", "triple_list": [["In", "PRODUCT-OF", "ASCT2"]]}, {"text": "In conclusion, immortalized SHR and WKY PTE cells take up l-alanine mainly through a high-affinity Na(+)-dependent  amino acid  transporter, with functional features of  ASCT2  transport", "triple_list": [["amino acid", "PRODUCT-OF", "a"]]}, {"text": "In the presence of the system L inhibitor BCH, Na(+)-dependent l- alanine  uptake in WKY and SHR PTE cells was inhibited by  alanine   serine, and cysteine, which is consistent with amino acid transport through  ASCT2   The saturable component of Na(+)-dependent l- alanine  transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values", "triple_list": [["alanine", "AGONIST", "system"]]}, {"text": "In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine,  serine   and cysteine, which is consistent with amino acid transport through  ASCT2   The saturable component of Na(+)-dependent l-alanine transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values", "triple_list": [["serine", "PRODUCT-OF", "serine"]]}, {"text": "In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and  cysteine   which is consistent with amino acid transport through  ASCT2   The saturable component of Na(+)-dependent l-alanine transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values", "triple_list": [["cysteine", "PRODUCT-OF", "transport"]]}, {"text": "In the presence of the system L inhibitor BCH, Na(+)-dependent  l-alanine  uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with amino acid transport through  ASCT2   The saturable component of Na(+)-dependent  l-alanine  transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values", "triple_list": [["of", "DOWNREGULATOR", "ASCT2"]]}, {"text": "In the presence of the system L inhibitor BCH, Na(+)-dependent l-alanine uptake in WKY and SHR PTE cells was inhibited by alanine, serine, and cysteine, which is consistent with  amino acid  transport through  ASCT2   The saturable component of Na(+)-dependent l-alanine transport under V(max) conditions in SHR PTE cells was one-half of that in WKY PTE cells, with similar K(m) values", "triple_list": [["amino acid", "ANTAGONIST", "in"]]}, {"text": "Differences in magnitude of Na(+)-dependent  l-alanine  uptake through  ASCT2  between WKY and SHR PTE cells correlated positively with differences in  ASCT2  protein expression, this being more abundant in WKY PTE cells", "triple_list": [["l-alanine", "DOWNREGULATOR", "cells"]]}, {"text": "In conclusion, immortalized SHR and WKY PTE cells take up  l-alanine  mainly through a high-affinity  Na(+)-dependent amino acid transporter   with functional features of ASCT2 transport", "triple_list": [["ASCT2", "ACTIVATOR", "Na(+)-dependent amino acid transporter"]]}, {"text": "In conclusion, immortalized SHR and WKY PTE cells take up  l-alanine  mainly through a high-affinity Na(+)-dependent amino acid transporter, with functional features of  ASCT2  transport", "triple_list": [["l-alanine", "ANTAGONIST", "functional"]]}, {"text": "This study examined the inward transport of  l-[(14)C]alanine   an  ASCT2  preferential substrate, in monolayers of immortalized renal proximal tubular epithelial (PTE) cells from Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats", "triple_list": [["l-[(14)C]alanine", "ANTAGONIST", "of"]]}, {"text": "Intravenous  arginine  significantly increased the acute  glucagon  response (129 +/- 12 vs 36 +/- 6 ng/l in controls; p < 0.01), notably without affecting plasma glucose", "triple_list": [["arginine", "DOWNREGULATOR", "significantly"]]}, {"text": "Isolated islets displayed improved  glucose  stimulated  insulin  secretion after GRA treatment (0.061 +/- 0.007 vs 0.030 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l  glucose ; p < 0.001), without affecting islet  glucose  oxidation", "triple_list": [["glucose", "PRODUCT-OF", "<"]]}, {"text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug,  sodium hydrosulphide  (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in  SP  concentration and expression of PPT-A and NK1-R in acinar cells", "triple_list": [["sodium hydrosulphide", "DOWNREGULATOR", "and"]]}, {"text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug,  sodium hydrosulphide  (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of  PPT-A  and NK1-R in acinar cells", "triple_list": [["sodium hydrosulphide", "AGONIST", "donor"]]}, {"text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug,  sodium hydrosulphide  (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and  NK1-R  in acinar cells", "triple_list": [["cells", "DOWNREGULATOR", "NK1-R"]]}, {"text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide ( NaHS  , (10, 50 and 100 muM), that resulted in a significant increase in  SP  concentration and expression of PPT-A and NK1-R in acinar cells", "triple_list": [["NaHS", "ANTAGONIST", "treated"]]}, {"text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide ( NaHS  , (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of  PPT-A  and NK1-R in acinar cells", "triple_list": [["NaHS", "ANTAGONIST", "cells"]]}, {"text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide ( NaHS  , (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and  NK1-R  in acinar cells", "triple_list": [["NaHS", "DOWNREGULATOR", "SP"]]}, {"text": " Caerulein  increased the levels of H(2)S and  CSE  mRNA expression while CBS mRNA expression was decreased", "triple_list": [["Caerulein", "AGONIST", "expression"]]}, {"text": "Furthermore,  substance P  (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue  caerulein  treated acinar cells", "triple_list": [["caerulein", "DOWNREGULATOR", "and"]]}, {"text": "Furthermore, substance P ( SP   concentration in the acini and expression of  SP  gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for  SP , are increased in secretagogue  caerulein  treated acinar cells", "triple_list": [["of", "AGONIST", "SP"]]}, {"text": "Furthermore, substance P ( SP ) concentration in the acini and expression of  SP  gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for  SP , are increased in secretagogue  caerulein  treated acinar cells", "triple_list": [["are", "DOWNREGULATOR", "SP"]]}, {"text": "Furthermore, substance P (SP) concentration in the acini and expression of SP gene ( preprotachykinin-A   PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue  caerulein  treated acinar cells", "triple_list": [["cells", "DOWNREGULATOR", "preprotachykinin-A"]]}, {"text": "Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A,  PPT-A   and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue  caerulein  treated acinar cells", "triple_list": [["secretagogue", "ANTAGONIST", "PPT-A"]]}, {"text": "Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and  neurokinin-1 receptor  (NK-1R), the primary receptor for SP, are increased in secretagogue  caerulein  treated acinar cells", "triple_list": [["gene", "DOWNREGULATOR", "neurokinin-1 receptor"]]}, {"text": "Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor ( NK-1R  , the primary receptor for SP, are increased in secretagogue  caerulein  treated acinar cells", "triple_list": [["concentration", "PRODUCT-OF", "NK-1R"]]}, {"text": " Caerulein  increased the levels of H(2)S and CSE mRNA expression while  CBS  mRNA expression was decreased", "triple_list": [["and", "PRODUCT-OF", "CBS"]]}, {"text": "In addition, cells pre-treated with  DL-propargylglycine  (PAG, 3 mM), a  CSE  inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that  CSE  may be the main enzyme involved in H(2)S formation in mouse acinar cells", "triple_list": [["3", "AGONIST", "CSE"]]}, {"text": "In addition, cells pre-treated with DL-propargylglycine ( PAG   3 mM), a  CSE  inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that  CSE  may be the main enzyme involved in H(2)S formation in mouse acinar cells", "triple_list": [["cells", "AGONIST", "CSE"]]}, {"text": "Inhibition of endogenous production of  H(2)S  by PAG significantly suppressed  SP  concentration, PPT-A expression and NK1-R expression in the acini", "triple_list": [["of", "ACTIVATOR", "SP"]]}, {"text": "Inhibition of endogenous production of  H(2)S  by PAG significantly suppressed SP concentration,  PPT-A  expression and NK1-R expression in the acini", "triple_list": [["concentration,", "AGONIST", "PPT-A"]]}, {"text": "Inhibition of endogenous production of  H(2)S  by PAG significantly suppressed SP concentration, PPT-A expression and  NK1-R  expression in the acini", "triple_list": [["acini", "PRODUCT-OF", "NK1-R"]]}, {"text": "These results suggest that the pro-inflammatory effect of  H(2)S  may be mediated by  SP  NK-1R related pathway in mouse pancreatic acinar cells.", "triple_list": [["These", "AGONIST", "SP"]]}, {"text": "These results suggest that the pro-inflammatory effect of  H(2)S  may be mediated by SP- NK-1R  related pathway in mouse pancreatic acinar cells.", "triple_list": [["the", "AGONIST", "NK-1R"]]}, {"text": "Hydrogen sulphide ( H(2)S   is synthesized from L-cysteine via the action of cystathionine-gamma-lyase ( CSE   and cystathionine-beta-synthase (CBS)", "triple_list": [["H(2)S", "AGONIST", "("]]}, {"text": "Hydrogen sulphide ( H(2)S   is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and  cystathionine-beta-synthase  (CBS)", "triple_list": [["(CBS)", "ACTIVATOR", "cystathionine-beta-synthase"]]}, {"text": "Hydrogen sulphide ( H(2)S   is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase ( CBS  ", "triple_list": [["H(2)S", "DOWNREGULATOR", "H(2)S"]]}, {"text": "Hydrogen sulphide ( H(2)S   is synthesized from L-cysteine via the action of  cystathionine-gamma-lyase  (CSE) and cystathionine-beta-synthase (CBS)", "triple_list": [["H(2)S", "DOWNREGULATOR", "synthesized"]]}, {"text": "In this study, we investigated the presence of  H(2)S  and the expression of  H(2)S  synthesizing enzymes,  CSE  and CBS, in isolated mouse pancreatic acini", "triple_list": [["mouse", "ACTIVATOR", "CSE"]]}, {"text": "In this study, we investigated the presence of  H(2)S  and the expression of  H(2)S  synthesizing enzymes, CSE and  CBS   in isolated mouse pancreatic acini", "triple_list": [["H(2)S", "AGONIST", "expression"]]}, {"text": "Hydrogen sulphide (H(2)S) is synthesized from  L-cysteine  via the action of cystathionine-gamma-lyase ( CSE   and cystathionine-beta-synthase (CBS)", "triple_list": [["L-cysteine", "AGONIST", "synthesized"]]}, {"text": "Hydrogen sulphide (H(2)S) is synthesized from  L-cysteine  via the action of cystathionine-gamma-lyase (CSE) and  cystathionine-beta-synthase  (CBS)", "triple_list": [["Hydrogen", "ANTAGONIST", "cystathionine-beta-synthase"]]}, {"text": "Hydrogen sulphide (H(2)S) is synthesized from  L-cysteine  via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase ( CBS  ", "triple_list": [["L-cysteine", "DOWNREGULATOR", "(CSE)"]]}, {"text": "Hydrogen sulphide (H(2)S) is synthesized from  L-cysteine  via the action of  cystathionine-gamma-lyase  (CSE) and cystathionine-beta-synthase (CBS)", "triple_list": [["L-cysteine", "ACTIVATOR", "(CBS)"]]}, {"text": " Hydrogen sulphide  (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase ( CSE   and cystathionine-beta-synthase (CBS)", "triple_list": [["Hydrogen sulphide", "ACTIVATOR", "is"]]}, {"text": " Hydrogen sulphide  (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and  cystathionine-beta-synthase  (CBS)", "triple_list": [["Hydrogen sulphide", "DOWNREGULATOR", "sulphide"]]}, {"text": " Hydrogen sulphide  (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase ( CBS  ", "triple_list": [["synthesized", "ACTIVATOR", "CBS"]]}, {"text": " Hydrogen sulphide  (H(2)S) is synthesized from L-cysteine via the action of  cystathionine-gamma-lyase  (CSE) and cystathionine-beta-synthase (CBS)", "triple_list": [["Hydrogen sulphide", "ACTIVATOR", "from"]]}, {"text": "In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a  CSE  inhibitor, reduced the formation of  H(2)S  in caerulein treated cells, suggesting that  CSE  may be the main enzyme involved in  H(2)S  formation in mouse acinar cells", "triple_list": [["H(2)S", "AGONIST", "(PAG,"]]}, {"text": "Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and  iNOS  induced by reIL-4, while  1400W dihydrochloride  (1400W), a selective inhibitor of  iNOS   decreased the expression of E-selectin, VEGF, and  iNOS ", "triple_list": [["1400W dihydrochloride", "PRODUCT-OF", "VEGF,"]]}, {"text": "Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while  1400W dihydrochloride  (1400W), a selective inhibitor of iNOS, decreased the expression of  E-selectin   VEGF, and iNOS", "triple_list": [["of", "ACTIVATOR", "E-selectin"]]}, {"text": "Dexamethasone (DXM) decreased the expression of CXCL-8,  VEGF , and iNOS induced by reIL-4, while  1400W dihydrochloride  (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin,  VEGF   and iNOS", "triple_list": [["1400W dihydrochloride", "ACTIVATOR", "iNOS,"]]}, {"text": "Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and  iNOS  induced by reIL-4, while  1400W dihydrochloride  (1400W), a selective inhibitor of  iNOS , decreased the expression of E-selectin, VEGF, and  iNOS   DXM and 1400W attenuated the mRNA expression of E-selectin and  iNOS  induced by the costimulation of reIL-4, reTNF-alpha, and LPS", "triple_list": [["(1400W),", "ACTIVATOR", "iNOS"]]}, {"text": "Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and  iNOS  induced by reIL-4, while  1400W  dihydrochloride ( 1400W  , a selective inhibitor of  iNOS   decreased the expression of E-selectin, VEGF, and  iNOS ", "triple_list": [["1400W", "PRODUCT-OF", "decreased"]]}, {"text": "Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and iNOS induced by reIL-4, while  1400W  dihydrochloride ( 1400W  , a selective inhibitor of iNOS, decreased the expression of  E-selectin   VEGF, and iNOS", "triple_list": [["expression", "ACTIVATOR", "E-selectin"]]}, {"text": "Dexamethasone (DXM) decreased the expression of CXCL-8,  VEGF , and iNOS induced by reIL-4, while  1400W  dihydrochloride ( 1400W  , a selective inhibitor of iNOS, decreased the expression of E-selectin,  VEGF   and iNOS", "triple_list": [["1400W", "ACTIVATOR", "E-selectin,"]]}, {"text": "Dexamethasone (DXM) decreased the expression of CXCL-8, VEGF, and  iNOS  induced by reIL-4, while  1400W  dihydrochloride ( 1400W  , a selective inhibitor of  iNOS , decreased the expression of E-selectin, VEGF, and  iNOS   DXM and  1400W  attenuated the mRNA expression of E-selectin and  iNOS  induced by the costimulation of reIL-4, reTNF-alpha, and LPS", "triple_list": [["while", "PRODUCT-OF", "iNOS"]]}, {"text": " DXM  and 1400W attenuated the mRNA expression of  E-selectin  and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS", "triple_list": [["DXM", "PRODUCT-OF", "by"]]}, {"text": " DXM  and 1400W attenuated the mRNA expression of E-selectin and  iNOS  induced by the costimulation of reIL-4, reTNF-alpha, and LPS", "triple_list": [["DXM", "ANTAGONIST", "1400W"]]}, {"text": "DXM and  1400W  attenuated the mRNA expression of  E-selectin  and iNOS induced by the costimulation of reIL-4, reTNF-alpha, and LPS", "triple_list": [["reIL-4,", "PRODUCT-OF", "E-selectin"]]}, {"text": "DXM and  1400W  attenuated the mRNA expression of E-selectin and  iNOS  induced by the costimulation of reIL-4, reTNF-alpha, and LPS", "triple_list": [["costimulation", "PRODUCT-OF", "iNOS"]]}, {"text": " Dexamethasone  (DXM) decreased the expression of  CXCL-8   VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS", "triple_list": [["Dexamethasone", "ANTAGONIST", "E-selectin,"]]}, {"text": " Dexamethasone  (DXM) decreased the expression of CXCL-8,  VEGF   and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin,  VEGF , and iNOS", "triple_list": [["1400W", "ACTIVATOR", "VEGF"]]}, {"text": " Dexamethasone  (DXM) decreased the expression of CXCL-8, VEGF, and  iNOS  induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of  iNOS , decreased the expression of E-selectin, VEGF, and  iNOS ", "triple_list": [["Dexamethasone", "PRODUCT-OF", "and"]]}, {"text": "Dexamethasone ( DXM   decreased the expression of  CXCL-8   VEGF, and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin, VEGF, and iNOS", "triple_list": [["DXM", "PRODUCT-OF", "decreased"]]}, {"text": "Dexamethasone ( DXM   decreased the expression of CXCL-8,  VEGF   and iNOS induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of iNOS, decreased the expression of E-selectin,  VEGF , and iNOS", "triple_list": [["DXM", "ANTAGONIST", "iNOS"]]}, {"text": "Dexamethasone ( DXM   decreased the expression of CXCL-8, VEGF, and  iNOS  induced by reIL-4, while 1400W dihydrochloride (1400W), a selective inhibitor of  iNOS , decreased the expression of E-selectin, VEGF, and  iNOS ", "triple_list": [["iNOS", "ANTAGONIST", "iNOS"]]}, {"text": "Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g.,  sotalol  or ibutilide in patients with a mutation in the  IKr  coding gene KCNH2 (HERG)", "triple_list": [["be", "ANTAGONIST", "IKr"]]}, {"text": "Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g.,  sotalol  or ibutilide in patients with a mutation in the IKr-coding gene  KCNH2  (HERG)", "triple_list": [["sotalol", "ACTIVATOR", "be"]]}, {"text": "Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g.,  sotalol  or ibutilide in patients with a mutation in the IKr-coding gene KCNH2 ( HERG  ", "triple_list": [["with", "AGONIST", "HERG"]]}, {"text": "Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or  ibutilide  in patients with a mutation in the  IKr  coding gene KCNH2 (HERG)", "triple_list": [["(HERG)", "ANTAGONIST", "IKr"]]}, {"text": "Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or  ibutilide  in patients with a mutation in the IKr-coding gene  KCNH2  (HERG)", "triple_list": [["(HERG)", "PRODUCT-OF", "KCNH2"]]}, {"text": "Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or  ibutilide  in patients with a mutation in the IKr-coding gene KCNH2 ( HERG  ", "triple_list": [["ibutilide", "AGONIST", "been"]]}, {"text": "The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not  ATP , whereas mammalian  serine racemase  activity is increased by  ATP   In addition to the results regarding the effect of  ATP  on enzyme activity and the phylogenetic analysis of eukaryotic  serine racemase s, the antiserum against Arabidopsis  serine racemase  did not form a precipitate with barley and rice  serine racemase s", "triple_list": [["by", "AGONIST", "serine racemase"]]}, {"text": " cAspAT  activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the  thiazolidinedione  (TZD) rosiglitazone", "triple_list": [["thiazolidinedione", "PRODUCT-OF", "well"]]}, {"text": " cAspAT  activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione ( TZD   rosiglitazone", "triple_list": [["3T3-F442A", "DOWNREGULATOR", "cAspAT"]]}, {"text": " cAspAT  activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD)  rosiglitazone   Conversely, the ratio of fatty acid to glycerol released into the medium decreased", "triple_list": [["rosiglitazone", "AGONIST", "the"]]}, {"text": " RORalpha  ectopic expression activated the cAspAT gene transcription in absence of  rosiglitazone , and its protein amount in nuclear extracts is 1.8-fold increased by  rosiglitazone  treatment of adipocytes", "triple_list": [["increased", "AGONIST", "RORalpha"]]}, {"text": "RORalpha ectopic expression activated the  cAspAT  gene transcription in absence of  rosiglitazone , and its protein amount in nuclear extracts is 1.8-fold increased by  rosiglitazone  treatment of adipocytes", "triple_list": [["rosiglitazone", "ANTAGONIST", "of"]]}, {"text": "Finally, the amounts of  RORalpha  and cAspAT mRNAs were similarly increased by  TZD  treatment of human adipose tissue explants, confirming coordinated regulation", "triple_list": [["explants,", "AGONIST", "RORalpha"]]}, {"text": "Finally, the amounts of RORalpha and  cAspAT  mRNAs were similarly increased by  TZD  treatment of human adipose tissue explants, confirming coordinated regulation", "triple_list": [["TZD", "AGONIST", "tissue"]]}, {"text": "Our data identify  cAspAT  as a new member of glyceroneogenesis, transcriptionally regulated by  TZD  via the control of RORalpha expression by PPARgamma in adipocytes.", "triple_list": [["PPARgamma", "ANTAGONIST", "cAspAT"]]}, {"text": "In summary, our data indicates that over-expression of h GST A4 at levels conferring high  GST   4-HNE  conjugating activity confers a partial growth advantage to HepG2 cells and protects against  4-HNE  oxidative injury", "triple_list": [["a", "AGONIST", "GST"]]}, {"text": "4-Hydroxynonenal ( 4-HNE   is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several  glutathione S-transferase  (GST) isoforms", "triple_list": [["mutagenic", "ANTAGONIST", "glutathione S-transferase"]]}, {"text": "4-Hydroxynonenal ( 4-HNE   is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase ( GST   isoforms", "triple_list": [["4-HNE", "ANTAGONIST", "("]]}, {"text": "However, the loss of proliferative capacity of  hGSTA4  cells challenged with levels of  4-HNE  associated with severe oxidative stress indicates a role of other aldehyde metabolizing enzymes, and/or GSH-electrophile transporter proteins, in providing full cellular protection against  4-HNE  toxicity.", "triple_list": [["4-HNE", "AGONIST", "GSH-electrophile"]]}, {"text": " 4-Hydroxynonenal  (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several  glutathione S-transferase  (GST) isoforms", "triple_list": [["4-Hydroxynonenal", "ANTAGONIST", "mutagenic"]]}, {"text": " 4-Hydroxynonenal  (4-HNE) is a mutagenic alpha,beta-unsaturated aldehyde produced during oxidative injury that is conjugated by several glutathione S-transferase ( GST   isoforms", "triple_list": [["4-Hydroxynonenal", "DOWNREGULATOR", "4-Hydroxynonenal"]]}, {"text": "The alpha class  human GSTA4-4  enzyme (hGSTA4-4) has a particularly high catalytic efficiency toward  4-HNE  conjugation", "triple_list": [["human", "AGONIST", "human GSTA4-4"]]}, {"text": "The alpha class human GSTA4-4 enzyme ( hGSTA4-4   has a particularly high catalytic efficiency toward  4-HNE  conjugation", "triple_list": [["high", "ACTIVATOR", "hGSTA4-4"]]}, {"text": "4-Hydroxynonenal (4-HNE) is a mutagenic  alpha,beta-unsaturated aldehyde  produced during oxidative injury that is conjugated by several  glutathione S-transferase  (GST) isoforms", "triple_list": [["alpha,beta-unsaturated aldehyde", "AGONIST", "that"]]}, {"text": "4-Hydroxynonenal (4-HNE) is a mutagenic  alpha,beta-unsaturated aldehyde  produced during oxidative injury that is conjugated by several glutathione S-transferase ( GST   isoforms", "triple_list": [["several", "ACTIVATOR", "GST"]]}, {"text": "Specifically,  hGSTA4  cells had significantly higher GSH concentrations when exposed to 5-15 microM  4-HNE   but not at 20 microM  4-HNE , suggesting extensive GSH utilization at high concentrations of  4-HNE ", "triple_list": [["high", "ANTAGONIST", "hGSTA4"]]}, {"text": "Specifically,  hGSTA4  cells had significantly higher GSH concentrations when exposed to 5-15 microM  4-HNE , but not at 20 microM  4-HNE   suggesting extensive GSH utilization at high concentrations of  4-HNE ", "triple_list": [["4-HNE", "AGONIST", "hGSTA4"]]}, {"text": "Recently, it has been shown that the activation of particular  T2R  bitter taste receptors is partially involved with the bitter aftertaste sensation of  saccharin  and acesulfame-K", "triple_list": [["and", "ANTAGONIST", "T2R"]]}, {"text": "Recently, it has been shown that the activation of particular  T2R  bitter taste receptors is partially involved with the bitter aftertaste sensation of saccharin and  acesulfame-K   To more fully understand the biology behind these phenomena we have addressed the question of whether AS could stimulate transient receptor potential vanilloid-1 (TRPV1) receptors, as these receptors are activated by a large range of structurally different chemicals", "triple_list": [["acesulfame-K", "PRODUCT-OF", "receptors"]]}, {"text": "We also found that  TRPV1  receptors are activated by  CuSO(4)   ZnSO(4), and FeSO(4), three salts known to produce a metallic taste sensation", "triple_list": [["CuSO(4)", "PRODUCT-OF", "FeSO(4),"]]}, {"text": "We also found that  TRPV1  receptors are activated by CuSO(4),  ZnSO(4)   and FeSO(4), three salts known to produce a metallic taste sensation", "triple_list": [["by", "PRODUCT-OF", "TRPV1"]]}, {"text": "We also found that  TRPV1  receptors are activated by CuSO(4), ZnSO(4), and  FeSO(4)   three salts known to produce a metallic taste sensation", "triple_list": [["taste", "PRODUCT-OF", "TRPV1"]]}, {"text": "We isolated partial cDNAs that codified for enzymes implicated in the  anthocyanin  biosynthesis such as  l-phenylalanine ammonia-lyase  (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)", "triple_list": [["anthocyanin", "DOWNREGULATOR", "(PAL)"]]}, {"text": "We isolated partial cDNAs that codified for enzymes implicated in the  anthocyanin  biosynthesis such as l-phenylalanine ammonia-lyase ( PAL   and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)", "triple_list": [["anthocyanin", "ANTAGONIST", "partial"]]}, {"text": "We isolated partial cDNAs that codified for enzymes implicated in the  anthocyanin  biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and  chalcone synthase  (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX)", "triple_list": [["synthase", "ANTAGONIST", "chalcone synthase"]]}, {"text": "We isolated partial cDNAs that codified for enzymes implicated in the  anthocyanin  biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase ( CHS  , and an antioxidant enzyme such as ascorbate peroxidase (APX)", "triple_list": [["anthocyanin", "ANTAGONIST", "enzymes"]]}, {"text": "We isolated partial cDNAs that codified for enzymes implicated in the  anthocyanin  biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as  ascorbate peroxidase  (APX)", "triple_list": [["anthocyanin", "DOWNREGULATOR", "an"]]}, {"text": "We isolated partial cDNAs that codified for enzymes implicated in the  anthocyanin  biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase ( APX  ", "triple_list": [["biosynthesis", "DOWNREGULATOR", "APX"]]}, {"text": "These effects were fully counteracted by dietary  phenolics  which inhibited ROS overproduction and GSH consumption, rendered the reactive transcription of glutathione-associated enzymes unnecessary and blocked the intracellular signals leading to the overexpression and rearrangement of  p66Shc  signalling molecule", "triple_list": [["and", "AGONIST", "p66Shc"]]}, {"text": "AIM: To assess the efficacy and safety of a 24-week treatment with  sitagliptin   a highly selective once-daily oral  dipeptidyl peptidase-4  (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin", "triple_list": [["sitagliptin", "AGONIST", "and"]]}, {"text": "AIM: To assess the efficacy and safety of a 24-week treatment with  sitagliptin   a highly selective once-daily oral dipeptidyl peptidase-4 ( DPP-4   inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin", "triple_list": [["sitagliptin", "PRODUCT-OF", "of"]]}, {"text": "Efficacy and safety of the  dipeptidyl peptidase-4  inhibitor,  sitagliptin   in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin", "triple_list": [["sitagliptin", "AGONIST", "or"]]}, {"text": " Miglustat   a small iminosugar molecule approved for the treatment of Gaucher disease, reversibly inhibits  glucosylceramide synthase   which catalyses the first committed step in glycosphingolipid synthesis", "triple_list": [["Miglustat", "ANTAGONIST", "glucosylceramide synthase"]]}, {"text": "At PND35, the medial prefrontal cortex (mPFC) of rats given  MPH  showed 55% greater immunoreactivity (-ir) for the catecholamine marker  tyrosine hydroxylase  (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density", "triple_list": [["for", "PRODUCT-OF", "tyrosine hydroxylase"]]}, {"text": "At PND35, the medial prefrontal cortex (mPFC) of rats given  MPH  showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase ( TH  , 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density", "triple_list": [["MPH", "AGONIST", "cortex"]]}, {"text": "In hippocampal dentate gyrus,  MPH  receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of  neural cell adhesion molecule  ", "triple_list": [["showed", "AGONIST", "neural cell adhesion molecule"]]}, {"text": "In hippocampal dentate gyrus,  MPH  receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA- NCAM  (polysialylated form of neural cell adhesion molecule)", "triple_list": [["marker", "ANTAGONIST", "NCAM"]]}, {"text": "In medial striatum, TH-ir decreased by 21%, and in hypothalamus  neuropeptide Y  ir increased by 10% in  MPH  exposed rats", "triple_list": [["in", "DOWNREGULATOR", "neuropeptide Y"]]}, {"text": "At PND35, the medial prefrontal cortex (mPFC) of rats given  MPH  showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less  norepinephrine transporter  (NET)-ir density", "triple_list": [["showed", "PRODUCT-OF", "norepinephrine transporter"]]}, {"text": "At PND35, the medial prefrontal cortex (mPFC) of rats given  MPH  showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter ( NET  -ir density", "triple_list": [["MPH", "ACTIVATOR", "immunoreactivity"]]}, {"text": "In hippocampal dentate gyrus,  MPH  receiving rats showed a 51% decrease in  NET  ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule)", "triple_list": [["In", "ACTIVATOR", "NET"]]}, {"text": "In medial striatum,  TH  ir decreased by 21%, and in hypothalamus neuropeptide Y-ir increased by 10% in  MPH  exposed rats", "triple_list": [["MPH", "PRODUCT-OF", "neuropeptide"]]}, {"text": "Noradrenaline and  phenylephrine  ( alpha(1)-adrenoceptor  agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively", "triple_list": [["contraction,", "PRODUCT-OF", "alpha(1)-adrenoceptor"]]}, {"text": "Prazosin (nonselective  alpha(1)-adrenoceptor  antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the  phenylephrine  induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)", "triple_list": [["phenylephrine", "DOWNREGULATOR", "antagonized"]]}, {"text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective  alpha(1A)-adrenoceptor  antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the  phenylephrine  induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)", "triple_list": [["and", "ANTAGONIST", "alpha(1A)-adrenoceptor"]]}, {"text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective  alpha(1D)-adrenoceptor  antagonist) competitively antagonized the  phenylephrine  induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)", "triple_list": [["phenylephrine", "PRODUCT-OF", "alpha(1D)-adrenoceptor"]]}, {"text": "alpha(1)-Adrenoceptor antagonists were tested against the  phenylephrine  ( alpha(1)-adrenoceptor  agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach", "triple_list": [["phenylephrine", "DOWNREGULATOR", "preparations"]]}, {"text": " Noradrenaline  and phenylephrine ( alpha(1)-adrenoceptor  agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively", "triple_list": [["Noradrenaline", "DOWNREGULATOR", "values"]]}, {"text": " Prazosin  (nonselective  alpha(1)-adrenoceptor  antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)", "triple_list": [["Prazosin", "AGONIST", "alpha(1D)-adrenoceptor"]]}, {"text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist),  silodosin  (selective  alpha(1A)-adrenoceptor  antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)", "triple_list": [["respectively)", "DOWNREGULATOR", "alpha(1A)-adrenoceptor"]]}, {"text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and  BMY-7378  (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective  alpha(1D)-adrenoceptor  antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)", "triple_list": [["BMY-7378", "PRODUCT-OF", "9.44+/-0.06"]]}, {"text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 ( 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride   (selective  alpha(1D)-adrenoceptor  antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively)", "triple_list": [["8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride", "DOWNREGULATOR", "phenylephrine-induced"]]}, {"text": "Indoleamine 2,3-dioxygenase ( IDO  , a  tryptophan  catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders", "triple_list": [["tryptophan", "DOWNREGULATOR", "2,3-dioxygenase"]]}, {"text": " Indoleamine 2,3-dioxygenase  (IDO), a  tryptophan  catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders", "triple_list": [["pathogenesis", "ANTAGONIST", "Indoleamine 2,3-dioxygenase"]]}, {"text": "OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting  alpha2 adrenergic receptor  (AR) agonist ( dexmedetomidine  ", "triple_list": [["centrally", "ANTAGONIST", "alpha2 adrenergic receptor"]]}, {"text": "OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting alpha2 adrenergic receptor ( AR   agonist ( dexmedetomidine  ", "triple_list": [["dexmedetomidine", "ACTIVATOR", "this"]]}, {"text": "In vitro,  acetaminophen  elicited a 4.4-fold selectivity toward  COX-2  inhibition (IC(50)=113.7 micromol/L for COX-1; IC(50)=25.8 micromol/L for  COX-2 )", "triple_list": [["vitro,", "ANTAGONIST", "COX-2"]]}, {"text": "In vitro,  acetaminophen  elicited a 4.4-fold selectivity toward COX-2 inhibition (IC(50)=113.7 micromol/L for  COX-1   IC(50)=25.8 micromol/L for COX-2)", "triple_list": [["COX-2)", "PRODUCT-OF", "COX-1"]]}, {"text": "In vitro,  acetaminophen  elicited a 4.4-fold selectivity toward  COX-2  inhibition (IC(50)=113.7 micromol/L for COX-1; IC(50)=25.8 micromol/L for  COX-2  ", "triple_list": [["acetaminophen", "ANTAGONIST", "for"]]}, {"text": " Acetaminophen  plasma concentrations remained above the in vitro IC(50) for  COX-2  for at least 5 h postadministration", "triple_list": [["for", "ANTAGONIST", "COX-2"]]}, {"text": " Acetaminophen  (paracetamol) is a selective  cyclooxygenase-2  inhibitor in man", "triple_list": [["in", "ANTAGONIST", "cyclooxygenase-2"]]}, {"text": "Acetaminophen ( paracetamol   is a selective  cyclooxygenase-2  inhibitor in man", "triple_list": [["paracetamol", "PRODUCT-OF", "in"]]}, {"text": "Ex vivo IC(50) values ( COX-1   105.2 micromol/L; COX-2: 26.3 micromol/L) of  acetaminophen  compared favorably with its in vitro IC(50) values", "triple_list": [["values", "PRODUCT-OF", "COX-1"]]}, {"text": "Ex vivo IC(50) values (COX-1: 105.2 micromol/L;  COX-2   26.3 micromol/L) of  acetaminophen  compared favorably with its in vitro IC(50) values", "triple_list": [["acetaminophen", "ACTIVATOR", "(COX-1:"]]}, {"text": "In contrast to previous concepts,  acetaminophen  inhibited  COX-2  by more than 80%, i.e., to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective  COX-2  inhibitors", "triple_list": [["acetaminophen", "AGONIST", "nonsteroidal"]]}, {"text": "In view of its substantial  COX-2  inhibition, recently defined cardiovascular warnings for use of  COX-2  inhibitors should also be considered for  acetaminophen  ", "triple_list": [["COX-2", "ACTIVATOR", "COX-2"]]}, {"text": "The fact that  acetaminophen  acts functionally as a selective  COX-2  inhibitor led us to investigate the hypothesis of whether it works via preferential  COX-2  blockade", "triple_list": [["acetaminophen", "ANTAGONIST", "functionally"]]}, {"text": "Ex vivo  COX  inhibition and pharmacokinetics of  acetaminophen  were assessed in 5 volunteers receiving single 1000 mg doses orally", "triple_list": [["single", "AGONIST", "COX"]]}, {"text": "Coagulation-induced  thromboxane B(2)  and lipopolysaccharide-induced prostaglandin E(2) were measured ex vivo and in vitro in human whole blood as indices of  COX-1  and COX-2 activity", "triple_list": [["ex", "DOWNREGULATOR", "COX-1"]]}, {"text": "Coagulation-induced thromboxane B(2) and lipopolysaccharide-induced  prostaglandin E(2)  were measured ex vivo and in vitro in human whole blood as indices of COX-1 and  COX-2  activity", "triple_list": [["ex", "ACTIVATOR", "COX-2"]]}, {"text": "Existing  ion channel  blockers, such as amiodarone, dronedarone, bepridil, aprindine, and  cibenzoline   have been found to have an NCX inhibitory action", "triple_list": [["cibenzoline", "ANTAGONIST", "dronedarone,"]]}, {"text": "Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, aprindine, and  cibenzoline   have been found to have an  NCX  inhibitory action", "triple_list": [["cibenzoline", "PRODUCT-OF", "as"]]}, {"text": "The pharmacology of  NCX  inhibitors has been studied extensively since the development of  KB-R7943   a prototype benzyloxyphenyl  NCX  inhibitor, in 1996", "triple_list": [["KB-R7943", "AGONIST", "NCX"]]}, {"text": "The pharmacology of  NCX  inhibitors has been studied extensively since the development of KB-R7943, a prototype  benzyloxyphenyl   NCX  inhibitor, in 1996", "triple_list": [["benzyloxyphenyl", "AGONIST", "a"]]}, {"text": "Intriguingly, the inhibitory potency of  benzyloxyphenyl   NCX  inhibitors is directly coupled to the rate of Na(+)(i)-dependent inactivation", "triple_list": [["inhibitors", "PRODUCT-OF", "NCX"]]}, {"text": "Existing  ion channel  blockers, such as  amiodarone   dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action", "triple_list": [["bepridil,", "ANTAGONIST", "ion channel"]]}, {"text": "Existing ion channel blockers, such as  amiodarone   dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an  NCX  inhibitory action", "triple_list": [["amiodarone", "ACTIVATOR", "have"]]}, {"text": "Existing  ion channel  blockers, such as amiodarone,  dronedarone   bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action", "triple_list": [["dronedarone", "ACTIVATOR", "and"]]}, {"text": "Existing ion channel blockers, such as amiodarone,  dronedarone   bepridil, aprindine, and cibenzoline, have been found to have an  NCX  inhibitory action", "triple_list": [["bepridil,", "ACTIVATOR", "NCX"]]}, {"text": "Existing  ion channel  blockers, such as amiodarone, dronedarone,  bepridil   aprindine, and cibenzoline, have been found to have an NCX inhibitory action", "triple_list": [["bepridil", "ACTIVATOR", "ion channel"]]}, {"text": "Existing ion channel blockers, such as amiodarone, dronedarone,  bepridil   aprindine, and cibenzoline, have been found to have an  NCX  inhibitory action", "triple_list": [["bepridil", "PRODUCT-OF", "channel"]]}, {"text": "Existing  ion channel  blockers, such as amiodarone, dronedarone, bepridil,  aprindine   and cibenzoline, have been found to have an NCX inhibitory action", "triple_list": [["channel", "ANTAGONIST", "ion channel"]]}, {"text": "Existing ion channel blockers, such as amiodarone, dronedarone, bepridil,  aprindine   and cibenzoline, have been found to have an  NCX  inhibitory action", "triple_list": [["aprindine", "PRODUCT-OF", "been"]]}, {"text": "The Na(+)/ Ca(2+)  exchanger (NCX) is a bidirectional transporter that normally extrudes  Ca(2+)  from the cell (forward mode), but also brings  Ca(2+)  into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization", "triple_list": [["mode),", "DOWNREGULATOR", "Na(+)/Ca(2+) exchanger"]]}, {"text": "The Na(+)/ Ca(2+)  exchanger (NCX) is a bidirectional transporter that normally extrudes  Ca(2+)  from the cell (forward mode), but also brings  Ca(2+)  into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization", "triple_list": [["membrane", "ANTAGONIST", "Na(+)/Ca(2+) exchanger"]]}, {"text": " Conivaptan  is a nonpeptide dual  V1a/V2 AVP receptor  antagonist", "triple_list": [["Conivaptan", "ACTIVATOR", "dual"]]}, {"text": " Conivaptan   a dual  vasopressin receptor v1a/v2  antagonist [corrected]", "triple_list": [["Conivaptan", "ACTIVATOR", "[corrected]"]]}, {"text": " Phosphate   a product of the reaction, was found to be a potent inhibitor of  MjAdSS  showing biphasic inhibition of enzyme activity", "triple_list": [["enzyme", "ACTIVATOR", "MjAdSS"]]}, {"text": "Adenylosuccinate synthetase ( AdSS   catalyzes the  Mg2+  dependent condensation of a molecule of IMP with aspartate to form adenylosuccinate, in a reaction driven by the hydrolysis of GTP to GDP", "triple_list": [["Mg2+", "AGONIST", "reaction"]]}, {"text": " Adenylosuccinate synthetase  (AdSS) catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form  adenylosuccinate   in a reaction driven by the hydrolysis of GTP to GDP", "triple_list": [["adenylosuccinate", "ANTAGONIST", "the"]]}, {"text": "Adenylosuccinate synthetase ( AdSS   catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form  adenylosuccinate   in a reaction driven by the hydrolysis of GTP to GDP", "triple_list": [["adenylosuccinate", "ACTIVATOR", "molecule"]]}, {"text": "Conformational variations of both  phosphodiesterase-5  and inhibitors provide the structural basis for the physiological effects of vardenafil and  sildenafil   Vardenafil has higher affinity to  phosphodiesterase-5  (PDE5) than  sildenafil  and lower administered dosage for the treatment of erectile dysfunction", "triple_list": [["sildenafil", "AGONIST", "administered"]]}, {"text": "Catalytic-site affinities for cGMP, vardenafil, sildenafil,  tadalafil   or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for  Q817A   and 59-, 448-, 71-, 137-, and 93-fold for F820A", "triple_list": [["respectively", "AGONIST", "Q817A"]]}, {"text": "In this report, we show that the hypolipidemic agent  atorvastatin  is a competitive inhibitor of  porcine DPP-IV  in vitro, with K(i)=57.8+/-2.3 microM", "triple_list": [["atorvastatin", "AGONIST", "agent"]]}, {"text": "These results may have implications in the development of novel  DPP-IV  inhibitors based on the use of  atorvastatin  as a lead compound for the treatment of type 2 diabetes.", "triple_list": [["atorvastatin", "ANTAGONIST", "the"]]}, {"text": "Inhibition of  dipeptidyl peptidase-IV  (DPP-IV) by  atorvastatin   Dipeptidyl peptidase-IV (DPP-IV) is an enzyme responsible for the inactivation of the glucoregulatory incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)", "triple_list": [["atorvastatin", "PRODUCT-OF", "(GLP-1)"]]}, {"text": "Inhibition of dipeptidyl peptidase-IV ( DPP-IV   by  atorvastatin   Dipeptidyl peptidase-IV ( DPP-IV ) is an enzyme responsible for the inactivation of the glucoregulatory incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)", "triple_list": [["atorvastatin", "ACTIVATOR", "for"]]}, {"text": "The ARB  eprosartan  is a nonbiphenyl nontetrazole  angiotensin II type 1 receptor  (AT1) antagonist, which acts to decrease total peripheral resistance", "triple_list": [["eprosartan", "AGONIST", "nonbiphenyl"]]}, {"text": "The ARB  eprosartan  is a nonbiphenyl nontetrazole angiotensin II type 1 receptor ( AT1   antagonist, which acts to decrease total peripheral resistance", "triple_list": [["a", "ACTIVATOR", "AT1"]]}, {"text": "Inhibitors of  PDE4  ( rolipram   0.1-10 microM) and PDE3 (cilostazol; 0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively", "triple_list": [["25%", "ACTIVATOR", "PDE4"]]}, {"text": "Inhibitors of PDE4 (rolipram; 0.1-10 microM) and  PDE3  ( cilostazol   0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively", "triple_list": [["of", "PRODUCT-OF", "PDE3"]]}, {"text": "Inhibitor of  cGMP-specific PDE5  ( zaprinast   0.1-10 microM) did not affect eosinophil apoptosis and only slightly increased spontaneous neutrophil apoptosis", "triple_list": [["zaprinast", "ANTAGONIST", "0.1-10"]]}, {"text": " Statins  increase p21 through inhibition of histone deacetylase activity and release of promoter-associated  HDAC1/2    Statins  are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors broadly used for the control of hypercholesterolemia", "triple_list": [["Statins", "PRODUCT-OF", "HDAC1/2"]]}, {"text": " Statins  increase  p21  through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2", "triple_list": [["deacetylase", "AGONIST", "p21"]]}, {"text": " Statins  are  3-hydroxy-3-methylglutaryl-CoA reductase  inhibitors broadly used for the control of hypercholesterolemia", "triple_list": [["Statins", "ANTAGONIST", "for"]]}, {"text": "In the subsequent enzymatic assay, it was shown that  lovastatin  inhibited  HDAC2  activity competitively with a K(i) value of 31.6 micromol/L", "triple_list": [["shown", "PRODUCT-OF", "HDAC2"]]}, {"text": " Statins  increase p21 through inhibition of  histone deacetylase  activity and release of promoter-associated HDAC1/2", "triple_list": [["of", "ANTAGONIST", "histone deacetylase"]]}, {"text": " Flavopiridol   a  cyclin-dependent kinase  inhibitor, arrests cell division and causes apoptosis in non-small lung cancer cells [283660]", "triple_list": [["division", "ANTAGONIST", "cyclin-dependent kinase"]]}, {"text": "In ex vivo experiments with tumor cells from refractory chronic lymphoblastic leukemia, dose-dependent  CDK2  inhibition associated with apoptotic changes was seen at concentrations greater than 100 nM of  flavopiridol   In vitro pharmacokinetic studies have shown that  flavopiridol  undergoes hepatic biotransformation to its corresponding glucoronide by uridine diphosphate glucoronosyltransferases [283791]", "triple_list": [["flavopiridol", "ACTIVATOR", "[283791]"]]}, {"text": " Flavopiridol  inhibits  CDK  with an IC50 value of 0.4 mM [285707]", "triple_list": [["Flavopiridol", "AGONIST", "CDK"]]}, {"text": "Both  risperidone  and 9-hydroxy risperidone  are substrates of  P-glycoprotein  (P-gp), a transport protein involved in drug absorption, distribution, and elimination", "triple_list": [["risperidone", "DOWNREGULATOR", "are"]]}, {"text": "Both  risperidone  and 9-hydroxy risperidone  are substrates of P-glycoprotein ( P-gp  , a transport protein involved in drug absorption, distribution, and elimination", "triple_list": [["risperidone", "AGONIST", "9-hydroxy"]]}, {"text": "Both risperidone and  9-hydroxyrisperidone  are substrates of  P-glycoprotein  (P-gp), a transport protein involved in drug absorption, distribution, and elimination", "triple_list": [["9-hydroxyrisperidone", "AGONIST", "Both"]]}, {"text": "Both risperidone and  9-hydroxyrisperidone  are substrates of P-glycoprotein ( P-gp  , a transport protein involved in drug absorption, distribution, and elimination", "triple_list": [["in", "AGONIST", "P-gp"]]}, {"text": "Risperidone is metabolized to its active metabolite,  9-hydroxyrisperidone   mainly by the  cytochrome P450  enzymes CYP2D6 and 3A4", "triple_list": [["9-hydroxyrisperidone", "ACTIVATOR", "and"]]}, {"text": " Risperidone  is metabolized to its active metabolite, 9-hydroxyrisperidone, mainly by the  cytochrome P450  enzymes CYP2D6 and 3A4", "triple_list": [["Risperidone", "DOWNREGULATOR", "CYP2D6"]]}, {"text": " EP(1)  and EP(3) receptor antagonists  ONO-8713  and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of  EP(1)  and EP(3) but not EP(4) for MB growth", "triple_list": [["proliferation,", "AGONIST", "EP(1)"]]}, {"text": "EP(1) and  EP(3) receptor  antagonists  ONO-8713  and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth", "triple_list": [["ONO-8713", "ACTIVATOR", "EP(4)"]]}, {"text": " EP(1)  and EP(3) receptor antagonists ONO-8713 and  ONO-AE3-240   but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of  EP(1)  and EP(3) but not EP(4) for MB growth", "triple_list": [["but", "AGONIST", "EP(1)"]]}, {"text": "EP(1) and  EP(3) receptor  antagonists ONO-8713 and  ONO-AE3-240   but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth", "triple_list": [["proliferation,", "AGONIST", "EP(3) receptor"]]}, {"text": "EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the  EP(4)  antagonists  ONO-AE3-208  and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not  EP(4)  for MB growth", "triple_list": [["ONO-AE3-208", "DOWNREGULATOR", "AH"]]}, {"text": "EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the  EP(4)  antagonists ONO-AE3-208 and  AH 23848   inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not  EP(4)  for MB growth", "triple_list": [["EP(3)", "DOWNREGULATOR", "EP(4)"]]}, {"text": "Tumor-growth-promoting  cyclooxygenase-2   prostaglandin E2  pathway provides medulloblastoma therapeutic targets", "triple_list": [["prostaglandin", "AGONIST", "cyclooxygenase-2"]]}, {"text": " PGE(2)  is synthesized from arachidonic acid by  cyclooxygenases  (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)", "triple_list": [["PGE(2)", "ANTAGONIST", "activity"]]}, {"text": " PGE(2)  is synthesized from arachidonic acid by cyclooxygenases ( COX   and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)", "triple_list": [["PGE(2)", "ACTIVATOR", "synthesized"]]}, {"text": " PGE(2)  is synthesized from arachidonic acid by cyclooxygenases (COX) and  prostaglandin E synthases  (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)", "triple_list": [["PGE(2)", "DOWNREGULATOR", "acid"]]}, {"text": " PGE(2)  is synthesized from arachidonic acid by cyclooxygenases (COX) and prostaglandin E synthases ( PGES   and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)", "triple_list": [["and", "DOWNREGULATOR", "PGES"]]}, {"text": "PGE(2) is synthesized from  arachidonic acid  by  cyclooxygenases  (COX) and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)", "triple_list": [["(COX)", "ANTAGONIST", "cyclooxygenases"]]}, {"text": "PGE(2) is synthesized from  arachidonic acid  by cyclooxygenases ( COX   and prostaglandin E synthases (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)", "triple_list": [["arachidonic acid", "ACTIVATOR", "("]]}, {"text": "PGE(2) is synthesized from  arachidonic acid  by cyclooxygenases (COX) and  prostaglandin E synthases  (PGES) and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)", "triple_list": [["arachidonic acid", "ACTIVATOR", "to"]]}, {"text": "PGE(2) is synthesized from  arachidonic acid  by cyclooxygenases (COX) and prostaglandin E synthases ( PGES   and mediates its biological activity through binding to the four prostanoid receptors EP(1) through EP(4)", "triple_list": [["by", "ANTAGONIST", "PGES"]]}, {"text": " Plerixafor  (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine  stromal cell-derived factor-1  (SDF-1) to its cognate receptor CXCR4", "triple_list": [["Plerixafor", "ACTIVATOR", "the"]]}, {"text": " Plerixafor  (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 ( SDF-1   to its cognate receptor CXCR4", "triple_list": [["its", "PRODUCT-OF", "SDF-1"]]}, {"text": " Plerixafor  (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor  CXCR4    Plerixafor  results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with G-CSF", "triple_list": [["cognate", "ANTAGONIST", "CXCR4"]]}, {"text": " Plerixafor  (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the  chemokine  stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4", "triple_list": [["binding", "PRODUCT-OF", "chemokine"]]}, {"text": "Plerixafor ( AMD3100   Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine  stromal cell-derived factor-1  (SDF-1) to its cognate receptor CXCR4", "triple_list": [["AMD3100", "ACTIVATOR", "antagonizes"]]}, {"text": "Plerixafor ( AMD3100   Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 ( SDF-1   to its cognate receptor CXCR4", "triple_list": [["that", "PRODUCT-OF", "SDF-1"]]}, {"text": "Plerixafor ( AMD3100   Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor  CXCR4   Plerixafor results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with G-CSF", "triple_list": [["AMD3100", "PRODUCT-OF", "bicyclam"]]}, {"text": "Plerixafor ( AMD3100   Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the  chemokine  stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4", "triple_list": [["stromal", "AGONIST", "chemokine"]]}, {"text": "Plerixafor (AMD3100, Genzyme Corporation) is a  bicyclam  molecule that antagonizes the binding of the chemokine  stromal cell-derived factor-1  (SDF-1) to its cognate receptor CXCR4", "triple_list": [["bicyclam", "AGONIST", "stromal cell-derived factor-1"]]}, {"text": "Plerixafor (AMD3100, Genzyme Corporation) is a  bicyclam  molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 ( SDF-1   to its cognate receptor CXCR4", "triple_list": [["is", "ANTAGONIST", "SDF-1"]]}, {"text": "Plerixafor (AMD3100, Genzyme Corporation) is a  bicyclam  molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor  CXCR4   Plerixafor results in the rapid and reversible mobilization of hematopoietic stem cells into the peripheral circulation and is synergistic when combined with G-CSF", "triple_list": [["bicyclam", "PRODUCT-OF", "binding"]]}, {"text": "Plerixafor (AMD3100, Genzyme Corporation) is a  bicyclam  molecule that antagonizes the binding of the  chemokine  stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4", "triple_list": [["stromal", "AGONIST", "chemokine"]]}, {"text": " Plerixafor   a  CXCR4  antagonist for the mobilization of hematopoietic stem cells", "triple_list": [["Plerixafor", "ACTIVATOR", "stem"]]}, {"text": "[Pharmacological effects of a  mu-opioid receptor  antagonist  naltrexone  on alcohol dependence]", "triple_list": [["naltrexone", "DOWNREGULATOR", "antagonist"]]}, {"text": "In many countries, a  mu-opioid receptor  antagonist  naltrexone  has been used in the treatment of alcohol dependence", "triple_list": [["naltrexone", "DOWNREGULATOR", "in"]]}, {"text": "Pretreatment of rats with the  MAO  inhibitor  tranylcypromine  prevented the increase in brain GABA and ALA levels with PLZ, but did not block the effect of VIG on GABA", "triple_list": [["rats", "ACTIVATOR", "MAO"]]}, {"text": "The effects of PLZ on both amino acids and their transaminases were blocked by pre-treatment with the  MAO  inhibitor  tranylcypromine   This pretreament had no effect on the inhibition of GABA-T or the elevation of brain GABA levels produced by VIG", "triple_list": [["of", "ANTAGONIST", "MAO"]]}, {"text": "The effects of PLZ on both amino acids and their  transaminases  were blocked by pre-treatment with the MAO inhibitor  tranylcypromine   This pretreament had no effect on the inhibition of GABA-T or the elevation of brain GABA levels produced by VIG", "triple_list": [["tranylcypromine", "AGONIST", "levels"]]}, {"text": "PURPOSE: To compare  phenelzine  (PLZ), an antidepressant drug with anxiolytic properties which inhibits  monoamine oxidase  (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)", "triple_list": [["ALA", "PRODUCT-OF", "monoamine oxidase"]]}, {"text": "PURPOSE: To compare  phenelzine  (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase ( MAO   but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of  MAO , GABA-T and ALA transaminase (ALA-T)", "triple_list": [["phenelzine", "ANTAGONIST", "by"]]}, {"text": "PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with  vigabatrin  (VIG), an anticonvulsant which elevates brain GABA by inhibition of  GABA transaminase  (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)", "triple_list": [["vigabatrin", "AGONIST", "of"]]}, {"text": "PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with  vigabatrin  (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase ( GABA-T  , with regard to their actions on brain levels of GABA and ALA and on activities of MAO,  GABA-T  and ALA transaminase (ALA-T)", "triple_list": [["of", "AGONIST", "GABA-T"]]}, {"text": "PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin ( VIG  , an anticonvulsant which elevates brain GABA by inhibition of  GABA transaminase  (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)", "triple_list": [["anticonvulsant", "PRODUCT-OF", "GABA transaminase"]]}, {"text": "PURPOSE: To compare phenelzine (PLZ), an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin ( VIG  , an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase ( GABA-T  , with regard to their actions on brain levels of GABA and ALA and on activities of MAO,  GABA-T  and ALA transaminase (ALA-T)", "triple_list": [["rat", "AGONIST", "GABA-T"]]}, {"text": "PURPOSE: To compare phenelzine ( PLZ  , an antidepressant drug with anxiolytic properties which inhibits  monoamine oxidase  (MAO) but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of MAO, GABA-T and ALA transaminase (ALA-T)", "triple_list": [["oxidase", "ANTAGONIST", "monoamine oxidase"]]}, {"text": "PURPOSE: To compare phenelzine ( PLZ  , an antidepressant drug with anxiolytic properties which inhibits monoamine oxidase ( MAO   but also elevates rat brain levels of the amino acids ?-aminobutyric acid (GABA) and alanine (ALA), with vigabatrin (VIG), an anticonvulsant which elevates brain GABA by inhibition of GABA transaminase (GABA-T), with regard to their actions on brain levels of GABA and ALA and on activities of  MAO , GABA-T and ALA transaminase (ALA-T)", "triple_list": [["on", "ANTAGONIST", "MAO"]]}, {"text": "RESULTS: Both  PLZ  and VIG inhibited  GABA-T  and elevated GABA levels", "triple_list": [["PLZ", "AGONIST", "and"]]}, {"text": "RESULTS: Both PLZ and  VIG  inhibited  GABA-T  and elevated GABA levels", "triple_list": [["VIG", "AGONIST", "GABA-T"]]}, {"text": "Only  PLZ  inhibited  MAO  and ALA-T and elevated ALA levels", "triple_list": [["PLZ", "PRODUCT-OF", "ALA"]]}, {"text": "Only  PLZ  inhibited MAO and  ALA-T  and elevated ALA levels", "triple_list": [["PLZ", "AGONIST", "levels"]]}, {"text": "Neurochemical effects of the  monoamine oxidase  inhibitor  phenelzine  on brain GABA and alanine: A comparison with vigabatrin", "triple_list": [["phenelzine", "PRODUCT-OF", "with"]]}, {"text": "This pretreament had no effect on the inhibition of  GABA-T  or the elevation of brain GABA levels produced by  VIG   CONCLUSIONS: At the doses studied, PLZ was as effective as  VIG  at elevating brain GABA levels, but, unlike  VIG , also inhibited MAO and ALA-T (and increased brain ALA levels)", "triple_list": [["VIG", "ANTAGONIST", "and"]]}, {"text": "CONCLUSIONS: At the doses studied, PLZ was as effective as  VIG  at elevating brain GABA levels, but, unlike  VIG   also inhibited  MAO  and ALA-T (and increased brain ALA levels)", "triple_list": [["the", "ANTAGONIST", "MAO"]]}, {"text": "CONCLUSIONS: At the doses studied, PLZ was as effective as  VIG  at elevating brain GABA levels, but, unlike  VIG   also inhibited MAO and  ALA-T  (and increased brain ALA levels)", "triple_list": [["VIG", "PRODUCT-OF", "as"]]}, {"text": " Ramelteon  (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin  MT(1)  MT(2) receptor agonist", "triple_list": [["Ramelteon", "ANTAGONIST", "Ramelteon"]]}, {"text": " Ramelteon  (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin MT(1)/ MT(2)  receptor agonist", "triple_list": [["orally", "DOWNREGULATOR", "MT(2)"]]}, {"text": "Unlike the sedative hypnotics that target GABA(A) receptor complexes,  ramelteon  is a chronohypnotic that acts on the melatonin  MT(1)  and MT(2) receptors, which are primarily located in the suprachiasmatic nucleus, the body's \"master clock.\" As such,  ramelteon  possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades", "triple_list": [["ramelteon", "PRODUCT-OF", "Unlike"]]}, {"text": "Unlike the sedative hypnotics that target GABA(A) receptor complexes,  ramelteon  is a chronohypnotic that acts on the melatonin MT(1) and  MT(2)  receptors, which are primarily located in the suprachiasmatic nucleus, the body's \"master clock.\" As such,  ramelteon  possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades", "triple_list": [["ramelteon", "ACTIVATOR", "located"]]}, {"text": "Pharmacology of  ramelteon   a selective  MT1  MT2 receptor agonist: a novel therapeutic drug for sleep disorders", "triple_list": [["of", "DOWNREGULATOR", "MT1"]]}, {"text": "Pharmacology of  ramelteon   a selective MT1/ MT2  receptor agonist: a novel therapeutic drug for sleep disorders", "triple_list": [["Pharmacology", "ANTAGONIST", "MT2"]]}, {"text": " Acarbose   an  alpha-glucosidase  inhibitor, delays the absorption of carbohydrate from the small intestine, thereby reducing postprandial hyperglycemia", "triple_list": [["Acarbose", "AGONIST", "alpha-glucosidase"]]}, {"text": "Clinical utility of  acarbose   an  alpha-glucosidase  inhibitor in cardiometabolic disorders", "triple_list": [["inhibitor", "ACTIVATOR", "alpha-glucosidase"]]}, {"text": "Prolonged use of  tolvaptan  leads to increased endogenous levels of  AVP  and perhaps over-stimulation of V(1A) receptors", "triple_list": [["tolvaptan", "PRODUCT-OF", "levels"]]}, {"text": "Prolonged use of  tolvaptan  leads to increased endogenous levels of AVP and perhaps over-stimulation of  V(1A) receptors   Theoretically this activation could lead to increased afterload and cardiac myocyte fibrosis, causing progression of CHF", "triple_list": [["tolvaptan", "DOWNREGULATOR", "fibrosis,"]]}, {"text": " Tolvaptan  is a selective  arginine vasopressin (AVP) V(2) receptor  blocker used to induce free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia", "triple_list": [["Tolvaptan", "ANTAGONIST", "to"]]}, {"text": "In addition,  tolvaptan  is metabolized by the  CYP3A4  system; thus physicians should be aware of the potential for increased interactions with other medications", "triple_list": [["tolvaptan", "ACTIVATOR", "In"]]}, {"text": " Tacrine   the first of the  cholinesterase  inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity", "triple_list": [["this", "ACTIVATOR", "cholinesterase"]]}, {"text": "Other  cholinesterase  inhibitors, including  rivastigmine   with superior properties in terms of specificity of action and low risk of adverse effects, have now been introduced", "triple_list": [["and", "ACTIVATOR", "cholinesterase"]]}, {"text": "In summary,  ketoconazole  had no clinically significant effect on the pharmacokinetics or safety profile of ambrisentan; therefore, no changes in ambrisentan dose should be necessary when the drug is administered concomitantly with known  CYP3A4  inhibitors.", "triple_list": [["ketoconazole", "PRODUCT-OF", "clinically"]]}, {"text": "The potential for  ketoconazole   the archetypal strong inhibitor of  CYP3A4   to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men", "triple_list": [["ketoconazole", "ACTIVATOR", "archetypal"]]}, {"text": " Ambrisentan  is an  endothelin type A (ET(A))-selective receptor  antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4", "triple_list": [["Ambrisentan", "DOWNREGULATOR", "is"]]}, {"text": " Ambrisentan  is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by  CYP3A4   The potential for ketoconazole, the archetypal strong inhibitor of  CYP3A4 , to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men", "triple_list": [["Ambrisentan", "DOWNREGULATOR", "strong"]]}, {"text": "Second,  probucol   an antiatherogenic compound reported to be an inactivator of  ABCA1  reduced hepatic alpha-tocopherol secretion", "triple_list": [["probucol", "AGONIST", "reduced"]]}, {"text": "alpha-Tocopherol transfer protein ( alpha-TTP  , the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma  alpha-tocopherol  level by mediating the secretion of  alpha-tocopherol  by the liver", "triple_list": [["alpha-tocopherol", "AGONIST", "in"]]}, {"text": " alpha-Tocopherol transfer protein  (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma  alpha-tocopherol  level by mediating the secretion of  alpha-tocopherol  by the liver", "triple_list": [["alpha-tocopherol", "ANTAGONIST", "in"]]}, {"text": "alpha-Tocopherol transfer protein ( alpha-TTP  , the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma  alpha-tocopherol  level by mediating the secretion of  alpha-tocopherol  by the liver", "triple_list": [["alpha-tocopherol", "ACTIVATOR", "in"]]}, {"text": " alpha-Tocopherol transfer protein  (alpha-TTP), the product of the gene responsible for familial isolated vitamin E deficiency, plays an important role in maintaining the plasma  alpha-tocopherol  level by mediating the secretion of  alpha-tocopherol  by the liver", "triple_list": [["alpha-tocopherol", "ACTIVATOR", "the"]]}, {"text": "First, addition of  apolipoprotein A-I  (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased  alpha-tocopherol  secretion in a dose-dependent manner", "triple_list": [["alpha-tocopherol", "ACTIVATOR", "the"]]}, {"text": "First, addition of apolipoprotein A-I ( apoA-I  , a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased  alpha-tocopherol  secretion in a dose-dependent manner", "triple_list": [["direct", "DOWNREGULATOR", "apoA-I"]]}, {"text": "First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the  ATP-binding cassette transporter A1  (ABCA1)-secreted lipids, increased  alpha-tocopherol  secretion in a dose-dependent manner", "triple_list": [["ATP-binding", "ACTIVATOR", "ATP-binding cassette transporter A1"]]}, {"text": "First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 ( ABCA1  -secreted lipids, increased  alpha-tocopherol  secretion in a dose-dependent manner", "triple_list": [["of", "ANTAGONIST", "ABCA1"]]}, {"text": " ATP-binding cassette transporter A1  is involved in hepatic  alpha-tocopherol  secretion", "triple_list": [["alpha-tocopherol", "ANTAGONIST", "cassette"]]}, {"text": "Third,  ABCA1  RNAi suppressed hepatic  alpha-tocopherol  secretion", "triple_list": [["suppressed", "ANTAGONIST", "ABCA1"]]}, {"text": "These results strongly suggest that  ABCA1  is substantially involved in hepatic  alpha-tocopherol  secretion.", "triple_list": [["that", "ANTAGONIST", "ABCA1"]]}, {"text": " AMPK  activators  metformin  and AICAR partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C", "triple_list": [["block,", "DOWNREGULATOR", "AMPK"]]}, {"text": " AMPK  activators metformin and  AICAR  partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C", "triple_list": [["metformin", "ANTAGONIST", "AMPK"]]}, {"text": "Moreover, kinetic analysis revealed that inhibition by  reserpine   a typical  VMAT2  inhibitor, was uncompetitive, decreasing maximum velocity and affinity for dopamine", "triple_list": [["was", "ANTAGONIST", "VMAT2"]]}, {"text": "These results suggest that fluoxetine inhibited the activity of  VMAT2  by a mechanism different from that of  reserpine  and did not directly interact with the active site of  VMAT2 .", "triple_list": [["of", "ACTIVATOR", "VMAT2"]]}, {"text": "These results suggest that  fluoxetine  inhibited the activity of  VMAT2  by a mechanism different from that of reserpine and did not directly interact with the active site of  VMAT2  ", "triple_list": [["fluoxetine", "ANTAGONIST", "mechanism"]]}, {"text": "These results suggest that  fluoxetine  inhibited the activity of  VMAT2  by a mechanism different from that of reserpine and did not directly interact with the active site of  VMAT2 .", "triple_list": [["reserpine", "ANTAGONIST", "VMAT2"]]}, {"text": "Moreover, kinetic analysis revealed that inhibition by reserpine, a typical  VMAT2  inhibitor, was uncompetitive, decreasing maximum velocity and affinity for  dopamine   Inhibition by fluoxetine was noncompetitive, only decreasing maximum velocity for  dopamine ", "triple_list": [["dopamine", "DOWNREGULATOR", "dopamine"]]}, {"text": "The present study examined the effect of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), on  VMAT2  activity by measuring adenosine triphosphate-dependent  [(3)H]dopamine  uptake into synaptic vesicles prepared from rat striatum", "triple_list": [["serotonin", "ANTAGONIST", "VMAT2"]]}, {"text": " Amitriptyline   but not any other tricyclic or selective serotonin reuptake inhibitor antidepressants, promotes  TrkA  autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells", "triple_list": [["or", "AGONIST", "TrkA"]]}, {"text": "Thus,  amitriptyline  acts as a TrkA and  TrkB  agonist and possesses marked neurotrophic activity.", "triple_list": [["as", "DOWNREGULATOR", "TrkB"]]}, {"text": "Thus,  amitriptyline  acts as a  TrkA  and TrkB agonist and possesses marked neurotrophic activity.", "triple_list": [["amitriptyline", "DOWNREGULATOR", "TrkA"]]}, {"text": " Amitriptyline  is a  TrkA  and TrkB receptor agonist that promotes  TrkA /TrkB heterodimerization and has potent neurotrophic activity", "triple_list": [["that", "ACTIVATOR", "TrkA"]]}, {"text": " Amitriptyline  is a TrkA and  TrkB  receptor agonist that promotes TrkA/ TrkB  heterodimerization and has potent neurotrophic activity", "triple_list": [["Amitriptyline", "DOWNREGULATOR", "and"]]}, {"text": "INTRODUCTION: In this study, we examined the effects of the  alpha-glucosidase  inhibitors acarbose and  voglibose  on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus", "triple_list": [["in", "PRODUCT-OF", "alpha-glucosidase"]]}, {"text": "INTRODUCTION: In this study, we examined the effects of the  alpha-glucosidase  inhibitors  acarbose  and voglibose on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus", "triple_list": [["diabetes", "PRODUCT-OF", "alpha-glucosidase"]]}, {"text": "INTRODUCTION: In this study, we examined the effects of the  alpha-glucosidase  inhibitors acarbose and voglibose on postprandial plasma  glucose  and serum triglyceride levels in patients with type 2 diabetes mellitus", "triple_list": [["glucose", "ANTAGONIST", "serum"]]}, {"text": "We evaluated the clinical effectiveness of  esmolol   an ultra-short-acting  beta 1-adrenergic receptor  blocking drug, to control the sinus tachycardia and increase in arterial blood pressures induced by electroconvulsive therapy (ECT)", "triple_list": [["ultra-short-acting", "ANTAGONIST", "beta 1-adrenergic receptor"]]}, {"text": " H1-receptor  antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which  histamine  is considered to be of pathogenic importance and conversely to help elucidate the role of  histamine  in disease, through an evaluation of their influence on disease expression", "triple_list": [["through", "ACTIVATOR", "H1-receptor"]]}, {"text": "While there is considerable indirect evidence to implicate  histamine  in the pathogenesis of asthma, a critical evaluation of  H1-receptor  antagonism in this condition has, until recently, proved difficult, as many of the early  H1-receptor  antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity", "triple_list": [["histamine", "ANTAGONIST", "of"]]}, {"text": "While there is considerable indirect evidence to implicate  histamine  in the pathogenesis of asthma, a critical evaluation of  H1-receptor  antagonism in this condition has, until recently, proved difficult, as many of the early  H1-receptor  antagonists possessed additional actions, such as anti-cholinergic, local anaesthetic, alpha-adrenoceptor antagonistic and anti-serotonin activity", "triple_list": [["histamine", "PRODUCT-OF", "until"]]}, {"text": " H1-receptor  antagonists have been utilized, following their initial chemical synthesis in 1933, both in the treatment of conditions in which  histamine  is considered to be of pathogenic importance and conversely to help elucidate the role of  histamine  in disease, through an evaluation of their influence on disease expression", "triple_list": [["pathogenic", "ANTAGONIST", "H1-receptor"]]}, {"text": "The recent development of  H1-receptor  antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-anti histamine s which achieve a greater degree of  H1-receptor  blockade within the airways, thus permitting a better appraisal of the role of  histamine  in this condition", "triple_list": [["histamine", "ACTIVATOR", "within"]]}, {"text": "The recent development of  H1-receptor  antagonists devoid of clinical sedative effects has enabled the administration of doses of H1-anti histamine s which achieve a greater degree of  H1-receptor  blockade within the airways, thus permitting a better appraisal of the role of  histamine  in this condition", "triple_list": [["histamine", "ACTIVATOR", "enabled"]]}, {"text": "Furthermore, the  Panx1  channel blockers  carbenoxolone  and Probenecid were less effective in inhibiting  Panx1  currents when Kvbeta3 was co-expressed", "triple_list": [["carbenoxolone", "ACTIVATOR", "Probenecid"]]}, {"text": "Furthermore, the  Panx1  channel blockers carbenoxolone and  Probenecid  were less effective in inhibiting  Panx1  currents when Kvbeta3 was co-expressed", "triple_list": [["Probenecid", "PRODUCT-OF", "the"]]}, {"text": "Terbutaline (Bricanyl) and its prodrug  Bambuterol  (Bambec) are highly potent  beta(2)-adrenoceptor  agonists often used in asthma patients", "triple_list": [["Bambuterol", "ANTAGONIST", "potent"]]}, {"text": "Terbutaline (Bricanyl) and its prodrug Bambuterol ( Bambec   are highly potent  beta(2)-adrenoceptor  agonists often used in asthma patients", "triple_list": [["Bambec", "PRODUCT-OF", "often"]]}, {"text": " Terbutaline  (Bricanyl) and its prodrug Bambuterol (Bambec) are highly potent  beta(2)-adrenoceptor  agonists often used in asthma patients", "triple_list": [["Terbutaline", "PRODUCT-OF", "its"]]}, {"text": "Terbutaline ( Bricanyl   and its prodrug Bambuterol (Bambec) are highly potent  beta(2)-adrenoceptor  agonists often used in asthma patients", "triple_list": [["are", "DOWNREGULATOR", "beta(2)-adrenoceptor"]]}, {"text": "Polymorphisms in dopamine transporter ( SLC6A3   are associated with stimulant effects of  D-amphetamine   an exploratory pharmacogenetic study using healthy volunteers", "triple_list": [["using", "AGONIST", "SLC6A3"]]}, {"text": "Polymorphisms in  dopamine transporter  (SLC6A3) are associated with stimulant effects of  D-amphetamine   an exploratory pharmacogenetic study using healthy volunteers", "triple_list": [["in", "AGONIST", "dopamine transporter"]]}, {"text": "We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the  chenodeoxycholic acid  (CDCA)-induced expression of  Cdx2  and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)", "triple_list": [["Cdx2", "AGONIST", "Cdx2"]]}, {"text": "We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the  chenodeoxycholic acid  (CDCA)-induced expression of Cdx2 and  MUC2  in normal rat gastric epithelial cells (RGM-1 cells)", "triple_list": [["chenodeoxycholic acid", "AGONIST", "in"]]}, {"text": "We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid ( CDCA  -induced expression of  Cdx2  and MUC2 in normal rat gastric epithelial cells (RGM-1 cells)", "triple_list": [["CDCA", "DOWNREGULATOR", "expression"]]}, {"text": "We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid ( CDCA  -induced expression of Cdx2 and  MUC2  in normal rat gastric epithelial cells (RGM-1 cells)", "triple_list": [["Cdx2", "ANTAGONIST", "MUC2"]]}, {"text": " CDCA  induced dose-dependent expression of  Cdx2  and MUC2 at both the mRNA and protein levels", "triple_list": [["the", "DOWNREGULATOR", "Cdx2"]]}, {"text": " CDCA  induced dose-dependent expression of Cdx2 and  MUC2  at both the mRNA and protein levels", "triple_list": [["protein", "ANTAGONIST", "MUC2"]]}, {"text": "The maximum stimulation of  Cdx2  and MUC2 mRNA induced by  CDCA  was observed at 3 h and by 6 h, respectively", "triple_list": [["CDCA", "AGONIST", "maximum"]]}, {"text": "The maximum stimulation of Cdx2 and  MUC2  mRNA induced by  CDCA  was observed at 3 h and by 6 h, respectively", "triple_list": [["CDCA", "AGONIST", "stimulation"]]}, {"text": "The effects of CDCA and GW4064 on expression of  Cdx2  and MUC2 were abolished by  guggulsterone   These findings suggest that bile acids may induce gastric intestinal metaplasia and carcinogenesis through the FXR.", "triple_list": [["guggulsterone", "PRODUCT-OF", "expression"]]}, {"text": "The effects of CDCA and GW4064 on expression of Cdx2 and  MUC2  were abolished by  guggulsterone   These findings suggest that bile acids may induce gastric intestinal metaplasia and carcinogenesis through the FXR.", "triple_list": [["and", "AGONIST", "MUC2"]]}, {"text": "RGM-1 cells were treated with  CDCA  or GW4064, an  FXR  agonist, in the presence or absence of guggulsterone, an  FXR  antagonist", "triple_list": [["GW4064,", "DOWNREGULATOR", "FXR"]]}, {"text": "RGM-1 cells were treated with CDCA or  GW4064   an  FXR  agonist, in the presence or absence of guggulsterone, an  FXR  antagonist", "triple_list": [["agonist,", "ACTIVATOR", "FXR"]]}, {"text": "RGM-1 cells were treated with CDCA or GW4064, an  FXR  agonist, in the presence or absence of  guggulsterone   an  FXR  antagonist", "triple_list": [["guggulsterone", "AGONIST", "agonist,"]]}, {"text": "A series of phenolic acids and phenol natural products, such as  p-hydroxybenzoic acid   p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the  metalloenzyme  carbonic anhydrase (CA, EC 4.2.1.1)", "triple_list": [["anhydrase", "AGONIST", "metalloenzyme"]]}, {"text": "A series of phenolic acids and phenol natural products, such as  p-hydroxybenzoic acid   p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme  carbonic anhydrase  (CA, EC 4.2.1.1)", "triple_list": [["p-hydroxybenzoic acid", "ANTAGONIST", "syringic"]]}, {"text": "A series of phenolic acids and phenol natural products, such as  p-hydroxybenzoic acid   p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ( CA   EC 4.2.1.1)", "triple_list": [["p-hydroxybenzoic acid", "AGONIST", "p-hydroxybenzoic"]]}, {"text": "A series of phenolic acids and phenol natural products, such as  p-hydroxybenzoic acid   p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA,  EC 4.2.1.1  ", "triple_list": [["against", "AGONIST", "EC 4.2.1.1"]]}, {"text": " Phenols  like the ones investigated here possess a  CA  inhibition mechanism distinct of that of the sulfonamides/sulfamates used clinically or the coumarins", "triple_list": [["Phenols", "PRODUCT-OF", "used"]]}, {"text": "Phenols like the ones investigated here possess a  CA  inhibition mechanism distinct of that of the  sulfonamides  sulfamates used clinically or the coumarins", "triple_list": [["distinct", "ACTIVATOR", "CA"]]}, {"text": "Phenols like the ones investigated here possess a  CA  inhibition mechanism distinct of that of the sulfonamides/ sulfamates  used clinically or the coumarins", "triple_list": [["used", "ACTIVATOR", "CA"]]}, {"text": "Phenols like the ones investigated here possess a  CA  inhibition mechanism distinct of that of the sulfonamides/sulfamates used clinically or the  coumarins   Unlike the sulfonamides, which bind to the catalytic zinc ion, phenols are anchored at the Zn(II)-coordinated water molecule and bind more externally within the active site cavity, making contacts with various amino acid residues", "triple_list": [["coumarins", "PRODUCT-OF", "more"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid,  p-coumaric acid   caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the  metalloenzyme  carbonic anhydrase (CA, EC 4.2.1.1)", "triple_list": [["p-coumaric acid", "AGONIST", "ellagic"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid,  p-coumaric acid   caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme  carbonic anhydrase  (CA, EC 4.2.1.1)", "triple_list": [["p-coumaric acid", "AGONIST", "ellagic"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid,  p-coumaric acid   caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ( CA   EC 4.2.1.1)", "triple_list": [["p-coumaric acid", "PRODUCT-OF", "syringic"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid,  p-coumaric acid   caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA,  EC 4.2.1.1  ", "triple_list": [["p-coumaric acid", "PRODUCT-OF", "p-coumaric"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid,  caffeic acid   ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the  metalloenzyme  carbonic anhydrase (CA, EC 4.2.1.1)", "triple_list": [["caffeic acid", "PRODUCT-OF", "syringic"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid,  caffeic acid   ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme  carbonic anhydrase  (CA, EC 4.2.1.1)", "triple_list": [["caffeic", "AGONIST", "carbonic anhydrase"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid,  caffeic acid   ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ( CA   EC 4.2.1.1)", "triple_list": [["of", "ACTIVATOR", "CA"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid,  caffeic acid   ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA,  EC 4.2.1.1  ", "triple_list": [["as", "ANTAGONIST", "EC 4.2.1.1"]]}, {"text": "Inhibition of  mammalian isoforms I-XIV  with a series of natural product  polyphenols  and phenolic acids", "triple_list": [["acids", "PRODUCT-OF", "mammalian isoforms I-XIV"]]}, {"text": "Inhibition of  mammalian isoforms I-XIV  with a series of natural product polyphenols and  phenolic acids   A series of  phenolic acids  and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1)", "triple_list": [["phenolic acids", "ACTIVATOR", "the"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid,  ferulic acid   gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the  metalloenzyme  carbonic anhydrase (CA, EC 4.2.1.1)", "triple_list": [["effects", "AGONIST", "metalloenzyme"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid,  ferulic acid   gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme  carbonic anhydrase  (CA, EC 4.2.1.1)", "triple_list": [["their", "PRODUCT-OF", "carbonic anhydrase"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid,  ferulic acid   gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ( CA   EC 4.2.1.1)", "triple_list": [["CA", "AGONIST", "CA"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid,  ferulic acid   gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA,  EC 4.2.1.1  ", "triple_list": [["and", "ANTAGONIST", "EC 4.2.1.1"]]}, {"text": "A series of  phenolic acids  and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the  metalloenzyme  carbonic anhydrase (CA, EC 4.2.1.1)", "triple_list": [["such", "ANTAGONIST", "metalloenzyme"]]}, {"text": "A series of  phenolic acids  and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme  carbonic anhydrase  (CA, EC 4.2.1.1)", "triple_list": [["acid,", "PRODUCT-OF", "carbonic anhydrase"]]}, {"text": "A series of  phenolic acids  and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ( CA   EC 4.2.1.1)", "triple_list": [["phenolic acids", "PRODUCT-OF", "acid,"]]}, {"text": "A series of  phenolic acids  and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA,  EC 4.2.1.1  ", "triple_list": [["phenolic acids", "AGONIST", "p-hydroxybenzoic"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid,  gallic acid   syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the  metalloenzyme  carbonic anhydrase (CA, EC 4.2.1.1)", "triple_list": [["gallic acid", "AGONIST", "were"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid,  gallic acid   syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme  carbonic anhydrase  (CA, EC 4.2.1.1)", "triple_list": [["phenol", "ACTIVATOR", "carbonic anhydrase"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid,  gallic acid   syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ( CA   EC 4.2.1.1)", "triple_list": [["acid,", "PRODUCT-OF", "CA"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid,  gallic acid   syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA,  EC 4.2.1.1  ", "triple_list": [["gallic acid", "ACTIVATOR", "(CA,"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid,  syringic acid   quercetin, and ellagic acid, were investigated for their inhibitory effects against the  metalloenzyme  carbonic anhydrase (CA, EC 4.2.1.1)", "triple_list": [["acid", "ACTIVATOR", "metalloenzyme"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid,  syringic acid   quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme  carbonic anhydrase  (CA, EC 4.2.1.1)", "triple_list": [["ferulic", "AGONIST", "carbonic anhydrase"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid,  syringic acid   quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ( CA   EC 4.2.1.1)", "triple_list": [["acid", "PRODUCT-OF", "CA"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid,  syringic acid   quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA,  EC 4.2.1.1  ", "triple_list": [["syringic acid", "AGONIST", "acid,"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid,  quercetin   and ellagic acid, were investigated for their inhibitory effects against the  metalloenzyme  carbonic anhydrase (CA, EC 4.2.1.1)", "triple_list": [["quercetin", "AGONIST", "metalloenzyme"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid,  quercetin   and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme  carbonic anhydrase  (CA, EC 4.2.1.1)", "triple_list": [["quercetin", "ACTIVATOR", "series"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid,  quercetin   and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ( CA   EC 4.2.1.1)", "triple_list": [["acid,", "ACTIVATOR", "CA"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid,  quercetin   and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA,  EC 4.2.1.1  ", "triple_list": [["anhydrase", "ANTAGONIST", "EC 4.2.1.1"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and  ellagic acid   were investigated for their inhibitory effects against the  metalloenzyme  carbonic anhydrase (CA, EC 4.2.1.1)", "triple_list": [["ellagic acid", "PRODUCT-OF", "acid"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and  ellagic acid   were investigated for their inhibitory effects against the metalloenzyme  carbonic anhydrase  (CA, EC 4.2.1.1)", "triple_list": [["against", "PRODUCT-OF", "carbonic anhydrase"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and  ellagic acid   were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ( CA   EC 4.2.1.1)", "triple_list": [["ferulic", "AGONIST", "CA"]]}, {"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and  ellagic acid   were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA,  EC 4.2.1.1  ", "triple_list": [["ellagic acid", "ACTIVATOR", "ferulic"]]}, {"text": "A series of  phenol ic acids and  phenol  natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the  metalloenzyme  carbonic anhydrase (CA, EC 4.2.1.1)", "triple_list": [["phenol", "AGONIST", "4.2.1.1)"]]}, {"text": "A series of  phenol ic acids and  phenol  natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme  carbonic anhydrase  (CA, EC 4.2.1.1)", "triple_list": [["phenol", "ANTAGONIST", "p-hydroxybenzoic"]]}, {"text": "A series of  phenol ic acids and  phenol  natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ( CA   EC 4.2.1.1)", "triple_list": [["phenol", "AGONIST", "metalloenzyme"]]}, {"text": "A series of  phenol ic acids and  phenol  natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA,  EC 4.2.1.1  ", "triple_list": [["phenol", "ANTAGONIST", "gallic"]]}, {"text": "Here, translocation studies using the human androgen receptor ( hAR ) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic  steroids  (AAS) were activating  hAR  and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and  hAR ", "triple_list": [["steroids", "ANTAGONIST", "the"]]}, {"text": "The contractions to 5-HT were inhibited by  ketanserin  and alosetron indicating involvement of  5-HT(2A)  and 5-HT(3) receptors, respectively", "triple_list": [["ketanserin", "ANTAGONIST", "and"]]}, {"text": "The contractions to 5-HT were inhibited by ketanserin and  alosetron  indicating involvement of 5-HT(2A) and  5-HT(3)  receptors, respectively", "triple_list": [["alosetron", "PRODUCT-OF", "respectively"]]}, {"text": " TAS-102  is a novel drug containing trifluorothymidine, which is phosphorylated by TK-1 to its active monophosphated form, that in turn can inhibit  TS    TAS-102  has been shown to exhibit antitumor activity in fluoropyrimidine-resistant human cancer cells", "triple_list": [["TAS-102", "AGONIST", "novel"]]}, {"text": " TAS-102  is a novel drug containing trifluorothymidine, which is phosphorylated by  TK-1  to its active monophosphated form, that in turn can inhibit TS", "triple_list": [["TAS-102", "AGONIST", "TS"]]}, {"text": "TAS-102 is a novel drug containing  trifluorothymidine   which is phosphorylated by  TK-1  to its active monophosphated form, that in turn can inhibit TS", "triple_list": [["by", "ACTIVATOR", "TK-1"]]}, {"text": " Thymidine kinase-1  (TK-1) and thymidylate synthase (TS) are key enzymes for salvage and de novo  pyrimidine  synthesis, respectively", "triple_list": [["enzymes", "DOWNREGULATOR", "Thymidine kinase-1"]]}, {"text": "Thymidine kinase-1 ( TK-1)  and thymidylate synthase (TS) are key enzymes for salvage and de novo  pyrimidine  synthesis, respectively", "triple_list": [["salvage", "AGONIST", "TK-1)"]]}, {"text": "Thymidine kinase-1 (TK-1) and  thymidylate synthase  (TS) are key enzymes for salvage and de novo  pyrimidine  synthesis, respectively", "triple_list": [["Thymidine", "ANTAGONIST", "thymidylate synthase"]]}, {"text": "Thymidine kinase-1 (TK-1) and thymidylate synthase ( TS   are key enzymes for salvage and de novo  pyrimidine  synthesis, respectively", "triple_list": [["pyrimidine", "ANTAGONIST", "TS"]]}, {"text": "Immunohistochemical characterization of  pyrimidine  synthetic enzymes,  thymidine kinase-1  and thymidylate synthase, in various types of cancer", "triple_list": [["pyrimidine", "ANTAGONIST", "and"]]}, {"text": "Immunohistochemical characterization of  pyrimidine  synthetic enzymes, thymidine kinase-1 and  thymidylate synthase   in various types of cancer", "triple_list": [["in", "AGONIST", "thymidylate synthase"]]}, {"text": "Gastrointestinal adenocarcinomas and squamous cell uterine carcinomas were often accompanied by high  TS  expression, indicating activation of  pyrimidine  synthesis through both the salvage and de novo pathways", "triple_list": [["pyrimidine", "ANTAGONIST", "often"]]}, {"text": "Assays examining the ability of  TFP  to block  S100A4 -mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of  S100A4  function occurs only at  TFP  concentrations that promote  S100A4  oligomerization", "triple_list": [["block", "DOWNREGULATOR", "S100A4"]]}, {"text": "Using a unique biosensor-based assay,  trifluoperazine  (TFP) was identified as an inhibitor that disrupts the  S100A4  myosin-IIA interaction", "triple_list": [["a", "PRODUCT-OF", "S100A4"]]}, {"text": "Using a unique biosensor-based assay,  trifluoperazine  (TFP) was identified as an inhibitor that disrupts the S100A4/ myosin-IIA  interaction", "triple_list": [["trifluoperazine", "PRODUCT-OF", "disrupts"]]}, {"text": "Using a unique biosensor-based assay, trifluoperazine ( TFP   was identified as an inhibitor that disrupts the  S100A4  myosin-IIA interaction", "triple_list": [["(", "ACTIVATOR", "S100A4"]]}, {"text": "Using a unique biosensor-based assay, trifluoperazine ( TFP   was identified as an inhibitor that disrupts the S100A4/ myosin-IIA  interaction", "triple_list": [["TFP", "PRODUCT-OF", "biosensor-based"]]}, {"text": " Phenothiazines  inhibit  S100A4  function by inducing protein oligomerization", "triple_list": [["function", "PRODUCT-OF", "S100A4"]]}, {"text": "Assays examining the ability of  TFP  to block  S100A4  mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of  S100A4  function occurs only at  TFP  concentrations that promote  S100A4  oligomerization", "triple_list": [["the", "AGONIST", "S100A4"]]}, {"text": "Assays examining the ability of  TFP  to block S100A4-mediated disassembly of  myosin-IIA  filaments demonstrate that significant inhibition of S100A4 function occurs only at  TFP  concentrations that promote S100A4 oligomerization", "triple_list": [["at", "PRODUCT-OF", "myosin-IIA"]]}, {"text": "Assays examining the ability of  TFP  to block  S100A4 -mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of  S100A4  function occurs only at  TFP  concentrations that promote  S100A4  oligomerization", "triple_list": [["TFP", "ANTAGONIST", "concentrations"]]}, {"text": "Together these studies support a unique mode of inhibition in which  phenothiazines  disrupt the  S100A4  myosin-IIA interaction by sequestering  S100A4  via small molecule-induced oligomerization.", "triple_list": [["disrupt", "AGONIST", "S100A4"]]}, {"text": "Together these studies support a unique mode of inhibition in which  phenothiazines  disrupt the S100A4/ myosin-IIA  interaction by sequestering S100A4 via small molecule-induced oligomerization.", "triple_list": [["phenothiazines", "AGONIST", "S100A4/"]]}, {"text": " Prednisolone  also inhibited ACTH and cortisol secretion in response to exogenous  CRH  stimulation, inferring rapid feedback inhibition at the anterior pituitary", "triple_list": [["response", "PRODUCT-OF", "CRH"]]}, {"text": "Prednisolone also inhibited ACTH and  cortisol  secretion in response to exogenous  CRH  stimulation, inferring rapid feedback inhibition at the anterior pituitary", "triple_list": [["cortisol", "ACTIVATOR", "the"]]}, {"text": " Rasagiline  is a novel, potent, and irreversible  monoamine oxidase type B  (MAO-B) inhibitor which has been approved for treatment of PD", "triple_list": [["PD", "PRODUCT-OF", "monoamine oxidase type B"]]}, {"text": " Rasagiline  is a novel, potent, and irreversible monoamine oxidase type B ( MAO-B   inhibitor which has been approved for treatment of PD", "triple_list": [["a", "PRODUCT-OF", "MAO-B"]]}, {"text": " Rasagiline  inhibits  MAO-B  more potently than selegiline and has the advantage of once-daily dosing", "triple_list": [["advantage", "ACTIVATOR", "MAO-B"]]}, {"text": "A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the  VEGFR  tyrosine kinase inhibitors sunitinib and/or  sorafenib   The primary endpoint of progression-free survival was increased from median 1.9 to 4.9 months (hazard ratio 0.33, P < 0.001) and 25% were still progression-free after 10 months of everolimus therapy", "triple_list": [["of", "PRODUCT-OF", "VEGFR"]]}, {"text": "A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR  tyrosine kinase  inhibitors sunitinib and/or  sorafenib   The primary endpoint of progression-free survival was increased from median 1.9 to 4.9 months (hazard ratio 0.33, P < 0.001) and 25% were still progression-free after 10 months of everolimus therapy", "triple_list": [["25%", "ACTIVATOR", "tyrosine kinase"]]}, {"text": " Everolimus  (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of  mTOR  (mammalian target of rapamycin) to reach the oncology clinic", "triple_list": [["oncology", "ACTIVATOR", "mTOR"]]}, {"text": " Everolimus  (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of mTOR ( mammalian target of rapamycin   to reach the oncology clinic", "triple_list": [["Everolimus", "ACTIVATOR", "of"]]}, {"text": "Everolimus ( RAD001   Afinitor((R)) Novartis) is the first oral inhibitor of  mTOR  (mammalian target of rapamycin) to reach the oncology clinic", "triple_list": [["RAD001", "PRODUCT-OF", "oncology"]]}, {"text": "Everolimus ( RAD001   Afinitor((R)) Novartis) is the first oral inhibitor of mTOR ( mammalian target of rapamycin   to reach the oncology clinic", "triple_list": [["RAD001", "PRODUCT-OF", "of"]]}, {"text": "Everolimus (RAD001,  Afinitor((R)) Novartis   is the first oral inhibitor of  mTOR  (mammalian target of rapamycin) to reach the oncology clinic", "triple_list": [["Afinitor((R)) Novartis", "PRODUCT-OF", "inhibitor"]]}, {"text": "Everolimus (RAD001,  Afinitor((R)) Novartis   is the first oral inhibitor of mTOR ( mammalian target of rapamycin   to reach the oncology clinic", "triple_list": [["Afinitor((R)) Novartis", "ANTAGONIST", "oncology"]]}, {"text": "A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the  VEGFR  tyrosine kinase inhibitors  sunitinib  and/or sorafenib", "triple_list": [["sunitinib", "PRODUCT-OF", "sunitinib"]]}, {"text": "A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR  tyrosine kinase  inhibitors  sunitinib  and/or sorafenib", "triple_list": [["sunitinib", "ANTAGONIST", "placebo-controlled"]]}, {"text": "After inflammation was established mice were dosed with the  H4R  antagonist,  JNJ 7777120   or anti-IL-13 antibody for comparison", "triple_list": [["anti-IL-13", "DOWNREGULATOR", "H4R"]]}, {"text": "Apoptosis studies (DAPI staining and  caspase 3  activity) showed a marked increase in the presence of  MXF  and VP-16 compared to VP-16 alone", "triple_list": [["and", "ANTAGONIST", "caspase 3"]]}, {"text": "Apoptosis studies (DAPI staining and  caspase 3  activity) showed a marked increase in the presence of MXF and  VP-16  compared to  VP-16  alone", "triple_list": [["VP-16", "AGONIST", "caspase"]]}, {"text": "Apoptosis studies (DAPI staining and  caspase 3  activity) showed a marked increase in the presence of MXF and  VP-16  compared to  VP-16  alone", "triple_list": [["and", "ANTAGONIST", "caspase 3"]]}, {"text": "In conclusion, the results suggest that the enhancement in the reduction of  topo II  activity by the combined  MXF  VP-16 treatments was probably due to the increase in the level of the DNA-enzyme cleavable complexes formed by both drugs", "triple_list": [["MXF", "ANTAGONIST", "level"]]}, {"text": "In conclusion, the results suggest that the enhancement in the reduction of  topo II  activity by the combined MXF/ VP-16  treatments was probably due to the increase in the level of the DNA-enzyme cleavable complexes formed by both drugs", "triple_list": [["conclusion,", "PRODUCT-OF", "topo II"]]}, {"text": " Etoposide  (VP-16) is a  topoisomerase-II  (topo II) inhibitor chemotherapeutic agent", "triple_list": [["inhibitor", "PRODUCT-OF", "topoisomerase-II"]]}, {"text": " Etoposide  (VP-16) is a topoisomerase-II ( topo II   inhibitor chemotherapeutic agent", "triple_list": [["topoisomerase-II", "PRODUCT-OF", "topo II"]]}, {"text": " MXF  or VP-16 slightly affected cellular  topo II  activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of  topo II   VP-16 induced cell cycle arrest at G2/M and the appearance of the subG1 peak which was increased by the addition of  MXF ", "triple_list": [["of", "AGONIST", "topo II"]]}, {"text": "MXF or  VP-16  slightly affected cellular  topo II  activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of  topo II    VP-16  induced cell cycle arrest at G2/M and the appearance of the subG1 peak which was increased by the addition of MXF", "triple_list": [["the", "ANTAGONIST", "topo II"]]}, {"text": "Etoposide ( VP-16   is a  topoisomerase-II  (topo II) inhibitor chemotherapeutic agent", "triple_list": [["VP-16", "ANTAGONIST", "(topo"]]}, {"text": "Etoposide ( VP-16   is a topoisomerase-II ( topo II   inhibitor chemotherapeutic agent", "triple_list": [["VP-16", "AGONIST", "is"]]}, {"text": " Rasagiline  is a propargylamine and irreversible  monoamine oxidase (MAO) B  inhibitor used for the treatment of Parkinson's disease (PD)", "triple_list": [["the", "PRODUCT-OF", "monoamine oxidase (MAO) B"]]}, {"text": "Rasagiline is a  propargylamine  and irreversible  monoamine oxidase (MAO) B  inhibitor used for the treatment of Parkinson's disease (PD)", "triple_list": [["propargylamine", "PRODUCT-OF", "used"]]}, {"text": "However, salicylate moiety appears to interfere with  aspirin  inhibitory action on platelets and vascular  COX   Such interaction, if present at the level of respiratory tract, may be of interest to pathogenesis of ASA-induced asthma", "triple_list": [["aspirin", "PRODUCT-OF", "to"]]}, {"text": " Aspirin  (ASA) and other non-steroidal anti-inflammatory drugs, which are  cyclooxygenase  (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients", "triple_list": [["Aspirin", "AGONIST", "asthmatic"]]}, {"text": " Aspirin  (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase ( COX   inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on  COX  by itself, is well tolerated by these patients", "triple_list": [["Aspirin", "ANTAGONIST", "("]]}, {"text": "Aspirin ( ASA   and other non-steroidal anti-inflammatory drugs, which are  cyclooxygenase  (COX) inhibitors, precipitate asthmatic attacks in  ASA -intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients", "triple_list": [["anti-inflammatory", "ANTAGONIST", "cyclooxygenase"]]}, {"text": "Aspirin ( ASA   and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase ( COX   inhibitors, precipitate asthmatic attacks in  ASA -intolerant patients, while sodium salicylate, hardly active on  COX  by itself, is well tolerated by these patients", "triple_list": [["ASA", "ANTAGONIST", "active"]]}, {"text": "Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between  salicylate  and ASA on  cyclo-oxygenase  locus in the respiratory tract in ASA-intolerant patients.", "triple_list": [["salicylate", "ACTIVATOR", "trilisate"]]}, {"text": "Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between salicylate and  ASA  on  cyclo-oxygenase  locus in the respiratory tract in  ASA -intolerant patients.", "triple_list": [["ASA", "ACTIVATOR", "locus"]]}, {"text": "Despite the structural similarity between benzothiazepines and BDZs, mutation of an amino acid important for diltiazem potency ( I1150A   did not affect  diazepam  potency", "triple_list": [["diazepam", "ACTIVATOR", "acid"]]}, {"text": "Although  L-VGCC  inhibition by  BDZs  occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up-regulation of  L-VGCC s during long-term treatment, pentobarbital and ethanol inhibited  L-VGCC s at clinically relevant concentrations.", "triple_list": [["BDZs", "ANTAGONIST", "concentrations."]]}, {"text": "Although L-VGCC inhibition by BDZs occurred at concentrations that are possibly too high to be clinically relevant and is not likely to play a role in the up-regulation of  L-VGCCs  during long-term treatment,  pentobarbital  and ethanol inhibited  L-VGCCs  at clinically relevant concentrations.", "triple_list": [["pentobarbital", "ACTIVATOR", "relevant"]]}, {"text": "BDZs and other positive GABA(A)R modulators, including  barbiturates   ethanol, and neurosteroids, can also inhibit  L-type voltage-gated calcium channels  (L-VGCCs), which could contribute to reduced neuronal excitability", "triple_list": [["and", "PRODUCT-OF", "L-type voltage-gated calcium channels"]]}, {"text": "BDZs and other positive GABA(A)R modulators, including  barbiturates   ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels ( L-VGCCs  , which could contribute to reduced neuronal excitability", "triple_list": [["barbiturates", "ANTAGONIST", "voltage-gated"]]}, {"text": "BDZs and other positive GABA(A)R modulators, including barbiturates,  ethanol   and neurosteroids, can also inhibit  L-type voltage-gated calcium channels  (L-VGCCs), which could contribute to reduced neuronal excitability", "triple_list": [["ethanol", "AGONIST", "excitability"]]}, {"text": "BDZs and other positive GABA(A)R modulators, including barbiturates,  ethanol   and neurosteroids, can also inhibit L-type voltage-gated calcium channels ( L-VGCCs  , which could contribute to reduced neuronal excitability", "triple_list": [["and", "ACTIVATOR", "L-VGCCs"]]}, {"text": "BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and  neurosteroids   can also inhibit  L-type voltage-gated calcium channels  (L-VGCCs), which could contribute to reduced neuronal excitability", "triple_list": [["neurosteroids", "ANTAGONIST", "L-type"]]}, {"text": "BDZs and other positive GABA(A)R modulators, including barbiturates, ethanol, and  neurosteroids   can also inhibit L-type voltage-gated calcium channels ( L-VGCCs  , which could contribute to reduced neuronal excitability", "triple_list": [["L-VGCCs", "ANTAGONIST", "L-VGCCs"]]}, {"text": " Ca(v)1.3  channels were less sensitive to  pentobarbital  inhibition than Ca(v)1.2 channels, similar to dihydropyridine (DHP) L-VGCC antagonists", "triple_list": [["pentobarbital", "PRODUCT-OF", "channels,"]]}, {"text": "Ca(v)1.3 channels were less sensitive to  pentobarbital  inhibition than  Ca(v)1.2  channels, similar to dihydropyridine (DHP) L-VGCC antagonists", "triple_list": [["than", "AGONIST", "Ca(v)1.2"]]}, {"text": " Ca(v)1.3  channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to  dihydropyridine  (DHP) L-VGCC antagonists", "triple_list": [["antagonists", "AGONIST", "Ca(v)1.3"]]}, {"text": "Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than  Ca(v)1.2  channels, similar to  dihydropyridine  (DHP) L-VGCC antagonists", "triple_list": [["inhibition", "ANTAGONIST", "Ca(v)1.2"]]}, {"text": " Ca(v)1.3  channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine ( DHP   L-VGCC antagonists", "triple_list": [["to", "ACTIVATOR", "Ca(v)1.3"]]}, {"text": "Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than  Ca(v)1.2  channels, similar to dihydropyridine ( DHP   L-VGCC antagonists", "triple_list": [["DHP", "PRODUCT-OF", "similar"]]}, {"text": "All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only  BDZs  and pentobarbital induced a negative shift in  Ca(v)1.2  channel inactivation", "triple_list": [["the", "AGONIST", "Ca(v)1.2"]]}, {"text": "All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only BDZs and  pentobarbital  induced a negative shift in  Ca(v)1.2  channel inactivation", "triple_list": [["pentobarbital", "ACTIVATOR", "inactivation"]]}, {"text": " BDZs  and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit  L-type voltage-gated calcium channels  (L-VGCCs), which could contribute to reduced neuronal excitability", "triple_list": [["neurosteroids,", "AGONIST", "L-type voltage-gated calcium channels"]]}, {"text": " BDZs  and other positive GABA(A)R modulators, including barbiturates, ethanol, and neurosteroids, can also inhibit L-type voltage-gated calcium channels ( L-VGCCs  , which could contribute to reduced neuronal excitability", "triple_list": [["excitability", "PRODUCT-OF", "L-VGCCs"]]}, {"text": "Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to  dihydropyridine  (DHP)  L-VGCC  antagonists", "triple_list": [["dihydropyridine", "DOWNREGULATOR", "Ca(v)1.2"]]}, {"text": "Ca(v)1.3 channels were less sensitive to pentobarbital inhibition than Ca(v)1.2 channels, similar to dihydropyridine ( DHP    L-VGCC  antagonists", "triple_list": [["DHP", "ACTIVATOR", "sensitive"]]}, {"text": "In a recent study using protein-specific anti-acetyl lysine antibodies and immunological methods, we demonstrated the ability of  aspirin  to acetylate the  tumor suppressor protein p53   In this review, we present current research from the literature on the  aspirin -induced acetylation of proteins", "triple_list": [["of", "PRODUCT-OF", "tumor suppressor protein p53"]]}, {"text": "Although the inhibition of  cyclooxygenases  by  aspirin   which leads to its anti-inflammatory/analgesic properties, has been well studied, the mechanisms involved in its chemopreventive effects as well as some of its adverse effects are as yet ill-defined", "triple_list": [["aspirin", "AGONIST", "has"]]}, {"text": "In addition, PSE inhibited the transcriptional activity of  NFAT  without interfering with the  calcium  induced  NFAT  dephosphorylation event, which represents the major signaling pathway for its activation", "triple_list": [["calcium", "AGONIST", "activation"]]}, {"text": "We found that  PSE  inhibits interleukin-2 (IL-2) and  tumor necrosis factor (TNF) alpha  gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line", "triple_list": [["and", "AGONIST", "tumor necrosis factor (TNF) alpha"]]}, {"text": "To further characterize the inhibitory mechanisms of  PSE  at the transcriptional level, we examined the transcriptional activities of nuclear factor kappa B ( NF-kappaB ), nuclear factor of activated T cells (NFAT), and activator protein-1 (AP-1) transcription factors and found that  PSE  inhibited  NF-kappaB  dependent transcriptional activity without affecting either the phosphorylation, the degradation of the cytoplasmic  NF-kappaB  inhibitory protein, IkappaBalpha or the DNA-binding activity", "triple_list": [["PSE", "ACTIVATOR", "inhibited"]]}, {"text": " Pseudoephedrine  inhibits T-cell activation by targeting  NF-kappaB   NFAT and AP-1 signaling pathways", "triple_list": [["NF-kappaB", "ACTIVATOR", "NF-kappaB"]]}, {"text": " Pseudoephedrine  inhibits T-cell activation by targeting NF-kappaB,  NFAT  and AP-1 signaling pathways", "triple_list": [["inhibits", "PRODUCT-OF", "NFAT"]]}, {"text": " Pseudoephedrine  inhibits T-cell activation by targeting NF-kappaB, NFAT and  AP-1  signaling pathways", "triple_list": [["Pseudoephedrine", "ACTIVATOR", "AP-1"]]}, {"text": "However, phosphorylation of the  p65  RelA subunit was clearly inhibited by  PSE  in stimulated cells", "triple_list": [["However,", "ANTAGONIST", "p65"]]}, {"text": "However, phosphorylation of the p65/ RelA  subunit was clearly inhibited by  PSE  in stimulated cells", "triple_list": [["PSE", "AGONIST", "subunit"]]}, {"text": "In addition,  PSE  inhibited the transcriptional activity of  NFAT  without interfering with the calcium-induced  NFAT  dephosphorylation event, which represents the major signaling pathway for its activation", "triple_list": [["PSE", "PRODUCT-OF", "transcriptional"]]}, {"text": "NFAT cooperates with c-Jun, a compound of the AP-1 complex, to activate target genes, and we also found that  PSE  inhibited both  JNK  activation and AP-1 transcriptional activity", "triple_list": [["PSE", "ANTAGONIST", "cooperates"]]}, {"text": "NFAT cooperates with c-Jun, a compound of the  AP-1  complex, to activate target genes, and we also found that  PSE  inhibited both JNK activation and  AP-1  transcriptional activity", "triple_list": [["PSE", "ANTAGONIST", "PSE"]]}, {"text": "We found that  PSE  inhibits  interleukin-2  (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line", "triple_list": [["PSE", "PRODUCT-OF", "transcription"]]}, {"text": "We found that  PSE  inhibits interleukin-2 ( IL-2   and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line", "triple_list": [["found", "ACTIVATOR", "IL-2"]]}, {"text": "Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the  VMAT  inhibitor  reserpine  and a proton ionophore, but not by tetrabenazine, which has a high affinity for  VMAT -2", "triple_list": [["blocked", "ANTAGONIST", "VMAT"]]}, {"text": "Because clinical studies investigating interactions between garlic and  human immunodeficiency virus protease  inhibitors  saquinavir  and ritonavir have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes", "triple_list": [["the", "ACTIVATOR", "human immunodeficiency virus protease"]]}, {"text": "Because clinical studies investigating interactions between garlic and  human immunodeficiency virus protease  inhibitors saquinavir and  ritonavir  have already been performed, we used these in vivo data to evaluate the in vitro results and the reliability of the models employed as screening tools for forecasting the potential of first-pass intestinal metabolism changes", "triple_list": [["immunodeficiency", "PRODUCT-OF", "human immunodeficiency virus protease"]]}, {"text": "Catecholamines ( adrenaline   nor adrenaline  and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase ( phenylalanine hydroxylase   EC 1.14.16.1)", "triple_list": [["phenylalanine", "ANTAGONIST", "phenylalanine hydroxylase"]]}, {"text": "Catecholamines ( adrenaline   nor adrenaline  and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase,  EC 1.14.16.1  ", "triple_list": [["adrenaline", "PRODUCT-OF", "inhibitors"]]}, {"text": "Catecholamines ( adrenaline   nor adrenaline  and dopamine) are potent inhibitors of  phenylalanine 4-monooxygenase  (phenylalanine hydroxylase, EC 1.14.16.1)", "triple_list": [["Catecholamines", "PRODUCT-OF", "phenylalanine 4-monooxygenase"]]}, {"text": "Catecholamines (adrenaline,  noradrenaline  and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase ( phenylalanine hydroxylase   EC 1.14.16.1)", "triple_list": [["noradrenaline", "ANTAGONIST", "and"]]}, {"text": "Catecholamines (adrenaline,  noradrenaline  and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase,  EC 1.14.16.1  ", "triple_list": [["are", "ACTIVATOR", "EC 1.14.16.1"]]}, {"text": "Catecholamines (adrenaline,  noradrenaline  and dopamine) are potent inhibitors of  phenylalanine 4-monooxygenase  (phenylalanine hydroxylase, EC 1.14.16.1)", "triple_list": [["noradrenaline", "AGONIST", "phenylalanine"]]}, {"text": "Catecholamines (adrenaline, noradrenaline and  dopamine   are potent inhibitors of phenylalanine 4-monooxygenase ( phenylalanine hydroxylase   EC 1.14.16.1)", "triple_list": [["dopamine", "AGONIST", "phenylalanine"]]}, {"text": "Catecholamines (adrenaline, noradrenaline and  dopamine   are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase,  EC 1.14.16.1  ", "triple_list": [["dopamine", "PRODUCT-OF", "hydroxylase,"]]}, {"text": "Catecholamines (adrenaline, noradrenaline and  dopamine   are potent inhibitors of  phenylalanine 4-monooxygenase  (phenylalanine hydroxylase, EC 1.14.16.1)", "triple_list": [["and", "AGONIST", "phenylalanine 4-monooxygenase"]]}, {"text": " Catecholamines  (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase ( phenylalanine hydroxylase   EC 1.14.16.1)", "triple_list": [["Catecholamines", "ANTAGONIST", "("]]}, {"text": " Catecholamines  (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase,  EC 1.14.16.1  ", "triple_list": [["Catecholamines", "ANTAGONIST", "noradrenaline"]]}, {"text": " Catecholamines  (adrenaline, noradrenaline and dopamine) are potent inhibitors of  phenylalanine 4-monooxygenase  (phenylalanine hydroxylase, EC 1.14.16.1)", "triple_list": [["noradrenaline", "ANTAGONIST", "phenylalanine 4-monooxygenase"]]}, {"text": "The treatment with  arsenic  exhibited a significant increase in some serum hepatic and renal biochemical parameters ( alanine aminotransferase   aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)", "triple_list": [["arsenic", "AGONIST", "The"]]}, {"text": "The treatment with  arsenic  exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase,  aspartate aminotransferase   alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine)", "triple_list": [["arsenic", "DOWNREGULATOR", "arsenic"]]}, {"text": "The treatment with  arsenic  exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase,  alkaline phosphatase   total protein, albumin, bilirubin, cholesterol, urea and creatinine)", "triple_list": [["treatment", "PRODUCT-OF", "alkaline phosphatase"]]}, {"text": "The treatment with  arsenic  exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein,  albumin   bilirubin, cholesterol, urea and creatinine)", "triple_list": [["arsenic", "PRODUCT-OF", "albumin"]]}, {"text": "They display sensitivity to  TK  inhibitors, including  gefitinib  and erlotinib", "triple_list": [["sensitivity", "AGONIST", "TK"]]}, {"text": "They display sensitivity to  TK  inhibitors, including gefitinib and  erlotinib   In contrast, the secondary mutation of the gatekeeper residue, T790M, reportedly confers inhibitor resistance on the oncogenic EGFR mutants", "triple_list": [["on", "AGONIST", "TK"]]}, {"text": " Epi  increased the activity of the  human WNT6 promoter  through Cav1-dependent binding of \u03b2-catenin to the proximal WNT6 promoter", "triple_list": [["proximal", "PRODUCT-OF", "human WNT6 promoter"]]}, {"text": " Epi  increased the activity of the human  WNT6 promoter  through Cav1-dependent binding of \u03b2-catenin to the proximal  WNT6 promoter    Epi  increased both WNT6/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg)", "triple_list": [["Epi", "AGONIST", "TAg)"]]}, {"text": " Epi  increased both  WNT6  Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg)", "triple_list": [["(CEA424-SV40", "PRODUCT-OF", "WNT6"]]}, {"text": " Epi  increased both WNT6/ Wnt6  and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg)", "triple_list": [["Epi", "ANTAGONIST", "model"]]}, {"text": " Epi  increased both WNT6/Wnt6 and  Cav1  expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg)", "triple_list": [["Epi", "AGONIST", "WNT6/Wnt6"]]}, {"text": "These results showed that  WNT6  and Cav1 are upregulated by chemotherapeutics and enhance the resistance of GC cells to  anthracycline  drugs", "triple_list": [["anthracycline", "PRODUCT-OF", "drugs"]]}, {"text": "These results showed that WNT6 and  Cav1  are upregulated by chemotherapeutics and enhance the resistance of GC cells to  anthracycline  drugs", "triple_list": [["drugs", "ANTAGONIST", "Cav1"]]}, {"text": "Differentiating the roles of  mGlu2  and mGlu3 receptors using  LY541850   an  mGlu2  agonist/mGlu3 antagonist", "triple_list": [["LY541850", "ANTAGONIST", "the"]]}, {"text": "These results confirm the selective  mGlu2  agonist and mGlu3 antagonist actions of  LY541850   A similar profile of activity was seen in medial perforant path synapse to the dentate gyrus", "triple_list": [["mGlu2", "DOWNREGULATOR", "mGlu2"]]}, {"text": " LY541850  was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric  mGlu2  agonist and mGlu3 antagonist", "triple_list": [["to", "ANTAGONIST", "mGlu2"]]}, {"text": "Differentiating the roles of mGlu2 and  mGlu3  receptors using  LY541850   an mGlu2 agonist/ mGlu3  antagonist", "triple_list": [["LY541850", "PRODUCT-OF", "Differentiating"]]}, {"text": "These results confirm the selective mGlu2 agonist and  mGlu3  antagonist actions of  LY541850   A similar profile of activity was seen in medial perforant path synapse to the dentate gyrus", "triple_list": [["LY541850", "ACTIVATOR", "results"]]}, {"text": " LY541850  was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric mGlu2 agonist and  mGlu3  antagonist", "triple_list": [["LY541850", "DOWNREGULATOR", "antagonist"]]}, {"text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of  [(3)H] dopamine  (DA) uptake and [(3)H]WIN 35428 binding in  human dopamine transporter  (DAT) wild-type and mutants with altered conformational equilibria", "triple_list": [["binding", "DOWNREGULATOR", "human dopamine transporter"]]}, {"text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of  [(3)H] dopamine  (DA) uptake and [(3)H]WIN 35428 binding in human dopamine transporter ( DAT   wild-type and mutants with altered conformational equilibria", "triple_list": [["its", "ANTAGONIST", "DAT"]]}, {"text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine ( DA   uptake and [(3)H]WIN 35428 binding in  human dopamine transporter  ( DA T) wild-type and mutants with altered conformational equilibria", "triple_list": [["DA", "DOWNREGULATOR", "tested"]]}, {"text": "METHODS: (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synthesized and tested for inhibition of [(3)H] dopamine ( DA   uptake and [(3)H]WIN 35428 binding in human dopamine transporter ( DA T  wild-type and mutants with altered conformational equilibria", "triple_list": [["wild-type", "ANTAGONIST", "DAT"]]}, {"text": "RESULTS: (+/-)-, R-, and S-modafinil bind to the  DA T and inhibit  DA  uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity than its S-enantiomer", "triple_list": [["DA", "ACTIVATOR", "S-modafinil"]]}, {"text": "In addition,  Silibinin  caused an increase in  p53  and p21 protein level as well as mRNA levels", "triple_list": [["Silibinin", "DOWNREGULATOR", "caused"]]}, {"text": "In addition,  Silibinin  caused an increase in p53 and  p21  protein level as well as mRNA levels", "triple_list": [["Silibinin", "PRODUCT-OF", "level"]]}, {"text": "In mechanistic studies,  Silibinin  decreased the protein level of  p34cdc2   which might be the possible molecular mechanism of  Silibinin  efficacy on the growth inhibition in SGC-7901 cells", "triple_list": [["SGC-7901", "AGONIST", "p34cdc2"]]}, {"text": "The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either  5-HT(1A)  receptors by  WAY100635   or 5-HT(2A/2C) receptors by ritanserin", "triple_list": [["WAY100635", "ANTAGONIST", "5-HT(1A)"]]}, {"text": "The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or  5-HT(2A/2C)  receptors by  ritanserin   These results suggest that the GABAergic system, but not the serotonergic system, is involved in the mechanism of the anxiolytic-like phenotype of Lu AF21934 in rodents", "triple_list": [["was", "ANTAGONIST", "5-HT(2A/2C)"]]}, {"text": "Previous studies demonstrated that the  Group III mGlu receptor  selective orthosteric agonist,  LSP1-2111  produced anxiolytic- but not antidepressant-like effects upon peripheral administration", "triple_list": [["studies", "DOWNREGULATOR", "Group III mGlu receptor"]]}, {"text": "The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the  benzodiazepine receptor  antagonist  flumazenil  (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin", "triple_list": [["flumazenil", "AGONIST", "SIH"]]}, {"text": "Anti-diabetic Activity of Swertiamarin is due to an Active Metabolite,  Gentianine   that Upregulates  PPAR-\u03b3  Gene Expression in 3T3-L1 cells", "triple_list": [["Anti-diabetic", "DOWNREGULATOR", "PPAR-\u03b3"]]}, {"text": " Swertiamarin  treatment had no significant effect on adipogenesis, or the mRNA expression of PPAR-\u03b3 and GLUT-4; however, there was a significant increase in the mRNA expression of  adiponectin   On the other hand, treatment with gentianine significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-\u03b3, GLUT-4 and  adiponectin ", "triple_list": [["with", "ANTAGONIST", "adiponectin"]]}, {"text": "On the other hand, treatment with  gentianine  significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of  PPAR-\u03b3   GLUT-4 and adiponectin", "triple_list": [["gentianine", "PRODUCT-OF", "other"]]}, {"text": "On the other hand, treatment with  gentianine  significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-\u03b3,  GLUT-4  and adiponectin", "triple_list": [["GLUT-4", "ANTAGONIST", "GLUT-4"]]}, {"text": "On the other hand, treatment with  gentianine  significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-\u03b3, GLUT-4 and  adiponectin   These findings suggest, for the first time, that the anti-diabetic effect of swertiamarin is due to  gentianine , an active metabolite of swertiamarin", "triple_list": [["gentianine", "AGONIST", "associated"]]}, {"text": "In the CCl4 hepatotoxicity model, pre-treatment with PSM or  silymarin  resulted in significantly increased activities of  ethylmorphine-N-demethylase  and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group", "triple_list": [["silymarin", "ANTAGONIST", "cytochrome"]]}, {"text": "In the CCl4 hepatotoxicity model, pre-treatment with PSM or  silymarin  resulted in significantly increased activities of ethylmorphine-N-demethylase and  aniline 4-hydroxylase  activity and cytochrome P450, compared to the CCl4 only group", "triple_list": [["silymarin", "ANTAGONIST", "compared"]]}, {"text": "In the CCl4 hepatotoxicity model, pre-treatment with PSM or  silymarin  resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and  cytochrome P450   compared to the CCl4 only group", "triple_list": [["silymarin", "AGONIST", "silymarin"]]}, {"text": "In the  CCl4  hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of  ethylmorphine-N-demethylase  and aniline 4-hydroxylase activity and cytochrome P450, compared to the  CCl4  only group", "triple_list": [["the", "ANTAGONIST", "ethylmorphine-N-demethylase"]]}, {"text": "In the  CCl4  hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and  aniline 4-hydroxylase  activity and cytochrome P450, compared to the  CCl4  only group", "triple_list": [["CCl4", "PRODUCT-OF", "aniline 4-hydroxylase"]]}, {"text": "In the  CCl4  hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and  cytochrome P450   compared to the  CCl4  only group", "triple_list": [["CCl4", "PRODUCT-OF", "of"]]}, {"text": "A significant decrease of  aspartate aminotransferase   alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after  CCl4  and PC administration alone", "triple_list": [["CCl4", "AGONIST", "lactate"]]}, {"text": "A significant decrease of aspartate aminotransferase,  alanine aminotransferase   lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after  CCl4  and PC administration alone", "triple_list": [["CCl4", "PRODUCT-OF", "malondialdehyde"]]}, {"text": "A significant decrease of aspartate aminotransferase, alanine aminotransferase,  lactate dehydrogenase  (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after  CCl4  and PC administration alone", "triple_list": [["activities", "AGONIST", "lactate dehydrogenase"]]}, {"text": "A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase ( LDH   activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after  CCl4  and PC administration alone", "triple_list": [["CCl4", "AGONIST", "glutathione"]]}, {"text": "For  AII  and ET1, MAP was also increased for the  fenofibrate  group but not in a dose-dependent fashion", "triple_list": [["fenofibrate", "AGONIST", "AII"]]}, {"text": "For AII and  ET1   MAP was also increased for the  fenofibrate  group but not in a dose-dependent fashion", "triple_list": [["ET1", "AGONIST", "ET1"]]}, {"text": "The lysosomal inhibitor  chloroquine  significantly increased  RCAN1  accumulation in +/+ cells, consistent with the hypothesis that higher lysosomal pH impairs  RCAN1  degradation, leading to a higher  RCAN1 /NFATc1 ratio and consequently NFATc1 inhibition", "triple_list": [["the", "DOWNREGULATOR", "RCAN1"]]}, {"text": "Exposure to  PAHs   their metabolites, and ROS further increase  AKRs  isoform expression that may amplify oxidative damage", "triple_list": [["PAHs", "PRODUCT-OF", "metabolites,"]]}, {"text": " Aldo-keto reductases  (AKRs) metabolize a wide range of substrates, including  polycyclic aromatic hydrocarbons  (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis", "triple_list": [["aromatic", "ACTIVATOR", "Aldo-keto reductases"]]}, {"text": "Aldo-keto reductases ( AKRs   metabolize a wide range of substrates, including  polycyclic aromatic hydrocarbons  (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis", "triple_list": [["generating", "AGONIST", "AKRs"]]}, {"text": " Aldo-keto reductases  (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons ( PAHs  , generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis", "triple_list": [["carcinogenesis", "ANTAGONIST", "Aldo-keto reductases"]]}, {"text": "Aldo-keto reductases ( AKRs   metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons ( PAHs  , generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis", "triple_list": [["(", "ANTAGONIST", "AKRs"]]}, {"text": " Aldo-keto reductases  (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites ( o-quinones   and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis", "triple_list": [["o-quinones", "ANTAGONIST", "("]]}, {"text": "Aldo-keto reductases ( AKRs   metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites ( o-quinones   and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis", "triple_list": [["o-quinones", "DOWNREGULATOR", "aromatic"]]}, {"text": " Aldo-keto reductases  (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive  oxygen  species (ROS), which are capable of initiating and promoting carcinogenesis", "triple_list": [["oxygen", "AGONIST", "(o-quinones)"]]}, {"text": "Aldo-keto reductases ( AKRs   metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive  oxygen  species (ROS), which are capable of initiating and promoting carcinogenesis", "triple_list": [["including", "ANTAGONIST", "AKRs"]]}, {"text": "Despite the importance of  AKRs  in  PAHs  metabolism, there are no studies that evaluate, in general human populations, the effect of  PAHs  on  AKRs  expression in peripheral blood lymphocytes (PBLs)", "triple_list": [["PAHs", "DOWNREGULATOR", "are"]]}, {"text": " TZDs  also inhibited  alkaline phosphatase  activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031)", "triple_list": [["and", "PRODUCT-OF", "alkaline phosphatase"]]}, {"text": " TZDs  also inhibited alkaline phosphatase activity (58-75%, p<0.046) and  osteocalcin  production (52-75%, p<0.031)", "triple_list": [["TZDs", "ACTIVATOR", "production"]]}, {"text": " TZD  effects on osteoblast viability, oleic acid uptake, alkaline phosphatase and osteocalcin production are independent of their effects on  aromatase  ", "triple_list": [["on", "ACTIVATOR", "aromatase"]]}, {"text": "We have previously reported that  TZDs  reduce estrogen synthesis by inhibiting  aromatase  activity in human granulosa cells (HGC)", "triple_list": [["TZDs", "ANTAGONIST", "(HGC)"]]}, {"text": "We studied mouse osteoblasts alone or in a co-culture with HGC to determine whether  TZD  inhibition of  aromatase  plays a role in their effects on bone metabolism", "triple_list": [["TZD", "ANTAGONIST", "or"]]}, {"text": "We have previously reported that TZDs reduce  estrogen  synthesis by inhibiting  aromatase  activity in human granulosa cells (HGC)", "triple_list": [["estrogen", "AGONIST", "by"]]}, {"text": "The ultimate carcinogenic Phase I BP metabolite anti-BP-7,8-dihydrodiol-9,10-epoxide (BPDE) can be detoxified by  glutathione  conjugate formation catalyzed by  glutathione  S-transferases  In the present study, differentiated human intestinal Caco-2 cells were used as a model for the human small intestine to investigate the detoxification of BPDE and excretion of stereoisomeric  glutathione  conjugates in the presence of an inhibitor of the  glutathione -cleaving enzyme \u03b3-glutamyl transpeptidase at the cell surface", "triple_list": [["glutathione", "ANTAGONIST", "Caco-2"]]}, {"text": " Multidrug resistance-associated proteins  are involved in the transport of the  glutathione  conjugates of the ultimate carcinogen of benzo[a]pyrene in human Caco-2 cells", "triple_list": [["glutathione", "DOWNREGULATOR", "proteins"]]}, {"text": "Inhibition studies revealed that the  multidrug resistance-associated proteins  (ABCCs) are involved in the transport of  BPDE glutathione  conjugates", "triple_list": [["BPDE glutathione", "ACTIVATOR", "glutathione"]]}, {"text": "Inhibition studies revealed that the multidrug resistance-associated proteins ( ABCCs   are involved in the transport of  BPDE glutathione  conjugates", "triple_list": [["BPDE glutathione", "ACTIVATOR", "proteins"]]}, {"text": "Stable  ABCC1   ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that  ABCC1  mediates the basolateral and ABCC2 the apical excretion of  BPDE glutathione  conjugates", "triple_list": [["BPDE glutathione", "ANTAGONIST", "mediates"]]}, {"text": "Stable ABCC1,  ABCC2  and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and  ABCC2  the apical excretion of  BPDE glutathione  conjugates", "triple_list": [["to", "ACTIVATOR", "ABCC2"]]}, {"text": "Stable  ABCC1 , ABCC2 and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that  ABCC1  mediates the basolateral and ABCC2 the apical excretion of  BPDE glutathione  conjugates", "triple_list": [["demonstrate", "ACTIVATOR", "ABCC1"]]}, {"text": "Stable ABCC1,  ABCC2  and ABCC3 knockdown cell lines were generated, thus making it possible to demonstrate that ABCC1 mediates the basolateral and  ABCC2  the apical excretion of  BPDE glutathione  conjugates", "triple_list": [["that", "DOWNREGULATOR", "ABCC2"]]}, {"text": " \u03b1-Amino-\u03b1\u00b4-Halomethylketones   Synthetic Methodologies and Pharmaceutical Applications as  Serine and Cysteine Protease  Inhibitors", "triple_list": [["\u03b1-Amino-\u03b1\u00b4-Halomethylketones", "ANTAGONIST", "Protease"]]}, {"text": "Phosphorylation of  AMPK  at Thr172 increased by 1.4-fold within 5 min, and remained elevated throughout a 30-min time course, in response to  2-deoxyglucose   Global rates of protein synthesis declined by 78% of control values", "triple_list": [["2-deoxyglucose", "PRODUCT-OF", "response"]]}, {"text": "Phosphorylation of ER-stress marker  eIF2\u03b1  was also increased but only at 30 min of  2-deoxyglucose  exposure", "triple_list": [["was", "PRODUCT-OF", "eIF2\u03b1"]]}, {"text": " 2-Deoxyglucose  increased phosphorylation of tuberous sclerosis complex 2 ( TSC2 ) on AMPK consensus sites but did not change the amount of TSC1 bound to  TSC2   Activation of AMPK did not result in changes in the amount of raptor bound to mTOR", "triple_list": [["TSC2", "DOWNREGULATOR", "TSC2"]]}, {"text": " 2-Deoxyglucose  increased phosphorylation of  tuberous sclerosis complex 2  (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2", "triple_list": [["consensus", "ANTAGONIST", "tuberous sclerosis complex 2"]]}, {"text": " 2-Deoxyglucose  increased phosphorylation of tuberous sclerosis complex 2 ( TSC2   on AMPK consensus sites but did not change the amount of TSC1 bound to  TSC2 ", "triple_list": [["not", "PRODUCT-OF", "TSC2"]]}, {"text": " 2-Deoxyglucose  increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on  AMPK  consensus sites but did not change the amount of TSC1 bound to TSC2", "triple_list": [["2-Deoxyglucose", "PRODUCT-OF", "2"]]}, {"text": "Exposure to  Cu  NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of lactate dehydrogenase, intracellular reactive oxygen species and  interleukin-8  that mirrored our findings from subacute in vivo inhalation studies in mice", "triple_list": [["Cu", "DOWNREGULATOR", "(p<0.01)"]]}, {"text": "Exposure to  Cu  NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of  lactate dehydrogenase   intracellular reactive oxygen species and interleukin-8 that mirrored our findings from subacute in vivo inhalation studies in mice", "triple_list": [["Cu", "AGONIST", "(p<0.01)"]]}, {"text": " Leukotriene D4  induces cognitive impairment through enhancement of  CysLT\u2081 R  mediated amyloid-\u03b2 generation in mice", "triple_list": [["in", "ANTAGONIST", "CysLT\u2081 R"]]}, {"text": " Leukotriene D4  induces cognitive impairment through enhancement of CysLT\u2081 R-mediated  amyloid-\u03b2  generation in mice", "triple_list": [["amyloid-\u03b2", "PRODUCT-OF", "amyloid-\u03b2"]]}, {"text": "Moreover,  LTD4  induced increases in  CysLT(1)R  and NF-\u03baB p65 in the brain were also attenuated by pranlukast", "triple_list": [["LTD4", "PRODUCT-OF", "in"]]}, {"text": "Moreover,  LTD4  induced increases in CysLT(1)R and  NF-\u03baB  p65 in the brain were also attenuated by pranlukast", "triple_list": [["increases", "ANTAGONIST", "NF-\u03baB"]]}, {"text": "Moreover,  LTD4  induced increases in CysLT(1)R and NF-\u03baB  p65  in the brain were also attenuated by pranlukast", "triple_list": [["LTD4", "DOWNREGULATOR", "p65"]]}, {"text": "These results suggest that  LTD4  increases  A\u03b2 peptide  burden via activation of CysLT(1)R, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway", "triple_list": [["CysLT(1)R,", "DOWNREGULATOR", "A\u03b2 peptide"]]}, {"text": "These results suggest that  LTD4  increases A\u03b2 peptide burden via activation of  CysLT(1)R   which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway", "triple_list": [["LTD4", "PRODUCT-OF", "of"]]}, {"text": "The results demonstrated that intracerebral infusions of  LTD4  (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of  A\u03b21-40  and A\u03b21-42 in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of amyloid precursor protein (APP)", "triple_list": [["LTD4", "DOWNREGULATOR", "The"]]}, {"text": "The results demonstrated that intracerebral infusions of  LTD4  (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A\u03b21-40 and  A\u03b21-42  in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of amyloid precursor protein (APP)", "triple_list": [["memory", "DOWNREGULATOR", "A\u03b21-42"]]}, {"text": "The results demonstrated that intracerebral infusions of  LTD4  (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A\u03b21-40 and A\u03b21-42 in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of  amyloid precursor protein  (APP)", "triple_list": [["LTD4", "AGONIST", "that"]]}, {"text": "The results demonstrated that intracerebral infusions of  LTD4  (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A\u03b21-40 and A\u03b21-42 in the hippocampus and cortex through increased activity of \u03b2- and \u03b3-secretases accompanied with increased expression of amyloid precursor protein ( APP  ", "triple_list": [["LTD4", "PRODUCT-OF", "A\u03b21-40"]]}, {"text": " LTD4  also induced expression of  cysteinyl leukotriene receptor 1  (CysLT(1)R) and NF-\u03baB p65 in the hippocampus and cortex", "triple_list": [["LTD4", "ANTAGONIST", "leukotriene"]]}, {"text": " LTD4  also induced expression of cysteinyl leukotriene receptor 1 ( CysLT(1)R   and NF-\u03baB p65 in the hippocampus and cortex", "triple_list": [["LTD4", "AGONIST", "and"]]}, {"text": " LTD4  also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and  NF-\u03baB  p65 in the hippocampus and cortex", "triple_list": [["LTD4", "PRODUCT-OF", "the"]]}, {"text": " LTD4  also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and NF-\u03baB  p65  in the hippocampus and cortex", "triple_list": [["induced", "PRODUCT-OF", "p65"]]}, {"text": "Moreover, LTD4-induced increases in  CysLT(1)R  and NF-\u03baB p65 in the brain were also attenuated by  pranlukast   These results suggest that LTD4 increases A\u03b2 peptide burden via activation of  CysLT(1)R , which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway", "triple_list": [["pranlukast", "PRODUCT-OF", "Moreover,"]]}, {"text": "Moreover, LTD4-induced increases in CysLT(1)R and  NF-\u03baB  p65 in the brain were also attenuated by  pranlukast   These results suggest that LTD4 increases A\u03b2 peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the  NF-\u03baB  pathway", "triple_list": [["of", "ANTAGONIST", "NF-\u03baB"]]}, {"text": "Moreover, LTD4-induced increases in CysLT(1)R and NF-\u03baB  p65  in the brain were also attenuated by  pranlukast   These results suggest that LTD4 increases A\u03b2 peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of \u03b2- and \u03b3-secretases via the NF-\u03baB pathway", "triple_list": [["and", "AGONIST", "p65"]]}, {"text": "Pretreatment with  pranlukast  (1.5 ng/mouse, intracerebroventricularly), a  CysLT(1)R  antagonist, blocked LTD4-induced amyloidogenesis, memory deficits", "triple_list": [["with", "PRODUCT-OF", "CysLT(1)R"]]}, {"text": "Although the treatment with  MSG  increased IRS-1 tyrosine phosphorylation ( pIRS-1   by 96\u00a0% ( MSG , 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1;  MSG , 22.2\u00a0\u00b1\u00a01.1\u00a0a.u.)", "triple_list": [["also", "DOWNREGULATOR", "pIRS-1"]]}, {"text": "Although the treatment with  MSG  increased IRS-1 tyrosine phosphorylation ( pIRS-1   by 96\u00a0% ( MSG   17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1;  MSG , 22.2\u00a0\u00b1\u00a01.1\u00a0a.u.)", "triple_list": [["17.02", "AGONIST", "pIRS-1"]]}, {"text": "Although the treatment with  MSG  increased IRS-1 tyrosine phosphorylation ( pIRS-1   by 96\u00a0% ( MSG , 17.02\u00a0\u00b1\u00a00.6; control, 8.7\u00a0\u00b1\u00a00.2\u00a0a.u.), exercise training also increased it in both groups (control, 13.6\u00a0\u00b1\u00a00.1;  MSG   22.2\u00a0\u00b1\u00a01.1\u00a0a.u.)", "triple_list": [["MSG", "AGONIST", "increased"]]}, {"text": "The results showed that IR tyrosine phosphorylation ( pIR   was reduced by 42\u00a0% in  MSG -obese mice ( MSG , 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased  pIR  by 76\u00a0% in  MSG  mice without affecting control mice ( MSG   11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)", "triple_list": [["MSG", "PRODUCT-OF", "training"]]}, {"text": "The results showed that IR tyrosine phosphorylation ( pIR ) was reduced by 42\u00a0% in  MSG -obese mice ( MSG , 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased  pIR  by 76\u00a0% in  MSG  mice without affecting control mice ( MSG   11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)", "triple_list": [["results", "ANTAGONIST", "pIR"]]}, {"text": "The results showed that IR tyrosine phosphorylation ( pIR   was reduced by 42\u00a0% in  MSG  obese mice ( MSG , 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased  pIR  by 76\u00a0% in  MSG  mice without affecting control mice ( MSG , 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)", "triple_list": [["MSG", "AGONIST", "0.3;"]]}, {"text": "The results showed that IR tyrosine phosphorylation ( pIR ) was reduced by 42\u00a0% in  MSG  obese mice ( MSG , 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased  pIR  by 76\u00a0% in  MSG  mice without affecting control mice ( MSG , 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)", "triple_list": [["MSG", "ANTAGONIST", "pIR"]]}, {"text": "The results showed that IR tyrosine phosphorylation ( pIR   was reduced by 42\u00a0% in  MSG -obese mice ( MSG   6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased  pIR  by 76\u00a0% in  MSG  mice without affecting control mice ( MSG , 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)", "triple_list": [["control,", "AGONIST", "pIR"]]}, {"text": "The results showed that IR tyrosine phosphorylation ( pIR ) was reduced by 42\u00a0% in  MSG -obese mice ( MSG   6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased  pIR  by 76\u00a0% in  MSG  mice without affecting control mice ( MSG , 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)", "triple_list": [["MSG", "PRODUCT-OF", "showed"]]}, {"text": "The results showed that IR tyrosine phosphorylation ( pIR   was reduced by 42\u00a0% in  MSG -obese mice ( MSG , 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased  pIR  by 76\u00a0% in  MSG  mice without affecting control mice ( MSG , 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)", "triple_list": [["(", "AGONIST", "pIR"]]}, {"text": "The results showed that IR tyrosine phosphorylation ( pIR ) was reduced by 42\u00a0% in  MSG -obese mice ( MSG , 6.7\u00a0\u00b1\u00a00.2\u00a0arbitrary units (a.u.); control, 11.5\u00a0\u00b1\u00a00.4\u00a0a.u.); on the other hand, exercise training increased  pIR  by 76\u00a0% in  MSG  mice without affecting control mice ( MSG , 11.8\u00a0\u00b1\u00a00.3; control, 12.8\u00a0\u00b1\u00a00.2\u00a0a.u.)", "triple_list": [["tyrosine", "AGONIST", "pIR"]]}, {"text": "The obtained results showed that  pioglitazone  improved the renal function, structural changes, renal malondialdehyde (MDA),  tumor necrosis factor alpha  (TNF-\u03b1), nuclear factor kappa B (NF-\u03baB) genes expression in cisplatin injected rats", "triple_list": [["pioglitazone", "DOWNREGULATOR", "changes,"]]}, {"text": "The obtained results showed that  pioglitazone  improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha ( TNF-\u03b1  , nuclear factor kappa B (NF-\u03baB) genes expression in cisplatin injected rats", "triple_list": [["malondialdehyde", "PRODUCT-OF", "TNF-\u03b1"]]}, {"text": "The obtained results showed that  pioglitazone  improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1),  nuclear factor kappa B  (NF-\u03baB) genes expression in cisplatin injected rats", "triple_list": [["results", "AGONIST", "nuclear factor kappa B"]]}, {"text": "The obtained results showed that  pioglitazone  improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1), nuclear factor kappa B ( NF-\u03baB   genes expression in cisplatin injected rats", "triple_list": [["pioglitazone", "AGONIST", "results"]]}, {"text": "The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA),  tumor necrosis factor alpha  (TNF-\u03b1), nuclear factor kappa B (NF-\u03baB) genes expression in  cisplatin  injected rats", "triple_list": [["cisplatin", "ACTIVATOR", "renal"]]}, {"text": "The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha ( TNF-\u03b1  , nuclear factor kappa B (NF-\u03baB) genes expression in  cisplatin  injected rats", "triple_list": [["tumor", "ANTAGONIST", "TNF-\u03b1"]]}, {"text": "The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1),  nuclear factor kappa B  (NF-\u03baB) genes expression in  cisplatin  injected rats", "triple_list": [["cisplatin", "AGONIST", "nuclear"]]}, {"text": "The obtained results showed that pioglitazone improved the renal function, structural changes, renal malondialdehyde (MDA), tumor necrosis factor alpha (TNF-\u03b1), nuclear factor kappa B ( NF-\u03baB   genes expression in  cisplatin  injected rats", "triple_list": [["rats", "PRODUCT-OF", "NF-\u03baB"]]}, {"text": "The results showed that  wogonoside  promotes the expression of  LC3-II  and Beclin-1", "triple_list": [["expression", "PRODUCT-OF", "LC3-II"]]}, {"text": "The results showed that  wogonoside  promotes the expression of LC3-II and  Beclin-1   Furthermore,  wogonoside  inhibited cell growth of MDA-MB-231 cells in a concentration- and time-dependent manner, which was associated with  wogonoside -induced autophagy", "triple_list": [["wogonoside", "PRODUCT-OF", "Beclin-1"]]}, {"text": " Wogonoside  also suppressed the activation of mammalian target of rapamycin (mTOR) and  p70-S6 kinase  (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway", "triple_list": [["Wogonoside", "ANTAGONIST", "the"]]}, {"text": " Wogonoside  also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase ( p70S6K)  by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway", "triple_list": [["suppressed", "ACTIVATOR", "p70S6K)"]]}, {"text": " Wogonoside  also suppressed the activation of  mammalian target of rapamycin  (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway", "triple_list": [["Wogonoside", "ACTIVATOR", "protein"]]}, {"text": " Wogonoside  also suppressed the activation of mammalian target of rapamycin ( mTOR   and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway", "triple_list": [["Wogonoside", "AGONIST", "(p70S6K)"]]}, {"text": "At a low pH (pH 7.4), but not pH 7.9,  ifenprodil  reduces the mean open time of  GluN1  GluN2B receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.", "triple_list": [["ifenprodil", "ACTIVATOR", "which"]]}, {"text": "At a low pH (pH 7.4), but not pH 7.9,  ifenprodil  reduces the mean open time of GluN1/ GluN2B  receptors, which may be responsible for its usefulness as a context-dependent inhibitor in conditions like ischemia and stroke, when the pH of the extracellular milieu becomes acidic.", "triple_list": [["ifenprodil", "ANTAGONIST", "for"]]}, {"text": "Also,  SB365  showed anti-angiogenic activity by decreasing the expression of  HIF-1\u03b1  and VEGF", "triple_list": [["SB365", "AGONIST", "Also,"]]}, {"text": "Also,  SB365  showed anti-angiogenic activity by decreasing the expression of HIF-1\u03b1 and  VEGF   These results were confirmed by an in vivo study showing that  SB365  significantly inhibited tumor growth by the induction of apoptosis and inhibition of angiogenesis with stronger anticancer activity than 5-FU", "triple_list": [["SB365", "ACTIVATOR", "VEGF"]]}, {"text": "When further examined for its anticancer mechanism,  SB365  effectively suppressed the  AKT  mTOR pathway both in vitro and in vivo", "triple_list": [["SB365", "AGONIST", "SB365"]]}, {"text": "When further examined for its anticancer mechanism,  SB365  effectively suppressed the AKT/ mTOR  pathway both in vitro and in vivo", "triple_list": [["mTOR", "AGONIST", "mTOR"]]}, {"text": "Taken together, our study demonstrated that  SB365  inhibits the  AKT  mTOR pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis", "triple_list": [["SB365", "ANTAGONIST", "together"]]}, {"text": "Taken together, our study demonstrated that  SB365  inhibits the AKT/ mTOR  pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis", "triple_list": [["SB365", "ACTIVATOR", "to"]]}, {"text": "In further studies, the diuretic effects of the  CB1  agonist  AM4054  were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]", "triple_list": [["the", "ANTAGONIST", "CB1"]]}, {"text": "In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of  WIN 55,212  antagonized by the  CB2  antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]", "triple_list": [["receptor", "PRODUCT-OF", "CB2"]]}, {"text": "Direct-acting  CB1  agonists, including  \u0394(9)-tetrahydrocannabinol   WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia", "triple_list": [["\u0394(9)-tetrahydrocannabinol", "PRODUCT-OF", "diuresis"]]}, {"text": "Direct-acting  CB1  agonists, including \u0394(9)-tetrahydrocannabinol,  WIN 55,212  [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia", "triple_list": [["WIN 55,212", "PRODUCT-OF", "lower"]]}, {"text": "Direct-acting  CB1  agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [ R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate  , AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia", "triple_list": [["R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate", "ACTIVATOR", "mesylate"]]}, {"text": "Direct-acting  CB1  agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate],  AM2389  [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia", "triple_list": [["AM2389", "PRODUCT-OF", "mesylate],"]]}, {"text": "Direct-acting  CB1  agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [ 9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol  , and AM4054 [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia", "triple_list": [["dose-dependent", "PRODUCT-OF", "CB1"]]}, {"text": "Direct-acting  CB1  agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and  AM4054  [9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia", "triple_list": [["AM4054", "ACTIVATOR", "agonists,"]]}, {"text": "Direct-acting  CB1  agonists, including \u0394(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [ 9\u03b2-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol  , produced dose-dependent increases in diuresis and decreases in colonic temperature, with slightly lower ED(50) values for diuresis than for hypothermia", "triple_list": [["55,212", "DOWNREGULATOR", "CB1"]]}, {"text": "Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the  CB2  agonist  AM1241  [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects", "triple_list": [["and", "ACTIVATOR", "CB2"]]}, {"text": "Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the  CB2  agonist AM1241 [ 1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole  , the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects", "triple_list": [["lesser", "ANTAGONIST", "CB2"]]}, {"text": "Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the  CB2  agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor  AM404   and the CB antagonist rimonabant did not have diuretic effects", "triple_list": [["had", "PRODUCT-OF", "CB2"]]}, {"text": "In further studies, the diuretic effects of the  CB1  agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with  rimonabant   but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]", "triple_list": [["rimonabant", "DOWNREGULATOR", "similar"]]}, {"text": "In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the  vanilloid receptor type I  antagonist  capsazepine   nor were the effects of WIN 55,212 antagonized by the CB2 antagonist AM630 [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]", "triple_list": [["capsazepine", "AGONIST", "not"]]}, {"text": "In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the  CB2  antagonist  AM630  [(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)]", "triple_list": [["similar", "AGONIST", "CB2"]]}, {"text": "In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the effects of WIN 55,212 antagonized by the  CB2  antagonist AM630 [ (6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)  ", "triple_list": [["(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) methanone)", "ACTIVATOR", "effects"]]}, {"text": " NaAsO(2)  increased the mRNA levels of the  light and medium subunits of neurofilament  and decreased the mRNA levels of tau and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin", "triple_list": [["was", "DOWNREGULATOR", "light and medium subunits of neurofilament"]]}, {"text": " NaAsO(2)  increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of  tau  and tubulin in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin", "triple_list": [["NaAsO(2)", "AGONIST", "in"]]}, {"text": " NaAsO(2)  increased the mRNA levels of the light and medium subunits of neurofilament and decreased the mRNA levels of tau and  tubulin  in a dose-dependent manner; no significant effect was found in the mRNA levels of the heavy subunit of neurofilament, microtubule-associated protein 2, or actin", "triple_list": [["NaAsO(2)", "ACTIVATOR", "of"]]}, {"text": " DBDCT  up-regulated the expression of  Bax , down-regulated the expression of Bcl-2, and significantly increased the ratio of  Bax  Bcl-2", "triple_list": [["DBDCT", "PRODUCT-OF", "Bcl-2"]]}, {"text": " DBDCT  up-regulated the expression of Bax, down-regulated the expression of  Bcl-2 , and significantly increased the ratio of Bax/ Bcl-2    DBDCT  also caused the phosphorylation of JNK and p38(MAPK)", "triple_list": [["expression", "ANTAGONIST", "Bcl-2"]]}, {"text": " DBDCT  up-regulated the expression of  Bax   down-regulated the expression of Bcl-2, and significantly increased the ratio of  Bax /Bcl-2", "triple_list": [["Bcl-2,", "AGONIST", "Bax"]]}, {"text": " DBDCT  also caused the phosphorylation of  JNK  and p38(MAPK)", "triple_list": [["caused", "ANTAGONIST", "JNK"]]}, {"text": " DBDCT  also caused the phosphorylation of JNK and  p38  MAPK)", "triple_list": [["DBDCT", "PRODUCT-OF", "p38"]]}, {"text": " DBDCT  also caused the phosphorylation of JNK and p38( MAPK  ", "triple_list": [["MAPK", "PRODUCT-OF", "MAPK"]]}, {"text": " DBDCT  up-regulated the expression of Bax, down-regulated the expression of  Bcl-2   and significantly increased the ratio of Bax/ Bcl-2 ", "triple_list": [["Bax,", "ACTIVATOR", "Bcl-2"]]}, {"text": "The results show that CYP2E1 inhibits  CYP2B4  mediated metabolism of  benzphetamine  (BNZ) with a K(i) of 0.04 \u00b5M", "triple_list": [["(BNZ)", "DOWNREGULATOR", "CYP2B4"]]}, {"text": "The results show that CYP2E1 inhibits  CYP2B4  mediated metabolism of benzphetamine ( BNZ   with a K(i) of 0.04 \u00b5M", "triple_list": [["BNZ", "ANTAGONIST", "BNZ"]]}, {"text": "However, CYP2B4 is not an inhibitor of  CYP2E1  mediated  p-nitrophenol  hydroxylation", "triple_list": [["p-nitrophenol", "ANTAGONIST", "hydroxylation"]]}, {"text": "Based on these studies, the frequency of spontaneous tail contractions at 26 hpf - a developmental stage with minimal  AChE  expression and activity - was significantly higher following exposure to  paraoxon  concentrations as low as 31.2 nM", "triple_list": [["paraoxon", "ANTAGONIST", "spontaneous"]]}, {"text": "We then showed that static exposure of embryos to  paraoxon  (31.2-500 nM) from 5 to 96 hpf resulted in significant stage- and concentration-dependent  AChE  inhibition, albeit these effects were fully reversible within 48 h following transfer to clean water", "triple_list": [["paraoxon", "ACTIVATOR", "AChE"]]}, {"text": "Using  paraoxon  as a reference  acetylcholinesterase  (AChE) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis", "triple_list": [["of", "PRODUCT-OF", "acetylcholinesterase"]]}, {"text": "Using  paraoxon  as a reference acetylcholinesterase ( AChE   inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis", "triple_list": [["inhibitor,", "AGONIST", "AChE"]]}, {"text": "The mRNA levels of  microphthalmia-associated transcription factor  (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by  artemisinic acid  treatment", "triple_list": [["artemisinic acid", "ANTAGONIST", "protein"]]}, {"text": "The mRNA levels of microphthalmia-associated transcription factor ( MITF   and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by  artemisinic acid  treatment", "triple_list": [["artemisinic acid", "ANTAGONIST", "its"]]}, {"text": "The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes  tyrosinase    tyrosinase -related protein (TRP)-1, and TRP-2 were reduced by  artemisinic acid  treatment", "triple_list": [["artemisinic acid", "ACTIVATOR", "downstream"]]}, {"text": "The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase,  tyrosinase-related protein (TRP)-1   and TRP-2 were reduced by  artemisinic acid  treatment", "triple_list": [["tyrosinase,", "ACTIVATOR", "tyrosinase-related protein (TRP)-1"]]}, {"text": "The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and  TRP-2  were reduced by  artemisinic acid  treatment", "triple_list": [["artemisinic acid", "ACTIVATOR", "by"]]}, {"text": "Additionally, the mRNA levels of melanogenesis-related genes ( c-KIT   stem cell factor (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by  artemisinic acid   Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by  artemisinic acid ", "triple_list": [["artemisinic acid", "ANTAGONIST", "Furthermore,"]]}, {"text": "Additionally, the mRNA levels of melanogenesis-related genes (c-KIT,  stem cell factor  (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by  artemisinic acid   Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by  artemisinic acid ", "triple_list": [["artemisinic acid", "ACTIVATOR", "suppressed"]]}, {"text": "Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor ( SCF  , and macrophage migration inhibitory factor (MIF)) were down-regulated by  artemisinic acid   Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by  artemisinic acid ", "triple_list": [["mRNA", "AGONIST", "SCF"]]}, {"text": "Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and  macrophage migration inhibitory factor  (MIF)) were down-regulated by  artemisinic acid   Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by  artemisinic acid ", "triple_list": [["artemisinic acid", "AGONIST", "of"]]}, {"text": "Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and macrophage migration inhibitory factor ( MIF  ) were down-regulated by  artemisinic acid   Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by  artemisinic acid ", "triple_list": [["artemisinic acid", "ANTAGONIST", "of"]]}, {"text": "Furthermore, cAMP production and  protein kinase A  (PKA) activity were suppressed by  artemisinic acid   Moreover, attempts to elucidate a possible mechanism underlying the  artemisinic acid -mediated effects revealed that  artemisinic acid  regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) \u03b1 gene", "triple_list": [["artemisinic acid", "ACTIVATOR", "of"]]}, {"text": "Furthermore, cAMP production and protein kinase A ( PKA   activity were suppressed by  artemisinic acid   Moreover, attempts to elucidate a possible mechanism underlying the  artemisinic acid -mediated effects revealed that  artemisinic acid  regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) \u03b1 gene", "triple_list": [["artemisinic acid", "AGONIST", "synthesis"]]}, {"text": "Moreover, attempts to elucidate a possible mechanism underlying the  artemisinic acid -mediated effects revealed that  artemisinic acid  regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the  hydroxymethylglutaryl CoA (HMG CoA) reductase  gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) \u03b1 gene", "triple_list": [["possible", "ANTAGONIST", "hydroxymethylglutaryl CoA (HMG CoA) reductase"]]}, {"text": "Moreover, attempts to elucidate a possible mechanism underlying the  artemisinic acid -mediated effects revealed that  artemisinic acid  regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the  CCAAT/enhancer-binding protein (C/EBP) \u03b1  gene", "triple_list": [["the", "ACTIVATOR", "CCAAT/enhancer-binding protein (C/EBP) \u03b1"]]}, {"text": " Artemisinic acid  inhibits melanogenesis through downregulation of  C/EBP \u03b1  dependent expression of HMG-CoA reductase gene", "triple_list": [["Artemisinic acid", "ANTAGONIST", "acid"]]}, {"text": " Artemisinic acid  inhibits melanogenesis through downregulation of C/EBP \u03b1-dependent expression of  HMG-CoA reductase  gene", "triple_list": [["Artemisinic acid", "PRODUCT-OF", "inhibits"]]}, {"text": "Taken together, these findings indicate that the inhibition of melanogenesis by  artemisinic acid  occurs through reduced expression of the  HMG CoA reductase  gene, which is mediated by C/EBP \u03b1 inhibition and suggest that  artemisinic acid  may be useful as a hyperpigmentation inhibitor.", "triple_list": [["inhibition", "ACTIVATOR", "HMG CoA reductase"]]}, {"text": "Taken together, these findings indicate that the inhibition of melanogenesis by  artemisinic acid  occurs through reduced expression of the HMG CoA reductase gene, which is mediated by  C/EBP \u03b1  inhibition and suggest that  artemisinic acid  may be useful as a hyperpigmentation inhibitor.", "triple_list": [["inhibition", "PRODUCT-OF", "C/EBP \u03b1"]]}, {"text": "8-pCPT-2'-O-Me-cAMP-AM potentiation of  insulin  secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor  bisindolylmaleimide I  (1 \u03bcM)", "triple_list": [["PKC", "AGONIST", "insulin"]]}, {"text": "Our data demonstrate that the actions of both tolbutamide and  gliclazide  are strongly potentiated by 8-pCPT-2'-O-Me-cAMP-AM, that  gliclazide  can stimulate  phospholipase C  activity via a partially pertussis toxin-sensitive mechanism, and that 8-pCPT-2'-O-Me-cAMP-AM potentiation of tolbutamide action may involve activation of a 2-APB-sensitive Ca(2+) influx.", "triple_list": [["gliclazide", "ANTAGONIST", "gliclazide"]]}, {"text": " Tolbutamide  and gliclazide block the K(ATP) channel K(ir)6.2/Sur1, causing membrane depolarization and stimulating  insulin  secretion in pancreatic beta cells", "triple_list": [["block", "ANTAGONIST", "insulin"]]}, {"text": " Insulin  secretion stimulated by both 200 \u03bcM  tolbutamide  and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells", "triple_list": [["tolbutamide", "AGONIST", "\u03bcM"]]}, {"text": " Insulin  secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM  gliclazide   concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells", "triple_list": [["gliclazide", "ANTAGONIST", "membrane"]]}, {"text": " Insulin  secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by  8-pCPT-2'-O-Me-cAMP-AM  at concentrations \u22652 \u03bcM in INS-1 cells", "triple_list": [["8-pCPT-2'-O-Me-cAMP-AM", "DOWNREGULATOR", "potentiated"]]}, {"text": "Both  tolbutamide  and gliclazide stimulated  phospholipase C  activity; however, only gliclazide did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin", "triple_list": [["independently", "AGONIST", "phospholipase C"]]}, {"text": "Both tolbutamide and  gliclazide  stimulated  phospholipase C  activity; however, only  gliclazide  did so independently of its activity at K(ATP) channels, and this activity was partially inhibited by pertussis toxin", "triple_list": [["gliclazide", "DOWNREGULATOR", "activity"]]}, {"text": "Both tolbutamide and  gliclazide  stimulated phospholipase C activity; however, only  gliclazide  did so independently of its activity at  K(ATP) channels   and this activity was partially inhibited by pertussis toxin", "triple_list": [["gliclazide", "ANTAGONIST", "tolbutamide"]]}, {"text": " 8-pCPT-2'-O-Me-cAMP-AM  potentiation of  insulin  secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM)", "triple_list": [["8-pCPT-2'-O-Me-cAMP-AM", "AGONIST", "\u03bcM)"]]}, {"text": "8-pCPT-2'-O-Me-cAMP-AM potentiation of  insulin  secretion stimulated by  tolbutamide  was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM)", "triple_list": [["(1", "AGONIST", "insulin"]]}, {"text": "8-pCPT-2'-O-Me-cAMP-AM potentiation of insulin secretion stimulated by tolbutamide was markedly inhibited by 2-APB (25 \u03bcM) and enhanced by the  PKC  inhibitor  bisindolylmaleimide I  (1 \u03bcM)", "triple_list": [["by", "PRODUCT-OF", "PKC"]]}, {"text": " Tolbutamide  and gliclazide block the  K(ATP) channel  K(ir)6.2/Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells", "triple_list": [["and", "ACTIVATOR", "K(ATP) channel"]]}, {"text": " Tolbutamide  and gliclazide block the K(ATP) channel  K(ir)6.2  Sur1, causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells", "triple_list": [["Tolbutamide", "ANTAGONIST", "the"]]}, {"text": " Tolbutamide  and gliclazide block the K(ATP) channel K(ir)6.2/ Sur1   causing membrane depolarization and stimulating insulin secretion in pancreatic beta cells", "triple_list": [["Tolbutamide", "ACTIVATOR", "K(ir)6.2/"]]}, {"text": " Insulin  secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by  thapsigargin  (1 \u03bcM) or the L-type Ca(2+) channel blocker nicardipine (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells", "triple_list": [["thapsigargin", "AGONIST", "concentrations"]]}, {"text": " Insulin  secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the L-type Ca(2+) channel blocker  nicardipine  (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells", "triple_list": [["nicardipine", "ANTAGONIST", "by"]]}, {"text": "Insulin secretion stimulated by both 200 \u03bcM tolbutamide and 20 \u03bcM gliclazide, concentrations that had equivalent effects on membrane potential, was inhibited by thapsigargin (1 \u03bcM) or the  L-type Ca(2+) channel  blocker  nicardipine  (2 \u03bcM) and was potentiated by 8-pCPT-2'-O-Me-cAMP-AM at concentrations \u22652 \u03bcM in INS-1 cells", "triple_list": [["had", "ANTAGONIST", "L-type Ca(2+) channel"]]}, {"text": "8-pCPT-2'-O-Me-cAMP-AM potentiation of  insulin  secretion stimulated by tolbutamide was markedly inhibited by  2-APB  (25 \u03bcM) and enhanced by the PKC inhibitor bisindolylmaleimide I (1 \u03bcM)", "triple_list": [["2-APB", "AGONIST", "insulin"]]}, {"text": "In addition, the number and area of  glutathione S-transferase placental form  (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg  MEG  compared with the control animals", "triple_list": [["male", "ANTAGONIST", "glutathione S-transferase placental form"]]}, {"text": "In addition, the number and area of glutathione S-transferase placental form ( GST-P   positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg  MEG  compared with the control animals", "triple_list": [["rats", "ANTAGONIST", "GST-P"]]}, {"text": "In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and  proliferating cell nuclear antigen  (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg  MEG  compared with the control animals", "triple_list": [["rats", "AGONIST", "proliferating cell nuclear antigen"]]}, {"text": "In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and proliferating cell nuclear antigen ( PCNA   positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg  MEG  compared with the control animals", "triple_list": [["compared", "AGONIST", "PCNA"]]}, {"text": "Furthermore,  N  BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced  Bim  expression", "triple_list": [["N", "ANTAGONIST", "signal-regulated"]]}, {"text": "Furthermore, N- BPs  decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced  Bim  expression", "triple_list": [["BPs", "AGONIST", "Ras"]]}, {"text": "The present results indicated that  N  BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of  caspase-9  and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways", "triple_list": [["N", "DOWNREGULATOR", "apoptosis"]]}, {"text": "The present results indicated that  N  BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and  caspase-3   and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways", "triple_list": [["N", "AGONIST", "the"]]}, {"text": "The present results indicated that  N  BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing  Bim  expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways", "triple_list": [["N", "AGONIST", "of"]]}, {"text": "The present results indicated that N- BPs  induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of  caspase-9  and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways", "triple_list": [["BPs", "ANTAGONIST", "mitochondrial"]]}, {"text": "The present results indicated that N- BPs  induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and  caspase-3   and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways", "triple_list": [["BPs", "PRODUCT-OF", "BPs"]]}, {"text": "The present results indicated that N- BPs  induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing  Bim  expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways", "triple_list": [["BPs", "AGONIST", "results"]]}, {"text": " Nitrogen  containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and  Bim  mediated activation of the intrinsic apoptotic pathway", "triple_list": [["Nitrogen", "DOWNREGULATOR", "pathways"]]}, {"text": "Nitrogen-containing  bisphosphonates  induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and  Bim  mediated activation of the intrinsic apoptotic pathway", "triple_list": [["bisphosphonates", "AGONIST", "Ras"]]}, {"text": "Furthermore,  N  BPs decreased the levels of  phosphorylated extracellular signal-regulated kinase  (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression", "triple_list": [["N", "AGONIST", "the"]]}, {"text": "Furthermore,  N  BPs decreased the levels of phosphorylated extracellular signal-regulated kinase ( ERK   and mTOR via suppression of Ras prenylation and enhanced Bim expression", "triple_list": [["N", "ANTAGONIST", "Furthermore,"]]}, {"text": "Furthermore,  N  BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and  mTOR  via suppression of Ras prenylation and enhanced Bim expression", "triple_list": [["N", "ACTIVATOR", "BPs"]]}, {"text": "Furthermore,  N  BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of  Ras  prenylation and enhanced Bim expression", "triple_list": [["N", "ACTIVATOR", "(ERK)"]]}, {"text": "Furthermore, N- BPs  decreased the levels of  phosphorylated extracellular signal-regulated kinase  (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression", "triple_list": [["N-", "PRODUCT-OF", "phosphorylated extracellular signal-regulated kinase"]]}, {"text": "Furthermore, N- BPs  decreased the levels of phosphorylated extracellular signal-regulated kinase ( ERK   and mTOR via suppression of Ras prenylation and enhanced Bim expression", "triple_list": [["BPs", "ACTIVATOR", "Bim"]]}, {"text": "Furthermore, N- BPs  decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and  mTOR  via suppression of Ras prenylation and enhanced Bim expression", "triple_list": [["BPs", "AGONIST", "of"]]}, {"text": "Furthermore, N- BPs  decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of  Ras  prenylation and enhanced Bim expression", "triple_list": [["BPs", "ANTAGONIST", "N-"]]}, {"text": "The present results indicated that  N  BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the  Ras  MEK/ERK and  Ras /mTOR pathways", "triple_list": [["N", "PRODUCT-OF", "through"]]}, {"text": "The present results indicated that  N  BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/ MEK  ERK and Ras/mTOR pathways", "triple_list": [["N", "PRODUCT-OF", "of"]]}, {"text": "The present results indicated that  N  BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ ERK  and Ras/mTOR pathways", "triple_list": [["N", "AGONIST", "increasing"]]}, {"text": "The present results indicated that  N  BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the  Ras /MEK/ERK and  Ras  mTOR pathways", "triple_list": [["N", "ACTIVATOR", "the"]]}, {"text": "The present results indicated that  N  BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/ mTOR  pathways", "triple_list": [["of", "PRODUCT-OF", "mTOR"]]}, {"text": "The present results indicated that N- BPs  induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the  Ras  MEK/ERK and  Ras /mTOR pathways", "triple_list": [["BPs", "ACTIVATOR", "indicated"]]}, {"text": "The present results indicated that N- BPs  induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/ MEK  ERK and Ras/mTOR pathways", "triple_list": [["BPs", "ANTAGONIST", "present"]]}, {"text": "The present results indicated that N- BPs  induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ ERK  and Ras/mTOR pathways", "triple_list": [["BPs", "ANTAGONIST", "Ras/MEK/"]]}, {"text": "The present results indicated that N- BPs  induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the  Ras /MEK/ERK and  Ras  mTOR pathways", "triple_list": [["N-", "PRODUCT-OF", "Ras"]]}, {"text": "The present results indicated that N- BPs  induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/ mTOR  pathways", "triple_list": [["enhancing", "PRODUCT-OF", "mTOR"]]}, {"text": " Nitrogen  containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of  Ras  signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway", "triple_list": [["activation", "AGONIST", "Ras"]]}, {"text": "Nitrogen-containing  bisphosphonates  induce apoptosis of hematopoietic tumor cells via inhibition of  Ras  signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway", "triple_list": [["bisphosphonates", "ACTIVATOR", "intrinsic"]]}, {"text": " Nitrogen  containing bisphosphonates (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small  G-proteins   However, the details of the apoptosis-inducing mechanism remain obscure", "triple_list": [["of", "PRODUCT-OF", "G-proteins"]]}, {"text": "Nitrogen-containing  bisphosphonates  (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small  G-proteins   However, the details of the apoptosis-inducing mechanism remain obscure", "triple_list": [["bisphosphonates", "PRODUCT-OF", "induce"]]}, {"text": " N itrogen-containing bisphosphonates ( N  BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small  G-proteins   However, the details of the apoptosis-inducing mechanism remain obscure", "triple_list": [["N", "ANTAGONIST", "tumor"]]}, {"text": "Nitrogen-containing bisphosphonates (N- BPs   induce apoptosis in tumor cells by inhibiting the prenylation of small  G-proteins   However, the details of the apoptosis-inducing mechanism remain obscure", "triple_list": [["of", "ANTAGONIST", "G-proteins"]]}, {"text": "Although both intracellular and membrane  Cx43  pools were markedly reduced in cells released from contact inhibition by  TCDD   siRNA-mediated  Cx43  knock-down was not sufficient to stimulate proliferation in contact-inhibited cells", "triple_list": [["TCDD", "AGONIST", "contact-inhibited"]]}, {"text": "Although both intracellular and membrane  Cx43  pools were markedly reduced in cells released from contact inhibition by  TCDD   siRNA-mediated  Cx43  knock-down was not sufficient to stimulate proliferation in contact-inhibited cells", "triple_list": [["TCDD", "PRODUCT-OF", "not"]]}, {"text": "Disruption of contact inhibition, which was induced by toxic AhR ligands  2,3,7,8-tetrachlorodibenzo-p-dioxin  (TCDD) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced  Cx43  protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner", "triple_list": [["Cx43", "ACTIVATOR", "Cx43"]]}, {"text": "Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin ( TCDD   or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced  Cx43  protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner", "triple_list": [["TCDD", "PRODUCT-OF", "in"]]}, {"text": "Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or  polycyclic aromatic hydrocarbons  in epithelial WB-F344 cells, reduced  Cx43  protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner", "triple_list": [["an", "PRODUCT-OF", "Cx43"]]}, {"text": "The pretreatment with 20\u00a0mg\u2009L(-1)  La(III)  could alleviate the effects of UV-B radiation on the activities of  nitrate reductase   glutamine synthetase, glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings", "triple_list": [["La(III)", "ANTAGONIST", "20"]]}, {"text": "The pretreatment with 20\u00a0mg\u2009L(-1)  La(III)  could alleviate the effects of UV-B radiation on the activities of nitrate reductase,  glutamine synthetase   glutamate synthase, and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings", "triple_list": [["effects", "PRODUCT-OF", "glutamine synthetase"]]}, {"text": "The pretreatment with 20\u00a0mg\u2009L(-1)  La(III)  could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase,  glutamate synthase   and glutamate dehydrogenase, promoting amino acid conversion and protein synthesis in soybean seedlings", "triple_list": [["La(III)", "ANTAGONIST", "glutamate"]]}, {"text": "The pretreatment with 20\u00a0mg\u2009L(-1)  La(III)  could alleviate the effects of UV-B radiation on the activities of nitrate reductase, glutamine synthetase, glutamate synthase, and  glutamate dehydrogenase   promoting amino acid conversion and protein synthesis in soybean seedlings", "triple_list": [["La(III)", "ANTAGONIST", "20"]]}, {"text": " \u03b2-ionone  was also shown to induce the expression of cleaved- caspase-3  and inhibit bcl-2 expression in SGC-7901 cells in a dose-dependent manner", "triple_list": [["in", "ANTAGONIST", "caspase-3"]]}, {"text": " \u03b2-ionone  was also shown to induce the expression of cleaved-caspase-3 and inhibit  bcl-2  expression in SGC-7901 cells in a dose-dependent manner", "triple_list": [["induce", "AGONIST", "bcl-2"]]}, {"text": "The significantly decreased levels of  p-PI3K  and p-AKT expression were observed in SGC-7901 cells after  \u03b2-ionone  treatments in a time- and dose-dependent manner (P\u00a0<\u00a00.01)", "triple_list": [["\u03b2-ionone", "ANTAGONIST", "expression"]]}, {"text": "The significantly decreased levels of p-PI3K and  p-AKT  expression were observed in SGC-7901 cells after  \u03b2-ionone  treatments in a time- and dose-dependent manner (P\u00a0<\u00a00.01)", "triple_list": [["\u03b2-ionone", "AGONIST", "significantly"]]}, {"text": "The concentration response to  levcromakalim  (LEVC), a  K(ATP) channel  opener, was significantly shifted to the left in the inflamed smooth-muscle cells", "triple_list": [["levcromakalim", "DOWNREGULATOR", "K(ATP)"]]}, {"text": "The concentration response to levcromakalim ( LEVC  , a  K(ATP) channel  opener, was significantly shifted to the left in the inflamed smooth-muscle cells", "triple_list": [["LEVC", "DOWNREGULATOR", ","]]}, {"text": "Sulfhydration of  sulfonylurea receptor 2B  (SUR2B) was induced by  NaHS  and colonic inflammation", "triple_list": [["and", "ANTAGONIST", "sulfonylurea receptor 2B"]]}, {"text": "Sulfhydration of sulfonylurea receptor 2B ( SUR2B   was induced by  NaHS  and colonic inflammation", "triple_list": [["NaHS", "PRODUCT-OF", "induced"]]}, {"text": " CCl(4)  administration triggered inflammatory response in mice livers by activating  nuclear factor-kappaB  (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 (COX-2)", "triple_list": [["CCl(4)", "ANTAGONIST", "nuclear factor-kappaB"]]}, {"text": " CCl(4)  administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB ( NF-\u03baB  , which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 (COX-2)", "triple_list": [["factor-kappaB", "AGONIST", "NF-\u03baB"]]}, {"text": " CCl(4)  administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of  tumor necrosis factor-alpha  (TNF-\u03b1) and cyclooxygenase-2 (COX-2)", "triple_list": [["coincided", "AGONIST", "tumor necrosis factor-alpha"]]}, {"text": " CCl(4)  administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha ( TNF-\u03b1   and cyclooxygenase-2 (COX-2)", "triple_list": [["CCl(4)", "AGONIST", "nuclear"]]}, {"text": " CCl(4)  administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and  cyclooxygenase-2  (COX-2)", "triple_list": [["CCl(4)", "AGONIST", "coincided"]]}, {"text": " CCl(4)  administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-\u03baB), which coincided with the induction of tumor necrosis factor-alpha (TNF-\u03b1) and cyclooxygenase-2 ( COX-2  ", "triple_list": [["mice", "PRODUCT-OF", "COX-2"]]}, {"text": " CCl(4)  intoxication caused hepatic necrosis and increased serum  ALT  activity", "triple_list": [["CCl(4)", "DOWNREGULATOR", "hepatic"]]}, {"text": "Furthermore, RA significantly inhibited the  CCl(4)  induced apoptosis, which was evident from decreased cleavage of  caspase-3   The hepatoprotective activity of RA coincided with enhanced NF-E2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) expression", "triple_list": [["oxygenase-1", "ANTAGONIST", "caspase-3"]]}, {"text": "Antiarrhythmic effects of  (-)-epicatechin-3-gallate   a novel  sodium channel  agonist in cultured neonatal rat ventricular myocytes", "triple_list": [["agonist", "ACTIVATOR", "sodium channel"]]}, {"text": "Both  5'-AMN  and 5'-MABN had high affinity for \u03ba-receptors (K (i) 1.36 \u00b1 0.98 and 0.27 \u00b1 0.08, respectively) and were revealed as potent \u03ba-antagonists (pA(2) 7.43 and 8.18, respectively) and  \u03bc-receptor  antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum", "triple_list": [["7.43", "ACTIVATOR", "\u03bc-receptor"]]}, {"text": "Both 5'-AMN and  5'-MABN  had high affinity for \u03ba-receptors (K (i) 1.36 \u00b1 0.98 and 0.27 \u00b1 0.08, respectively) and were revealed as potent \u03ba-antagonists (pA(2) 7.43 and 8.18, respectively) and  \u03bc-receptor  antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum", "triple_list": [["5'-MABN", "AGONIST", "and"]]}, {"text": "Finally, we found that liver kinase B1 (LKB1) phosphorylation is required for the  phillyrin  enhanced activation of  AMPK  in HepG2 hepatocytes", "triple_list": [["required", "ANTAGONIST", "AMPK"]]}, {"text": "These results indicate that  phillyrin  prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through  LKB1  AMPK activation, suggesting that  phillyrin  is a novel AMPK activator with a role in the prevention and treatment of obesity.", "triple_list": [["treatment", "AGONIST", "LKB1"]]}, {"text": "These results indicate that  phillyrin  prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1/ AMPK  activation, suggesting that  phillyrin  is a novel  AMPK  activator with a role in the prevention and treatment of obesity.", "triple_list": [["novel", "AGONIST", "AMPK"]]}, {"text": " Phillyrin  attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of  LKB1  AMP-activated protein kinase-dependent signalling", "triple_list": [["the", "ANTAGONIST", "LKB1"]]}, {"text": " Phillyrin  attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1/ AMP-activated protein kinase  dependent signalling", "triple_list": [["Phillyrin", "ANTAGONIST", "high"]]}, {"text": "These results indicate that  phillyrin  prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1/ AMPK  activation, suggesting that  phillyrin  is a novel  AMPK  activator with a role in the prevention and treatment of obesity.", "triple_list": [["phillyrin", "AGONIST", "cells"]]}, {"text": "Phillyrin strongly inhibited high  glucose  induced  fatty acid synthase  (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation", "triple_list": [["induced", "ANTAGONIST", "fatty acid synthase"]]}, {"text": "Phillyrin strongly inhibited high  glucose  induced fatty acid synthase ( FAS   expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation", "triple_list": [["high", "DOWNREGULATOR", "FAS"]]}, {"text": "Moreover, use of the pharmacological  AMP-activated protein kinase  (AMPK) inhibitor  compound C  revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells", "triple_list": [["compound C", "AGONIST", "suppressing"]]}, {"text": "Moreover, use of the pharmacological AMP-activated protein kinase ( AMPK   inhibitor  compound C  revealed that  AMPK  is essential for suppressing SREBP-1c expression in phillyrin-treated cells", "triple_list": [["that", "AGONIST", "AMPK"]]}, {"text": "Moreover, use of the pharmacological AMP-activated protein kinase ( AMPK ) inhibitor  compound C  revealed that  AMPK  is essential for suppressing SREBP-1c expression in phillyrin-treated cells", "triple_list": [["is", "ACTIVATOR", "AMPK"]]}, {"text": "These results indicate that  phillyrin  prevents lipid accumulation in HepG2 cells by blocking the expression of  SREBP-1c  and FAS through LKB1/AMPK activation, suggesting that  phillyrin  is a novel AMPK activator with a role in the prevention and treatment of obesity.", "triple_list": [["activator", "ANTAGONIST", "SREBP-1c"]]}, {"text": "These results indicate that  phillyrin  prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and  FAS  through LKB1/AMPK activation, suggesting that  phillyrin  is a novel AMPK activator with a role in the prevention and treatment of obesity.", "triple_list": [["in", "AGONIST", "FAS"]]}, {"text": " Phillyrin  strongly inhibited high glucose-induced  fatty acid synthase  (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation", "triple_list": [["Phillyrin", "AGONIST", "element-binding"]]}, {"text": " Phillyrin  strongly inhibited high glucose-induced fatty acid synthase ( FAS   expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation", "triple_list": [["Phillyrin", "ACTIVATOR", "modulating"]]}, {"text": " [-]-Huperzine A  ([-]-Hup A), is a naturally occurring potent reversible  AChE  inhibitor that penetrates the blood-brain barrier", "triple_list": [["[-]-Huperzine A", "ANTAGONIST", "the"]]}, {"text": "[-]-Huperzine A ( [-]-Hup A  , is a naturally occurring potent reversible  AChE  inhibitor that penetrates the blood-brain barrier", "triple_list": [["[-]-Hup A", "PRODUCT-OF", "that"]]}, {"text": "The synthetic stereoisomer,  [+]-Hup A   is less toxic due to poor  AChE  inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity", "triple_list": [["[+]-Hup A", "ANTAGONIST", "less"]]}, {"text": "An increase in the  ADP  ATP ratio opens  K(ATP) channels   leading to membrane hyperpolarization", "triple_list": [["ADP", "DOWNREGULATOR", "ATP"]]}, {"text": "An increase in the ADP/ ATP  ratio opens K( ATP ) channels  leading to membrane hyperpolarization", "triple_list": [["ADP/", "ANTAGONIST", "K(ATP) channels"]]}, {"text": "The  mitochondrial respiratory chain complex IV  (cytochrome c oxidase) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular  oxygen   yielding water", "triple_list": [["oxygen", "DOWNREGULATOR", "molecular"]]}, {"text": "The mitochondrial respiratory chain complex IV ( cytochrome c oxidase   is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular  oxygen   yielding water", "triple_list": [["oxygen", "ANTAGONIST", "is"]]}, {"text": "These findings demonstrate that cinnamon  polyphenols  can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of  iNOS   NF-\u03baB activation.", "triple_list": [["polyphenols", "PRODUCT-OF", "of"]]}, {"text": "These findings demonstrate that cinnamon  polyphenols  can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of iNOS,  NF-\u03baB  activation.", "triple_list": [["polyphenols", "AGONIST", "attenuating"]]}, {"text": "As revealed by glucose oxidase (GOD) and radioimmunoassay (RIA), both  dimethyldiguanide  (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood glucose and  insulin  levels in serum, while the levels of oxidative stress markers were markedly lowered through ELISA assay", "triple_list": [["and", "AGONIST", "insulin"]]}, {"text": "The two basic mainstays of gastrointestinal stromal tumours (GIST) treatment are surgery and  imatinib   a selective  tyrosine kinase  inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable/metastatic GIST", "triple_list": [["imatinib", "ACTIVATOR", "stable"]]}, {"text": "One of the  CB2  agonists,  N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine  (19, -logEC(50)=7.5, E(max)=255%) was selected for further development", "triple_list": [["of", "DOWNREGULATOR", "CB2"]]}, {"text": "As far as we are aware, the compound's  1,3,5-triazine  scaffold represents a new core structure for  CB2  agonists", "triple_list": [["compound's", "PRODUCT-OF", "CB2"]]}, {"text": "Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of  2,4,6-trisubstituted 1,3,5-triazines  as  CB2  agonists", "triple_list": [["2,4,6-trisubstituted 1,3,5-triazines", "ACTIVATOR", "by"]]}, {"text": "Binding of the agonist angiotensin II (AngII) and inverse agonist  losartan  in wild-type  AT1R  changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific \"lid\" conformations of ECL2", "triple_list": [["Binding", "ANTAGONIST", "AT1R"]]}, {"text": "In muscle and liver,  TCDD  (10 ng/kg/day) induced increases in methylation and decreases in mRNA expression of  Igf2r   These results show that the robust effects of  TCDD  on the mRNA expression of Snrpn, Peg3 and  Igf2r  genes in the sperm and of  Igf2r  in the muscle and liver are unrelated to changes in methylation in their respective genes.", "triple_list": [["TCDD", "ACTIVATOR", "of"]]}, {"text": "We report here the optimization of  human 17\u03b2-HSD2  inhibitors in the  2,5-thiophene amide  class by varying the size of the linker (n equals 0 and 2) between the amide moiety and the phenyl group", "triple_list": [["(n", "ACTIVATOR", "human 17\u03b2-HSD2"]]}, {"text": "While none of the phenethylamides (n = 2) were active, most of the  anilides  (n = 0) turned out to moderately or strongly inhibit  17\u03b2-HSD2   The four most active compounds showed an IC\u2085\u2080 of around 60 nM and a very good selectivity toward 17\u03b2-HSD1, 17\u03b2-HSD4, 17\u03b2-HSD5, 11\u03b2-HSD1, 11\u03b2-HSD2 and the estrogen receptors \u03b1 and \u03b2", "triple_list": [["anilides", "PRODUCT-OF", "selectivity"]]}, {"text": "Structural optimization of  2,5-thiophene amides  as highly potent and selective  17\u03b2-hydroxysteroid dehydrogenase type 2  inhibitors for the treatment of osteoporosis", "triple_list": [["2,5-thiophene amides", "ACTIVATOR", "for"]]}, {"text": "Taken together, the data provide evidence that the synergistic antiproliferative effect of  resveratrol  and clofarabine is linked to the inhibition of  Akt  and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.", "triple_list": [["this", "ANTAGONIST", "Akt"]]}, {"text": "Taken together, the data provide evidence that the synergistic antiproliferative effect of  resveratrol  and clofarabine is linked to the inhibition of Akt and  Sp1  activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.", "triple_list": [["resveratrol", "AGONIST", "data"]]}, {"text": "Taken together, the data provide evidence that the synergistic antiproliferative effect of resveratrol and  clofarabine  is linked to the inhibition of  Akt  and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.", "triple_list": [["and", "PRODUCT-OF", "Akt"]]}, {"text": "Taken together, the data provide evidence that the synergistic antiproliferative effect of resveratrol and  clofarabine  is linked to the inhibition of Akt and  Sp1  activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.", "triple_list": [["clofarabine", "AGONIST", "mesothelioma."]]}, {"text": "In combination with  clofarabine   the ability of resveratrol to reduce the contents of  Sp1  and its target gene products was also evident in a time- and dose-dependent experiment", "triple_list": [["clofarabine", "ACTIVATOR", "the"]]}, {"text": "In combination with clofarabine, the ability of  resveratrol  to reduce the contents of  Sp1  and its target gene products was also evident in a time- and dose-dependent experiment", "triple_list": [["products", "AGONIST", "Sp1"]]}, {"text": "The inhibition of  phosphoinositide 3-kinase  using  Ly294002  augmented a decrease in the p21 level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1", "triple_list": [["expression", "ACTIVATOR", "phosphoinositide 3-kinase"]]}, {"text": "The inhibition of phosphoinositide 3-kinase using  Ly294002  augmented a decrease in the  p21  level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1", "triple_list": [["by", "PRODUCT-OF", "p21"]]}, {"text": " Emodin-6-O-\u03b2-D-glucoside  inhibits  HMGB1  induced inflammatory responses in vitro and in vivo", "triple_list": [["Emodin-6-O-\u03b2-D-glucoside", "PRODUCT-OF", "in"]]}, {"text": " TCDD  decreased the expression of the  glucose transporter   SLC2A1, and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate", "triple_list": [["TCDD", "ACTIVATOR", "glucose transporter"]]}, {"text": " TCDD  decreased the expression of the glucose transporter,  SLC2A1   and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate", "triple_list": [["the", "AGONIST", "SLC2A1"]]}, {"text": "Mitochondrial  glutathione (GSH) reductase  activity and the GSH/glutathione disulfide ratio were decreased by  TCDD   ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide", "triple_list": [["ultimately", "ANTAGONIST", "glutathione (GSH) reductase"]]}, {"text": "Nanobody-albumin nanoparticles (NANAPs) for the delivery of a  multikinase  inhibitor  17864  to EGFR overexpressing tumor cells", "triple_list": [["Nanobody-albumin", "ACTIVATOR", "multikinase"]]}, {"text": "Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the  multikinase  inhibitor  17864  L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment", "triple_list": [["17864", "ACTIVATOR", "reductive"]]}, {"text": " HSYA  suppressed the expression of TLR-4,  Myd88   ICAM-1, TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells", "triple_list": [["the", "ACTIVATOR", "Myd88"]]}, {"text": " HSYA  suppressed the expression of TLR-4, Myd88,  ICAM-1   TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells", "triple_list": [["HSYA", "ANTAGONIST", "leukocytes"]]}, {"text": " HSYA  suppressed the expression of TLR-4, Myd88, ICAM-1,  TNF\u03b1   IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells", "triple_list": [["of", "AGONIST", "TNF\u03b1"]]}, {"text": " HSYA  suppressed the expression of TLR-4, Myd88, ICAM-1, TNF\u03b1,  IL-1\u03b2  and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells", "triple_list": [["HSYA", "PRODUCT-OF", "HSYA"]]}, {"text": " HSYA  suppressed the expression of TLR-4, Myd88, ICAM-1, TNF\u03b1, IL-1\u03b2 and  IL-6  at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells", "triple_list": [["HSYA", "PRODUCT-OF", "of"]]}, {"text": " HSYA  suppressed the expression of  TLR-4   Myd88, ICAM-1, TNF\u03b1, IL-1\u03b2 and IL-6 at the mRNA and protein level, and inhibited the adhesion of leukocytes to A549 cells", "triple_list": [["HSYA", "PRODUCT-OF", "and"]]}, {"text": " HSYA  treatment also decreased  NF-\u03baB  p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK)", "triple_list": [["and", "PRODUCT-OF", "NF-\u03baB"]]}, {"text": " HSYA  treatment also decreased NF-\u03baB  p65  nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK)", "triple_list": [["p38", "ANTAGONIST", "p65"]]}, {"text": " HSYA  treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of  p38  mitogen-activated protein kinase ( p38  MAPK)", "triple_list": [["MAPK)", "ACTIVATOR", "p38"]]}, {"text": " HSYA  treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of p38  mitogen-activated protein kinase  (p38 MAPK)", "triple_list": [["phosphorylation", "AGONIST", "mitogen-activated protein kinase"]]}, {"text": " HSYA  treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of  p38  mitogen-activated protein kinase ( p38  MAPK)", "triple_list": [["treatment", "PRODUCT-OF", "p38"]]}, {"text": " HSYA  treatment also decreased NF-\u03baB p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38  MAPK  ", "triple_list": [["p65", "AGONIST", "MAPK"]]}, {"text": "First, we showed that intracerebroventricular administration of  glucose  in rats increases  DBI  expression in hypothalamic glial-like tanycytes", "triple_list": [["glucose", "ANTAGONIST", "in"]]}, {"text": "Western blots showed a decrease in nuclear p65 protein expression after exposure to different concentrations of  cinobufagin   while the phosphorylation of  GSK-3\u03b2  was simultaneously increased", "triple_list": [["cinobufagin", "AGONIST", "of"]]}, {"text": "Transduction with constitutively active forms of GSK-3\u03b2 could protect against the downregulation of p65 and upregulation of cleaved- PARP  that are induced by  cinobufagin  treatment", "triple_list": [["cinobufagin", "ANTAGONIST", "of"]]}, {"text": "However, combined treatment with  cinobufagin  and SB216367 resulted in a significant reduction in p65 and an increase in cleaved- PARP  in U2OS cells", "triple_list": [["cinobufagin", "ANTAGONIST", "cinobufagin"]]}, {"text": "However, combined treatment with cinobufagin and  SB216367  resulted in a significant reduction in p65 and an increase in cleaved- PARP  in U2OS cells", "triple_list": [["SB216367", "ANTAGONIST", "SB216367"]]}, {"text": "Furthermore, we validated the inhibition of  GSK-3\u03b2  NF-\u03baB signaling following  cinobufagin  treatment", "triple_list": [["Furthermore,", "ANTAGONIST", "GSK-3\u03b2"]]}, {"text": "Furthermore, we validated the inhibition of GSK-3\u03b2/ NF-\u03baB  signaling following  cinobufagin  treatment", "triple_list": [["following", "ANTAGONIST", "NF-\u03baB"]]}, {"text": "Western blots showed a decrease in nuclear  p65  protein expression after exposure to different concentrations of  cinobufagin   while the phosphorylation of GSK-3\u03b2 was simultaneously increased", "triple_list": [["showed", "ACTIVATOR", "p65"]]}, {"text": "Transduction with constitutively active forms of GSK-3\u03b2 could protect against the downregulation of  p65  and upregulation of cleaved-PARP that are induced by  cinobufagin  treatment", "triple_list": [["cinobufagin", "ANTAGONIST", "of"]]}, {"text": "However, combined treatment with  cinobufagin  and SB216367 resulted in a significant reduction in  p65  and an increase in cleaved-PARP in U2OS cells", "triple_list": [["resulted", "PRODUCT-OF", "p65"]]}, {"text": "However, combined treatment with cinobufagin and  SB216367  resulted in a significant reduction in  p65  and an increase in cleaved-PARP in U2OS cells", "triple_list": [["increase", "PRODUCT-OF", "p65"]]}, {"text": "Based on these suggestions, the rational redesign of  furanopyrimidine  24 (clog\u2009P=7.41;  Aurora\u2005A  IC(50) =43\u2005nM; HCT-116 IC(50) =400\u2005nM) led to the identification of quinazoline 67 (clog\u2009P=5.28;  Aurora\u2005A  IC(50) =25\u2005nM; HCT-116 IC(50) =23\u2005nM)", "triple_list": [["of", "AGONIST", "Aurora\u2005A"]]}, {"text": "Based on these suggestions, the rational redesign of furanopyrimidine 24 (clog\u2009P=7.41;  Aurora\u2005A  IC(50) =43\u2005nM; HCT-116 IC(50) =400\u2005nM) led to the identification of  quinazoline  67 (clog\u2009P=5.28;  Aurora\u2005A  IC(50) =25\u2005nM; HCT-116 IC(50) =23\u2005nM)", "triple_list": [["(clog", "ANTAGONIST", "Aurora\u2005A"]]}, {"text": "Three different 3D-QSAR models were built and validated by using a set of 66  pyrazole  (Model\u2005I) and furanopyrimidine (Model\u2005II) compounds with IC(50) values toward  Aurora kinase\u2005A  ranging from 33\u2005nM to 10.5\u2005\u03bcM", "triple_list": [["pyrazole", "ANTAGONIST", "33"]]}, {"text": "Three different 3D-QSAR models were built and validated by using a set of 66 pyrazole (Model\u2005I) and  furanopyrimidine  (Model\u2005II) compounds with IC(50) values toward  Aurora kinase\u2005A  ranging from 33\u2005nM to 10.5\u2005\u03bcM", "triple_list": [["set", "PRODUCT-OF", "Aurora kinase\u2005A"]]}, {"text": "3D-QSAR-assisted drug design: identification of a potent  quinazoline  based  Aurora kinase  inhibitor", "triple_list": [["quinazoline", "AGONIST", "based"]]}, {"text": "Pharmacophore identification of  c-Myc  inhibitor  10074-G5   A structure-activity relationship (SAR) study of the  c-Myc  (Myc) inhibitor  10074-G5  (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore", "triple_list": [["inhibitor", "ANTAGONIST", "c-Myc"]]}, {"text": "Importantly, the carboxylic acid of  JY-3-094  improves the physicochemical properties of the lead compound, which will facilitate the incorporation of additional hydrophobicity that might enhance  Myc  inhibitory activity further still.", "triple_list": [["of", "ACTIVATOR", "Myc"]]}, {"text": "A structure-activity relationship (SAR) study of the  c-Myc  (Myc) inhibitor  10074-G5  (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore", "triple_list": [["domain", "ANTAGONIST", "c-Myc"]]}, {"text": "A structure-activity relationship (SAR) study of the c- Myc  ( Myc   inhibitor  10074-G5  (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the  Myc  oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore", "triple_list": [["10074-G5", "PRODUCT-OF", "A"]]}, {"text": "A structure-activity relationship (SAR) study of the  c-Myc  (Myc) inhibitor 10074-G5 ( N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine   1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore", "triple_list": [["N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine", "PRODUCT-OF", "A"]]}, {"text": "A structure-activity relationship (SAR) study of the c- Myc  ( Myc   inhibitor 10074-G5 ( N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine   1) - which targets a hydrophobic domain of the  Myc  oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore", "triple_list": [["N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine", "ACTIVATOR", "is"]]}, {"text": "In contrast to parenteral delivery of rBChE, which currently requires posttranslational modification for good plasma stability, an unmodified aer-rBChE pretreatment given 1-40h prior to >1 LD50 of aer- paraoxon  (Px) was able to prevent inhibition of circulating  cholinesterase  in a dose-dependent manner", "triple_list": [["of", "DOWNREGULATOR", "cholinesterase"]]}, {"text": " Ozone  plus PM(2.5) exposure, however, induced  CRP   IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way", "triple_list": [["Ozone", "DOWNREGULATOR", "Ozone"]]}, {"text": " Ozone  plus PM(2.5) exposure, however, induced CRP,  IL-6   CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way", "triple_list": [["Ozone", "AGONIST", "induced"]]}, {"text": " Ozone  plus PM(2.5) exposure, however, induced CRP, IL-6,  CK   LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way", "triple_list": [["IL-6,", "AGONIST", "CK"]]}, {"text": " Ozone  plus PM(2.5) exposure, however, induced CRP, IL-6, CK,  LDH  and MDA increase, SOD and HRV decrease significantly in a dose-response way", "triple_list": [["in", "PRODUCT-OF", "LDH"]]}, {"text": " Ozone  plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and MDA increase,  SOD  and HRV decrease significantly in a dose-response way", "triple_list": [["LDH", "ANTAGONIST", "SOD"]]}, {"text": "This stimulation was attenuated by the  Pak  inhibitor  2,2'-dihydroxy-1,1'-dinaphthyldisulfide  (IPA3) or dominant-negative  Pak 1", "triple_list": [["This", "PRODUCT-OF", "Pak"]]}, {"text": "This stimulation was attenuated by the  Pak  inhibitor 2,2'-dihydroxy-1,1'-dinaphthyldisulfide ( IPA3   or dominant-negative  Pak 1", "triple_list": [["(", "PRODUCT-OF", "Pak"]]}, {"text": "Importantly, pre-treatment with buthionine sulfoximine (BS BSO  an inhibitor of \u03b3- \u03b3-GCS  revented \u03b1-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity", "triple_list": [["BSO", "AGONIST", "cytotoxicity"]]}, {"text": "Neither the superoxide radical scavenger, tiron, nor the inhibitor of the do dopamine (DA) transporter  B GBR 12909  revented the metabolites' toxicity", "triple_list": [["scavenger,", "PRODUCT-OF", "dopamine (DA) transporter"]]}, {"text": "Importantly, pre-treatment with bu buthionine sulfoximine  SO), an inhibitor of \u03b3- \u03b3-GCS  revented \u03b1-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity", "triple_list": [["\u03b3-GCS", "PRODUCT-OF", "\u03b3-GCS"]]}, {"text": " (-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one  (KCA-1490) exhibits moderate dual  PDE3/4  inhibitory activity and promises as a combined bronchodilatory/anti-inflammatory agent", "triple_list": [["(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one", "AGONIST", "PDE3/4"]]}, {"text": "(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one ( KCA-1490   exhibits moderate dual  PDE3/4  inhibitory activity and promises as a combined bronchodilatory/anti-inflammatory agent", "triple_list": [["KCA-1490", "AGONIST", "and"]]}, {"text": " N  alkylation of the pyridazinone ring markedly enhances potency against  PDE4  but suppresses PDE3 inhibition", "triple_list": [["pyridazinone", "PRODUCT-OF", "PDE4"]]}, {"text": " N  alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses  PDE3  inhibition", "triple_list": [["of", "PRODUCT-OF", "PDE3"]]}, {"text": "N-alkylation of the  pyridazinone  ring markedly enhances potency against  PDE4  but suppresses PDE3 inhibition", "triple_list": [["PDE3", "AGONIST", "PDE4"]]}, {"text": "N-alkylation of the  pyridazinone  ring markedly enhances potency against PDE4 but suppresses  PDE3  inhibition", "triple_list": [["pyridazinone", "PRODUCT-OF", "pyridazinone"]]}, {"text": "Addition of a  6-aryl-4,5-dihydropyridazin-3(2H)-one  extension to the N-alkyl group facilitates both enhancement of  PDE4  inhibitory activity and restoration of potent PDE3 inhibition", "triple_list": [["6-aryl-4,5-dihydropyridazin-3(2H)-one", "ANTAGONIST", "inhibition"]]}, {"text": "Addition of a  6-aryl-4,5-dihydropyridazin-3(2H)-one  extension to the N-alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent  PDE3  inhibition", "triple_list": [["6-aryl-4,5-dihydropyridazin-3(2H)-one", "PRODUCT-OF", "Addition"]]}, {"text": "Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the  N  alkyl group facilitates both enhancement of  PDE4  inhibitory activity and restoration of potent PDE3 inhibition", "triple_list": [["inhibitory", "ANTAGONIST", "PDE4"]]}, {"text": "Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the  N  alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent  PDE3  inhibition", "triple_list": [["N", "ANTAGONIST", "activity"]]}, {"text": "Identification of a novel  benzimidazole  derivative as a highly potent  NPY Y5 receptor  antagonist with an anti-obesity profile", "triple_list": [["benzimidazole", "DOWNREGULATOR", "antagonist"]]}, {"text": " OMT  showed partial protection in the cortical neurons via down-regulation of NR2B containing NMDA receptors and up-regulation of  Bcl-2  family", "triple_list": [["of", "DOWNREGULATOR", "Bcl-2"]]}, {"text": "Western blot analysis revealed that  OMT  decreased the expression of  Bax  and repaired the balance of pro- and anti-apoptotic proteins", "triple_list": [["OMT", "ANTAGONIST", "of"]]}, {"text": "Furthermore,  OMT  significantly reversed the up-regulation of  NR2B  and inhibited the calcium overload in the cultured neurons after challenging the NMDA", "triple_list": [["significantly", "AGONIST", "NR2B"]]}, {"text": " OMT  showed partial protection in the cortical neurons via down-regulation of  NR2B  containing NMDA receptors and up-regulation of Bcl-2 family", "triple_list": [["OMT", "ACTIVATOR", "partial"]]}, {"text": " OMT  showed partial protection in the cortical neurons via down-regulation of NR2B containing  NMDA receptors  and up-regulation of Bcl-2 family", "triple_list": [["OMT", "ACTIVATOR", "down-regulation"]]}, {"text": "The reactivation of brain  AChE  inhibited with tabun demonstrated better activity of new compound  BT-07-4M   TMB-4 and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure", "triple_list": [["BT-07-4M", "DOWNREGULATOR", "brain"]]}, {"text": "The reactivation of brain  AChE  inhibited with tabun demonstrated better activity of new compound BT-07-4M,  TMB-4  and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure", "triple_list": [["asymmetric", "AGONIST", "AChE"]]}, {"text": "The reactivation of brain  AChE  inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and  obidoxime  from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure", "triple_list": [["obidoxime", "PRODUCT-OF", "better"]]}, {"text": "The reactivation of brain  AChE  inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric  oximes   and BT-05 and BT-03 possessing asymmetric structure", "triple_list": [["symmetric", "DOWNREGULATOR", "AChE"]]}, {"text": "The reactivation of brain  AChE  inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes, and  BT-05  and BT-03 possessing asymmetric structure", "triple_list": [["BT-05", "ANTAGONIST", "of"]]}, {"text": "The reactivation of brain  AChE  inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes, and BT-05 and  BT-03  possessing asymmetric structure", "triple_list": [["brain", "DOWNREGULATOR", "AChE"]]}, {"text": " AChE  was easier reactivated after  paraoxon  treatment", "triple_list": [["AChE", "DOWNREGULATOR", "AChE"]]}, {"text": "All compounds showed low activity toward inhibition of  AChE  caused by  dichlorvos   Comparison of two main structure types (symmetric/asymmetric) showed that the symmetric compounds reactivated better  AChE , inhibited with this OPC, than asymmetric ones.", "triple_list": [["dichlorvos", "PRODUCT-OF", "AChE"]]}, {"text": "Reactivators showed different activity in the reactivation of  rat brain AChE  after  dichlorvos   paraoxon and tabun inhibition", "triple_list": [["dichlorvos", "ANTAGONIST", "of"]]}, {"text": "Reactivators showed different activity in the reactivation of  rat brain AChE  after dichlorvos,  paraoxon  and tabun inhibition", "triple_list": [["paraoxon", "ANTAGONIST", "Reactivators"]]}, {"text": "Reactivators showed different activity in the reactivation of  rat brain AChE  after dichlorvos, paraoxon and  tabun  inhibition", "triple_list": [["tabun", "PRODUCT-OF", "and"]]}, {"text": "Inhibition by  phenformin  of oxygen consumption via  complex I  respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of  phenformin  on  complex I  respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts", "triple_list": [["rat", "ACTIVATOR", "complex I"]]}, {"text": "Role of organic cation/carnitine transporter 1 in uptake of  phenformin  and inhibitory effect on  complex I  respiration in mitochondria", "triple_list": [["mitochondria", "ACTIVATOR", "complex I"]]}, {"text": " Phenformin  causes lactic acidosis in clinical situations due to inhibition of  mitochondrial respiratory chain complex I   It is reportedly taken up by hepatocytes and exhibits mitochondrial toxicity in the liver", "triple_list": [["the", "ACTIVATOR", "mitochondrial respiratory chain complex I"]]}, {"text": "Inhibition by  phenformin  of oxygen consumption via  complex I  respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of  phenformin  on  complex I  respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts", "triple_list": [["liver", "PRODUCT-OF", "complex I"]]}, {"text": "These observations suggest that uptake of  phenformin  into liver mitochondria is at least partly mediated by OCTN1 and functionally relevant to its inhibition potential of  complex I  respiration", "triple_list": [["mediated", "PRODUCT-OF", "complex I"]]}, {"text": "In this study, uptake of  phenformin  and [(14)C]tetraethylammonium (TEA) and  complex I  inhibition by  phenformin  were examined in isolated liver and heart mitochondria", "triple_list": [["phenformin", "PRODUCT-OF", "by"]]}, {"text": "Role of  organic cation/carnitine transporter 1  in uptake of  phenformin  and inhibitory effect on complex I respiration in mitochondria", "triple_list": [["phenformin", "DOWNREGULATOR", "transporter"]]}, {"text": "These observations suggest that uptake of  phenformin  into liver mitochondria is at least partly mediated by  OCTN1  and functionally relevant to its inhibition potential of complex I respiration", "triple_list": [["phenformin", "ACTIVATOR", "into"]]}, {"text": "CONCLUSIONS A diet that partially replaces  carbohydrate  with unsaturated fat may improve  insulin  sensitivity in a population at risk for cardiovascular disease", "triple_list": [["with", "PRODUCT-OF", "insulin"]]}, {"text": "Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for  VK2  induced  cytochrome c  (cyt c) release and cell death", "triple_list": [["family,", "DOWNREGULATOR", "cytochrome c"]]}, {"text": "Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for  VK2  induced cytochrome c ( cyt c   release and cell death", "triple_list": [["are", "PRODUCT-OF", "cyt c"]]}, {"text": "Here, we demonstrate that  peptidyl-prolyl cis/trans-isomerase A1  (Pin1), an enzyme that catalyzes the conversion of the peptide bond of  pSer  pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification", "triple_list": [["pSer", "ANTAGONIST", "trans,"]]}, {"text": "Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 ( Pin1  , an enzyme that catalyzes the conversion of the peptide bond of  pSer  pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification", "triple_list": [["bond", "ACTIVATOR", "Pin1"]]}, {"text": "Here, we demonstrate that  peptidyl-prolyl cis/trans-isomerase A1  (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer/ pThr  Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification", "triple_list": [["enzyme", "ACTIVATOR", "peptidyl-prolyl cis/trans-isomerase A1"]]}, {"text": "Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 ( Pin1  , an enzyme that catalyzes the conversion of the peptide bond of pSer/ pThr  Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification", "triple_list": [["of", "DOWNREGULATOR", "Pin1"]]}, {"text": "Here, we demonstrate that  peptidyl-prolyl cis/trans-isomerase A1  (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr- Pro  moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification", "triple_list": [["in", "AGONIST", "peptidyl-prolyl cis/trans-isomerase A1"]]}, {"text": "Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 ( Pin1  , an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr- Pro  moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification", "triple_list": [["Here,", "DOWNREGULATOR", "Pin1"]]}, {"text": "These results suggest that  CYP2B6  genotype is the most important patient variable for predicting the level of  CYP2B6  activity in women, when measured by the metabolism of  bupropion   The  bupropion  metabolic ratio appears to detect known differences in  CYP2B6  activity associated with genetic polymorphism, across different ethnic groups", "triple_list": [["ethnic", "ANTAGONIST", "CYP2B6"]]}, {"text": "These results suggest that  CYP2B6  genotype is the most important patient variable for predicting the level of  CYP2B6  activity in women, when measured by the metabolism of  bupropion   The  bupropion  metabolic ratio appears to detect known differences in  CYP2B6  activity associated with genetic polymorphism, across different ethnic groups", "triple_list": [["bupropion", "DOWNREGULATOR", "metabolic"]]}, {"text": "The  bupropion  metabolic ratio appears to detect known differences in  CYP2B6  activity associated with genetic polymorphism, across different ethnic groups", "triple_list": [["bupropion", "AGONIST", "activity"]]}, {"text": "To identify important covariates associated with interindividual variation in  CYP2B6  activity in vivo, we evaluated these effects in healthy volunteers using  bupropion  (Wellbutrin SR GlaxoSmithKline, Research Triangle Park, NC) as a  CYP2B6  probe substrate", "triple_list": [["bupropion", "DOWNREGULATOR", "variation"]]}, {"text": "To identify important covariates associated with interindividual variation in  CYP2B6  activity in vivo, we evaluated these effects in healthy volunteers using bupropion ( Wellbutrin SR  GlaxoSmithKline, Research Triangle Park, NC) as a  CYP2B6  probe substrate", "triple_list": [["Wellbutrin SR", "DOWNREGULATOR", "interindividual"]]}, {"text": "The influence of sex, ethnicity, and  CYP2B6  genotype on  bupropion  metabolism as an index of hepatic  CYP2B6  activity in humans", "triple_list": [["bupropion", "ANTAGONIST", "hepatic"]]}, {"text": "The  CYP3A4  activity could be induced 2-fold by  rifampicin   whereas CYP2C9 activity remained equally high", "triple_list": [["activity", "ANTAGONIST", "CYP3A4"]]}, {"text": "The CYP3A4 activity could be induced 2-fold by  rifampicin   whereas  CYP2C9  activity remained equally high", "triple_list": [["activity", "DOWNREGULATOR", "CYP2C9"]]}, {"text": " Mammalian ALDH1B1   another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable of metabolizing  acetaldehyde  but has a tissue distribution and pattern of activity distinct from that of ALDH2", "triple_list": [["also", "AGONIST", "Mammalian ALDH1B1"]]}, {"text": "Mammalian ALDH1B1, another mitochondrial enzyme sharing 72% identity with  ALDH2   is also capable of metabolizing  acetaldehyde  but has a tissue distribution and pattern of activity distinct from that of  ALDH2 ", "triple_list": [["72%", "DOWNREGULATOR", "ALDH2"]]}, {"text": " Beta-glucogallin  reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of  aldose reductase  in murine macrophages and ocular tissues", "triple_list": [["lipopolysaccharide-induced", "PRODUCT-OF", "aldose reductase"]]}, {"text": " Beta-glucogallin  (BGG), a recently described  AR  inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis)", "triple_list": [["Beta-glucogallin", "AGONIST", "the"]]}, {"text": "Beta-glucogallin ( BGG  , a recently described  AR  inhibitor, was purified from extracts of the Indian gooseberry (Emblica officinalis)", "triple_list": [["BGG", "PRODUCT-OF", "AR"]]}, {"text": "In this study, we found that  BGG  showed low cytotoxicity in Raw264.7 murine macrophages and effectively inhibited  AR  activity as measured by a decrease in sorbitol accumulation", "triple_list": [["BGG", "ACTIVATOR", "and"]]}, {"text": "In addition,  BGG  mediated inhibition of  AR  prevented LPS-induced activation of JNK and p38 and lowered ROS levels, which could inhibit LPS-induced apoptosis", "triple_list": [["BGG", "ANTAGONIST", "levels,"]]}, {"text": "In addition,  BGG  mediated inhibition of AR prevented LPS-induced activation of  JNK  and p38 and lowered ROS levels, which could inhibit LPS-induced apoptosis", "triple_list": [["prevented", "AGONIST", "JNK"]]}, {"text": "In addition,  BGG  mediated inhibition of AR prevented LPS-induced activation of JNK and  p38  and lowered ROS levels, which could inhibit LPS-induced apoptosis", "triple_list": [["could", "ACTIVATOR", "p38"]]}, {"text": " Aldose reductase  (AR) catalyzes the reduction of toxic lipid  aldehydes  to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)", "triple_list": [["aldehydes", "ANTAGONIST", "by"]]}, {"text": "Aldose reductase ( AR   catalyzes the reduction of toxic lipid  aldehydes  to their alcohol products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)", "triple_list": [["signals", "AGONIST", "AR"]]}, {"text": " Aldose reductase  (AR) catalyzes the reduction of toxic lipid aldehydes to their  alcohol  products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)", "triple_list": [["reduction", "ANTAGONIST", "Aldose reductase"]]}, {"text": "Aldose reductase ( AR   catalyzes the reduction of toxic lipid aldehydes to their  alcohol  products and mediates inflammatory signals triggered by lipopolysaccharide (LPS)", "triple_list": [["(", "ANTAGONIST", "AR"]]}, {"text": "Mechanisms limiting distribution of the  threonine-protein kinase B-RaF  V600E) inhibitor  dabrafenib  to the brain: implications for the treatment of melanoma brain metastases", "triple_list": [["dabrafenib", "PRODUCT-OF", "V600E)"]]}, {"text": "Mechanisms limiting distribution of the threonine-protein kinase B-RaF( V600E   inhibitor  dabrafenib  to the brain: implications for the treatment of melanoma brain metastases", "triple_list": [["of", "AGONIST", "V600E"]]}, {"text": "Further, compared with  vemurafenib   another  BRAF  V600E) inhibitor, dabrafenib showed greater brain penetration with a similar dose", "triple_list": [["similar", "ANTAGONIST", "BRAF"]]}, {"text": "Further, compared with  vemurafenib   another BRAF( V600E   inhibitor, dabrafenib showed greater brain penetration with a similar dose", "triple_list": [["vemurafenib", "ANTAGONIST", "dabrafenib"]]}, {"text": "In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that  dabrafenib  is an avid substrate for both  P-gp  and BCRP", "triple_list": [["II", "ANTAGONIST", "P-gp"]]}, {"text": "In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that  dabrafenib  is an avid substrate for both P-gp and  BCRP   Directional flux studies revealed greater transport in the basolateral to apical direction with corrected efflux ratios greater than 2 for both P-gp and Bcrp1 transfected cell lines", "triple_list": [["Madin-Darby", "AGONIST", "BCRP"]]}, {"text": "This study explored whether  curcumin  improves colonic inflammation in a rat colitis model through inhibition of the  TLR4  NF-\u03baB signaling pathway and IL-27 expression", "triple_list": [["curcumin", "PRODUCT-OF", "signaling"]]}, {"text": "This study explored whether  curcumin  improves colonic inflammation in a rat colitis model through inhibition of the TLR4/ NF-\u03baB  signaling pathway and IL-27 expression", "triple_list": [["curcumin", "AGONIST", "curcumin"]]}, {"text": "This study explored whether  curcumin  improves colonic inflammation in a rat colitis model through inhibition of the TLR4/NF-\u03baB signaling pathway and  IL-27  expression", "triple_list": [["expression", "PRODUCT-OF", "IL-27"]]}, {"text": "Compared with the untreated colitis group, the  curcumin  treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of  NF-\u03baB  mRNA, IL-27 mRNA, TLR4 protein,  NF-\u03baB  p65 protein, and IL-27 p28 protein (p < 0.05)", "triple_list": [["curcumin", "PRODUCT-OF", "0.05)"]]}, {"text": "Compared with the untreated colitis group, the  curcumin  treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA,  IL-27  mRNA, TLR4 protein, NF-\u03baB p65 protein, and  IL-27  p28 protein (p < 0.05)", "triple_list": [["curcumin", "ACTIVATOR", "histological"]]}, {"text": "Compared with the untreated colitis group, the  curcumin  treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA,  TLR4  protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05)", "triple_list": [["(p", "ANTAGONIST", "TLR4"]]}, {"text": "Compared with the untreated colitis group, the  curcumin  treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of  NF-\u03baB  mRNA, IL-27 mRNA, TLR4 protein,  NF-\u03baB  p65 protein, and IL-27 p28 protein (p < 0.05)", "triple_list": [["curcumin", "ACTIVATOR", "disease"]]}, {"text": "Compared with the untreated colitis group, the  curcumin  treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB  p65  protein, and IL-27 p28 protein (p < 0.05)", "triple_list": [["curcumin", "ANTAGONIST", "myeloperoxidase"]]}, {"text": "Compared with the untreated colitis group, the  curcumin  treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA,  IL-27  mRNA, TLR4 protein, NF-\u03baB p65 protein, and  IL-27  p28 protein (p < 0.05)", "triple_list": [["of", "AGONIST", "IL-27"]]}, {"text": "Compared with the untreated colitis group, the  curcumin  treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27  p28  protein (p < 0.05)", "triple_list": [["showed", "PRODUCT-OF", "p28"]]}, {"text": "Compared with the untreated colitis group, the  curcumin  treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score,  myeloperoxidase  activity, and expressions of NF-\u03baB mRNA, IL-27 mRNA, TLR4 protein, NF-\u03baB p65 protein, and IL-27 p28 protein (p < 0.05)", "triple_list": [["curcumin", "PRODUCT-OF", "IL-27"]]}, {"text": " Curcumin  improves TNBS-induced colitis in rats by inhibiting  IL-27  expression via the TLR4/NF-\u03baB signaling pathway", "triple_list": [["Curcumin", "ACTIVATOR", "inhibiting"]]}, {"text": " Curcumin  improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the  TLR4  NF-\u03baB signaling pathway", "triple_list": [["Curcumin", "ACTIVATOR", "via"]]}, {"text": " Curcumin  improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the TLR4/ NF-\u03baB  signaling pathway", "triple_list": [["Curcumin", "PRODUCT-OF", "pathway"]]}, {"text": "There was no significant difference in  TLR4   NF-\u03baB, and IL-27 mRNA and proteins between  curcumin  treated and sulfasalazine-treated groups", "triple_list": [["curcumin", "ANTAGONIST", "and"]]}, {"text": "There was no significant difference in TLR4,  NF-\u03baB   and IL-27 mRNA and proteins between  curcumin  treated and sulfasalazine-treated groups", "triple_list": [["curcumin", "ACTIVATOR", "was"]]}, {"text": "There was no significant difference in TLR4, NF-\u03baB, and  IL-27  mRNA and proteins between  curcumin  treated and sulfasalazine-treated groups", "triple_list": [["TLR4,", "PRODUCT-OF", "IL-27"]]}, {"text": "There was no significant difference in  TLR4   NF-\u03baB, and IL-27 mRNA and proteins between curcumin-treated and  sulfasalazine  treated groups", "triple_list": [["curcumin-treated", "ANTAGONIST", "TLR4"]]}, {"text": "There was no significant difference in TLR4,  NF-\u03baB   and IL-27 mRNA and proteins between curcumin-treated and  sulfasalazine  treated groups", "triple_list": [["and", "PRODUCT-OF", "NF-\u03baB"]]}, {"text": "There was no significant difference in TLR4, NF-\u03baB, and  IL-27  mRNA and proteins between curcumin-treated and  sulfasalazine  treated groups", "triple_list": [["proteins", "PRODUCT-OF", "IL-27"]]}, {"text": "The anti-inflammatory actions of  curcumin  on colitis may involve inhibition of the  TLR4  NF-\u03baB signaling pathway and of IL-27 expression.", "triple_list": [["curcumin", "ACTIVATOR", "actions"]]}, {"text": "The anti-inflammatory actions of  curcumin  on colitis may involve inhibition of the TLR4/ NF-\u03baB  signaling pathway and of IL-27 expression.", "triple_list": [["actions", "ANTAGONIST", "NF-\u03baB"]]}, {"text": "The anti-inflammatory actions of  curcumin  on colitis may involve inhibition of the TLR4/NF-\u03baB signaling pathway and of  IL-27  expression.", "triple_list": [["pathway", "PRODUCT-OF", "IL-27"]]}, {"text": "Central and peripheral administration of  kisspeptin  stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a  gonadotrophin releasing hormone  (GnRH) antagonist abolishes this effect", "triple_list": [["gonadotrophin releasing hormone", "ANTAGONIST", "hypothalamic-pituitary-gonadal"]]}, {"text": "Central and peripheral administration of  kisspeptin  stimulates the hypothalamic-pituitary-gonadal (HPG) axis whilst pre-administration of a gonadotrophin releasing hormone ( GnRH   antagonist abolishes this effect", "triple_list": [["this", "ACTIVATOR", "kisspeptin"]]}, {"text": "Several inhibitors of  Lp-PLA(2)  have been described, including  darapladib   which is currently in phase 3 clinical development for the treatment of atherosclerosis", "triple_list": [["darapladib", "AGONIST", "Several"]]}, {"text": "We show that both  darapladib  and a novel class of structurally distinct carbamate inhibitors inactivate  Lp-PLA(2)  in mouse tissues and human cell lines with high selectivity", "triple_list": [["darapladib", "PRODUCT-OF", "darapladib"]]}, {"text": "We show that both darapladib and a novel class of structurally distinct  carbamate  inhibitors inactivate  Lp-PLA(2)  in mouse tissues and human cell lines with high selectivity", "triple_list": [["carbamate", "ANTAGONIST", "and"]]}, {"text": "Identification of  benzofuran  central cores for the inhibition of  leukotriene A(4) hydrolase   Leukotrienes (LT's) are known to play a physiological role in inflammatory immune response", "triple_list": [["benzofuran", "PRODUCT-OF", "play"]]}, {"text": "This paper describes the identification and synthesis of substituted  benzofurans  as  LTH(4)H  inhibitors", "triple_list": [["benzofurans", "PRODUCT-OF", "This"]]}, {"text": " Benzofuran  28 showed dose responsive target engagement and provides a useful tool to explore a  LTA(4)H  inhibitor for the treatment of inflammatory diseases, such as asthma and inflammatory bowel disease (IBD).", "triple_list": [["(IBD).", "ANTAGONIST", "LTA(4)H"]]}, {"text": "Leukotriene A(4) hydrolase ( LTA(4) H  is a cystolic enzyme that stereospecifically catalyzes the transformation of  LTA(4)  to LTB(4)", "triple_list": [["is", "AGONIST", "LTA(4)H"]]}, {"text": " Leukotriene A(4) hydrolase  ( LTA(4) H) is a cystolic enzyme that stereospecifically catalyzes the transformation of  LTA(4)  to LTB(4)", "triple_list": [["LTA(4)", "DOWNREGULATOR", "the"]]}, {"text": "Leukotriene A(4) hydrolase ( LTA(4)H   is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to  LTB(4)    LTB(4)  is a known pro-inflammatory mediator", "triple_list": [["LTB(4)", "AGONIST", "Leukotriene"]]}, {"text": " Leukotriene A(4) hydrolase  (LTA(4)H) is a cystolic enzyme that stereospecifically catalyzes the transformation of LTA(4) to  LTB(4)    LTB(4)  is a known pro-inflammatory mediator", "triple_list": [["LTB(4)", "AGONIST", "that"]]}, {"text": "In addition, we found that  neoechinulin A  significantly suppressed the production of neurotoxic inflammatory mediator  tumour necrosis factor-\u03b1  (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells", "triple_list": [["neoechinulin A", "ANTAGONIST", "the"]]}, {"text": "In addition, we found that  neoechinulin A  significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 ( TNF-\u03b1  , interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells", "triple_list": [["found", "ANTAGONIST", "TNF-\u03b1"]]}, {"text": "In addition, we found that  neoechinulin A  significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1),  interleukin-1\u03b2  (IL-1\u03b2), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells", "triple_list": [["neoechinulin A", "PRODUCT-OF", "of"]]}, {"text": "In addition, we found that  neoechinulin A  significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 ( IL-1\u03b2  , interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells", "triple_list": [["neoechinulin A", "ACTIVATOR", "factor-\u03b1"]]}, {"text": "In addition, we found that  neoechinulin A  significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2),  interleukin-6  (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells", "triple_list": [["neoechinulin A", "ANTAGONIST", "mediator"]]}, {"text": "In addition, we found that  neoechinulin A  significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-\u03b1 (TNF-\u03b1), interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 ( IL-6  , and prostaglandin E2 (PGE2) in activated BV-2 cells", "triple_list": [["prostaglandin", "PRODUCT-OF", "IL-6"]]}, {"text": " Neoechinulin A  suppresses  amyloid-\u03b2  oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity", "triple_list": [["Neoechinulin A", "PRODUCT-OF", "toxicity"]]}, {"text": "The molecular mechanism studies suggested that  neoechinulin A  may block the phosphorylation of  mitogen-activated protein kinase  (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits", "triple_list": [["neoechinulin A", "AGONIST", "1"]]}, {"text": "The molecular mechanism studies suggested that  neoechinulin A  may block the phosphorylation of mitogen-activated protein kinase ( MAPK   molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits", "triple_list": [["neoechinulin A", "AGONIST", "(NF-\u03baB)"]]}, {"text": "The molecular mechanism studies suggested that  neoechinulin A  may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule  p38   apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits", "triple_list": [["neoechinulin A", "AGONIST", "mechanism"]]}, {"text": "The molecular mechanism studies suggested that  neoechinulin A  may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38,  apoptosis signal-regulating kinase 1  (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits", "triple_list": [["neoechinulin A", "ACTIVATOR", "1"]]}, {"text": "The molecular mechanism studies suggested that  neoechinulin A  may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 ( ASK-1   and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and p50 subunits", "triple_list": [["signal-regulating", "PRODUCT-OF", "ASK-1"]]}, {"text": "The molecular mechanism studies suggested that  neoechinulin A  may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of  nuclear factor-\u03baB  (NF-\u03baB) p65 and p50 subunits", "triple_list": [["neoechinulin A", "ANTAGONIST", "of"]]}, {"text": "The molecular mechanism studies suggested that  neoechinulin A  may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB ( NF-\u03baB   p65 and p50 subunits", "triple_list": [["and", "ACTIVATOR", "NF-\u03baB"]]}, {"text": "The molecular mechanism studies suggested that  neoechinulin A  may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB)  p65  and p50 subunits", "triple_list": [["the", "AGONIST", "p65"]]}, {"text": "The molecular mechanism studies suggested that  neoechinulin A  may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) p65 and  p50  subunits", "triple_list": [["nuclear", "ANTAGONIST", "p50"]]}, {"text": "In this study, focus was given to evaluate the ability of  neoechinulin A   an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric  amyloid-\u03b2 1-42  (A\u03b242)", "triple_list": [["neoechinulin A", "PRODUCT-OF", "1-42"]]}, {"text": "In this study, focus was given to evaluate the ability of  neoechinulin A   an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-\u03b2 1-42 ( A\u03b242  ", "triple_list": [["neoechinulin A", "ANTAGONIST", "study,"]]}, {"text": "In this study, focus was given to evaluate the ability of neoechinulin A, an  indole  alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric  amyloid-\u03b2 1-42  (A\u03b242)", "triple_list": [["indole", "ACTIVATOR", "ability"]]}, {"text": "In this study, focus was given to evaluate the ability of neoechinulin A, an  indole  alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-\u03b2 1-42 ( A\u03b242  ", "triple_list": [["indole", "AGONIST", "ability"]]}, {"text": " Neoechinulin A  treatment significantly inhibited the generation of reactive oxygen and nitrogen species in  A\u03b242  activated BV-2 microglia cells", "triple_list": [["Neoechinulin A", "PRODUCT-OF", "and"]]}, {"text": " Jaspamide  also inhibited other channels including  Cav1.2   Cav3.2, and HCN2; however, the Kv11.1 (hERG) channel was minimally affected", "triple_list": [["Jaspamide", "ANTAGONIST", "inhibited"]]}, {"text": " Jaspamide  also inhibited other channels including Cav1.2,  Cav3.2   and HCN2; however, the Kv11.1 (hERG) channel was minimally affected", "triple_list": [["Jaspamide", "PRODUCT-OF", "Jaspamide"]]}, {"text": " Jaspamide  also inhibited other channels including Cav1.2, Cav3.2, and  HCN2   however, the Kv11.1 (hERG) channel was minimally affected", "triple_list": [["other", "ACTIVATOR", "HCN2"]]}, {"text": "Among the isolated compounds,  trans-dihydromorin  (8), oxyresveratrol (9), and steppogenin (12) were found to exhibit significant  tyrosinase  inhibition activities", "triple_list": [["trans-dihydromorin", "PRODUCT-OF", "significant"]]}, {"text": "Among the isolated compounds, trans-dihydromorin (8),  oxyresveratrol  (9), and steppogenin (12) were found to exhibit significant  tyrosinase  inhibition activities", "triple_list": [["oxyresveratrol", "PRODUCT-OF", "trans-dihydromorin"]]}, {"text": "Among the isolated compounds, trans-dihydromorin (8), oxyresveratrol (9), and  steppogenin  (12) were found to exhibit significant  tyrosinase  inhibition activities", "triple_list": [["significant", "ANTAGONIST", "tyrosinase"]]}, {"text": " Cortisol  and IFNT stimulated endometrial  HSD11B1  expression and activity, increased endometrial PTGS2 activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium", "triple_list": [["Cortisol", "ANTAGONIST", "many"]]}, {"text": " Cortisol  and IFNT stimulated endometrial HSD11B1 expression and activity, increased endometrial  PTGS2  activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium", "triple_list": [["Cortisol", "DOWNREGULATOR", "elongation-related"]]}, {"text": "In study 1, cyclic ewes received vehicle, cortisol,  PF 915275  (PF; a selective inhibitor of  HSD11B1  , cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus", "triple_list": [["PF 915275", "ANTAGONIST", "or"]]}, {"text": "In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF,  meloxicam  (a selective inhibitor of  PTGS2  , cortisol and  meloxicam , recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus", "triple_list": [["meloxicam", "PRODUCT-OF", "received"]]}, {"text": "The primary aim of these studies was to test the hypothesis that  HSD11B1  derived  cortisol  has a biological role in endometrial function and conceptus development during early pregnancy in sheep", "triple_list": [["sheep", "AGONIST", "HSD11B1"]]}, {"text": "During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce  prostaglandins  (PG) via  PG synthase 2  (PTGS2) and cortisol via hydroxysteroid (11-\u03b2) dehydrogenase 1 (HSD11B1)", "triple_list": [["(IFNT)", "ACTIVATOR", "PG synthase 2"]]}, {"text": "During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce  prostaglandins  (PG) via PG synthase 2 ( PTGS2   and cortisol via hydroxysteroid (11-\u03b2) dehydrogenase 1 (HSD11B1)", "triple_list": [["prostaglandins", "DOWNREGULATOR", "pregnancy"]]}, {"text": "These results suggest that  HSD11B1  derived  cortisol  mediates, in part, actions of ovarian progesterone and the conceptus on endometrial function and support the hypothesis that IFNT, PG, and  cortisol  coordinately regulate endometrial functions important for conceptus elongation and implantation during early pregnancy in sheep.", "triple_list": [["endometrial", "ANTAGONIST", "HSD11B1"]]}, {"text": "During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and  cortisol  via  hydroxysteroid (11-\u03b2) dehydrogenase 1  (HSD11B1)", "triple_list": [["elongating", "ANTAGONIST", "hydroxysteroid (11-\u03b2) dehydrogenase 1"]]}, {"text": "During early pregnancy in sheep, the elongating conceptus secretes interferon-\u03c4 (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and  cortisol  via hydroxysteroid (11-\u03b2) dehydrogenase 1 ( HSD11B1  ", "triple_list": [["cortisol", "ANTAGONIST", "and"]]}, {"text": "Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean  isoflavone  increased gene expression of  heme oxygenase-1  (HO-1), a major antioxidative stress enzyme", "triple_list": [["isoflavone", "PRODUCT-OF", "and"]]}, {"text": "Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean  isoflavone  increased gene expression of heme oxygenase-1 ( HO-1  , a major antioxidative stress enzyme", "triple_list": [["isoflavone", "ANTAGONIST", "breast"]]}, {"text": "Overall, higher alcohol production was reduced by  ammonium  supplementation, and this can be correlated with a general downregulation of genes encoding  decarboxylases  and dehydrogenases of the Ehrlich pathway", "triple_list": [["ammonium", "ACTIVATOR", "be"]]}, {"text": "Overall, higher alcohol production was reduced by  ammonium  supplementation, and this can be correlated with a general downregulation of genes encoding decarboxylases and  dehydrogenases  of the Ehrlich pathway", "triple_list": [["ammonium", "ACTIVATOR", "Ehrlich"]]}, {"text": "An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a ( SCH 900229  , a potent,  PS1  selective \u03b3-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease", "triple_list": [["SCH", "ACTIVATOR", "PS1"]]}, {"text": "An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a ( SCH 900229  , a potent, PS1-selective  \u03b3-secretase  inhibitor and clinical candidate for the treatment of Alzheimer's disease", "triple_list": [["detailed", "PRODUCT-OF", "\u03b3-secretase"]]}, {"text": "Structure activity relationship studies of  tricyclic bispyran sulfone   \u03b3-secretase  inhibitors", "triple_list": [["tricyclic bispyran sulfone", "AGONIST", "inhibitors"]]}, {"text": "In this study, aldosterone ( ALD  -induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of  calpain  signaling were clarified", "triple_list": [["ALD", "AGONIST", "the"]]}, {"text": " ALD  increased  calpain  expression and caspase-3 activity and promoted Bid cleavage", "triple_list": [["calpain", "PRODUCT-OF", "calpain"]]}, {"text": " ALD  increased calpain expression and  caspase-3  activity and promoted Bid cleavage", "triple_list": [["ALD", "PRODUCT-OF", "and"]]}, {"text": "Activation of an apoptotic signal transduction pathway involved in the upregulation of  calpain  and apoptosis-inducing factor in  aldosterone  induced primary cultured cardiomyocytes", "triple_list": [["aldosterone", "PRODUCT-OF", "apoptotic"]]}, {"text": "Activation of an apoptotic signal transduction pathway involved in the upregulation of calpain and  apoptosis-inducing factor  in  aldosterone  induced primary cultured cardiomyocytes", "triple_list": [["aldosterone", "AGONIST", "apoptotic"]]}, {"text": "The upregulation of  calpain   tBid and caspase-3 activity were further inhibited by treatment with EGTA in the presence of  ALD   Additionally, AIF levels in the cytosol decreased due to EGTA but not due to calpeptin", "triple_list": [["ALD", "ANTAGONIST", "due"]]}, {"text": "The upregulation of calpain,  tBid  and caspase-3 activity were further inhibited by treatment with EGTA in the presence of  ALD   Additionally, AIF levels in the cytosol decreased due to EGTA but not due to calpeptin", "triple_list": [["due", "ANTAGONIST", "tBid"]]}, {"text": "The upregulation of calpain, tBid and  caspase-3  activity were further inhibited by treatment with EGTA in the presence of  ALD   Additionally, AIF levels in the cytosol decreased due to EGTA but not due to calpeptin", "triple_list": [["activity", "PRODUCT-OF", "caspase-3"]]}, {"text": "Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of  ALD  but reversed the  ALD  induced increase of  calpain  and AIF levels.", "triple_list": [["ALD", "DOWNREGULATOR", "attenuated"]]}, {"text": "Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of  ALD  but reversed the  ALD  induced increase of calpain and  AIF  levels.", "triple_list": [["ALD", "DOWNREGULATOR", "AIF"]]}, {"text": "In this study,  aldosterone  (ALD)-induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of  calpain  signaling were clarified", "triple_list": [["aldosterone", "AGONIST", "study,"]]}, {"text": "The upregulation of  calpain   tBid and caspase-3 activity were further inhibited by treatment with  EGTA  in the presence of ALD", "triple_list": [["EGTA", "ACTIVATOR", "upregulation"]]}, {"text": "The upregulation of calpain,  tBid  and caspase-3 activity were further inhibited by treatment with  EGTA  in the presence of ALD", "triple_list": [["EGTA", "AGONIST", "ALD"]]}, {"text": "The upregulation of calpain, tBid and  caspase-3  activity were further inhibited by treatment with  EGTA  in the presence of ALD", "triple_list": [["The", "PRODUCT-OF", "caspase-3"]]}, {"text": "Additionally,  AIF  levels in the cytosol decreased due to  EGTA  but not due to calpeptin", "triple_list": [["to", "AGONIST", "AIF"]]}, {"text": "Furthermore, treatment with  spironoclactone  not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of  calpain  and AIF levels.", "triple_list": [["spironoclactone", "PRODUCT-OF", "spironoclactone"]]}, {"text": "Furthermore, treatment with  spironoclactone  not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of calpain and  AIF  levels.", "triple_list": [["spironoclactone", "ACTIVATOR", "and"]]}, {"text": "Furthermore, compared with control groups, the plaque endothelium level of  p75(NTR)  was 3-fold increased and the liver level of  p75(NTR)  was 17.4-fold increased by  SFO  HD", "triple_list": [["SFO", "DOWNREGULATOR", "17.4-fold"]]}, {"text": "Furthermore, compared with control groups, the plaque endothelium level of  p75(NTR)  was 3-fold increased and the liver level of  p75(NTR)  was 17.4-fold increased by  SFO  HD", "triple_list": [["SFO", "ANTAGONIST", "SFO"]]}, {"text": "Meanwhile, the serum level of KC (a functional homolog of  IL-8  and the main proinflammatory alpha chemokine in mice) in apoE(-/-) mice was up to 357pg/ml in  SFO  HD treated group", "triple_list": [["SFO", "PRODUCT-OF", "mice)"]]}, {"text": "Meanwhile, the serum level of KC (a functional homolog of IL-8 and the main proinflammatory  alpha chemokine  in mice) in apoE(-/-) mice was up to 357pg/ml in  SFO  HD treated group", "triple_list": [["SFO", "PRODUCT-OF", "Meanwhile,"]]}, {"text": "Thus,  SFO  contributes to the instability of atherosclerotic plaque in apoE(-/-) mice through activating  p75(NTR)  and IL-8 and cell apoptosis in plaque.", "triple_list": [["and", "AGONIST", "p75(NTR)"]]}, {"text": "Thus,  SFO  contributes to the instability of atherosclerotic plaque in apoE(-/-) mice through activating p75(NTR) and  IL-8  and cell apoptosis in plaque.", "triple_list": [["Thus,", "DOWNREGULATOR", "IL-8"]]}, {"text": "\u03b2-Amyloid aggregation results showed that all compounds exhibited remarkable  A\u03b2  fibril aggregation inhibition activity with a nearly similar potential as the reference compound  rifampicin   which makes them promising anti-Alzheimer drug candidates", "triple_list": [["rifampicin", "AGONIST", "\u03b2-Amyloid"]]}, {"text": "To develop new drugs for treatment of Alzheimer's disease, a group of  N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones  was designed, synthesized and tested for their ability to inhibit  acetylcholinesterase   butyrylcholinesterase and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42)", "triple_list": [["N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones", "PRODUCT-OF", "1-42"]]}, {"text": "To develop new drugs for treatment of Alzheimer's disease, a group of  N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones  was designed, synthesized and tested for their ability to inhibit acetylcholinesterase,  butyrylcholinesterase  and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42)", "triple_list": [["N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones", "PRODUCT-OF", "disease,"]]}, {"text": "Synthesis, molecular modeling and evaluation of novel  N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone  derivatives as dual inhibitors for  cholinesterases  and A\u03b2 aggregation", "triple_list": [["novel", "AGONIST", "cholinesterases"]]}, {"text": "Synthesis, molecular modeling and evaluation of novel  N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone  derivatives as dual inhibitors for cholinesterases and  A\u03b2  aggregation", "triple_list": [["N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone", "ACTIVATOR", "aggregation"]]}, {"text": "Furthermore,  DOX  treated WT and  p65 (-/-) MEFs differed in their expression of various apoptosis-associated molecules, when the former demonstrated a decrease in the percentage of  p65  positive and a more prominent decrease in the percentage of p53-positive cells, while a decreased percentage of I\u03baB\u03b1-positive and a more prominent decrease in the percentage of bcl-2-positive cells was detected among the latter", "triple_list": [["DOX", "ACTIVATOR", "and"]]}, {"text": "G6PC2: A Negative Regulator of Basal  Glucose  Stimulated  Insulin  Secretion", "triple_list": [["Regulator", "DOWNREGULATOR", "Insulin"]]}, {"text": "G6pc2 deletion resulted in a leftward shift in the dose-response curve for  glucose  stimulated  insulin  secretion (GSIS)", "triple_list": [["glucose", "DOWNREGULATOR", "in"]]}, {"text": "These data suggest that  G6pc2  represents a novel, negative regulator of basal GSIS that acts by hydrolyzing  glucose-6-phosphate   thereby reducing glycolytic flux.", "triple_list": [["data", "ANTAGONIST", "G6pc2"]]}, {"text": " Fisetin  treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma  insulin   The treatment also improved the antioxidant status in pancreas as well as plasma of diabetic rats indicating the antioxidant potential of fisetin", "triple_list": [["in", "PRODUCT-OF", "insulin"]]}, {"text": " Fisetin  treatment showed a significant decline in the levels of blood glucose,  glycosylated hemoglobin  (HbA1c), NF-kB p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin", "triple_list": [["showed", "PRODUCT-OF", "glycosylated hemoglobin"]]}, {"text": " Fisetin  treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin ( HbA1c  , NF-kB p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin", "triple_list": [["Fisetin", "ACTIVATOR", "nitric"]]}, {"text": " Fisetin  treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c),  NF-kB  p65 unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin", "triple_list": [["Fisetin", "AGONIST", "glucose,"]]}, {"text": " Fisetin  treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB  p65  unit (in pancreas) and IL-1\u03b2 (plasma), serum nitric oxide (NO) with an elevation in plasma insulin", "triple_list": [["decline", "PRODUCT-OF", "p65"]]}, {"text": " Fisetin  treatment showed a significant decline in the levels of blood glucose, glycosylated hemoglobin (HbA1c), NF-kB p65 unit (in pancreas) and  IL-1\u03b2  (plasma), serum nitric oxide (NO) with an elevation in plasma insulin", "triple_list": [["glycosylated", "AGONIST", "IL-1\u03b2"]]}, {"text": "Next to  Glut-4   the predominant protein influencing  glucose  metabolism is PPAR\u03b1 and \u03b3 whose expressions were also positively modulated", "triple_list": [["were", "AGONIST", "Glut-4"]]}, {"text": "Absorption and secretion of  fluoride  increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a F(-)/H(+) cotransporter or a  F(-)/OH(-) antiporter   The results also suggest transcellular participation of mechanisms involved in transport of Cl(-) and of an active transport in the secretory direction", "triple_list": [["a", "ANTAGONIST", "F(-)/OH(-) antiporter"]]}, {"text": "Absorption and secretion of  fluoride  increase at acid pH levels, possibly because of its non-ionized state at these pHs and/or because of participation of a  F(-)/H(+) cotransporter  or a F(-)/OH(-) antiporter", "triple_list": [["increase", "ANTAGONIST", "F(-)/H(+) cotransporter"]]}, {"text": " KCNK1   a member of the family of two-pore K(+) ion channels, is specifically induced in the livers of male mice after  phenobarbital  treatment", "triple_list": [["phenobarbital", "ANTAGONIST", "specifically"]]}, {"text": "KCNK1, a member of the family of two-pore  K(+) ion channels   is specifically induced in the livers of male mice after  phenobarbital  treatment", "triple_list": [["mice", "DOWNREGULATOR", "K(+) ion channels"]]}, {"text": "Here, we have determined the molecular mechanism of this male-specific activation of the  Kcnk1  gene and characterized KCNK1 as a  phenobarbital  inducible antihyperplasia factor", "triple_list": [["mechanism", "AGONIST", "Kcnk1"]]}, {"text": "Here, we have determined the molecular mechanism of this male-specific activation of the Kcnk1 gene and characterized  KCNK1  as a  phenobarbital  inducible antihyperplasia factor", "triple_list": [["phenobarbital", "AGONIST", "we"]]}, {"text": "Upon activation by  phenobarbital    nuclear receptor  CAR binds the 97-bp response element (-2441/-2345) within the Kcnk1 promoter", "triple_list": [["activation", "PRODUCT-OF", "nuclear receptor"]]}, {"text": "Upon activation by  phenobarbital   nuclear receptor  CAR  binds the 97-bp response element (-2441/-2345) within the Kcnk1 promoter", "triple_list": [["response", "DOWNREGULATOR", "CAR"]]}, {"text": "These results indicate that  phenobarbital  treatment induces  KCNK1  to elicit a male-specific and growth-suppressing signal", "triple_list": [["results", "AGONIST", "KCNK1"]]}, {"text": "The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of  navitoclax   a selective inhibitor of both  BCL-2  and  BCL-2 -like 1 (BCL-X(L)), which has shown clinical efficacy in some  BCL-2 -dependent hematological cancers", "triple_list": [["both", "ANTAGONIST", "BCL-2"]]}, {"text": "The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of  navitoclax   a selective inhibitor of both BCL-2 and  BCL-2-like 1  (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers", "triple_list": [["navitoclax", "PRODUCT-OF", "BCL-2"]]}, {"text": "The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of  navitoclax   a selective inhibitor of both BCL-2 and BCL-2-like 1 ( BCL-X(L)  , which has shown clinical efficacy in some BCL-2-dependent hematological cancers", "triple_list": [["was", "PRODUCT-OF", "BCL-X(L)"]]}, {"text": "Here we report the re-engineering of  navitoclax  to create a highly potent, orally bioavailable and  BCL-2  selective inhibitor, ABT-199", "triple_list": [["ABT-199", "PRODUCT-OF", "BCL-2"]]}, {"text": "Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and  BCL-2  selective inhibitor,  ABT-199   This compound inhibits the growth of  BCL-2 -dependent tumors in vivo and spares human platelets", "triple_list": [["navitoclax", "ACTIVATOR", "BCL-2"]]}, {"text": " ABT-199   a potent and selective  BCL-2  inhibitor, achieves antitumor activity while sparing platelets", "triple_list": [["selective", "ACTIVATOR", "BCL-2"]]}, {"text": "Cotreatments of 5, 10 and 20 \u00b5g/mL concentrations of MEP with  aflatoxin B(1)  decreased the frequencies of SCE and the malondialdehyde level and increased amount of  superoxide dismutase   glutathione and glutathione peroxidase which were decreased by aflatoxin", "triple_list": [["aflatoxin B(1)", "DOWNREGULATOR", "Cotreatments"]]}, {"text": "Cotreatments of 5, 10 and 20 \u00b5g/mL concentrations of MEP with  aflatoxin  B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase, glutathione and  glutathione peroxidase  which were decreased by  aflatoxin   The data obtained from this work have clearly shown that MEP has significant antigenotoxic effects which are thought to be partly due to the antioxidant activities and antioxidant inducing capability of MEP", "triple_list": [["from", "PRODUCT-OF", "glutathione peroxidase"]]}, {"text": " All-trans retinoic acid  protects hepatocellular carcinoma cells against serum-starvation-induced cell death by upregulating  collagen 8A2   As a therapeutic or chemopreventative agent for various cancers, all-trans retinoic acid (atRA) has been reported to inhibit growth, induce apoptosis or cause differentiation", "triple_list": [["All-trans retinoic acid", "ANTAGONIST", "cells"]]}, {"text": "Local  PGE2  administration prevented the increase of airway  IL-13  and osteopontin and kept lung plasmacytoid dendritic cell counts close to baseline", "triple_list": [["PGE2", "AGONIST", "IL-13"]]}, {"text": "Local  PGE2  administration prevented the increase of airway IL-13 and  osteopontin  and kept lung plasmacytoid dendritic cell counts close to baseline", "triple_list": [["cell", "ACTIVATOR", "osteopontin"]]}, {"text": "Lung inflammation,  IL-4  production, and airway mast cell activity were also prevented under this early short-term treatment with  PGE2   Interestingly, a Th2 response was already committed on day 5 of exposure to HDM", "triple_list": [["PGE2", "ACTIVATOR", "mast"]]}, {"text": "The IC50 values for  Gli1  mRNA inhibition in the tumor and skin by  TAK-441  were estimated to be 0.0457 and 0.113 \u03bcg/ml, respectively", "triple_list": [["TAK-441", "PRODUCT-OF", "Gli1"]]}, {"text": "6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide ( TAK-441   is a potent, selective  hedgehog  signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer", "triple_list": [["TAK-441", "AGONIST", "cancer"]]}, {"text": "Pharmacokinetic and pharmacodynamic modeling of  hedgehog  inhibitor  TAK-441  for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice", "triple_list": [["TAK-441", "ACTIVATOR", "and"]]}, {"text": "Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor  TAK-441  for the inhibition of  Gli1  messenger RNA expression and antitumor efficacy in xenografted tumor model mice", "triple_list": [["TAK-441", "ACTIVATOR", "of"]]}, {"text": "An amphiphile with branched  poly(ethylene glycol)  architecture also activated the  lectin  pathway but only through L-ficolin recognition", "triple_list": [["poly(ethylene glycol)", "DOWNREGULATOR", "activated"]]}, {"text": "In addition, the new compound  perviridicin B  (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant  NF-\u03baB  (p65) inhibitory activity in an ELISA assay.", "triple_list": [["12),", "PRODUCT-OF", "NF-\u03baB"]]}, {"text": "In addition, the new compound  perviridicin B  (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB ( p65   inhibitory activity in an ELISA assay.", "triple_list": [["perviridicin B", "ANTAGONIST", "showed"]]}, {"text": "In addition, the new compound perviridicin B (2), three known  rocaglate  derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant  NF-\u03baB  (p65) inhibitory activity in an ELISA assay.", "triple_list": [["assay.", "ANTAGONIST", "NF-\u03baB"]]}, {"text": "In addition, the new compound perviridicin B (2), three known  rocaglate  derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB ( p65   inhibitory activity in an ELISA assay.", "triple_list": [["known", "AGONIST", "p65"]]}, {"text": "In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known  sesquiterpene   2-oxaisodauc-5-en-12-al (17), showed significant  NF-\u03baB  (p65) inhibitory activity in an ELISA assay.", "triple_list": [["sesquiterpene", "AGONIST", "known"]]}, {"text": "In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known  sesquiterpene   2-oxaisodauc-5-en-12-al (17), showed significant NF-\u03baB ( p65   inhibitory activity in an ELISA assay.", "triple_list": [["assay.", "AGONIST", "p65"]]}, {"text": "In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene,  2-oxaisodauc-5-en-12-al  (17), showed significant  NF-\u03baB  (p65) inhibitory activity in an ELISA assay.", "triple_list": [["rocaglate", "AGONIST", "NF-\u03baB"]]}, {"text": "In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene,  2-oxaisodauc-5-en-12-al  (17), showed significant NF-\u03baB ( p65   inhibitory activity in an ELISA assay.", "triple_list": [["2-oxaisodauc-5-en-12-al", "PRODUCT-OF", "known"]]}, {"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported  NRF2  target genes in response to  NRF2  inducers ( sulforaphane   tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments", "triple_list": [["highly", "ANTAGONIST", "NRF2"]]}, {"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported  NRF2  target genes in response to  NRF2  inducers ( sulforaphane   tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments", "triple_list": [["sulforaphane", "ANTAGONIST", "cells,"]]}, {"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers ( sulforaphane   tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the  aldo-keto reductase (AKR) 1C1  is highly inducible by all treatments", "triple_list": [["is", "PRODUCT-OF", "aldo-keto reductase (AKR) 1C1"]]}, {"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported  NRF2  target genes in response to  NRF2  inducers (sulforaphane,  tert-butylhydroquinone   cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments", "triple_list": [["tert-butylhydroquinone", "AGONIST", "aldehyde,"]]}, {"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported  NRF2  target genes in response to  NRF2  inducers (sulforaphane,  tert-butylhydroquinone   cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments", "triple_list": [["by", "DOWNREGULATOR", "NRF2"]]}, {"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane,  tert-butylhydroquinone   cinnamic aldehyde, and hydrogen peroxide) showed that the  aldo-keto reductase (AKR) 1C1  is highly inducible by all treatments", "triple_list": [["tert-butylhydroquinone", "ANTAGONIST", "NRF2"]]}, {"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported  NRF2  target genes in response to  NRF2  inducers (sulforaphane, tert-butylhydroquinone,  cinnamic aldehyde   and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments", "triple_list": [["aldo-keto", "ANTAGONIST", "NRF2"]]}, {"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported  NRF2  target genes in response to  NRF2  inducers (sulforaphane, tert-butylhydroquinone,  cinnamic aldehyde   and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments", "triple_list": [["the", "PRODUCT-OF", "NRF2"]]}, {"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone,  cinnamic aldehyde   and hydrogen peroxide) showed that the  aldo-keto reductase (AKR) 1C1  is highly inducible by all treatments", "triple_list": [["(sulforaphane,", "ANTAGONIST", "aldo-keto reductase (AKR) 1C1"]]}, {"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported  NRF2  target genes in response to  NRF2  inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and  hydrogen peroxide   showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments", "triple_list": [["the", "PRODUCT-OF", "NRF2"]]}, {"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported  NRF2  target genes in response to  NRF2  inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and  hydrogen peroxide   showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments", "triple_list": [["the", "DOWNREGULATOR", "NRF2"]]}, {"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and  hydrogen peroxide   showed that the  aldo-keto reductase (AKR) 1C1  is highly inducible by all treatments", "triple_list": [["epithelial", "PRODUCT-OF", "aldo-keto reductase (AKR) 1C1"]]}, {"text": "The treatment of U937 cells with  NRF2  inducers including  sulforaphane  effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3", "triple_list": [["sulforaphane", "ANTAGONIST", "1C1,"]]}, {"text": "The treatment of U937 cells with NRF2 inducers including  sulforaphane  effectively elevated the expression of  AKR1B1, 1B10, 1C1, 1C2, and 1C3   Whereas, the levels of both the basal and  sulforaphane -inducible expression of AKR1C1 were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells", "triple_list": [["sulforaphane", "PRODUCT-OF", "inducers"]]}, {"text": "Whereas, the levels of both the basal and  sulforaphane  inducible expression of  AKR1C1  were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells", "triple_list": [["and", "ANTAGONIST", "AKR1C1"]]}, {"text": " PTE  also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins ( Bax   Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27", "triple_list": [["and", "PRODUCT-OF", "Bax"]]}, {"text": " PTE  also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax,  Bak   cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27", "triple_list": [["PTE", "PRODUCT-OF", "proteins"]]}, {"text": " PTE  also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic  Cytochrome c   and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27", "triple_list": [["PTE", "ANTAGONIST", "of"]]}, {"text": " PTE  also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved  Caspase3   and cyclin-dependent kinase inhibitors such as p21 and p27", "triple_list": [["p21", "ANTAGONIST", "Caspase3"]]}, {"text": " PTE  also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as  p21  and p27", "triple_list": [["cleaved", "ANTAGONIST", "p21"]]}, {"text": " PTE  also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and  p27    PTE , used in combination with a known JAK2/STAT3 inhibitor, AG490, further decreased the viability of osteosarcoma cells", "triple_list": [["PTE", "AGONIST", "the"]]}, {"text": " Pterostilbene  exerts antitumor activity against human osteosarcoma cells by inhibiting the  JAK2  STAT3 signaling pathway", "triple_list": [["Pterostilbene", "ANTAGONIST", "activity"]]}, {"text": " Pterostilbene  exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/ STAT3  signaling pathway", "triple_list": [["exerts", "AGONIST", "STAT3"]]}, {"text": "Furthermore,  PTE  treatment directly inhibited the phosphorylation of  JAK2  at Tyr 1007 and the downstream activation of STAT3", "triple_list": [["JAK2", "ACTIVATOR", "JAK2"]]}, {"text": "Furthermore,  PTE  treatment directly inhibited the phosphorylation of JAK2 at Tyr 1007 and the downstream activation of  STAT3    PTE  also down-regulated the expression of  STAT3  target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27", "triple_list": [["up-regulation", "ANTAGONIST", "STAT3"]]}, {"text": " PTE  also down-regulated the expression of  STAT3  target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27", "triple_list": [["pathway-related", "ANTAGONIST", "STAT3"]]}, {"text": " PTE  also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins  Bcl-xL  and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27", "triple_list": [["PTE", "ANTAGONIST", "Caspase3)"]]}, {"text": " PTE  also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and  Mcl-1   leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27", "triple_list": [["PTE", "ANTAGONIST", "the"]]}, {"text": "PTE, used in combination with a known  JAK2  STAT3 inhibitor,  AG490   further decreased the viability of osteosarcoma cells", "triple_list": [["used", "ACTIVATOR", "JAK2"]]}, {"text": "PTE, used in combination with a known JAK2/ STAT3  inhibitor,  AG490   further decreased the viability of osteosarcoma cells", "triple_list": [["with", "ACTIVATOR", "STAT3"]]}, {"text": "Taken together,  PTE  is a potent inhibitor of osteosarcoma cell growth that targets the  JAK2  STAT3 signaling pathway", "triple_list": [["PTE", "AGONIST", "JAK2"]]}, {"text": "Taken together,  PTE  is a potent inhibitor of osteosarcoma cell growth that targets the JAK2/ STAT3  signaling pathway", "triple_list": [["PTE", "ACTIVATOR", "inhibitor"]]}, {"text": "These data suggest that inhibition of  JAK2  STAT3 signaling is a novel mechanism of action for  PTE  during therapeutic intervention in osteosarcoma cancers.", "triple_list": [["PTE", "ANTAGONIST", "a"]]}, {"text": "These data suggest that inhibition of JAK2/ STAT3  signaling is a novel mechanism of action for  PTE  during therapeutic intervention in osteosarcoma cancers.", "triple_list": [["PTE", "ANTAGONIST", "These"]]}, {"text": "In Alexander cells, only when they were transfected with FXR+RXR,  GW4064  caused up-regulation of  SHP  and OST\u03b2, and a down-regulation of CYP27A1", "triple_list": [["and", "DOWNREGULATOR", "SHP"]]}, {"text": "In Alexander cells, only when they were transfected with FXR+RXR,  GW4064  caused up-regulation of SHP and  OST\u03b2   and a down-regulation of CYP27A1", "triple_list": [["GW4064", "DOWNREGULATOR", "transfected"]]}, {"text": "Moreover, GCs have a synergistic effect on  GW4064  induced  FXR  activation, whereas chenodeoxycholate and  GW4064  have an additive effect", "triple_list": [["GCs", "PRODUCT-OF", "FXR"]]}, {"text": "In Alexander cells, only when they were transfected with FXR+RXR,  GW4064  caused up-regulation of SHP and OST\u03b2, and a down-regulation of  CYP27A1   GCs had the opposite effect on these genes, both in the absence and in the presence of FXR expression", "triple_list": [["GW4064", "AGONIST", "with"]]}, {"text": "With the elevated doses of  PhIP , malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3)  PhIP  at the doses of 10mg/kg and/or 15mg/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and  c-jun  expression relative to control", "triple_list": [["contents,", "PRODUCT-OF", "c-jun"]]}, {"text": "With the elevated doses of  PhIP , malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3)  PhIP  at the doses of 10mg/kg and/or 15mg/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced  c-fos  and c-jun expression relative to control", "triple_list": [["10mg/kg", "ANTAGONIST", "c-fos"]]}, {"text": "The data indicated that  PhIP  could cause stomach injury, oxidative stress in rat stomachs as well as the activation of  c-fos  and c-jun and inactivation of p16, which may play a role in the pathogenesis of  PhIP -associated stomach cancer.", "triple_list": [["PhIP", "ANTAGONIST", "stomachs"]]}, {"text": "The data indicated that  PhIP  could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and  c-jun  and inactivation of p16, which may play a role in the pathogenesis of  PhIP -associated stomach cancer.", "triple_list": [["PhIP", "DOWNREGULATOR", "in"]]}, {"text": "The results showed that (1) 15mg/kg body weight  PhIP  induced obvious histopathological changes in gastric mucosa; (2)  PhIP  (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased  catalase  (CAT) activity compared with the control", "triple_list": [["PhIP", "ANTAGONIST", "(1)"]]}, {"text": "The results showed that (1) 15mg/kg body weight  PhIP  induced obvious histopathological changes in gastric mucosa; (2)  PhIP  (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase ( CAT   activity compared with the control", "triple_list": [["PhIP", "ANTAGONIST", "(SOD)"]]}, {"text": "With the elevated doses of  PhIP , malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3)  PhIP  at the doses of 10mg/kg and/or 15mg/kg significantly inhibited  p16  mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control", "triple_list": [["the", "PRODUCT-OF", "p16"]]}, {"text": "The data indicated that  PhIP  could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and c-jun and inactivation of  p16   which may play a role in the pathogenesis of  PhIP -associated stomach cancer.", "triple_list": [["stomachs", "AGONIST", "p16"]]}, {"text": "The results showed that (1) 15mg/kg body weight  PhIP  induced obvious histopathological changes in gastric mucosa; (2)  PhIP  (10 and/or 15mg/kg) significantly decreased  superoxide dismutase  (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control", "triple_list": [["PhIP", "PRODUCT-OF", "15mg/kg)"]]}, {"text": "The results showed that (1) 15mg/kg body weight  PhIP  induced obvious histopathological changes in gastric mucosa; (2)  PhIP  (10 and/or 15mg/kg) significantly decreased superoxide dismutase ( SOD   and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control", "triple_list": [["PhIP", "ACTIVATOR", "(CAT)"]]}, {"text": "The results showed that (1) 15mg/kg body weight  PhIP  induced obvious histopathological changes in gastric mucosa; (2)  PhIP  (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and  glutathioneperoxidase  (GPx) activities, while increased catalase (CAT) activity compared with the control", "triple_list": [["PhIP", "ANTAGONIST", "weight"]]}, {"text": "The results showed that (1) 15mg/kg body weight  PhIP  induced obvious histopathological changes in gastric mucosa; (2)  PhIP  (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase ( GPx   activities, while increased catalase (CAT) activity compared with the control", "triple_list": [["(SOD)", "ACTIVATOR", "GPx"]]}, {"text": "military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective  acetylcholinesterase  reactivator,  1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate  (MMB-4)", "triple_list": [["1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate", "AGONIST", "under"]]}, {"text": "military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective  acetylcholinesterase  reactivator, 1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate ( MMB-4  ", "triple_list": [["military", "ANTAGONIST", "acetylcholinesterase"]]}, {"text": "Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to  SiO(2)  NPs, the messenger RNA level of apoptotic genes ( caspase-3  and caspase-9) were upregulated in a dose-dependent manner", "triple_list": [["SiO(2)", "PRODUCT-OF", "dose-dependent"]]}, {"text": "Quantitative real-time polymerase chain reaction analysis showed that following the exposure of cells to  SiO(2)  NPs, the messenger RNA level of apoptotic genes (caspase-3 and  caspase-9   were upregulated in a dose-dependent manner", "triple_list": [["SiO(2)", "PRODUCT-OF", "chain"]]}, {"text": "Moreover, activities of  caspase-3  and caspase-9 enzymes were also significantly higher in both kinds of cells exposed to  SiO(2)  NPs", "triple_list": [["and", "ANTAGONIST", "caspase-3"]]}, {"text": "Moreover, activities of caspase-3 and  caspase-9  enzymes were also significantly higher in both kinds of cells exposed to  SiO(2)  NPs", "triple_list": [["SiO(2)", "AGONIST", "higher"]]}, {"text": "The mouse  CYP2J  subfamily includes members that have wide tissue distribution and are active in the metabolism of  arachidonic acid  (AA), linoleic acid (LA), and other lipids and xenobiotics", "triple_list": [["are", "AGONIST", "CYP2J"]]}, {"text": "The mouse  CYP2J  subfamily includes members that have wide tissue distribution and are active in the metabolism of arachidonic acid (AA),  linoleic acid  (LA), and other lipids and xenobiotics", "triple_list": [["linoleic acid", "AGONIST", "and"]]}, {"text": "Particularly, the effects of  doxycycline  used as a non selective  MMP  inhibitor in experimental and clinical studies will be discussed.", "triple_list": [["non", "ACTIVATOR", "MMP"]]}, {"text": "Functional and biochemical studies indicated that  TES  signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the  androgen receptor  and culminated in enhanced production of cGMP and microvascular vasodilation", "triple_list": [["B", "PRODUCT-OF", "androgen receptor"]]}, {"text": "These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by  peroxynitrite  formed from  xanthine oxidase  generated superoxide and NO", "triple_list": [["analytical", "ACTIVATOR", "xanthine oxidase"]]}, {"text": "These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from  xanthine oxidase  generated  superoxide  and NO", "triple_list": [["vasodilation", "ACTIVATOR", "xanthine oxidase"]]}, {"text": "These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from  xanthine oxidase  generated superoxide and  NO   This response was associated with activation of the PI3 kinase-Akt signaling cascade initiated by activation of the androgen receptor", "triple_list": [["NO", "DOWNREGULATOR", "formed"]]}, {"text": "As predicted,  TES  enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and  xanthine oxidase  was identified as the likely source of  TES  stimulated superoxide production", "triple_list": [["TES", "ANTAGONIST", "of"]]}, {"text": "As predicted, TES enhanced the production of both peroxynitrite precursors (i.e.,  superoxide  and nitic oxide), and  xanthine oxidase  was identified as the likely source of TES-stimulated  superoxide  production", "triple_list": [["oxide),", "DOWNREGULATOR", "xanthine oxidase"]]}, {"text": " Butein  also increased  heme oxygenase-1  (HO-1) protein expression and HO activity", "triple_list": [["heme", "PRODUCT-OF", "heme oxygenase-1"]]}, {"text": " Butein  also increased heme oxygenase-1 ( HO-1   protein expression and HO activity", "triple_list": [["Butein", "DOWNREGULATOR", "protein"]]}, {"text": " Butein  also increased heme oxygenase-1 ( HO -1) protein expression and  HO  activity", "triple_list": [["(", "DOWNREGULATOR", "HO"]]}, {"text": "Furthermore,  butein  treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of  antioxidant response elements  (AREs)", "triple_list": [["2", "ANTAGONIST", "antioxidant response elements"]]}, {"text": "Furthermore,  butein  treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 (Nrf2) and increased the promoter activity of antioxidant response elements ( AREs  ", "triple_list": [["elements", "DOWNREGULATOR", "AREs"]]}, {"text": "Furthermore,  butein  treatment caused nuclear accumulation of  nuclear factor-E2-related factor 2  (Nrf2) and increased the promoter activity of antioxidant response elements (AREs)", "triple_list": [["butein", "AGONIST", "treatment"]]}, {"text": "Furthermore,  butein  treatment caused nuclear accumulation of nuclear factor-E2-related factor 2 ( Nrf2   and increased the promoter activity of antioxidant response elements (AREs)", "triple_list": [["and", "AGONIST", "Nrf2"]]}, {"text": "Treatment of HDP cells with a c-Jun NH2-terminal kinase (JNK) inhibitor also reduced  butein  induced  HO-1  expression, and  butein  treatment led to increased JNK phosphorylation", "triple_list": [["butein", "PRODUCT-OF", "kinase"]]}, {"text": "Treatment of HDP cells with a c-Jun NH2-terminal kinase ( JNK ) inhibitor also reduced  butein -induced HO-1 expression, and  butein  treatment led to increased  JNK  phosphorylation", "triple_list": [["inhibitor", "ANTAGONIST", "JNK"]]}, {"text": "Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor  manumycin A  caused elevation of  ApoA-I  secretion from hepatocytes and from transgenic mice expressing h ApoA-I  and cholesterol ester transfer protein transgenes", "triple_list": [["manumycin A", "AGONIST", "ApoA-I"]]}, {"text": "Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor  manumycin A  caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing  hApoA-I  and cholesterol ester transfer protein transgenes", "triple_list": [["manumycin A", "AGONIST", "Repression"]]}, {"text": "Repression of  farnesyltransferase  (FNTA) by siRNA and the enzyme inhibitor  manumycin A  caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes", "triple_list": [["manumycin A", "PRODUCT-OF", "enzyme"]]}, {"text": "Repression of farnesyltransferase ( FNTA   by siRNA and the enzyme inhibitor  manumycin A  caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes", "triple_list": [["(", "AGONIST", "FNTA"]]}, {"text": "Interestingly,  ursolic acid  increased the phosphorylation of  AMPK  and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas  ursolic acid  attenuated the phosphorylation of AKT and mTOR in HepG2 cells", "triple_list": [["acid", "ANTAGONIST", "AMPK"]]}, {"text": "Interestingly,  ursolic acid  increased the phosphorylation of AMPK and  coenzyme A carboxylase  and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas  ursolic acid  attenuated the phosphorylation of AKT and mTOR in HepG2 cells", "triple_list": [["also", "PRODUCT-OF", "coenzyme A carboxylase"]]}, {"text": "Interestingly,  ursolic acid  increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of  GSK3\u03b2  at inactive form serine 9, whereas  ursolic acid  attenuated the phosphorylation of AKT and mTOR in HepG2 cells", "triple_list": [["phosphorylation", "AGONIST", "GSK3\u03b2"]]}, {"text": "Activation of  AMP-activated Protein Kinase  and Phosphorylation of Glycogen Synthase Kinase3 \u03b2 Mediate  Ursolic Acid  Induced Apoptosis in HepG2 Liver Cancer Cells", "triple_list": [["Ursolic Acid", "ANTAGONIST", "Mediate"]]}, {"text": "Activation of AMP-activated Protein Kinase and Phosphorylation of  Glycogen Synthase Kinase3 \u03b2  Mediate  Ursolic Acid  Induced Apoptosis in HepG2 Liver Cancer Cells", "triple_list": [["Ursolic Acid", "ANTAGONIST", "Ursolic"]]}, {"text": "Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of  PARP  and caspase 3 induced by  ursolic acid  in HepG2 cells", "triple_list": [["ursolic acid", "AGONIST", "C"]]}, {"text": "Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and  caspase 3  induced by  ursolic acid  in HepG2 cells", "triple_list": [["ursolic acid", "DOWNREGULATOR", "cells"]]}, {"text": "Furthermore, proteosomal inhibitor  MG132  suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased  AEG-1  induced by ursolic acid in HepG2 cells", "triple_list": [["MG132", "PRODUCT-OF", "PARP"]]}, {"text": "Furthermore, proteosomal inhibitor MG132 suppressed  AMPK  activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased AEG-1 induced by  ursolic acid  in HepG2 cells", "triple_list": [["and", "DOWNREGULATOR", "AMPK"]]}, {"text": "Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation,  GSK3\u03b2  phosphorylation, cleaved PARP and deceased AEG-1 induced by  ursolic acid  in HepG2 cells", "triple_list": [["inhibitor", "ANTAGONIST", "GSK3\u03b2"]]}, {"text": "Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased  AEG-1  induced by  ursolic acid  in HepG2 cells", "triple_list": [["ursolic acid", "AGONIST", "cleaved"]]}, {"text": "Overall, our findings suggest that  ursolic acid  induced apoptosis in HepG2 cells via  AMPK  activation and GSK3\u03b2 phosphorylation as a potent chemopreventive agent", "triple_list": [["chemopreventive", "DOWNREGULATOR", "AMPK"]]}, {"text": "Overall, our findings suggest that  ursolic acid  induced apoptosis in HepG2 cells via AMPK activation and  GSK3\u03b2  phosphorylation as a potent chemopreventive agent", "triple_list": [["in", "DOWNREGULATOR", "GSK3\u03b2"]]}, {"text": "Interestingly,  ursolic acid  increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas  ursolic acid  attenuated the phosphorylation of  AKT  and mTOR in HepG2 cells", "triple_list": [["coenzyme", "AGONIST", "AKT"]]}, {"text": "Interestingly,  ursolic acid  increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3\u03b2 at inactive form serine 9, whereas  ursolic acid  attenuated the phosphorylation of AKT and  mTOR  in HepG2 cells", "triple_list": [["ursolic acid", "AGONIST", "of"]]}, {"text": "Conversely, AMPK inhibitor  compound C  or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and  caspase 3  induced by ursolic acid in HepG2 cells", "triple_list": [["compound C", "AGONIST", "induced"]]}, {"text": "Conversely,  AMPK  inhibitor  compound C  or GSK3\u03b2 inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells", "triple_list": [["compound C", "PRODUCT-OF", "SB216763"]]}, {"text": "Conversely, AMPK inhibitor compound C or  GSK3\u03b2  inhibitor  SB216763  blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells", "triple_list": [["SB216763", "AGONIST", "blocked"]]}, {"text": "Conversely, AMPK inhibitor compound C or GSK3\u03b2 inhibitor  SB216763  blocked the cleavages of PARP and  caspase 3  induced by ursolic acid in HepG2 cells", "triple_list": [["caspase", "ACTIVATOR", "caspase 3"]]}, {"text": "Furthermore, proteosomal inhibitor  MG132  suppressed  AMPK  activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells", "triple_list": [["proteosomal", "AGONIST", "AMPK"]]}, {"text": "Furthermore, proteosomal inhibitor  MG132  suppressed AMPK activation,  GSK3\u03b2  phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells", "triple_list": [["MG132", "AGONIST", "GSK3\u03b2"]]}, {"text": "Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3\u03b2 phosphorylation, cleaved PARP and deceased  AEG-1  induced by  ursolic acid  in HepG2 cells", "triple_list": [["AEG-1", "PRODUCT-OF", "AEG-1"]]}, {"text": "Uptake of the radiolabeled model substrates  estradiol 17\u03b2-glucuronide   estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either  OATP1B1  or OATP1B3", "triple_list": [["estradiol 17\u03b2-glucuronide", "ACTIVATOR", "absence"]]}, {"text": "Uptake of the radiolabeled model substrates  estradiol 17\u03b2-glucuronide   estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or  OATP1B3   Several of compounds 1-6 inhibited OATP-mediated uptake of all three model substrates, suggesting that they could also be potential substrates", "triple_list": [["all", "ANTAGONIST", "OATP1B3"]]}, {"text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide,  estrone 3-sulfate   and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either  OATP1B1  or OATP1B3", "triple_list": [["estrone", "ACTIVATOR", "OATP1B1"]]}, {"text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide,  estrone 3-sulfate   and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or  OATP1B3   Several of compounds 1-6 inhibited OATP-mediated uptake of all three model substrates, suggesting that they could also be potential substrates", "triple_list": [["Chinese", "ACTIVATOR", "OATP1B3"]]}, {"text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and  dehydroepiandrosterone sulfate  (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either  OATP1B1  or OATP1B3", "triple_list": [["Chinese", "AGONIST", "OATP1B1"]]}, {"text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and  dehydroepiandrosterone sulfate  (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or  OATP1B3   Several of compounds 1-6 inhibited OATP-mediated uptake of all three model substrates, suggesting that they could also be potential substrates", "triple_list": [["dehydroepiandrosterone sulfate", "AGONIST", "absence"]]}, {"text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate ( DHEAS   was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either  OATP1B1  or OATP1B3", "triple_list": [["DHEAS", "DOWNREGULATOR", "("]]}, {"text": "Uptake of the radiolabeled model substrates estradiol 17\u03b2-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate ( DHEAS   was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or  OATP1B3   Several of compounds 1-6 inhibited OATP-mediated uptake of all three model substrates, suggesting that they could also be potential substrates", "triple_list": [["or", "AGONIST", "OATP1B3"]]}, {"text": "Compound 6 stimulated  OATP1B3 -mediated  estradiol 17\u03b2-glucuronide  uptake by increasing the apparent affinity of  OATP1B3  for its substrate", "triple_list": [["estradiol 17\u03b2-glucuronide", "DOWNREGULATOR", "-mediated"]]}, {"text": "Compound 6 stimulated  OATP1B3  mediated  estradiol 17\u03b2-glucuronide  uptake by increasing the apparent affinity of  OATP1B3  for its substrate", "triple_list": [["estradiol 17\u03b2-glucuronide", "ACTIVATOR", "its"]]}, {"text": "Transport by  OATP1B1  and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several  quercetin  derivatives", "triple_list": [["quercetin", "ACTIVATOR", "Transport"]]}, {"text": "Transport by OATP1B1 and  OATP1B3  enhances the cytotoxicity of epigallocatechin 3-O-gallate and several  quercetin  derivatives", "triple_list": [["OATP1B3", "ANTAGONIST", "OATP1B3"]]}, {"text": "Transport by  OATP1B1  and OATP1B3 enhances the cytotoxicity of  epigallocatechin 3-O-gallate  and several quercetin derivatives", "triple_list": [["epigallocatechin 3-O-gallate", "ACTIVATOR", "epigallocatechin"]]}, {"text": "Transport by OATP1B1 and  OATP1B3  enhances the cytotoxicity of  epigallocatechin 3-O-gallate  and several quercetin derivatives", "triple_list": [["epigallocatechin 3-O-gallate", "ANTAGONIST", "by"]]}, {"text": "Cytotoxicity assays demonstrated that  epigallocatechin 3-O-gallate  (EGCG) and most of compounds 1-6 killed preferentially  OATP  expressing CHO cells", "triple_list": [["epigallocatechin 3-O-gallate", "AGONIST", "OATP"]]}, {"text": "Cytotoxicity assays demonstrated that epigallocatechin 3-O-gallate ( EGCG   and most of compounds 1-6 killed preferentially  OATP  expressing CHO cells", "triple_list": [["(", "DOWNREGULATOR", "OATP"]]}, {"text": " EGCG , 1, and 3 were the most potent cytotoxic compounds, with  EGCG  and 3 selectively killing  OATP1B3  expressing cells", "triple_list": [["EGCG", "ACTIVATOR", "were"]]}, {"text": "The TXM peptides were effective in inhibiting  AuF  induced  MAPK   JNK and p38( MAPK ) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation", "triple_list": [["AuF", "ANTAGONIST", "correlation"]]}, {"text": "The TXM peptides were effective in inhibiting  AuF  induced MAPK,  JNK  and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation", "triple_list": [["AuF", "DOWNREGULATOR", "were"]]}, {"text": "The TXM peptides were effective in inhibiting  AuF  induced MAPK, JNK and  p38  MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation", "triple_list": [["with", "ANTAGONIST", "p38"]]}, {"text": "The TXM peptides were effective in inhibiting  AuF  induced  MAPK , JNK and p38( MAPK   phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation", "triple_list": [["AuF", "AGONIST", "MAPK"]]}, {"text": "The Trx mimetics peptides (TXM) protected insulinoma INS 832/13 cells from oxidative stress induced by selectively inhibiting  TrxR  with  auranofin  (AuF)", "triple_list": [["inhibiting", "ANTAGONIST", "TrxR"]]}, {"text": "The Trx mimetics peptides (TXM) protected insulinoma INS 832/13 cells from oxidative stress induced by selectively inhibiting  TrxR  with auranofin ( AuF  ", "triple_list": [["The", "AGONIST", "TrxR"]]}, {"text": "Since the original discovery of  azoles  analogs as  PXR  antagonists, we have preliminarily defined an important  PXR  antagonist pharmacophore and developed less-toxic  PXR  antagonists", "triple_list": [["important", "ACTIVATOR", "PXR"]]}, {"text": "Since the original discovery of  azoles  analogs as  PXR  antagonists, we have preliminarily defined an important  PXR  antagonist pharmacophore and developed less-toxic  PXR  antagonists", "triple_list": [["antagonists,", "ACTIVATOR", "PXR"]]}, {"text": "Since the original discovery of  azoles  analogs as  PXR  antagonists, we have preliminarily defined an important  PXR  antagonist pharmacophore and developed less-toxic  PXR  antagonists", "triple_list": [["pharmacophore", "PRODUCT-OF", "PXR"]]}, {"text": "Moreover,  curcumin  alleviated  Sim2  expression, and reversely raised Drebrin expression in neurons treated with hyperglycaemia", "triple_list": [["with", "DOWNREGULATOR", "Sim2"]]}, {"text": "Moreover,  curcumin  alleviated Sim2 expression, and reversely raised  Drebrin  expression in neurons treated with hyperglycaemia", "triple_list": [["curcumin", "DOWNREGULATOR", "raised"]]}, {"text": "It was found that expression of  Sim2  protein in cortical neurons was increased in  streptozotocin  induced diabetes mellitus rat model", "triple_list": [["streptozotocin", "AGONIST", "neurons"]]}, {"text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of  p21  WAF1/CIP1) and p53", "triple_list": [["Pinosylvin", "ANTAGONIST", "by"]]}, {"text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21( WAF1  CIP1) and p53", "triple_list": [["upregulation", "AGONIST", "WAF1"]]}, {"text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/ CIP1   and p53", "triple_list": [["Pinosylvin", "AGONIST", "the"]]}, {"text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and  p53    Pinosylvin  was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway", "triple_list": [["Pinosylvin", "ANTAGONIST", "Pinosylvin"]]}, {"text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of  cyclin D1   cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53", "triple_list": [["phase", "ANTAGONIST", "cyclin D1"]]}, {"text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1,  cyclin E   cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53", "triple_list": [["Pinosylvin", "AGONIST", "of"]]}, {"text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E,  cyclin A   cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53", "triple_list": [["kinase", "ACTIVATOR", "cyclin A"]]}, {"text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A,  cyclin dependent kinase 2  (CDK2), CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53", "triple_list": [["Pinosylvin", "ACTIVATOR", "A,"]]}, {"text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 ( CDK2  , CDK4, c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53", "triple_list": [["Pinosylvin", "ANTAGONIST", "by"]]}, {"text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2),  CDK4   c-Myc, and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53", "triple_list": [["Pinosylvin", "PRODUCT-OF", "the"]]}, {"text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4,  c-Myc   and retinoblastoma protein (pRb), and the upregulation of p21(WAF1/CIP1) and p53", "triple_list": [["retinoblastoma", "AGONIST", "c-Myc"]]}, {"text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and  retinoblastoma protein  (pRb), and the upregulation of p21(WAF1/CIP1) and p53", "triple_list": [["Pinosylvin", "PRODUCT-OF", "arresting"]]}, {"text": " Pinosylvin  inhibited the proliferation of HCT 116 cells by arresting transition of cell cycle from G1 to S phase along with the downregulation of cyclin D1, cyclin E, cyclin A, cyclin dependent kinase 2 (CDK2), CDK4, c-Myc, and retinoblastoma protein ( pRb  , and the upregulation of p21(WAF1/CIP1) and p53", "triple_list": [["proliferation", "AGONIST", "pRb"]]}, {"text": " Pinosylvin  was also found to attenuate the activation of proteins involved in f ocal adhesion kinase  (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway", "triple_list": [["(FAK)/c-Src/extracellular", "AGONIST", "ocal adhesion kinase"]]}, {"text": " Pinosylvin  was also found to attenuate the activation of proteins involved in focal adhesion kinase ( FAK  /c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway", "triple_list": [["Pinosylvin", "AGONIST", "Pinosylvin"]]}, {"text": " Pinosylvin  was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/ c-Src  extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway", "triple_list": [["Pinosylvin", "ACTIVATOR", "kinase"]]}, {"text": " Pinosylvin  was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/ extracellular signal-regulated kinase  (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway", "triple_list": [["Pinosylvin", "PRODUCT-OF", "signal-regulated"]]}, {"text": " Pinosylvin  was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase ( ERK   signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway", "triple_list": [["Pinosylvin", "ANTAGONIST", "attenuate"]]}, {"text": " Pinosylvin  was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and  phosphoinositide 3-kinase  (PI3K)/Akt/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway", "triple_list": [["focal", "ANTAGONIST", "phosphoinositide 3-kinase"]]}, {"text": " Pinosylvin  was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase ( PI3K  /Akt/ glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway", "triple_list": [["signaling,", "AGONIST", "PI3K"]]}, {"text": " Pinosylvin  was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/ Akt   glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) signaling pathway", "triple_list": [["3\u03b2", "ACTIVATOR", "Akt"]]}, {"text": " Pinosylvin  was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/  glycogen synthase kinase 3\u03b2  (GSK-3\u03b2) signaling pathway", "triple_list": [["signaling", "ACTIVATOR", "glycogen synthase kinase 3\u03b2"]]}, {"text": " Pinosylvin  was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3\u03b2 ( GSK-3\u03b2   signaling pathway", "triple_list": [["3\u03b2", "PRODUCT-OF", "GSK-3\u03b2"]]}, {"text": "Subsequently,  pinosylvin  suppressed the nuclear translocation of  \u03b2-catenin   one of downstream molecules of PI3K/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of  \u03b2-catenin -mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc", "triple_list": [["survivin,", "ACTIVATOR", "\u03b2-catenin"]]}, {"text": "Subsequently,  pinosylvin  suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of  PI3K  Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc", "triple_list": [["of", "ACTIVATOR", "PI3K"]]}, {"text": "Subsequently,  pinosylvin  suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/ Akt  GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc", "triple_list": [["the", "PRODUCT-OF", "Akt"]]}, {"text": "Subsequently,  pinosylvin  suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/Akt/ GSK-3\u03b2  signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc", "triple_list": [["pinosylvin", "PRODUCT-OF", "of"]]}, {"text": "Subsequently,  pinosylvin  suppressed the nuclear translocation of  \u03b2-catenin , one of downstream molecules of PI3K/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of  \u03b2-catenin  mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc", "triple_list": [["and", "ANTAGONIST", "\u03b2-catenin"]]}, {"text": "Subsequently,  pinosylvin  suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including  BMP4   ID2, survivin, cyclin D1, MMP7, and c-Myc", "triple_list": [["signaling,", "ACTIVATOR", "BMP4"]]}, {"text": "Subsequently,  pinosylvin  suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4,  ID2   survivin, cyclin D1, MMP7, and c-Myc", "triple_list": [["pinosylvin", "PRODUCT-OF", "of"]]}, {"text": "Subsequently,  pinosylvin  suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2,  survivin   cyclin D1, MMP7, and c-Myc", "triple_list": [["downregulation", "ANTAGONIST", "survivin"]]}, {"text": "Subsequently,  pinosylvin  suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin,  cyclin D1   MMP7, and c-Myc", "triple_list": [["sequential", "ANTAGONIST", "cyclin D1"]]}, {"text": "Subsequently,  pinosylvin  suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1,  MMP7   and c-Myc", "triple_list": [["survivin,", "ACTIVATOR", "MMP7"]]}, {"text": "Subsequently,  pinosylvin  suppressed the nuclear translocation of \u03b2-catenin, one of downstream molecules of PI3K/Akt/GSK-3\u03b2 signaling, and these events led to the sequential downregulation of \u03b2-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and  c-Myc   These findings demonstrate that the anti-proliferative activity of  pinosylvin  might be associated with the cell cycle arrest and downregulation of cell proliferation regulating signaling pathways in human colorectal cancer cells.", "triple_list": [["arrest", "ANTAGONIST", "c-Myc"]]}, {"text": "Suppression of  Src  ERK and GSK-3/\u03b2-catenin signaling by  pinosylvin  inhibits the growth of human colorectal cancer cells", "triple_list": [["pinosylvin", "PRODUCT-OF", "Suppression"]]}, {"text": "Suppression of Src/ ERK  and GSK-3/\u03b2-catenin signaling by  pinosylvin  inhibits the growth of human colorectal cancer cells", "triple_list": [["human", "AGONIST", "ERK"]]}, {"text": "Suppression of Src/ERK and  GSK-3  \u03b2-catenin signaling by  pinosylvin  inhibits the growth of human colorectal cancer cells", "triple_list": [["human", "AGONIST", "GSK-3"]]}, {"text": "Suppression of Src/ERK and GSK-3/ \u03b2-catenin  signaling by  pinosylvin  inhibits the growth of human colorectal cancer cells", "triple_list": [["of", "PRODUCT-OF", "\u03b2-catenin"]]}, {"text": "However, recent clinical studies have shown that a single low-dose injection of  ketamine   an  N-methyl d-aspartate receptor  (NMDAR) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting", "triple_list": [["ketamine", "PRODUCT-OF", "N-methyl d-aspartate receptor"]]}, {"text": "However, recent clinical studies have shown that a single low-dose injection of  ketamine   an N-methyl d-aspartate receptor ( NMDAR   antagonist, has rapid antidepressant effects that are observed within hours and are long lasting", "triple_list": [["single", "PRODUCT-OF", "NMDAR"]]}, {"text": "4.\u2002Administration of a single dose of  DEX-P  showed a temporal increase in  CYP3A  activity in both tissues and the induction ratios reached maximum values at 12\u2009h after  DEX-P  administration", "triple_list": [["in", "DOWNREGULATOR", "CYP3A"]]}, {"text": "4.\u2002Administration of a single dose of  DEX-P  showed a temporal increase in  CYP3A  activity in both tissues and the induction ratios reached maximum values at 12\u2009h after  DEX-P  administration", "triple_list": [["DEX-P", "ANTAGONIST", "Administration"]]}, {"text": "Time-dependent changes in hepatic and intestinal induction of  cytochrome P450 3A  after administration of  dexamethasone  to rats", "triple_list": [["dexamethasone", "DOWNREGULATOR", "in"]]}, {"text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal  cytochrome P450 3A  (CYP3A) in rats using  dexamethasone 21-phosphate  (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively", "triple_list": [["dexamethasone 21-phosphate", "ANTAGONIST", "CYP3A,"]]}, {"text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ( CYP3A   in rats using  dexamethasone 21-phosphate  (DEX-P) and midazolam (MDZ) as an inducer and a substrate to  CYP3A , respectively", "triple_list": [["investigated", "PRODUCT-OF", "CYP3A"]]}, {"text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ( CYP3A ) in rats using  dexamethasone 21-phosphate  (DEX-P) and midazolam (MDZ) as an inducer and a substrate to  CYP3A   respectively", "triple_list": [["of", "PRODUCT-OF", "CYP3A"]]}, {"text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal  cytochrome P450 3A  (CYP3A) in rats using dexamethasone 21-phosphate ( DEX-P   and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively", "triple_list": [["DEX-P", "AGONIST", "1."]]}, {"text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ( CYP3A   in rats using dexamethasone 21-phosphate ( DEX-P   and midazolam (MDZ) as an inducer and a substrate to  CYP3A , respectively", "triple_list": [["rats", "AGONIST", "CYP3A"]]}, {"text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ( CYP3A ) in rats using dexamethasone 21-phosphate ( DEX-P   and midazolam (MDZ) as an inducer and a substrate to  CYP3A   respectively", "triple_list": [["DEX-P", "AGONIST", "and"]]}, {"text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ( CYP3A ) in rats using dexamethasone 21-phosphate (DEX-P) and  midazolam  (MDZ) as an inducer and a substrate to  CYP3A   respectively", "triple_list": [["midazolam", "AGONIST", "respectively"]]}, {"text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ( CYP3A ) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam ( MDZ   as an inducer and a substrate to  CYP3A   respectively", "triple_list": [["as", "AGONIST", "CYP3A"]]}, {"text": "3.\u2002 CYP3A  induction in the liver increased depending on the dose of  DEX-P   whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of  DEX-P ", "triple_list": [["DEX-P", "DOWNREGULATOR", "the"]]}, {"text": "3.\u2002 CYP3A  induction in the liver increased depending on the dose of  DEX-P , whereas that in intestine showed a mild increase, but the induction level was almost constant regardless of the dose of  DEX-P   4.\u2002Administration of a single dose of  DEX-P  showed a temporal increase in  CYP3A  activity in both tissues and the induction ratios reached maximum values at 12\u2009h after  DEX-P  administration", "triple_list": [["single", "ANTAGONIST", "CYP3A"]]}, {"text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ( CYP3A ) in rats using  dexamethasone 21-phosphate  (DEX-P) and midazolam (MDZ) as an inducer and a substrate to  CYP3A   respectively", "triple_list": [["dexamethasone 21-phosphate", "ACTIVATOR", "intestinal"]]}, {"text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ( CYP3A ) in rats using dexamethasone 21-phosphate ( DEX-P   and midazolam (MDZ) as an inducer and a substrate to  CYP3A   respectively", "triple_list": [["21-phosphate", "ACTIVATOR", "CYP3A"]]}, {"text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal  cytochrome P450 3A  (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and  midazolam  (MDZ) as an inducer and a substrate to CYP3A, respectively", "triple_list": [["midazolam", "DOWNREGULATOR", "number"]]}, {"text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ( CYP3A   in rats using dexamethasone 21-phosphate (DEX-P) and  midazolam  (MDZ) as an inducer and a substrate to  CYP3A , respectively", "triple_list": [["cytochrome", "ACTIVATOR", "CYP3A"]]}, {"text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ( CYP3A ) in rats using dexamethasone 21-phosphate (DEX-P) and  midazolam  (MDZ) as an inducer and a substrate to  CYP3A   respectively", "triple_list": [["midazolam", "ACTIVATOR", "a"]]}, {"text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ( CYP3A   in rats using dexamethasone 21-phosphate (DEX-P) and midazolam ( MDZ   as an inducer and a substrate to  CYP3A , respectively", "triple_list": [["MDZ", "DOWNREGULATOR", "("]]}, {"text": "Abstract 1.\u2002We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A ( CYP3A ) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam ( MDZ   as an inducer and a substrate to  CYP3A   respectively", "triple_list": [["duration", "DOWNREGULATOR", "CYP3A"]]}, {"text": "Altogether, our findings support a model in which Top2\u03b2 deficiency promotes  CPT  induced apoptosis in quiescent non-S-phase cells, possibly due to RNAP LS depletion and  p53  accumulation.", "triple_list": [["induced", "AGONIST", "p53"]]}, {"text": "To explore the molecular basis for  CPT  hypersensitivity in Top2\u03b2-deficient cells, we found that upon  CPT  exposure, the  RNA polymerase II large subunit  (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2\u03b2-deficient cells", "triple_list": [["CPT", "PRODUCT-OF", "depleted"]]}, {"text": "To explore the molecular basis for  CPT  hypersensitivity in Top2\u03b2-deficient cells, we found that upon  CPT  exposure, the RNA polymerase II large subunit ( RNAP LS   became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas  RNAP LS  remained depleted without recovery in Top2\u03b2-deficient cells", "triple_list": [["CPT", "AGONIST", "explore"]]}, {"text": "To explore the molecular basis for  CPT  hypersensitivity in Top2\u03b2-deficient cells, we found that upon  CPT  exposure, the RNA polymerase II large subunit ( RNAP LS ) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas  RNAP LS  remained depleted without recovery in Top2\u03b2-deficient cells", "triple_list": [["without", "ACTIVATOR", "RNAP LS"]]}, {"text": "Altogether, our findings support a model in which Top2\u03b2 deficiency promotes  CPT  induced apoptosis in quiescent non-S-phase cells, possibly due to  RNAP LS  depletion and p53 accumulation.", "triple_list": [["CPT", "PRODUCT-OF", "in"]]}, {"text": "Second,  ICRF-187   a  Top2  catalytic inhibitor known to deplete  Top2 \u03b2, specifically sensitized MEFs to CPT", "triple_list": [["ICRF-187", "ACTIVATOR", "to"]]}, {"text": "Second,  ICRF-187   a Top2 catalytic inhibitor known to deplete  Top2\u03b2   specifically sensitized MEFs to CPT", "triple_list": [["ICRF-187", "AGONIST", "inhibitor"]]}, {"text": " NCFP  binds to the CPPHA site on  mGlu5  and potentiates  mGlu5  mediated responses in both recombinant and native systems", "triple_list": [["mGlu5", "AGONIST", "mGlu5"]]}, {"text": "Dietary  EPA  DHA treatment restored endogenous biosynthesis of n-3 derived lipid mediators in obesity while attenuating adipose tissue inflammation and improving  insulin  sensitivity", "triple_list": [["EPA", "ANTAGONIST", "lipid"]]}, {"text": "Notably,  17-HDHA  treatment reduced adipose tissue expression of inflammatory cytokines, increased  adiponectin  expression and improved glucose tolerance parallel to insulin sensitivity in obese mice", "triple_list": [["17-HDHA", "AGONIST", "reduced"]]}, {"text": "Notably,  17-HDHA  treatment reduced adipose tissue expression of inflammatory cytokines, increased adiponectin expression and improved glucose tolerance parallel to  insulin  sensitivity in obese mice", "triple_list": [["17-HDHA", "AGONIST", "adipose"]]}, {"text": "Dietary EPA/ DHA  treatment restored endogenous biosynthesis of n-3 derived lipid mediators in obesity while attenuating adipose tissue inflammation and improving  insulin  sensitivity", "triple_list": [["restored", "AGONIST", "insulin"]]}, {"text": "Notably,  17-HDHA  treatment reduced adipose tissue expression of inflammatory  cytokines   increased adiponectin expression and improved glucose tolerance parallel to insulin sensitivity in obese mice", "triple_list": [["insulin", "ANTAGONIST", "cytokines"]]}, {"text": "We describe the discovery of several  pyrrolopyrazines  as potent and selective  Syk  inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies", "triple_list": [["pyrrolopyrazines", "ANTAGONIST", "selective"]]}, {"text": " Pyrrolopyrazines  as Selective  Spleen Tyrosine Kinase  Inhibitors", "triple_list": [["Pyrrolopyrazines", "AGONIST", "Spleen Tyrosine Kinase"]]}, {"text": "We describe here the isolation and biochemical characterization of the marine natural  sesquiterpene  palinurin as a  GSK-3\u03b2  inhibitor", "triple_list": [["natural", "AGONIST", "GSK-3\u03b2"]]}, {"text": "We describe here the isolation and biochemical characterization of the marine natural sesquiterpene  palinurin  as a  GSK-3\u03b2  inhibitor", "triple_list": [["as", "AGONIST", "GSK-3\u03b2"]]}, {"text": "Experimental studies performed for characterizing the inhibitory mechanism indicate that  GSK-3\u03b2  inhibition by  palinurin  cannot be competed out by ATP nor peptide substrate", "triple_list": [["palinurin", "PRODUCT-OF", "cannot"]]}, {"text": "Moreover, molecular dynamics simulations have identified an allosteric mechanism by which binding of  palinurin  leads to  GSK-3\u03b2  inhibition", "triple_list": [["palinurin", "ACTIVATOR", "molecular"]]}, {"text": " Type 2 11\u03b2-hydroxysteroid dehydrogenase  encoded by the HSD11B2 gene converts  cortisol  to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids", "triple_list": [["cortisol", "ACTIVATOR", "activity"]]}, {"text": "Type 2 11\u03b2-hydroxysteroid dehydrogenase encoded by the  HSD11B2  gene converts  cortisol  to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids", "triple_list": [["by", "DOWNREGULATOR", "HSD11B2"]]}, {"text": " Type 2 11\u03b2-hydroxysteroid dehydrogenase  encoded by the HSD11B2 gene converts cortisol to inactive  cortisone   and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids", "triple_list": [["cortisone", "ANTAGONIST", "encoded"]]}, {"text": "Type 2 11\u03b2-hydroxysteroid dehydrogenase encoded by the  HSD11B2  gene converts cortisol to inactive  cortisone   and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids", "triple_list": [["cortisone", "ACTIVATOR", "by"]]}, {"text": "A series of  xanthine  derivatives in which a methylene was inserted at position 8 of  xanthine  scaffold was synthesized and evaluated as inhibitors of  dipeptidyl peptidase 4  (DPP-4) for the treatment of type 2 diabetes", "triple_list": [["xanthine", "AGONIST", "4"]]}, {"text": "A series of  xanthine  derivatives in which a methylene was inserted at position 8 of  xanthine  scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 ( DPP-4   for the treatment of type 2 diabetes", "triple_list": [["xanthine", "PRODUCT-OF", "peptidase"]]}, {"text": "A series of  xanthine  derivatives in which a methylene was inserted at position 8 of  xanthine  scaffold was synthesized and evaluated as inhibitors of  dipeptidyl peptidase 4  (DPP-4) for the treatment of type 2 diabetes", "triple_list": [["scaffold", "ANTAGONIST", "dipeptidyl peptidase 4"]]}, {"text": "A series of  xanthine  derivatives in which a methylene was inserted at position 8 of  xanthine  scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 ( DPP-4   for the treatment of type 2 diabetes", "triple_list": [["xanthine", "AGONIST", "2"]]}, {"text": "The activity of the human nasal mucosa microsomes was inhibited by  8-methoxypsoralen   a known  CYP2A  inhibitor", "triple_list": [["the", "ACTIVATOR", "CYP2A"]]}, {"text": " PP242  induced reversal of  deptor  suppression by TGF\u03b2 was associated with a significant inhibition of TGF\u03b2-stimulated protein synthesis and hypertrophy", "triple_list": [["PP242", "DOWNREGULATOR", "hypertrophy"]]}, {"text": "Using the  mTOR  inhibitor  PP242,  we found that TGF\u03b2-induced both early and sustained activation of TORC1 and TORC2 was necessary for deptor suppression", "triple_list": [["suppression", "ANTAGONIST", "mTOR"]]}, {"text": "Based on recent reports that the small molecules,  isatin  and phthalimide, are suitable scaffolds for the design of high potency  monoamine oxidase  (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues", "triple_list": [["a", "ACTIVATOR", "monoamine oxidase"]]}, {"text": "Based on recent reports that the small molecules,  isatin  and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase ( MAO   inhibitors, the present study examines the  MAO  inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues", "triple_list": [["of", "ANTAGONIST", "MAO"]]}, {"text": "Based on recent reports that the small molecules, isatin and  phthalimide   are suitable scaffolds for the design of high potency  monoamine oxidase  (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues", "triple_list": [["of", "AGONIST", "monoamine oxidase"]]}, {"text": "Based on recent reports that the small molecules, isatin and  phthalimide   are suitable scaffolds for the design of high potency monoamine oxidase ( MAO   inhibitors, the present study examines the  MAO  inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues", "triple_list": [["phthalimide", "PRODUCT-OF", "small"]]}, {"text": "In most instances, C6-substituted  phthalides  exhibit  MAO-B  specific inhibition", "triple_list": [["In", "PRODUCT-OF", "MAO-B"]]}, {"text": "The results also show that the binding modes of representative  phthalides  are reversible and competitive at both  MAO  isoforms", "triple_list": [["also", "PRODUCT-OF", "MAO"]]}, {"text": "Inhibition of  monoamine oxidase  by  phthalide  analogues", "triple_list": [["monoamine", "ANTAGONIST", "monoamine oxidase"]]}, {"text": "Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase ( MAO ) inhibitors, the present study examines the  MAO  inhibitory properties of a series of  phthalide  [2-benzofuran-1(3H)-one] analogues", "triple_list": [["phthalide", "ANTAGONIST", "examines"]]}, {"text": "Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase ( MAO ) inhibitors, the present study examines the  MAO  inhibitory properties of a series of phthalide [ 2-benzofuran-1(3H)-one   analogues", "triple_list": [["high", "ACTIVATOR", "MAO"]]}, {"text": "A novel class of  quinoxalines  has been discovered as antagonists of the  IgG  FcRn protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.", "triple_list": [["screen.", "DOWNREGULATOR", "IgG"]]}, {"text": "A novel class of  quinoxalines  has been discovered as antagonists of the IgG: FcRn  protein-protein interaction through optimization of a hit derived from a virtual ligand-based screen.", "triple_list": [["quinoxalines", "AGONIST", "FcRn"]]}, {"text": "Guided by the  acetylcholinesterase  inhibiting activity, the  bisindole alkaloid  3'-R/S-hydroxyvoacamine was isolated from a stem extract of Tabernaemontana divaricata, a plant used in Thailand in traditional rejuvenation remedies for improving the memory", "triple_list": [["bisindole alkaloid", "ANTAGONIST", "bisindole"]]}, {"text": "Guided by the  acetylcholinesterase  inhibiting activity, the bisindole alkaloid  3'-R/S-hydroxyvoacamine  was isolated from a stem extract of Tabernaemontana divaricata, a plant used in Thailand in traditional rejuvenation remedies for improving the memory", "triple_list": [["3'-R/S-hydroxyvoacamine", "PRODUCT-OF", "activity,"]]}, {"text": " 3'-R/S-Hydroxyvoacamine   a potent  acetylcholinesterase  inhibitor from Tabernaemontana divaricata", "triple_list": [["3'-R/S-Hydroxyvoacamine", "AGONIST", "acetylcholinesterase"]]}, {"text": " Cadmium  activates  NADPH oxidase   ROS produced by this oxidase activates Src, enable that in turn, transactivates EGFR that activates Stat3 in tyrosine, allowing its dimerization", "triple_list": [["Cadmium", "AGONIST", "Cadmium"]]}, {"text": "However, after 12h  CdCl2  treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in  p53  activation and the pro-apoptotic protein Bax.", "triple_list": [["and", "AGONIST", "p53"]]}, {"text": "However, after 12h  CdCl2  treatment, cell viability diminished in 50%, accompanied by a drastic decrease of metallothionein-II production, and an increase in p53 activation and the pro-apoptotic protein  Bax  ", "triple_list": [["after", "PRODUCT-OF", "Bax"]]}, {"text": "However, after 12h  CdCl2  treatment, cell viability diminished in 50%, accompanied by a drastic decrease of  metallothionein-II  production, and an increase in p53 activation and the pro-apoptotic protein Bax.", "triple_list": [["CdCl2", "ACTIVATOR", "CdCl2"]]}, {"text": " Catalpol  also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of I\u03baB\u03b1 and the nuclear localization of  NF-\u03baB   Moreover, the production of intracellular reactive oxygen species (ROS) elicited by AGE was also suppressed by catalpol treatment, through dual action of reducing ROS itself and inhibiting NADPH oxidase activity", "triple_list": [["Catalpol", "PRODUCT-OF", "oxygen"]]}, {"text": " Catalpol  also suppressed AGE-induced phosphorylation of  mitogen activated protein (MAP) kinases   degradation of I\u03baB\u03b1 and the nuclear localization of NF-\u03baB", "triple_list": [["(MAP)", "AGONIST", "mitogen activated protein (MAP) kinases"]]}, {"text": " Catalpol  also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of  I\u03baB\u03b1  and the nuclear localization of NF-\u03baB", "triple_list": [["kinases,", "PRODUCT-OF", "I\u03baB\u03b1"]]}, {"text": "Moreover, the production of intracellular reactive oxygen species (ROS) elicited by AGE was also suppressed by  catalpol  treatment, through dual action of reducing ROS itself and inhibiting  NADPH oxidase  activity", "triple_list": [["catalpol", "ACTIVATOR", "through"]]}, {"text": "Our findings indicate that  catalpol  suppresses AGE-mediated inflammation by inhibiting ROS production and  NF-\u03baB  activity", "triple_list": [["NF-\u03baB", "AGONIST", "NF-\u03baB"]]}, {"text": " Catalpol  reduced the expression of pro-inflammatory mediates, such as  monocyte chemotactic protein-1  (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE)", "triple_list": [["of", "ANTAGONIST", "monocyte chemotactic protein-1"]]}, {"text": " Catalpol  reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 ( MCP-1  , tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE)", "triple_list": [["(TNF-\u03b1),", "ANTAGONIST", "MCP-1"]]}, {"text": " Catalpol  reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1),  tumor necrosis factor-\u03b1  (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE (RAGE)", "triple_list": [["Catalpol", "ANTAGONIST", "(iNOS),"]]}, {"text": " Catalpol  reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 ( TNF-\u03b1  , inducible NO synthase (iNOS), and receptor for AGE (RAGE)", "triple_list": [["Catalpol", "PRODUCT-OF", "and"]]}, {"text": " Catalpol  reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1),  inducible NO synthase  (iNOS), and receptor for AGE (RAGE)", "triple_list": [["for", "PRODUCT-OF", "inducible NO synthase"]]}, {"text": " Catalpol  reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase ( iNOS  , and receptor for AGE (RAGE)", "triple_list": [["(MCP-1),", "PRODUCT-OF", "iNOS"]]}, {"text": " Catalpol  reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and  receptor for AGE  (RAGE)", "triple_list": [["protein-1", "PRODUCT-OF", "receptor for AGE"]]}, {"text": " Catalpol  reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), inducible NO synthase (iNOS), and receptor for AGE ( RAGE  ", "triple_list": [["Catalpol", "ANTAGONIST", "RAGE"]]}, {"text": "Promoter and electromobility shift assays showed that transcriptional activation of  NF-\u03baB  was significantly reduced by  catalpol  treatment, while AP-1 was not", "triple_list": [["catalpol", "AGONIST", "while"]]}, {"text": "In this study, we assessed the effects of  clopidogrel  and clarithromycin, known  CYP2B6  and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with  CYP2B6  polymorphisms in humans", "triple_list": [["CYP2B6", "PRODUCT-OF", "CYP2B6"]]}, {"text": "In this study, we assessed the effects of  clopidogrel  and clarithromycin, known  CYP2B6  and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with  CYP2B6  polymorphisms in humans", "triple_list": [["clopidogrel", "PRODUCT-OF", "enantioselective"]]}, {"text": "In this study, we assessed the effects of  clopidogrel  and clarithromycin, known CYP2B6 and  CYP3A  inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans", "triple_list": [["clopidogrel", "AGONIST", "polymorphisms"]]}, {"text": "In this study, we assessed the effects of clopidogrel and  clarithromycin   known  CYP2B6  and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with  CYP2B6  polymorphisms in humans", "triple_list": [["clarithromycin", "AGONIST", "CYP2B6"]]}, {"text": "In this study, we assessed the effects of clopidogrel and  clarithromycin   known CYP2B6 and  CYP3A  inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans", "triple_list": [["clarithromycin", "ANTAGONIST", "CYP3A"]]}, {"text": "Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by  cyclopiazonic acid  (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial  SERCA  pump", "triple_list": [["cyclopiazonic acid", "ANTAGONIST", "receptor"]]}, {"text": "Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the G protein-coupled receptor agonist acetylcholine (ACh) and by cyclopiazonic acid ( CPA  , which promotes store-operated Ca(2+) entry by inhibiting the endothelial  SERCA  pump", "triple_list": [["CPA", "PRODUCT-OF", "acid"]]}, {"text": "Potentiation was prevented by catalase, the catalase/superoxide dismutase mimetic manganese porphyrin and the  NADPH oxidase  inhibitor  apocynin   By contrast in aortic rings, that exhibited negligible EDHF-type responses, endothelium-dependent NO-mediated relaxations evoked by CPA and ACh were unaffected by arsenite", "triple_list": [["by", "AGONIST", "NADPH oxidase"]]}, {"text": "Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the  G protein-coupled receptor  agonist  acetylcholine  (ACh) and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump", "triple_list": [["acetylcholine", "DOWNREGULATOR", "the"]]}, {"text": "Endothelium-dependent relaxations, nitric oxide (NO) and endothelium derived hyperpolarizing factor (EDHF)-type, were studied in rabbit iliac artery and aortic rings using the  G protein-coupled receptor  agonist acetylcholine ( ACh   and by cyclopiazonic acid (CPA), which promotes store-operated Ca(2+) entry by inhibiting the endothelial SERCA pump", "triple_list": [["by", "PRODUCT-OF", "G protein-coupled receptor"]]}, {"text": "Our results suggest that arsenite can potentiate EDHF-type relaxations via a mechanism that is dependent on hydrogen peroxide, thus demonstrating that dismutation of the  superoxide  anion generated by  NADPH oxidase  can potentially offset loss of NO bioavailability under conditions of reduced eNOS activity", "triple_list": [["superoxide", "AGONIST", "demonstrating"]]}, {"text": "The  hemoglobin A1c  (HbA1c) of all patients improved significantly from 8.1\u00b11.2% to 7.6\u00b11.1% after 12 weeks of add-on therapy with  sitagliptin  (p<0.01), and the insulin dosage was reduced from 27.3\u00b115.8 U/day to 24.5\u00b116.5 U/day (p<0.001)", "triple_list": [["sitagliptin", "ANTAGONIST", "significantly"]]}, {"text": "The hemoglobin A1c ( HbA1c   of all patients improved significantly from 8.1\u00b11.2% to 7.6\u00b11.1% after 12 weeks of add-on therapy with  sitagliptin  (p<0.01), and the insulin dosage was reduced from 27.3\u00b115.8 U/day to 24.5\u00b116.5 U/day (p<0.001)", "triple_list": [["sitagliptin", "AGONIST", "7.6\u00b11.1%"]]}, {"text": "Add-on therapy with the  DPP-4  inhibitor  sitagliptin  improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus", "triple_list": [["sitagliptin", "ACTIVATOR", "therapy"]]}, {"text": "Diclofenac-\u03b2-d-glucuronide,  clopidogrel-\u03b2-d-glucuronide   ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited  hCES1   with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2", "triple_list": [["(S)-naproxen-\u03b2-d-glucuronide", "AGONIST", "hCES1"]]}, {"text": "Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide,  ibuprofen-\u03b2-d-glucuronide   (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited  hCES1   with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2", "triple_list": [["but", "PRODUCT-OF", "hCES1"]]}, {"text": "Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide,  (R)-naproxen-\u03b2-d-glucuronide   and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited  hCES1   with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2", "triple_list": [["(R)-naproxen-\u03b2-d-glucuronide", "ANTAGONIST", "respectively,"]]}, {"text": "Diclofenac-\u03b2-d-glucuronide, clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and  (S)-naproxen-\u03b2-d-glucuronide  selectively inhibited  hCES1   with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2", "triple_list": [["clopidogrel-\u03b2-d-glucuronide,", "AGONIST", "hCES1"]]}, {"text": "Conclusion: Drug-drug interaction studies may be warranted for drugs that metabolize to  acyl glucuronides  due to the potential inhibition of  hCESs  ", "triple_list": [["be", "AGONIST", "hCESs"]]}, {"text": "Objective: This study explores the ability of  acyl glucuronides  to act as substrates or inhibitors of  human carboxylesterases 1  (hCES1) and 2 (hCES2)", "triple_list": [["1", "AGONIST", "human carboxylesterases 1"]]}, {"text": "Objective: This study explores the ability of  acyl glucuronides  to act as substrates or inhibitors of human carboxylesterases 1 ( hCES1   and 2 (hCES2)", "triple_list": [["of", "AGONIST", "hCES1"]]}, {"text": "Objective: This study explores the ability of  acyl glucuronides  to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 ( hCES2  ", "triple_list": [["inhibitors", "ANTAGONIST", "hCES2"]]}, {"text": "Reversible inhibition of  human carboxylesterases  by  acyl glucuronides   Carboxylesterases hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively", "triple_list": [["glucuronides", "AGONIST", "human carboxylesterases"]]}, {"text": " Diclofenac-\u03b2-d-glucuronide   clopidogrel-\u03b2-d-glucuronide, ibuprofen-\u03b2-d-glucuronide, (R)-naproxen-\u03b2-d-glucuronide, and (S)-naproxen-\u03b2-d-glucuronide selectively inhibited  hCES1   with Ki values of 4.32 \u00b1 0.47, 24.8 \u00b1 4.2, 355 \u00b1 38, 468 \u00b1 21, 707 \u00b1 64 \u00b5M, respectively, but did not significantly inhibit hCES2", "triple_list": [["Diclofenac-\u03b2-d-glucuronide", "PRODUCT-OF", "38,"]]}, {"text": " Carboxylesterases  hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting  alcohols   amines, and thiols, respectively", "triple_list": [["alcohols", "ANTAGONIST", "and"]]}, {"text": " Uridine 5'-diphosphate- glucuronosyltransferases  are colocalized with carboxylesterases and have the potential to further metabolize  carboxylic acids  to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases", "triple_list": [["to", "DOWNREGULATOR", "Uridine 5'-diphosphate- glucuronosyltransferases"]]}, {"text": "Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with  carboxylesterases  and have the potential to further metabolize  carboxylic acids  to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with  carboxylesterases ", "triple_list": [["carboxylic acids", "ACTIVATOR", "glucuronides,"]]}, {"text": " Carboxylesterases  hydrolyze  esters   amides, and thio esters  to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively", "triple_list": [["and", "DOWNREGULATOR", "Carboxylesterases"]]}, {"text": " Uridine 5'-diphosphate- glucuronosyltransferases  are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to  acyl glucuronides   but it is currently unknown if  acyl glucuronides , being esters, also interact with carboxylesterases", "triple_list": [["acyl glucuronides", "ACTIVATOR", "metabolize"]]}, {"text": "Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with  carboxylesterases  and have the potential to further metabolize carboxylic acids to  acyl glucuronides   but it is currently unknown if  acyl glucuronides , being esters, also interact with  carboxylesterases ", "triple_list": [["acyl glucuronides", "ANTAGONIST", "to"]]}, {"text": " Uridine 5'-diphosphate- glucuronosyltransferases  are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to  acyl glucuronides , but it is currently unknown if  acyl glucuronides   being esters, also interact with carboxylesterases", "triple_list": [["acyl glucuronides", "ANTAGONIST", "acyl"]]}, {"text": " Carboxylesterases  hydrolyze esters,  amides   and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively", "triple_list": [["amides", "ANTAGONIST", "resulting"]]}, {"text": "Objective: This study explores the ability of  acyl glucuronides  to act as substrates or inhibitors of  human carboxylesterases 1  (hCES1) and 2 (hCES2)", "triple_list": [["as", "ANTAGONIST", "human carboxylesterases 1"]]}, {"text": "Objective: This study explores the ability of  acyl glucuronides  to act as substrates or inhibitors of human carboxylesterases 1 ( hCES1   and 2 (hCES2)", "triple_list": [["This", "DOWNREGULATOR", "hCES1"]]}, {"text": "Objective: This study explores the ability of  acyl glucuronides  to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 ( hCES2  ", "triple_list": [["as", "DOWNREGULATOR", "hCES2"]]}, {"text": " Carboxylesterases  hydrolyze esters, amides, and  thioesters  to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively", "triple_list": [["and", "DOWNREGULATOR", "Carboxylesterases"]]}, {"text": "Methods: The stability of six  acyl glucuronides  in the presence of  hCES1   hCES2, and buffer alone (100 mM potassium phosphate, pH 7.4, 37\u00b0C) were investigated", "triple_list": [["acyl glucuronides", "ACTIVATOR", "glucuronides"]]}, {"text": "Methods: The stability of six  acyl glucuronides  in the presence of hCES1,  hCES2   and buffer alone (100 mM potassium phosphate, pH 7.4, 37\u00b0C) were investigated", "triple_list": [["six", "DOWNREGULATOR", "hCES2"]]}, {"text": " Carboxylesterases  hydrolyze esters, amides, and thioesters to produce  carboxylic acids  and resulting alcohols, amines, and thiols, respectively", "triple_list": [["carboxylic acids", "ANTAGONIST", "produce"]]}, {"text": " Carboxylesterases  hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols,  amines   and thiols, respectively", "triple_list": [["amides,", "ANTAGONIST", "Carboxylesterases"]]}, {"text": " Carboxylesterases  hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and  thiols   respectively", "triple_list": [["thiols", "ANTAGONIST", "and"]]}, {"text": "Our results showed that low dose  BPA  and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of  Oct4  and Nanog proteins, while only  BPA  could downregulate the expression of E-cadherin protein", "triple_list": [["of", "DOWNREGULATOR", "Oct4"]]}, {"text": "Our results showed that low dose  BPA  and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and  Nanog  proteins, while only  BPA  could downregulate the expression of E-cadherin protein", "triple_list": [["BPA", "PRODUCT-OF", "downregulate"]]}, {"text": "Our results showed that low dose  BPA  and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only  BPA  could downregulate the expression of  E-cadherin  protein", "triple_list": [["only", "PRODUCT-OF", "E-cadherin"]]}, {"text": "Given these findings, a unified PK model including the inhibition of  MAO-A   and CYP2D6-catalyzed 5-MeO-DMT metabolism by  harmaline  was developed to describe blood  harmaline   5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models", "triple_list": [["harmaline", "ACTIVATOR", "the"]]}, {"text": "Given these findings, a unified PK model including the inhibition of MAO-A- and  CYP2D6  catalyzed 5-MeO-DMT metabolism by  harmaline  was developed to describe blood  harmaline   5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg- CYP2D6  mouse models", "triple_list": [["harmaline", "AGONIST", "in"]]}, {"text": "Given these findings, a unified PK model including the inhibition of MAO-A- and  CYP2D6 -catalyzed 5-MeO-DMT metabolism by  harmaline  was developed to describe blood  harmaline   5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg- CYP2D6  mouse models", "triple_list": [["and", "ANTAGONIST", "CYP2D6"]]}, {"text": "Our recent study has demonstrated that coadministration of  monoamine oxidase A  (MAO-A) inhibitor  harmaline  (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine", "triple_list": [["oxidase", "PRODUCT-OF", "monoamine oxidase A"]]}, {"text": "Our recent study has demonstrated that coadministration of monoamine oxidase A ( MAO-A   inhibitor  harmaline  (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine", "triple_list": [["metabolite", "ANTAGONIST", "MAO-A"]]}, {"text": "Our data revealed that inhibition of  MAO-A  mediated metabolic elimination by  harmaline  (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations", "triple_list": [["MAO-A", "AGONIST", "MAO-A"]]}, {"text": "Pharmacokinetic Interactions between  Monoamine Oxidase A  Inhibitor  Harmaline  and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status", "triple_list": [["Harmaline", "ACTIVATOR", "the"]]}, {"text": "The in vivo inhibitory effect of  harmaline  on  CYP2D6  catalyzed bufotenine formation was confirmed by in vitro study using purified  CYP2D6 ", "triple_list": [["study", "AGONIST", "CYP2D6"]]}, {"text": "The in vivo inhibitory effect of  harmaline  on  CYP2D6 -catalyzed bufotenine formation was confirmed by in vitro study using purified  CYP2D6   Given these findings, a unified PK model including the inhibition of MAO-A- and  CYP2D6 -catalyzed 5-MeO-DMT metabolism by  harmaline  was developed to describe blood  harmaline , 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg- CYP2D6  mouse models", "triple_list": [["was", "ANTAGONIST", "CYP2D6"]]}, {"text": "Given these findings, a unified PK model including the inhibition of  MAO-A   and CYP2D6-catalyzed 5-MeO-DMT metabolism by  harmaline  was developed to describe blood  harmaline , 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models", "triple_list": [["harmaline", "ACTIVATOR", "MAO-A"]]}, {"text": "Given these findings, a unified PK model including the inhibition of MAO-A- and  CYP2D6  catalyzed 5-MeO-DMT metabolism by  harmaline  was developed to describe blood  harmaline , 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg- CYP2D6  mouse models", "triple_list": [["Given", "AGONIST", "CYP2D6"]]}, {"text": "Given these findings, a unified PK model including the inhibition of MAO-A- and  CYP2D6 -catalyzed 5-MeO-DMT metabolism by  harmaline  was developed to describe blood  harmaline , 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg- CYP2D6  mouse models", "triple_list": [["harmaline", "PRODUCT-OF", "model"]]}, {"text": "Given these findings, a unified PK model including the inhibition of  MAO-A   and CYP2D6-catalyzed  5-MeO-DMT  metabolism by harmaline was developed to describe blood harmaline,  5-MeO-DMT   and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models", "triple_list": [["was", "AGONIST", "MAO-A"]]}, {"text": "Given these findings, a unified PK model including the inhibition of MAO-A- and  CYP2D6  catalyzed  5-MeO-DMT  metabolism by harmaline was developed to describe blood harmaline,  5-MeO-DMT   and bufotenine PK profiles in both wild-type and Tg- CYP2D6  mouse models", "triple_list": [["5-MeO-DMT", "ANTAGONIST", "unified"]]}, {"text": "Given these findings, a unified PK model including the inhibition of MAO-A- and  CYP2D6 -catalyzed  5-MeO-DMT  metabolism by harmaline was developed to describe blood harmaline,  5-MeO-DMT   and bufotenine PK profiles in both wild-type and Tg- CYP2D6  mouse models", "triple_list": [["5-MeO-DMT", "AGONIST", "these"]]}, {"text": "The in vivo inhibitory effect of harmaline on  CYP2D6  catalyzed  bufotenine  formation was confirmed by in vitro study using purified  CYP2D6 ", "triple_list": [["of", "ANTAGONIST", "CYP2D6"]]}, {"text": "The in vivo inhibitory effect of harmaline on  CYP2D6 -catalyzed  bufotenine  formation was confirmed by in vitro study using purified  CYP2D6   Given these findings, a unified PK model including the inhibition of MAO-A- and  CYP2D6 -catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and  bufotenine  PK profiles in both wild-type and Tg- CYP2D6  mouse models", "triple_list": [["and", "AGONIST", "CYP2D6"]]}, {"text": "Given these findings, a unified PK model including the inhibition of  MAO-A   and CYP2D6-catalyzed  5-MeO-DMT  metabolism by harmaline was developed to describe blood harmaline,  5-MeO-DMT , and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models", "triple_list": [["5-MeO-DMT", "ACTIVATOR", "Tg-CYP2D6"]]}, {"text": "Given these findings, a unified PK model including the inhibition of MAO-A- and  CYP2D6  catalyzed  5-MeO-DMT  metabolism by harmaline was developed to describe blood harmaline,  5-MeO-DMT , and bufotenine PK profiles in both wild-type and Tg- CYP2D6  mouse models", "triple_list": [["a", "AGONIST", "CYP2D6"]]}, {"text": "Given these findings, a unified PK model including the inhibition of MAO-A- and  CYP2D6 -catalyzed  5-MeO-DMT  metabolism by harmaline was developed to describe blood harmaline,  5-MeO-DMT , and bufotenine PK profiles in both wild-type and Tg- CYP2D6  mouse models", "triple_list": [["5-MeO-DMT", "DOWNREGULATOR", "and"]]}, {"text": "In addition,  ethanol  induced degradation of  DNA methyltransferases  (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway", "triple_list": [["ethanol", "ACTIVATOR", "ethanol"]]}, {"text": "In addition,  ethanol  induced degradation of DNA methyltransferases ( DNMT-  ,  DNMT- 3a, and  DNMT- 3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway", "triple_list": [["ethanol", "PRODUCT-OF", "methyltransferases"]]}, {"text": "In addition,  ethanol  induced degradation of DNA methyltransferases (DNMT-1,  DNMT-3a   and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway", "triple_list": [["ethanol", "PRODUCT-OF", "addition,"]]}, {"text": "In addition,  ethanol  induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and  DNMT-3b  , as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway", "triple_list": [["ethanol", "ACTIVATOR", "In"]]}, {"text": "In addition,  ethanol  induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the  methyl CpG-binding proteins  (MeCP-2, MBD-2 and MBD-3), in MEF cells by the proteasomal pathway", "triple_list": [["ethanol", "ANTAGONIST", "(MeCP-2,"]]}, {"text": "In addition,  ethanol  induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins ( MeCP-2   MBD-2 and MBD-3), in MEF cells by the proteasomal pathway", "triple_list": [["ethanol", "ACTIVATOR", "MBD-2"]]}, {"text": "In addition,  ethanol  induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2,  MBD-2  and MBD-3), in MEF cells by the proteasomal pathway", "triple_list": [["in", "PRODUCT-OF", "MBD-2"]]}, {"text": "In addition,  ethanol  induced degradation of DNA methyltransferases (DNMT-1, DNMT-3a, and DNMT-3b), as well as the methyl CpG-binding proteins (MeCP-2, MBD-2 and  MBD-3  , in MEF cells by the proteasomal pathway", "triple_list": [["ethanol", "AGONIST", "DNA"]]}, {"text": "The  A2A adenosine receptor  agonist CGS21680 ( C23H29N7O6.HCl.xH2O   (0.001-0.1 \u03bcM) did not alter NE oxidation currents", "triple_list": [["A2A", "PRODUCT-OF", "A2A adenosine receptor"]]}, {"text": "Adenosine and N(6)-cyclopentyl-adenosine ( CPA    A1R  agonist) constricted MVs but not MAs", "triple_list": [["(", "ANTAGONIST", "A1R"]]}, {"text": " Adenosine  and N(6)-cyclopentyl-adenosine (CPA,  A1R  agonist) constricted MVs but not MAs", "triple_list": [["Adenosine", "DOWNREGULATOR", "MAs"]]}, {"text": "Adenosine and  N(6)-cyclopentyl-adenosine  (CPA,  A1R  agonist) constricted MVs but not MAs", "triple_list": [["N(6)-cyclopentyl-adenosine", "PRODUCT-OF", "A1R"]]}, {"text": "The  A2A adenosine receptor  agonist  CGS21680  (C23H29N7O6.HCl.xH2O) (0.001-0.1 \u03bcM) did not alter NE oxidation currents", "triple_list": [["adenosine", "DOWNREGULATOR", "A2A adenosine receptor"]]}, {"text": "Nitric oxide products of  VP-16  displayed significantly diminished  topoisomerase II  dependent cleavage of DNA and cytotoxicity to human HL-60 leukemia cells", "triple_list": [["diminished", "ACTIVATOR", "topoisomerase II"]]}, {"text": "The values of mean corpuscular  hemoglobin  concentration and mean corpuscular  hemoglobin  increased in the  STX  group", "triple_list": [["in", "ANTAGONIST", "hemoglobin"]]}, {"text": "The values of mean corpuscular  hemoglobin  concentration and mean corpuscular  hemoglobin  increased in the  STX  group", "triple_list": [["hemoglobin", "AGONIST", "hemoglobin"]]}, {"text": "Co-treatment of astrocytes with antofine and the intracellular Ca(2+) chelator  BAPTA-AM  prevented downregulation of  Cx43  and inhibition of GJIC", "triple_list": [["BAPTA-AM", "ANTAGONIST", "Co-treatment"]]}, {"text": "Taken together, these findings indicate that  antofine  induces Cx43 gap junction disassembly by the  PKC\u03b2  signaling pathway", "triple_list": [["findings", "AGONIST", "PKC\u03b2"]]}, {"text": "Levels of  Cx43  protein were also decreased in a dose- and time-dependent manner following  antofine  treatment", "triple_list": [["antofine", "AGONIST", "Cx43"]]}, {"text": "Co-treatment of astrocytes with  antofine  and the intracellular Ca(2+) chelator BAPTA-AM prevented downregulation of  Cx43  and inhibition of GJIC", "triple_list": [["with", "ACTIVATOR", "Cx43"]]}, {"text": "Moreover, co-treatment with  antofine  and a specific PKC\u03b2 inhibitor prevented endocytosis of gap junctions, downregulation of  Cx43   and inhibition of GJIC", "triple_list": [["PKC\u03b2", "PRODUCT-OF", "Cx43"]]}, {"text": "Our previous work, built on the early pioneering multikinase inhibitor  LY294002   resulted in the only  PI3K  vascular-targeted  PI3K  inhibitor prodrug, SF1126, which has now completed Phase I clinical trials", "triple_list": [["Our", "ANTAGONIST", "PI3K"]]}, {"text": "Our previous work, built on the early pioneering multikinase inhibitor  LY294002   resulted in the only  PI3K  vascular-targeted  PI3K  inhibitor prodrug, SF1126, which has now completed Phase I clinical trials", "triple_list": [["LY294002", "AGONIST", "only"]]}, {"text": "Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only  PI3K  vascular-targeted  PI3K  inhibitor prodrug,  SF1126   which has now completed Phase I clinical trials", "triple_list": [["SF1126", "AGONIST", "completed"]]}, {"text": "Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only  PI3K  vascular-targeted  PI3K  inhibitor prodrug,  SF1126   which has now completed Phase I clinical trials", "triple_list": [["early", "ANTAGONIST", "PI3K"]]}, {"text": "This work resulted in the discovery of the  5-morpholino-7H-thieno[3,2-b]pyran-7-one  system as the foundation of a new compound class of potential  PI3K  inhibitors having improved potency toward  PI3K ", "triple_list": [["inhibitors", "ACTIVATOR", "PI3K"]]}, {"text": "This work resulted in the discovery of the  5-morpholino-7H-thieno[3,2-b]pyran-7-one  system as the foundation of a new compound class of potential  PI3K  inhibitors having improved potency toward  PI3K   The synthesis and cancer stem cell-based activity of these compounds are reported herein.", "triple_list": [["5-morpholino-7H-thieno[3,2-b]pyran-7-one", "PRODUCT-OF", "synthesis"]]}, {"text": "Synthesis and cancer stem cell-based activity of substituted  5-morpholino-7H-thieno[3,2-b]pyran-7-ones  designed as next generation  PI3K  inhibitors", "triple_list": [["and", "ANTAGONIST", "PI3K"]]}, {"text": "Spiro heterocycles as potential inhibitors of  SIRT1   Pd/C-mediated synthesis of novel  N-indolylmethyl spiroindoline-3,2'-quinazolines   Novel N-indolylmethyl substituted spiroindoline-3,2'-quinazolines were designed as potential inhibitiors of  SIRT1 ", "triple_list": [["as", "AGONIST", "SIRT1"]]}, {"text": "Novel  N-indolylmethyl substituted spiroindoline-3,2'-quinazolines  were designed as potential inhibitiors of  SIRT1   These compounds were synthesized in good yields by using Pd/C-Cu mediated coupling-cyclization strategy as a key step involving the reaction of 1-(prop-2-ynyl)-1'H-spiro[indoline-3,2'-quinazoline]-2,4'(3'H)-dione with 2-iodoanilides", "triple_list": [["N-indolylmethyl substituted spiroindoline-3,2'-quinazolines", "ACTIVATOR", "in"]]}, {"text": "Furthermore, the up-regulation of  IL-12  and TNF-\u03b1 was found in the  procyanidin  trimers-treated cells in the presence of OVA", "triple_list": [["procyanidin", "ANTAGONIST", "IL-12"]]}, {"text": "Furthermore, the up-regulation of IL-12 and  TNF-\u03b1  was found in the  procyanidin  trimers-treated cells in the presence of OVA", "triple_list": [["procyanidin", "PRODUCT-OF", "in"]]}, {"text": "A significant decrease in  HLA-DR  expression was observed in the AP and fractionated  procyanidin  treated cells in the presence of ovalbumin (OVA), but no effect on CD86 expression was observed", "triple_list": [["(OVA),", "ANTAGONIST", "HLA-DR"]]}, {"text": "Apple  polyphenols  suppress antigen presentation of  ovalbumin  by THP-1-derived dendritic cells", "triple_list": [["by", "ANTAGONIST", "ovalbumin"]]}, {"text": "In relation to  zinc  bioavailability,  \u03b1-CPPs   \u03b2-CPPs, \u03b1(s1)-CN(64-74)4P and \u03b2-CN(1-25)4P increased  zinc  uptake", "triple_list": [["zinc", "AGONIST", "\u03b1-CPPs"]]}, {"text": "In relation to  zinc  bioavailability, \u03b1-CPPs,  \u03b2-CPPs   \u03b1(s1)-CN(64-74)4P and \u03b2-CN(1-25)4P increased  zinc  uptake", "triple_list": [["\u03b1-CPPs,", "AGONIST", "\u03b2-CPPs"]]}, {"text": "In relation to  zinc  bioavailability, \u03b1-CPPs, \u03b2-CPPs,  \u03b1(s1)-CN  64-74)4P and \u03b2-CN(1-25)4P increased  zinc  uptake", "triple_list": [["zinc", "DOWNREGULATOR", "relation"]]}, {"text": "In relation to  zinc  bioavailability, \u03b1-CPPs, \u03b2-CPPs, \u03b1(s1)-CN(64-74)4P and  \u03b2-CN  1-25)4P increased  zinc  uptake", "triple_list": [["and", "DOWNREGULATOR", "\u03b2-CN"]]}, {"text": "It has been reported that oligomeric  procyanidins  of lotus seedpod (LSOPC) is effective in the alleviation of Alzheimer's disease and diabetes through its antioxidant and  insulin  potentiating activities", "triple_list": [["that", "AGONIST", "insulin"]]}, {"text": "A new inhibitor of  VEGF receptor tyrosine kinases    vegfrecine  (1), was isolated from the culture broth of Streptomyces sp", "triple_list": [["isolated", "ANTAGONIST", "VEGF receptor tyrosine kinases"]]}, {"text": " Vegfrecine   an Inhibitor of  VEGF Receptor Tyrosine Kinases  Isolated from the Culture Broth of Streptomyces sp", "triple_list": [["Vegfrecine", "PRODUCT-OF", "Receptor"]]}, {"text": "Although  thioredoxin reductase  (TRR) inhibitors ( aurothioglucose  and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction", "triple_list": [["aurothioglucose", "ACTIVATOR", "(TRR)"]]}, {"text": "Although thioredoxin reductase ( TRR   inhibitors ( aurothioglucose  and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat  TRR  plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction", "triple_list": [["Sb(III))", "ACTIVATOR", "TRR"]]}, {"text": "Although  thioredoxin reductase  (TRR) inhibitors (aurothioglucose and  Sb(III)   inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction", "triple_list": [["Sb(III)", "PRODUCT-OF", "cytosol,"]]}, {"text": "Although thioredoxin reductase ( TRR   inhibitors (aurothioglucose and  Sb(III)   inhibited cytosolic DMAs(V) reduction, recombinant rat  TRR  plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction", "triple_list": [["Sb(III)", "AGONIST", "TRR"]]}, {"text": "Pretreatment of rats with glutathione (GSH) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect  methyltransferase  inhibitor periodate-oxidized  adenosine  was without effect", "triple_list": [["adenosine", "ANTAGONIST", "with"]]}, {"text": "Although  glutathione S-transferase omega 1  (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze  DMAs(V)  reduction, their role in  DMAs(V)  reduction in vivo, or in cell extracts is uncertain", "triple_list": [["DMAs(V)", "ANTAGONIST", "extracts"]]}, {"text": "Although glutathione S-transferase omega 1 (GSTO1) and  arsenic methyltransferase  have been shown or thought to catalyze  DMAs(V)  reduction, their role in  DMAs(V)  reduction in vivo, or in cell extracts is uncertain", "triple_list": [["vivo,", "ACTIVATOR", "arsenic methyltransferase"]]}, {"text": "In this study, a novel series of  2-hydroxydiarylamide  derivatives were synthesized and evaluated for inhibiting  TMPRSS4  serine protease activity and suppressing cancer cell invasion", "triple_list": [["2-hydroxydiarylamide", "PRODUCT-OF", "In"]]}, {"text": "In this study, a novel series of  2-hydroxydiarylamide  derivatives were synthesized and evaluated for inhibiting TMPRSS4  serine protease  activity and suppressing cancer cell invasion", "triple_list": [["2-hydroxydiarylamide", "AGONIST", "activity"]]}, {"text": "Discovery of novel  2-hydroxydiarylamide  derivatives as  TMPRSS4  inhibitors", "triple_list": [["Discovery", "ACTIVATOR", "TMPRSS4"]]}, {"text": "Consumption of  alcohol  for 8weeks induced severe liver damage with increases in prognostic indicators such as  aspartate transaminase   alanine transaminase in serum whereas co-administration of CNF suppressed their increases", "triple_list": [["for", "DOWNREGULATOR", "aspartate transaminase"]]}, {"text": "Consumption of  alcohol  for 8weeks induced severe liver damage with increases in prognostic indicators such as aspartate transaminase,  alanine transaminase  in serum whereas co-administration of CNF suppressed their increases", "triple_list": [["alcohol", "ANTAGONIST", "serum"]]}, {"text": "Chronic consumption of  alcohol  also stimulated abrupt increases in pro-inflammatory cytokines such as  nuclear factor (NF)-\u03baB   tumor necrosis factor (TNF)-\u03b1 and interleukin (IL)-1\u03b2 in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently", "triple_list": [["nuclear", "ANTAGONIST", "nuclear factor (NF)-\u03baB"]]}, {"text": "Chronic consumption of  alcohol  also stimulated abrupt increases in pro-inflammatory cytokines such as nuclear factor (NF)-\u03baB,  tumor necrosis factor (TNF)-\u03b1  and interleukin (IL)-1\u03b2 in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently", "triple_list": [["alcohol", "ANTAGONIST", "Chronic"]]}, {"text": "Chronic consumption of  alcohol  also stimulated abrupt increases in pro-inflammatory cytokines such as nuclear factor (NF)-\u03baB, tumor necrosis factor (TNF)-\u03b1 and  interleukin (IL)-1\u03b2  in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently", "triple_list": [["alcohol", "DOWNREGULATOR", "(TNF)-\u03b1"]]}, {"text": " DNA methyltransferase 3a  expression was increased in all  BPA  males and  BPA  0.5 females and reduced in  BPA  200 females", "triple_list": [["DNA", "PRODUCT-OF", "DNA methyltransferase 3a"]]}, {"text": " DNA methyltransferase 3a  expression was increased in all  BPA  males and  BPA  0.5 females and reduced in  BPA  200 females", "triple_list": [["0.5", "DOWNREGULATOR", "DNA methyltransferase 3a"]]}, {"text": " DNA methyltransferase 3a  expression was increased in all  BPA  males and  BPA  0.5 females and reduced in  BPA  200 females", "triple_list": [["BPA", "ANTAGONIST", "200"]]}, {"text": "The  calcium  homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium  calcium  exchanger-1, phospholamban ( PLB  , phospho- PLB , and calsequestrin 2 are important for contraction and relaxation", "triple_list": [["2", "DOWNREGULATOR", "PLB"]]}, {"text": "The  calcium  homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium  calcium  exchanger-1, phospholamban (PLB),  phospho-PLB   and calsequestrin 2 are important for contraction and relaxation", "triple_list": [["(SERCA2a),", "DOWNREGULATOR", "phospho-PLB"]]}, {"text": "The  calcium  homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium  calcium  exchanger-1, phospholamban (PLB), phospho-PLB, and  calsequestrin 2  are important for contraction and relaxation", "triple_list": [["sodium", "AGONIST", "calsequestrin 2"]]}, {"text": "The  calcium  homeostasis proteins  sarcoendoplasmic reticulum ATPase 2a  (SERCA2a), sodium  calcium  exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation", "triple_list": [["calcium", "ANTAGONIST", "sarcoendoplasmic reticulum ATPase 2a"]]}, {"text": "The  calcium  homeostasis proteins sarcoendoplasmic reticulum ATPase 2a ( SERCA2a  , sodium  calcium  exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation", "triple_list": [["calcium", "AGONIST", "proteins"]]}, {"text": "The  calcium  homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium  calcium  exchanger-1  phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation", "triple_list": [["phospho-PLB,", "AGONIST", "sodium calcium exchanger-1"]]}, {"text": "The  calcium  homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium  calcium  exchanger-1,  phospholamban  (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation", "triple_list": [["calcium", "AGONIST", "calcium"]]}, {"text": "The results suggested that both the  EtOAc  extract and berberine were able to activate  PPAR\u03b1/\u03b2/\u03b3   and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine", "triple_list": [["EtOAc", "ACTIVATOR", "PPARs"]]}, {"text": "The results suggested that both the EtOAc extract and  berberine  were able to activate  PPAR\u03b1/\u03b2/\u03b3   and Rhizoma Coptis contains potential natural agonists of PPARs besides  berberine ", "triple_list": [["that", "ANTAGONIST", "PPAR\u03b1/\u03b2/\u03b3"]]}, {"text": "The results suggested that both the EtOAc extract and  berberine  were able to activate  PPAR\u03b1/\u03b2/\u03b3   and Rhizoma Coptis contains potential natural agonists of PPARs besides  berberine   In conclusion, the developed HTS assay is a simple, rapid, stable, and specific method for the screening of PPARs natural agonists.", "triple_list": [["berberine", "ANTAGONIST", "of"]]}, {"text": "The results suggested that both the EtOAc extract and  berberine  were able to activate PPAR\u03b1/\u03b2/\u03b3, and Rhizoma Coptis contains potential natural agonists of  PPARs  besides  berberine   In conclusion, the developed HTS assay is a simple, rapid, stable, and specific method for the screening of  PPARs  natural agonists.", "triple_list": [["berberine", "DOWNREGULATOR", "PPARs"]]}, {"text": "Similarly,  pelargonidin  induced the expression of  CYP1A1  mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (TCDD), the most potent activator of AhR", "triple_list": [["pelargonidin", "AGONIST", "and"]]}, {"text": "Similarly, pelargonidin induced the expression of  CYP1A1  mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM  2,3,7,8-tetrachlorodibenzodioxin  (TCDD), the most potent activator of AhR", "triple_list": [["cells", "AGONIST", "CYP1A1"]]}, {"text": "Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM  2,3,7,8-tetrachlorodibenzodioxin  (TCDD), the most potent activator of  AhR   CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme", "triple_list": [["(TCDD),", "DOWNREGULATOR", "AhR"]]}, {"text": "Similarly, pelargonidin induced the expression of  CYP1A1  mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin ( TCDD  , the most potent activator of AhR", "triple_list": [["TCDD", "DOWNREGULATOR", "and"]]}, {"text": "Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin ( TCDD  , the most potent activator of  AhR   CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of  TCDD  potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme", "triple_list": [["CYP1A1", "DOWNREGULATOR", "AhR"]]}, {"text": " CYP1A1  and CYP1A2 mRNAs were also increased by  pelargonidin  in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in  CYP1A1  protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of  CYP1A1  enzyme", "triple_list": [["three", "PRODUCT-OF", "CYP1A1"]]}, {"text": "CYP1A1 and  CYP1A2  mRNAs were also increased by  pelargonidin  in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme", "triple_list": [["in", "PRODUCT-OF", "CYP1A2"]]}, {"text": " CYP1A1  and CYP1A2 mRNAs were also increased by  pelargonidin  in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in  CYP1A1  protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of  CYP1A1  enzyme", "triple_list": [["pelargonidin", "PRODUCT-OF", "in"]]}, {"text": " CYP1A1  and CYP1A2 mRNAs were also increased by  pelargonidin  in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in  CYP1A1  protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of  CYP1A1  enzyme", "triple_list": [["pelargonidin", "PRODUCT-OF", "of"]]}, {"text": " CYP1A1  and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of  TCDD  potency) and the increase in  CYP1A1  protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of  CYP1A1  enzyme", "triple_list": [["and", "PRODUCT-OF", "CYP1A1"]]}, {"text": "CYP1A1 and  CYP1A2  mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of  TCDD  potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme", "triple_list": [["in", "AGONIST", "CYP1A2"]]}, {"text": " CYP1A1  and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of  TCDD  potency) and the increase in  CYP1A1  protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of  CYP1A1  enzyme", "triple_list": [["human", "DOWNREGULATOR", "CYP1A1"]]}, {"text": " CYP1A1  and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of  TCDD  potency) and the increase in  CYP1A1  protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of  CYP1A1  enzyme", "triple_list": [["human", "PRODUCT-OF", "CYP1A1"]]}, {"text": " Pelargonidin  activates the  AhR  and induces CYP1A1 in primary human hepatocytes and human cancer cell lines HepG2 and LS174T", "triple_list": [["Pelargonidin", "AGONIST", "the"]]}, {"text": "Overall, although most anthocyanidins had no effects on  AhR -CYP1A1 signaling,  pelargonidin  can bind to and activate the  AhR  and  AhR -dependent gene expression, and  pelargonidin  and delphinidin inhibit the CYP1A1 catalytic activity.", "triple_list": [["pelargonidin", "PRODUCT-OF", "activity."]]}, {"text": " AhR  dependent reporter gene expression in transfected HepG2 cells was increased by  pelargonidin  in a concentration-dependent manner at 24h", "triple_list": [["pelargonidin", "DOWNREGULATOR", "was"]]}, {"text": "Enzyme kinetic analyses using human liver microsomes revealed inhibition of  CYP1A1  activity by  delphinidin  (IC50 78 \u03bcM) and pelargonidin (IC50 33 \u03bcM)", "triple_list": [["delphinidin", "PRODUCT-OF", "microsomes"]]}, {"text": "Enzyme kinetic analyses using human liver microsomes revealed inhibition of  CYP1A1  activity by delphinidin (IC50 78 \u03bcM) and  pelargonidin  (IC50 33 \u03bcM)", "triple_list": [["pelargonidin", "ANTAGONIST", "(IC50"]]}, {"text": "Overall, although most anthocyanidins had no effects on AhR- CYP1A1  signaling,  pelargonidin  can bind to and activate the AhR and AhR-dependent gene expression, and  pelargonidin  and delphinidin inhibit the  CYP1A1  catalytic activity.", "triple_list": [["pelargonidin", "ACTIVATOR", "although"]]}, {"text": "Overall, although most anthocyanidins had no effects on AhR- CYP1A1  signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and pelargonidin and  delphinidin  inhibit the  CYP1A1  catalytic activity.", "triple_list": [["delphinidin", "AGONIST", "effects"]]}, {"text": "Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of  resveratrol  while PPAR\u03b1 inhibition prevented the effects of this  SIRT1  activator", "triple_list": [["SIRT1", "ANTAGONIST", "SIRT1"]]}, {"text": "SIRT1 co-precipitated with PPAR\u03b1 and  nicotinamide  increased the acetylation of the PPAR\u03b1 coactivator  PGC-1\u03b1   which was suppressed by resveratrol", "triple_list": [["nicotinamide", "PRODUCT-OF", "PGC-1\u03b1"]]}, {"text": "To determine whether dysregulation of  SIRT1  promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of  SIRT1  ( nicotinamide   sirtinol, EX527) in aorta segments isolated from young Wistar rats", "triple_list": [["endothelial", "AGONIST", "SIRT1"]]}, {"text": "To determine whether dysregulation of  SIRT1  promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of  SIRT1  (nicotinamide,  sirtinol   EX527) in aorta segments isolated from young Wistar rats", "triple_list": [["sirtinol", "PRODUCT-OF", "and"]]}, {"text": "To determine whether dysregulation of  SIRT1  promotes NADPH oxidase-dependent production of reactive oxygen species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of  SIRT1  (nicotinamide, sirtinol,  EX527   in aorta segments isolated from young Wistar rats", "triple_list": [["EX527", "PRODUCT-OF", "species"]]}, {"text": "Endothelial dysfunction induced by SIRT1 inhibition was prevented by treatment of the vessels with the  NADPH oxidase  inhibitor  apocynin  or superoxide dismutase", "triple_list": [["apocynin", "ANTAGONIST", "NADPH"]]}, {"text": "Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced  NADPH oxidase  activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by  resveratrol   Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of  resveratrol  while PPAR\u03b1 inhibition prevented the effects of this SIRT1 activator", "triple_list": [["oxidase", "AGONIST", "NADPH oxidase"]]}, {"text": "Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits  p22(phox)  and NOX4, which were prevented by  resveratrol   Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of  resveratrol  while PPAR\u03b1 inhibition prevented the effects of this SIRT1 activator", "triple_list": [["resveratrol", "PRODUCT-OF", "enhanced"]]}, {"text": "Inhibition of SIRT1 significantly increased vascular superoxide production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and  NOX4   which were prevented by  resveratrol   Peroxisome proliferator-activated receptor-\u03b1 (PPAR\u03b1) activation mimicked the effects of  resveratrol  while PPAR\u03b1 inhibition prevented the effects of this SIRT1 activator", "triple_list": [["effects", "ANTAGONIST", "NOX4"]]}, {"text": "SIRT1 co-precipitated with PPAR\u03b1 and nicotinamide increased the acetylation of the PPAR\u03b1 coactivator  PGC-1\u03b1   which was suppressed by  resveratrol   In conclusion, impaired activity of SIRT1 induces endothelial dysfunction and up-regulates NADPH oxidase-derived ROS production in the vascular wall, mimicking the vascular aging phenotype", "triple_list": [["in", "ACTIVATOR", "PGC-1\u03b1"]]}, {"text": "To determine whether dysregulation of SIRT1 promotes  NADPH oxidase  dependent production of reactive  oxygen  species (ROS) and impairs endothelial function we assessed the effects of three structurally different inhibitors of SIRT1 (nicotinamide, sirtinol, EX527) in aorta segments isolated from young Wistar rats", "triple_list": [["determine", "AGONIST", "NADPH oxidase"]]}, {"text": "Inhibition of  SIRT1  significantly increased vascular  superoxide  production, enhanced NADPH oxidase activity, and mRNA expression of its subunits p22(phox) and NOX4, which were prevented by resveratrol", "triple_list": [["superoxide", "AGONIST", "vascular"]]}, {"text": "This is described in a case study of the expedited review and approval of  peramivir   a novel  neuraminidase  inhibitor, in Japan in the context of the emergence of new strain of influenza in 2009", "triple_list": [["of", "ANTAGONIST", "neuraminidase"]]}, {"text": "In conclusion,  IL-8  production and neutrophil infiltration are increased in high- glucose  environment due to elevated ROS level and contributed to impaired wound healing in diabetic skin", "triple_list": [["glucose", "DOWNREGULATOR", "elevated"]]}, {"text": "Using cultured human keratinocytes and diabetic rat model, the current study showed that high- glucose  environment enhanced  IL-8  production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes", "triple_list": [["IL-8", "PRODUCT-OF", "IL-8"]]}, {"text": "High- glucose  environment enhanced oxidative stress and increased  interleukin-8  secretion from keratinocytes: New insights on impaired diabetic wound healing", "triple_list": [["glucose", "DOWNREGULATOR", "impaired"]]}, {"text": "Upon co-exposure to  V(5+)  and TCDD,  V(5+)  significantly potentiated the TCDD-mediated induction of the  Cyp1a1   Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h", "triple_list": [["induction", "AGONIST", "Cyp1a1"]]}, {"text": "Upon co-exposure to  V(5+)  and TCDD,  V(5+)  significantly potentiated the TCDD-mediated induction of the Cyp1a1,  Cyp1a2   and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h", "triple_list": [["V(5+)", "DOWNREGULATOR", "and"]]}, {"text": "Upon co-exposure to  V(5+)  and TCDD,  V(5+)  significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and  Cyp1b1  mRNA, protein, and catalytic activity levels at 24\u00a0h", "triple_list": [["V(5+)", "PRODUCT-OF", "catalytic"]]}, {"text": "Upon co-exposure to V(5+) and  TCDD   V(5+) significantly potentiated the  TCDD -mediated induction of the  Cyp1a1   Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h", "triple_list": [["TCDD", "ANTAGONIST", "Cyp1b1"]]}, {"text": "Upon co-exposure to V(5+) and  TCDD   V(5+) significantly potentiated the  TCDD -mediated induction of the Cyp1a1,  Cyp1a2   and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h", "triple_list": [["co-exposure", "DOWNREGULATOR", "Cyp1a2"]]}, {"text": "Upon co-exposure to V(5+) and  TCDD   V(5+) significantly potentiated the  TCDD -mediated induction of the Cyp1a1, Cyp1a2, and  Cyp1b1  mRNA, protein, and catalytic activity levels at 24\u00a0h", "triple_list": [["TCDD", "AGONIST", "Cyp1b1"]]}, {"text": "Upon co-exposure to  V(5+)  and TCDD,  V(5+)  significantly potentiated the TCDD-mediated induction of the  Cyp1a1   Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h", "triple_list": [["V(5+)", "DOWNREGULATOR", "catalytic"]]}, {"text": "Upon co-exposure to  V(5+)  and TCDD,  V(5+)  significantly potentiated the TCDD-mediated induction of the Cyp1a1,  Cyp1a2   and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h", "triple_list": [["V(5+)", "AGONIST", "and"]]}, {"text": "Upon co-exposure to  V(5+)  and TCDD,  V(5+)  significantly potentiated the TCDD-mediated induction of the Cyp1a1, Cyp1a2, and  Cyp1b1  mRNA, protein, and catalytic activity levels at 24\u00a0h", "triple_list": [["V(5+)", "AGONIST", "mRNA,"]]}, {"text": "Upon co-exposure to V(5+) and  TCDD , V(5+) significantly potentiated the  TCDD  mediated induction of the  Cyp1a1   Cyp1a2, and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h", "triple_list": [["TCDD", "ANTAGONIST", "Upon"]]}, {"text": "Upon co-exposure to V(5+) and  TCDD , V(5+) significantly potentiated the  TCDD  mediated induction of the Cyp1a1,  Cyp1a2   and Cyp1b1 mRNA, protein, and catalytic activity levels at 24\u00a0h", "triple_list": [["TCDD", "DOWNREGULATOR", "h"]]}, {"text": "Upon co-exposure to V(5+) and  TCDD , V(5+) significantly potentiated the  TCDD  mediated induction of the Cyp1a1, Cyp1a2, and  Cyp1b1  mRNA, protein, and catalytic activity levels at 24\u00a0h", "triple_list": [["TCDD", "PRODUCT-OF", "catalytic"]]}, {"text": " V(5+)  also increased  serum hemoglobin  (Hb) levels in animals treated for 24\u00a0h", "triple_list": [["hemoglobin", "ANTAGONIST", "serum hemoglobin"]]}, {"text": " V(5+)  also increased serum hemoglobin ( Hb   levels in animals treated for 24\u00a0h", "triple_list": [["V(5+)", "AGONIST", "animals"]]}, {"text": "In vitro, V(5+) decreased the  TCDD  mediated induction of  Cyp1a1  mRNA, protein, and catalytic activity levels", "triple_list": [["TCDD", "DOWNREGULATOR", "Cyp1a1"]]}, {"text": "Furthermore, V(5+) significantly inhibited the  TCDD  induced  AhR  dependent luciferase activity", "triple_list": [["TCDD", "PRODUCT-OF", "inhibited"]]}, {"text": "Upon treatment of isolated hepatocytes with Hb alone or in the presence of  TCDD   there was an increase in the  AhR  dependent luciferase activity", "triple_list": [["the", "DOWNREGULATOR", "AhR"]]}, {"text": "In vitro,  V(5+)  decreased the TCDD-mediated induction of  Cyp1a1  mRNA, protein, and catalytic activity levels", "triple_list": [["decreased", "AGONIST", "Cyp1a1"]]}, {"text": "Furthermore,  V(5+)  significantly inhibited the TCDD-induced  AhR  dependent luciferase activity", "triple_list": [["significantly", "ANTAGONIST", "AhR"]]}, {"text": "In support of the hypothesis that  TCDD  decreases canonical Wnt signaling, we identify inhibitory effects of  TCDD  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of  TCDD  on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of  Lgr5   a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  TCDD ", "triple_list": [["TCDD", "ANTAGONIST", "expression"]]}, {"text": "In support of the hypothesis that  TCDD  decreases canonical Wnt signaling, we identify inhibitory effects of  TCDD  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of  TCDD  on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a  RSPO receptor  that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  TCDD ", "triple_list": [["pathway", "ACTIVATOR", "RSPO receptor"]]}, {"text": "In support of the hypothesis that  TCDD  decreases canonical Wnt signaling, we identify inhibitory effects of  TCDD  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of  TCDD  on prostatic bud formation: (1) expression of  R-spondins  (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  TCDD ", "triple_list": [["pathway", "AGONIST", "R-spondins"]]}, {"text": "In support of the hypothesis that  TCDD  decreases canonical Wnt signaling, we identify inhibitory effects of  TCDD  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of  TCDD  on prostatic bud formation: (1) expression of R-spondins ( Rspo2  and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  TCDD ", "triple_list": [["TCDD", "PRODUCT-OF", "(4)"]]}, {"text": "In support of the hypothesis that  TCDD  decreases canonical Wnt signaling, we identify inhibitory effects of  TCDD  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of  TCDD  on prostatic bud formation: (1) expression of R-spondins (Rspo2 and  Rspo3   that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  TCDD ", "triple_list": [["effect", "AGONIST", "Rspo3"]]}, {"text": "In support of the hypothesis that  TCDD  decreases canonical Wnt signaling, we identify inhibitory effects of  TCDD  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of  TCDD  on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of  Lef1   Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  TCDD ", "triple_list": [["Wnt", "AGONIST", "Lef1"]]}, {"text": "In support of the hypothesis that  TCDD  decreases canonical Wnt signaling, we identify inhibitory effects of  TCDD  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of  TCDD  on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1,  Tcf1   and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  TCDD ", "triple_list": [["RSPO", "ANTAGONIST", "Tcf1"]]}, {"text": "In support of the hypothesis that  TCDD  decreases canonical Wnt signaling, we identify inhibitory effects of  TCDD  on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of  TCDD  on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and  Wif1   established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by  TCDD ", "triple_list": [["TCDD", "ACTIVATOR", "on"]]}, {"text": " TCDD  inhibition of canonical  wnt  signaling disrupts prostatic bud formation in mouse urogenital sinus", "triple_list": [["sinus", "AGONIST", "wnt"]]}, {"text": "Thus, the  TCDD  induced reduction in canonical  Wnt  signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway", "triple_list": [["increase", "AGONIST", "Wnt"]]}, {"text": "Thus, the  TCDD  induced reduction in canonical Wnt signaling is associated with a decrease in activators ( Rspo2  and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway", "triple_list": [["TCDD", "ACTIVATOR", "Rspo2"]]}, {"text": "Thus, the  TCDD  induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and  Rspo3   rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway", "triple_list": [["pathway", "ANTAGONIST", "Rspo3"]]}, {"text": "Thus, the  TCDD  induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors ( Dkk1  and Dkk2) of the pathway", "triple_list": [["TCDD", "PRODUCT-OF", "of"]]}, {"text": "Thus, the  TCDD  induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and  Dkk2   of the pathway", "triple_list": [["activators", "ACTIVATOR", "Dkk2"]]}, {"text": "This study focuses on determining whether treatment of  TCDD -exposed UGS organ cultures with RSPO2 and/or RSPO3 is capable of rescuing the inhibitory effects of  TCDD  on canonical  Wnt  signaling and prostatic bud formation", "triple_list": [["TCDD", "ANTAGONIST", "Wnt"]]}, {"text": "We discovered that each RSPO alone or in combination partially rescues  TCDD  inhibition of both canonical  Wnt  signaling and prostatic bud formation.", "triple_list": [["TCDD", "PRODUCT-OF", "partially"]]}, {"text": "In support of the hypothesis that  TCDD  decreases canonical  Wnt  signaling, we identify inhibitory effects of  TCDD  on multiple components of the canonical  Wnt  signaling pathway in the UGS that temporally coincide with the inhibitory effect of  TCDD  on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical  Wnt  signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical  Wnt  target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical  Wnt  signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical  Wnt  signaling, is not increased by  TCDD ", "triple_list": [["inhibitory", "ACTIVATOR", "Wnt"]]}, {"text": "Luciferase reporter assays showed that transcription of  FDX1  was synergistically activated by the NR5A family and  8Br-cAMP  treatment through two SF-1 binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN", "triple_list": [["and", "AGONIST", "FDX1"]]}, {"text": "These results indicate transcription of  FDX1  is regulated by the NR5A family and  cAMP  signaling, and participates in steroid hormone production in ovarian granulosa cells.", "triple_list": [["production", "PRODUCT-OF", "FDX1"]]}, {"text": "Ferredoxin 1 ( FDX1   adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including  steroid  hormone synthesis in mammalian tissues", "triple_list": [["steroid", "DOWNREGULATOR", "that"]]}, {"text": "Ferredoxin 1 (FDX1;  adrenodoxin   is an iron-sulfur protein that is involved in various metabolic processes, including  steroid  hormone synthesis in mammalian tissues", "triple_list": [["steroid", "ACTIVATOR", "is"]]}, {"text": " Ferredoxin 1  (FDX1; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including  steroid  hormone synthesis in mammalian tissues", "triple_list": [["steroid", "ACTIVATOR", "various"]]}, {"text": "Ferredoxin 1 ( FDX1   adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including  steroid hormone  synthesis in mammalian tissues", "triple_list": [["steroid hormone", "DOWNREGULATOR", "mammalian"]]}, {"text": "Ferredoxin 1 (FDX1;  adrenodoxin   is an iron-sulfur protein that is involved in various metabolic processes, including  steroid hormone  synthesis in mammalian tissues", "triple_list": [["steroid hormone", "AGONIST", "in"]]}, {"text": " Ferredoxin 1  (FDX1; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including  steroid hormone  synthesis in mammalian tissues", "triple_list": [["steroid hormone", "ACTIVATOR", "steroid"]]}, {"text": "These results indicate transcription of  FDX1  is regulated by the NR5A family and cAMP signaling, and participates in  steroid  hormone production in ovarian granulosa cells.", "triple_list": [["of", "DOWNREGULATOR", "FDX1"]]}, {"text": "Furthermore,  sinapic acid  reduced hepatic hydroxyproline content, which correlated with a reduction in the expression of  type I collagen  mRNA and histological analysis of collagen in liver tissue", "triple_list": [["sinapic acid", "ANTAGONIST", "with"]]}, {"text": "Additionally, the expression of hepatic fibrosis-related factors such as  \u03b1-smooth muscle actin  and transforming growth factor-\u03b21 (TGF-\u03b21), were reduced in rats treated with  sinapic acid   Sinapic acid exhibited strong scavenging activity", "triple_list": [["sinapic acid", "ACTIVATOR", "the"]]}, {"text": "Additionally, the expression of hepatic fibrosis-related factors such as \u03b1-smooth muscle actin and  transforming growth factor-\u03b21  (TGF-\u03b21), were reduced in rats treated with  sinapic acid   Sinapic acid exhibited strong scavenging activity", "triple_list": [["exhibited", "ANTAGONIST", "transforming growth factor-\u03b21"]]}, {"text": "Additionally, the expression of hepatic fibrosis-related factors such as \u03b1-smooth muscle actin and transforming growth factor-\u03b21 ( TGF-\u03b21  , were reduced in rats treated with  sinapic acid   Sinapic acid exhibited strong scavenging activity", "triple_list": [["sinapic acid", "PRODUCT-OF", "were"]]}, {"text": "In conclusion, we find that  sinapic acid  exhibits hepatoprotective and antifibrotic effects against DMN-induced liver injury, most likely due to its antioxidant activities of scavenging radicals, its capacity to suppress  TGF-\u03b21  and its ability to attenuate activation of hepatic stellate cells", "triple_list": [["conclusion,", "AGONIST", "TGF-\u03b21"]]}, {"text": " Genistin  decreased  myosin light chain kinase  (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects", "triple_list": [["Genistin", "ACTIVATOR", "and"]]}, {"text": " Genistin  decreased myosin light chain kinase ( MLCK   protein contents and  MLCK  mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of  MLCK  contents and inhibition of  MLCK  activity are involved in the genistin-induced inhibitory effects", "triple_list": [["Genistin", "PRODUCT-OF", "decrease"]]}, {"text": " Genistin  decreased myosin light chain kinase ( MLCK ) protein contents and  MLCK  mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of  MLCK  contents and inhibition of  MLCK  activity are involved in the genistin-induced inhibitory effects", "triple_list": [["in", "PRODUCT-OF", "MLCK"]]}, {"text": " Genistin  decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)- ATPase  activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects", "triple_list": [["Genistin", "PRODUCT-OF", "involved"]]}, {"text": "Genistin decreased myosin light chain kinase ( MLCK ) protein contents and  MLCK  mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of  MLCK  contents and inhibition of  MLCK  activity are involved in the  genistin  induced inhibitory effects", "triple_list": [["genistin", "PRODUCT-OF", "myosin,"]]}, {"text": "Genistin decreased myosin light chain kinase ( MLCK ) protein contents and  MLCK  mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of  MLCK  contents and inhibition of  MLCK  activity are involved in the  genistin  induced inhibitory effects", "triple_list": [["of", "AGONIST", "MLCK"]]}, {"text": " Cycloxygenase-2  (COX-2)-derived  prostaglandin E2  (PGE2) has been shown to be important in esophageal tumorigenesis", "triple_list": [["prostaglandin E2", "ACTIVATOR", "important"]]}, {"text": "Cycloxygenase-2 ( COX-2  -derived  prostaglandin E2  (PGE2) has been shown to be important in esophageal tumorigenesis", "triple_list": [["prostaglandin E2", "AGONIST", "in"]]}, {"text": "We conclude that  mPGES1  mediates acid-induced increase in  PGE2  production and cell proliferation", "triple_list": [["mPGES1", "AGONIST", "mPGES1"]]}, {"text": " Cycloxygenase-2  (COX-2)-derived prostaglandin E2 ( PGE2   has been shown to be important in esophageal tumorigenesis", "triple_list": [["PGE2", "AGONIST", "E2"]]}, {"text": "Cycloxygenase-2 ( COX-2  -derived prostaglandin E2 ( PGE2   has been shown to be important in esophageal tumorigenesis", "triple_list": [["PGE2", "ACTIVATOR", "important"]]}, {"text": "We have shown that  COX-2  mediates acid-induced  PGE2  production", "triple_list": [["PGE2", "ACTIVATOR", "have"]]}, {"text": "(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole ( GSK2251052   is a novel boron-containing antibiotic that inhibits  bacterial leucyl tRNA synthetase   and that has been in development for the treatment of serious Gram-negative infections", "triple_list": [["GSK2251052", "PRODUCT-OF", "infections"]]}, {"text": " (S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole  (GSK2251052) is a novel boron-containing antibiotic that inhibits  bacterial leucyl tRNA synthetase   and that has been in development for the treatment of serious Gram-negative infections", "triple_list": [["synthetase", "PRODUCT-OF", "bacterial leucyl tRNA synthetase"]]}, {"text": "A combination of in vitro metabolism experiments and a pharmacokinetic study in monkeys with the inhibitor  4-methylpyrazole  provided strong evidence that  alcohol dehydrogenase   potentially in association with aldehyde dehydrogenase, is the primary enzyme involved in the formation of the M3 metabolite.", "triple_list": [["with", "PRODUCT-OF", "alcohol dehydrogenase"]]}, {"text": "The treatment of mice with  Fe-NTA  alone enhances  ornithine decarboxylase  activity to 4.6 folds, protein carbonyl formation increased up to 2.9 folds and DNA synthesis expressed in terms of [(3)H] thymidine incorporation increased to 3.2 folds, and antioxidants and antioxidant enzymes decreased to 1.8-2.5 folds, compared with the corresponding saline-treated controls", "triple_list": [["Fe-NTA", "DOWNREGULATOR", "compared"]]}, {"text": "Moreover, overexpressed CYP2J2 and  EETs  inhibited  Ang II  induced macrophage migration in a VSMC-macrophage coculture system", "triple_list": [["EETs", "PRODUCT-OF", "VSMC-macrophage"]]}, {"text": "In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and  EETs  markedly suppressed  Ang II  induced inflammatory cytokine expression", "triple_list": [["EETs", "PRODUCT-OF", "Ang"]]}, {"text": "In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and  EETs  markedly suppressed Ang II-induced inflammatory  cytokine  expression", "triple_list": [["rAAV-mediated", "PRODUCT-OF", "cytokine"]]}, {"text": " Cytochrome P450 epoxygenase 2J2  (CYP2J2) metabolizes arachidonic acids to form epoxyeicosatrienoic acids ( EETs  , which possess various beneficial effects on the cardiovascular system", "triple_list": [["effects", "ACTIVATOR", "Cytochrome P450 epoxygenase 2J2"]]}, {"text": "Cytochrome P450 epoxygenase 2J2 ( CYP2J2   metabolizes arachidonic acids to form epoxyeicosatrienoic acids ( EETs  , which possess various beneficial effects on the cardiovascular system", "triple_list": [["EETs", "AGONIST", "("]]}, {"text": "However, whether increasing  EETs  production by  CYP2J2  overexpression in vivo could prevent abdominal aortic aneurysm (AAA) remains unknown", "triple_list": [["EETs", "ANTAGONIST", "could"]]}, {"text": " Cytochrome P450 epoxygenase 2J2  (CYP2J2) metabolizes  arachidonic acids  to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system", "triple_list": [["arachidonic acids", "ACTIVATOR", "epoxygenase"]]}, {"text": "Cytochrome P450 epoxygenase 2J2 ( CYP2J2   metabolizes  arachidonic acids  to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system", "triple_list": [["arachidonic acids", "DOWNREGULATOR", "the"]]}, {"text": " Cytochrome P450 epoxygenase 2J2  (CYP2J2) metabolizes arachidonic acids to form  epoxyeicosatrienoic acids  (EETs), which possess various beneficial effects on the cardiovascular system", "triple_list": [["epoxyeicosatrienoic acids", "AGONIST", "cardiovascular"]]}, {"text": "Cytochrome P450 epoxygenase 2J2 ( CYP2J2   metabolizes arachidonic acids to form  epoxyeicosatrienoic acids  (EETs), which possess various beneficial effects on the cardiovascular system", "triple_list": [["epoxyeicosatrienoic acids", "ACTIVATOR", "form"]]}, {"text": "The expression of  regucalcin  is stimulated through the action of insulin in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by  streptozotocin  administration in vivo", "triple_list": [["in", "ANTAGONIST", "regucalcin"]]}, {"text": "Previously, we have found that  BRN-103   a nicotinamide derivative, inhibits vascular endothelial growth factor ( VEGF  -mediated angiogenesis signaling in human endothelial cells", "triple_list": [["BRN-103", "ANTAGONIST", "VEGF"]]}, {"text": "Previously, we have found that  BRN-103   a nicotinamide derivative, inhibits  vascular endothelial growth factor  (VEGF)-mediated angiogenesis signaling in human endothelial cells", "triple_list": [["BRN-103", "AGONIST", "Previously,"]]}, {"text": "Previously, we have found that BRN-103, a  nicotinamide  derivative, inhibits vascular endothelial growth factor ( VEGF  -mediated angiogenesis signaling in human endothelial cells", "triple_list": [["vascular", "PRODUCT-OF", "VEGF"]]}, {"text": "Previously, we have found that BRN-103, a  nicotinamide  derivative, inhibits  vascular endothelial growth factor  (VEGF)-mediated angiogenesis signaling in human endothelial cells", "triple_list": [["nicotinamide", "ACTIVATOR", "factor"]]}, {"text": "Furthermore,  BRN-250  inhibited the  VEGF  induced phosphorylation and intracellular tyrosine kinase activity of  VEGF  receptor 2 ( VEGF R2) and the activation of its downstream AKT pathway", "triple_list": [["downstream", "AGONIST", "VEGF"]]}, {"text": "Furthermore,  BRN-250  inhibited the VEGF-induced phosphorylation and intracellular  tyrosine kinase  activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway", "triple_list": [["tyrosine", "PRODUCT-OF", "tyrosine kinase"]]}, {"text": "Furthermore,  BRN-250  inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of  VEGF receptor 2  (VEGFR2) and the activation of its downstream AKT pathway", "triple_list": [["BRN-250", "ACTIVATOR", "of"]]}, {"text": "Furthermore,  BRN-250  inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 ( VEGFR2   and the activation of its downstream AKT pathway", "triple_list": [["VEGF", "PRODUCT-OF", "VEGFR2"]]}, {"text": "Furthermore,  BRN-250  inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream  AKT  pathway", "triple_list": [["BRN-250", "PRODUCT-OF", "inhibited"]]}, {"text": "Gelatin zymography showed that  DMBT  inhibited secretion and activity of  MMP-9   Western blotting demonstrated that  DMBT  effectively suppressed the expression of VEGF, p-VEGFR-2, p-EGFR, and p-Akt", "triple_list": [["DMBT", "ANTAGONIST", "and"]]}, {"text": "Western blotting demonstrated that  DMBT  effectively suppressed the expression of  VEGF   p- VEGF R-2, p-EGFR, and p-Akt", "triple_list": [["VEGF", "ANTAGONIST", "VEGF"]]}, {"text": "Western blotting demonstrated that  DMBT  effectively suppressed the expression of VEGF,  p-VEGFR-2   p-EGFR, and p-Akt", "triple_list": [["DMBT", "ANTAGONIST", "DMBT"]]}, {"text": "Western blotting demonstrated that  DMBT  effectively suppressed the expression of VEGF, p-VEGFR-2,  p-EGFR   and p-Akt", "triple_list": [["DMBT", "ANTAGONIST", "and"]]}, {"text": "Western blotting demonstrated that  DMBT  effectively suppressed the expression of VEGF, p-VEGFR-2, p-EGFR, and  p-Akt   These results suggested that  DMBT  could inhibit invasion and angiogenesis by downregulation of VEGFand MMP-9, resulting from the inhibition of Akt pathway", "triple_list": [["DMBT", "ACTIVATOR", "pathway"]]}, {"text": "Inhibition of angiogenesis and invasion by  DMBT  is mediated by downregulation of VEGF and MMP-9 through  Akt  pathway in MDA-MB-231 breast cancer cells", "triple_list": [["MDA-MB-231", "ANTAGONIST", "Akt"]]}, {"text": "Inhibition of angiogenesis and invasion by  DMBT  is mediated by downregulation of  VEGF  and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells", "triple_list": [["invasion", "ANTAGONIST", "VEGF"]]}, {"text": "Inhibition of angiogenesis and invasion by  DMBT  is mediated by downregulation of VEGF and  MMP-9  through Akt pathway in MDA-MB-231 breast cancer cells", "triple_list": [["DMBT", "PRODUCT-OF", "cancer"]]}, {"text": "These results suggested that  DMBT  could inhibit invasion and angiogenesis by downregulation of  VEGF  nd MMP-9, resulting from the inhibition of Akt pathway", "triple_list": [["downregulation", "ACTIVATOR", "VEGF"]]}, {"text": "These results suggested that  DMBT  could inhibit invasion and angiogenesis by downregulation of VEGFand  MMP-9   resulting from the inhibition of Akt pathway", "triple_list": [["downregulation", "ACTIVATOR", "MMP-9"]]}, {"text": "These results suggested that  DMBT  could inhibit invasion and angiogenesis by downregulation of VEGFand MMP-9, resulting from the inhibition of  Akt  pathway", "triple_list": [["and", "PRODUCT-OF", "Akt"]]}, {"text": "Concentration-dependent inhibitory effects of  baicalin  on the metabolism of dextromethorphan, a dual probe of  CYP2D  and CYP3A, in rats", "triple_list": [["rats", "ACTIVATOR", "CYP2D"]]}, {"text": "Concentration-dependent inhibitory effects of  baicalin  on the metabolism of dextromethorphan, a dual probe of CYP2D and  CYP3A   in rats", "triple_list": [["baicalin", "ACTIVATOR", "of"]]}, {"text": "The activity of  CYP3A  in excised liver samples from rats following multiple  baicalin  treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of  baicalin  had no obvious effect on the activity of CYP2D", "triple_list": [["baicalin", "AGONIST", "CYP3A"]]}, {"text": "Taken together, these data demonstrate that  baicalin  inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic  CYP2D  and CYP3A activities.", "triple_list": [["metabolism", "AGONIST", "CYP2D"]]}, {"text": "Taken together, these data demonstrate that  baicalin  inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and  CYP3A  activities.", "triple_list": [["baicalin", "ACTIVATOR", "CYP3A"]]}, {"text": "In the current study, we reveal the inhibitory effects of  baicalin  on the metabolism of dextromethorphan (DXM), a dual probe substrate of  CYP2D  and CYP3A, in rats", "triple_list": [["baicalin", "PRODUCT-OF", "CYP2D"]]}, {"text": "In the current study, we reveal the inhibitory effects of  baicalin  on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and  CYP3A   in rats", "triple_list": [["inhibitory", "ACTIVATOR", "CYP3A"]]}, {"text": "Lineweaver-Burk plots demonstrated that  baicalin  inhibited the activities of  CYP2D  and CYP3A in a non-competitive manner in rat liver microsomes (RLMs)", "triple_list": [["baicalin", "ACTIVATOR", "in"]]}, {"text": "Lineweaver-Burk plots demonstrated that  baicalin  inhibited the activities of CYP2D and  CYP3A  in a non-competitive manner in rat liver microsomes (RLMs)", "triple_list": [["manner", "AGONIST", "CYP3A"]]}, {"text": "Concentration-dependent inhibitory effects of baicalin on the metabolism of  dextromethorphan   a dual probe of  CYP2D  and CYP3A, in rats", "triple_list": [["on", "DOWNREGULATOR", "CYP2D"]]}, {"text": "Concentration-dependent inhibitory effects of baicalin on the metabolism of  dextromethorphan   a dual probe of CYP2D and  CYP3A   in rats", "triple_list": [["Concentration-dependent", "AGONIST", "CYP3A"]]}, {"text": "Taken together, these data demonstrate that baicalin inhibits the metabolism of  DXM  in a concentration-dependent manner in rats, possibly through inhibiting hepatic  CYP2D  and CYP3A activities.", "triple_list": [["DXM", "ANTAGONIST", "concentration-dependent"]]}, {"text": "Taken together, these data demonstrate that baicalin inhibits the metabolism of  DXM  in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and  CYP3A  activities.", "triple_list": [["DXM", "DOWNREGULATOR", "demonstrate"]]}, {"text": "In the current study, we reveal the inhibitory effects of baicalin on the metabolism of  dextromethorphan  (DXM), a dual probe substrate of  CYP2D  and CYP3A, in rats", "triple_list": [["dextromethorphan", "AGONIST", "reveal"]]}, {"text": "In the current study, we reveal the inhibitory effects of baicalin on the metabolism of  dextromethorphan  (DXM), a dual probe substrate of CYP2D and  CYP3A   in rats", "triple_list": [["dextromethorphan", "ANTAGONIST", "of"]]}, {"text": "In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan ( DXM  , a dual probe substrate of  CYP2D  and CYP3A, in rats", "triple_list": [["CYP3A,", "AGONIST", "CYP2D"]]}, {"text": "In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan ( DXM  , a dual probe substrate of CYP2D and  CYP3A   in rats", "triple_list": [["effects", "ACTIVATOR", "CYP3A"]]}, {"text": "The structure-activity relationship of a series of  dihydroisoquinoline   BACE-1  inhibitors is described", "triple_list": [["dihydroisoquinoline", "ACTIVATOR", "is"]]}, {"text": "Structure-based design of novel  dihydroisoquinoline   BACE-1  inhibitors that do not engage the catalytic aspartates", "triple_list": [["dihydroisoquinoline", "AGONIST", "not"]]}, {"text": "The modification of the inhibitor scaffold of 1 and 2 from a  dihydroquinolinone  core to a tetrahydropyrazolopyridinone core led to discovery of a new series of potent  KAT II  inhibitors with excellent physicochemical properties", "triple_list": [["a", "ANTAGONIST", "KAT II"]]}, {"text": "The modification of the inhibitor scaffold of 1 and 2 from a dihydroquinolinone core to a  tetrahydropyrazolopyridinone  core led to discovery of a new series of potent  KAT II  inhibitors with excellent physicochemical properties", "triple_list": [["tetrahydropyrazolopyridinone", "AGONIST", "core"]]}, {"text": "The structure-based design, synthesis, and biological evaluation of a new  pyrazole  series of irreversible  KAT II  inhibitors are described herein", "triple_list": [["and", "ANTAGONIST", "KAT II"]]}, {"text": " PF-04859989  as a template for structure-based drug design: identification of new pyrazole series of irreversible  KAT II  inhibitors with improved lipophilic efficiency", "triple_list": [["PF-04859989", "PRODUCT-OF", "improved"]]}, {"text": "PF-04859989 as a template for structure-based drug design: identification of new  pyrazole  series of irreversible  KAT II  inhibitors with improved lipophilic efficiency", "triple_list": [["II", "PRODUCT-OF", "KAT II"]]}, {"text": "Structure-activity relationship studies indicated that  5-(p-toluenesulfonylamino)phthalimide  moiety is a favorable scaffold to exert the  \u03b1-glucosidase  inhibitory activity and substituents at the N2 position have considerable influence on the efficacy of the inhibition activities.", "triple_list": [["5-(p-toluenesulfonylamino)phthalimide", "AGONIST", "influence"]]}, {"text": "Several members of a new family of non-sugar-type  \u03b1-glycosidase  inhibitors, bearing a  5-(p-toluenesulfonylamino)phthalimide  moiety and various substituent at the N2 position, were synthesized and their activities were investigated", "triple_list": [["5-(p-toluenesulfonylamino)phthalimide", "AGONIST", "of"]]}, {"text": "A new series of  N2-substituted-5-(p-toluenesulfonylamino)phthalimide  analogues as  \u03b1-glucosidase  inhibitors", "triple_list": [["of", "PRODUCT-OF", "\u03b1-glucosidase"]]}, {"text": "We previously employed a chemical genomic strategy to identify a novel small molecule,  MAC13243   as a likely inhibitor of the  bacterial lipoprotein  targeting chaperone, LolA", "triple_list": [["likely", "AGONIST", "bacterial lipoprotein"]]}, {"text": "We previously employed a chemical genomic strategy to identify a novel small molecule,  MAC13243   as a likely inhibitor of the bacterial lipoprotein targeting  chaperone   LolA", "triple_list": [["the", "AGONIST", "chaperone"]]}, {"text": "We previously employed a chemical genomic strategy to identify a novel small molecule,  MAC13243   as a likely inhibitor of the bacterial lipoprotein targeting chaperone,  LolA   Here, we report on the degradation of  MAC13243  into the active species, S-(4-chlorobenzyl)isothiourea", "triple_list": [["genomic", "ACTIVATOR", "LolA"]]}, {"text": "Thus, in 158N cells, the ability of  oxysterols  to trigger a mode of cell death by apoptosis involving  GSK-3  and caspase-3 activation is independent of the increase in the Ca(2+) level and of their accumulation in lipid raft microdomains.", "triple_list": [["mode", "AGONIST", "GSK-3"]]}, {"text": "Thus, in 158N cells, the ability of  oxysterols  to trigger a mode of cell death by apoptosis involving GSK-3 and  caspase-3  activation is independent of the increase in the Ca(2+) level and of their accumulation in lipid raft microdomains.", "triple_list": [["oxysterols", "PRODUCT-OF", "caspase-3"]]}, {"text": "To this end, 158N murine oligodendrocytes were treated with  7KC  or 7\u03b2OHC inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving  Mcl-1   and caspase-3 activation", "triple_list": [["7KC", "ANTAGONIST", "condensation/fragmentation"]]}, {"text": "To this end, 158N murine oligodendrocytes were treated with  7KC  or 7\u03b2OHC inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving Mcl-1, and  caspase-3  activation", "triple_list": [["were", "PRODUCT-OF", "caspase-3"]]}, {"text": "To this end, 158N murine oligodendrocytes were treated with 7KC or  7\u03b2OHC  inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving  Mcl-1   and caspase-3 activation", "triple_list": [["by", "PRODUCT-OF", "Mcl-1"]]}, {"text": "To this end, 158N murine oligodendrocytes were treated with 7KC or  7\u03b2OHC  inducing an apoptotic mode of cell death characterized by condensation/fragmentation of the nuclei, dephosphorylation of Akt and GSK3, mitochondrial depolarization involving Mcl-1, and  caspase-3  activation", "triple_list": [["158N", "AGONIST", "caspase-3"]]}, {"text": "This inhibition was blocked when mice were pretreated with the selective  H3R  agonist  R-(alpha)-methyl-histamine  (10\u00a0mg/kg)", "triple_list": [["R-(alpha)-methyl-histamine", "ANTAGONIST", "H3R"]]}, {"text": "Subsequent analysis revealed that  cucurbitacin I  strongly activates  RhoA  and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers", "triple_list": [["cucurbitacin I", "AGONIST", "of"]]}, {"text": "Subsequent analysis revealed that  cucurbitacin I  strongly activates  Rho A and the  Rho  effector  Rho  kinase (ROCK) in breast cancer cells and induces the formation of stress fibers", "triple_list": [["and", "DOWNREGULATOR", "Rho"]]}, {"text": "Subsequent analysis revealed that  cucurbitacin I  strongly activates RhoA and the Rho effector  Rho kinase  (ROCK) in breast cancer cells and induces the formation of stress fibers", "triple_list": [["cucurbitacin I", "AGONIST", "the"]]}, {"text": "Subsequent analysis revealed that  cucurbitacin I  strongly activates RhoA and the Rho effector Rho kinase ( ROCK   in breast cancer cells and induces the formation of stress fibers", "triple_list": [["and", "ANTAGONIST", "ROCK"]]}, {"text": "Lastly, we found that  RhoA  activation by  cucurbitacin I  is mediated by reactive oxygen species (ROS)", "triple_list": [["(ROS)", "AGONIST", "RhoA"]]}, {"text": "The ROS scavenger  N-acetyl l-cysteine  and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on  Rac1  activation", "triple_list": [["cucurbitacin", "ANTAGONIST", "Rac1"]]}, {"text": " Cucurbitacin I  inhibits  rac1  activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1", "triple_list": [["Cucurbitacin I", "AGONIST", "cells"]]}, {"text": "Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of  cucurbitacin I  on  Rac1  activation by heregulin", "triple_list": [["pathway", "AGONIST", "Rac1"]]}, {"text": "The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of  cucurbitacin I  on  Rac1  activation", "triple_list": [["l-cysteine", "AGONIST", "Rac1"]]}, {"text": "Moreover, they established that the inhibitory effect of  cucurbitacin I  on  Rac1  activity involves the alteration of the balance between Rho and Rac.", "triple_list": [["Moreover,", "ANTAGONIST", "Rac1"]]}, {"text": "Here we found that the anticancer agent  cucurbitacin I   a  Jak2  inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells", "triple_list": [["response", "ANTAGONIST", "Jak2"]]}, {"text": "Here we found that the anticancer agent  cucurbitacin I   a Jak2 inhibitor, reduced the activation of  Rac1  and motility in response to the ErbB3 ligand heregulin in breast cancer cells", "triple_list": [["cucurbitacin I", "ANTAGONIST", "I"]]}, {"text": "The major ingredient of ginger,  [6]-gingerol   could inhibit  angiotensin II type 1 receptor  activation, which partially clarified the mechanism of ginger regulating blood pressure and strengthening heart in the cardiovascular system.", "triple_list": [["[6]-gingerol", "ACTIVATOR", "inhibit"]]}, {"text": " [6]-Gingerol  derived from Zingiber officinale Roscoe (ginger) was identified as a novel  angiotensin II type 1 receptor  antagonist, with an IC50 value of 8.173 \u00b5M", "triple_list": [["[6]-Gingerol", "AGONIST", "II"]]}, {"text": " [6]-gingerol   a novel  AT\u2081  antagonist for the treatment of cardiovascular disease", "triple_list": [["[6]-gingerol", "DOWNREGULATOR", "the"]]}, {"text": "Saturated  palmitic and stearic acids  increased ceramides, up-regulated  PTP1B   and had AKt and  PTP1B  phosphorylation at Ser 50 impaired", "triple_list": [["AKt", "ANTAGONIST", "PTP1B"]]}, {"text": "Saturated  palmitic and stearic acids  increased ceramides, up-regulated PTP1B, and had  AKt  and PTP1B phosphorylation at Ser 50 impaired", "triple_list": [["and", "PRODUCT-OF", "AKt"]]}, {"text": "Saturated  palmitic and stearic acids  increased ceramides, up-regulated  PTP1B , and had AKt and  PTP1B  phosphorylation at Ser 50 impaired", "triple_list": [["palmitic and stearic acids", "DOWNREGULATOR", "AKt"]]}, {"text": "Cells were also evaluated in the presence of  wortmannin   an inhibitor of  phosphatidylinositol 3-kinases  and thus AKt (0-100 nM)", "triple_list": [["phosphatidylinositol", "ACTIVATOR", "phosphatidylinositol 3-kinases"]]}, {"text": "Cells were also evaluated in the presence of  wortmannin   an inhibitor of phosphatidylinositol 3-kinases and thus  AKt  (0-100 nM)", "triple_list": [["were", "ACTIVATOR", "AKt"]]}, {"text": "Only FFAs that increased  ceramides  caused impairment of  AKt  and PTP1B phosphorylation at Ser 50", "triple_list": [["that", "ANTAGONIST", "AKt"]]}, {"text": "Only FFAs that increased  ceramides  caused impairment of AKt and  PTP1B  phosphorylation at Ser 50", "triple_list": [["of", "ACTIVATOR", "PTP1B"]]}, {"text": "Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly  telmisartan   are partial agonists at  peroxisome proliferator-activated receptor-\u03b3   All of these properties are comprehensively reviewed in this article", "triple_list": [["telmisartan", "ACTIVATOR", "II"]]}, {"text": "Although generally highly specific for  angiotensin II type 1 receptors   some ARBs, particularly  telmisartan   are partial agonists at peroxisome proliferator-activated receptor-\u03b3", "triple_list": [["type", "AGONIST", "angiotensin II type 1 receptors"]]}, {"text": "A head-to-head comparison between  insulin  detemir and NPH  insulin  in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma  glucose  improved with  insulin  detemir without an increased incidence of hypoglycaemia", "triple_list": [["insulin", "PRODUCT-OF", "insulin"]]}, {"text": "In this study, we employed virtual screening and chemical synthesis to identify a series of  N-(thiophen-2-yl) benzamide  derivatives as potent  BRAF  V600E) inhibitors", "triple_list": [["N-(thiophen-2-yl) benzamide", "ANTAGONIST", "N-(thiophen-2-yl)"]]}, {"text": "In this study, we employed virtual screening and chemical synthesis to identify a series of  N-(thiophen-2-yl) benzamide  derivatives as potent BRAF( V600E   inhibitors", "triple_list": [["potent", "ANTAGONIST", "V600E"]]}, {"text": "Identification and synthesis of  N-(thiophen-2-yl) benzamide  derivatives as  BRAF  V600E) inhibitors", "triple_list": [["N-(thiophen-2-yl) benzamide", "ACTIVATOR", "Identification"]]}, {"text": "Identification and synthesis of  N-(thiophen-2-yl) benzamide  derivatives as BRAF( V600E   inhibitors", "triple_list": [["and", "AGONIST", "V600E"]]}, {"text": "Methylation-specific PCR and bisulfite sequencing identified methylation of this  CpG  ((m) CpG ) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in  DNA methyl transferase 3a  concentrations noted with advancing postnatal age (PN14 vs PN3)", "triple_list": [["increase", "DOWNREGULATOR", "DNA methyl transferase 3a"]]}, {"text": "Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG ( (m)CpG   island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in  DNA methyl transferase 3a  concentrations noted with advancing postnatal age (PN14 vs PN3)", "triple_list": [["(m)CpG", "AGONIST", "PN3)"]]}, {"text": "5'-flanking region of  glut3 -luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that  (m)CpGs  inhibit  glut3  transcription", "triple_list": [["(m)CpGs", "PRODUCT-OF", "(m)CpGs"]]}, {"text": "Separate  5-aza-2'-deoxycytidine  pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting  Mecp2  and Creb1 separately or together depleting  Mecp2  and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells", "triple_list": [["and/or", "ACTIVATOR", "Mecp2"]]}, {"text": "Separate  5-aza-2'-deoxycytidine  pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and  Creb1  separately or together depleting Mecp2 and/or  Creb1  binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells", "triple_list": [["specific", "PRODUCT-OF", "Creb1"]]}, {"text": "Separate 5-aza-2'-deoxycytidine pretreatment or in combination with  trichostatin A  reduced (m)CpG and specific small interference RNAs targeting  Mecp2  and Creb1 separately or together depleting  Mecp2  and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells", "triple_list": [["Mecp2", "ANTAGONIST", "Mecp2"]]}, {"text": "Separate 5-aza-2'-deoxycytidine pretreatment or in combination with  trichostatin A  reduced (m)CpG and specific small interference RNAs targeting Mecp2 and  Creb1  separately or together depleting Mecp2 and/or  Creb1  binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells", "triple_list": [["trichostatin A", "AGONIST", "Mecp2"]]}, {"text": "The most potent in\u2005vitro DASI discovered is an  imidazole  derivative with IC50 values against  aromatase  and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5\u2005nM, respectively", "triple_list": [["imidazole", "PRODUCT-OF", "sulfatase"]]}, {"text": "The most potent in\u2005vitro DASI discovered is an  imidazole  derivative with IC50 values against aromatase and  steroid sulfatase  in a JEG-3 cell preparation of 0.2 and 2.5\u2005nM, respectively", "triple_list": [["is", "ANTAGONIST", "steroid sulfatase"]]}, {"text": "The parent  phenol  of this compound inhibits  aromatase  with an IC50 value of 0.028\u2005nM in the same assay.", "triple_list": [["phenol", "PRODUCT-OF", "with"]]}, {"text": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated ( F   Cl, Br) derivatives are first-generation dual  aromatase  and sulfatase inhibitors (DASIs)", "triple_list": [["Br)", "PRODUCT-OF", "aromatase"]]}, {"text": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated ( F   Cl, Br) derivatives are first-generation dual aromatase and  sulfatase  inhibitors (DASIs)", "triple_list": [["F", "ANTAGONIST", "are"]]}, {"text": "Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual  Aromatase  Sulfatase Inhibitor  4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate    4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate  and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)", "triple_list": [["4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate", "AGONIST", "ortho-halogenated"]]}, {"text": "Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase- Sulfatase  Inhibitor  4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate    4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate  and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs)", "triple_list": [["are", "AGONIST", "Sulfatase"]]}, {"text": " 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate  and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual  aromatase  and sulfatase inhibitors (DASIs)", "triple_list": [["4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate", "ANTAGONIST", "inhibitors"]]}, {"text": " 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate  and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and  sulfatase  inhibitors (DASIs)", "triple_list": [["4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate", "ACTIVATOR", "and"]]}, {"text": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F,  Cl   Br) derivatives are first-generation dual  aromatase  and sulfatase inhibitors (DASIs)", "triple_list": [["Cl", "AGONIST", "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl"]]}, {"text": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F,  Cl   Br) derivatives are first-generation dual aromatase and  sulfatase  inhibitors (DASIs)", "triple_list": [["(F,", "PRODUCT-OF", "sulfatase"]]}, {"text": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl,  Br   derivatives are first-generation dual  aromatase  and sulfatase inhibitors (DASIs)", "triple_list": [["derivatives", "PRODUCT-OF", "aromatase"]]}, {"text": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl,  Br   derivatives are first-generation dual aromatase and  sulfatase  inhibitors (DASIs)", "triple_list": [["Br", "AGONIST", "(DASIs)"]]}, {"text": "A series of  pyrido-quinazolines  have been synthesised, characterised and tested for their in vitro  EGFR  tyrosine kinase inhibitory activity", "triple_list": [["tyrosine", "ANTAGONIST", "EGFR"]]}, {"text": "A series of  pyrido-quinazolines  have been synthesised, characterised and tested for their in vitro EGFR  tyrosine kinase  inhibitory activity", "triple_list": [["been", "ANTAGONIST", "tyrosine kinase"]]}, {"text": "Synthesis and in vitro evaluation of  N-Aryl pyrido-quinazolines  derivatives as potent  EGFR  inhibitors", "triple_list": [["Synthesis", "AGONIST", "EGFR"]]}, {"text": "In the in vitro assay,  kinsenoside  (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO),  lactic dehydrogenase  (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system", "triple_list": [["kinsenoside", "ANTAGONIST", "vitro"]]}, {"text": "In the in vitro assay,  kinsenoside  (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase ( LDH  , superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system", "triple_list": [["kinsenoside", "ACTIVATOR", "cells"]]}, {"text": "In the in vitro assay,  kinsenoside  (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH),  superoxide dismutase  (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system", "triple_list": [["kinsenoside", "ANTAGONIST", "by"]]}, {"text": "In the in vitro assay,  kinsenoside  (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase ( SOD  , and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system", "triple_list": [["cells", "ACTIVATOR", "SOD"]]}, {"text": "In the in vitro assay,  kinsenoside  (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and  catalase  (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system", "triple_list": [["kinsenoside", "ACTIVATOR", "oxide"]]}, {"text": "In the in vitro assay,  kinsenoside  (20 and 50\u03bcg/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase ( CAT  ) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system", "triple_list": [["kinsenoside", "AGONIST", "metalloproteinases-the"]]}, {"text": "The vascular protective effects of  kinsenoside  were speculated to be attributed to oxidative stress inhibition and the reduction of  nuclear factor kappa B  (NF-\u03baB) mRNA expression levels in high glucose conditions", "triple_list": [["of", "ANTAGONIST", "nuclear factor kappa B"]]}, {"text": "The vascular protective effects of  kinsenoside  were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B ( NF-\u03baB   mRNA expression levels in high glucose conditions", "triple_list": [["kinsenoside", "PRODUCT-OF", "stress"]]}, {"text": " Cholesterol  uptake from  lipoproteins   intracellular vesicle transport and lipid transfer are also modified by oxysterols", "triple_list": [["Cholesterol", "ACTIVATOR", "are"]]}, {"text": "Activation of  ALDH2  with  ethanol  attenuates diabetes induced myocardial injury in rats", "triple_list": [["rats", "ANTAGONIST", "ALDH2"]]}, {"text": "This study assessed changes in myocardial  ALDH2  expression in the diabetic rat, in particular the diabetic rat pretreated with  ALDH2  activator  ethanol  (EtOH)", "triple_list": [["ethanol", "AGONIST", "particular"]]}, {"text": "This study assessed changes in myocardial  ALDH2  expression in the diabetic rat, in particular the diabetic rat pretreated with  ALDH2  activator ethanol ( EtOH  ", "triple_list": [["EtOH", "ANTAGONIST", "rat,"]]}, {"text": "Compared with DM8W group,  SOD  and ALDH2 in  EtOH  DM8W group was increased, MDA was decreased", "triple_list": [["Compared", "ANTAGONIST", "SOD"]]}, {"text": "Compared with DM8W group, SOD and  ALDH2  in  EtOH  DM8W group was increased, MDA was decreased", "triple_list": [["EtOH", "AGONIST", "MDA"]]}, {"text": " HbA1c  level in DM12W group was higher than in DM4W group,  HbA1c  level in  EtOH  DM8W group was lower than in DM8W group", "triple_list": [["EtOH", "ACTIVATOR", "group"]]}, {"text": " EROD  activity induction in peripheral blood lymphocytes, liver and brain tissues of rats orally exposed to  polycyclic aromatic hydrocarbons   Little is known in terms of multi-matrix cytochrome P450 activity induction under repeated oral exposure to planar halogenated and  polycyclic aromatic hydrocarbons  (PHH, PAH)", "triple_list": [["activity", "DOWNREGULATOR", "EROD"]]}, {"text": "Little is known in terms of multi-matrix  cytochrome P450  activity induction under repeated oral exposure to planar  halogenated and polycyclic aromatic hydrocarbons  (PHH, PAH)", "triple_list": [["halogenated and polycyclic aromatic hydrocarbons", "ANTAGONIST", "multi-matrix"]]}, {"text": "Little is known in terms of multi-matrix  cytochrome P450  activity induction under repeated oral exposure to planar halogenated and polycyclic aromatic hydrocarbons (PHH,  PAH  ", "triple_list": [["PAH", "DOWNREGULATOR", "terms"]]}, {"text": "A novel  benzo[d]imidazole  derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of  NLRP3  inflammasome", "triple_list": [["of", "PRODUCT-OF", "NLRP3"]]}, {"text": "Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of  caspase-1  in peritoneal macrophages were detected in  Fc11a  2-treated mice", "triple_list": [["Fc11a", "ACTIVATOR", "decreased"]]}, {"text": "The mechanism of action of  Fc11a-2  was related to the inhibition of the cleavage of  pro-caspase-1   pro-IL-1\u03b2 and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome", "triple_list": [["Fc11a-2", "ACTIVATOR", "in"]]}, {"text": "The mechanism of action of  Fc11a-2  was related to the inhibition of the cleavage of pro-caspase-1,  pro-IL-1\u03b2  and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome", "triple_list": [["cleavage", "ACTIVATOR", "pro-IL-1\u03b2"]]}, {"text": "The mechanism of action of  Fc11a-2  was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1\u03b2 and  pro-IL-18  which in turn suppressed the activation of NLRP3 inflammasome", "triple_list": [["Fc11a-2", "AGONIST", "Fc11a-2"]]}, {"text": "The mechanism of action of  Fc11a-2  was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1\u03b2 and pro-IL-18 which in turn suppressed the activation of  NLRP3  inflammasome", "triple_list": [["and", "ACTIVATOR", "NLRP3"]]}, {"text": "Taken together, our results demonstrate the ability of  Fc11a-2  to inhibit  NLRP3  inflammasome activation and its potential use in the treatment of inflammatory bowel diseases.", "triple_list": [["Fc11a-2", "AGONIST", "the"]]}, {"text": "In addition, the disease activity index, histopathologic scores and  myeloperoxidase  activity were also significantly reduced by  Fc11a-2  treatment", "triple_list": [["the", "ACTIVATOR", "myeloperoxidase"]]}, {"text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory  cytokines  in colon, including TNF-\u03b1, IL-1\u03b2, IL-18, IL-17A and IFN-\u03b3, were markedly suppressed by  Fc11a-2   Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in  Fc11a-2 -treated mice", "triple_list": [["Fc11a-2", "ANTAGONIST", "IL-1\u03b2,"]]}, {"text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including  TNF-\u03b1   IL-1\u03b2, IL-18, IL-17A and IFN-\u03b3, were markedly suppressed by  Fc11a-2   Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in  Fc11a-2 -treated mice", "triple_list": [["Fc11a-2", "AGONIST", "DSS-induced"]]}, {"text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1,  IL-1\u03b2   IL-18, IL-17A and IFN-\u03b3, were markedly suppressed by  Fc11a-2   Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in  Fc11a-2 -treated mice", "triple_list": [["detected", "ANTAGONIST", "IL-1\u03b2"]]}, {"text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2,  IL-18   IL-17A and IFN-\u03b3, were markedly suppressed by  Fc11a-2   Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in  Fc11a-2 -treated mice", "triple_list": [["Furthermore,", "ANTAGONIST", "IL-18"]]}, {"text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2, IL-18,  IL-17A  and IFN-\u03b3, were markedly suppressed by  Fc11a-2   Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in  Fc11a-2 -treated mice", "triple_list": [["Fc11a-2", "AGONIST", "including"]]}, {"text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-\u03b1, IL-1\u03b2, IL-18, IL-17A and  IFN-\u03b3   were markedly suppressed by  Fc11a-2   Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in  Fc11a-2 -treated mice", "triple_list": [["Fc11a-2", "ACTIVATOR", "were"]]}, {"text": "We also observed that  fisetin  efficiently suppressed the phosphorylation of  Akt   S6K1 and mTORC1 in adipose tissue", "triple_list": [["fisetin", "ACTIVATOR", "Akt"]]}, {"text": "We also observed that  fisetin  efficiently suppressed the phosphorylation of Akt,  S6K1  and mTORC1 in adipose tissue", "triple_list": [["that", "ACTIVATOR", "S6K1"]]}, {"text": "We also observed that  fisetin  efficiently suppressed the phosphorylation of Akt, S6K1 and  mTORC1  in adipose tissue", "triple_list": [["of", "ACTIVATOR", "mTORC1"]]}, {"text": "Collectively, these results suggest that inhibition of  mTORC1  signaling by  fisetin  prevents adipocyte differentiation of 3T3-L1 preadipocytes and obesity in HFD-fed mice", "triple_list": [["fisetin", "ACTIVATOR", "by"]]}, {"text": " Fisetin  treatment of preadipocytes reduced the phosphorylation of  S6K1  and mTORC1 in a time- and concentration-dependent manner", "triple_list": [["the", "ANTAGONIST", "S6K1"]]}, {"text": " Fisetin  treatment of preadipocytes reduced the phosphorylation of S6K1 and  mTORC1  in a time- and concentration-dependent manner", "triple_list": [["preadipocytes", "AGONIST", "mTORC1"]]}, {"text": "To further our understanding of how  fisetin  negatively regulates  mTORC1  signaling, we analyzed the phosphorylation of S6K1, mTOR and Akt in  fisetin -treated TSC2-knockdown cells", "triple_list": [["analyzed", "PRODUCT-OF", "mTORC1"]]}, {"text": "The results suggested that  fisetin  treatment inhibits  mTORC1  activity in an Akt-dependent manner", "triple_list": [["fisetin", "AGONIST", "mTORC1"]]}, {"text": "The results suggested that  fisetin  treatment inhibits mTORC1 activity in an  Akt  dependent manner", "triple_list": [["The", "PRODUCT-OF", "Akt"]]}, {"text": "Fisetin treatment inhibited adipocyte differentiation, consistent with the negative effect of  fisetin  on  mTOR   The inhibitory effect of  fisetin  on adipogenesis is dependent of  mTOR  activity, suggesting that  fisetin  inhibits adipogenesis and the accumulation of intracellular triglycerides during adipocyte differentiation by targeting  mTOR C1 signaling", "triple_list": [["The", "ACTIVATOR", "mTOR"]]}, {"text": " Amprenavir  mediated  PXR  activation stimulated the expression of several key intestinal genes involved in lipid homeostasis", "triple_list": [["Amprenavir", "ANTAGONIST", "in"]]}, {"text": " Amprenavir  efficiently activated  PXR  and induced  PXR  target gene expression in vitro and in vivo", "triple_list": [["Amprenavir", "ANTAGONIST", "PXR"]]}, {"text": " Amprenavir  efficiently activated  PXR  and induced  PXR  target gene expression in vitro and in vivo", "triple_list": [["expression", "AGONIST", "PXR"]]}, {"text": "Pregnane X Receptor Mediates Dyslipidemia Induced by the  HIV Protease  Inhibitor  Amprenavir  in Mice", "triple_list": [["the", "PRODUCT-OF", "HIV Protease"]]}, {"text": "In the present study, we identified  amprenavir   a widely used HIV PI, as a potent  PXR  selective agonist", "triple_list": [["selective", "ANTAGONIST", "PXR"]]}, {"text": "One exception is  tranexamic acid  (TXA), which, as a lysine mimetic, inhibits binding of  plasminogen  to fibrin", "triple_list": [["tranexamic acid", "ACTIVATOR", "binding"]]}, {"text": "One exception is  tranexamic acid  (TXA), which, as a lysine mimetic, inhibits binding of plasminogen to  fibrin   However, the daily dose of TXA is high due to its modest potency and pharmacokinetic properties", "triple_list": [["tranexamic acid", "PRODUCT-OF", "is"]]}, {"text": "One exception is tranexamic acid ( TXA  , which, as a lysine mimetic, inhibits binding of  plasminogen  to fibrin", "triple_list": [["TXA", "AGONIST", "("]]}, {"text": "One exception is tranexamic acid ( TXA  , which, as a lysine mimetic, inhibits binding of plasminogen to  fibrin   However, the daily dose of  TXA  is high due to its modest potency and pharmacokinetic properties", "triple_list": [["TXA", "ACTIVATOR", "However,"]]}, {"text": "One exception is tranexamic acid (TXA), which, as a  lysine  mimetic, inhibits binding of  plasminogen  to fibrin", "triple_list": [["lysine", "PRODUCT-OF", "binding"]]}, {"text": "One exception is tranexamic acid (TXA), which, as a  lysine  mimetic, inhibits binding of plasminogen to  fibrin   However, the daily dose of TXA is high due to its modest potency and pharmacokinetic properties", "triple_list": [["to", "ACTIVATOR", "fibrin"]]}, {"text": "Coupling this computational technique with a high-quality low-throughput screen identified  5-(4-piperidyl)-3-isoxazolol  (4-PIOL) as a potent  plasminogen  binding inhibitor with the potential for the treatment of various bleeding disorders", "triple_list": [["the", "AGONIST", "plasminogen"]]}, {"text": "Coupling this computational technique with a high-quality low-throughput screen identified 5-(4-piperidyl)-3-isoxazolol ( 4-PIOL   as a potent  plasminogen  binding inhibitor with the potential for the treatment of various bleeding disorders", "triple_list": [["4-PIOL", "ANTAGONIST", "of"]]}, {"text": "Polo-like kinase-2 ( Plk-2 ) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of  dihydropteridinone  based  Plk-2  inhibitors", "triple_list": [["dihydropteridinone", "ACTIVATOR", "of"]]}, {"text": " Crocin  (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of  caspase 3  and release of cytochrome c to the cytosol induced by DZN", "triple_list": [["Crocin", "DOWNREGULATOR", "caspase 3"]]}, {"text": "RESULTS:  DZN  induced histophatological damages and elevated the level of cardiac marker  CK-MB   These effects were associated with increased MDA level, lower level of reduced GSH and induction of apoptosis through elevation of Bax/Bcl2 ratio (both protein and mRNA levels), cytochrome c release to the cytosol and activation caspase 3 in cardiac tissue", "triple_list": [["and", "PRODUCT-OF", "CK-MB"]]}, {"text": "Crocin (25 and 50mg/kg) or  vitamin E  improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of  caspase 3  and release of cytochrome c to the cytosol induced by DZN", "triple_list": [["vitamin E", "AGONIST", "content"]]}, {"text": "Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of  Bax  Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by  DZN   In summary,  DZN  induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure", "triple_list": [["damages,", "PRODUCT-OF", "Bax"]]}, {"text": "Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of  caspase 3  and release of cytochrome c to the cytosol induced by  DZN   In summary,  DZN  induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure", "triple_list": [["DZN", "DOWNREGULATOR", "mitochondrial-mediated"]]}, {"text": "Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of  cytochrome c  to the cytosol induced by  DZN   In summary,  DZN  induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure", "triple_list": [["(25", "AGONIST", "cytochrome c"]]}, {"text": " Crocin  (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and  CK-MB   increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN", "triple_list": [["Crocin", "ANTAGONIST", "content"]]}, {"text": " Crocin  (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of  Bax  Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN", "triple_list": [["induced", "ACTIVATOR", "Bax"]]}, {"text": " Crocin  (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/ Bcl2  ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN", "triple_list": [["Crocin", "PRODUCT-OF", "c"]]}, {"text": " Crocin  (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of  cytochrome c  to the cytosol induced by DZN", "triple_list": [["Crocin", "ANTAGONIST", "content"]]}, {"text": "Crocin (25 and 50mg/kg) or  vitamin E  improved histopathological damages, decreased MDA and  CK-MB   increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN", "triple_list": [["the", "AGONIST", "CK-MB"]]}, {"text": "Crocin (25 and 50mg/kg) or  vitamin E  improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of  Bax  Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN", "triple_list": [["damages,", "AGONIST", "Bax"]]}, {"text": "Crocin (25 and 50mg/kg) or  vitamin E  improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/ Bcl2  ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN", "triple_list": [["vitamin E", "AGONIST", "CK-MB,"]]}, {"text": "Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/ Bcl2  ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by  DZN   In summary,  DZN  induced mitochondrial-mediated apoptosis in heart tissue of rat following subchronic exposure", "triple_list": [["DZN", "PRODUCT-OF", "apoptosis"]]}, {"text": " Phenobarbital  (PB), a typical  CAR  activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a", "triple_list": [["of", "DOWNREGULATOR", "CAR"]]}, {"text": " Phenobarbital  (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including  erythropoietin   heme oxygenase-1 and vascular endothelial growth factor-a", "triple_list": [["Phenobarbital", "DOWNREGULATOR", "growth"]]}, {"text": " Phenobarbital  (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin,  heme oxygenase-1  and vascular endothelial growth factor-a", "triple_list": [["livers", "ANTAGONIST", "heme oxygenase-1"]]}, {"text": " Phenobarbital  (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and  vascular endothelial growth factor-a   PB induced an accumulation of nuclear HIF-1\u03b1 and an increase in the HIF-responsive element-mediated transactivation in HepG2 cells", "triple_list": [["Phenobarbital", "ANTAGONIST", "activator,"]]}, {"text": " Cobalt chloride   a typical  HIF  activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver", "triple_list": [["an", "PRODUCT-OF", "HIF"]]}, {"text": " Cobalt chloride   a typical HIF activator, induced the gene expression of CAR-target genes, including  cyp2b9  and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver", "triple_list": [["the", "ANTAGONIST", "cyp2b9"]]}, {"text": " Cobalt chloride   a typical HIF activator, induced the gene expression of CAR-target genes, including cyp2b9 and  cyp2b10   an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver", "triple_list": [["gene", "ANTAGONIST", "cyp2b10"]]}, {"text": "Sixteen of 34  CGPs  inhibited  MRP1  mediated E217\u03b2G uptake by >50% (IC50's 0.7-7.6 \u03bcM)", "triple_list": [["E217\u03b2G", "ACTIVATOR", "MRP1"]]}, {"text": "When tested in the intact cells, only 4 of 16  CGPs  (at 10 \u03bcM) inhibited  MRP1  mediated calcein efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%", "triple_list": [["inhibited", "PRODUCT-OF", "MRP1"]]}, {"text": "These five  CGPs  also inhibited [(3)H]E217\u03b2G uptake by  MRP4   In contrast, their effects on MRP2 varied with two (V-4, V-6) inhibiting E217\u03b2G transport (IC50's 2.0, 9.2 \u03bcM), two (V-3, III-1) stimulating transport (>2-fold), while CGP I-5 had no effect", "triple_list": [["inhibiting", "ACTIVATOR", "MRP4"]]}, {"text": "Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of  [(3)H]estradiol glucuronide  (E217\u03b2G) (a prototypical  MRP  substrate) into  MRP -enriched inside-out membrane vesicles", "triple_list": [["[(3)H]estradiol glucuronide", "ANTAGONIST", "classes"]]}, {"text": "Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide ( E217\u03b2G   (a prototypical  MRP  substrate) into  MRP -enriched inside-out membrane vesicles", "triple_list": [["-enriched", "DOWNREGULATOR", "MRP"]]}, {"text": "Sixteen of 34 CGPs inhibited  MRP1  mediated  E217\u03b2G  uptake by >50% (IC50's 0.7-7.6 \u03bcM)", "triple_list": [["E217\u03b2G", "ANTAGONIST", ">50%"]]}, {"text": "When tested in the intact cells, only 4 of 16 CGPs (at 10 \u03bcM) inhibited  MRP1  mediated  calcein  efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%", "triple_list": [["calcein", "ACTIVATOR", "16"]]}, {"text": "These five CGPs also inhibited  [(3)H]E217\u03b2G  uptake by  MRP4   In contrast, their effects on MRP2 varied with two (V-4, V-6) inhibiting E217\u03b2G transport (IC50's 2.0, 9.2 \u03bcM), two (V-3, III-1) stimulating transport (>2-fold), while CGP I-5 had no effect", "triple_list": [["their", "ACTIVATOR", "MRP4"]]}, {"text": "Results: Our results demonstrate that treatment with  LBH589  leads to  NIS  RNA expression as shown by RT-PCR and luciferase assay, and to protein expression as determined by immunofluorescence in vitro and by immunohistochemistry in xenograft tumors", "triple_list": [["that", "DOWNREGULATOR", "NIS"]]}, {"text": "Methods: Stabilized anaplastic thyroid cancer cell lines (BHT-101 and CAL-62) and primary cultures from patients who underwent thyroidectomy for anaplastic thyroid cancer were treated with the  histone deacetylase  inhibitor  LBH589   After treatment, we evaluated the expression and function of NIS", "triple_list": [["LBH589", "ACTIVATOR", "the"]]}, {"text": "Using a transient heterologous cell expression system, we find that the transport activities of the  short OATP2B1  variant towards substrates  estrone sulfate  and rosuvastatin are similar to the well-characterized full length variant", "triple_list": [["estrone sulfate", "DOWNREGULATOR", "OATP2B1"]]}, {"text": "Using a transient heterologous cell expression system, we find that the transport activities of the  short OATP2B1  variant towards substrates estrone sulfate and  rosuvastatin  are similar to the well-characterized full length variant", "triple_list": [["of", "DOWNREGULATOR", "short OATP2B1"]]}, {"text": "In four (10\u00a0%) patients the peak  ACTH  stimulated  cortisol  values were lower than 18\u00a0\u03bcg/dL", "triple_list": [["than", "ANTAGONIST", "ACTH"]]}, {"text": " ACTH  stimulated peak  cortisol   delta  cortisol , and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover", "triple_list": [["due", "AGONIST", "ACTH"]]}, {"text": " ACTH  stimulated peak cortisol,  delta cortisol   and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover", "triple_list": [["turnover", "DOWNREGULATOR", "ACTH"]]}, {"text": " ACTH  stimulated peak cortisol, delta cortisol, and  delta DHEA  S levels are decreased during hyperthyroidism, probably due to increased turnover", "triple_list": [["delta DHEA", "ANTAGONIST", "cortisol,"]]}, {"text": "Synthesis and in Vitro Characterisation of  Ifenprodil  Based Fluorescein Conjugates as  GluN1  GluN2B N-Methyl-D-aspartate Receptor Antagonists", "triple_list": [["Ifenprodil", "DOWNREGULATOR", "Synthesis"]]}, {"text": "Synthesis and in Vitro Characterisation of  Ifenprodil  Based Fluorescein Conjugates as GluN1/ GluN2B  N-Methyl-D-aspartate Receptor Antagonists", "triple_list": [["Ifenprodil", "PRODUCT-OF", "GluN2B"]]}, {"text": "Synthesis and in Vitro Characterisation of  Ifenprodil  Based Fluorescein Conjugates as GluN1/GluN2B  N-Methyl-D-aspartate Receptor  Antagonists", "triple_list": [["Receptor", "ACTIVATOR", "N-Methyl-D-aspartate Receptor"]]}, {"text": "Synthesis and in Vitro Characterisation of Ifenprodil-Based  Fluorescein  Conjugates as  GluN1  GluN2B N-Methyl-D-aspartate Receptor Antagonists", "triple_list": [["Receptor", "ACTIVATOR", "GluN1"]]}, {"text": "Synthesis and in Vitro Characterisation of Ifenprodil-Based  Fluorescein  Conjugates as GluN1/ GluN2B  N-Methyl-D-aspartate Receptor Antagonists", "triple_list": [["Fluorescein", "DOWNREGULATOR", "Characterisation"]]}, {"text": "Synthesis and in Vitro Characterisation of Ifenprodil-Based  Fluorescein  Conjugates as GluN1/GluN2B  N-Methyl-D-aspartate Receptor  Antagonists", "triple_list": [["Vitro", "PRODUCT-OF", "N-Methyl-D-aspartate Receptor"]]}, {"text": " Ifenprodil   known as the  GluNR2B  antagonist of reference, was chosen as the template for the elaboration of probes", "triple_list": [["the", "DOWNREGULATOR", "GluNR2B"]]}, {"text": " Nitrooxy  derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective  COX-2  inhibitors in in vitro experimental models", "triple_list": [["while", "ACTIVATOR", "COX-2"]]}, {"text": "Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as  cyclooxygenase-2  inhibiting  nitric oxide  donors", "triple_list": [["nitric oxide", "ACTIVATOR", "as"]]}, {"text": "Novel analgesic/anti-inflammatory agents:  1,5-diarylpyrrole nitrooxyalkyl ethers  and related compounds as  cyclooxygenase-2  inhibiting nitric oxide donors", "triple_list": [["1,5-diarylpyrrole nitrooxyalkyl ethers", "AGONIST", "and"]]}, {"text": "New classes of  pyrrole  derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as  COX-2  selective inhibitors and NO donors were synthesized and are herein reported", "triple_list": [["of", "PRODUCT-OF", "COX-2"]]}, {"text": "New classes of pyrrole-derived  nitrooxyalkyl  inverse esters, carbonates, and ethers (7-10) as  COX-2  selective inhibitors and NO donors were synthesized and are herein reported", "triple_list": [["carbonates,", "ANTAGONIST", "COX-2"]]}, {"text": "New classes of pyrrole-derived nitrooxyalkyl inverse  esters   carbonates, and ethers (7-10) as  COX-2  selective inhibitors and NO donors were synthesized and are herein reported", "triple_list": [["esters", "ACTIVATOR", "synthesized"]]}, {"text": "New classes of pyrrole-derived nitrooxyalkyl inverse esters,  carbonates   and ethers (7-10) as  COX-2  selective inhibitors and NO donors were synthesized and are herein reported", "triple_list": [["carbonates", "AGONIST", "donors"]]}, {"text": "New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and  ethers  (7-10) as  COX-2  selective inhibitors and NO donors were synthesized and are herein reported", "triple_list": [["and", "ANTAGONIST", "COX-2"]]}, {"text": "Synthesis and structure-activity relationship of  pyripyropene A  derivatives as potent and selective  acyl-CoA:cholesterol acyltransferase 2  (ACAT2) inhibitors: Part 2", "triple_list": [["pyripyropene A", "AGONIST", "potent"]]}, {"text": "Synthesis and structure-activity relationship of  pyripyropene A  derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 ( ACAT2   inhibitors: Part 2", "triple_list": [["pyripyropene A", "ANTAGONIST", "acyl-CoA:cholesterol"]]}, {"text": "Blockade of  JAK  and ERK pathways with  AG490  and U0126, respectively, abrogated the myocardial infarct size reduction by NDP-\u03b1-MSH", "triple_list": [["AG490", "AGONIST", "AG490"]]}, {"text": "Blockade of JAK and  ERK  pathways with AG490 and  U0126   respectively, abrogated the myocardial infarct size reduction by NDP-\u03b1-MSH", "triple_list": [["and", "AGONIST", "ERK"]]}, {"text": "A decrease in  ADA  activity was observed when the slices were exposed to  organoselenium  at the concentrations of 1, 10 and 30 \u00b5M", "triple_list": [["slices", "ACTIVATOR", "ADA"]]}, {"text": "Taken together, our results suggested that  Rg1  protected against A\u03b225-35-induced apoptosis at least in part by two complementary GR-dependent  ERK  phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades", "triple_list": [["Rg1", "ANTAGONIST", "mitochondrial"]]}, {"text": "Activating  glucocorticoid receptor  ERK signaling pathway contributes to  ginsenoside Rg1  protection against \u03b2-amyloid peptide-induced human endothelial cells apoptosis", "triple_list": [["ginsenoside Rg1", "ANTAGONIST", "glucocorticoid"]]}, {"text": "Activating glucocorticoid receptor- ERK  signaling pathway contributes to  ginsenoside Rg1  protection against \u03b2-amyloid peptide-induced human endothelial cells apoptosis", "triple_list": [["ERK", "AGONIST", "ERK"]]}, {"text": "Taken together, our results suggested that  Rg1  protected against  A\u03b225-35  induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades", "triple_list": [["Rg1", "PRODUCT-OF", "down-regulating"]]}, {"text": "Taken together, our results suggested that  Rg1  protected against A\u03b225-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating  HIF-1\u03b1  initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades", "triple_list": [["Rg1", "ACTIVATOR", "together,"]]}, {"text": "Activating glucocorticoid receptor-ERK signaling pathway contributes to  ginsenoside Rg1  protection against  \u03b2-amyloid peptide  induced human endothelial cells apoptosis", "triple_list": [["induced", "ACTIVATOR", "\u03b2-amyloid peptide"]]}, {"text": "These data provided a novel insight to the mechanisms of  Rg1  rotective effects on  A\u03b225-35  induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it.", "triple_list": [["Rg1", "ACTIVATOR", "to"]]}, {"text": " Rg1  attenuated the  A\u03b225-35  associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1\u03b1 expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination", "triple_list": [["nitrogen", "ANTAGONIST", "A\u03b225-35"]]}, {"text": " Rg1  attenuated the A\u03b225-35-associated mitochondrial apoptotic events, accompanied by inhibiting  HIF-1\u03b1  expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination", "triple_list": [["Rg1", "ANTAGONIST", "and"]]}, {"text": "These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or  p-ERK  inhibitor  U0126  rather than estrogen receptor \u03b1 antagonist ICI 82,780", "triple_list": [["glucocorticoid", "AGONIST", "p-ERK"]]}, {"text": "These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than  estrogen receptor \u03b1  antagonist  ICI 82,780   Taken together, our results suggested that Rg1 protected against A\u03b225-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1\u03b1 initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades", "triple_list": [["ICI 82,780", "DOWNREGULATOR", "rather"]]}, {"text": "These protective effects were abolished by  glucocorticoid receptor  (GR) antagonist  RU486  or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780", "triple_list": [["receptor", "PRODUCT-OF", "glucocorticoid receptor"]]}, {"text": "These protective effects were abolished by glucocorticoid receptor ( GR   antagonist  RU486  or p-ERK inhibitor U0126 rather than estrogen receptor \u03b1 antagonist ICI 82,780", "triple_list": [["RU486", "PRODUCT-OF", "antagonist"]]}, {"text": "Here, we have now found that activation of  p38  MAPK by  anisomycin  potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes", "triple_list": [["now", "PRODUCT-OF", "p38"]]}, {"text": "Here, we have now found that activation of p38  MAPK  by  anisomycin  potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes", "triple_list": [["anisomycin", "DOWNREGULATOR", "ligand"]]}, {"text": "Here, we have now found that activation of p38 MAPK by  anisomycin  potentiated induction of  CYP2B6  mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes", "triple_list": [["anisomycin", "PRODUCT-OF", "of"]]}, {"text": "siRNA knockdown of p38 MAPK abrogated the ability of  anisomycin  to synergistically induce  CYP2B6  mRNA", "triple_list": [["anisomycin", "ANTAGONIST", "p38"]]}, {"text": "In addition to  CYP2B6    anisomycin  co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs", "triple_list": [["anisomycin", "ANTAGONIST", "addition"]]}, {"text": "In addition to CYP2B6,  anisomycin  co-treatment potentiated an increase in  CYP2A7  and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs", "triple_list": [["anisomycin", "AGONIST", "In"]]}, {"text": "In addition to CYP2B6,  anisomycin  co-treatment potentiated an increase in CYP2A7 and  CYP2C9  mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs", "triple_list": [["anisomycin", "ANTAGONIST", "CYP2B6,"]]}, {"text": "FCEO significantly inhibited  nitric oxide  (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible  nitric oxide  synthase (iNOS) and cyclooxygenase (COX)-2, respectively", "triple_list": [["nitric oxide", "ACTIVATOR", "the"]]}, {"text": "FCEO significantly inhibited  nitric oxide  (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible  nitric oxide  synthase ( iNOS   and cyclooxygenase (COX)-2, respectively", "triple_list": [["significantly", "ANTAGONIST", "iNOS"]]}, {"text": "FCEO significantly inhibited nitric oxide ( NO   and prostaglandin E2 (PGE2) by suppressing the protein expression of  inducible nitric oxide synthase  (i NO S) and cyclooxygenase (COX)-2, respectively", "triple_list": [["nitric", "ACTIVATOR", "inducible nitric oxide synthase"]]}, {"text": "FCEO significantly inhibited nitric oxide ( NO   and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (i NO S  and cyclooxygenase (COX)-2, respectively", "triple_list": [["and", "AGONIST", "iNOS"]]}, {"text": "FCEO significantly inhibited nitric oxide (NO) and  prostaglandin E2  (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and  cyclooxygenase (COX)-2   respectively", "triple_list": [["inhibited", "ANTAGONIST", "cyclooxygenase (COX)-2"]]}, {"text": "FCEO significantly inhibited nitric oxide (NO) and prostaglandin E2 ( PGE2   by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and  cyclooxygenase (COX)-2   respectively", "triple_list": [["synthase", "ACTIVATOR", "cyclooxygenase (COX)-2"]]}, {"text": " Aldosterone  induced  ENaC  and basal Na(+)/K(+)-ATPase trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIII\u03b2 trans Golgi signalling in M1 cortical collecting duct cells", "triple_list": [["cortical", "AGONIST", "ENaC"]]}, {"text": " Aldosterone  induced ENaC and basal  Na(+)/K(+)-ATPase  trafficking via protein kinase D1-phosphatidylinositol 4-kinaseIII\u03b2 trans Golgi signalling in M1 cortical collecting duct cells", "triple_list": [["Aldosterone", "DOWNREGULATOR", "Golgi"]]}, {"text": " Aldosterone  also induces the rapid phosphorylation of  Protein Kinase D1  (PKD1)", "triple_list": [["Aldosterone", "AGONIST", "the"]]}, {"text": " Aldosterone  also induces the rapid phosphorylation of Protein Kinase D1 ( PKD1  ", "triple_list": [["PKD1", "PRODUCT-OF", "PKD1"]]}, {"text": "Thus, we found that  5HHMF  enhances  heme oxygenase-1  (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation", "triple_list": [["2-related", "PRODUCT-OF", "heme oxygenase-1"]]}, {"text": "Thus, we found that  5HHMF  enhances heme oxygenase-1 ( HO-1   expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation", "triple_list": [["activation", "PRODUCT-OF", "HO-1"]]}, {"text": "Thus, we found that  5HHMF  enhances heme oxygenase-1 (HO-1) expression via  nuclear factor-erythroid 2-related factor 2  (Nrf2) activation", "triple_list": [["5HHMF", "DOWNREGULATOR", "oxygenase-1"]]}, {"text": "Thus, we found that  5HHMF  enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 ( Nrf2   activation", "triple_list": [["factor", "ANTAGONIST", "Nrf2"]]}, {"text": "In addition,  cobalt protoporphyrin  (CoPP), a specific  HO-1  inducer, predominantly suppressed LPS-induced NO production", "triple_list": [["suppressed", "ANTAGONIST", "HO-1"]]}, {"text": "In addition, cobalt protoporphyrin ( CoPP  , a specific  HO-1  inducer, predominantly suppressed LPS-induced NO production", "triple_list": [["(", "DOWNREGULATOR", "HO-1"]]}, {"text": " 5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone  inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-\u03baB suppression and  Nrf-2  dependent heme oxygenase-1 induction", "triple_list": [["lipopolysaccharide-stimulated", "AGONIST", "Nrf-2"]]}, {"text": " 5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone  inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-\u03baB suppression and Nrf-2-dependent  heme oxygenase-1  induction", "triple_list": [["NF-\u03baB", "DOWNREGULATOR", "heme oxygenase-1"]]}, {"text": "Further,  5HHMF  increased specific DNA-binding activity of  Nrf2   and transient knockdown with  Nrf2  siRNA subsequently reversed  5HHMF -induced NO inhibition, which was followed by suppression of HO-1 activity", "triple_list": [["5HHMF", "ANTAGONIST", "subsequently"]]}, {"text": "Further,  5HHMF  increased specific DNA-binding activity of  Nrf2 , and transient knockdown with  Nrf2  siRNA subsequently reversed  5HHMF -induced NO inhibition, which was followed by suppression of HO-1 activity", "triple_list": [["was", "PRODUCT-OF", "Nrf2"]]}, {"text": "Further,  5HHMF  increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed  5HHMF -induced NO inhibition, which was followed by suppression of  HO-1  activity", "triple_list": [["activity", "DOWNREGULATOR", "HO-1"]]}, {"text": "Further,  5HHMF  increased specific DNA-binding activity of  Nrf2   and transient knockdown with  Nrf2  siRNA subsequently reversed  5HHMF  induced NO inhibition, which was followed by suppression of HO-1 activity", "triple_list": [["inhibition,", "AGONIST", "Nrf2"]]}, {"text": "Further,  5HHMF  increased specific DNA-binding activity of  Nrf2 , and transient knockdown with  Nrf2  siRNA subsequently reversed  5HHMF  induced NO inhibition, which was followed by suppression of HO-1 activity", "triple_list": [["5HHMF", "ANTAGONIST", "reversed"]]}, {"text": "Taken together, our findings indicate that  5HHMF  suppresses NO production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of  Nrf2  dependent HO-1 activity.", "triple_list": [["and", "PRODUCT-OF", "Nrf2"]]}, {"text": "Taken together, our findings indicate that  5HHMF  suppresses NO production through modulation of iNOS, consequently suppressing NF-\u03baB activity and induction of Nrf2-dependent  HO-1  activity.", "triple_list": [["5HHMF", "ANTAGONIST", "consequently"]]}, {"text": "Taken together, our findings indicate that 5HHMF suppresses  NO  production through modulation of i NO S, consequently suppressing  NF-\u03baB  activity and induction of Nrf2-dependent HO-1 activity.", "triple_list": [["NO", "ACTIVATOR", "NO"]]}, {"text": "Taken together, our findings indicate that 5HHMF suppresses  NO  production through modulation of i NO S, consequently suppressing NF-\u03baB activity and induction of  Nrf2  dependent HO-1 activity.", "triple_list": [["NO", "AGONIST", "modulation"]]}, {"text": "Taken together, our findings indicate that 5HHMF suppresses  NO  production through modulation of i NO S, consequently suppressing NF-\u03baB activity and induction of Nrf2-dependent  HO-1  activity.", "triple_list": [["NO", "PRODUCT-OF", "S,"]]}, {"text": "In addition,  5HHMF  blocked LPS-induced phosphorylation of  I\u03baB   resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression", "triple_list": [["in", "AGONIST", "I\u03baB"]]}, {"text": "In addition,  5HHMF  blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of  nuclear factor-\u03baB  (NF-\u03baB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression", "triple_list": [["(NF-\u03baB)", "ACTIVATOR", "nuclear factor-\u03baB"]]}, {"text": "In addition,  5HHMF  blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB ( NF-\u03baB   subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression", "triple_list": [["5HHMF", "ANTAGONIST", "molecules"]]}, {"text": "In addition,  5HHMF  blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely  p65  and p50, which are important molecules involved in the regulation of iNOS expression", "triple_list": [["of", "ANTAGONIST", "p65"]]}, {"text": "In addition,  5HHMF  blocked LPS-induced phosphorylation of I\u03baB, resulting in suppression of the nuclear translocation of nuclear factor-\u03baB (NF-\u03baB) subunits, namely p65 and  p50   which are important molecules involved in the regulation of iNOS expression", "triple_list": [["5HHMF", "AGONIST", "blocked"]]}, {"text": "In this study, we found that  5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone  (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of  inducible NO synthase  (iNOS) in BV2 microglia", "triple_list": [["this", "PRODUCT-OF", "inducible NO synthase"]]}, {"text": "In this study, we found that  5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone  (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase ( iNOS   in BV2 microglia", "triple_list": [["in", "ANTAGONIST", "iNOS"]]}, {"text": " Pyrrolidine dithiocarbamate  (PDTC), a specific  NF-\u03baB  inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing  NF-\u03baB  activity", "triple_list": [["inhibitor,", "ACTIVATOR", "NF-\u03baB"]]}, {"text": " Pyrrolidine dithiocarbamate  (PDTC), a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced  iNOS  expression, which indirectly suggested that 5HHMF downregulated  iNOS  expression by suppressing NF-\u03baB activity", "triple_list": [["specific", "AGONIST", "iNOS"]]}, {"text": "Pyrrolidine dithiocarbamate ( PDTC  , a specific  NF-\u03baB  inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing  NF-\u03baB  activity", "triple_list": [["inhibitor", "AGONIST", "NF-\u03baB"]]}, {"text": "Pyrrolidine dithiocarbamate ( PDTC  , a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced  iNOS  expression, which indirectly suggested that 5HHMF downregulated  iNOS  expression by suppressing NF-\u03baB activity", "triple_list": [["which", "PRODUCT-OF", "iNOS"]]}, {"text": "Pyrrolidine dithiocarbamate (PDTC), a specific NF-\u03baB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced  iNOS  expression, which indirectly suggested that  5HHMF  downregulated  iNOS  expression by suppressing NF-\u03baB activity", "triple_list": [["NF-\u03baB", "ANTAGONIST", "iNOS"]]}, {"text": "Pyrrolidine dithiocarbamate (PDTC), a specific  NF-\u03baB  inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that  5HHMF  downregulated iNOS expression by suppressing  NF-\u03baB  activity", "triple_list": [["inhibited", "AGONIST", "NF-\u03baB"]]}, {"text": "In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone ( 5HHMF   from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of  inducible NO synthase  (iNOS) in BV2 microglia", "triple_list": [["5HHMF", "ANTAGONIST", "inducible"]]}, {"text": "In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone ( 5HHMF   from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase ( iNOS   in BV2 microglia", "triple_list": [["5HHMF", "ACTIVATOR", "in"]]}, {"text": " 5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone  inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via  NF-\u03baB  suppression and Nrf-2-dependent heme oxygenase-1 induction", "triple_list": [["NF-\u03baB", "ANTAGONIST", "NF-\u03baB"]]}, {"text": "In contrast,  zinc protoporphyrin  (ZnPP), a specific  HO-1  inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production", "triple_list": [["zinc protoporphyrin", "ANTAGONIST", "LPS-induced"]]}, {"text": "In contrast, zinc protoporphyrin ( ZnPP  , a specific  HO-1  inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production", "triple_list": [["ZnPP", "ACTIVATOR", "partial"]]}, {"text": "Further,  5HHMF  increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed  5HHMF  induced NO inhibition, which was followed by suppression of  HO-1  activity", "triple_list": [["which", "ANTAGONIST", "HO-1"]]}, {"text": "Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced  NO  inhibition, which was followed by suppression of  HO-1  activity", "triple_list": [["of", "PRODUCT-OF", "HO-1"]]}, {"text": "Taken together, our findings indicate that  5HHMF  suppresses NO production through modulation of iNOS, consequently suppressing  NF-\u03baB  activity and induction of Nrf2-dependent HO-1 activity.", "triple_list": [["5HHMF", "ANTAGONIST", "Nrf2-dependent"]]}, {"text": "We confirm the correlation between higher  hCTR1  levels and higher  Pt  drug uptake in tumor cells sensitive to the drug", "triple_list": [["Pt", "ACTIVATOR", "drug"]]}, {"text": "It has been claimed that  hCTR1   the human high affinity copper transporter, is the major entry pathway for  cDDP  and related drugs via a mechanism that mimics copper", "triple_list": [["cDDP", "ANTAGONIST", "copper"]]}, {"text": "It has been claimed that hCTR1, the  human high affinity copper transporter   is the major entry pathway for  cDDP  and related drugs via a mechanism that mimics copper", "triple_list": [["cDDP", "ANTAGONIST", "copper"]]}, {"text": "Taken together, our study for the first time suggests that  2-hydroxy-3-methylanthraquinone  is able to enhance apoptosis of U937 cells, at least in part, through activation of  p-p38MAPK  and downregulation of p-ERK1/2", "triple_list": [["2-hydroxy-3-methylanthraquinone", "ANTAGONIST", "able"]]}, {"text": "Our results showed that  2-hydroxy-3-methylanthraquinone  decreased phosphorylation-ERK1/2 (p-ERK1/2), and increased  p-p38MAPK   but did not affect expressions of p-JNK1/2 in U937 cells", "triple_list": [["did", "AGONIST", "p-p38MAPK"]]}, {"text": "Moreover, treatment of U937 cells with  2-hydroxy-3-methylanthraquinone  resulted in activation of  caspase-3   Furthermore, PD98059 (ERK1/2 inhibitor) significantly enhanced  2-hydroxy-3-methylanthraquinone -induced apoptosis in U937 cells, whereas  caspase-3  inhibitor or SB203580 (p-p38MAPK inhibitor), decreased apoptosis in U937 cells", "triple_list": [["apoptosis", "DOWNREGULATOR", "caspase-3"]]}, {"text": "Furthermore, PD98059 (ERK1/2 inhibitor) significantly enhanced 2-hydroxy-3-methylanthraquinone-induced apoptosis in U937 cells, whereas caspase-3 inhibitor or  SB203580  ( p-p38MAPK  inhibitor), decreased apoptosis in U937 cells", "triple_list": [["SB203580", "AGONIST", "("]]}, {"text": " ThioTEPA  ( CYP2B6  inhibitor, 25 \u03bcM) and the monoclonal antibody against  CYP2B6  but not troleandomycin (CYP3A4 inhibitor, 25 \u03bcM) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations", "triple_list": [["ThioTEPA", "ANTAGONIST", "but"]]}, {"text": "ThioTEPA (CYP2B6 inhibitor, 25 \u03bcM) and the monoclonal antibody against CYP2B6 but not  troleandomycin  ( CYP3A4  inhibitor, 25 \u03bcM) or the monoclonal antibody against  CYP3A4  inhibited ketamine N-demethylation at clinically relevant concentrations", "triple_list": [["ketamine", "ACTIVATOR", "CYP3A4"]]}, {"text": "The intrinsic clearance for both  ketamine  enantiomers by the high affinity enzyme in HLMs with  CYP2B6*1  *1 genotype were at least 2-fold and 6-fold higher, respectively, than those for  CYP2B6*1 /*6 genotype and CYP2B6*6/*6 genotype", "triple_list": [["2-fold", "DOWNREGULATOR", "CYP2B6*1"]]}, {"text": "The  CYP2B6*6  Allele Significantly Alters the N-demethylation of  Ketamine  Enantiomers In Vitro", "triple_list": [["In", "ACTIVATOR", "CYP2B6*6"]]}, {"text": " Ketamine  is primarily metabolized to norketamine by hepatic  cytochrome P450 (CYP) 2B6  and CYP3A4-mediated N-demethylation", "triple_list": [["Ketamine", "DOWNREGULATOR", "N-demethylation"]]}, {"text": " Ketamine  is primarily metabolized to norketamine by hepatic cytochrome P450 (CYP) 2B6 and  CYP3A4  mediated N-demethylation", "triple_list": [["Ketamine", "DOWNREGULATOR", "norketamine"]]}, {"text": "These results indicate a major role of  CYP2B6  in  ketamine  N-demethylation in vitro and a significant impact of the  CYP2B6 *6 allele on enzyme- ketamine  binding and catalytic activity.", "triple_list": [["ketamine", "ACTIVATOR", "activity."]]}, {"text": "These results indicate a major role of CYP2B6 in  ketamine  N-demethylation in vitro and a significant impact of the  CYP2B6*6  allele on enzyme- ketamine  binding and catalytic activity.", "triple_list": [["ketamine", "ANTAGONIST", "on"]]}, {"text": "The  CYP2B6*6  allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in  ketamine  metabolism", "triple_list": [["to", "ANTAGONIST", "CYP2B6*6"]]}, {"text": "We examined the N-demethylation of individual  ketamine  enantiomers using human liver microsomes (HLMs) genotyped for the  CYP2B6*6  allele, insect cell expressed recombinant CYP2B6 and CYP3A4 enzymes and COS-1 cell expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant", "triple_list": [["N-demethylation", "ACTIVATOR", "CYP2B6*6"]]}, {"text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active  HFC  glucuronidation catalysts were  UGT1A10  followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs", "triple_list": [["HFC", "AGONIST", "\u00b5M,"]]}, {"text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active  HFC  glucuronidation catalysts were UGT1A10 followed by  UGT1A6  >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M  UGT1A6  was about 10 times better catalyst than the other recombinant UGTs", "triple_list": [["catalyst", "DOWNREGULATOR", "UGT1A6"]]}, {"text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active  HFC  glucuronidation catalysts were UGT1A10 followed by UGT1A6 > UGT1A7  >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs", "triple_list": [["better", "DOWNREGULATOR", "UGT1A7"]]}, {"text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active  HFC  glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 > UGT2A1   whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant UGTs", "triple_list": [["HFC", "DOWNREGULATOR", "4."]]}, {"text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active  HFC  glucuronidation catalysts were UGT1A10 followed by  UGT1A6  >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M  UGT1A6  was about 10 times better catalyst than the other recombinant UGTs", "triple_list": [["better", "DOWNREGULATOR", "UGT1A6"]]}, {"text": "4.\u2002 At a substrate concentration of 20\u2009\u00b5M, the most active  HFC  glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300\u2009\u00b5M UGT1A6 was about 10 times better catalyst than the other recombinant  UGTs   The activities of  UGTs  1A3, 1A8, 1A9, 2B4 and 2B7 were low, whereas UGT1A1 and UGT2B17 exhibited no  HFC  glucuronidation activity", "triple_list": [["of", "AGONIST", "UGTs"]]}, {"text": "A high throughput assay for the glucuronidation of  7-hydroxy-4-trifluoromethylcoumarin  by recombinant  human UDP-glucuronosyltransferases  and liver microsomes", "triple_list": [["7-hydroxy-4-trifluoromethylcoumarin", "DOWNREGULATOR", "glucuronidation"]]}, {"text": "UGT1A6 exhibited a significantly higher Vmax and Km values toward both  HFC  and UDP-glucuronic acid than the other  UGTs   5.\u2002 Human, pig and rabbit, but not rat liver microsomes, catalyzed  HFC  glucuronidation at high rates", "triple_list": [["HFC", "ANTAGONIST", "5."]]}, {"text": " UGT1A6  exhibited a significantly higher Vmax and Km values toward both  HFC  and UDP-glucuronic acid than the other UGTs", "triple_list": [["the", "ACTIVATOR", "UGT1A6"]]}, {"text": "UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and  UDP  glucuronic acid than the other  UGTs   5.\u2002 Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates", "triple_list": [["and", "ACTIVATOR", "UGTs"]]}, {"text": " UGT1A6  exhibited a significantly higher Vmax and Km values toward both HFC and  UDP  glucuronic acid than the other UGTs", "triple_list": [["UGT1A6", "DOWNREGULATOR", "UGT1A6"]]}, {"text": "UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP- glucuronic acid  than the other  UGTs   5.\u2002 Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates", "triple_list": [["HFC", "ANTAGONIST", "UGTs"]]}, {"text": " UGT1A6  exhibited a significantly higher Vmax and Km values toward both HFC and UDP- glucuronic acid  than the other UGTs", "triple_list": [["glucuronic acid", "AGONIST", "toward"]]}, {"text": "2.\u2002 We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of  7-hydroxy-4-trifluoromethylcoumarin  (HFC) for several  UGTs   3.\u2002 We have used this method to screen 11 recombinant human  UGTs  for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes", "triple_list": [["the", "AGONIST", "UGTs"]]}, {"text": "2.\u2002 We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin ( HFC   for several  UGTs   3.\u2002 We have used this method to screen 11 recombinant human  UGTs  for  HFC  glucuronidation activity and studied the reaction kinetics with the most active enzymes", "triple_list": [["method", "ACTIVATOR", "UGTs"]]}, {"text": "3.\u2002 We have used this method to screen 11 recombinant  human UGTs  for  HFC  glucuronidation activity and studied the reaction kinetics with the most active enzymes", "triple_list": [["HFC", "DOWNREGULATOR", "human UGTs"]]}, {"text": "In PFC,  DEX  caused activation of  AKT   augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2/Bax protein ratio, as well Bcl-2 translocation to mitochondria", "triple_list": [["DEX", "ANTAGONIST", "pro-survival"]]}, {"text": "In PFC,  DEX  caused activation of AKT, augmentation of pro-survival  Bcl-2  protein and enhanced  Bcl-2 /Bax protein ratio, as well  Bcl-2  translocation to mitochondria", "triple_list": [["DEX", "DOWNREGULATOR", "In"]]}, {"text": "In PFC,  DEX  caused activation of AKT, augmentation of pro-survival  Bcl-2  protein and enhanced  Bcl-2  Bax protein ratio, as well  Bcl-2  translocation to mitochondria", "triple_list": [["DEX", "DOWNREGULATOR", "enhanced"]]}, {"text": "In PFC,  DEX  caused activation of AKT, augmentation of pro-survival Bcl-2 protein and enhanced Bcl-2/ Bax  protein ratio, as well Bcl-2 translocation to mitochondria", "triple_list": [["Bcl-2", "PRODUCT-OF", "Bax"]]}, {"text": "Results of RT-PCR analysis showed decrease of  p53  mRNA level and no significant difference in Bcl-2 and Bax mRNA expressions in  DEX  treated rats", "triple_list": [["DEX", "ANTAGONIST", "significant"]]}, {"text": " PIP5K1B  encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate  phosphatidylinositol-4,5-bisphosphate  [PI(4,5)P2]", "triple_list": [["4-phosphate", "ACTIVATOR", "PIP5K1B"]]}, {"text": "PIP5K1B encodes  phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I  (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate  phosphatidylinositol-4,5-bisphosphate  [PI(4,5)P2]", "triple_list": [["phosphatidylinositol-4,5-bisphosphate", "DOWNREGULATOR", "(pip5k1\u03b2),"]]}, {"text": "PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I ( pip5k1\u03b2  , an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate  phosphatidylinositol-4,5-bisphosphate  [PI(4,5)P2]", "triple_list": [["phosphatidylinositol-4,5-bisphosphate", "AGONIST", "encodes"]]}, {"text": " PIP5K1B  encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [ PI(4,5)P2  ", "triple_list": [["PI(4,5)P2", "ANTAGONIST", "[PI(4)P]"]]}, {"text": "PIP5K1B encodes  phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I  (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [ PI(4,5)P2  ", "triple_list": [["PI(4,5)P2", "ACTIVATOR", "\u03b2"]]}, {"text": "PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I ( pip5k1\u03b2  , an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [ PI(4,5)P2  ", "triple_list": [["4-phosphate", "AGONIST", "pip5k1\u03b2"]]}, {"text": "Accordingly, loss of  pip5k1\u03b2  function in FRDA cells was accompanied by decreased  PI(4,5)P2  levels and was shown instrumental for destabilization of the actin network and delayed cell spreading", "triple_list": [["actin", "DOWNREGULATOR", "pip5k1\u03b2"]]}, {"text": " PIP5K1B  encodes  phosphatidylinositol 4-phosphate  5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates  phosphatidylinositol 4-phosphate  [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]", "triple_list": [["to", "ACTIVATOR", "PIP5K1B"]]}, {"text": "PIP5K1B encodes  phosphatidylinositol 4-phosphate  5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates  phosphatidylinositol 4-phosphate  [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]", "triple_list": [["phosphatidylinositol 4-phosphate", "DOWNREGULATOR", "[PI(4,5)P2]"]]}, {"text": "PIP5K1B encodes  phosphatidylinositol 4-phosphate  5-kinase \u03b2 type I ( pip5k1\u03b2  , an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates  phosphatidylinositol 4-phosphate  [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]", "triple_list": [["to", "ACTIVATOR", "pip5k1\u03b2"]]}, {"text": " PIP5K1B  encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [ PI(4)P   to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]", "triple_list": [["PIP5K1B", "AGONIST", "PIP5K1B"]]}, {"text": "PIP5K1B encodes  phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I  (pip5k1\u03b2), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [ PI(4)P   to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]", "triple_list": [["PI(4)P", "ANTAGONIST", "to"]]}, {"text": "PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase \u03b2 type I ( pip5k1\u03b2  , an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [ PI(4)P   to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2]", "triple_list": [["to", "ANTAGONIST", "pip5k1\u03b2"]]}, {"text": "Regarding  urease  inhibition,  n-butanol  was the most potent fraction (IC50: 97 \u00b5g/mL)", "triple_list": [["n-butanol", "ACTIVATOR", "potent"]]}, {"text": "Treatment of A549 and H1299 cells with  dioscin  caused a dose-dependent increase in ERK1/2 and  JNK1/2  activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR", "triple_list": [["dioscin", "PRODUCT-OF", "JNK1/2"]]}, {"text": "Treatment of A549 and H1299 cells with  dioscin  caused a dose-dependent increase in  ERK1/2  and JNK1/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR", "triple_list": [["dioscin", "DOWNREGULATOR", "and"]]}, {"text": "Meanwhile, autophagy was detected as early as 12\u00a0h after an exposure to low-dose  dioscin   as indicated by an up-regulated expression of  LC3-II  and beclin-1 proteins", "triple_list": [["dioscin", "PRODUCT-OF", "after"]]}, {"text": "Meanwhile, autophagy was detected as early as 12\u00a0h after an exposure to low-dose  dioscin   as indicated by an up-regulated expression of LC3-II and  beclin-1  proteins", "triple_list": [["dioscin", "ANTAGONIST", "to"]]}, {"text": "Treatment of A549 and H1299 cells with  dioscin  caused a dose-dependent increase in ERK1/2 and JNK1/2 activity, accompanied with a decreased  PI3K  expression and decreased phosphorylation of Akt and mTOR", "triple_list": [["dioscin", "ACTIVATOR", "and"]]}, {"text": "Treatment of A549 and H1299 cells with  dioscin  caused a dose-dependent increase in ERK1/2 and JNK1/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of  Akt  and mTOR", "triple_list": [["dioscin", "ACTIVATOR", "and"]]}, {"text": "Treatment of A549 and H1299 cells with  dioscin  caused a dose-dependent increase in ERK1/2 and JNK1/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and  mTOR   Taken together, this study demonstrated for the first time that autophagy occurred earlier than apoptosis during  dioscin -induced human lung cancer cell line apoptosis", "triple_list": [["dioscin", "PRODUCT-OF", "and"]]}, {"text": "High  glucose  (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates tuberin and activates  mTOR   HG also increases the levels of Nox4 and Nox1 and NADPH oxidase activity", "triple_list": [["glucose", "PRODUCT-OF", "mTOR"]]}, {"text": "Pharmacological doses of the  mTOR  inhibitor  rapamycin  reduce albuminura in diabetes", "triple_list": [["rapamycin", "ANTAGONIST", "doses"]]}, {"text": "High  glucose  (HG) induces apoptosis of podocytes, inhibits  AMPK  activation, inactivates tuberin and activates mTOR", "triple_list": [["activates", "ACTIVATOR", "AMPK"]]}, {"text": "High  glucose  (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates  tuberin  and activates mTOR", "triple_list": [["induces", "AGONIST", "tuberin"]]}, {"text": "Inhibition of  mTOR  by low dose  rapamycin  decreases HG-induced Nox4 and Nox1, NADPH oxidase activity and podocyte apoptosis", "triple_list": [["NADPH", "AGONIST", "mTOR"]]}, {"text": "Inhibition of mTOR by low dose  rapamycin  decreases HG-induced  Nox4  and Nox1, NADPH oxidase activity and podocyte apoptosis", "triple_list": [["rapamycin", "ANTAGONIST", "oxidase"]]}, {"text": "Inhibition of mTOR by low dose  rapamycin  decreases HG-induced Nox4 and  Nox1   NADPH oxidase activity and podocyte apoptosis", "triple_list": [["rapamycin", "PRODUCT-OF", "dose"]]}, {"text": "Inhibition of mTOR by low dose  rapamycin  decreases HG-induced Nox4 and Nox1,  NADPH oxidase  activity and podocyte apoptosis", "triple_list": [["rapamycin", "PRODUCT-OF", "apoptosis"]]}, {"text": "Inhibition of  mTOR  by small dose of  rapamycin  reduces podocyte apoptosis, attenuates glomerular injury and albuminuria", "triple_list": [["dose", "PRODUCT-OF", "mTOR"]]}, {"text": "Correlation between activation of  PPAR\u03b3  and resistin downregulation in a mouse adipocyte cell line by a series of  thiazolidinediones   The present study shows significant correlations between the EC50 for  PPAR\u03b3  activation in a reporter gene cell line and resistin downregulation in mouse adipocytes, and between the IC50 for resistin downregulation and the already published minimum effective dose for antihyperglycemic activity in a mouse model", "triple_list": [["thiazolidinediones", "DOWNREGULATOR", "dose"]]}, {"text": "Correlation between activation of PPAR\u03b3 and  resistin  downregulation in a mouse adipocyte cell line by a series of  thiazolidinediones   The present study shows significant correlations between the EC50 for PPAR\u03b3 activation in a reporter gene cell line and  resistin  downregulation in mouse adipocytes, and between the IC50 for  resistin  downregulation and the already published minimum effective dose for antihyperglycemic activity in a mouse model", "triple_list": [["thiazolidinediones", "PRODUCT-OF", "between"]]}, {"text": "In addition,  vinblastine  induces the DNA-binding activities of the transcription factor  NF-\u03baB   HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins", "triple_list": [["HSF1,", "ANTAGONIST", "NF-\u03baB"]]}, {"text": "In addition,  vinblastine  induces the DNA-binding activities of the transcription factor NF-\u03baB,  HSF1   AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins", "triple_list": [["of", "AGONIST", "HSF1"]]}, {"text": "In addition,  vinblastine  induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1,  AP-1   and ATF-2, together with the expression of HSP70 and Bax proteins", "triple_list": [["and", "ANTAGONIST", "AP-1"]]}, {"text": "In addition,  vinblastine  induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and  ATF-2   together with the expression of HSP70 and Bax proteins", "triple_list": [["vinblastine", "PRODUCT-OF", "induces"]]}, {"text": "In addition,  vinblastine  induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and ATF-2, together with the expression of  HSP70  and Bax proteins", "triple_list": [["proteins", "PRODUCT-OF", "HSP70"]]}, {"text": "In addition,  vinblastine  induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and ATF-2, together with the expression of HSP70 and  Bax  proteins", "triple_list": [["vinblastine", "PRODUCT-OF", "activities"]]}, {"text": "Also,  vinblastine  enhances the phosphorylation of  Ras homologous protein A   the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1", "triple_list": [["vinblastine", "ANTAGONIST", "oxygen"]]}, {"text": "Also,  vinblastine  enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of  apoptosis signal-regulating kinase 1   c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1", "triple_list": [["vinblastine", "AGONIST", "phosphorylation"]]}, {"text": "Also,  vinblastine  enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1,  c-jun-N-terminal kinase   p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1", "triple_list": [["homologous", "PRODUCT-OF", "c-jun-N-terminal kinase"]]}, {"text": "Also,  vinblastine  enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase,  p38   inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1", "triple_list": [["(I\u03baB\u03b1)", "PRODUCT-OF", "p38"]]}, {"text": "Also,  vinblastine  enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38,  inhibitor of kappaB\u03b1  (I\u03baB\u03b1) kinase, and inositol requiring enzyme 1\u03b1", "triple_list": [["vinblastine", "PRODUCT-OF", "signal-regulating"]]}, {"text": "Also,  vinblastine  enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 ( I\u03baB\u03b1   kinase, and inositol requiring enzyme 1\u03b1", "triple_list": [["vinblastine", "AGONIST", "c-jun-N-terminal"]]}, {"text": "Also,  vinblastine  enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating  kinase  1, c-jun-N-terminal  kinase , p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1)  kinase   and inositol requiring enzyme 1\u03b1", "triple_list": [["vinblastine", "PRODUCT-OF", "A,"]]}, {"text": "Also,  vinblastine  enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaB\u03b1 (I\u03baB\u03b1) kinase, and  inositol requiring enzyme 1\u03b1   In addition,  vinblastine  induces the DNA-binding activities of the transcription factor NF-\u03baB, HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins", "triple_list": [["with", "DOWNREGULATOR", "inositol requiring enzyme 1\u03b1"]]}, {"text": "In further evaluation, the representative compound  N,N-diethyl-N-(2-(N-methyltetradecanamido)ethyl)prop-2-en-1-aminium bromide  (3b) exhibited potent pro-apoptotic activity, through  RhoB  activation, in HeLa cells.", "triple_list": [["N,N-diethyl-N-(2-(N-methyltetradecanamido)ethyl)prop-2-en-1-aminium bromide", "PRODUCT-OF", "in"]]}, {"text": "To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate  Nrf2  and related antioxidant proteins in bleomycin-treated fibroblasts using a putative  Nrf2  activator,  caffeic acid phenethyl ester   and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance", "triple_list": [["To", "PRODUCT-OF", "Nrf2"]]}, {"text": "In a cell-based model,  bleomycin  suppressed Nrf2 activation via  extracellular signal-related kinase  phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion", "triple_list": [["species", "ANTAGONIST", "extracellular signal-related kinase"]]}, {"text": "To confirm this novel mechanism of  bleomycin  induced fibrogenesis, we attempted to upregulate  Nrf2  and related antioxidant proteins in  bleomycin -treated fibroblasts using a putative  Nrf2  activator, caffeic acid phenethyl ester, and the results showed that  bleomycin -induced fibroblast proliferation and collagen content were attenuated through improved redox balance", "triple_list": [["bleomycin", "AGONIST", "attempted"]]}, {"text": "Treatment of C57 BL/6 mice with  bleomycin  increased fibroblast viability and collagen production and significantly downregulated  Nrf2   In addition, prominent oxidative stress was indicated by changes in superoxide dismutase, catalase activity, and glutathione and thiobarbituric acid-reactive substance levels", "triple_list": [["Nrf2", "AGONIST", "Nrf2"]]}, {"text": "In a cell-based model,  bleomycin  suppressed  Nrf2  activation via extracellular signal-related kinase phosphorylation, enhancing intracellular reactive oxygen species in lung fibroblasts and stimulating abnormal cell proliferation and collagen secretion", "triple_list": [["bleomycin", "AGONIST", "fibroblasts"]]}, {"text": "The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic  CYP3A  subfamily-mediated metabolism (21.9% decrease) of  doxorubicin   These results might have broader implications to understand the altered pharmacokinetics and/or pharmacologic effects of  doxorubicin  via biliary excretion and hepatic metabolism in experimental and clinical estrogen-induced cholestasis.", "triple_list": [["doxorubicin", "DOWNREGULATOR", "pharmacologic"]]}, {"text": " Doxorubicin  is mainly excreted into the bile via  P-glycoprotein  (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily", "triple_list": [["in", "ANTAGONIST", "P-glycoprotein"]]}, {"text": " Doxorubicin  is mainly excreted into the bile via P-glycoprotein ( P-gp   and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily", "triple_list": [["Doxorubicin", "AGONIST", "P450"]]}, {"text": " Doxorubicin  is mainly excreted into the bile via P-glycoprotein (P-gp) and  multidrug resistance-associated protein 2  (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily", "triple_list": [["subfamily", "ACTIVATOR", "multidrug resistance-associated protein 2"]]}, {"text": " Doxorubicin  is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 ( Mrp2   in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily", "triple_list": [["Doxorubicin", "ACTIVATOR", "via"]]}, {"text": " Doxorubicin  is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via  cytochrome P450 (CYP) 3A  subfamily", "triple_list": [["in", "ACTIVATOR", "cytochrome P450 (CYP) 3A"]]}, {"text": "Exposure of cells to 4mM  NaF  for 24h induced  caspase-3  activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent", "triple_list": [["Bax", "PRODUCT-OF", "caspase-3"]]}, {"text": " Fluoride  treatment also increased phosphorylation of  JNK  and ERK, but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with  JNK  or ERK inhibitors, respectively", "triple_list": [["Fluoride", "PRODUCT-OF", "partly"]]}, {"text": " Fluoride  treatment also increased phosphorylation of JNK and  ERK   but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or  ERK  inhibitors, respectively", "triple_list": [["Fluoride", "PRODUCT-OF", "ERK"]]}, {"text": " 6-DHSG  was metabolised by GSH to form a GSH conjugate (GS- 6-DHSG ) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of  glutathione-S-transferase  (GST)", "triple_list": [["a", "AGONIST", "glutathione-S-transferase"]]}, {"text": " 6-DHSG  was metabolised by GSH to form a GSH conjugate (GS- 6-DHSG ) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase ( GST  ", "triple_list": [["6-DHSG", "ANTAGONIST", "was"]]}, {"text": "6-DHSG was metabolised by GSH to form a GSH conjugate ( GS-6-DHSG   in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of  glutathione-S-transferase  (GST)", "triple_list": [["GS-6-DHSG", "ANTAGONIST", "via"]]}, {"text": "6-DHSG was metabolised by GSH to form a GSH conjugate ( GS-6-DHSG   in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase ( GST  ", "triple_list": [["GS-6-DHSG", "DOWNREGULATOR", "a"]]}, {"text": "A series of  carbamoylmethylene  linked prodrugs of 1 (BMS-582949), a clinical  p38\u03b1  inhibitor, were synthesized and evaluated", "triple_list": [["(BMS-582949),", "PRODUCT-OF", "p38\u03b1"]]}, {"text": "A series of carbamoylmethylene linked prodrugs of 1 ( BMS-582949  , a clinical  p38\u03b1  inhibitor, were synthesized and evaluated", "triple_list": [["BMS-582949", "PRODUCT-OF", "series"]]}, {"text": "Synthesis and evaluation of  carbamoylmethylene  linked prodrugs of BMS-582949, a clinical  p38\u03b1  inhibitor", "triple_list": [["prodrugs", "ACTIVATOR", "p38\u03b1"]]}, {"text": "Synthesis and evaluation of carbamoylmethylene linked prodrugs of  BMS-582949   a clinical  p38\u03b1  inhibitor", "triple_list": [["BMS-582949", "PRODUCT-OF", "carbamoylmethylene"]]}, {"text": "Here we studied the effects of the recently developed  monoacylglycerol lipase  inhibitor  JZL184  on basal and stress-induced corticosterone levels in male CD1 mice, and found that this compound dramatically increased basal levels without affecting stress responses", "triple_list": [["studied", "AGONIST", "monoacylglycerol lipase"]]}, {"text": "Mechanisms of Glucose Lowering of  Dipeptidyl Peptidase-4  Inhibitor  Sitagliptin  When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study", "triple_list": [["A", "ANTAGONIST", "Dipeptidyl Peptidase-4"]]}, {"text": "Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of  p21  WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by  rofecoxib  a selective COX-2 inhibitor) and rescued by exogenous PGE2", "triple_list": [["PGE2", "DOWNREGULATOR", "p21"]]}, {"text": "Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21( WAF1  CIP1) and upregulation of cyclinB1, since these effects were prevented by  rofecoxib  a selective COX-2 inhibitor) and rescued by exogenous PGE2", "triple_list": [["rofecoxib", "PRODUCT-OF", "and"]]}, {"text": "Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/ CIP1   and upregulation of cyclinB1, since these effects were prevented by  rofecoxib  a selective COX-2 inhibitor) and rescued by exogenous PGE2", "triple_list": [["rofecoxib", "DOWNREGULATOR", "CIP1"]]}, {"text": "Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of  cyclinB1   since these effects were prevented by  rofecoxib  a selective COX-2 inhibitor) and rescued by exogenous PGE2", "triple_list": [["rofecoxib", "ACTIVATOR", "cyclinB1"]]}, {"text": "Platelet-induced  COX-2 -dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by  rofecoxib  a selective  COX-2  inhibitor) and rescued by exogenous PGE2", "triple_list": [["effects", "ACTIVATOR", "COX-2"]]}, {"text": " Cyclooxygenase(COX)-2  derived  prostanoids  can influence several processes that are linked to carcinogenesis", "triple_list": [["prostanoids", "DOWNREGULATOR", "derived"]]}, {"text": "Platelet-induced  COX-2  dependent  PGE2  synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective  COX-2  inhibitor) and rescued by exogenous  PGE2 ", "triple_list": [["PGE2", "DOWNREGULATOR", "by"]]}, {"text": "Synthesis and antitumor activity of  1,3,4-oxadiazole  possessing 1,4-benzodioxan moiety as a novel class of potent  methionine aminopeptidase type II  inhibitors", "triple_list": [["inhibitors", "ANTAGONIST", "methionine aminopeptidase type II"]]}, {"text": "Synthesis and antitumor activity of 1,3,4-oxadiazole possessing  1,4-benzodioxan  moiety as a novel class of potent  methionine aminopeptidase type II  inhibitors", "triple_list": [["of", "ACTIVATOR", "methionine aminopeptidase type II"]]}, {"text": "Such model of  Nox4  activity regulation could provide new insight into the understanding of the molecular mechanism of the electron transfer through the enzyme, i.e., its potential redox regulation, and could also define new therapeutic targets in diseases in which  quinones  and  Nox4  are implicated.", "triple_list": [["quinones", "ANTAGONIST", "Nox4"]]}, {"text": " Nox4  oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific  quinone  derivatives could modulate this activity", "triple_list": [["modulate", "AGONIST", "Nox4"]]}, {"text": "Nox4  oxidase  activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific  quinone  derivatives could modulate this activity", "triple_list": [["quinone", "ANTAGONIST", "at"]]}, {"text": "In fact, we demonstrated a significant stimulation of  Nox4  activity by 4  quinone  derivatives (AA-861, tBuBHQ, tBuBQ, and duro quinone ) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines", "triple_list": [["quinone", "AGONIST", "Nox4"]]}, {"text": "In fact, we demonstrated a significant stimulation of  Nox4  activity by 4 quinone derivatives ( AA-861   tBuBHQ, tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines", "triple_list": [["cellular", "PRODUCT-OF", "Nox4"]]}, {"text": "In fact, we demonstrated a significant stimulation of  Nox4  activity by 4 quinone derivatives (AA-861,  tBuBHQ   tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines", "triple_list": [["quinone", "ANTAGONIST", "Nox4"]]}, {"text": "In fact, we demonstrated a significant stimulation of  Nox4  activity by 4 quinone derivatives (AA-861, tBuBHQ,  tBuBQ   and duroquinone) observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines", "triple_list": [["tBuBQ", "AGONIST", "chondrocyte"]]}, {"text": "In fact, we demonstrated a significant stimulation of  Nox4  activity by 4 quinone derivatives (AA-861, tBuBHQ, tBuBQ, and  duroquinone   observed in 3 different cellular models, HEK293E, T-REx\u2122, and chondrocyte cell lines", "triple_list": [["duroquinone", "DOWNREGULATOR", "fact,"]]}, {"text": " Allicin  treatment showed reduced production of pro-inflammatory cytokines and NO and increased  HO-1  activity", "triple_list": [["NO", "DOWNREGULATOR", "HO-1"]]}, {"text": " Allicin  treatment showed reduced production of pro-inflammatory  cytokines  and NO and increased HO-1 activity", "triple_list": [["Allicin", "ACTIVATOR", "NO"]]}, {"text": "In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that  TCDD  up-regulated the expression and secretion of  tumor necrosis factor-alpha  (TNF-\u03b1) in a time-dependent manner in cultured HAPI microglial cells", "triple_list": [["TCDD", "DOWNREGULATOR", "and"]]}, {"text": "In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that  TCDD  up-regulated the expression and secretion of tumor necrosis factor-alpha ( TNF-\u03b1   in a time-dependent manner in cultured HAPI microglial cells", "triple_list": [["TCDD", "DOWNREGULATOR", "secretion"]]}, {"text": " TCDD  also caused a fast (within 30min as judged by the increase in its mRNA level) activation of  cytosolic phospholipase A2  (cPLA2)", "triple_list": [["its", "DOWNREGULATOR", "cytosolic phospholipase A2"]]}, {"text": " TCDD  also caused a fast (within 30min as judged by the increase in its mRNA level) activation of cytosolic phospholipase A2 ( cPLA2  ", "triple_list": [["TCDD", "PRODUCT-OF", "caused"]]}, {"text": "This initial action was accompanied by up-regulation of  cyclooxygenase-2  (COX-2), an important inflammation marker within 1h after  TCDD  treatment", "triple_list": [["TCDD", "DOWNREGULATOR", "accompanied"]]}, {"text": "This initial action was accompanied by up-regulation of cyclooxygenase-2 ( COX-2  , an important inflammation marker within 1h after  TCDD  treatment", "triple_list": [["TCDD", "AGONIST", "of"]]}, {"text": "Further,  TCDD  exposure could induce phosphorylation- and ubiquitination-dependent degradation of  I\u043aB\u03b1   and the translocation of NF-\u03baB p65 from the cytosol to the nucleus in this microglial cell line", "triple_list": [["TCDD", "AGONIST", "TCDD"]]}, {"text": "Thus, the  NF-\u03baB  signaling pathway can be activated after  TCDD  treatment", "triple_list": [["TCDD", "ANTAGONIST", "NF-\u03baB"]]}, {"text": "However, Ca(2+) blockers also obviously attenuated  NF-\u03baB  activation and transnuclear transport induced by  TCDD   In concert with these results, we highlighted that the secretion of pro-inflammatory cytokine and  NF-\u03baB  activation induced by  TCDD  can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.", "triple_list": [["TCDD", "DOWNREGULATOR", "Ca(2+)"]]}, {"text": "In concert with these results, we highlighted that the secretion of pro-inflammatory  cytokine  and NF-\u03baB activation induced by  TCDD  can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.", "triple_list": [["TCDD", "PRODUCT-OF", "induced"]]}, {"text": "In concert with these results, we highlighted that the secretion of pro-inflammatory cytokine and  NF-\u03baB  activation induced by  TCDD  can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.", "triple_list": [["[Ca(2+)]i", "PRODUCT-OF", "NF-\u03baB"]]}, {"text": " Vandetanib  (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and  epidermal growth-factor receptors   It is the first systemic drug with demonstrated anti-tumor benefits in advanced MTC, and it has recently been approved for locally advanced or metastatic MTC by the United States Food and Drug Administration (April 2011) and the European Medicines Agency (February 2012)", "triple_list": [["Vandetanib", "ACTIVATOR", "advanced"]]}, {"text": " Vandetanib  (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral  tyrosine kinase  inhibitor that selectively inhibits signalling mediated by growth-factor receptor  tyrosine kinase  RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors", "triple_list": [["inhibitor", "ANTAGONIST", "tyrosine kinase"]]}, {"text": " Vandetanib  (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by  growth-factor receptor tyrosine kinase  RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors", "triple_list": [["Vandetanib", "ANTAGONIST", "RET"]]}, {"text": " Vandetanib  (Caprelsa(\u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase  RET  (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors", "triple_list": [["Vandetanib", "PRODUCT-OF", "tyrosine"]]}, {"text": "Vandetanib ( Caprelsa  \u00ae), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and  epidermal growth-factor receptors   It is the first systemic drug with demonstrated anti-tumor benefits in advanced MTC, and it has recently been approved for locally advanced or metastatic MTC by the United States Food and Drug Administration (April 2011) and the European Medicines Agency (February 2012)", "triple_list": [["locally", "ANTAGONIST", "epidermal growth-factor receptors"]]}, {"text": "Vandetanib ( Caprelsa  \u00ae), AstraZeneca) is a once-daily oral  tyrosine kinase  inhibitor that selectively inhibits signalling mediated by growth-factor receptor  tyrosine kinase  RET (constitutively activated in roughly 60\u00a0% of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors", "triple_list": [["Caprelsa", "PRODUCT-OF", "mediated"]]}, {"text": "Chelation of calcium ions by BAPTA-AM or blockade of  ERK1/2  activation by  UO126  also prevented the NMDA effects", "triple_list": [["UO126", "ANTAGONIST", "blockade"]]}, {"text": "Thus prolonged activation of NMDA receptors in hippocampal neurons reduced  GABAR \u03b4 subunit  expression through  Ca2+  entry and at least in part by ERK1/2 activation.", "triple_list": [["Ca2+", "ACTIVATOR", "in"]]}, {"text": "Promoter assay revealed that  prunetin  inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of  iNOS  and COX-2 at the transcriptional level", "triple_list": [["prunetin", "ACTIVATOR", "the"]]}, {"text": "Promoter assay revealed that  prunetin  inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of iNOS and  COX-2  at the transcriptional level", "triple_list": [["prunetin", "AGONIST", "LPS-induced"]]}, {"text": "Anti-inflammatory effect of  prunetin  via the suppression of  NF-\u03baB  pathway", "triple_list": [["NF-\u03baB", "ANTAGONIST", "NF-\u03baB"]]}, {"text": "In addition,  prunetin  inhibits  NF-\u03baB  dependent inflammatory responses by modulating I\u03baB kinase (IKK)-inhibitor \u03baB\u03b1 (I\u03baB\u03b1)- NF-\u03baB  signaling", "triple_list": [["NF-\u03baB", "AGONIST", "NF-\u03baB"]]}, {"text": "Consistent with these results,  prunetin  significantly reduced serum levels of inflammatory  cytokines  and mortality in mice challenged with lipopolysaccharide", "triple_list": [["prunetin", "ANTAGONIST", "lipopolysaccharide"]]}, {"text": "Introduction: 5-Lipoxygenase ( 5-LO   is a crucial enzyme of the  arachidonic acid  (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the  5-LO -activating protein", "triple_list": [["arachidonic acid", "AGONIST", "5-LO"]]}, {"text": "Introduction:  5-Lipoxygenase  (5-LO) is a crucial enzyme of the  arachidonic acid  (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein", "triple_list": [["arachidonic acid", "AGONIST", "(5-LO)"]]}, {"text": "The reduction of  P2X3  expression levels was reversed by the proteasomal inhibitor  MG-132   Moreover, neuronal CASK/ P2X3  interaction was upregulated by NGF signaling and downregulated by  P2X3  agonist-induced desensitization", "triple_list": [["P2X3", "ANTAGONIST", "P2X3"]]}, {"text": "A series of  phosphorylated flavonoids  were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic  cholesterol esterase  (CEase) and acetylcholinesterase (AChE)", "triple_list": [["phosphorylated flavonoids", "ACTIVATOR", "phosphorylated"]]}, {"text": "A series of  phosphorylated flavonoids  were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase ( CEase   and acetylcholinesterase (AChE)", "triple_list": [["phosphorylated flavonoids", "ANTAGONIST", "of"]]}, {"text": "A series of  phosphorylated flavonoids  were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase (CEase) and  acetylcholinesterase  (AChE)", "triple_list": [["of", "AGONIST", "acetylcholinesterase"]]}, {"text": "A series of  phosphorylated flavonoids  were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic cholesterol esterase (CEase) and acetylcholinesterase ( AChE  ", "triple_list": [["phosphorylated flavonoids", "ACTIVATOR", "as"]]}, {"text": "The results showed that most of the synthesized compounds exhibited nanomolar potency against  CEase   much better than the parent  flavonoids   Furthermore, these phosphorylated  flavonoids  demonstrated good to high selectivity for  CEase  over AChE, which only showed micromolar potency inhibition of AChE", "triple_list": [["flavonoids", "AGONIST", "much"]]}, {"text": "Furthermore, these  phosphorylated flavonoids  demonstrated good to high selectivity for  CEase  over AChE, which only showed micromolar potency inhibition of AChE", "triple_list": [["which", "ACTIVATOR", "CEase"]]}, {"text": "Furthermore, these  phosphorylated flavonoids  demonstrated good to high selectivity for CEase over  AChE   which only showed micromolar potency inhibition of  AChE ", "triple_list": [["phosphorylated flavonoids", "PRODUCT-OF", "selectivity"]]}, {"text": "Furthermore, these  phosphorylated flavonoids  demonstrated good to high selectivity for CEase over  AChE , which only showed micromolar potency inhibition of  AChE   The most selective and potent inhibitor of CEase (3e) had IC50 value of 0.72\u00a0nM and 11800-fold selectivity for CEase over  AChE ", "triple_list": [[",", "ANTAGONIST", "AChE"]]}, {"text": "The structure-activity relationships revealed that the free  hydroxyl  group at position 5 and phosphate group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of  CEase   The inhibition mechanism and kinetic characterization studies indicated that they are irreversible competitive inhibitors of  CEase .", "triple_list": [["structure-activity", "AGONIST", "CEase"]]}, {"text": "The structure-activity relationships revealed that the free hydroxyl group at position 5 and  phosphate  group at position 7 of the phosphorylated flavonoids are favorable to the inhibition of  CEase   The inhibition mechanism and kinetic characterization studies indicated that they are irreversible competitive inhibitors of  CEase .", "triple_list": [["5", "AGONIST", "CEase"]]}, {"text": "The structure-activity relationships revealed that the free hydroxyl group at position 5 and phosphate group at position 7 of the  phosphorylated flavonoids  are favorable to the inhibition of  CEase   The inhibition mechanism and kinetic characterization studies indicated that they are irreversible competitive inhibitors of  CEase .", "triple_list": [["inhibition", "AGONIST", "CEase"]]}, {"text": "Synthesis and biological evaluation of  phosphorylated flavonoids  as potent and selective inhibitors of  cholesterol esterase   A series of  phosphorylated flavonoids  were synthesized and investigated in\u00a0vitro as inhibitors of pancreatic  cholesterol esterase  (CEase) and acetylcholinesterase (AChE)", "triple_list": [["phosphorylated flavonoids", "AGONIST", "Synthesis"]]}, {"text": " Pasireotide  (Signifor(\u00ae)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of  corticotropin  from the pituitary adenoma in patients with Cushing's disease", "triple_list": [["new", "AGONIST", "corticotropin"]]}, {"text": "Pasireotide ( Signifor  \u00ae)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of  corticotropin  from the pituitary adenoma in patients with Cushing's disease", "triple_list": [["acts", "ANTAGONIST", "corticotropin"]]}, {"text": "No effects were observed when  fenclozic acid  was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major  human cytochrome P450  enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells", "triple_list": [["fenclozic", "PRODUCT-OF", "human cytochrome P450"]]}, {"text": "No effects were observed when  fenclozic acid  was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary  efflux transporters  BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells", "triple_list": [["P450-independent", "ACTIVATOR", "efflux transporters"]]}, {"text": "No effects were observed when  fenclozic acid  was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters  BSEP  and MRP2 or mitochondrial toxicity to THLE or HepG2 cells", "triple_list": [["fenclozic acid", "PRODUCT-OF", "or"]]}, {"text": "No effects were observed when  fenclozic acid  was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters BSEP and  MRP2  or mitochondrial toxicity to THLE or HepG2 cells", "triple_list": [["fenclozic acid", "AGONIST", "human"]]}, {"text": " Sphingosine-1-phosphate  promotes the nuclear translocation of \u03b2-catenin and thereby induces  osteoprotegerin  gene expression in osteoblast-like cell lines", "triple_list": [["Sphingosine-1-phosphate", "DOWNREGULATOR", "promotes"]]}, {"text": " S1P  increased the amount of  osteoprotegerin  at both mRNA and protein levels, and increased the activity of alkaline phosphatase, leading to the mineralization", "triple_list": [["S1P", "AGONIST", "amount"]]}, {"text": "These findings suggest that  S1P  activates the  PI3K  Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.", "triple_list": [["and", "PRODUCT-OF", "PI3K"]]}, {"text": "These findings suggest that  S1P  activates the PI3K/ Akt  signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.", "triple_list": [["leading", "DOWNREGULATOR", "Akt"]]}, {"text": "These findings suggest that  S1P  activates the PI3K/Akt signaling pathway leading to the promotion of nuclear translocation of  \u03b2-catenin  in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.", "triple_list": [["that", "DOWNREGULATOR", "\u03b2-catenin"]]}, {"text": "These findings suggest that  S1P  activates the PI3K/Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of  osteoptotegerin  and osteoblast differentiation markers including alkaline phosphatase, probably relating to the inhibition of osteoclast formation and the mineralization, respectively.", "triple_list": [["S1P", "PRODUCT-OF", "promotion"]]}, {"text": "These findings suggest that  S1P  activates the PI3K/Akt signaling pathway leading to the promotion of nuclear translocation of \u03b2-catenin in osteoblast-like cells, resulting in the upregulation of osteoptotegerin and osteoblast differentiation markers including  alkaline phosphatase   probably relating to the inhibition of osteoclast formation and the mineralization, respectively.", "triple_list": [["S1P", "ANTAGONIST", "These"]]}, {"text": " S1P  activated  phosphatidylinositol 3-kinase  (PI3K)/Akt signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells", "triple_list": [["transcriptional", "AGONIST", "phosphatidylinositol 3-kinase"]]}, {"text": " S1P  activated phosphatidylinositol 3-kinase ( PI3K  /Akt signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells", "triple_list": [["S1P", "AGONIST", "the"]]}, {"text": " S1P  activated phosphatidylinositol 3-kinase (PI3K)/ Akt  signaling, leading to the inhibition of glycogen synthase kinase-3\u03b2 and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells", "triple_list": [["(PI3K)/", "DOWNREGULATOR", "Akt"]]}, {"text": " S1P  activated phosphatidylinositol 3-kinase (PI3K)/Akt signaling, leading to the inhibition of  glycogen synthase kinase-3\u03b2  and the nuclear translocation of \u03b2-catenin, followed by the increase of the transcriptional activity by \u03b2-catenin/T-cell factor complex formation in both SaOS-2 cells and MC3T3-E1 cells", "triple_list": [["in", "AGONIST", "glycogen synthase kinase-3\u03b2"]]}, {"text": "Results: The administration of  prallethrin  1.6% w/w created significant increased changes in the levels of total WBC, lymphocytes, RBC,  hemoglobin   packed cell volume, platelets, mean corpuscular volume, and mean corpuscular  hemoglobin  in rats after 24, 48, and 72\u2009h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48\u2009h to return to normal after 72\u2009h", "triple_list": [["prallethrin", "PRODUCT-OF", "h"]]}, {"text": "Results: The administration of  prallethrin  1.6% w/w created significant increased changes in the levels of total WBC, lymphocytes, RBC,  hemoglobin , packed cell volume, platelets, mean corpuscular volume, and mean corpuscular  hemoglobin  in rats after 24, 48, and 72\u2009h of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48\u2009h to return to normal after 72\u2009h", "triple_list": [["72", "AGONIST", "hemoglobin"]]}, {"text": "Result showed that  vitamin C  treatment resulted in markedly reduced  c-Rel  nuclear translocation", "triple_list": [["vitamin", "ACTIVATOR", "c-Rel"]]}, {"text": "All these results demonstrate that  vitamin C  prevents CS(E)-induced  NF-\u03baB  activation and thus it could be used for the prevention of CS-induced inflammatory diseases.", "triple_list": [["vitamin C", "PRODUCT-OF", "diseases."]]}, {"text": "It is possible that  vitamin C   an antioxidant, may prevent cigarette smoke (CS)-induced  NF-\u03baB  activation that involves degradation of I-\u03baB\u03b5 and nuclear translocation of c-Rel/p50 in alveolar epithelial cells", "triple_list": [["activation", "PRODUCT-OF", "NF-\u03baB"]]}, {"text": "It is possible that  vitamin C   an antioxidant, may prevent cigarette smoke (CS)-induced NF-\u03baB activation that involves degradation of  I-\u03baB\u03b5  and nuclear translocation of c-Rel/p50 in alveolar epithelial cells", "triple_list": [["NF-\u03baB", "PRODUCT-OF", "I-\u03baB\u03b5"]]}, {"text": "We observed a significant reduction in CSE induced luciferase expression, NF-\u03baB DNA binding,  I-\u03baB\u03b5  degradation and c-Rel nuclear translocation in cells pretreated with  vitamin C   To further validate the result, we examined sub-cellular distribution of c-Rel in lungs of CS-exposed guinea pigs treated or untreated with  vitamin C ", "triple_list": [["distribution", "ANTAGONIST", "I-\u03baB\u03b5"]]}, {"text": " Vitamin C  forestalls cigarette smoke induced  NF-\u03baB  activation in alveolar epithelial cells", "triple_list": [["C", "AGONIST", "NF-\u03baB"]]}, {"text": "Suppression of  T\u03b2R1  by the pharmacological inhibitor ( SB431542   markedly reduced VEGF release by HFL-1 in response to CSE and this effect was confirmed by  T\u03b2R1  siRNA", "triple_list": [["HFL-1", "AGONIST", "T\u03b2R1"]]}, {"text": "Suppression of T\u03b2R1 by the pharmacological inhibitor ( SB431542   markedly reduced  VEGF  release by HFL-1 in response to CSE and this effect was confirmed by T\u03b2R1 siRNA", "triple_list": [["T\u03b2R1", "ANTAGONIST", "VEGF"]]}, {"text": " Rapamycin  inhibits  proteinase  and selected peptidase activities of the catalytic core proteasome at low micromolar concentrations", "triple_list": [["Rapamycin", "ACTIVATOR", "activities"]]}, {"text": " Rapamycin  inhibits proteinase and selected  peptidase  activities of the catalytic core proteasome at low micromolar concentrations", "triple_list": [["proteasome", "AGONIST", "peptidase"]]}, {"text": " Rapamycin  inhibits proteinase and selected peptidase activities of the catalytic core  proteasome  at low micromolar concentrations", "triple_list": [["Rapamycin", "ACTIVATOR", "inhibits"]]}, {"text": " MNU  induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of E-cadherin, and high  MGMT  staining", "triple_list": [["induced", "PRODUCT-OF", "MGMT"]]}, {"text": " MNU  induced lesions presented markers indicative of an aggressive phenotype: lack of basal cells, rupture of the smooth muscle cell layer, loss of  E-cadherin   and high MGMT staining", "triple_list": [["cell", "ANTAGONIST", "E-cadherin"]]}, {"text": " Methylphenidate  increased  DAT  Vmax in SHR mPFC and decreased  DAT  Vmax in WKY OFC", "triple_list": [["in", "AGONIST", "DAT"]]}, {"text": "Thus, the increase in mPFC  DAT  function was an SHR-specific long term consequence of  methylphenidate  treatment during adolescence, which may be responsible for the treatment-induced alterations in behavior including the observed increases in cocaine self-administration.", "triple_list": [["methylphenidate", "PRODUCT-OF", "observed"]]}, {"text": " Methylphenidate   an inhibitor of  dopamine and norepinephrine transporters  (DAT and NET, respectively), is a standard treatment for ADHD", "triple_list": [["of", "PRODUCT-OF", "dopamine and norepinephrine transporters"]]}, {"text": " Methylphenidate   an inhibitor of dopamine and norepinephrine transporters ( DAT  and NET, respectively), is a standard treatment for ADHD", "triple_list": [["Methylphenidate", "ACTIVATOR", "Methylphenidate"]]}, {"text": " Methylphenidate   an inhibitor of dopamine and norepinephrine transporters (DAT and  NET   respectively), is a standard treatment for ADHD", "triple_list": [["Methylphenidate", "ANTAGONIST", "treatment"]]}, {"text": " Methylphenidate  increased  DAT  Vmax in SHR mPFC and decreased  DAT  Vmax in WKY OFC", "triple_list": [["Vmax", "PRODUCT-OF", "DAT"]]}, {"text": "Also,  methylphenidate  decreased  DAT  Km in WIS OFC", "triple_list": [["WIS", "ACTIVATOR", "DAT"]]}, {"text": "In the  IB-MECA  group,  \u03b1-amylase  activity was decreased with statistically high significance compared to group I", "triple_list": [["IB-MECA", "ACTIVATOR", "I"]]}, {"text": "The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the  adenosine A3 receptor  agonist  IB-MECA  (1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide at a dose of 0.75\u00a0mg/kg b.w", "triple_list": [["experiments", "PRODUCT-OF", "adenosine A3 receptor"]]}, {"text": "The experiments were performed on 80 male Wistar rats, 58 of which survived, subdivided into 3 groups: C-control rats, I-EAP group, and II-EAP group treated with the  adenosine A3 receptor  agonist IB-MECA  (1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide  at a dose of 0.75\u00a0mg/kg b.w", "triple_list": [["(1-deoxy-1-6[[(3-iodophenyl) methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide", "DOWNREGULATOR", "performed"]]}, {"text": "The effects of the  adenosine A3 receptor  agonist  IB-MECA  on sodium taurocholate-induced experimental acute pancreatitis", "triple_list": [["receptor", "ANTAGONIST", "adenosine A3 receptor"]]}, {"text": "The use of  A3 receptor  agonist  IB-MECA  attenuates EAP", "triple_list": [["IB-MECA", "PRODUCT-OF", "A3 receptor"]]}, {"text": "The data show that  CP[c]Ph  is less potent at inducing  CYP1A  gene expression in rainbow trout than benzo[a]pyrene (B[a]P), a well-known Ah-receptor agonist", "triple_list": [["CP[c]Ph", "ANTAGONIST", "The"]]}, {"text": "The data show that CP[c]Ph is less potent at inducing  CYP1A  gene expression in rainbow trout than  benzo[a]pyrene  (B[a]P), a well-known Ah-receptor agonist", "triple_list": [["benzo[a]pyrene", "PRODUCT-OF", "inducing"]]}, {"text": "The data show that CP[c]Ph is less potent at inducing  CYP1A  gene expression in rainbow trout than benzo[a]pyrene ( B[a]P  , a well-known Ah-receptor agonist", "triple_list": [["B[a]P", "DOWNREGULATOR", "B[a]P"]]}, {"text": "Interestingly, the  CP[c]Ph  dependent up-regulation of  CYP1A  mRNA is positively correlated with the incidences of clastogenic changes in rainbow trout erythrocytes", "triple_list": [["CP[c]Ph", "PRODUCT-OF", "correlated"]]}, {"text": " CP[c]Ph  has, comparably to B[a]P, a potential to repress expression of  tumor suppressor p53   in the head kidney of rainbow trout", "triple_list": [["CP[c]Ph", "AGONIST", "trout"]]}, {"text": "CP[c]Ph has, comparably to  B[a]P   a potential to repress expression of  tumor suppressor p53   in the head kidney of rainbow trout", "triple_list": [["comparably", "ANTAGONIST", "tumor suppressor p53"]]}, {"text": "Combined treatment of  Mn  and DA further augments cell toxicity, ROS production and  JNK  phosphorylation in LRRK2 deficient cells compared to controls", "triple_list": [["Mn", "PRODUCT-OF", "DA"]]}, {"text": " Type I deiodinase   liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by  TCPP   while TDCPP induced CYP3A37 and CYP2H1", "triple_list": [["protein", "PRODUCT-OF", "Type I deiodinase"]]}, {"text": "Type I deiodinase,  liver fatty-acid binding protein  and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by  TCPP   while TDCPP induced CYP3A37 and CYP2H1", "triple_list": [["significantly", "DOWNREGULATOR", "liver fatty-acid binding protein"]]}, {"text": "Type I deiodinase, liver fatty-acid binding protein and  cytochrome P450 (CYP) 3A37  mRNA levels were significantly induced by  TCPP   while TDCPP induced CYP3A37 and CYP2H1", "triple_list": [["Type", "DOWNREGULATOR", "cytochrome P450 (CYP) 3A37"]]}, {"text": "Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while  TDCPP  induced  CYP3A37  and CYP2H1", "triple_list": [["TDCPP", "AGONIST", "CYP3A37"]]}, {"text": "Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while  TDCPP  induced CYP3A37 and  CYP2H1   Chemical analysis of egg contents at incubation days 0, 5, 11, 18, and 19 revealed that >92% of the injected TCPP or  TDCPP  concentration was detectable up to day 5; however, <1% was detected by day 19", "triple_list": [["TDCPP", "DOWNREGULATOR", "revealed"]]}, {"text": "The results showed that administration of  AlCl3  resulted in a significant elevation in the levels of  AchE  activity, CRP, NF-\u03baB, and MCP-1 accompanied with a significant depletion in the Ach level", "triple_list": [["AlCl3", "ANTAGONIST", "The"]]}, {"text": "The results showed that administration of  AlCl3  resulted in a significant elevation in the levels of AchE activity,  CRP   NF-\u03baB, and MCP-1 accompanied with a significant depletion in the Ach level", "triple_list": [["AchE", "ANTAGONIST", "CRP"]]}, {"text": "The results showed that administration of  AlCl3  resulted in a significant elevation in the levels of AchE activity, CRP,  NF-\u03baB   and MCP-1 accompanied with a significant depletion in the Ach level", "triple_list": [["AlCl3", "ANTAGONIST", "results"]]}, {"text": "The results showed that administration of  AlCl3  resulted in a significant elevation in the levels of AchE activity, CRP, NF-\u03baB, and  MCP-1  accompanied with a significant depletion in the Ach level", "triple_list": [["AlCl3", "AGONIST", "the"]]}, {"text": "In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of  serotonin   possibly by facilitating the interaction of  serotonin  with transport-ready conformations of  SERT  when concentrations of  serotonin  were low and rate limiting", "triple_list": [["serotonin", "ANTAGONIST", "possibly"]]}, {"text": "In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of  serotonin , possibly by facilitating the interaction of  serotonin  with transport-ready conformations of  SERT  when concentrations of  serotonin  were low and rate limiting", "triple_list": [["concentrations", "AGONIST", "SERT"]]}, {"text": "In functional transport assays, we found that one of the identified molecules, ATM7, increased the reuptake of  serotonin , possibly by facilitating the interaction of  serotonin  with transport-ready conformations of  SERT  when concentrations of  serotonin  were low and rate limiting", "triple_list": [["serotonin", "AGONIST", "the"]]}, {"text": "In the local presence into the LC of the  \u03b12-adrenoceptor  antagonist  RS79948  (1\u00a0\u03bcM), systemic citalopram increased NA in the LC (Emax\u2009=\u2009157\u2009\u00b1\u200925\u00a0%) and PFC (Emax\u2009=\u2009175\u2009\u00b1\u200924\u00a0%)", "triple_list": [["the", "DOWNREGULATOR", "\u03b12-adrenoceptor"]]}, {"text": "Local LC citalopram effect was abolished by LC presence of the  5-HT3  receptor antagonist  MDL72222  (1\u00a0\u03bcM) but not the 5-HT1/2 receptor antagonist methiothepin (1\u00a0\u03bcM)", "triple_list": [["5-HT3", "AGONIST", "5-HT3"]]}, {"text": "Local LC citalopram effect was abolished by LC presence of the 5-HT3 receptor antagonist MDL72222 (1\u00a0\u03bcM) but not the  5-HT1/2  receptor antagonist  methiothepin  (1\u00a0\u03bcM)", "triple_list": [["LC", "PRODUCT-OF", "5-HT1/2"]]}, {"text": "Additionally,  MPTP  significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in  Bax  expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment", "triple_list": [["MPTP", "ANTAGONIST", "Additionally,"]]}, {"text": "Additionally,  MPTP  significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved- caspase-3  expression, whereas these were inhibited by CRE or EB treatment", "triple_list": [["MPTP", "PRODUCT-OF", "EB"]]}, {"text": "Additionally,  MPTP  significantly down-regulated  Bcl-2  expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment", "triple_list": [["MPTP", "ACTIVATOR", "increase"]]}, {"text": " Cholesterol esterase  (CE) induced surface erosion of poly(ethylene carbonate) ( PEC   and drug release from  PEC  under mild physiological environment was investigated", "triple_list": [["PEC", "ANTAGONIST", "Cholesterol"]]}, {"text": "Cholesterol esterase ( CE   induced surface erosion of poly(ethylene carbonate) ( PEC   and drug release from  PEC  under mild physiological environment was investigated", "triple_list": [["investigated", "AGONIST", "CE"]]}, {"text": " Cholesterol esterase  (CE) induced surface erosion of  poly(ethylene carbonate)  (PEC) and drug release from PEC under mild physiological environment was investigated", "triple_list": [["poly(ethylene carbonate)", "ANTAGONIST", "carbonate)"]]}, {"text": "Cholesterol esterase ( CE   induced surface erosion of  poly(ethylene carbonate)  (PEC) and drug release from PEC under mild physiological environment was investigated", "triple_list": [["poly(ethylene carbonate)", "AGONIST", "and"]]}, {"text": "A series of  benzenesulfonamides  incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA,  EC 4.2.1.1   from Saccharomyces cerevisiae, ScCA", "triple_list": [["benzenesulfonamides", "AGONIST", "anhydrase"]]}, {"text": "A series of  benzenesulfonamides  incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae,  ScCA   Some of these compounds were low nanomolar or subnanomolar  ScCA  inhibitors and showed selectivity ratios in the range of 4.91-69.86 for inhibiting the yeast enzyme over the offtarget human (h) isoforms hCA I and of 6.46-13.52 for inhibiting  ScCA  over hCA II", "triple_list": [["low", "PRODUCT-OF", "ScCA"]]}, {"text": "A series of  benzenesulfonamides  incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the  \u03b2-carbonic anhydrase  (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA", "triple_list": [["series", "PRODUCT-OF", "\u03b2-carbonic anhydrase"]]}, {"text": "A series of  benzenesulfonamides  incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase ( CA   EC 4.2.1.1) from Saccharomyces cerevisiae, Sc CA ", "triple_list": [["benzenesulfonamides", "AGONIST", "(tyrphostine"]]}, {"text": "A series of benzenesulfonamides incorporating  cyanoacrylamide  moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA,  EC 4.2.1.1   from Saccharomyces cerevisiae, ScCA", "triple_list": [["of", "PRODUCT-OF", "EC 4.2.1.1"]]}, {"text": "A series of benzenesulfonamides incorporating  cyanoacrylamide  moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae,  ScCA   Some of these compounds were low nanomolar or subnanomolar  ScCA  inhibitors and showed selectivity ratios in the range of 4.91-69.86 for inhibiting the yeast enzyme over the offtarget human (h) isoforms hCA I and of 6.46-13.52 for inhibiting  ScCA  over hCA II", "triple_list": [["cyanoacrylamide", "ANTAGONIST", "for"]]}, {"text": "A series of benzenesulfonamides incorporating  cyanoacrylamide  moieties (tyrphostine analogs) were assayed as inhibitors of the  \u03b2-carbonic anhydrase  (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA", "triple_list": [["4.2.1.1)", "PRODUCT-OF", "\u03b2-carbonic anhydrase"]]}, {"text": "A series of benzenesulfonamides incorporating  cyanoacrylamide  moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase ( CA   EC 4.2.1.1) from Saccharomyces cerevisiae, Sc CA ", "triple_list": [["cyanoacrylamide", "ANTAGONIST", "4.2.1.1)"]]}, {"text": "A series of benzenesulfonamides incorporating cyanoacrylamide moieties ( tyrphostine  analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA,  EC 4.2.1.1   from Saccharomyces cerevisiae, ScCA", "triple_list": [["tyrphostine", "PRODUCT-OF", "analogs)"]]}, {"text": "A series of benzenesulfonamides incorporating cyanoacrylamide moieties ( tyrphostine  analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae,  ScCA   Some of these compounds were low nanomolar or subnanomolar  ScCA  inhibitors and showed selectivity ratios in the range of 4.91-69.86 for inhibiting the yeast enzyme over the offtarget human (h) isoforms hCA I and of 6.46-13.52 for inhibiting  ScCA  over hCA II", "triple_list": [["tyrphostine", "ANTAGONIST", "selectivity"]]}, {"text": "A series of benzenesulfonamides incorporating cyanoacrylamide moieties ( tyrphostine  analogs) were assayed as inhibitors of the  \u03b2-carbonic anhydrase  (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA", "triple_list": [["the", "AGONIST", "\u03b2-carbonic anhydrase"]]}, {"text": "A series of benzenesulfonamides incorporating cyanoacrylamide moieties ( tyrphostine  analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase ( CA   EC 4.2.1.1) from Saccharomyces cerevisiae, Sc CA ", "triple_list": [["incorporating", "ACTIVATOR", "CA"]]}, {"text": " Benzenesulfonamides  incorporating cyanoacrylamide moieties strongly inhibit  Saccharomyces cerevisiae \u03b2-carbonic anhydrase   A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA", "triple_list": [["as", "AGONIST", "Saccharomyces cerevisiae \u03b2-carbonic anhydrase"]]}, {"text": "Benzenesulfonamides incorporating  cyanoacrylamide  moieties strongly inhibit  Saccharomyces cerevisiae \u03b2-carbonic anhydrase   A series of benzenesulfonamides incorporating  cyanoacrylamide  moieties (tyrphostine analogs) were assayed as inhibitors of the \u03b2-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA", "triple_list": [["cyanoacrylamide", "ANTAGONIST", "from"]]}, {"text": " Juglone   isolated from Juglans mandshurica Maxim, induces apoptosis via down-regulation of  AR  expression in human prostate cancer LNCaP cells", "triple_list": [["Juglone", "PRODUCT-OF", "down-regulation"]]}, {"text": "Moreover, we found that  juglone  significantly inhibited the expression levels of  androgen receptor  (AR) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT)", "triple_list": [["as", "ACTIVATOR", "androgen receptor"]]}, {"text": "Moreover, we found that  juglone  significantly inhibited the expression levels of androgen receptor ( AR   and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of  AR  and PSA genes with and/or without dihydrotestosterone (DHT)", "triple_list": [["(DHT)", "PRODUCT-OF", "AR"]]}, {"text": "Moreover, we found that  juglone  significantly inhibited the expression levels of androgen receptor (AR) and  prostate-specific antigen  (PSA) in a dose-dependent manner, as well as abrogated up-regulation of AR and PSA genes with and/or without dihydrotestosterone (DHT)", "triple_list": [["with", "PRODUCT-OF", "prostate-specific antigen"]]}, {"text": "Moreover, we found that  juglone  significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen ( PSA   in a dose-dependent manner, as well as abrogated up-regulation of AR and  PSA  genes with and/or without dihydrotestosterone (DHT)", "triple_list": [["juglone", "AGONIST", "as"]]}, {"text": "Moreover, we found that  juglone  significantly inhibited the expression levels of androgen receptor ( AR ) and prostate-specific antigen (PSA) in a dose-dependent manner, as well as abrogated up-regulation of  AR  and PSA genes with and/or without dihydrotestosterone (DHT)", "triple_list": [["(", "PRODUCT-OF", "AR"]]}, {"text": "Moreover, we found that  juglone  significantly inhibited the expression levels of androgen receptor (AR) and prostate-specific antigen ( PSA ) in a dose-dependent manner, as well as abrogated up-regulation of AR and  PSA  genes with and/or without dihydrotestosterone (DHT)", "triple_list": [["juglone", "ANTAGONIST", "antigen"]]}, {"text": "Take together, our results demonstrated that  juglone  might induce the apoptosis in LNCaP cell via down-regulation of  AR  expression", "triple_list": [["juglone", "ANTAGONIST", "Take"]]}, {"text": "In addition, pretreatment with  Z-Val-Ala-Asp-fluoromethylketone  (Z-VAD-fmk), a broad spectrum of  caspase  inhibitor, could not rescue apoptotic cells from ClpP toxicity", "triple_list": [["Z-Val-Ala-Asp-fluoromethylketone", "AGONIST", "with"]]}, {"text": "In addition, pretreatment with Z-Val-Ala-Asp-fluoromethylketone ( Z-VAD-fmk  , a broad spectrum of  caspase  inhibitor, could not rescue apoptotic cells from ClpP toxicity", "triple_list": [["a", "ACTIVATOR", "caspase"]]}, {"text": "Among these differentially expressed lncRNAs, the greatest change was noted for  uc002mbe.2   which had more than 300 folds induction upon  TSA  treatment", "triple_list": [["TSA", "DOWNREGULATOR", "these"]]}, {"text": " TSA  selectively induced  uc002mbe.2  in four studied HCC cell lines", "triple_list": [["TSA", "ANTAGONIST", "selectively"]]}, {"text": "The  TSA  induced  uc002mbe.2  expression was positively correlated with the apoptotic effect of  TSA  in HCC cells", "triple_list": [["TSA", "PRODUCT-OF", "cells"]]}, {"text": "Considerable attention has focused on the antitumor effect of  histone deacetylase  inhibitor ( Trichostatin A   TSA) as well as the coding gene expression-induced apoptosis of cancer cells", "triple_list": [["Trichostatin A", "ACTIVATOR", "of"]]}, {"text": "Considerable attention has focused on the antitumor effect of  histone deacetylase  inhibitor (Trichostatin A,  TSA   as well as the coding gene expression-induced apoptosis of cancer cells", "triple_list": [["the", "ACTIVATOR", "histone deacetylase"]]}, {"text": "RESULTS: Fractionated bulb extracts and the two isolated  steroidal glycoalkaloids  (1) and (2) induced NO production and  TGF-\u03b2 receptor I  mRNA expression in fibroblast cell culture", "triple_list": [["Fractionated", "AGONIST", "TGF-\u03b2 receptor I"]]}, {"text": "Compared with aripiprazole, which significantly inhibited the firing activity of VTA DA neurons,  brexpiprazole  displayed less efficacy at  D2 receptors   In the hippocampus,  brexpiprazole  acted as a full agonist at 5-HT1A receptors on pyramidal neurons", "triple_list": [["firing", "ANTAGONIST", "D2 receptors"]]}, {"text": "In the DRN,  brexpiprazole  completely inhibited the firing of 5-HT neurons via  5-HT1A  agonism and was more potent than aripiprazole (ED50 = 230 and 700 mug/kg, respectively)", "triple_list": [["brexpiprazole", "DOWNREGULATOR", "more"]]}, {"text": "In the DRN, brexpiprazole completely inhibited the firing of 5-HT neurons via  5-HT1A  agonism and was more potent than  aripiprazole  (ED50 = 230 and 700 mug/kg, respectively)", "triple_list": [["=", "ANTAGONIST", "5-HT1A"]]}, {"text": "In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential  5-HT2A  receptor agonist  DOI  (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating  5-HT2A  antagonistic action", "triple_list": [["agonist", "ACTIVATOR", "5-HT2A"]]}, {"text": "In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential  5-HT2A  receptor agonist DOI ( 2,5-dimethoxy-4-iodoamphetamine   on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating  5-HT2A  antagonistic action", "triple_list": [["5-HT2A", "ANTAGONIST", "5-HT2A"]]}, {"text": "Brexpiprazole reversed the inhibitory effect of the DA agonist  apomorphine  on VTA DA neurons (ED50 = 61 mug/kg), whereas it was ineffective when administered alone, indicating partial agonistic action on  D2 receptors   Compared with aripiprazole, which significantly inhibited the firing activity of VTA DA neurons, brexpiprazole displayed less efficacy at  D2 receptors ", "triple_list": [["action", "DOWNREGULATOR", "D2 receptors"]]}, {"text": "In the hippocampus,  brexpiprazole  acted as a full agonist at  5-HT1A  receptors on pyramidal neurons", "triple_list": [["on", "DOWNREGULATOR", "5-HT1A"]]}, {"text": "In the lateral geniculate nucleus,  brexpiprazole  displayed  alpha1B-adrenoceptor  antagonistic action", "triple_list": [["brexpiprazole", "PRODUCT-OF", "geniculate"]]}, {"text": "The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a  5-HT1A  selective agonist,  8-hydroxy-2-(di-n-propylamino)tetralin   was inactive", "triple_list": [["minaprine", "ANTAGONIST", "5-HT1A"]]}, {"text": "The memory-improving effect of minaprine on cycloheximide-induced amnesia was potentiated by a selective  5-HT2  antagonist,  ritanserin   These results suggest that the beneficial effect of minaprine on cycloheximide-induced amnesia may be related not only to cholinergic but also serotonergic neuronal systems ( 5-HT2  receptors).", "triple_list": [["ritanserin", "ACTIVATOR", "potentiated"]]}, {"text": "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating  histamine H1-receptor  antagonists  terfenadine   astemizole, loratadine, and acrivastine are reviewed", "triple_list": [["chemistry,", "DOWNREGULATOR", "histamine H1-receptor"]]}, {"text": "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating  histamine H1-receptor  antagonists terfenadine,  astemizole   loratadine, and acrivastine are reviewed", "triple_list": [["astemizole", "PRODUCT-OF", "astemizole"]]}, {"text": "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating  histamine H1-receptor  antagonists terfenadine, astemizole,  loratadine   and acrivastine are reviewed", "triple_list": [["adverse", "ACTIVATOR", "histamine H1-receptor"]]}, {"text": "The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosages of the nonsedating  histamine H1-receptor  antagonists terfenadine, astemizole, loratadine, and  acrivastine  are reviewed", "triple_list": [["acrivastine", "AGONIST", "clinical"]]}, {"text": " Terfenadine  and astemizole are chemically unrelated to  histamine H1-receptor  antagonists such as diphenhydramine and chlorpheniramine", "triple_list": [["Terfenadine", "ACTIVATOR", "Terfenadine"]]}, {"text": "Terfenadine and  astemizole  are chemically unrelated to  histamine H1-receptor  antagonists such as diphenhydramine and chlorpheniramine", "triple_list": [["astemizole", "ACTIVATOR", "chlorpheniramine"]]}, {"text": "Terfenadine and astemizole are chemically unrelated to  histamine H1-receptor  antagonists such as  diphenhydramine  and chlorpheniramine", "triple_list": [["histamine", "ACTIVATOR", "histamine H1-receptor"]]}, {"text": "Terfenadine and astemizole are chemically unrelated to  histamine H1-receptor  antagonists such as diphenhydramine and  chlorpheniramine   Loratadine is structurally related to the antihistamine azatadine, and acrivastine is a side-chain-reduced metabolite of the antihistamine triprolidine", "triple_list": [["chlorpheniramine", "AGONIST", "chemically"]]}, {"text": " Esmolol   a unique cardioselective  beta 1-adrenergic receptor  blocker with a half-life of 9 minutes, can enable some patients with relative contraindications to beta blockers to nevertheless benefit from early beta-blocking therapy", "triple_list": [["to", "ANTAGONIST", "beta 1-adrenergic receptor"]]}, {"text": "Felodipine and the  p-chloro  analogue inhibited the actin-activated  Mg2+-ATPase  activity of smooth muscle myosin (IC50 = 25.1 microM)", "triple_list": [["p-chloro", "PRODUCT-OF", "of"]]}, {"text": "Felodipine and the  p-chloro  analogue inhibited the actin-activated Mg2+-ATPase activity of smooth muscle  myosin  (IC50 = 25.1 microM)", "triple_list": [["p-chloro", "PRODUCT-OF", "p-chloro"]]}, {"text": "Similarly,  felodipine  and the p-chloro analogue blocked  myosin  filament assembly induced by low concentrations of calmodulin, whereas the oxidized and t-butyl analogues did not", "triple_list": [["felodipine", "AGONIST", "p-chloro"]]}, {"text": "Similarly, felodipine and the  p-chloro  analogue blocked  myosin  filament assembly induced by low concentrations of calmodulin, whereas the oxidized and t-butyl analogues did not", "triple_list": [["p-chloro", "ACTIVATOR", "whereas"]]}, {"text": "We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine  Ca2+ channel  blocker  felodipine  and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies", "triple_list": [["three", "AGONIST", "Ca2+ channel"]]}, {"text": "Again, inhibition of the actin-activated  myosin  Mg2+-ATPase and  myosin  filament assembly by  felodipine  and the p-chloro analogue could be reversed by raising the calmodulin concentration", "triple_list": [["felodipine", "AGONIST", "assembly"]]}, {"text": "Again, inhibition of the actin-activated myosin  Mg2+-ATPase  and myosin filament assembly by  felodipine  and the p-chloro analogue could be reversed by raising the calmodulin concentration", "triple_list": [["felodipine", "AGONIST", "myosin"]]}, {"text": "Again, inhibition of the actin-activated  myosin  Mg2+-ATPase and  myosin  filament assembly by  felodipine  and the p-chloro analogue could be reversed by raising the calmodulin concentration", "triple_list": [["felodipine", "ANTAGONIST", "the"]]}, {"text": "Again, inhibition of the actin-activated  myosin  Mg2+-ATPase and  myosin  filament assembly by felodipine and the  p-chloro  analogue could be reversed by raising the calmodulin concentration", "triple_list": [["by", "PRODUCT-OF", "myosin"]]}, {"text": "Again, inhibition of the actin-activated myosin  Mg2+-ATPase  and myosin filament assembly by felodipine and the  p-chloro  analogue could be reversed by raising the calmodulin concentration", "triple_list": [["raising", "AGONIST", "Mg2+-ATPase"]]}, {"text": "Again, inhibition of the actin-activated  myosin  Mg2+-ATPase and  myosin  filament assembly by felodipine and the  p-chloro  analogue could be reversed by raising the calmodulin concentration", "triple_list": [["Again,", "ACTIVATOR", "myosin"]]}, {"text": "These observations suggest that some of the pharmacological actions of  felodipine  on smooth muscle may involve inhibition of  calmodulin-dependent enzymes  which are functionally involved in the regulation of smooth muscle contraction.", "triple_list": [["felodipine", "ACTIVATOR", "involved"]]}, {"text": "The  cAMP phosphodiesterase  was inhibited completely by  felodipine  and the p-chloro analogue with IC50 values of 3.7 and 1.5 microM respectively", "triple_list": [["1.5", "ANTAGONIST", "cAMP phosphodiesterase"]]}, {"text": "The  cAMP phosphodiesterase  was inhibited completely by felodipine and the  p-chloro  analogue with IC50 values of 3.7 and 1.5 microM respectively", "triple_list": [["analogue", "ACTIVATOR", "cAMP phosphodiesterase"]]}, {"text": " Felodipine  and the p-chloro analogue inhibited the basal (Ca2+/calmodulin-independent) activity of  cAMP phosphodiesterase  as well as the calmodulin-stimulated activity", "triple_list": [["Felodipine", "AGONIST", "as"]]}, {"text": " Felodipine  and the p-chloro analogue inhibited the basal (Ca2+/ calmodulin -independent) activity of cAMP phosphodiesterase as well as the  calmodulin  stimulated activity", "triple_list": [["Felodipine", "ACTIVATOR", "as"]]}, {"text": "Felodipine and the  p-chloro  analogue inhibited the basal (Ca2+/calmodulin-independent) activity of  cAMP phosphodiesterase  as well as the calmodulin-stimulated activity", "triple_list": [["calmodulin-stimulated", "ACTIVATOR", "cAMP phosphodiesterase"]]}, {"text": "Felodipine and the  p-chloro  analogue inhibited the basal (Ca2+/ calmodulin -independent) activity of cAMP phosphodiesterase as well as the  calmodulin  stimulated activity", "triple_list": [["p-chloro", "ACTIVATOR", "calmodulin"]]}, {"text": "Calmodulin was relatively ineffective in preventing inhibition of  cAMP phosphodiesterase  by  felodipine  and the p-chloro analogue", "triple_list": [["was", "PRODUCT-OF", "cAMP phosphodiesterase"]]}, {"text": "Calmodulin was relatively ineffective in preventing inhibition of  cAMP phosphodiesterase  by felodipine and the  p-chloro  analogue", "triple_list": [["p-chloro", "PRODUCT-OF", "Calmodulin"]]}, {"text": " Felodipine  and the p-chloro analogue inhibited Ca2+/calmodulin-dependent  caldesmon kinase  with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition", "triple_list": [["similar", "PRODUCT-OF", "caldesmon kinase"]]}, {"text": "Felodipine and the  p-chloro  analogue inhibited Ca2+/calmodulin-dependent  caldesmon kinase  with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition", "triple_list": [["Ca2+/calmodulin-dependent", "PRODUCT-OF", "caldesmon kinase"]]}, {"text": "Similarly,  felodipine  and the p-chloro analogue inhibited  myosin light chain kinase  activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact myosin (IC50 = 11.0 microM) was used as substrate", "triple_list": [["kD", "ANTAGONIST", "myosin light chain kinase"]]}, {"text": "Effects of  felodipine  (a dihydropyridine  calcium channel  blocker) and analogues on calmodulin-dependent enzymes", "triple_list": [["calmodulin-dependent", "AGONIST", "calcium channel"]]}, {"text": "Effects of felodipine (a  dihydropyridine   calcium channel  blocker) and analogues on calmodulin-dependent enzymes", "triple_list": [["dihydropyridine", "ANTAGONIST", "Effects"]]}, {"text": "Similarly, felodipine and the  p-chloro  analogue inhibited  myosin light chain kinase  activity whether the isolated 20 kD light chain (IC50 = 12.6 microM) or intact myosin (IC50 = 11.0 microM) was used as substrate", "triple_list": [["p-chloro", "ANTAGONIST", "20"]]}, {"text": " Felodipine  and the p-chloro analogue inhibited the actin-activated  Mg2+-ATPase  activity of smooth muscle myosin (IC50 = 25.1 microM)", "triple_list": [["Felodipine", "AGONIST", "of"]]}, {"text": " Felodipine  and the p-chloro analogue inhibited the actin-activated Mg2+-ATPase activity of smooth muscle  myosin  (IC50 = 25.1 microM)", "triple_list": [["Felodipine", "ACTIVATOR", "muscle"]]}, {"text": "In all patients  loperamide  induced a significant fall in plasma  ACTH  levels", "triple_list": [["a", "AGONIST", "ACTH"]]}, {"text": " Loperamide  is a peripheral opiate agonist able to inhibit  ACTH  secretion", "triple_list": [["Loperamide", "PRODUCT-OF", "peripheral"]]}, {"text": " CRH  caused a rise in plasma ACTH after both  loperamide  (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of  CRH  induced ACTH secretion was significantly lower after  loperamide   These data demonstrate that  loperamide  differently modifies the stimulatory action of LVP and  CRH  on ACTH secretion: namely, LVP and  loperamide  act in an additive manner, while  CRH  and  loperamide  interact in a non additive way", "triple_list": [["of", "AGONIST", "CRH"]]}, {"text": "CRH caused a rise in plasma  ACTH  after both  loperamide  (from 30 +/- 16.6 to a peak of 108 +/- 31 pmol/l) and placebo (from 98.5 +/- 47 to 211 +/- 61.7 pmol/l): the interaction between treatments and time was significant, and the first phase of CRH-induced  ACTH  secretion was significantly lower after  loperamide   These data demonstrate that  loperamide  differently modifies the stimulatory action of LVP and CRH on  ACTH  secretion: namely, LVP and  loperamide  act in an additive manner, while CRH and  loperamide  interact in a non additive way", "triple_list": [["61.7", "ACTIVATOR", "ACTH"]]}, {"text": "A  naloxone-steroid hybrid azine  with selective and long-acting opioid antagonism at  delta receptors  in vitro", "triple_list": [["long-acting", "PRODUCT-OF", "delta receptors"]]}, {"text": "Actions of  nizatidine   a selective  histamine H2-receptor  antagonist, on gastric acid secretion in dogs, rats and frogs", "triple_list": [["and", "ACTIVATOR", "histamine H2-receptor"]]}, {"text": " Nizatidine  (LY139037), a selective  histamine H2-receptor  antagonist, is a potent inhibitor of gastric acid secretion", "triple_list": [["Nizatidine", "DOWNREGULATOR", "secretion"]]}, {"text": "Nizatidine ( LY139037  , a selective  histamine H2-receptor  antagonist, is a potent inhibitor of gastric acid secretion", "triple_list": [["histamine", "ACTIVATOR", "histamine H2-receptor"]]}, {"text": " ORF 17583   a  histamine H2-receptor  antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o", "triple_list": [["=", "ACTIVATOR", "histamine H2-receptor"]]}, {"text": "Effects of  ORF 17583   other  histamine H2-receptor  antagonists and omeprazole on gastric acid secretory states in rats and dogs", "triple_list": [["ORF 17583", "AGONIST", "states"]]}, {"text": " Acetylcholinesterase  (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by  oximes  due to dealkylation of the soman-enzyme complex", "triple_list": [["oximes", "ANTAGONIST", "reactivation"]]}, {"text": "Acetylcholinesterase ( AChE   inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by  oximes  due to dealkylation of the soman-enzyme complex", "triple_list": [["Acetylcholinesterase", "PRODUCT-OF", "AChE"]]}, {"text": "The effect of the four mono- and bisquaternary ammonium compounds tetramethylammonium (TMA), hexamethonium, decamethonium and suxamethonium on the reactivatability of  soman  inhibited, solubilized  AChE  from human erythrocytes was investigated in vitro", "triple_list": [["soman", "PRODUCT-OF", "bisquaternary"]]}, {"text": " Acetylcholinesterase  (AChE) inhibited by the  organophosphate  soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex", "triple_list": [["by", "ACTIVATOR", "Acetylcholinesterase"]]}, {"text": "Acetylcholinesterase ( AChE   inhibited by the  organophosphate  soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex", "triple_list": [["organophosphate", "ACTIVATOR", "becomes"]]}, {"text": " Acetylcholinesterase  (AChE) inhibited by the organophosphate  soman  (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the  soman -enzyme complex", "triple_list": [["soman", "ANTAGONIST", "the"]]}, {"text": "Acetylcholinesterase ( AChE   inhibited by the organophosphate  soman  (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the  soman -enzyme complex", "triple_list": [["soman", "ACTIVATOR", "organophosphate"]]}, {"text": " Acetylcholinesterase  (AChE) inhibited by the organophosphate soman ( 1,2,2-trimethyl-propylmethylphosphonofluoridate   rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex", "triple_list": [["1,2,2-trimethyl-propylmethylphosphonofluoridate", "PRODUCT-OF", "complex"]]}, {"text": "Acetylcholinesterase ( AChE   inhibited by the organophosphate soman ( 1,2,2-trimethyl-propylmethylphosphonofluoridate   rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex", "triple_list": [["1,2,2-trimethyl-propylmethylphosphonofluoridate", "PRODUCT-OF", "by"]]}, {"text": "Effects of some mono- and bisquaternary ammonium compounds on the reactivatability of  soman  inhibited  human acetylcholinesterase  in vitro", "triple_list": [["soman", "AGONIST", "inhibited"]]}, {"text": "If the effectors were added after 5 min of aging they increased the activity of  soman  inhibited  AChE   but to a considerably smaller extent than HI 6", "triple_list": [["were", "ANTAGONIST", "AChE"]]}, {"text": "Pharmacological properties of  lorglumide  as a member of a new class of  cholecystokinin  antagonists", "triple_list": [["a", "AGONIST", "cholecystokinin"]]}, {"text": "The most potent compound,  D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid  (lorglumide, CR 1409), has a great affinity for the pancreatic  CCK  receptors and is a competitive, specific and potent  CCK  antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the  CCK -induced amylase secretion of isolated pancreatic acini", "triple_list": [["the", "AGONIST", "CCK"]]}, {"text": "Derivatives of  5-(dipentylamino)-5-oxo-pentanoic acid  are a new class of non-peptide cholecystokinin ( CCK   antagonists", "triple_list": [["5-(dipentylamino)-5-oxo-pentanoic acid", "PRODUCT-OF", "non-peptide"]]}, {"text": "Derivatives of  5-(dipentylamino)-5-oxo-pentanoic acid  are a new class of non-peptide  cholecystokinin  (CCK) antagonists", "triple_list": [["acid", "AGONIST", "cholecystokinin"]]}, {"text": "The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid ( lorglumide   CR 1409), has a great affinity for the pancreatic  CCK  receptors and is a competitive, specific and potent  CCK  antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the  CCK -induced amylase secretion of isolated pancreatic acini", "triple_list": [["lorglumide", "DOWNREGULATOR", "tanoic"]]}, {"text": "The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide,  CR 1409  , has a great affinity for the pancreatic  CCK  receptors and is a competitive, specific and potent  CCK  antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the  CCK -induced amylase secretion of isolated pancreatic acini", "triple_list": [["CR 1409", "ACTIVATOR", "on"]]}, {"text": "The activation may be accelerated by an acute inflammatory process provoked by  oleate   which is supported by such clinical manifestations as mild fever, retrosternal pain leukocytosis and an increase in plasma  fibrinogen  level which was observed in all during the period.", "triple_list": [["pain", "AGONIST", "fibrinogen"]]}, {"text": "In vitro studies, however, revealed that  EO  inhibits  fibrin  clot formation because of the Ca2+-chelating ability of its constituent ethanolamine, although oleate or benzyl alcohol exhibited procoagulant activity in FPA formation in vitro", "triple_list": [["constituent", "PRODUCT-OF", "fibrin"]]}, {"text": "The efficacy of  astemizole   a new, long acting, oral  histamine H1-receptor  antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982", "triple_list": [["for", "DOWNREGULATOR", "histamine H1-receptor"]]}, {"text": " Astemizole   a potent  histamine H1-receptor  antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels", "triple_list": [["rhinoconjunctivitis,", "PRODUCT-OF", "histamine H1-receptor"]]}, {"text": "Selective precipitation of cytosol receptors with 36%  (NH4)2SO4  reduced  CBG  concentrations to negligible levels", "triple_list": [["(NH4)2SO4", "ANTAGONIST", "to"]]}, {"text": "Although inhibition of  LH  release can be achieved by  estrogen  and progestins, an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an  LH RH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the  LH  responsiveness to  LH RH.", "triple_list": [["the", "AGONIST", "LH"]]}, {"text": "Although inhibition of  LH  release can be achieved by estrogen and  progestins   an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an  LH RH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the  LH  responsiveness to  LH RH.", "triple_list": [["progestins", "ACTIVATOR", "a"]]}, {"text": "The results of this study suggest that  noradrenaline  predominantly, but not exclusively, mediates contraction of rat aorta through the activation of an  alphalD-adrenoceptor  ", "triple_list": [["contraction", "DOWNREGULATOR", "alphalD-adrenoceptor"]]}, {"text": " Alprenolol  and BAAM at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of  beta-adrenoceptor  blockade", "triple_list": [["Alprenolol", "ANTAGONIST", "the"]]}, {"text": "Alprenolol and  BAAM  at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of  beta-adrenoceptor  blockade", "triple_list": [["and", "AGONIST", "beta-adrenoceptor"]]}, {"text": "Alprenolol and BAAM also caused surmountable antagonism of  isoprenaline  responses, and this  beta 1-adrenoceptor  antagonism was slowly reversible", "triple_list": [["surmountable", "ANTAGONIST", "beta 1-adrenoceptor"]]}, {"text": "We conclude that  alprenolol  and BAAM are competitive slowly reversible  beta 1-adrenoceptor  antagonists on rat left atria.", "triple_list": [["alprenolol", "PRODUCT-OF", "are"]]}, {"text": "We conclude that alprenolol and  BAAM  are competitive slowly reversible  beta 1-adrenoceptor  antagonists on rat left atria.", "triple_list": [["beta", "AGONIST", "beta 1-adrenoceptor"]]}, {"text": " Alprenolol  and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the  beta 1-adrenoceptors  of rat left atria", "triple_list": [["left", "ACTIVATOR", "beta 1-adrenoceptors"]]}, {"text": "Alprenolol and  bromoacetylalprenololmenthane  are competitive slowly reversible antagonists at the  beta 1-adrenoceptors  of rat left atria", "triple_list": [["Alprenolol", "DOWNREGULATOR", "beta 1-adrenoceptors"]]}, {"text": " Alprenolol  and BAAM also caused surmountable antagonism of isoprenaline responses, and this  beta 1-adrenoceptor  antagonism was slowly reversible", "triple_list": [["Alprenolol", "DOWNREGULATOR", "Alprenolol"]]}, {"text": "Alprenolol and  BAAM  also caused surmountable antagonism of isoprenaline responses, and this  beta 1-adrenoceptor  antagonism was slowly reversible", "triple_list": [["BAAM", "PRODUCT-OF", "also"]]}, {"text": "In HEK-293 cells stably transfected with this receptor,  serotonin  elicits a potent stimulation of  adenylyl cyclase  activity, which is blocked by antipsychotic and antidepressant drugs", "triple_list": [["serotonin", "PRODUCT-OF", "adenylyl"]]}, {"text": "Both  5 alpha-NET  and 3 beta, 5 alpha-NET  blocked the  PR  down-regulation induced by P4 as assessed by Western and Northern blot methods", "triple_list": [["Northern", "PRODUCT-OF", "PR"]]}, {"text": "Both 5 alpha-NET and  3 beta,5 alpha-NET  blocked the  PR  down-regulation induced by P4 as assessed by Western and Northern blot methods", "triple_list": [["3 beta,5 alpha-NET", "PRODUCT-OF", "by"]]}, {"text": "The inhibition of UG synthesis and  PR  down-regulation by  5 alpha-NET  and 3 beta, 5 alpha-NET  indicates that these NET metabolites possess antiprogestational properties.", "triple_list": [["5 alpha-NET", "AGONIST", "5"]]}, {"text": "As determined by Western and Northern blot analyses,  5 alpha-NET  inhibited the P4-induced  UG  gene expression in a dose-dependent manner", "triple_list": [["alpha-NET", "ACTIVATOR", "UG"]]}, {"text": "The estrogenic agent  3 beta,5 alpha-NET  and estradiol at a dose of 1.0 mg also inhibited the  UG  gene expression induced by P4", "triple_list": [["3 beta,5 alpha-NET", "PRODUCT-OF", "by"]]}, {"text": "The estrogenic agent 3 beta,5 alpha-NET and  estradiol  at a dose of 1.0 mg also inhibited the  UG  gene expression induced by P4", "triple_list": [["also", "AGONIST", "UG"]]}, {"text": "The inhibition of  UG  synthesis and PR down-regulation by  5 alpha-NET  and 3 beta, 5 alpha-NET  indicates that these NET metabolites possess antiprogestational properties.", "triple_list": [["and", "ANTAGONIST", "UG"]]}, {"text": "The inhibition of  UG  synthesis and PR down-regulation by 5 alpha-NET and  3 beta,5 alpha-NET  indicates that these NET metabolites possess antiprogestational properties.", "triple_list": [["PR", "ANTAGONIST", "UG"]]}, {"text": "The inhibition of UG synthesis and  PR  down-regulation by 5 alpha-NET and  3 beta,5 alpha-NET  indicates that these NET metabolites possess antiprogestational properties.", "triple_list": [["alpha-NET", "ACTIVATOR", "PR"]]}, {"text": "The inhibition of  UG  synthesis and PR down-regulation by 5 alpha- NET  and 3 beta,5 alpha- NET  indicates that these  NET  metabolites possess antiprogestational properties.", "triple_list": [["NET", "ANTAGONIST", "properties."]]}, {"text": "The inhibition of UG synthesis and  PR  down-regulation by 5 alpha- NET  and 3 beta,5 alpha- NET  indicates that these  NET  metabolites possess antiprogestational properties.", "triple_list": [["NET", "PRODUCT-OF", "antiprogestational"]]}, {"text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the  dopamine D1 receptor  antagonist  SCH 39166  ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg)", "triple_list": [["mg/kg)", "AGONIST", "dopamine D1 receptor"]]}, {"text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the  dopamine D1 receptor  antagonist SCH 39166 ( (-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine   and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg)", "triple_list": [["D2", "ACTIVATOR", "dopamine D1 receptor"]]}, {"text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the  dopamine D2 receptor  antagonist  raclopride  (both at 0.003-0.03 mg/kg)", "triple_list": [["mg/kg)", "DOWNREGULATOR", "dopamine D2 receptor"]]}, {"text": " Indomethacin  inhibited both  hCOX-1  and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2", "triple_list": [["Indomethacin", "PRODUCT-OF", "Dup-697"]]}, {"text": " Indomethacin  inhibited both hCOX-1 and  hCOX-2   whereas NS-398 and Dup-697 selectively inhibited  hCOX-2 ", "triple_list": [["Indomethacin", "ANTAGONIST", "Dup-697"]]}, {"text": "Indomethacin inhibited both hCOX-1 and  hCOX-2 , whereas  NS-398  and Dup-697 selectively inhibited  hCOX-2   Both  NS-398  and Dup-697 exhibited time-dependent inactivation of  hCOX-2 , as did indomethacin on both enzymes", "triple_list": [[",", "ANTAGONIST", "hCOX-2"]]}, {"text": "Indomethacin inhibited both hCOX-1 and  hCOX-2 , whereas NS-398 and  Dup-697  selectively inhibited  hCOX-2   Both NS-398 and  Dup-697  exhibited time-dependent inactivation of  hCOX-2 , as did indomethacin on both enzymes", "triple_list": [["Dup-697", "ACTIVATOR", "on"]]}, {"text": "Both  NS-398  and Dup-697 exhibited time-dependent inactivation of  hCOX-2   as did indomethacin on both enzymes", "triple_list": [["hCOX-2", "ACTIVATOR", "hCOX-2"]]}, {"text": "Both NS-398 and  Dup-697  exhibited time-dependent inactivation of  hCOX-2   as did indomethacin on both enzymes", "triple_list": [["Dup-697", "AGONIST", "on"]]}, {"text": "Both NS-398 and Dup-697 exhibited time-dependent inactivation of  hCOX-2   as did  indomethacin  on both enzymes", "triple_list": [["both", "PRODUCT-OF", "hCOX-2"]]}, {"text": "The competitive inhibitor of  hCOX-1    mefenamic acid   also displayed competitive inhibition of hCOX-2", "triple_list": [["displayed", "ANTAGONIST", "hCOX-1"]]}, {"text": "The competitive inhibitor of hCOX-1,  mefenamic acid   also displayed competitive inhibition of  hCOX-2   These results demonstrate the ability to generate selective non-steroidal anti-inflammatory drugs (NSAIDs), which could provide useful improvement therapeutically in the treatment of chronic inflammatory disease.", "triple_list": [["in", "AGONIST", "hCOX-2"]]}, {"text": "The enzyme  cyclo-oxygenase  catalyses the oxygenation of arachidonic acid, leading to the formation of  prostaglandins   Recently two forms of  cyclo-oxygenase  have been described: a constitutive (COX-1) enzyme present in most cells and tissues, and an inducible (COX-2) isoenzyme observed in many cells in response to pro-inflammatory cytokines", "triple_list": [["cyclo-oxygenase", "DOWNREGULATOR", "cyclo-oxygenase"]]}, {"text": "The enzyme  cyclo-oxygenase  catalyses the oxygenation of  arachidonic acid   leading to the formation of prostaglandins", "triple_list": [["to", "ACTIVATOR", "cyclo-oxygenase"]]}, {"text": " hCOX-1  had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for  arachidonate  and Vmax", "triple_list": [["arachidonate", "AGONIST", "13.8"]]}, {"text": "of 1500 nmol of O2/nmol of enzyme, whereas  hCOX-2  had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for  arachidonate  and a Vmax", "triple_list": [["arachidonate", "ACTIVATOR", "enzyme,"]]}, {"text": "The channel activators  avermectin  and moxidectin usually retain their inhibitory potency in the  Rdl  subunit mutants", "triple_list": [["potency", "ACTIVATOR", "Rdl"]]}, {"text": "The channel activators avermectin and  moxidectin  usually retain their inhibitory potency in the  Rdl  subunit mutants", "triple_list": [["moxidectin", "ANTAGONIST", "and"]]}, {"text": " Agmatine   locally synthesized, is an endogenous agonist at  imidazoline receptors   a noncatecholamine ligand at alpha 2-adrenergic receptors and may act as a neurotransmitter.", "triple_list": [["Agmatine", "DOWNREGULATOR", "synthesized,"]]}, {"text": "Both  BRL  and SAL produced a significant increase in postural finger tremor in keeping with  beta 2-adrenoceptor  stimulation, and this response was totally abolished by pretreatment with N20", "triple_list": [["with", "DOWNREGULATOR", "beta 2-adrenoceptor"]]}, {"text": "Both BRL and  SAL  produced a significant increase in postural finger tremor in keeping with  beta 2-adrenoceptor  stimulation, and this response was totally abolished by pretreatment with N20", "triple_list": [["postural", "AGONIST", "beta 2-adrenoceptor"]]}, {"text": "Cardiac effects of the  beta 3-adrenoceptor  agonist  BRL35135  in man", "triple_list": [["BRL35135", "ACTIVATOR", "of"]]}, {"text": "The aim of the present study was to evaluate the cardiac effects of the  beta 3-adrenoceptor  agonist  BRL35135   and determine whether beta 3-receptors are involved in mediating chronotropic or inotropic responses in man", "triple_list": [["3-adrenoceptor", "DOWNREGULATOR", "beta 3-adrenoceptor"]]}, {"text": "Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective  beta 2-adrenoceptor  agonist  salbutamol  8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors", "triple_list": [["salbutamol", "ANTAGONIST", "20"]]}, {"text": "Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective  beta 2-adrenoceptor  agonist salbutamol 8 mg ( SAL  , after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors", "triple_list": [["oral", "ACTIVATOR", "beta 2-adrenoceptor"]]}, {"text": "Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL),  bisoprolol  5 mg (B5) as a selective  beta 1-adrenoceptor  antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors", "triple_list": [["bisoprolol", "AGONIST", "doses"]]}, {"text": "In catalytic properties, mouse  CA V  is closest to CA I; however, in inhibition by  acetazolamide   ethoxzolamide, and cyanate,  CA V  is very similar to CA II", "triple_list": [["acetazolamide", "AGONIST", "inhibition"]]}, {"text": "In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by  acetazolamide   ethoxzolamide, and cyanate, CA V is very similar to  CA II   Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway", "triple_list": [["acetazolamide", "PRODUCT-OF", "pathway"]]}, {"text": "In catalytic properties, mouse  CA V  is closest to CA I; however, in inhibition by acetazolamide,  ethoxzolamide   and cyanate,  CA V  is very similar to CA II", "triple_list": [["however,", "ACTIVATOR", "CA V"]]}, {"text": "In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide,  ethoxzolamide   and cyanate, CA V is very similar to  CA II   Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway", "triple_list": [["a", "PRODUCT-OF", "CA II"]]}, {"text": "In catalytic properties, mouse  CA V  is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and  cyanate    CA V  is very similar to CA II", "triple_list": [["cyanate", "ANTAGONIST", "catalytic"]]}, {"text": "In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and  cyanate   CA V is very similar to  CA II   Mouse CA V has a tyrosine at position 64, where the highly active isozyme II has histidine serving as a proton shuttle in the catalytic pathway", "triple_list": [["cyanate", "ANTAGONIST", "II"]]}, {"text": "It is concluded that  D-1997  contracts the canine basilar artery by stimulating  5-HT1-like receptors  unrelated to either the 5-HT1A or 5-HT1B receptor subtypes", "triple_list": [["D-1997", "ANTAGONIST", "5-HT1B"]]}, {"text": "It is concluded that  D-1997  contracts the canine basilar artery by stimulating 5-HT1-like receptors unrelated to either the  5-HT1A  or 5-HT1B receptor subtypes", "triple_list": [["D-1997", "AGONIST", "5-HT1A"]]}, {"text": "It is concluded that  D-1997  contracts the canine basilar artery by stimulating 5-HT1-like receptors unrelated to either the 5-HT1A or  5-HT1B  receptor subtypes", "triple_list": [["artery", "PRODUCT-OF", "5-HT1B"]]}, {"text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the  beta-adrenoceptor  blocker with high affinity for 5-HT1A and 5-HT1B binding sites  (+/-)-pindolol  (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)", "triple_list": [["spiroxatrine", "ACTIVATOR", "beta-adrenoceptor"]]}, {"text": " 2-(2-Aminoethyl)-quinoline  (D-1997): a novel agonist at  5-hydroxytryptamine1-like receptors  in the canine basilar artery", "triple_list": [["2-(2-Aminoethyl)-quinoline", "ANTAGONIST", "artery"]]}, {"text": "2-(2-Aminoethyl)-quinoline ( D-1997  : a novel agonist at  5-hydroxytryptamine1-like receptors  in the canine basilar artery", "triple_list": [["D-1997", "ACTIVATOR", "receptors"]]}, {"text": "In contrast, the  D-1997  induced responses were potently and concentration-dependently antagonized by the mixed  5-HT1-like  and 5-HT2 receptor antagonist methiothepin (0.01-1 microM)", "triple_list": [["and", "DOWNREGULATOR", "5-HT1-like"]]}, {"text": "In contrast, the  D-1997  induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and  5-HT2 receptor  antagonist methiothepin (0.01-1 microM)", "triple_list": [["the", "ANTAGONIST", "5-HT2 receptor"]]}, {"text": "In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed  5-HT1-like  and 5-HT2 receptor antagonist  methiothepin  (0.01-1 microM)", "triple_list": [["methiothepin", "PRODUCT-OF", "(0.01-1"]]}, {"text": "In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and  5-HT2 receptor  antagonist  methiothepin  (0.01-1 microM)", "triple_list": [["methiothepin", "ACTIVATOR", "were"]]}, {"text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the  5-HT2 receptor  antagonist  ketanserin  (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)", "triple_list": [["ketanserin", "PRODUCT-OF", "microM),"]]}, {"text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the  5-HT3  and 5-HT4 receptor antagonist ICS205930 ( tropisetron   0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)", "triple_list": [["tropisetron", "PRODUCT-OF", "antagonist"]]}, {"text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and  5-HT4  receptor antagonist ICS205930 ( tropisetron   0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)", "triple_list": [["tropisetron", "AGONIST", "not"]]}, {"text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the  5-HT1A  receptor antagonist  spiroxatrine  (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for  5-HT1A  and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM)", "triple_list": [["the", "PRODUCT-OF", "5-HT1A"]]}, {"text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the  alpha 1-adrenoceptor  antagonist  prazosin  (0.01-1 microM)", "triple_list": [["of", "PRODUCT-OF", "alpha 1-adrenoceptor"]]}, {"text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its  proline-42-to-alanine  mutant (Pro42Ala) have been studied by monitoring tyrosine burial and  2'-cytidine monophosphate  (2'CMP) inhibitor binding", "triple_list": [["2'-cytidine monophosphate", "ANTAGONIST", "inhibitor"]]}, {"text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant ( Pro42Ala   have been studied by monitoring tyrosine burial and  2'-cytidine monophosphate  (2'CMP) inhibitor binding", "triple_list": [["2'-cytidine monophosphate", "PRODUCT-OF", "disulfide-intact"]]}, {"text": "The refolding kinetics of guanidine-denatured disulfide-intact  bovine pancreatic ribonuclease A  (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and  2'-cytidine monophosphate  (2'CMP) inhibitor binding", "triple_list": [["2'-cytidine monophosphate", "PRODUCT-OF", "tyrosine"]]}, {"text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A ( RNase A   and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and  2'-cytidine monophosphate  (2'CMP) inhibitor binding", "triple_list": [["2'-cytidine monophosphate", "AGONIST", "have"]]}, {"text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its  proline-42-to-alanine  mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate ( 2'CMP   inhibitor binding", "triple_list": [["refolding", "PRODUCT-OF", "proline-42-to-alanine"]]}, {"text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant ( Pro42Ala   have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate ( 2'CMP   inhibitor binding", "triple_list": [["2'CMP", "AGONIST", "monitoring"]]}, {"text": "The refolding kinetics of guanidine-denatured disulfide-intact  bovine pancreatic ribonuclease A  (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate ( 2'CMP   inhibitor binding", "triple_list": [["proline-42-to-alanine", "ANTAGONIST", "bovine pancreatic ribonuclease A"]]}, {"text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A ( RNase A   and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate ( 2'CMP   inhibitor binding", "triple_list": [["2'CMP", "AGONIST", "A"]]}, {"text": "The folding rate for wild-type  RNase A  is faster in the presence of the inhibitor  2'CMP  than in its absence, indicating that the transition-state structure in the rate-determining step is stabilized by  2'CMP ", "triple_list": [["2'CMP", "AGONIST", "rate-determining"]]}, {"text": "The anti-inflammatory drugs  sodium salicylate  and aspirin inhibited the activation of  NF-kappa B   which further explains the mechanism of action of these drugs", "triple_list": [["of", "ACTIVATOR", "NF-kappa B"]]}, {"text": "The anti-inflammatory drugs sodium salicylate and  aspirin  inhibited the activation of  NF-kappa B   which further explains the mechanism of action of these drugs", "triple_list": [["aspirin", "PRODUCT-OF", "NF-kappa"]]}, {"text": " Sodium salicylate  and aspirin also inhibited  NF-kappa B  dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.", "triple_list": [["inhibited", "AGONIST", "NF-kappa B"]]}, {"text": " Sodium salicylate  and aspirin also inhibited NF-kappa B-dependent transcription from the  Ig kappa  enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.", "triple_list": [["Sodium", "PRODUCT-OF", "Ig kappa"]]}, {"text": "Sodium salicylate and  aspirin  also inhibited  NF-kappa B  dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.", "triple_list": [["aspirin", "PRODUCT-OF", "dependent"]]}, {"text": "Sodium salicylate and  aspirin  also inhibited NF-kappa B-dependent transcription from the  Ig kappa  enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.", "triple_list": [["(HIV)", "AGONIST", "Ig kappa"]]}, {"text": "These nonadrenoceptor binding sites may explain certain novel platelet aggregatory properties previously ascribed to  clonidine  and endogenous  clonidine -displacing substance(s), and may serve as markers of  imidazoline receptors  in humans.", "triple_list": [["clonidine", "DOWNREGULATOR", "and"]]}, {"text": " DEX  enhanced the ratio  IFN-gamma  IL-4 (mean +/- SEM: control, 28.7 +/- 17.6; with 10-7 M  DEX , 55.0 +/- 27.5, P<0.005)", "triple_list": [["+/-", "ANTAGONIST", "IFN-gamma"]]}, {"text": " DEX  enhanced the ratio IFN-gamma/ IL-4  (mean +/- SEM: control, 28.7 +/- 17.6; with 10-7 M  DEX , 55.0 +/- 27.5, P<0.005)", "triple_list": [["DEX", "AGONIST", "DEX"]]}, {"text": "Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and  IL-2R alpha  expression and proliferation; 1) In low IL-2 producers  DEX  blocked IL-2 production and decreased  IL-2R alpha  expression and proliferation; 2) In high IL-2 producers  DEX  inhibited IL-2 production partially and enhanced  IL-2R alpha  expression and proliferation", "triple_list": [["DEX", "PRODUCT-OF", "production"]]}, {"text": "Dexamethasone ( DEX   inhibited the anti- CD3  induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested", "triple_list": [["DEX", "PRODUCT-OF", "("]]}, {"text": "Dexamethasone ( DEX   inhibited the anti-CD3-induced production of  IL-4   IL-5 and IFN-gamma in all 20 clones tested", "triple_list": [["DEX", "ANTAGONIST", "production"]]}, {"text": "Dexamethasone ( DEX   inhibited the anti-CD3-induced production of IL-4,  IL-5  and IFN-gamma in all 20 clones tested", "triple_list": [["IL-5", "PRODUCT-OF", "IL-5"]]}, {"text": "Dexamethasone ( DEX   inhibited the anti-CD3-induced production of IL-4, IL-5 and  IFN-gamma  in all 20 clones tested", "triple_list": [["clones", "PRODUCT-OF", "IFN-gamma"]]}, {"text": " GCS  therapy results in reduced mRNA expression of  interleukin-4  (IL-4) and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma", "triple_list": [["of", "ANTAGONIST", "interleukin-4"]]}, {"text": " GCS  therapy results in reduced mRNA expression of interleukin-4 ( IL-4   and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma", "triple_list": [["GCS", "ACTIVATOR", "IFN-gamma"]]}, {"text": " GCS  therapy results in reduced mRNA expression of interleukin-4 (IL-4) and  IL-5  in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma", "triple_list": [["but", "ACTIVATOR", "IL-5"]]}, {"text": "Interestingly, two categories of clones were distinguished based on the effects of GCS on  IL-2  production and  IL-2 R alpha expression and proliferation; 1) In low  IL-2  producers  DEX  blocked  IL-2  production and decreased  IL-2 R alpha expression and proliferation; 2) In high  IL-2  producers  DEX  inhibited  IL-2  production partially and enhanced  IL-2 R alpha expression and proliferation", "triple_list": [["DEX", "ANTAGONIST", "2)"]]}, {"text": "Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and  IL-2R alpha  expression and proliferation; 1) In low IL-2 producers  DEX  blocked IL-2 production and decreased  IL-2R alpha  expression and proliferation; 2) In high IL-2 producers  DEX  inhibited IL-2 production partially and enhanced  IL-2R alpha  expression and proliferation", "triple_list": [["DEX", "AGONIST", "of"]]}, {"text": "Interestingly, two categories of clones were distinguished based on the effects of GCS on  IL-2  production and  IL-2 R alpha expression and proliferation; 1) In low  IL-2  producers  DEX  blocked  IL-2  production and decreased  IL-2 R alpha expression and proliferation; 2) In high  IL-2  producers  DEX  inhibited  IL-2  production partially and enhanced  IL-2 R alpha expression and proliferation", "triple_list": [["DEX", "ACTIVATOR", "DEX"]]}, {"text": "In conclusion, the production of  IL-4  and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by  DEX  than that of IFN-gamma, which may account for the therapeutic effects of glucocorticosteroids in patients with asthma", "triple_list": [["effects", "PRODUCT-OF", "IL-4"]]}, {"text": "In conclusion, the production of IL-4 and  IL-5  by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by  DEX  than that of IFN-gamma, which may account for the therapeutic effects of glucocorticosteroids in patients with asthma", "triple_list": [["DEX", "ANTAGONIST", "blood)"]]}, {"text": "In conclusion, the production of IL-4 and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by  DEX  than that of  IFN-gamma   which may account for the therapeutic effects of glucocorticosteroids in patients with asthma", "triple_list": [["DEX", "ANTAGONIST", "IFN-gamma"]]}, {"text": "In vitro studies with blood-derived T cells, however, show inhibition of all three  cytokines  by  GCS   We studied the effects of  GCS  on T cells from BAL in vitro, namely Th0-, Th1, and Th2-like clones; and we compared BAL- with blood-derived clones", "triple_list": [["GCS", "ACTIVATOR", "T"]]}, {"text": " Dexamethasone  (DEX) inhibited the anti- CD3  induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested", "triple_list": [["IL-5", "AGONIST", "CD3"]]}, {"text": " Dexamethasone  (DEX) inhibited the anti-CD3-induced production of  IL-4   IL-5 and IFN-gamma in all 20 clones tested", "triple_list": [["clones", "PRODUCT-OF", "IL-4"]]}, {"text": " Dexamethasone  (DEX) inhibited the anti-CD3-induced production of IL-4,  IL-5  and IFN-gamma in all 20 clones tested", "triple_list": [["Dexamethasone", "ANTAGONIST", "in"]]}, {"text": " Dexamethasone  (DEX) inhibited the anti-CD3-induced production of IL-4, IL-5 and  IFN-gamma  in all 20 clones tested", "triple_list": [["IL-4,", "AGONIST", "IFN-gamma"]]}, {"text": "Structural features of the central cannabinoid  CB1  receptor involved in the binding of the specific  CB1  antagonist  SR 141716A   The antagonist  SR 141716A  has a high specificity for the central  CB1  cannabinoid receptor and negligeable affinity for the peripheral CB2 receptor, making it an excellent tool for probing receptor structure-activity relationships", "triple_list": [["SR 141716A", "DOWNREGULATOR", "of"]]}, {"text": "Histamine and  Ca  added to NSAIDs amplified the activating effect of the latter on  CA II   Association of PGE2 or acetazolamide to NSAIDs reduced NSAID-induced activation of CA I and  CA II ", "triple_list": [["Ca", "AGONIST", "the"]]}, {"text": " Indomethacin  abolished the inhibitory effect of acetazolamide on  CA I  and  CA I I", "triple_list": [["Indomethacin", "PRODUCT-OF", "and"]]}, {"text": " Indomethacin  abolished the inhibitory effect of acetazolamide on CA I and  CA II   Our data imply that between CA and cyclooxygenase there is an inverse relationship, CA activation being accompanied by reduction of cyclooxygenase activity, a reduction achieved by the pH modifications induced by CA activation", "triple_list": [["CA", "DOWNREGULATOR", "CA II"]]}, {"text": "Association of PGE2 or  acetazolamide  to NSAIDs reduced NSAID-induced activation of  CA I  and  CA I I", "triple_list": [["reduced", "PRODUCT-OF", "CA I"]]}, {"text": "Association of PGE2 or  acetazolamide  to NSAIDs reduced NSAID-induced activation of CA I and  CA II   Indomethacin abolished the inhibitory effect of  acetazolamide  on CA I and  CA II ", "triple_list": [["acetazolamide", "AGONIST", "II"]]}, {"text": "Indomethacin abolished the inhibitory effect of  acetazolamide  on  CA I  and  CA I I", "triple_list": [["acetazolamide", "ACTIVATOR", "and"]]}, {"text": "Indomethacin abolished the inhibitory effect of  acetazolamide  on CA I and  CA II   Our data imply that between CA and cyclooxygenase there is an inverse relationship, CA activation being accompanied by reduction of cyclooxygenase activity, a reduction achieved by the pH modifications induced by CA activation", "triple_list": [["and", "ACTIVATOR", "CA II"]]}, {"text": "Previous studies by this research team proved that vasodilating  prostaglandins  (PGs) E1, E2 and I2 inhibit  carbonic anhydrase  (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs", "triple_list": [["gastric", "ACTIVATOR", "carbonic anhydrase"]]}, {"text": "Previous studies by this research team proved that vasodilating  prostaglandins  (PGs) E1, E2 and I2 inhibit carbonic anhydrase ( CA   in vitro and in vivo, which suggested involvement of  CA  in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs", "triple_list": [["vasodilating", "ANTAGONIST", "CA"]]}, {"text": "Previous studies by this research team proved that vasodilating prostaglandins ( PGs   E1, E2 and I2 inhibit  carbonic anhydrase  (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of  PGs ", "triple_list": [["E2", "PRODUCT-OF", "carbonic anhydrase"]]}, {"text": "Previous studies by this research team proved that vasodilating prostaglandins ( PGs   E1, E2 and I2 inhibit carbonic anhydrase ( CA   in vitro and in vivo, which suggested involvement of  CA  in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of  PGs ", "triple_list": [["PGs", "ACTIVATOR", "CA"]]}, {"text": " (+)-Tamsulosin   (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned  human alpha 1D adrenoceptors   The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15/2739 > RS 17053 = SNAP 1069", "triple_list": [[">", "AGONIST", "human alpha 1D adrenoceptors"]]}, {"text": "(+)-Tamsulosin,  (-)-tamsulosin   SL 89,0591, Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned  human alpha 1D adrenoceptors   The following rank order was obtained: prazosin =  (-)-tamsulosin  > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15/2739 > RS 17053 = SNAP 1069", "triple_list": [["(-)-tamsulosin", "AGONIST", "cloned"]]}, {"text": "(+)-Tamsulosin, (-)-tamsulosin,  SL 89,0591   Rec 15/2739, SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned  human alpha 1D adrenoceptors   The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin >  SL 89,0591  = (+)-tamsulosin > Rec 15/2739 > RS 17053 = SNAP 1069", "triple_list": [["rank", "DOWNREGULATOR", "human alpha 1D adrenoceptors"]]}, {"text": "(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591,  Rec 15/2739   SNAP 1069 and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned  human alpha 1D adrenoceptors   The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin >  Rec 15/2739  > RS 17053 = SNAP 1069", "triple_list": [["(-)-tamsulosin", "DOWNREGULATOR", "human alpha 1D adrenoceptors"]]}, {"text": "(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739,  SNAP 1069  and RS 17053 appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned  human alpha 1D adrenoceptors   The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15/2739 > RS 17053 =  SNAP 1069 ", "triple_list": [["SNAP 1069", "PRODUCT-OF", "appeared"]]}, {"text": "(+)-Tamsulosin, (-)-tamsulosin, SL 89,0591, Rec 15/2739, SNAP 1069 and  RS 17053  appeared to act as competitive antagonists of noradrenaline-mediated contractions of rat aorta yielding pA2 affinity estimates which were similar to binding affinities at cloned  human alpha 1D adrenoceptors   The following rank order was obtained: prazosin = (-)-tamsulosin > doxazosin > SL 89,0591 = (+)-tamsulosin > Rec 15/2739 >  RS 17053  = SNAP 1069", "triple_list": [["RS 17053", "AGONIST", "was"]]}, {"text": "These results suggest that  epinastine   although identified as a 5-HT antagonist, acts as a 5-HT1 agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional  5-HT1-like receptor   located to sensory nerves.", "triple_list": [["epinastine", "ANTAGONIST", "noncholinergic"]]}, {"text": "These results suggest that  epinastine   although identified as a 5-HT antagonist, acts as a  5-HT1  agonist and that it inhibits the noncholinergic contraction in guinea-pig airways through stimulation of a prejunctional  5-HT1 -like receptor, located to sensory nerves.", "triple_list": [["as", "DOWNREGULATOR", "5-HT1"]]}, {"text": "Pretreatment of the tissues with combined  5-HT1  5-HT2 antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of  epinastine  on the noncholinergic contraction", "triple_list": [["epinastine", "DOWNREGULATOR", "on"]]}, {"text": "Pretreatment of the tissues with combined 5-HT1/ 5-HT2  antagonists, methysergide (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of  epinastine  on the noncholinergic contraction", "triple_list": [["tissues", "ANTAGONIST", "5-HT2"]]}, {"text": "Pretreatment of the tissues with combined  5-HT1  5-HT2 antagonists,  methysergide  (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction", "triple_list": [["the", "DOWNREGULATOR", "5-HT1"]]}, {"text": "Pretreatment of the tissues with combined 5-HT1/ 5-HT2  antagonists,  methysergide  (1 microM) or methiothepin (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction", "triple_list": [["methysergide", "AGONIST", "the"]]}, {"text": "Pretreatment of the tissues with combined  5-HT1  5-HT2 antagonists, methysergide (1 microM) or  methiothepin  (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction", "triple_list": [["methiothepin", "PRODUCT-OF", "microM),"]]}, {"text": "Pretreatment of the tissues with combined 5-HT1/ 5-HT2  antagonists, methysergide (1 microM) or  methiothepin  (0.1 microM), significantly attenuated the inhibitory effect of epinastine on the noncholinergic contraction", "triple_list": [["methiothepin", "DOWNREGULATOR", "antagonists,"]]}, {"text": "Pretreatment with  tropisetron  (1 microM), a  5-HT3  antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect", "triple_list": [["tropisetron", "AGONIST", "(10"]]}, {"text": "Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist,  ketanserin  (10 microM), a  5-HT2  antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect", "triple_list": [["microM),", "AGONIST", "5-HT2"]]}, {"text": "Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist,  thioperamide  (10 microM), a  histamine H3  antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect", "triple_list": [["thioperamide", "PRODUCT-OF", "a"]]}, {"text": " Chlorpheniramine  (10 microM), another  histamine H1 receptor  antagonist without significant 5-HT receptor binding affinity, did not produce any inhibition of the eNANC contraction", "triple_list": [["Chlorpheniramine", "DOWNREGULATOR", "another"]]}, {"text": "(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of  alpha 1B-adrenoceptors  by treatment with  chlorethylclonidine   which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to  chlorethylclonidine ", "triple_list": [["chlorethylclonidine", "ACTIVATOR", "the"]]}, {"text": "These results indicate that the positive inotropic effect, mediated via (+/-)-tamsulosin- and  oxymetazoline  sensitive subtype of  alpha 1-adrenoceptors   is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.", "triple_list": [["of", "ACTIVATOR", "alpha 1-adrenoceptors"]]}, {"text": " Phenylephrine  elicited a concentration-dependent positive inotropic effect via  alpha 1-adrenoceptors  in the presence of either (+/-)-bupranolol or S(-)-timolol", "triple_list": [["or", "PRODUCT-OF", "alpha 1-adrenoceptors"]]}, {"text": "(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of  phenylephrine  even after inactivation of  alpha 1B-adrenoceptors  by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine", "triple_list": [["positive", "ACTIVATOR", "alpha 1B-adrenoceptors"]]}, {"text": "The influence of  (+/-)-tamsulosin   a selective  alpha 1A-adrenoceptor  antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another  alpha 1A-adrenoceptor  ligand oxymetazoline in the rabbit ventricular myocardium", "triple_list": [["(+/-)-tamsulosin", "PRODUCT-OF", "of"]]}, {"text": "These results indicate that the positive inotropic effect, mediated via  (+/-)-tamsulosin   and oxymetazoline-sensitive subtype of  alpha 1-adrenoceptors   is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.", "triple_list": [["exerted", "PRODUCT-OF", "alpha 1-adrenoceptors"]]}, {"text": " (+/-)-Tamsulosin  effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of  alpha 1B-adrenoceptors  by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine", "triple_list": [["even", "PRODUCT-OF", "alpha 1B-adrenoceptors"]]}, {"text": " (+/-)-tamsulosin   an  alpha 1A-adrenoceptor  antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart", "triple_list": [["in", "PRODUCT-OF", "alpha 1A-adrenoceptor"]]}, {"text": " (+/-)-Tamsulosin   over the range of concentrations at which it antagonized the positive inotropic effect mediated by  alpha 1-adrenoceptors   did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine", "triple_list": [["(+/-)-Tamsulosin", "AGONIST", "did"]]}, {"text": "The potency of the antipsychotic drug,  risperidone   to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and  alpha 1B-adrenoceptor  mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists", "triple_list": [["to", "AGONIST", "alpha 1B-adrenoceptor"]]}, {"text": "The potency of the antipsychotic drug,  risperidone   to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of  alpha 1-adrenoceptor  subtype-discriminating antagonists", "triple_list": [["contractions", "AGONIST", "alpha 1-adrenoceptor"]]}, {"text": "The potency of the antipsychotic drug,  risperidone   to antagonize  alpha 1A-adrenoceptor  mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists", "triple_list": [["contraction", "ACTIVATOR", "alpha 1A-adrenoceptor"]]}, {"text": "TREK-1 currents are insensitive to pharmacological agents that block  TWIK-1  activity such as  quinine  and quinidine", "triple_list": [["quinine", "AGONIST", "that"]]}, {"text": "TREK-1 currents are insensitive to pharmacological agents that block  TWIK-1  activity such as quinine and  quinidine   Extensive inhibitions of TREK-1 activity are observed after activation of protein kinases A and C", "triple_list": [["are", "ACTIVATOR", "TWIK-1"]]}, {"text": "Conversely, opioid antagonists such as naloxone and  naltrexone  (which bind to non-selectively  opioid receptors   have been shown to decrease alcohol consumption under various experimental conditions", "triple_list": [["naltrexone", "AGONIST", "opioid"]]}, {"text": "Conversely, opioid antagonists such as  naloxone  and naltrexone (which bind to non-selectively  opioid receptors   have been shown to decrease alcohol consumption under various experimental conditions", "triple_list": [["naloxone", "DOWNREGULATOR", "to"]]}, {"text": "We have examined the effect of dihydropyridine  Ca2+-channel  blockers  felodipine  and nicardipine on CaMPDE", "triple_list": [["felodipine", "ACTIVATOR", "and"]]}, {"text": "We have examined the effect of dihydropyridine  Ca2+-channel  blockers felodipine and  nicardipine  on CaMPDE", "triple_list": [["the", "ANTAGONIST", "Ca2+-channel"]]}, {"text": "The results suggest that the 63-kDa ( PDE 1B1   and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by  felodipine  and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other", "triple_list": [["and", "ANTAGONIST", "PDE 1B1"]]}, {"text": "The results suggest that the 63-kDa (PDE 1B1) and 60-kDa ( PDE 1A2   CaMPDE isozymes are inhibited by  felodipine  and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other", "triple_list": [["felodipine", "AGONIST", "Ca2+"]]}, {"text": "The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (PDE 1A2)  CaMPDE  isozymes are inhibited by  felodipine  and nicardipine by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other", "triple_list": [["felodipine", "ACTIVATOR", "isozymes"]]}, {"text": "The results suggest that the 63-kDa ( PDE 1B1   and 60-kDa (PDE 1A2) CaMPDE isozymes are inhibited by felodipine and  nicardipine  by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other", "triple_list": [["counteract", "PRODUCT-OF", "PDE 1B1"]]}, {"text": "The results suggest that the 63-kDa (PDE 1B1) and 60-kDa ( PDE 1A2   CaMPDE isozymes are inhibited by felodipine and  nicardipine  by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other", "triple_list": [["CaMPDE", "AGONIST", "PDE 1A2"]]}, {"text": "The results suggest that the 63-kDa (PDE 1B1) and 60-kDa (PDE 1A2)  CaMPDE  isozymes are inhibited by felodipine and  nicardipine  by partial competitive inhibition and that these two Ca2+ antagonists appear to counteract each other", "triple_list": [["nicardipine", "PRODUCT-OF", "other"]]}, {"text": "Felodipine and nicardipine have similar affinities for 60-kDa  CaMPDE  isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by  dihydropyridine  Ca2+-channel blockers.", "triple_list": [["dihydropyridine", "PRODUCT-OF", "nicardipine"]]}, {"text": "Felodipine and nicardipine have similar affinities for 60-kDa CaMPDE isozymes but bring about different levels of enzyme inhibition, suggesting the possibility of designing specific drugs that can protect the enzyme from inhibition by  dihydropyridine   Ca2+-channel  blockers.", "triple_list": [["dihydropyridine", "PRODUCT-OF", "Ca2+-channel"]]}, {"text": "We have examined the effect of  dihydropyridine   Ca2+-channel  blockers felodipine and nicardipine on CaMPDE", "triple_list": [["dihydropyridine", "PRODUCT-OF", "Ca2+-channel"]]}, {"text": "These actions are consistent with a pre-junctional inhibition of neuropeptide release from perivascular afferents of the trigeminal nerve, as confirmed by independent studies showing that  zolmitriptan  blocks elevations of  calcitonin-gene-related peptide  in jugular venous blood during electrical stimulation of the trigeminal ganglion", "triple_list": [["zolmitriptan", "PRODUCT-OF", "from"]]}, {"text": "Zolmitriptan (Zomig; formerly  311C90   is a novel  5-hydroxytryptamine (5HT)1B/1D  receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura", "triple_list": [["311C90", "DOWNREGULATOR", "aura"]]}, {"text": "Pre-clinical pharmacology of  zolmitriptan  (Zomig; formerly 311C90), a centrally and peripherally acting  5HT1B/1D  agonist for migraine", "triple_list": [["zolmitriptan", "ANTAGONIST", "Pre-clinical"]]}, {"text": " Zolmitriptan  (Zomig; formerly 311C90) is a novel  5-hydroxytryptamine (5HT)1B/1D  receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura", "triple_list": [["(Zomig;", "ACTIVATOR", "5-hydroxytryptamine (5HT)1B/1D"]]}, {"text": "Pre-clinical pharmacology of zolmitriptan ( Zomig   formerly 311C90), a centrally and peripherally acting  5HT1B/1D  agonist for migraine", "triple_list": [["Zomig", "DOWNREGULATOR", "centrally"]]}, {"text": "Pre-clinical pharmacology of zolmitriptan (Zomig; formerly  311C90  , a centrally and peripherally acting  5HT1B/1D  agonist for migraine", "triple_list": [["311C90", "DOWNREGULATOR", "for"]]}, {"text": "Zolmitriptan ( Zomig   formerly 311C90) is a novel  5-hydroxytryptamine (5HT)1B/1D  receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura", "triple_list": [["novel", "ACTIVATOR", "5-hydroxytryptamine (5HT)1B/1D"]]}, {"text": "Treatment of Rat-2 fibroblast cells with  C2-ceramide  caused the stimulation of  c-fos SRE  dependent reporter gene activity in a dose- and time-dependent manner by transient transfection analysis", "triple_list": [["C2-ceramide", "PRODUCT-OF", "dependent"]]}, {"text": "Next, we examined the role of Rho family GTPases in the  ceramide  induced signalling to  SRE  activation", "triple_list": [["of", "DOWNREGULATOR", "SRE"]]}, {"text": "By reporter gene analysis following transient transfections with various plasmids expressing a dominant negative mutant form of Cdc42, Rac1 or RhoA,  C2-ceramide  induced  SRE  activation was shown to be selectively repressed by pEXV-RacN17 encoding a dominant negative mutant of Rac1, suggesting that Rac activity is essential for the signalling cascade of ceramide to the nucleus", "triple_list": [["C2-ceramide", "AGONIST", "transient"]]}, {"text": "Exogenous  C2-ceramide  activates  c-fos serum response element  via Rac-dependent signalling pathway", "triple_list": [["C2-ceramide", "DOWNREGULATOR", "activates"]]}, {"text": "In a further study to analyse the downstream mediator of Rac in the ceramide-signalling pathway, we observed that either pretreatment with mepacrine, a potent and specific inhibitor of phospholipase A2, or co-transfection with antisense cytosolic phospholipase A2 (cPLA2) oligonucleotide repressed the  C2-ceramide  induced  SRE  activation selectively, implying a critical role of cPLA2 in  C2-ceramide -induced signalling to nucleus", "triple_list": [["-induced", "DOWNREGULATOR", "SRE"]]}, {"text": "Together, our findings suggest the critical role of 'Rac and subsequent activation of  phospholipase A2   in  ceramide  signalling to nucleus.", "triple_list": [["findings", "DOWNREGULATOR", "phospholipase A2"]]}, {"text": "Consistent with these results, the translocation of cPLA2 protein as well as the release of  arachidonic acid   a principal product of  phospholipase A2   was rapidly induced by the addition of C2-ceramide in a Rac-dependent manner", "triple_list": [["as", "ACTIVATOR", "phospholipase A2"]]}, {"text": "Because gastric  AADC  and COMT degrade levodopa, the drug is given with inhibitors of  AADC  (carbidopa or  benserazide  , and inhibitors of COMT will also enter clinical use", "triple_list": [["benserazide", "AGONIST", "benserazide"]]}, {"text": "Because gastric  AADC  and COMT degrade levodopa, the drug is given with inhibitors of  AADC  ( carbidopa  or benserazide), and inhibitors of COMT will also enter clinical use", "triple_list": [["COMT", "PRODUCT-OF", "AADC"]]}, {"text": " Levodopa  is absorbed in the small bowel and is rapidly catabolized by  aromatic-L-amino-acid decarboxylase  (AADC) and catechol-O-methyltransferase (COMT)", "triple_list": [["is", "ACTIVATOR", "aromatic-L-amino-acid decarboxylase"]]}, {"text": " Levodopa  is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase ( AADC   and catechol-O-methyltransferase (COMT)", "triple_list": [["Levodopa", "DOWNREGULATOR", "bowel"]]}, {"text": " Levodopa  is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and  catechol-O-methyltransferase  (COMT)", "triple_list": [["Levodopa", "DOWNREGULATOR", "is"]]}, {"text": " Levodopa  is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol-O-methyltransferase ( COMT  ", "triple_list": [["the", "ANTAGONIST", "COMT"]]}, {"text": "Because gastric  AADC  and COMT degrade  levodopa   the drug is given with inhibitors of  AADC  (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use", "triple_list": [["levodopa", "AGONIST", "degrade"]]}, {"text": "Because gastric AADC and  COMT  degrade  levodopa   the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of  COMT  will also enter clinical use", "triple_list": [["given", "ANTAGONIST", "COMT"]]}, {"text": "Two mechanisms of action have been identified for  A77 1726   inhibition of  dihydroorotate dehydrogenase  (DHODH) and inhibition of tyrosine kinases", "triple_list": [["A77 1726", "ANTAGONIST", "dihydroorotate"]]}, {"text": "Two mechanisms of action have been identified for  A77 1726   inhibition of dihydroorotate dehydrogenase ( DHODH   and inhibition of tyrosine kinases", "triple_list": [["A77 1726", "AGONIST", "A77"]]}, {"text": "Two mechanisms of action have been identified for  A77 1726   inhibition of dihydroorotate dehydrogenase (DHODH) and inhibition of  tyrosine kinases   DHODH inhibition occurs at lower concentrations of  A77 1726  than that of  tyrosine kinases  and is currently considered the major mode of action", "triple_list": [["A77 1726", "AGONIST", "A77"]]}, {"text": " DHODH  inhibition occurs at lower concentrations of  A77 1726  than that of tyrosine kinases and is currently considered the major mode of action", "triple_list": [["A77 1726", "AGONIST", "lower"]]}, {"text": "DHODH inhibition occurs at lower concentrations of  A77 1726  than that of  tyrosine kinases  and is currently considered the major mode of action", "triple_list": [["major", "AGONIST", "tyrosine kinases"]]}, {"text": "The purified  phosphodiester alpha-GlcNAcase  has a specific activity of 498 micromol of  [3H]GlcNAc-alpha-phosphomannose-alpha-methyl  cleaved per h per mg of protein using 0.5 mM  [3H]GlcNAc-alpha-phosphomannose-alpha-methyl  as substrate", "triple_list": [["[3H]GlcNAc-alpha-phosphomannose-alpha-methyl", "ACTIVATOR", "cleaved"]]}, {"text": "The purified  phosphodiester alpha-GlcNAcase  has a specific activity of 498 micromol of  [3H]GlcNAc-alpha-phosphomannose-alpha-methyl  cleaved per h per mg of protein using 0.5 mM  [3H]GlcNAc-alpha-phosphomannose-alpha-methyl  as substrate", "triple_list": [["[3H]GlcNAc-alpha-phosphomannose-alpha-methyl", "AGONIST", "The"]]}, {"text": " N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase  (EC 3.1.4.45; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the  mannose 6-phosphate  determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome", "triple_list": [["newly", "DOWNREGULATOR", "N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase"]]}, {"text": "N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase ( EC 3.1.4.45   phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the  mannose 6-phosphate  determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome", "triple_list": [["lysosomal", "ACTIVATOR", "EC 3.1.4.45"]]}, {"text": "N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase (EC 3.1.4.45;  phosphodiester alpha-GlcNAcase   catalyzes the second step in the synthesis of the  mannose 6-phosphate  determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome", "triple_list": [["synthesized", "AGONIST", "phosphodiester alpha-GlcNAcase"]]}, {"text": "Both the  5 alpha-reductase  inhibitor  finasteride  and alpha 1-adrenoceptor antagonists (e.g", "triple_list": [["alpha", "ACTIVATOR", "5 alpha-reductase"]]}, {"text": "In another experiment,  cyanopindolol   an antagonist of the  serotonin terminal autoreceptor   also prolonged the clearance of 5-HT from the CA3 region", "triple_list": [["cyanopindolol", "AGONIST", "of"]]}, {"text": "From these data, it is inferred that both the  SERT  and NET contribute to the active clearance of exogenously applied  5-HT  in the dentate gyrus", "triple_list": [["5-HT", "ANTAGONIST", "the"]]}, {"text": "From these data, it is inferred that both the SERT and  NET  contribute to the active clearance of exogenously applied  5-HT  in the dentate gyrus", "triple_list": [["5-HT", "ANTAGONIST", "that"]]}, {"text": "These and other data have generated a working hypothesis that activation of the terminal serotonin autoreceptor enhances the kinetics of  5-HT  uptake through an effect on the  serotonin transporter  ", "triple_list": [["5-HT", "DOWNREGULATOR", "generated"]]}, {"text": "These and other data have generated a working hypothesis that activation of the terminal  serotonin autoreceptor  enhances the kinetics of  5-HT  uptake through an effect on the serotonin transporter.", "triple_list": [["5-HT", "ACTIVATOR", "generated"]]}]